<SEC-DOCUMENT>0001104659-26-034554.txt : 20260325
<SEC-HEADER>0001104659-26-034554.hdr.sgml : 20260325
<ACCEPTANCE-DATETIME>20260325163405
ACCESSION NUMBER:		0001104659-26-034554
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260325
DATE AS OF CHANGE:		20260325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41429
		FILM NUMBER:		26792914

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pmn-20251231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/25/2026 1:44:19 PM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pmn="http://www.promisneurosciences.com/20251231" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>PROMIS NEUROSCIENCES&#160;INC._December&#160;31, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration" id="Hidden_olqw5_anRE-ovFTa05ir5g">http://xbrl.sec.gov/country/2024#CA</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" xs:nil="true" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_l39J4Y1B40mg3R9l36E2rg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" xs:nil="true" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_sKnba67HJUyKJfz0lH5rZQ"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityCentralIndexKey" id="Tc_rucG13QTg0OVmCb4N2yaXA_2_1">0001374339</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentFiscalPeriodFocus" id="Tc_mZh2zab32UePXY86VKReoA_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:AmendmentFlag" id="Tc_vIqMGYCKlEiYu7t2P6GoUg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" id="Hidden_GhxEAIH_YkG5x-Ih-SQnQg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" id="Hidden_3xvePPGvP0eierxX7svGGg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" id="Hidden_-mp4ech9zk6NryxWw8E4mQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" id="Hidden_BbSWnuivdEu78V4TAp4ZYg">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2025_Z_D8BnWwH0KI4VRbsA5wGw" name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="Hidden_SdkTB3HWa020CccPjwzO6Q">Unlimited</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" xs:nil="true" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" name="us-gaap:CommonStockValue" id="Hidden_6oppxBhmXEeEh4xZRJJ3vQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" xs:nil="true" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" name="us-gaap:CommonStockValue" id="Hidden_b4hNM_E66Ua0TaTRWn1_tA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_EKVA16217E2dxeEyM3doRA">0.04</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_krcSoJs8uEGhJeQTOJRxjQ" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_NcV6rL8tMk-QI6TxetjyIg">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GjkWBqs9q06nWLBBRIYSgA" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_xwYBGyVeBki9Pw78B3ou9w">P2Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_okOBjDtFkk6dhuoxmA-XUw" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Hidden_YqiLGZ_RnUeciaPL5_1Scw">314170</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_mnaOojJ8ckOxdhKed7q5Fg" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Hidden_zqmpoD10K0mYm-cj5Mnc8w">314170</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_PmbPPIZSikyMOvx6yPh_Ag" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_TkWIfmwCtk2L1o77RyTsVw">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_K9LLXyDMFk2irW-0jw4rvw">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_aET_q1kz20eyyiAplvmU3A" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_NKYPClXPwkOL6W5cM2Ychw">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_g16vuarcVkaajTr5ylg-0Q" decimals="INF" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" id="Hidden_sIX-I_ihFUyckByqXSCcEg">112150</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_IjbEDJQXzEyRlHeHW-e5vA" decimals="INF" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" id="Hidden_rAT-TO71IkG83cETElUNVQ">112150</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_C_yFUr1E9EemPsRRHjvb2g" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_vE8nknvrREuwISKkbV-t1g">14.70</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_5TAIotjO30iMxfHyMzA2CA" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_sDMpaTJpt02AivVLsCelvw">0.53</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_qwWinEz9-E2cc-au3SCIuw" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_UiLMq0ECGUuuIc3ZT61PGA">4.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_p9xR5oScN0uow2EdFjwW2w" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_bE979HFoxkSnleUqfJBh_Q">0.039</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_eO14_co7TEenwcFziElAIw" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_qaJfvU25ukC0j9SFajVEUw">0.043</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_yidCUH_4PUG39J6n_b7EEQ" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_z2jv6MWYFkOFbHtRCJPIPQ">1.065</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_w0AL93LAOE2_XbQOQb0LCQ" decimals="INF" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" id="Hidden_2uiJ2Xl62UWXxUyC2yNBhA">138812</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_RGzUOpKNXUufjxjn7adS1A" decimals="INF" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" id="Hidden_u1jGCHE0JUyEOMipzgeTYA">138812</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_CajStywymUK5c3CbpY5bmQ" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_88CXrfs02k61Q4fWLfzeFg">20.88</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_B8nAGHl8yECKdcx4365Ong" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_XdTVGA3HiEy71yJOaEE4tg">0.52</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_PI4broZKXEewo9ML5txgmg" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_Dh34ZOTg80WsRg6qGMRmNA">4.01</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_gC5uKZAs906va_wVMOoBxQ" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_p37SpWW4dk6Jm7sLGseshg">0.039</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_w1492Mmr_kecq-xQFv__cg" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_fQaxwlZiKkGwEDVd1NMCVQ">0.043</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_DYaPxO1FXk29eQlC70YMrA" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_DM6veFeJkkWgBQ6DbhWYUw">1.074</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_bzJ1h69P5Uu2r6edpFDPOQ">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_uNKYSpxl1EOc5rSnKnyhFA">0.04</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" name="us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration" id="Hidden_ek1qQB57M0uiwz7O77M-zA">http://xbrl.sec.gov/country/2024#CA</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Hidden_VGlBM7hgKUyWd-Dp-bhCdA">28.75</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceOneMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_Q86c3TOUPUerZkUpsynvOQ" decimals="2" name="pmn:ClassOfWarrantOrRightPricePerWarrant" id="Hidden_g2-t6Gg1-USHvtLxsXmEHw">10.77</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_MI2T6mOoo0yiJyx9T1pfEg" decimals="2" name="pmn:ClassOfWarrantOrRightPricePerWarrant" id="Hidden_z_3eEpwo3UirEsenSR7Cow">10.77</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_p9u06d6usECaMSjjXOcQkA" decimals="2" name="pmn:ClassOfWarrantOrRightPricePerWarrant" id="Hidden_bKWVPXSjm0mG5YAXBCSUsw">12.13</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pmn-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_jgbAwglzZ0mcOj7IwSXxRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_cyhzjHJjgkSJTrqFS2S_jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_VQxtOloCU0Kve5DNgHGdOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_gC5uKZAs906va_wVMOoBxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_B8nAGHl8yECKdcx4365Ong"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_Gcz0PPFqSkCFQ8-TE6lbgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_rc0mwg3aNEm7zVK6UJmkYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_uFsROG-NVU2k94DCS0QXRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_w1492Mmr_kecq-xQFv__cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_PI4broZKXEewo9ML5txgmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_e9DEwqxr8EKiOrKOtaJIGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_FP_FrTOu2Uu1Wd6byIXwSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_CajStywymUK5c3CbpY5bmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_DYaPxO1FXk29eQlC70YMrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_aHA4MFp8MUyKpl5PvcxEWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_sQgJPaD0DE-aVvUQ9j8Tng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_PVYYZPfc3UauSC4uMd_VJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_nNyk22XD9EK1oyNQIa_tUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Okge8-wzBU2jlOsUJvycVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Ywf0QSn_MU67VjykM1HpRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_GvLUVdGT7kKjraQdVt5bsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DuvCQ_GM9UKztjhwWQu6pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_dJb2jjHN40ybk15--NzTxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_p9xR5oScN0uow2EdFjwW2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_5TAIotjO30iMxfHyMzA2CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y-QIx4_sEUmBnP424eXzYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DRD7WoeXBU-JH-rKWT9PFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_-BYZBHNW00qP6PIyK-XiTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_eO14_co7TEenwcFziElAIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_qwWinEz9-E2cc-au3SCIuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Gqt906yAIEyMV9y-5GtbIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_wj2kZqXnhEOGN-1dq0Xllg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_C_yFUr1E9EemPsRRHjvb2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_yidCUH_4PUG39J6n_b7EEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_neufGN5uEk2IUYIIK5t4qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_y4m6ZNV0Q0Kp3hRUT7r-aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_xEmsDgSeNU-j_EYzMwwGPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_YtOhhYng_UGNJq2bFO6jYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_aepTXAELwE2v1b_eEMAxzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_AD1d2zJY0Ue1O3lheBiTPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_sgCMr1pSoUC2ePK4kj1p-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qIdSELbVFkaYdmFaMjb2AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hE5JvZ3pGkuLwiBtavfN2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RbMHvC0yfUeVN1ARzZnBIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_C7t5pUTfOU2-H7yBZeKMnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OBE-rahe30mjEaB9k6wKdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0ulmsA0VAkKV0dAMZCrDbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SMlc3z5xwU2h8j7yM4L-sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_irrRYii8eE21ooTnYfcNCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_oIAjV4RAJk26fwCLgDL5rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember_QgKzyfBAJkiVQVpxeqeEuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_pmn_NonCapitalLossCarryforwardMember_i2OXSaXBF0CPpT0LBRI-Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pmn:NonCapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_Nk1_WvPkJUiSujdxjoOzOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_x5pcthNFT0ihjd4LzbTnhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_hIXk7T7AhEypKsAQMXXglg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pmn:DirectorsAndManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_6VuupOYBAkOYhCWeJHRGrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_B_WytrX9uEGjxCiY6yXfMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_bj8OdyKOgkSN2xamZTJ45w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_jzjohLSy8kiD2BCrS5ZH6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zYsxCnpXe0KHopuDgqbqvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:Series2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T2FBENRGJ0aV_HOn6Nz-tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:Series2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-28</xbrli:startDate><xbrli:endDate>2025-11-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__TYAGjaVLEGvdKi8ag1ZZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r75dt_d2N0-jq-dK5XbpKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1hHfoCkg_ky9CLByNbJgvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L4zZj1oYT0W-2XHWII1COQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5FgCE8zX30-mupqCfqO9Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEDCy0IDbk6AIgd9hmwmxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EQwMMLg4YEGiDu7FMobu8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMw169EA8Uy88PupRPJN3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bZ9SGI8L40et_WctpSEuqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Oh5tArIfbUWmdvd8QxM1uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__rxEw1kCCEqZzbbgn51WGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_a3Lixc5gK0udx4DuG-SYdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:Series2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w7-zVhUC1kKywOJd7lAuXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_LlWSStT2D0-0Npx7XslrPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_oUDs-NDYv0qB68laQ04sGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_535wZCcGeEeaUhW6qrPQIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_ZnKVIeo_bUW1r1sdCiTiBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_DAPNYxdYn0qZikf9-Z1Hkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Pm7NX9q6C0GTLtp_fVq02Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ArrangementOptionInitialAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_lzS6k88pCESIdR5eDOhhpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_HkhKPStIm06ybEXHIFwi_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YXkmIVrXsUao5mEA8VBliw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ShareBasedPaymentArrangementOptionPerformanceAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hegnycuWWk64ZdX1vlM55g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ArrangementOptionInitialAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CgSeHaCH60uJVtf2HXDdBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ShareBasedPaymentArrangementOptionPerformanceAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1Gx3t3xx065WtYKYn1A9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ArrangementOptionInitialAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_Y-LkZ-hLQ0uB5SljT10LcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pmn:DirectorsAndManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_C9tRwMO6rE-LT1JzUAMX2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_krcSoJs8uEGhJeQTOJRxjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GjkWBqs9q06nWLBBRIYSgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_DFTrDh2oYk6khT-4RADKcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__MZVg_HiDUGOdFb43rdmsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iyRZGqr_Ek6zR0Ofkljmjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v5tCRtG69EORGsNwZgNgJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qb681Op0wU2HNAyg8TBGWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_anrOgR3un0mVCIt8ZEvpkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_AXkBdGaKv0Sxf5BYb0bqKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_47_m4S0qR0iRJtAX5RQLIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_c27Fx9k4pkmbZZyNSQSBcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nE9oOriQukSZ_Xm8_Ompeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GFBuNQasRUSBVwbZTVEbuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_JgwQ5vRSwU6dCCuhwG_xZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:UnitedStatesDollarDenominatedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_xaU9LQGLVkuHu1Sq5gLwdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_eoUbqM8EvkG5L47UIBVk4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:UnitedStatesDollarDenominatedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_qo_eeZpMdkKWqiKn5hBbMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-23</xbrli:startDate><xbrli:endDate>2024-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_Ec-PTVWrHU6jtSro-6pQ3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_T8HONw3a-0-21izjx6PztQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_PmbPPIZSikyMOvx6yPh_Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CanadianDollarDenominatedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_aET_q1kz20eyyiAplvmU3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CanadianDollarDenominatedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_YoanmoqTME6ncgb6u864pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CurrencyAxis_currency_USD_AW-HI8NCBUijoCTjKG1Vyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_CurrencyAxis_currency_USD_2N501AziF0iBtEVWWSNtGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6VYWxtDOn0yRARELn8NX6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2025_Z_D8BnWwH0KI4VRbsA5wGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionAndIncentivePlan2025Member_8TYcGUAhwU2A4TqH-py3Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionAndIncentivePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_okOBjDtFkk6dhuoxmA-XUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_mnaOojJ8ckOxdhKed7q5Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_JIhTf2m0-0KabLXPYhKDMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_n8K5Hi-d6EKuzXBWSyVZug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_igRnDfASGkG63gecqvoxGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_YLC21hJnUUecfOnIoqyf6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_NrDzHyxGB0mKB6zttI9Mtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2030Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd3125Member_BEwiO-eDbUWWmJRIGGfGtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:July2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd31.25Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd6250Member_ZBhfqWXuAEO3TU5tCv6HmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:July2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd62.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2027Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_OxC1c99JokOfGf-9JXcpPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:January2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd50.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_BLU4_tV9gUySljXY2fjsag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:January2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd50.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_February2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd4375Member_96PtobwXOEKcI7qN4vYumA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:February2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd43.75Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd31500Member_xOPbGlUKKEeb6s_MpQYu2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:August2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd315.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd24000Member_3gS1r2Q7ikiBMcspRxwhdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:August2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd240.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd18750Member_DceMNtnvik6aFW0Sn6WY3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:April2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd187.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd15250Member_M2aoRgqepE2Z5hmL4ieMNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:April2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd152.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd025Member_QbxyhQijfEureNNbf38Kiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd0.25Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_TP3g5_42vkuIAbWzNvhidg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_IxRv2RxvLk-C6APbD0vZoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_7IREftZcLkyg0wHsVKlqFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_SKI98Sng40qCm1MAstf_uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OTZaBhXrTk-ATiBJ5MN0xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_YRF1DtgvqEykJgtUIbZvgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2BUfm8XxKEiVAOa9cCeI-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qm2HZYqej0K6tZkucd3Jzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I1pUDf-UVkWE1fMJu2oIPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DtZmtuC1ykum9CataBZk8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_-Oj0jlKSiEGQv00Y8TYf4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmn:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I_iDsTdFrk6-anUo_VHT0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a-CEo9VCBE-UkGXp15OLEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_fsghA6bgmEe7eA6MOqoAlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmn:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_8kidyz1Xz0e1GRFRPcmD0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lI1_7YZGDkiVsD04bzBKuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rhZmPGlkfEOEJZUvfYbOgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_bAqN9UYOfk6qG8Vt8Q_g7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-qWN91AyB0iMTTieOzW1eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4me8oDqyvUC5VCBKaBFb0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_cuRNgn1GhEKPKyrtju0bxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_FcVZtKmJ30yeYVCm5Ilgeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_ywYEmzxlq0GiCBn4u9aJUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_8DzdAeeke06K0IAuzwW1iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_vATcI-2w8ku4HaP9mKA02A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_1g3BSYKGr0uWzgGWV2G3HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KTeicbzkpEaKVTYwByBWeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_RegisteredDirectOfferingMember_CC8gh5SgoE2iWhbtumf2UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4P_Kz5oy5k-CBSt-JdWqyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_I6q6e-G_hkObQ4WrMKNO1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ShareBasedPaymentArrangementOptionPerformanceAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:DeferredShareUnitPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4m9O5GYGnEyywiNYhqVX6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2016_To_4_30_2016_pOn31i6lLEW5JuoImgoy_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_yUl-HCLG1kqLzAcQbh7uGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmn:CollaborativeResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_DdNjmpvgs0aZ4rzq8r7w_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmn:CollaborativeResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_w1RADThn2Uar_4m_e19qyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_WoxRD2BhjUizfdZS0HDjoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_v_5AQ8INOEWby_KGMYOsxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OX19e1OjNUi2f5RsX_WMag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_bpZRccBbfUmU6W3r5YkXHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_6T695C591UiyeQbCleHuxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_sO-pqyxjMUuCAIj5bfCXDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_3sNvUqnERk29CoEwJ1LNig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_Cj0bmR9KNU-gOSr3An81OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_8p18K6uLmk6qW32n10mbgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_JaWdR8WEoEu-vtz5zRuEhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_RQMPznxiJUaeXSv1Kr1dkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-23</xbrli:startDate><xbrli:endDate>2024-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_TerminationWithoutCauseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Wm0yqUihf0aj0uy8QZAwtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:TerminationWithoutCauseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_ChangeInControlOfCompanyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ce9A_GawfUqwocEsnGglEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:ChangeInControlOfCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2025_To_8_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_TnDWza_UfEC6NE6VKGF_Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_Kfapro2AwUiDsFbp7-NsnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_4lfKtp945kqn9mXeMmjskQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pmn:UbcAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_atViPoIYo0CLfKm49OwGMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pmn:DirectorsAndManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_br3i9uDnNUeb1G3P44Ok7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_MI2T6mOoo0yiJyx9T1pfEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsIssuePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_p9u06d6usECaMSjjXOcQkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsIssuePriceThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceOneMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_Q86c3TOUPUerZkUpsynvOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsIssuePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_0I2NUUyQSkuP1T4GHvUZvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_qwFZGwi9q0GjlBqTpS8zEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_w0AL93LAOE2_XbQOQb0LCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_RGzUOpKNXUufjxjn7adS1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_T1JrdAuH_EGgMvUA5bYqhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_g16vuarcVkaajTr5ylg-0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_IjbEDJQXzEyRlHeHW-e5vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_yEzxtOjj-EyFV6MUX2x0TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_SWJwnPT2MUWAT21zy7PWMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_wj_YaF2jk02-OwZm2Ww4xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_iEMqWL4XT0SxMr2o3-qqIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y36YA1aV8EG9tI8Bg4zyLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-22</xbrli:startDate><xbrli:endDate>2025-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_Oi4UAzx7LkqdsUQQKfYJbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pmn:UbcAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_7w8rUzbi_Uy4GsvvvVtdxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2026_SY15PzBp9E2bG8QJJwE36w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g"><xbrli:measure>pmn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ"><xbrli:measure>pmn:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_I7wc_r8nuUinrT38wY9WLA"><xbrli:measure>pmn:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_ETwbko2pdkCFGeE5avOMiw"><xbrli:measure>pmn:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_JjSvLYrH-EWdNko9j1YiTg"><xbrli:measure>pmn:D</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ed1fcb5d_34eb_48fc_9337_a67c549c0af9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentType" id="Narr_ewbUS11rzUK9eONFHbpzdw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentAnnualReport" id="Narr_GG_0b8XqBUC2UEZI_AlRHw"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><b style="font-size:8pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentPeriodEndDate" id="Narr_gCpdL26VEUK6qgDEwu9Opg"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:CurrentFiscalYearEndDate" id="Narr_brryoR3qXkiGiPUuPv7cAQ"><b style="font-size:9pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentFiscalYearFocus" id="Narr_4M9FcTpPXU6OrJ9yDFDL2w"><b style="font-size:9pt;font-weight:bold;">2025</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentTransitionReport" id="Narr_V54GSep9f0aPyCttsenKOw"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For The Transition Period From</b><span style="display:inline-block;width:32.46pt;"></span><b style="font-weight:bold;">To</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityFileNumber" id="Narr_Qpr8PjRbQ0CI327H45VqaA"><b style="font-size:9pt;font-weight:bold;">001-41429</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityRegistrantName" id="Narr_EF4I3nnfuk6sVJMJ8vpVJQ"><b style="font-weight:bold;">PROMIS NEUROSCIENCES&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1bf57171_d0f8_4867_a08d_c072e98daeb1"></a><a id="Tc_QRk9GfE4Nkqf66kI1IHoTA_2_0"></a><a id="Tc_gEWj4f1ZxkSQT9ayvoOOVA_2_1"></a><a id="Tc_fUAv5tOmIEi3GWn_MrN7dQ_3_0"></a><a id="Tc_wHCv008_9UyK8AV7lU5hxA_4_0"></a><a id="Tc_27eeuc4krkOr1kEmdE7u4A_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityIncorporationStateCountryCode" id="Tc_vIfiU3gC-k-4y2YjM-uxjw_1_0"><b style="font-size:9pt;font-weight:bold;">Ontario, Canada</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityTaxIdentificationNumber" id="Tc_bdA1_jVYgUeh8eKE2cYTeg_1_1"><b style="font-size:9pt;font-weight:bold;">98-0647155</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityAddressAddressLine1" id="Narr_vhTNbiL2vkyW1XCdawtuqw"><b style="font-size:9pt;font-weight:bold;">Suite&#160;200, 1920 Yonge Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityAddressCityOrTown" id="Narr_CEgHcUchpUiC_8ii4fmMVA"><b style="font-size:9pt;font-weight:bold;">Toronto</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityAddressStateOrProvince" id="Narr_FJZmim7T3UamUzmJBNVlGA"><b style="font-size:9pt;font-weight:bold;">Ontario</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityAddressPostalZipCode" id="Tc_VB-r5-5D10mVfgTeNOSFeA_3_1"><b style="font-size:9pt;font-weight:bold;">M4S 3E2</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:CityAreaCode" id="Narr_pDSSUpSog0KrEhLhvAYOAA"><b style="font-size:9pt;font-weight:bold;">416</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:LocalPhoneNumber" id="Narr_7zZlGe9h0UCf0C9PbwamYA"><b style="font-size:9pt;font-weight:bold;">847-6898</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_d8257bbf_9f48_464b_be16_f7fd586dd21f"></a><a id="Tc_3ZNo2dBrtkCgbUT7SH43YA_1_2"></a><a id="Tc_wlpP0rSloUavpwOZA-xTrQ_2_0"></a><a id="Tc_yAq-Zc9c2UyaP6IjVTEqdw_2_1"></a><a id="Tc_QJ4cIcO45Uaov_GX_nlNvQ_2_2"></a><a id="Tc_7WEPSm7uQEeR5WNh26LlLA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr style=""><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</b></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">On Which Registered</b></p></td></tr><tr style=""><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:Security12bTitle" id="Tc_reXv-EeFokKtAtp3ljMxSQ_3_0"><b style="font-size:9pt;font-weight:bold;">Common Shares, No Par Value per Share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:TradingSymbol" id="Tc_F8b_e-EfUEq5Hef44h8P9Q_3_1"><b style="font-size:9pt;font-weight:bold;">PMN</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">The </b><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:SecurityExchangeName" id="Narr_E-L-JfFen0SsKUoHAVmWLw"><b style="font-size:9pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> Capital Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_-cMKrf3fvkiATKrqhQ-i_w"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityVoluntaryFilers" id="Narr_Z0xonDd25kSWBvIVlSh0Pw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;white-space:pre-wrap;">Indicate by check mark whether the registrant:  (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityCurrentReportingStatus" id="Narr_0JSALouM502mSnlQ24sn0g"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityInteractiveDataCurrent" id="Narr__evg077LaEWWjVUJnqUSLw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;white-space:pre-wrap;">   No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:19.38%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:16.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:20.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Large accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityFilerCategory" id="Narr_LwZcE8eSEke6jMiOU_GmbA"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntitySmallBusiness" id="Narr_KonyUNWMHk6vQeXBjtzGwA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityEmergingGrowthCompany" id="Narr_StkcTvkFHkqa9CK-MH_QJg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityExTransitionPeriod" id="Narr_bTvkGAYYI0uLHRQ7SPNHcg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:IcfrAuditorAttestationFlag" id="Narr_34kqMcRUfEizFfW6v_YWPA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.07;margin:3pt 0pt 0pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_6W1wY_vVnU6GFvpBuEH7Rw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.07;margin:3pt 0pt 0pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.07;margin:3pt 0pt 0pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;239.90D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:EntityShellCompany" id="Narr_KSmc7wciXEa2JmXg24s9FA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 5pt 0pt;">Based on the closing price as reported on the Nasdaq Capital Market, the aggregate market value of the Registrant&#8217;s Common Stock held by non-affiliates on June 30, 2025, the last day of its most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" format="ixt:num-dot-decimal" scale="6" contextRef="As_Of_6_30_2025_7w8rUzbi_Uy4GsvvvVtdxQ" decimals="-5" name="dei:EntityPublicFloat" id="Narr_M4q0rgeWDEyHP1XC-pC_Dw">29.7</ix:nonFraction> million. Shares of Common Stock held by each executive officer and director and by each shareholder affiliated with a director or an executive officer have been excluded from this calculation because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The number of outstanding Common Shares of the Registrant as of March 25, 2026 was <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_25_2026_SY15PzBp9E2bG8QJJwE36w" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_SEe38r8beU-DCa21Bn2G8g">8,967,693</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_M7UQKzvVBEWS8JIR6Otxuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 5pt 0pt;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2026 annual meeting of shareholders, or the 2026 Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2026 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:14.4pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a89cc58b_a608_4ad2_b725_be7c4e6a3841"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:90.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:6.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><a href="#PARTI_563640"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1Business_677024"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Business</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1ARiskFactors_192570"><span style="font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_71850"><span style="font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">97</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1CCybersecurity_537304"><span style="font-style:normal;font-weight:normal;">Item&#160;1C. Cybersecurity</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">97</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item2Properties_166556"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Properties</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item3LegalProceedings_235845"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_791437"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><a href="#PARTII_149212"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item6_513958"><span style="font-style:normal;font-weight:normal;">Item&#160;6. Reserved</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">110</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">100</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9AControlsandProcedures_177201"><span style="font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">100</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9BOtherInformation_880196"><span style="font-style:normal;font-weight:normal;">Item&#160;9B. Other Information</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIII_789338"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_175783"><span style="font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#_Item_13._Certain"><span style="font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#_Item_14._Principal"><span style="font-style:normal;font-weight:normal;">Item&#160;14. Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><a href="#PartIV_782813"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#_Item_15._Exhibits"><span style="font-style:normal;font-weight:normal;">Item&#160;15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#_Item_16._Form"><span style="font-style:normal;font-weight:normal;">Item&#160;16. Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:90.88%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#SIGNATURES_18917"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">110</p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#INDEXTOCONSOLIDATEDFINANCIALSTATEMENT"><span style="font-style:normal;font-weight:normal;">Index to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_3d73bf79_300d_4321_88d7_c5bfa2061b1e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks are described more fully in Item 1A &#8211; &#8220;Risk Factors&#8221; and include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to the Development of Our Product Candidates</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates are still in the early stages of development and there is significant uncertainty that any such products will be approved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have concentrated a portion of our research and development efforts on the treatment of Alzheimer&#8217;s Disease, a field that has seen very limited success in drug development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of PMN310 and any future product candidates that we may develop or acquire, including PMN442 and PMN267.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical and nonclinical drug development involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical trials are not always predictive of future results. PMN310 or any other product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interim, &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce or publish from time to time may change as more data become available and is subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We cannot be certain that PMN310, PMN442, PMN267 or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market our product candidates.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred losses since inception, we anticipate that we will incur continued losses for the foreseeable future and will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have no product candidates approved for commercial sale, we have never generated any revenue from product sales and we may never be profitable.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to the Commercialization of Our Product Candidates</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for PMN310, PMN442, PMN267, and future product candidates, if approved, may be smaller than we anticipate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process to commercialize our potential products, which may not be successful.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will rely on third parties to supply components, research, develop, test, and manufacture our product candidates and market, if approved. The loss of any of these third-party relationships or the failure of any of them to meet their obligations to us could affect our ability to develop and obtain approval of our product candidates in a timely manner.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If any of our third-party manufacturers encounter difficulties in production of PMN310, PMN267, PMN442 or any future product candidate we develop, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or, if approved, for commercial sale could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to Our Intellectual Property</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates, and other proprietary technologies if approved, may be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through in-licenses.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to Legal and Regulatory Compliance Matters</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize future product candidates, and our ability to generate revenue be materially impaired. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we obtain regulatory approval for PMN310, PMN442, PMN267 or any future product candidates, they will remain subject to ongoing regulatory oversight, which may result in significant additional expense.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to Our Business and Industry</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective than ours.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">Risks Related to Ownership of Our Common Shares and Our Status as a U.S. Public Company</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Investment in our Common Shares is speculative, involves risk, and there is no guarantee of a return.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our Common Shares may be volatile.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other shareholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There is no active market for our warrants and pre-funded warrants.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">General Risk Factors</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The elimination of monetary liability against our directors, officers, and employees under Canadian law and the existence of indemnification rights for our obligations to our directors, officers, and employees may result in substantial expenditures by us and may discourage lawsuits against our directors, officers, and employees.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2ff457f2_ddb5_4c85_8f07_3242ed03c007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">This Annual Report on Form 10-K, or Annual Report includes statements that express ProMIS&#8217; opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, &#8220;forward-looking statements.&#8221; These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;seeks,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or &#8220;should&#8221; or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Annual Report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, our ability to continue as a going concern, patent term expiration dates, prospects, growth, strategies and the markets in which ProMIS operates. Such forward-looking statements are based on available current market material and management&#8217;s expectations, beliefs and forecasts concerning future events impacting ProMIS. Factors that may impact such forward- looking statements include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anticipated amount, timing and accounting of contingent, milestone, royalty and other payments under licensing or collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax positions and contingencies; research and development costs; compensation and other selling, general and administrative expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency exchange risk;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimated fair value of assets and liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential impact of increased competition in the markets in which we compete;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans and investments in our portfolio as well as implementation of our corporate strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that we will maintain enough liquidity to execute our business plan and our ability to continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expected use of proceeds from sales of our common shares or common share equivalents in offerings or &#8220;at-the-market&#8221; offerings and the period over which such proceeds, together with existing cash, will be sufficient to meet our operating needs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expectations, development plans and anticipated timelines, including costs and timing of clinical trials, filings and approvals, of our products candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the direct and indirect impact of health crises on our business and operations, including expenses, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of global financial, economic, political and health events, such as rising inflation, market volatility, fluctuating interest rates, capital markets disruptions, legislative action, possible government shutdowns and international tariffs;</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential impact of healthcare reform in the United States and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that we become characterized as a passive foreign investment company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to prevent and successfully remediate any significant deficiencies or material weaknesses in internal controls over financial reporting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of new laws (including tax and tariff policies), executive orders, regulatory requirements, judicial decisions and accounting standards.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">The forward-looking statements contained in this Annual Report on Form 10-K are based on ProMIS&#8217; current expectations and beliefs concerning future developments and their potential effects on ProMIS. There can be no assurance that future developments affecting ProMIS will be those that ProMIS has anticipated. These forward-looking statements involve a number of risks, uncertainties, some of which are beyond ProMIS&#8217; control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading &#8220;Risk Factors.&#8221; Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Moreover, the occurrence of the events described in the &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K may adversely affect ProMIS. ProMIS will not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a06c721e_0d67_4f1c_9a91_21d41c1144a7"></a><a id="PARTI_563640"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_677024"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer&#8217;s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson&#8217;s disease, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS&#8217; technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS&#8217; EpiSelect<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>Platform Technology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ProMIS&#8217; scientific foundation is centered on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. Genetic and experimental research in the neuroscience community has demonstrated that propagating, neurotoxic, misfolded proteins (also referred to as prion-like particles or toxic soluble oligomers) are fundamental drivers of multiple neurodegenerative diseases, including AD, MSA, and ALS. ProMIS&#8217; EpiSelect<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> platform technology allows for the identification of conformational epitopes that become exposed on toxic, misfolded forms of a given protein but are not present on the properly folded form of the same protein. Such disease-specific epitopes (DSEs) can then be used to generate therapeutic antibody candidates that selectively target toxic forms of the protein without interfering with essential functions of the healthy protein. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The ability to model protein misfolding <i style="font-style:italic;">in silico</i> to predict target epitopes restricted to toxic, misfolded forms of a protein was a transformational advance for the development of therapeutic antibodies in terms of speed and quality of the antibodies generated. Earlier methods using less defined immunogens, such as synthetic protein aggregates, relied on chance and extensive screening to identify promising antibody clones, and could never quite achieve strict selectivity for the toxic, misfolded protein. The Company first licensed exclusive rights to ProMIS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM </sup>target epitope identification technology from the University of British Columbia (UBC) to predict novel DSEs on the molecular surface of misfolded proteins. ProMIS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is an &#8220;in silico&#8221; rational selection approach that could be applied to any protein where the normal folding structure is at least partially known. The Company subsequently acquired a worldwide license from UBC to EpiSelect<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> a computational algorithm that supersedes ProMIS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, employing thermodynamics and statistical mechanics to model protein misfolding. This proprietary computational discovery platform provides a unique and robust engine to predict DSEs on the molecular surface of misfolded proteins. The amino acid sequence of the toxic, misfolded form and the healthy, properly folded form of a target protein are the same but they differ in their conformation. The ProMIS platform offers the ability to identify targets (conformational epitopes) unique to the toxic, misfolded form. Cyclic peptides containing the conformational epitopes are created and used to immunize mice or rabbits to generate selective monoclonal antibodies (mAbs) that are designed to attack the disease-causing form of the protein without interfering with the healthy form of the same protein. The mAbs raised in animals are humanized (the critical binding regions are inserted into a human antibody framework) for potential use in patients. &#160;We believe the ProMIS approach has the potential to produce more effective and safer antibodies compared to traditional methods of immunization with whole proteins/peptides or aggregates which result in pan-reactive antibodies that cross-react with all forms of a target protein. &#160;The lack of selectivity of such antibodies dilutes their efficacy by binding to non-toxic forms of the protein and can potentially interfere with the function of the properly folded protein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing a pipeline of antibodies aimed at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative diseases without interfering with the essential functions of the same properly folded proteins.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:217.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <img src="pmn-20251231x10k001.jpg" alt="Graphic" style="display:inline-block;height:217.9pt;width:468pt;"/></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Arrows denote the stage of each program</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.15;margin:1.1pt 2.15pt 0pt 2.9pt;">ALS: Amyotrophic lateral sclerosis, FTD: Frontotemporal dementia, PD: Parkinson&#8217;s disease, DLB: Dementia with Lewy bodies, HD: Huntington&#8217;s disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.15;margin:1.1pt 2.15pt 0pt 2.9pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-style:italic;margin-left:0pt;margin-right:0pt;vertical-align:super;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ProMIS&#8217; Objectives for 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company plans to pursue the following key objectives for 2026:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Progression of the PRECISE-AD Phase 1b trial of PMN310 for Alzheimer's disease, maintaining rigorous execution and data integrity. Based on current clinical trial patient visit schedules, the Company expects to complete the six-month assessments in the second quarter of 2026, with the blinded interim analysis anticipated in early third quarter 2026. Completion of dosing and all patient visits is expected in the fourth quarter of 2026, with top-line data anticipated in early 2027 following database lock and statistical analysis.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Strategic Growth and Corporate Visibility: Enhance corporate awareness by engaging strategically with investors and industry stakeholders, while evaluating partnership and business development opportunities that underscore the value of the company's pipeline. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Operational Readiness for Future Success: Strengthen organizational infrastructure and capabilities to support potential clinical milestones and position the company for long-term growth.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">PRODUCT CANDIDATES</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Development of a Therapy for the Treatment of Alzheimer&#8217;s Disease (AD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">AD Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">AD, a progressive neurodegenerative disease, is the most common type of dementia, accounting for approximately 60&#160;&#8211; 80% of all dementia cases. Early symptoms of AD include recent memory loss, as well as apathy and depression. As the disease progresses inexorably, language deterioration, impaired ability to mentally manipulate visual information, poor judgment, confusion, restlessness, and profound mood swings develop. Eventually AD destroys cognition, personality, and the ability to function. The early symptoms of AD, especially at the inaugural stage of mild cognitive impairment </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(MCI), are often missed because they are frequently and mistakenly taken for natural signs of ageing. In 2020, reports concluded that 50% of primary care physicians believed the medical profession was not prepared to meet the expected increase in demands the projected rise in AD and dementia cases will create.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2024, it was estimated there were 6.9 million Americans 65 and older living with AD, and that number is projected to rise to 12.7 million by 2050 (www.alz.org, Alzheimer&#8217;s disease Facts and Figures 2024). In the United States, one in three seniors dies of AD or another dementia, which kills more people than breast cancer and prostate cancer combined. AD is the sixth leading cause of death in the United States, according to the Alzheimer&#8217;s Association. In 2023, AD and other dementias cost the U.S. $592 billion, and those costs are projected to rise with the increasing number of patients. Approximately 11 million Americans are reported to be unpaid caregivers, who in 2022 provided support for patients valued at $339 billion, to people with AD and other dementias.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Historically, a major challenge in AD has been diagnosis. Twenty&#160;years ago, diagnosis of AD could only be confirmed by autopsy. Consensus guidelines have since been developed that established new diagnostic criteria&#160;&#8212; A/T/N. The methods used are based on sophisticated approaches to brain imaging: amyloid positron emission tomography (PET) scans measuring amyloid plaque as a proxy for pathology, tau PET scans measuring tau tangles as a proxy for pathology, and cortical magnetic resonance imaging measuring cortical atrophy as a measure of neurodegeneration. Each of these tests costs thousands of dollars, affordable perhaps to diagnose patients for a clinical trial, but not practical for screening millions of people who might be at risk or have pre-symptomatic AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are now blood-based biomarkers (diagnostic assays) that can provide information that correlates with expensive A/T/N imaging. Plasma levels of ptau 217 and ptau 181 (tau protein phosphorylated at amino acids 217 and 181 respectively) correlate with brain imaging measures, AD diagnosis, and disease progression (Mattson et al. JAMA 2023, Jack et al. Brain 2023, Therriant et al. JAMA 2023). These advances have implications for ProMIS&#8217; strategy. Better diagnostics can facilitate more efficient clinical trials, both in terms of identifying potential subjects for the trial and also detecting a potential treatment effect in early, small trials. Secondly, the ability to diagnose disease prior to symptoms raises the possibility of preventive treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">According to the World Alzheimer Report 2022, the current dementia market comprises two product categories, namely, AChE inhibitors and N-methyl-D-aspartate receptor antagonists. AChE inhibitors dominate the market. The overall market is dominated by four leading brands&#160;&#8212; Aricept, Namenda, Exelon and Ebixa. Aricept, whose active ingredient is an AChE inhibitor, holds the largest market share. North America was the largest market for AD drugs in 2019, accounting for approximately 35% of total worldwide AD pharmaceutical sales in that&#160;year. Three mAbs (Aduhelm, Leqembi, Kisunla) were approved from 2021 to 2024, which creates a third category of marketed AD treatments, and the first to be considered disease modifying. Aduhelm was approved in 2021 under the U.S. Food and Drug Administration&#8217;s (FDA) Accelerated Approval pathway but commercialization was discontinued in January 2024. &#160;Leqembi and Kisunla received traditional approval in 2023 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although there is no scientific consensus on the causation of AD or method of action to treat AD, evidence from some genetic and preclinical studies suggests a causative role for A&#946; in the pathogenesis of AD. Published genetic studies support a direct link between increased levels of A&#946; and disease susceptibility. Research suggests that genetic mutations in the A&#946; precursor protein (APP) and in the presenilin 1 and 2 genes responsible for familial forms of early onset AD all result in increased production of A&#946; and A&#946; aggregates (<i style="font-style:italic;">Citron et al, 1992; Borchelt et al, 1996</i>). Down Syndrome patients with three copies of the APP gene on chromosome 21 also have elevated levels of APP and A&#946; deposits and often develop AD at a premature age (<i style="font-style:italic;">Podlisny et al, 1987</i>). A&#946; brain concentration can also increase due to age associated reduction of clearance. Along the same lines, the APOE4 allele, which has been linked to an increased risk of late onset AD, is associated with increased A&#946; deposit, while the APOE2 allele, which has been linked to a decreased risk, is associated with decreased A&#946; levels (<i style="font-style:italic;">Holtzman et al, 2012</i>). Finally, the only known protective mutation against AD is found in the APP gene and research suggests that this leads to a reduction in the formation of A&#946; (<i style="font-style:italic;">Jonsson et al, 2012</i>). In a preclinical study, it was reported that intracerebral injection of A&#946;-containing brain extracts from human AD patients into susceptible mice induced cerebral amyloidosis and associated pathology. Depletion of A&#946; from the extracts reversed this activity, supporting a link between A&#946; and disease induction (<i style="font-style:italic;">Meyer-Luehmann et al, 2006</i>).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:105.73pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the presence of A&#946; plaque is a distinguishing feature of AD, there is a growing body of scientific evidence that the synaptic loss and neurodegenerative spread of AD is primarily mediated by soluble oligomers of misfolded A&#946; rather than plaque (<i style="font-style:italic;">Cleary et al, 2004; Jin et al, 2011</i>). Reports from several groups indicate that plaque burden correlates poorly with memory impairment (<i style="font-style:italic;">Cleary et al, 2004; Ferreira et al, 2015</i>) and insoluble A&#946; fibrils show little or no demonstrable toxicity <i style="font-style:italic;">in vitro </i>or <i style="font-style:italic;">in vivo </i>(<i style="font-style:italic;">Balducci et al, 2010; Shankar et al, 2008</i>). In contrast, a significant correlation between disease severity and levels of soluble A&#946; in the central nervous system was reported by Lue et al (<i style="font-style:italic;">Lue et al, 1999</i>), and the direct neurotoxicity of soluble A&#946; oligomers was demonstrated in neuronal cultures in vitro by separate groups (<i style="font-style:italic;">Lauren et al, 2009; Jin et al, 2011</i>). In published reports using rodent models, the injection of soluble oligomeric A&#946;, but not soluble monomers or plaque, was shown to induce synaptic damage and cognitive dysfunction (<i style="font-style:italic;">Cleary et al, 2005; Hong et al, 2016).</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Figure 1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k003.jpg" alt="Graphic" style="display:inline-block;height:105.73pt;width:276.71pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Synaptotoxicity of A<span style="font-family:'Symbol';">b</span> oligomers on hippocampal neurons in vitro (<i style="font-style:italic;">Lacor et al, 2007, J Neuroscience</i>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The mechanism by which soluble oligomeric A&#946; generates neuronal damage contributing to AD has been well-studied. A convergence of evidence from multiple studies suggests that the progressive nature of AD arises from the formation and spread of a prion-like subset of misfolded oligomers of A&#946; that adopt a &#946;-sheet-rich conformation transmissible to native A&#946; in a template-like manner. The self-propagation of these prion-like oligomers follows the stereotypical progression of AD, with initial involvement of the enthorhinal cortex followed by spreading to the hippocampus and neocortex as described by Khan et al (<i style="font-style:italic;">Khan et al, 2014</i>). The prion-like spread of A&#946; oligomers has been well-documented in animal models by different groups following the injection of purified oligomers or brain extracts from AD patients or diseased animals (<i style="font-style:italic;">Cleary et al, 2005; Meyer-Luehmann et al, 2006; Watts et al, 2014; Hong et al, 2016</i>). There is also <i style="font-style:italic;">in vitro </i>evidence that such misfolded &#8220;A&#946; prions&#8221; from AD brain can catalyze the misfolding and hyperphosphorylation of tau, another protein involved in the pathogenesis of AD as reported by Jin et al (<i style="font-style:italic;">Jin et al, 2011</i>). Targeting of A&#946; oligomers therefore represents an attractive strategy to inhibit progression of the neurodegenerative A&#946;-tau cascade (<i style="font-style:italic;">Choi et al, 2015; Khan et al, 2014</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">PMN310</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS&#8217; lead therapeutic program is PMN310, a mAb designed to treat AD by selectively targeting the toxic misfolded form of A&#946;. Based on the understanding of A&#946; biology described above, PMN310 was designed to be more selective for the toxic oligomer of amyloid than other anti-A&#946; antibodies such as aducanumab from Biogen, lecanemab, co-developed by Eisai Co. and Biogen, donanemab from Lilly, ACU193 from Acumen and the Prothena PRX012 antibody. These antibodies bind oligomers, which could account for the efficacy seen by the marketed drugs, but they also appear to bind plaque, which may result in a higher incidence of ARIA (E and H). This off-target binding of plaque may limit the benefit of treatment by both limiting the highest dose that can be safely administered and by &#8220;wasting&#8221; a substantial portion of the administered antibody which binds plaque, reducing what is available to neutralize the toxic oligomers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Recent clinical trial results show that antibodies that bind A&#946; monomers (bapineuzumab, solanezumab, crenezumab, gantenerumab) are not efficacious in AD (<i style="font-style:italic;">Salloway et al, 2014, NEJM;</i> <i style="font-style:italic;">Carlson et al, 2016, Alzheimer&#8217;s and Dementia; Ostrowitzki et al, 2022, JAMA Neurol;https://www.roche.com/media/releases/med-cor-2022-11-14</i>), suggesting that high selectivity for low abundance toxic A&#946;O is desirable to prevent mAbs from being consumed by unproductive binding to non-pathogenic, abundant monomers (target distraction). Other antibodies with reduced binding to monomers and more </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">selectivity for aggregated A&#946; have produced more promising results, including aducanumab (Aduhelm), lecanemab (Leqembi) and donanemab (Kisunla), which received approval from the FDA. However, treatment with all of these antibodies was associated with the dose-limiting adverse events of ARIA-E (brain edema) and ARIA-H (microhemorrhages) correlated with binding to insoluble deposits of A&#946; in the vasculature and plaque. We believe that a selective, oligomer-specific antibody that does not bind monomers or plaque could circumvent these issues and potentially provide an improved product profile with enhanced efficacy. Results of our analysis of the binding response of A&#946;-directed antibodies were presented at the Alzheimers&#8217;s Association International Conference and the American Academy of Neurology in 2023 and published in 2025 (<i style="font-style:italic;">Kaplan et al, 2025, Alzheimer&#8217;s Dement. 2025, &#160;</i>http://dx.doi.org/10.1002/trc2.70184). All antibodies showed some binding signal to toxic A&#946;O from human brain extracts but target distraction by monomers abolished or reduced binding. Only the antibodies that retained measurable binding to oligomers (aducanumab, donanemab and lecanemab) in the face of competition by monomers have shown improvement on cognitive endpoints in previous clinical trials, and that improvement was modest. In our analysis, PMN310 avoided monomer target distraction, with the smallest&#160;percent inhibition of binding to brain oligomers when compared to other A&#946;-directed antibodies. We believe these data support the therapeutic potential of PMN310.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Development of PMN310 began with using the ProMIS computational platform, which produced <i style="font-style:italic;">in silico</i> six different conformational epitopes as potential targets exposed on toxic misfolded A&#946;O but not A&#946; monomers or plaque. The use of A<span style="font-family:'Symbol';">b</span>O-restricted epitopes as the immunogen to generate antibodies is drastically different from the conventional immunization methods used by others. &#160;Immunization with A<span style="font-family:'Symbol';">b</span> peptide or synthetic aggregates used by others to generate A<span style="font-family:'Symbol';">b</span>-directed antibodies virtually always results in non-selective antibodies that react not only with oligomers but also to varying degrees with monomers and plaque. In contrast, mAbs raised against cyclic peptides containing our predicted A<span style="font-family:'Symbol';">b</span>O conformational epitopes displayed selectivity for A&#946; oligomers vs monomers or plaque, and inhibited A&#946;O toxicity and propagation <i style="font-style:italic;">in vitro</i>. The Company designated the PMN310 antibody as its lead candidate for development in AD. As described in our published preclinical studies (<i style="font-style:italic;">Gibbs et. al., 2019, Scientific Reports</i>), PMN310 displayed the desired selective profile with binding to synthetic A&#946;O and little or no binding to A&#946; monomers as determined by surface plasmon resonance (SPR), and no detectable binding to plaque or vascular deposits in AD brain sections as determined by immunohistochemistry (IHC). In SPR studies with brain extracts from multiple individuals who died of AD, PMN310 also showed binding to fractions containing the toxic A<span style="font-family:'Symbol';">b</span>O species suggesting that PMN310 can recognize an A&#946;O epitope shared across AD brains. <i style="font-style:italic;">In vitro</i>, PMN310 inhibited A&#946;O propagation in a thioflavin-T (ThT) based assay measuring the formation of A&#946; aggregates with a beta-sheet structure over time (<i style="font-style:italic;">Gibbs et al, 2019, Scientific Reports</i>). PMN310 also reduced the killing of primary mouse neurons by toxic A&#946;O in culture (Fig.1). <i style="font-style:italic;">In vivo</i>, the activity of murine PMN310 was tested in two different models. In one model conducted at SynAging (Vandoeuvre-les-Nancy, France), PMN310 and a preparation of toxic A&#946;O were co-delivered (mAb:A&#946;O ratio of 2:1) by intracerebroventricular (ICV) injection into male, 3-month old, wild-type C57Bl6/J mouse to determine whether PMN310 might improve cognitive performance and molecular markers in this model of A&#946;O-induced neurotoxicity. Treatment groups consisted of day 0 ICV injection of vehicle alone, A&#946;O alone, vehicle with PMN310 or A&#946;O with PMN310, and contained 12 mice per group to achieve statistical significance. Cognitive performance was assessed on&#160;days 7&#160;&#8211; 8 using the novel object recognition (NOR) assay. Mice were sacrificed and perfused on day 10, the hippocampus was isolated and levels of synaptic (PSD-95, SNAP25) and inflammation (TNF-&#945;) markers were measured by ELISA in hippocampal homogenates from individual mice. A&#946;O-injected mice failed to recognize a new object and displayed a discrimination index of 0 or less. Co-injection of PMN310 with the toxic oligomers prevented this cognitive deficit. As expected, ICV injection of PMN310 alone had no effect (Fig. 2). The cognitive deficit induced by ICV injection of A&#946;O was associated with inflammation and synaptic damage in the hippocampus, a region important in the development of memory. Hippocampal homogenates from A&#946;O-treated mice displayed an increase in levels of TNF-&#945; and decreases in PSD-95 and SNAP25. Partial protection from these changes was observed in mice co-injected with synthetic A&#946;O and PMN310.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:172.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k004.jpg" alt="Graphic" style="display:inline-block;height:171.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:380.25pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 2. Administration of PMN310 to mice prevented the loss of short-term memory formation caused by toxic A&#946;O.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">*p&lt;0.05 vs Vehicle, <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup>p&lt;0.05 vs A&#946;O. Discrimination index = (time exploring new object&#160;&#8211; time exploring familiar object)/total exploration time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a second <i style="font-style:italic;">in vivo</i> model conducted at reMYND (Leuven, Belgium), the potential effect of treatment with murine PMN310 (mouse IgG2a) was tested in the transgenic (Tg) hAPP[V717I] mouse model of AD. Characterization of the model indicates that these hAPP-Tg mice display spontaneous, progressive accumulation of A&#946; in the brain, eventually resulting in amyloid plaques around 10-11&#160;months of age. In the pre-plaque stage of the pathology, there is a clear cognitive and long-term synaptic potentiation (LTP) deficit in these mice suggesting that impairment is caused by soluble toxic species such as A&#946;O rather than plaque. The aim of the study was to assess the impact of seven weekly doses of PMN310 administered intraperitoneally (i.p.) at 30 mg/kg to female mice, beginning at 5.0&#160;months of age. Experimental groups consisted of hAPP-Tg mice treated with vehicle or PMN310, and non-Tg, age-matched littermates treated with vehicle as a control, with 17 mice per group to achieve statistical significance. Spatial learning and memory performance were assessed using the Morris Water Maze task at 6.4&#160;months of age (after seven doses of antibody) which measures the ability of mice to learn and remember the location of a hidden platform in a pool of water. Compared to non-Tg littermates, the hAPP-Tg mice were significantly impaired and showed an increase in both escape latency (time required to find the hidden platform, p=0.0024) and the search path or distance traveled to reach the platform (p=0.0047). Treatment of hAPP-Tg mice with PMN310 significantly improved these outcomes with a decrease in escape latency (p=0.0187) and search path (p=0.0071) (Fig. 3).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:141.73pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pmn-20251231x10k005.jpg" alt="Graphic" style="display:inline-block;height:141.73pt;width:485.18pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 3. Systemic administration of PMN310 provides a cognitive benefit in a mouse model of AD (hAPP[V717I] Tg mice)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PMN310 brain exposure and kinetics after systemic i.p. administration were assessed in mice (<i style="font-style:italic;">Gibbs et. al., 2019, Scientific Reports</i>). The results suggested that PMN310 is comparable to other therapeutic mAbs and is able to cross the blood-brain barrier to reach its target, an observation supported by the human Phase 1a trial. The Company believes that the greater selectivity of PMN310 for A&#946;O may result in greater neutralization of this disease-causing species (no target distraction) compared with A&#946; antibodies derived from immunization with synthetic aggregates. By avoiding plaque binding, PMN310 may also lower the risk of the ARIA adverse events that have been reported associated with plaque-binding antibodies and allow for higher doses to treat the dementia. This premise is supported by preclinical toxicology studies in which weekly dosing of a murine IgG2a version of PMN310 in plaque-bearing knock-in APP<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SAA</sup> mice at 800 mg/kg for 26 weeks did not cause brain hemorrhages (ARIA-H) upon microscopic examination using Perls&#8217; Prussian Blue staining to detect the presence of hemosiderin (<i style="font-style:italic;">Kaplan et al, 2025, Alzheimer&#8217;s Dement. </i><i style="font-style:italic;">2025, &#160;</i>http://dx.doi.org/10.1002/trc2.70184).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">The Company has conducted a toxicology study following Good Laboratory Practice (GLP) guidelines in cynomolgus monkeys. PMN310 was administered as a 30-<span style="white-space:pre-wrap;">minute intravenous (IV) infusion, on a weekly basis (Days 1, 8, 15, 22, and 29), at dose levels of 0, 200, 500, and 1,200 mg/kg/day. Administration of PMN310 was not associated with any adverse effects on clinical observations (local or systemic), body weight, food consumption, ECG, or hematology, coagulation, or urinalysis endpoints.  No organ weight effects, macroscopic observations, or microscopic observations were attributed to PMN310 treatment at any doses. PMN310-related changes in clinical chemistry parameters were limited to mildly to moderately increased globulins (1.31x-2.00x) at 1200 mg/kg on Days 2 and 30 likely resulting from circulating PMN310 given one day prior.  Based on the results of this study, the PMN310 NOAEL was considered to be 1,200 mg/kg/day in nonhuman primates when administered as a weekly 30-minute IV infusion over four weeks, which is five times higher than the comparable dose in humans that will be used in our Phase 1 trials. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical Development Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">The Company successfully manufactured PMN310 clinical supply under cGMP conditions and received clearance on its Investigational New Drug (IND) application with the FDA in May 2023 to initiate a Phase 1a clinical trial of PMN310. The Phase 1a trial was initiated in November 2023 as a placebo-controlled single ascending dose (SAD) trial in healthy volunteers testing single intravenous doses of PMN310 escalating from 2.5 to 40 mg/kg in 2-fold increments (NCT06105528). Each dosing cohort consisted of 6 drug-treated and 2 placebo-treated subjects. &#160;Results from all cohorts were presented at the Clinical Trials on Alzheimer&#8217;s Disease Alzheimer Congress in October 2024. PMN310 was well-tolerated and there were no adverse events that precluded dose escalation. PMN310 crossed the blood brain barrier in a dose dependent manner with kinetics suggesting that monthly dosing can provide levels of PMN310 adequate for target engagement. The results informed dose selection for the Phase 1b, multiple ascending dose (MAD) study in patients with mild cognitive impairment due to AD or early AD. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">Initiation of the Phase 1b PRECISE-AD trial (NCT06750432) commenced in December 2024 and was announced in early January 2025.  In July 2025, PMN310 was granted Fast Track designation by the FDA. The ongoing PRECISE-AD </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">trial is a randomized, double-blind, placebo-controlled, MAD study of PMN310 to evaluate safety, tolerability,  pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple intravenous infusions of PMN310 in patients with early Alzheimer's disease. The study will also evaluate key biomarkers and clinical measures of efficacy to gather data on PMN310&#8217;s therapeutic potential. Enrollment in the PRECISE-AD study was completed in December 2025 with 144 subjects enrolled across 21 active sites in the United States. The subjects are dosed monthly at one of three dose levels (5, 10, 20 mg/kg) or placebo over 12 months with assessment of safety, tolerability, PK, and pharmacodynamic blood-and CSF-based biomarkers of treatment effect at baseline and every three months. Frequent MRI scans throughout the study are being conducted to monitor for any emergence of ARIA. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">To date, PMN310 has demonstrated a generally favorable safety profile, with limited patient discontinuations and no treatment-related serious adverse events (SAEs) reported during the trial. Based on current clinical trial patient visit schedules, the Company expects to complete the six-month assessments in the second quarter of 2026, with the blinded interim analysis anticipated in early third quarter 2026. Completion of all patient visits is expected in the fourth quarter of 2026, with top-line data anticipated in early 2027 following database lock and statistical analysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Safety will be a primary outcome with particular emphasis on assessing the expectation that, as a non-plaque binder, PMN310 will have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. The study has been designed with a sample size intended to provide sufficient power to provide meaningful insight into effects of PMN310 on biomarkers and clinical outcomes. PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against toxic A&#946; oligomers on biomarkers associated with AD pathology and clinical outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Development of a Therapy for the Treatment of Amyotrophic Lateral Sclerosis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ALS Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig&#8217;s Disease, is a progressive neurodegenerative disease that causes muscle weakness, paralysis and, ultimately, respiratory failure leading to death. ALS attacks randomly, and occurs throughout the world with no racial, ethnic or socioeconomic boundaries. It is estimated there are currently 30,000 people in the United States and 450,000 people worldwide, suffering from ALS, with approximately 5,000 new cases arising in the United States annually. Patients with ALS present symptoms such as progressive weakness, muscle atrophy and spasticity. These neurodegenerative and neuromuscular symptoms arise due to the ultimate degeneration of motor neurons in the spinal cord, the brain stem and in the brain cortex. Incurable and usually fatal within five&#160;years, ALS gradually robs a patient of the ability to walk, talk and breathe. Currently, there is no confirmatory test for ALS and many people go undiagnosed at early phases of the disease. Approximately two-thirds of those afflicted by ALS are currently undergoing some form of symptomatic treatment. There are no therapies approved that halt or significantly slow progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biological mechanisms that cause ALS are only partially understood. Misfolded, aggregated TDP-43 forming inside neurons has been implicated in the pathogenesis of ALS (as well as frontotemporal lobe dementia or FTLD, and limbic-predominant age-related TDP-43 encephalopathy or LATE) through direct toxicity, loss of function of normal TDP-43, induction of misfolding of other neuronal proteins, and prion-like, cell-to-cell propagation of disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Experimentally, misfolded aggregates of TDP-43 are toxic to neural cells, and the prion-like propagation of TDP-43 aggregates has been demonstrated in cell culture and animal models. Importantly, misfolded TDP-43 has been found to induce the misfolding of other proteins into pathogenic aggregates (e.g., SOD1, nuclear pore proteins and transport proteins, DISC1), such that targeting misfolded TDP-43 potentially represents an opportunity to not only neutralize TDP-43 pathology but also interrupt this pathogenic interactome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PMN267</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Using the ProMIS discovery platform, we identified epitopes present on misfolded TDP-43 and generated high affinity antibodies (Fig. 4) that selectively recognized misfolded cytoplasmic aggregates of TDP-43 with no detectable interaction with normal TDP-43. &#160;Normal TDP-43 is located in the nucleus and is important for normal cell function (Fig. 5). The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:241.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">antibodies recognized and stained pathogenic TDP-43 aggregates in spinal cord sections from ALS patients and brain sections from FTLD patients (immunohistochemistry) indicating that they have the potential to target disease-causing TDP-43. <i style="font-style:italic;">In vitro </i>data showed that such antibodies can inhibit the cell-to-cell transmission of misfolded TDP-43 in the extracellular space thereby offering the potential to inhibit spreading of pathology (Fig. 6).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k006.jpg" alt="Graphic" style="display:inline-block;height:241.5pt;width:450pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 4. High affinity mAbs. In Surface Plasmon Resonance (SPR) studies, serial dilutions of test mAbs were flowed over the target epitope immobilized on sensorchips to assess the binding kinetics and affinity. Binding curves were fitted to a Langmuir 1:1 interaction model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k007.jpg" alt="Graphic" style="display:inline-block;height:129.73pt;width:417.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fig. 5. Selective binding of mAb to misfolded, cytoplasmic aggregates of TDP-43. Staining of HEK293 cells transfected with mutant TDP-43 shows cytoplasmic aggregates of misfolded TDP-43 (red). Staining of the same cells with a PMN mAb (green) shows co-localization with TDP-43 aggregates with no staining of endogenous, normal TDP-43 in the nucleus (nuclei stained blue).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:186pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k008.jpg" alt="Graphic" style="display:inline-block;height:186pt;width:450pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 6. Inhibition of cell-to-cell transmission of misfolded TDP-43 by mAbs. Supernatant from HEK293 cells transfected with misfolding mutant TDP-43 was incubated with test antibodies and added to na&#239;ve recipient cells to assess transmission of misfolding TDP-43 (HA-tagged). Compared to a mouse IgG1 negative control (mIgG1), several mAbs inhibited transmission to recipient cells as determined by a reduction in the density of the HA band on a Western blot of recipient cell lysate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A complementary approach is to target intracellular TDP-43 to reduce toxic gains-of-function within the cell by generating intrabody versions of the TDP-43 antibodies. Intrabodies (from intracellular and antibody) are expressed from within the cell and were designed to target intracellular aggregates of TDP-43. Testing indicated that intrabodies expressed inside HEK293 cells associated selectively with pathogenic aggregates of TDP-43 in the cytoplasm (Fig. 7) and promoted degradation of the aggregates without affecting normal TDP-43 function or harming the cells (Fig. 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 7</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k009.jpg" alt="Graphic" style="display:inline-block;height:150.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:450pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 7. Co-localization of intrabody with misfolded, cytoplasmic aggregates of TDP-43. Staining of HEK293 cells co-transfected with mutant TDP-43 (green) and plasmid encoding a PMN intrabody (red) shows co-localization of the two. There was no interaction of the intrabody with endogenous, normal TDP-43 in the nucleus (nuclei stained blue).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:193.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 8</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k010.jpg" alt="Graphic" style="display:inline-block;height:192.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:285pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 8. Clearance of TDP-43 aggregates by intrabody. Transfection of HEK293 cells with a ProMIS intrabody results in degradation of HA-tagged mutant TDP-43 (dNLS) aggregates as measured by reduction in the density of the HA band on a Western blot of cell lysate compared to an empty vector (EV) control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These results support the potential for using a mAb to selectively target and protect against pathogenic TDP-43. We believe an extracellular antibody could be used to interfere with the cell-to-cell spread of misfolded aggregates of TDP-43 in the extracellular space and slow disease progression. &#160;An intrabody construct delivered inside the cells via viral vectors used alone or in combination could be used to degrade intracellular aggregates and prevent further propagation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The mAbs for TDP-43 generated using the ProMIS platform were tested for selective reactivity with misfolded TDP-43 aggregates and protective activity. Screening of multiple mAbs yielded PMN267 as the lead candidate exhibiting the desired properties. PMN267 bound its target epitope with high affinity in the 10E-11M range. In a cell system, PMN267 showed selective recognition of misfolded, cytoplasmic TDP-43 aggregates and no detectable interaction with endogenous normal TDP-43 in the nucleus. Similarly, PMN267 did not react with TDP-43 in stress granules, which are important in protection against oxidative stress. PMN267 also showed binding to exosomes derived from the brains of deceased FTLD individuals. Systemic IP delivery of PMN267 was tested in a transgenic mouse model of ALS/FTLD. In this model, doxycycline-regulated expression of human &#916;NLS-TDP-43 is under control of the neurofilament heavy chain promoter such that progression of disease is driven by intracellular expression of aggregating &#916;NLS-TDP-43 in all neurons, with little or no contribution of cell-to-cell spread of aggregates. In this aggressive model, a trend for improvement was observed with PMN267 treatment (30 mg/kg/week for 9 weeks) in the majority of motor function read-outs evaluated, including hind limb clasping, hind limb paralysis, grill test of agility, paw coordination, and footfall pattern. We believe the results suggest evidence of protection against motor function deficits by systemic, extracellular delivery of PMN267. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An intrabody version of PMN267 (single chain antibody sequence encoded into a plasmid) expressed from within cells showed co-localization with cytoplasmic aggregates of TDP-43 and no detectable binding to normal, nuclear TDP-43. Expression of the intrabody promoted degradation of misfolded TDP-43 aggregates in the HEK293 cell system by approximately 58% (Fig. 7). <i style="font-style:italic;">In vitro </i>studies were also performed in collaboration with Dr.&#160;Gene Yeo at University of California, San Diego using iPSC-derived motor neurons from ALS patients, the cell type predominantly affected in ALS. In these studies, neurons transduced with vectorized PMN267 intrabody or a control protein (luciferase) were subjected to prolonged stress by puromycin-induced suppression of protein synthesis for 24 hours, giving rise to TDP-43 aggregates that persisted after another 24 hours of recovery. Neurons expressing PMN267 intrabody compared to control protein showed a 30-60% reduction in the amount of stress-induced TDP-43 aggregates as quantitated by high-content imaging. The Company believes that the observed selectivity of PMN267 for misfolded TDP-43 and avoidance of normal TDP-43 has the potential to allow for inhibition of disease without compromising essential TDP-43 function. PMN267 has been </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">humanized in a human IgG1 framework for IND-enabling studies to support the systemic, extracellular administration form. Development of the intrabody form would involve collaboration with a partner with expertise in viral vectorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Development of a Therapy for synucleinopathies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Strong genetic and experimental evidence supports a causative role for alpha-synuclein (a-syn) in the pathogenesis of several progressive neurodegenerative disorders known collectively as synucleinopathies, including Parkinson&#8217;s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) (<i style="font-style:italic;">Brundin et al, 2017, Exp Neurol; Lashuel et al, 2013, Nat Rev Neurosci</i>). Current evidence indicates that a-syn pathogenicity resides primarily with soluble, misfolded aggregates of the protein. &#160;In particular, oligomers and small soluble fibrils/protofibrils of a-syn have been reported to mediate neurotoxicity and progression of disease (<i style="font-style:italic;">Fusco et al, 2017, Science; Bengoa-Vergniory et al, 2017, Acta Neuropathol)</i>. &#160;In contrast, a-syn monomers and insoluble fibrils appear to carry little or no direct toxicity (<i style="font-style:italic;">Fusco et al, 2017, Science).</i> &#160;Lewy bodies and Lewy neurites containing insoluble fibrillar deposits of a-syn are characteristic of disease but have actually been proposed to serve a protective role by sequestering toxic, misfolded aggregates of a-syn away from the cellular machinery (<i style="font-style:italic;">Bengoa-Vergniory et al, 2017, Acta Neuropathol)</i>. &#160;Selective targeting of pathogenic forms of a-syn with antibodies represents an attractive therapeutic strategy. &#160;The advantage of selective antibodies, as opposed to a pan a-syn targeting approach, lies in preserving normal a-syn function and minimizing the diversion of active antibody from the target by non-toxic forms of the protein. &#160;By avoiding binding to abundant a-syn monomers in the blood and brain interstitial fluid, selective antibodies have the potential to achieve greater therapeutic effectiveness and reduce the risk of infusion reactions. Our candidate antibody targeting misfolded a-syn has the potential to be used across synucleinopathies sharing the same basic a-syn-driven pathogenesis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PD<span style="white-space:pre-wrap;"> is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons located in the midbrain and the presence of intraneuronal inclusions (Lewy bodies/Lewy neurites) consisting mainly of aggregates of a-syn.  Typical disease symptoms include tremors, rigidity, bradykinesia and postural instability.  The average age of onset is typically early to mid 60&#8217;s and it is estimated that over 1.1 million people in the U.S. and over 8.5 million worldwide are affected by the disease (</span><i style="font-style:italic;">parkinson.org/understanding-parkinsons/statistics</i><span style="white-space:pre-wrap;">).  There is no cure for PD but several drugs are used to mitigate motor symptoms including dopamine, dopamine agonists, drugs that inhibit dopamine break-down and anticholinergics. While initially effective, symptoms can reappear as disease progresses.  Deep brain stimulation using an electrode surgically implanted into brain tissue is also approved to treat dyskinesia, typically in patients who initially respond to dopamine treatment but develop symptoms despite drug therapy. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">DLB is a progressive neurodegenerative disease characterized by deposits of insoluble a-syn fibrils (Lewy bodies, Lewy neurites) in the brainstem, limbic system and cerebral cortex leading to cognitive deficits, visual hallucinations and movement disorders. &#160;DLB affects approximately 1.0-1.4 million people in the U.S. with symptoms typically manifesting after age 50 (<i style="font-style:italic;">medlineplus.gov/genetics/condition/dementia-with-lewy-bodies</i>). &#160;There is no cure and life expectancy is typically 5-8 years after diagnosis. &#160;Treatment is limited to managing symptoms including cholinesterase inhibitors to improve cognition, dopamine for motor symptoms and antipsychotics in some cases.MSA is a rare neurodegenerative disease with an estimated prevalence of 3.4&#160;&#8211; 4.9 cases per 100,000 population. MSA is characterized by rapidly progressive autonomic failure and motor symptoms with predominant parkinsonian features (MSA-P) or dominant cerebellar features (MSA-C). There is no effective treatment and the mean survival from the onset of symptoms is 6&#160;&#8211; 10&#160;years. Histologically, the disease is characterized by a-syn aggregates in the cytoplasm of oligodendrocytes and, to a lesser extent, in neurons and other glial cells. <span style="color:#3f3f3f;">A-syn aggregates from MSA brain homogenates have been demonstrated to </span>cause MSA-like neurodegeneration in mice. The characteristics of MSA, although devastating for the patients, present several advantages for clinical development: disease progression is rapid allowing for earlier detection of therapeutic potential; high levels of neurofilament light chain (NfL) in serum represent a potential biomarker for inhibition of neuronal damage; and no placebo effects have been observed in clinical trials to date. Even though MSA is a rare disease, recruitment for clinical trials of other candidates has been facilitated by the unmet need and existence of a global MSA Registry (GLOMAR), along with supporting organizations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:102pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is an urgent unmet medical need for the development of therapies against synucleinopathies. &#160;Selective targeting of pathogenic a-syn species with our candidate has the potential to provide a clinical benefit where no satisfactory safe and effective options currently exist. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">PMN442</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Multiple studies indicate that pathogenic aggregates of a-syn can propagate from cell-to-cell in a prion-like manner causing progressive neuronal damage and disease symptoms. Using the ProMIS platform, several conformational epitopes were identified as likely to become exposed on misfolded, pathogenic forms of a-syn (toxic oligomers and soluble seeding fibrils). MAbs were raised against these epitopes and were tested for the desired binding profile and ability to protect neurons against toxic a-syn species <i style="font-style:italic;">in vitro</i>. &#160;Traditional methods are unable to generate antibodies with adequate precision to selectively target these neurotoxic forms of a-syn. ProMIS used its proprietary technology platform for generating and developing antibodies that can uniquely and precisely target these specific toxic forms. &#160;As illustrated in figure 9, ProMIS mAbs showed the ability to selectively bind the pathogenic forms of a-syn (toxic oligomers and small soluble fibrils) but not a-syn monomers that play an important functional role in the brain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 9</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k011.jpg" alt="Graphic" style="display:inline-block;height:101.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:450pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 9. Selectivity of mAbs for pathogenic species of a-syn. The binding response of a representative mAb to various concentrations of a-syn monomers, toxic oligomers and soluble fibrils (sonicated PFFs) measured in a Millipore immunoassay. Mean <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">+</span> SD of triplicates shown with the calculated lower limit of quantitation (LLOQ) for each species.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Multiple mAbs were screened and PMN442 emerged as the lead candidate and PMN411 as a back-up with the desired characteristics for this program. As measured by surface plasmon resonance (SPR), PMN442 showed robust binding to toxic a-syn oligomers and seeding fibrils, with negligible binding to a-syn monomers and physiologic tetramers which are required for normal neuronal function (Figure 10). PMN442 also reacted with native toxic a-syn present in brain homogenates from individuals with MSA and DLB (Figure 11).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:195.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k012.jpg" alt="Graphic" style="display:inline-block;height:195.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:284.96pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 10. Selective binding of PMN442 to pathogenic species of a-syn by SPR. &#160;The binding response of immobilized PMN442 to a-syn monomers, toxic oligomers, soluble (seeding) preformed fibrils (PFFs) and physiologic (Phys.) tetramers was measured by SPR. &#160;The same pattern of binding was observed in 4 independent experiments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 11</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k013.jpg" alt="Graphic" style="display:inline-block;height:137.98pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:409.44pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 11. Binding to native pathogenic a-syn species in patient brain extract. The binding response of immobilized PMN442 to a-syn in brain extract from dementia with Lewy bodies (DLB) (A)&#160;and MSA (B)&#160;patients was measured by SPR. A pan a-syn reactive antibody and mouse IgG1 (mIgG1) were used as controls. Results shown are the mean <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">+</span> SEM of two (A)&#160;or four (B)&#160;independent studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In activity assays, PMN442 protected rat dopaminergic neurons against neuronal death by a-syn toxic oligomers (Figure 12). In separate assays, PMN442 also inhibited the processes involved in the cell-to-cell propagation of a-syn aggregates: it reduced the uptake of human a-syn seeding fibrils by neurons and the subsequent formation of intracellular aggregates, as well as the recruitment of endogenous normal a-syn into those aggregates (Figure 13). Taken together, these results support the potential of PMN442 to selectively target and protect against a-syn pathogenic species in patients with MSA and other synucleinopathies. PMN442 has been humanized in a human IgG1 framework for advancement to IND-enabling studies. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:147.73pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 12</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k014.jpg" alt="Graphic" style="display:inline-block;height:139.48pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:371.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fig. 12. Protection against neurotoxicity. PMN442 inhibition of oligomer toxicity for dopaminergic neurons. Cultures of primary rat dopaminergic neurons were exposed to toxic a-syn oligomers with or without PMN442. Survival is expressed as the&#160;percentage of viable neurons compared to a control culture with vehicle only (CTL). Results shown are the mean <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">+</span> SEM of 6 replicate cultures. BDNF was used as a positive control. # p = 0.0004 vs. CTL, *p <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&lt;</span> 0.002 vs. a-synO, **p <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&lt;</span> 0.003 vs. a-synO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 13</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k015.jpg" alt="Graphic" style="display:inline-block;height:147.73pt;width:249.71pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fig. 13. Inhibition of seeding activity. PMN442 inhibition of the recruitment of endogenous rat a-syn into phosphorylated aggregates. Cultures of primary rat hippocampal neurons were exposed to soluble human a-syn preformed fibrils (PFF) with or without PMN442. CTL = neurons incubated with vehicle alone. Results are expressed as a&#160;percentage of the phosphorylated rat a-syn staining area with PFF alone and show the mean <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">+</span> SEM of 6 replicate cultures. *p&lt;0.02 vs PFF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">DEVELOPMENT PROGRAMS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expansion to Include Other Neurodegenerative and Misfolded Protein Diseases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The ProMIS discovery platform is being applied to other toxic misfolded proteins that drive disease including DISC1 in schizophrenia, and RACK1 in ALS in order to potentially generate antibody therapies for these disorders. Under disease conditions, misfolding of each of these proteins leads to the formation of toxic aggregates inside brain cells that can spread damage by propagating from cell-to-cell. Disease-associated conformational epitopes identified through ProMIS&#8217; computational platform are being used to generate potentially therapeutic antibodies. Additionally, we are using the epitopes identified in the amyloid-beta, alpha-synuclein and TDP-43 discovery programs to generate vaccine candidates that potentially could be used for prophylactic treatment of Alzheimer&#8217;s disease, synucleinopathies and ALS, respectively. The Discovery phase of the process comprises two distinct stages: (1) <span style="color:#231f20;">computational modeling to predict and construct </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">conformational peptide epitopes present on the misfolded, toxic form of a protein, followed by either immunization with the peptide epitopes to generate antibodies/ intrabodies, or incorporation of the peptide antigen into a therapeutic vaccine and (2) screening and validation of multiple candidates in vitro and in vivo to select a lead for preclinical development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Schizophrenia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">DISC1 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Protein misfolding and proteostasis defects have been found to play a role in neurodevelopmental diseases, but until recently, the proteins implicated in these disease processes were not known. &#160;Just such a protein was first identified in a Scottish family with an autosomal dominant neurodevelopmental syndrome including schizophrenia, and was subsequently named &#8220;disrupted in schizophrenia,&#8221; or DISC1 (Soares et al. 2011). DISC1 is an important hub protein participating in neurogenesis, mitochondrial transport and dynamics in dendrites, cytoskeletal function, and protein translation in adults, especially at the synapse and under conditions of oxidative stress. DISC1 has been shown to misfold and aggregate in schizophrenia, as indicated by impaired detergent solubility in brains of individuals dying with sporadic (non-genetic) schizophrenia (Leliveld et al. 2008), and the induced co-aggregation of DISC1 by TDP-43 inclusions in human frontotemporal dementia (Endo et al. 2018). &#160;In addition, many genetic variants in interactors of DISC1 show significant association with schizophrenia and cognitive decline. Finally, misfolded DISC1 has been shown to exhibit prion-like attributes with transmission from cell-to-cell that can trigger misfolding of healthy DISC1 in the recipient cell (Korth 2012). Thus, DISC1 can be designated a misfolding protein in schizophrenia, just like amyloid and tau are misfolded proteins in AD. We believe application of the ProMIS platform to DISC1 and its interactome offers the potential to generate selective antibodies to selectively degrade toxic misfolded DISC1 while sparing normally folded DISC1 to perform its physiological function. Immunizations have been performed with epitopes predicted by EpiSelect<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM </sup>to be present specifically on misfolded DISC1 and the resulting mAbs are being characterized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Amyotrophic Lateral Sclerosis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">RACK1</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">RACK1 is a core ribosomal protein of the eukaryotic small (40S) ribosomal subunit. It is a scaffold protein that interacts with several other proteins thereby regulating a variety of signaling pathways critical for cell proliferation, transcription and protein synthesis. It is essential for proper neuronal function. In ALS, our own findings and those of others indicate that misfolded RACK1 co-localizes into cytoplasmic aggregates in motor neurons of the spinal cord which may play a role in disease pathology. For example, in a cell system, we and others have found that mutant TDP-43 suppresses global protein synthesis by co-aggregating with RACK1 on polyribosomes. Our recent work indicates that the same observations also apply to the interaction between RACK1 and Fused in sarcoma/translocated in sarcoma (FUS), another protein associated with ALS pathogenesis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To investigate RACK1 as a potential target for ALS, ProMIS explored the impact of RACK1 knock-down (KD) (i.e., what happens in the absence of RACK1). Our findings were recently published in <i style="font-style:italic;">Acta Neuropathologica Communications</i> (https://doi.org/10.1186/s40478-023-01705-8). In a cell system, RACK1 was observed to co-aggregate with misfolded mutant TDP-43 or mutant FUS in the cytoplasm. Knock-down of RACK1 expression resulted in disaggregation of cytoplasmic TDP-43 or FUS and even relocation to the nucleus (normal location) in some of the cells, accompanied by a reversal of the suppression of protein synthesis. In fruit flies (<i style="font-style:italic;">Drosophila melanogaster</i>) experiencing neurodegeneration as a result of human TDP-43 expression, RACK1 KD alleviated degeneration of neurons in the retina and improved the climbing ability of the flies. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Results from the literature and ProMIS&#8217; proof of concept data using RACK1 KD support targeting of RACK1 as a potential therapeutic approach for ALS. The ProMIS platform identified epitopes present on misfolded RACK1 and generated antibodies selective for pathogenic, aggregated RACK1. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS has generated five mAbs with the desired selectivity and intrabody versions have been generated for testing. These mAbs recognize diseased tissue (ALS and FTD) but not normal tissue, suggesting that RACK1 is misfolded and aggregated in disease. Research is ongoing to continue to characterize the mAbs and select a candidate. &#160;Selective KD of RACK1 is another avenue being pursued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Alzheimer&#8217;s Vaccine Program </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the same peptide antigens that generate a mAb infusion therapy can be used to create a vaccine. The goal of a therapeutic vaccine is to spur the human immune system to generate antibodies that neutralize toxic oligomers, just as the infusion antibodies will hopefully do. The advantage is that a single course of therapy, usually an initial vaccination followed by a booster, can potentially provide&#160;years of therapeutic benefit, eliminating the need for frequent costly infusions. Progress in the reliability of blood-based biomarkers of neurodegeneration will likely increase screening to identify individuals in the early stages of AD or at risk of developing the disease. A vaccine capable of inducing an effective antibody response against A&#946;O could be administered prophylactically to at-risk individuals to potentially prevent development of symptomatic disease; and the vaccine could also be given therapeutically to individuals living with a diagnosis of AD to potentially inhibit disease progression. Initial results obtained with peptide 301 (the conformational A&#946;O epitope of PMN310) in a vaccine configuration showed robust induction of antibodies selective for A&#946;O with no binding to monomers or plaque. &#160;There was also no induction of a potentially deleterious T cell response observed previously with other A<span style="font-family:'Symbol';">b</span> vaccines. ProMIS performed studies to optimize adjuvant formulation and dosing regimen as well as to explore multivalent vaccine configurations containing additional A<span style="font-family:'Symbol';">b</span>O-restricted epitopes identified by the ProMIS discovery platform. Results from these studies showed that maximal reactivity with toxic oligomers from AD brain was achieved with immune IgG against conformational epitope 301 alone and that there was no advantage of including additional epitopes in the vaccine. These data were presented at the 2024 Alzheimer&#8217;s Association International Conference. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In previous studies reported in the literature, a first-generation vaccine consisting of aggregated human A&#946; protein with QS1 adjuvant induced antibody production in AD patients but elicited meningoencephalitis (brain inflammation) and had to be discontinued for safety reasons. Subsequent studies indicated that T helper (Th) cell epitopes in the A&#946; vaccine gave rise to a pro-inflammatory Th1-type response against the same A&#946; epitopes in the brain<i style="font-style:italic;">)</i>. The Company believes it can avoid this issue with a vaccine candidate consisting of its A&#946;O B cell epitope (no A&#946; Th epitopes) conjugated to keyhole limpet hemocyanin (KLH) as a carrier protein. KLH has been used in humans and provides Th cell epitopes that are needed to help the development of an antibody response by B cells. Since KLH is a foreign protein not present in human brain, immunization is expected to result in an antibody response against A&#946;O without a potentially detrimental Th cell inflammatory response (Fig. 14). This premise is supported by initial preclinical studies that we conducted in collaboration with the University of Saskatchewan&#8217;s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), a global leader in vaccine research and development. &#160;The results were first presented at the AD/PD conference in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In these studies, 5-6 week old Balb/c mice (n=6/group) received two intramuscular (IM) injections (days 0 and 28) of a vaccine candidate construct containing ProMIS&#8217; A&#946;O 301 peptide epitope linked to KLH and formulated with different adjuvants. Analysis of serum samples collected on day 0 and after 1 or 2 vaccinations on&#160;days 28 and 48 showed induction of a robust antibody response against the A&#946;O epitope as measured by ELISA (Fig. 15). ELISPOT analysis of spleen cells (immune cells) collected from immunized mice at the end of the study on day 48 showed a lack of Th cell cytokine production in response to stimulation with the A&#946;O epitope thereby indicating that the peptide only contains a B cell epitope. As expected, T cell help was provided by the carrier protein and stimulation with KLH gave rise to the production of Th cytokines. These results support the premise that a vaccine consisting of A&#946;O-restricted conformational B cell epitopes conjugated to KLH for T cell help may successfully induce a protective antibody response against A&#946;O without eliciting a potentially inflammatory A&#946;-directed Th response. Characterization of immune sera from the mice also showed the desired antibody binding profile: selective binding to A&#946;O compared to A&#946; monomers as determined by SPR, and no binding to plaque in brain sections from AD patients as determined by IHC. &#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:222.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 14</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k016.jpg" alt="Graphic" style="display:inline-block;height:222.72pt;width:381.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fig. 14. Illustration of vaccine concept</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Figure 15</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231x10k017.jpg" alt="Graphic" style="display:inline-block;height:215.22pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:271.46pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fig. 15. Induction of robust antibody response against A&#946;O epitope. Titers of IgG antibodies against the 301 peptide epitope were measured by ELISA. Values for individual mice at baseline and on&#160;days 28 and 48 post-immunization are shown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using the ProMIS discovery platform, our aim is to devise a safe and effective vaccine to induce a specific immune response against toxic A&#946;Os. We have identified a lead candidate vaccine to induce antibodies that selectively bind A&#946;Os. The immediate goal for this program is to progress this amyloid vaccine into preclinical development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Alpha-Synuclein &amp; TDP-43 Vaccine Program </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The same principle of immunization with conformational peptide epitopes of misfolded toxic proteins was applied to alpha-synuclein (a-syn) for vaccination against synucleinopathies such as MSA, PD and LBD.  </span><span style="white-space:pre-wrap;">Potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein were identified by the ProMIS platform. Formulations of several of these epitopes were tested in mouse vaccination studies leading to the selection of a lead vaccine candidate for testing in mouse models replicating cognitive and motor deficits of human disease.  This pioneering work was made possible through a C$1.16 million research grant by the Weston Family Foundation to the University of British Columbia to support the research of the team led by Neil Cashman, M.D., ProMIS Chief Scientific Officer and Professor Emeritus at the University of British Columbia. The team also includes Scott Napper, Ph.D., from the Vaccine and Infectious Disease Organization (VIDO) and Professor of Biochemistry, Microbiology, and Immunology at the University of Saskatchewan, Marco Prado, Ph.D., the Canada Research Chair in Neurochemistry of Dementia and Professor of Anatomy &amp; Cell Biology / Physiology and Pharmacology, at the University of Western Ontario, and Joel Watts, Ph.D., Canada Research Chair in Protein Misfolding Disorders and Associate Professor within the Department of Biochemistry and the Tanz Centre for Research in Neurodegenerative Diseases at the University of Toronto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Results from vaccination studies were presented at the 2025 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and related neurological disorders (AD/PD) and at the American Academy of Neurology (AAN) conference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Similarly, an epitope determined to be restricted to misfolded pathogenic TDP-43 was formulated as a vaccine.  Results from a mouse vaccination study were accepted for presentation at the 2026 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and related neurological disorders (AD/PD).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ProMIS&#8217; Technology Platform and Intellectual Property Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The basis of ProMIS&#8217; proprietary technology platform is the ability to identify small regions of toxic proteins, including their specific shape or &#8220;conformation&#8221; that are displayed only on the toxic forms of that protein. We have developed patented methods and know-how combining biology and physics, to identify these small regions of proteins which can be the targets for antibodies. When displayed on the toxic protein, these small regions are known as &#8220;epitopes.&#8221; ProMIS makes copies of these epitopes, in a precisely defined shape. These drug development tools are called peptide antigens and we believe they are the key to our ability to create antibody therapies, vaccines, and diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ProMIS computational platform is based on the EpiSelect<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> algorithm that combines physics and biology to simulate the folding, or misfolding of proteins. ProMIS has successfully applied this computational algorithm to several misfolded protein categories, looking for epitopes exposed only on a misfolded toxic form which can be used as an antigen to generate an antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Peptide antigens are the key to creating selective antibodies that target toxic misfolded proteins, like our lead therapeutic antibody candidate (PMN310 for AD). PMN310 was created using a peptide antigen that we correctly predicted to be exposed only on toxic A&#946;Os, not the monomeric or plaque forms of A&#946;. ProMIS has generated a portfolio of over 20 peptide antigens that have led to selective antibodies against toxic misfolded forms of A&#946; for AD, a-syn for MSA and PD, tau for AD, FTLD, PSP, and CBD, TDP-43 and SOD1 for ALS, RACK1 for ALS and HD, and DISC1 for schizophrenia. Those peptide antigens, and the corresponding selective antibodies, represent proprietary reagents that potentially can be used to create proprietary diagnostic tests in neurodegenerative diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Finally, peptide antigens are also a potential key to making vaccines. Therapeutic vaccines are designed to treat a disease by causing the patient&#8217;s immune system to make antibodies (or T-Cells, in some areas like cancer) that neutralize the toxic disease driver. The potential advantage of a therapeutic vaccine, if effective, is that a single course of therapy might provide benefit for many&#160;years, not requiring frequent, expensive and inconvenient infusions. In preventive therapy, we believe such an approach may be particularly valuable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview of ProMIS&#8217; Intellectual Property (IP) Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The ProMIS IP program consists of a three-layered strategy. The first layer of protection comprises two computational algorithms, ProMIS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM </sup>and EpiSelect<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, obtained under worldwide exclusive license from the UBC. These algorithms are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">used to predict the specific site and shape (conformation) of epitopes on misfolded proteins implicated in the development of neurodegenerative diseases and on other complex proteins. PCT applications for these disease specific epitopes have been submitted and comprise the second layer of IP protection. Finally, the third layer of protection consists of the composition of matter for the antibodies targeting these disease related epitopes, including use(s)&#160;thereof. The second and third layers of this strategy may be in the same patent application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements and Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">License Agreement with the University of British Columbia (UBC)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February&#160;4, 2009, ProMIS (under its previous name, Amorfix Life Sciences&#160;Ltd.) entered into an exclusive license agreement with UBC in which ProMIS gained exclusive worldwide rights to develop and commercialize certain intellectual property rights belonging to UBC, based on its technology relating to misfolded proteins. Such agreement was amended and restated effective October&#160;6, 2015 (as amended and restated, the &#8220;UBC License Agreement&#8221;). Under the terms of the UBC License Agreement, ProMIS has a worldwide exclusive license to UBC&#8217;s rights in existing and future intellectual property (Improvements as defined in the UBC License Agreement) related to misfolded protein technology, with the right to sublicense. ProMIS is also responsible for managing the filing, maintenance and prosecution of the licensed patents and applications and is responsible for costs associated with the same. The UBC License Agreement expires on a product by product and country by country basis upon the expiration of ProMIS&#8217; obligation to pay royalties to UBC under the terms thereof (unless terminated earlier pursuant to the terms of the UBC License Agreement). The Company&#8217;s obligation to pay royalties under the UBC License Agreement expires upon the longer of the life of the Patents (as defined in the UBC License Agreement), including those identified in Schedule A thereto (as amended from time to time), and ten&#160;<span style="white-space:pre-wrap;">years following the First Commercial Sale of a Product (as those terms are defined in the UBC License Agreement) in any country. Since the Company has not made commercial sales under the UBC License Agreement to date, the UBC License Agreement is currently expected to expire no earlier than February 19, 2044. However, this date may be adjusted upon the Company&#8217;s First Commercial Sale of a Product or upon an amendment to Schedule A to the UBC License Agreement to add additional patents. The UBC License Agreement may also be terminated by UBC, at its option, upon the occurrence of certain events including, but not limited to, our insolvency, winding up,  liquidation, if the subject technology becomes subject to a security interest that is not released, if ProMIS or any of its directors or officers have materially breached or failed to comply with securities laws, in the event of certain breaches of, or our failure to perform obligations under, the UBC License Agreement or other agreements between ProMIS and UBC or other terminations of existence. Either party may terminate the license for breaches pursuant to the terms thereof, unless remedied within a certain period specified in the UBC License Agreement. ProMIS also has the right, in its sole discretion, to terminate the UBC License Agreement upon written notice to UBC. The UBC License Agreement calls for certain customary payments such as an annual license fee and payment to UBC of a low to high single digit royalty on revenues. As of December 31, 2025, the Company has paid a total of C$275,000 to UBC pursuant to the terms of the UBC License Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The foregoing description of the UBC License Agreement is qualified in its entirety by reference to the UBC License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">The UBC Patents</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The UBC patent license includes a patent family directed toward systems and methods for predicting therapeutic targets in misfolding proteins. This patent family (referred to as Collective Coordinates target identification technology) includes one issued U.S. patent, eight issued foreign patents and one allowed Canadian application. Issued patents from this family are expected to expire in November&#160;2036, absent any disclaimers or extensions available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The UBC patent license also includes several patent families directed to biologics including antibodies targeting neurological disease related toxic misfolded proteins and methods related thereto, many of which targets were identified using their proprietary prediction systems and methods, including several families related to immunogens, antibodies and methods directed to various misfolded A&#946; targets relevant in AD and related diseases (AD family), several families related to immunogens, antibodies and methods directed to various misfolded TDP-43 targets relevant in ALS and related diseases (ALS disease family-TDP-43), a patent family related to antisense molecules and biologics directed at RACK1 relevant in ALS and Huntington&#8217;s (ALS disease family-RACK1), a patent family related to ubiquitin ligase </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">fusions directed to misfolded SOD1 targets relevant in ALS and related diseases (ALS disease family &#8211; SOD1), a PCT patent application related to vaccine compositions, and a patent family related to immunogens and antibodies directed to a-synuclein targets relevant in PD, MSA, LBD and related diseases (PD family).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The AD family includes patent families related to three A&#946; epitope targets. The first A&#946; epitope target patent family  includes several patent subfamilies and includes specifically four issued U.S. patents, three pending U.S. applications, nineteen issued foreign patents and seven foreign pending patent applications. Issued patents from this family are expected to expire in November&#160;2036, July&#160;2037 or July&#160;2038, depending on the subfamily and country and absent any disclaimers or extensions available. The second A&#946; epitope target patent family includes two issued U.S. patents, two issued foreign patents and five foreign pending applications. Issued patents from this family are expected to expire in November&#160;2036, absent any disclaimers or extensions available. The third A&#946; epitope target patent family includes two issued U.S. patents, three issued foreign patents and one foreign pending application. Issued patents from this family are expected to expire in November&#160;2036, absent any disclaimers or extensions available. The AD family also includes one issued U.S. patent directed to combinations of the three A&#946; epitope target antibodies and an issued U.S. patent directed to combinations of the three A&#946; epitope target immunogens. Issued patents from this family are expected to expire in November&#160;2036, absent any disclaimers or extensions available.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The ALS disease family-TDP-43 includes patent families directed to two TDP-43 epitope targets. The first TDP-43 epitope target family includes one issued U.S. patent, one pending U.S. application, one issued foreign patent, and two pending foreign applications. Issued patents from this family are expected to expire in May&#160;2038, absent any disclaimers or extensions available. The second TDP-43 epitope target family includes two patent subfamilies, the earlier of which includes one allowed U.S. patent application, one pending U.S. patent application, and seven pending foreign applications, and a later patent subfamily directed more specifically to intrabodies, that includes one pending U.S. application and 5 foreign patent applications. Patents that issue from this family would be expected to expire in December&#160;2039 and April&#160;2041, respectively, absent any disclaimers or extensions available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The ALS disease family- SOD1 includes a patent family related to a SOD1 epitope target. The patent family includes one pending U.S. application and eight pending foreign applications. Patents that issue from this family would be expected to expire in February 2044, absent any disclaimers or extensions available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The ALS disease family also includes a patent family related to RACK1 nucleic acid targets. The RACK1 nucleic acid target family includes one pending U.S. patent application and five pending foreign applications. Patents that issue from this family are expected to expire April&#160;2041, absent any disclaimers or extensions available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The PD disease family includes a patent family related to alpha-synuclein epitope target. The a-syn patent family includes one issued U.S. patent, one pending U.S. patent application, two issued foreign patents, and four foreign pending patent applications. Issued patents from this family are expected to expire in October&#160;2039, absent any disclaimers or extensions available. The PD disease family also includes a PCT application directed to vaccine compositions. Patents that issue from applications related to this PCT would be expected to expire in May 2045, absent any disclaimers or extensions available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Other Patents</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are the current owner of two U.S. patents related to SOD1 epitope targets that were co-owned and then acquired from University Health Network (UHN) by assignment. These patents expire on March 2026 and December 2026, absent any disclaimers or further extensions available. We also own a U.S. patent related to SOD-1 immunogens and/or antibodies which is expected to expire March 2026. We also own one U.S. patent directed to detecting misfolded disease associated proteins. This patent is expected to expire in July 2034, absent any disclaimers or further extensions available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In the countries in which we file, the patent term is 20&#160;years from the earliest non-provisional filing date, subject to any disclaimers or extensions and to the timely payment of maintenance fees. The term of a patent in the United States can be adjusted due to any failure of the U.S. Patent Office (USPTO) following certain statutory deadlines for issuing a patent.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For a discussion of the risks we face relating to our intellectual property, see &#8220;<i style="font-style:italic;">Risk &#160;Factors&#160;&#8212; Risks Related to our Intellectual Property&#160;&#8212; If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates, and other proprietary technologies if approved, may be adversely affected.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Industry Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Markets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS is applying its in-licensed patented technology platform to build a portfolio of antibody therapies and therapeutic vaccines, for neurodegenerative diseases such as AD, ALS, MSA, FTLD, PSP, CBD, and schizophrenia. A common biologic cause contributes to each of these conditions, in that misfolded versions of proteins which normally perform a needed function can cause neuronal degeneration and death when misfolded, contributing to morbidity and mortality. &#160;ProMIS&#8217; technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and artificial intelligence. We believe this platform provides a potential advantage by allowing us to selectively target the toxic misfolded proteins with therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketing Plans and Milestones</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketing and commercial launch of any products in the ProMIS portfolio which successfully progress in development must be planned in relation to its available resources. ProMIS intends to out-license the marketing and sales of its products, should they progress successfully in development, to strategic partners for commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, manufacture, testing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, as well as diagnostics. Generally, before a new drug, biologic or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable regulatory authority.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory Approval and Certification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All commercial applications of ProMIS&#8217; technology will be subject to substantial regulation and certification in the jurisdictions in which ProMIS or its strategic partners intend to sell its therapeutic products. The initial markets for ProMIS&#8217; product candidates are expected to be the U.S. and Canada and, because the Canadian healthcare marketplace is regulated in a similar manner as in the United States, ProMIS intends to conform its regulatory and certification scheme to the more rigorous standards imposed by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Therapeutic Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) and its implementing regulations and biologics under the FD&amp;C Act and the Public Health Service Act (PHS Act) and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations, such as those related to competition. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative actions or judicial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">sanctions. These actions and sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal fines or penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, the market acceptance of our product candidates, if approved, and our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates must be approved by the FDA through either a New Drug Application (NDA) or a Biologics License Application (BLA) process before they may be legally marketed in the United States. The process generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with Good Laboratory Practices (GLP) requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an Institutional Review Board (IRB) or independent ethics committee (EC) at each clinical trial site before each human trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, Good Clinical Practices (GCP) requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA or BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with Current Good Manufacturing Practices (cGMP) requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential FDA audit of the clinical trial sites that generated the data in support of the NDA or BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees for FDA review of the NDA or BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and the regulatory scheme for drugs and biologics is evolving and subject to change at any time. We cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical and Clinical Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS&#8217; human therapeutic product applications will be subject to rigorous preclinical and clinical testing and other approval procedures by the FDA and similar regulatory agencies in other countries. First, preclinical testing of human therapeutics is conducted in nonclinical models and on animals in the laboratory to evaluate the potential efficacy, safety and toxicity of a pharmaceutical product candidate. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results of these studies, along with applicable chemistry, manufacturing, and controls information are submitted to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">humans, and must become effective before human clinical trials may begin. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, notifies the applicant of safety concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. Additionally, the review of information in an IND submission may prompt FDA to, among other things, scrutinize existing INDs or any marketed products and could generate requests for information or clinical holds on other product candidates or programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable related to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. The FDA, the IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about applicable clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Typically, the clinical evaluation process involves three phases. In Phase 1, clinical trials are conducted with a small number of healthy human subjects, or in a small number of patients to determine the early safety profile, the pattern of therapeutic drug distribution and metabolism. The total number of subjects included in Phase 1 clinical trials varies but is generally in the range of 20 to 80. In Phase 2, clinical trials are conducted with groups of patients who have the disease being evaluated to determine preliminary evidence of efficacy, the optimal dosages, and more extensive evidence of safety. Phase 2 clinical trials are typically controlled and conducted in a limited population, usually involving no more than several hundred subjects. In Phase 3, large scale, statistically-driven multi-center, well-controlled clinical trials are conducted with patients afflicted with a target disease in order to provide enough data to demonstrate the efficacy and safety required by the FDA. Phase 3 clinical trials usually involve several hundred to several thousand subjects. In most, though not all, cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to support approval of a drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Data from clinical trials conducted outside the U.S. may be accepted by the FDA subject to certain conditions. For example, the clinical trial must be conducted in accordance with GCP) requirements and/or the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. Where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will not approve the application on the basis of foreign data alone unless those data are considered applicable to the U.S. patient population and U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data is considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or <i style="font-style:italic;">in vitro</i> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketing Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (PDUFA) guidelines that are currently in effect, the FDA has a goal of ten&#160;months from the date of &#8220;filing&#8221; of a standard NDA or BLA, for a new molecular entity to review and act on the submission. This review typically takes twelve&#160;months from the date the NDA or BLA is submitted to the FDA because the FDA has approximately two&#160;months to make a &#8220;filing&#8221; decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of all NDAs or BLAs within the first 60&#160;days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA or BLA to determine, among other things, whether the drug or biologic is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality, and purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug or biologic to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to ensure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">After evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA or BLA and may require additional clinical or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s or biologic&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy (REMS) which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same approved use or indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same approved use or indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs or biologics to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to expedite the development and review of new products that are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. While these programs are intended to expedite product development and approval, they do not alter the standards for FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A drug may be eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the agency may review portions of the marketing application before the sponsor submits the complete application. In addition, a drug may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review designation, once an NDA or BLA is submitted, if the drug that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six&#160;months compared to ten&#160;months for a standard review. Products are eligible for Accelerated Approval if they are in development for a serious or life-threatening condition and can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit. The FDA may withdraw approval of a drug or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product, other evidence demonstrates that the product is not shown to be safe and effective under conditions of use, or required post-approval studies are not conducted with due diligence. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted Accelerated Approval. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the Agency, that all advertising and promotional materials intended for dissemination or publication within 120&#160;days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30&#160;days prior to the intended time of initial dissemination or publication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pediatric Information and Pediatric Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the Pediatric Research Equity Act (PREA), certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act (FDASIA) amended the FD&amp;C Act to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration, unless the drug is for an indication for which orphan designation has been granted and is not for a molecularly targeted cancer indication, submit an initial Pediatric Study Plan (PSP) within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A drug or biologic product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and, for drugs, patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or, for drugs, patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Drugs or biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products and the establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, drug and biologic manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics, and those supplying products, ingredients, and components of them, are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with ongoing regulatory requirements, including cGMP requirements. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. &#160;Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once an approval of a drug or biologic is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.<span style="font-family:'Arial','Helvetica','sans-serif';"> O</span>ther potential consequences include, among other things: </p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:24.5pt;margin-top:0pt;padding-left:24.45pt;text-align:justify;text-indent:-24.45pt;"><span style="display:inline-block;min-width:24.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:24.5pt;margin-top:0pt;padding-left:24.45pt;text-align:justify;text-indent:-24.45pt;"><span style="display:inline-block;min-width:24.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:24.5pt;margin-top:0pt;padding-left:24.45pt;text-align:justify;text-indent:-24.45pt;"><span style="display:inline-block;min-width:24.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>fines, warning letters or untitled letters or holds on post-approval clinical trials; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:24.5pt;margin-top:0pt;padding-left:24.45pt;text-align:justify;text-indent:-24.45pt;"><span style="display:inline-block;min-width:24.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:24.5pt;margin-top:0pt;padding-left:24.45pt;text-align:justify;text-indent:-24.45pt;"><span style="display:inline-block;min-width:24.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>product seizure or detention, or refusal to permit the import or export of products; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:24.5pt;margin-top:0pt;padding-left:24.45pt;text-align:justify;text-indent:-24.45pt;"><span style="display:inline-block;min-width:24.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>injunctions or the imposition of civil or criminal penalties; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:24.5pt;margin-top:0pt;padding-left:24.45pt;text-align:justify;text-indent:-24.45pt;"><span style="display:inline-block;min-width:24.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs or mandated modification of promotional materials and labeling and issuance of corrective information. </div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In many foreign countries, drugs and biologics are subject to regulatory requirements in addition to and sometimes different than the U.S. requirements described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidance, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which pharmaceutical products are regulated and marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Companion Diagnostics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA defines an <i style="font-style:italic;">in vitro</i> companion diagnostic (IVD) device as an <i style="font-style:italic;">in vitro </i>diagnostic device that provides essential information for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, including the label. Applications for an IVD companion diagnostic device and its corresponding therapeutic product will be reviewed and approved according to applicable regulatory requirements. The IVD companion diagnostic device application will be reviewed and approved or cleared under the device authorities of the FD&amp;C Act and relevant medical device regulations; the therapeutic product application will be reviewed and approved under section 505 of the FD&amp;C Act (i.e., drug products) or section 351 of the Public Health Service Act (i.e., biological products) and relevant drug and biological product regulations. The FDA intends to review each IVD companion diagnostic device submission within the context of, or in conjunction with, its corresponding therapeutic product, and FDA review of the IVD companion diagnostic device and the therapeutic product will be carried out collaboratively among relevant FDA offices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Ideally, a therapeutic product and its corresponding IVD companion diagnostic device should be developed contemporaneously, with the clinical performance and clinical significance of the IVD companion diagnostic device established using data from the clinical development program of the corresponding therapeutic product. Some of our current and future product development candidates may depend upon co-development of accurate genetic and potentially </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other IVDs. Thus, we will likely need to comply with both FDA drug and medical device regulations. This adds additional cost and complexity to our development programs. Ultimately, FDA approval of a companion diagnostic may be required to allow approval of some of our products. However, technical difficulties or other issues could delay or disrupt the development of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Patent Term Extension and Marketing Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of FDA approval of a drug or biologic, some U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits extension of a patent term of up to five years beyond the normal expiration date of the patent as compensation for patent term lost during the FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension. An NDA or BLA applicant may apply for extension of patent term for its currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketing exclusivity provisions under the FD&amp;C Act also can delay the submission or the approval of certain applications. The FD&amp;C Act provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA), or a 505(b)(2) NDA submitted by another Company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FD&amp;C Act also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biosimilars and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our product candidates are regulated as biologics. An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), as part of the ACA. This amendment to the PHS Act, in part, attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Complexities associated with the larger, and often more complex, structure of biological products as compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A reference biological product is granted four and twelve year exclusivity periods from the time of first licensure of the product. The FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and the FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor. The law is complex and is still being interpreted and implemented by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs for drugs and biologics. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect such operations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute is a criminal statute which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil monetary penalties;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from the federal government, including Medicare, Medicaid and other government payors, that are false or fraudulent or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. federal government. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery. </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Several pharmaceutical and other healthcare companies have been prosecuted under these </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA which created additional federal criminal statutes that prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false or fraudulent statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and its implementing regulations, impose certain requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal transparency laws, including the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to: (i)&#160;payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, certain other licensed healthcare practitioners,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and teaching hospitals, and (ii)&#160;ownership and investment interests held by physicians and their immediate family members);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FCPA which prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations; state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers; and state and local laws that require the registration of pharmaceutical sales representatives.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">disgorgement, imprisonment, exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Environmental Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company may also be subject to foreign and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. There can be no assurance that the Company will not incur significant costs to comply with laws and regulations in the future or that such laws or regulations will not have a material adverse effect upon the Company&#8217;s business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pricing and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Precision therapeutic products and their accompanying companion diagnostic are largely paid for based on third-party payor reimbursement. In the United States., concurrent with approval for commercialization of such therapeutic products by the FDA, each therapeutic product is assigned a product code, and its associated companion diagnostic assigned a similar code, or CPT. Each product code and CPT is then assigned a reimbursement level by CMS.&#160;Third-party insurance payors typically establish a specific fee to be paid for each code submitted. Third-party payor reimbursement policies are generally determined with reference to the reimbursement for CPT codes for Medicare patients which themselves are determined on a national basis by CMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules&#160;and regulations are likely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In recent&#160;years, Congress has considered reductions in Medicare reimbursement levels for drugs administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The U.S. government, state legislatures, and foreign governments have continued implementing cost- containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">countries where they may be sold at lower prices than in the United States. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Increasingly, third-party payors are also requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any products that we commercialize and, if reimbursement is available, the level of reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Parallel to this regulatory reimbursement scheme in the United States., other countries also regulate reimbursement similarly to the United States. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets outside the United States., the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits Therefore, it is important that ProMIS establish for its human diagnostic and therapeutic products reimbursement schemes, which provide ultimate financial payment for ProMIS&#8217; products consistent with its business plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Reform Measures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government- paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Affordable Care Act (ACA) substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. Among other things, the ACA subjected biologic products to potential competition by lower-cost biosimilars; increased the minimum Medicaid rebates owed by most manufacturers; ; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer&#8201;70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (a requirement that was later replaced by the Part D Manufacturer Discount Program under the Inflation Reduction Act of 2022); and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since passage of the ACA.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Budget Control Act of 2011 and subsequent legislation, among other things, resulted in reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal&#160;year through 2031.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The United States Inflation Reduction Act of 2022, or the IRA, was signed into law. The IRA included substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part&#160;D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one or more orphan designations and for which the only approved indications are for rare diseases or conditions. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The IRA could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect the IRA will have on our business and the pharmaceutical industry in general is not yet known.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The One Big Beautiful Bill Act of 2025 (OBBBA), for example, imposed significant reductions in Medicaid funding, additional work requirements for Medicaid recipients, and more frequent reenrollment requirements. These changes are expected to place substantial pressure on state Medicaid budgets, reduce enrollment, and limit covered services, which could decrease utilization of, and reimbursement for, our products, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The costs of drugs have also been the subject of considerable discussion in the United States. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. The Trump Administration has issued executive orders and supported proposed regulatory initiatives in 2025 that could have a significant impact on the prices that we, or any collaborators, may receive for any approved products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">On May 12, 2025, President Trump signed an executive order directing the Secretary of HHS to set and communicate most-favored-nation (MFN) price targets to manufacturers and propose a rulemaking plan to impose MFN pricing if &#8220;significant progress&#8221; is not made, and also directing the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets. The executive order further states that the Administration will take additional action (for example, examining whether marketing approvals should be modified or rescinded or considering individual drug importation waiver authorities) should manufacturers fail to offer American consumers the MFN lowest price. In July 2025, President Trump sent letters to certain pharmaceutical companies demanding that these companies extend MFN pricing to Medicaid and newly launched drugs as well as move to direct-to-consumer models priced at MFN pricing, and soliciting binding commitments by September 29, 2025. Since this time, multiple drug manufacturers have announced plans to, for certain of their drugs, lower prices to reflect similar pricing around the world, and to sell these reduced-price drugs on a direct-to-consumer purchasing platform developed by the federal government; however, it is not known what results will occur to the extent the recipients of these letters do not reduce their U.S. prices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model (GLOBE) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) model for Medicare Part D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies. As proposed, GLOBE would begin a five year performance period on October 1, 2026 and GUARD would begin its performance period in 2027. These proposals will likely be subject to legal challenges that could delay their implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November 2025, CMS introduced the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model, a voluntary MFN framework for manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS Model could also impact the drug pricing landscape for manufacturers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Further legislative and regulatory changes under the Affordable Care Act remain possible. It is unknown what form any such changes or any law would take, and how or whether it may affect our business in the future. We expect that changes or additions to the Affordable Care Act, the Medicare and Medicaid programs, allowing the federal government to directly </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Individual States in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, if approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impact of the current U.S. administration on FDA and NIH policies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in U.S. government administration and potential reforms to the FDA and NIH may adversely affect the regulatory environment and our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The regulatory landscape for biotechnology and pharmaceutical companies is heavily influenced by policies set by the U.S. government, including the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). With the current presidential administration implementing new priorities, there is a heightened risk of regulatory uncertainty, policy shifts, and potential reform efforts that could impact drug development, clinical trial oversight, and funding for biomedical research.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Proposed changes to FDA approval processes, accelerated pathways, or regulatory requirements could result in delays, increased costs, or additional hurdles in advancing our clinical programs, including the PRECISE-AD Phase 1b trial in Alzheimer's disease. Additionally, modifications to NIH funding priorities or grant allocations could impact broader research collaborations and the availability of scientific resources that support our programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">If the current administration enacts policies that slow down clinical trial approvals, alter market access dynamics, or introduce new compliance burdens, our ability to efficiently develop and commercialize our therapies could be adversely affected. We continue to monitor regulatory developments and engage with industry stakeholders to navigate potential challenges; however, there can be no assurance that future policy changes will not materially and negatively impact our business, financial condition, or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulation Outside of the United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to regulations in the United States, we may be subject to a variety of regulations in foreign jurisdictions that govern, among other things, clinical trials and any commercial sales and distribution of our products, if approved, either directly or through our distribution partners. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign jurisdictions prior to the commencement of clinical trials or marketing and sale of the product in those countries. The foreign regulatory approval process and the time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Some foreign jurisdictions have a drug product approval process similar to that in the U.S., which requires the submission of a clinical trial application much like the IND prior to the commencement of clinical studies. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Moreover, some nations may not accept clinical studies performed for U.S. approval to support approval in their countries or require that additional studies be performed on natives of their countries. In addition, in certain foreign markets, the pricing of drug </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">products is subject to government control and reimbursement may in some cases be unavailable or insufficient. We face the risk that the resulting prices would be insufficient to generate an acceptable return to us or any future partner of ours. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Commercial Marketing Plans and Strategies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS currently does not intend to market its therapeutic products or any companion diagnostics it develops that require extensive distribution channels. Instead, ProMIS expects to license to, or enter into strategic alliances with, pharmaceutical entities that are equipped to manufacture and/or market ProMIS&#8217; products through their distribution networks. ProMIS may license some or all of its patent rights to more than one company to achieve the fullest development, marketing and distribution of its products. To this end, ProMIS intends to continue to develop and improve its proprietary technologies and to expand the applications of its technologies in the healthcare markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Generate Product Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revenues, if any, from its precision therapeutics pipeline and companion diagnostics are expected to be generated from research funding, license fees, milestone payments, co-development funding, and royalties from partnerships to be completed by ProMIS with selected third-party, multi-national health care firms. As of the date of this form, ProMIS has not generated any significant product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Develop Collaborative Customer-Funded Commercialization Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to increase market exposure of its products and to capitalize on a partner&#8217;s clinical development competencies, market position, and distribution capabilities, ProMIS intends to develop its projects with collaborative commercial partners who will fund further product development projects incorporating ProMIS&#8217; technology. These collaborative arrangements typically will provide for a jointly funded development project and contemplate a licensing arrangement (which may be entered into at the same time as the development project or at a later date) under which, if a project is commercialized by the collaborative partner, ProMIS would potentially receive license fees, royalty payments from product sales and manufacturing revenue. ProMIS believes that such arrangements with major commercial partners will serve to validate its proprietary technologies in human healthcare areas and thereby assist ProMIS in attracting additional licensing arrangements on favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enhance Out-licensing of ProMIS Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Where practical, ProMIS will outsource its product manufacturing and has explored and will continue to evaluate the possibility of entering into strategic manufacturing alliances with appropriate third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Healthcare Products Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ProMIS will compete with many large and small pharmaceutical companies that are developing and/or marketing therapeutic compounds for AD, ALS and/or PD. Many large pharmaceutical companies and smaller biotechnology companies maintain well-funded research departments concentrating on therapeutic approaches to neurodegenerative diseases. ProMIS expects substantial competition from these companies as they develop different and/or novel approaches to the treatment of these diseases. Some of these approaches may directly compete with the technology that ProMIS is currently developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Although we believe PMN310 currently is differentiated from other products on the market or in development, if approved, PMN310 will compete with therapies currently approved for the treatment of patients with AD, which have primarily been developed to treat the symptoms of AD rather than the underlying cause of the disease, such as memantine and cholinesterase inhibitors. PMN310 may also compete with one or more potentially disease-modifying therapeutics that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">target A&#946; or amyloid plaques. Biogen&#8217;s aducanumab (Aduhelm) was approved by the FDA in June 2021 under the Accelerated Approval pathway, but commercialization was discontinued in January 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Eisai and Biogen&#8217;s lecanemab (Leqembi) and Lilly&#8217;s donanemab (Kisunla) received traditional approval in 2023 and 2024, respectively. In many therapeutic categories, after initial approvals validate a general mechanistic approach, competitive dynamics are driven by relative safety, efficacy, convenience, and cost effectiveness. We expect this will be the case in the anti-amyloid immunotherapy category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other companies known to be developing therapies with A&#946;/amyloid plaque-related targets include Alzheon,&#160;Inc., Alzinova AB, Chugai Pharmaceutical Co.&#160;Ltd., Cognition Therapeutics,&#160;Inc., Eisai Co.,&#160;Ltd., Eli Lilly and Company, Grifols, S.A., KalGene Pharmaceuticals,&#160;Inc., Neurimmune AG, Novartis AG, Acumen Pharmaceuticals&#160;Inc., Prothena Biosciences,&#160;Inc., Roche Holding AG (including Genentech, its wholly owned subsidiary) and Wren Therapeutics,&#160;Inc. Additionally, PMN310, if approved, may also compete with other potential therapies intended to address underlying causes of AD that are being developed by several companies, including AbbVie&#160;Inc., AC Immune SA, Alector,&#160;Inc., Anavex Life Sciences Corp., Annovis Bio,&#160;Inc., Athira Pharma,&#160;Inc., Biohaven Pharmaceuticals,&#160;Inc., Cortexyme,&#160;Inc., Denali Therapeutics,&#160;Inc., Johnson&#160;&amp; Johnson (including Janssen, its wholly-owned subsidiary) and Takeda Pharmaceutical Co.&#160;Ltd. Some of these competitors are developing therapies that either seek to block the aggregation of amyloid oligomers (for example, Alzheon,&#160;Inc.), or mitigate the toxicity of amyloid oligomers (for example, Cognition Therapeutics,&#160;Inc.). These and other therapies may end up being used as complementary therapies in clinical practice, in addition to antibodies targeting aggregated amyloid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the intense competitive environment that is the human pharmaceutical industry, those companies that complete clinical trials, obtain regulatory approval and commercialize their therapeutic products first may enjoy competitive advantages. ProMIS believes that it will develop compounds with characteristics that may enable them, if fully developed, to have a market impact. A number of major human pharmaceutical companies have significant programs to develop drugs for the treatment of neurodegenerative disease. These companies include Eisai/Pfizer, Novartis, Merck, Genentech, Lilly, Biogen, Amgen and Johnson&#160;&amp; Johnson.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Proprietary Protection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">ProMIS has acquired the rights to certain proprietary discovery platforms for the identification of proteins involved in misfolding diseases embodied in various national and international patent applications. ProMIS has also filed international patent applications related to immunotherapy targeting toxic forms of TDP-43 and RACK1 for ALS, toxic oligomers of A&#946; for AD and toxic aggregates for a-syn for PD to further protect its intellectual property rights related to its therapeutic programs. In addition, the Company has obtained proprietary rights to a computational algorithm (EpiSelect<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>) for &#160;identification of disease-specific epitopes (DSEs) in protein misfolding diseases as well as predicted DSEs against multiple disease targets. ProMIS intends to aggressively protect the commercial applications for diagnostic, therapeutic and prophylactic applications of these discoveries. In addition, ProMIS has developed know-how, which it may elect to keep as trade secrets and not publicly disclose in patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Human Capital Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">ProMIS seeks to hire qualified scientists and key employees as needed. As of December 31, 2025, the Company employed ten full-time employees and one part-time employee. The remainder of the scientists and key personnel had consulting agreements with ProMIS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our future success depends on our ability to attract, develop and retain key personnel, maintain our culture, and ensure diversity and inclusion in our board, management and broader workforce. Our human resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. As these areas directly impact our ability to compete and innovate, they are key focus areas for our board of directors and senior executives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Corporate Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">ProMIS Neurosciences&#160;Inc. was incorporated on January&#160;23, 2004 under the name 4203801 Canada&#160;Inc. pursuant to the Canada Business Corporations Act (CBCA). The Company changed its name to Amorfix Life Sciences&#160;Ltd. on August&#160;24, 2004 and to ProMIS Neurosciences&#160;Inc. effective July&#160;8, 2015. On July 13, 2023, the Company continued its existence from a corporation incorporated under the CBCA into the Province of Ontario under the Business Corporations Act (Ontario) (OBCA) (Continuance). The Continuance was approved by the Company&#8217;s shareholders at the Company&#8217;s 2023 Annual Meeting of Shareholders held on June 29, 2023. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">On November 17, 2025, the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 25:1, effective November&#160;28, 2025 (the 2025 Reverse Share Split). All information included in this Annual Report on Form 10-K has been adjusted to reflect the 2025 Reverse Share Split. Unless otherwise stated herein, all share and per share numbers relating to the Company&#8217;s Common Shares prior to the effectiveness of the 2025 Reverse Share Split&#160;have been adjusted to give effect to the 2025 Reverse Share Split, including the consolidated financial statements and notes thereto. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;margin:0pt;">Our head office is located at 1920 Yonge Street, Suite&#160;200, Toronto, Ontario, Canada M4S 3E2 and our registered and records office is located at 1055 West Georgia Street, Vancouver, British Columbia, Canada V6E 4N7. Our telephone number is (416) 847-6898 and our website address is www.promisneurosciences.com. The information provided on our website is not part of this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;background:#ffffff;margin:0pt;">We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This Annual Report on Form 10-K may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174;, &#8482; or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;background:#ffffff;margin:0pt;">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;ProMIS,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar terms refer to ProMIS Neurosciences Inc. and its consolidated subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Unless otherwise indicated, all references to &#8220;$&#8221; or &#8220;US$&#8221; in this Annual Report on Form 10-K refer to U.S. dollars, and all references to &#8220;C$&#8221; refer to Canadian dollars. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8.5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">We will make available on our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains an Internet site, http://www.sec.gov, containing reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">Investors and others should note that we announce material information to our investors using our investor relations website (https://www.promisneurosciences.com/investors), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media, including LinkedIn and our Twitter (@ProMISInc), to communicate with the public about our company, our business, our product candidates and other matters. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website. Information that is contained in and can be accessed through our website or our social media posts are not incorporated into, and does not form a part of, this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_35c729ce_e131_446d_a610_5ee08162b88d"></a><a id="Item1ARiskFactors_192570"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investors should carefully consider the following risk factors, together with all of the other information included in this Annual Report on Form 10-K, before making an investment decision. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have an adverse effect on our business, cash flows, financial condition and results of operations. You should also carefully consider the following risk factors in addition to the other information included herein, including matters addressed in the section entitled &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements,&#8221; and all other information in the Company&#8217;s other public filings prior to making an investment decision. We may face additional risks and uncertainties that are not presently known to us or that we currently deem immaterial, which may also impair our business or financial condition. Additionally, investors should not interpret the disclosure of a risk to imply that the risk has not already materialized. The following discussion should be read in conjunction with the financial statements and notes to the financial statements included herein</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates are still in the early stages of development and there is significant uncertainty that any such products will ever be approved .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates are at an early stage of development. Significant additional investment in research and development, product validation, technology transfer to manufacturing, production scale-up, manufacturing, clinical testing, and regulatory submissions of such product candidates is required prior to commercialization. There can be no assurance that any such product candidates will actually be developed and, if developed, will be approved. The development and regulatory processes may require access to rare biofluid and tissue samples from people and animals which may not be available to us in sufficient amounts or in a timely fashion to allow us to complete the development or receive regulatory approval of any product candidate or process. A commitment of substantial time and resources is required to conduct research and clinical trials if we are to complete the development of any product candidate. It is not known whether any of these product or process candidates will meet applicable health regulatory standards and obtain required regulatory approvals, or whether such products, if approved, can be produced in commercial quantities at reasonable costs and be successfully marketed, or if our investment in any such products will be recovered through sales or royalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to incur substantial capital expenditures in connection with the development of our product candidates. If we fail to successfully develop and sell all or any of our product candidates, if approved, then we will not earn any return on our investment in these future products, which will adversely affect our results of operations and could adversely affect the market price of the Common Shares. Our success in developing and selling new products will depend upon multiple factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop safe and effective products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our serology assays and vaccines achieving the desired sensitivity for antibody-based immunity and immune response, as applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product by the medical community and by patients and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inherent development risks, such as the product proving to be unsafe or unreliable, or not having the anticipated effectiveness; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop repeatable processes to manufacture new products in sufficient quantities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of these factors cannot be overcome, we may not be able to develop and introduce our products in a timely or cost-effective manner, which could adversely affect our future growth and results of operations. Our failure to develop and obtain approval of our product candidates could adversely affect the market price of the Common Shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of PMN310 and any future product candidates that we may develop or acquire, including PMN442 and PMN267.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no products approved for sale, and our lead product candidate is in early stages of development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of PMN310. However, given our stage of development, it may be many&#160;years, if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The clinical and commercial success of PMN310 and any future product candidates that we may develop or acquire will depend on a number of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise any additional required capital on acceptable terms, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to complete IND enabling studies and successfully submit INDs or comparable applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in enrolling and retaining patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience of our treatment or dosing regimen;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or any future product candidates, if approved;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the U.S. and internationally, if approved for</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient demand for our product candidates, if approved, including patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our current clinical development plans for PMN310 may change as a result of clinical trial outcomes and future interactions with the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our approach to the potential treatment of AD is based on a novel therapeutic approach, which exposes us to unforeseen risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is no current scientific or general consensus on the causation of AD or method of action to treat AD. We have discovered and are developing PMN310, a humanized antibody that selectively targets A&#946;O, or A&#946;Os, to treat AD. Our approach is based on research on A&#946;Os, globular assemblies of the A&#946; peptide that are distinct from other forms of amyloid. A&#946;Os have gained scientific acceptance as primary toxins involved in the initiation and propagation of AD pathology. Based on the results of our studies to date, we believe PMN310 is different from current and prior clinical-stage anti-amyloid drugs and product candidates based on its selectivity for A&#946;Os. We believe that this is a novel mechanism which has the potential to provide more favorable outcomes, as compared to approved therapies and product candidates in development and may potentially slow disease progression. However, we may ultimately discover that PMN310 does not possess properties required for therapeutic effectiveness. We may spend substantial funds attempting to develop PMN310 or other product candidates and never succeed in doing so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market for any products that we successfully develop, if any, will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it would cost to commercially manufacture PMN310, if approved, and the actual cost to manufacture PMN310 or any drug we develop in the future could materially and adversely affect the commercial viability of the drug. We may also find that the manufacture of our product candidates is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical trials or, if approved, commercial supply. If we do not successfully develop PMN310 or any other drug we develop with drug product that can be reliably and economically manufactured at scale, we will not become profitable, which would materially and adversely affect the value of our Common Shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for PMN310 or by in-licensing or acquiring additional product candidates for other diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A key element of our strategy is to build and expand our pipeline of product candidates, including by developing PMN310 for the treatment AD, and by identifying other product candidates. In addition, we may in-license or acquire additional product candidates for other diseases. We may not be able to identify or develop additional product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify, in-license or acquire may not be suitable for clinical development. For example, our research methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side effects or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We cannot guarantee that we will be successful in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license new and valuable product candidates from other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nonclinical and clinical drug development involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical trials are not always predictive of future results. PMN310 or any other product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval<span style="font-style:normal;font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The research and development of product candidates is extremely risky. Only a small&#160;percentage of product candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete nonclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results of nonclinical studies and early clinical trials are not necessarily predictive of future results and PMN310, or any other product candidate that we may develop, may not be further developed or have favorable results in later studies or trials. Clinical trial failure may result from a multitude of factors including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the pharmaceutical industry have suffered setbacks in the advancement of their product candidates into later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding results in earlier nonclinical studies or clinical trials. In addition, the results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. This is particularly true in AD, where failure rates historically are higher than in most other disease areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of negative or inconclusive results, we may decide, or regulatory authorities may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from clinical trials and nonclinical studies is susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit or prevent development efforts, clinical trials or marketing approval. Furthermore, as more competing product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to complete nonclinical studies or clinical trials of PMN310 or future product candidates, due to safety concerns or otherwise, or if the results of these trials are not sufficient to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization on a timely basis or at all. Even if we are able to obtain marketing approval for PMN310 or any future product candidates, those approvals may be for indications or dose levels that deviate from our desired approach or may contain other limitations that would adversely affect our ability to generate revenue from sales of those product candidates. Moreover, if we are not able to differentiate our product candidate against other approved product candidates within the same class of drugs, or if any of the other circumstances described above occur, our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical failure can occur at any stage of clinical development and our Company has not completed any pivotal clinical trial or submitted a BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts for PMN310 and we have only completed one Phase 1a clinical trial. We will need to successfully complete our ongoing and planned clinical trials, including pivotal clinical trials, in order to obtain FDA approval to market PMN310 or any other product candidate we seek to develop. Carrying out clinical trials and the submission of a successful BLA is a complicated process. Although members of our team have significant experience in clinical development of drugs through regulatory approval, as an organization, we have limited experience in conducting any clinical trials with PMN310, we have limited experience in preparing regulatory submissions with PMN310 and we have not previously submitted a BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of PMN310 will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission and approval of PMN310 or any other product candidate. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our current or planned clinical trials, could prevent us from or delay us in commercializing PMN310 or any future product candidates we may develop, and failure to successfully complete any of these activities in a timely manner could have a material adverse impact on our business and financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities, Institutional Review Boards (IRBs) or Ethics Committees (ECs), may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or we may fail to reach a consensus with regulatory authorities on trial design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities in jurisdictions in which we seek to conduct clinical trials may differ from each other on our trial design, and it may be difficult or impossible to satisfy all such authorities with one approach;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to add or be delayed in adding a sufficient number of clinical trial sites and obtaining IRB or independent EC approval at each clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may fail to show safety or efficacy or otherwise produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enrollment in our clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in having subjects complete a clinical trial or returning for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to clinical trial protocols;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors, including clinical investigators, contract manufacturers and vendors may fail to comply with applicable regulatory requirements, lose their licenses or permits, or otherwise fail, or lose the ability to, meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may lack adequate funding to continue one or more clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites may deviate from clinical trial protocol or drop out of a clinical trial; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">occurrence of serious adverse events in trials of the same class of agents conducted by other companies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Adverse side effects, properties or other safety risks associated with PMN310, PMN267, PMN442 or any future product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is the case with pharmaceuticals generally, it is possible that there may be side effects and adverse events associated with the use of PMN310, PMN267, PMN442 or any future product candidates we may develop. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics as the clinical trials progress to greater exposures and a larger number of patients. Undesirable side effects caused by, or unexpected or unacceptable characteristics associated with, PMN310, PMN267, PMN442 or any future product candidates we may develop, could result in the delay, suspension or termination of clinical trials by us, the FDA or other regulatory authorities, or IRBs for a number of reasons. We may also elect to limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for such product candidate if approved. If we elect or are required to further delay, suspend or terminate any clinical trial of any product candidates we may develop, the commercial prospects of such product candidates will be harmed and our ability to generate drug revenues from any such product candidates will be delayed or eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">It is possible that, as we test our product candidates in clinical trials, or as the use of a product candidate becomes more widespread if it receives regulatory approval, we may identify additional adverse events that were not identified or not considered significant in our earlier trials. If such side effects become later known in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly. If we or others later identify undesirable side effects, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw, suspend or limit approval of a product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a drug or change the way such drug is administered to patients;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings or statements in the labeling, such as a boxed warning or a contraindication or issue safety alerts, press releases or other communications containing warnings or other safety information about the product candidate, for example, field alerts to physicians and pharmacies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require us to implement a REMS to ensure that the benefits of the drug outweigh its risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way a drug is distributed or administered, conduct additional clinical trials or be required to conduct additional post-marketing studies or surveillance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to regulatory investigations and government enforcement actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may decide to remove such product candidates, if approved, from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of the drug may decrease significantly or become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may experience delays or difficulties in the enrollment and retention of patients in clinical trials, which could delay or prevent our receipt of regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population and competition for patients eligible for our clinical trials with competitors which may have ongoing clinical trials for product candidates that are under development to treat the same indications as one or more of our product candidates or approved products for the conditions for which we are developing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA or foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity and difficulty of diagnosing the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility and exclusion criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population and process for identifying patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks and benefits of the product candidate in the trial, including relating to cell therapy approaches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of competing commercially available therapies and other competing therapeutic candidates&#8217; clinical trials for the disease or condition under investigation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to be enrolled in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential disruptions caused by any global health crisis, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity and availability of clinical trial sites for prospective patients.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance. Even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim, top-line and preliminary results from our planned clinical trials that we may announce or publish from time to time may change as more data become available and is subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, as we continue existing and initiate new clinical trials, we may publish interim, top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are reported. Differences between preliminary, top-line or interim data and final data could significantly harm our business prospects and may cause the trading price of our Common Shares to fluctuate significantly. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular development program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed meaningful by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We cannot be certain that PMN310, PMN267, PMN442 or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no product candidates approved for sale and we cannot guarantee that we will ever have marketable product candidates. Our ability to generate revenue related to sales of PMN310, PMN267 and PMN442, if ever, will depend on the successful development and regulatory approval of such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The development of a product candidate and its approval and commercialization, including the product candidate&#8217;s design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to extensive regulation by the FDA, the EMA and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the U.S., Europe or other countries until we receive approval of a BLA from the FDA or MAA from the EMA, respectively. We have not submitted any marketing applications for any product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BLAs and MAAs, and other foreign equivalents must include extensive nonclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. BLAs and MAAs must also include significant information regarding the chemistry, manufacturing and controls for the drug. Obtaining approval of a BLA or a MAA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA and the EMA review processes can take&#160;years to complete and approval is never guaranteed. If we submit a BLA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators of other jurisdictions, such as the EMA, have their own procedures for approval of product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if a drug is approved, the FDA or the EMA, or other foreign equivalent, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the U.S. and Europe also have requirements for approval of product candidates with which we must comply prior with marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the U.S., Europe or other countries may be based upon many factors, including regulatory requests for additional analyses, reports, data, nonclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period of drug development and the emergence of new information regarding PMN310, PMN267, PMN442 or other product candidates we may develop in the future. Also, regulatory approval for any of our product candidates may be withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before we submit a BLA to the FDA or a MAA to the EMA for a product candidate, we will be required to successfully complete our clinical trials. The FDA generally requires two pivotal clinical trials to support approval. In addition, we must scale up manufacturing and complete other standard nonclinical and clinical studies. We cannot predict whether clinical trials will be successful or whether regulators will agree with our conclusions regarding the nonclinical studies and the clinical trials we conduct. The FDA, EMA, and other comparable regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be granted for any product candidate that we develop and may decide that our data are insufficient for approval or require additional preclinical, clinical, or other data. The U.S. Supreme Court&#8217;s July 2024 decision to overturn prior established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, PMN310, is being developed for the treatment of AD, a disease that has seen limited success in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Efforts by biopharmaceutical and pharmaceutical companies in treating AD have seen limited success in drug development. Only three disease-modifying therapeutic options have been approved by the FDA. Biogen&#8217;s Aduhelm, a mAb administered via infusion, received Accelerated Approval from the FDA on June&#160;7, 2021 but commercialization was discontinued in January 2024. Eisai and Biogen&#8217;s lecanemab (Leqembi) and Lilly&#8217;s donanemab (Kisunla) received </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">traditional approval in 2023 and 2024, respectively. We cannot be certain that our approach will lead to the development of approvable or marketable products. With the exception of Leqembi and Kisunla, the only available FDA-approved drugs to treat patients with AD address the symptoms of the disease. Since 2003, over 500 clinical studies have been completed and only Aduhelm (discontinued), Leqembi and Kisunla have been approved by the FDA as disease-modifying therapeutic options. As a result, the FDA has a limited set of products to rely on in evaluating PMN310. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of PMN310 for the treatment of AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the significant uncertainty related to insurance coverage and reimbursement of all newly- approved products, there is greater uncertainty for products approved for the treatment of AD. For example, the&#160;yearly wholesale acquisition out of pocket cost of the maintenance dose of Aduhelm was $28,200. CMS issued a draft determination that proposes to cover the cost of anti-amyloid monoclonal antibodies, including Aduhelm, only in the context of clinical trials approved by CMS or by the National Institutes of Health. These include only randomized controlled trials conducted in hospital-based outpatient settings, and require patient diversity reflecting that of the U.S. population diagnosed with AD. In April&#160;2022, CMS confirmed this determination and announced that it would deny routine payment for Aduhelm and finalized a strict policy to require patients to enroll in clinical trials for the government to cover the drug. Biogen announced discontinuation of Aduhelm commercialization in January 2024. &#160;In contrast, Leqembi was priced at $26,500 and is covered by Medicare Part B and some private insurers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may in the future conduct clinical trials for our product candidates outside the U.S., and the FDA, EMA and other foreign regulatory authorities may not accept data from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may in the future choose to conduct one or more of our clinical trials outside the U.S. The acceptance of study data from clinical trials conducted outside the U.S. by FDA, or of data collected outside the jurisdiction by any foreign regulatory body, may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice; and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP, regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. Additionally, recent policy proposals in the U.S., if enacted in the future, may make acceptance by the FDA or inclusion in a marketing application of foreign data more difficult or costly. There can be no assurance that the FDA, EMA or any other foreign regulatory authority will accept data from trials conducted outside of their jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of nonclinical studies and clinical trials and the submission of regulatory filings, including BLA submissions. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may develop PMN310, PMN442, PMN267 and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may develop PMN310, PMN442, PMN267 and future product candidates for use in combination with one or more other approved therapies for the disease state being studied. Even if any product candidate we develop were to receive </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA, EMA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, we will not be able to market and sell any product candidate we develop in combination with an unapproved therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved therapies face the same risks described with respect to our product candidates currently in development, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As product candidates proceed through nonclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such changes carry the risk that they will not achieve our intended objectives. Any such changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes to our upstream and downstream processes across our pipeline, which could delay the development of our future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Capital Needs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred losses since inception and we anticipate that we will incur continued losses for the foreseeable future. We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The development of biopharmaceutical therapeutic candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned preclinical studies of our development programs, conduct existing and initiate new clinical trials for our therapeutic candidates and seek regulatory approval for our current therapeutic candidates and any future therapeutic candidates we may develop. If we obtain regulatory approval for any of our therapeutic candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our therapeutic candidates. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We had operating losses of $40.2 million and working capital of approximately ($1.2) million as of and for the year ended December 31, 2025. We will require substantial additional funds for further research and development, current and planned clinical testing, regulatory approvals, establishment of manufacturing capabilities and, if necessary, the marketing and sale of our products. Our ability to raise additional financing and maintain operations in the future could be at substantial risk and there can be no assurance that additional funding or partnerships will be available on acceptable terms, if at all, that would foster successful commercialization of our products. Failing to raise capital when needed or on attractive terms could force us to delay, reduce or eliminate our research and development programs or any future commercialization efforts. We may attempt to raise additional funds for these purposes through public or private equity or debt financing, use of &#8220;at-the-market&#8221; offerings, collaborations with other biopharmaceutical companies and/or from other sources.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have no product candidates approved for commercial sale, we have never generated any revenue from sales and we may never be profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no product candidates approved for sale, have never generated any revenue from sales, have never been profitable and do not expect to be profitable in the foreseeable future. We have not recorded any revenues from the sale of biopharmaceutical products. As of December 31, 2025, we had a deficit of $130.4 million. The cumulative deficit incurred from when we changed our name and focus in July&#160;2015, through December&#160;31, 2025 was $100.1 million. We expect to incur additional losses during the periods of research and development, clinical testing, and application for regulatory approval of its product candidates. We also expect to incur losses unless and until such time as payments from corporate collaborations, product sales and/or royalty payments generate sufficient revenues to fund its continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have devoted most of our financial resources to research and development of PMN310, including our clinical and nonclinical development activities of PMN310, and corporate overhead. We expect that it will be several&#160;years, if ever, before we have a product candidate approved and ready for commercialization. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, PMN310 and any other product candidate we may develop in the future, prepare for and begin the commercialization of any approved product candidates and add infrastructure and personnel to support our drug development efforts and operations as a public company. We anticipate that any such losses could be significant for the next several&#160;years. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our shareholders&#8217; equity and working capital. Further, these net losses may fluctuate significantly from quarter-to-quarter or&#160;year-to-year. To become and remain profitable, we must develop and eventually commercialize PMN310 or another drug with significant revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may never succeed in developing a commercial drug and, even if we succeed in commercializing one or more product candidates, we may never generate revenues that are large enough to achieve profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown challenges. Because of these numerous risks and uncertainties, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenues or achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis, and we will continue to incur substantial research and development costs and other expenditures to develop and market additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Commercialization of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Successful commercialization of our product candidates, if approved, will depend on a number of factors and we cannot guarantee that we will be able to successfully commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Successful commercialization of our products, if at all, will depend on a number of factors, including our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raise sufficient capital to fund future commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">build a commercial team and supporting organizational infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain necessary licenses, on commercially reasonable terms, for certain offerings we may contemplate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish partnerships and alliances with third parties to secure commercial capabilities that we may not wish to build;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market and distribute our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distinguish our products from others available on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain any necessary regulatory approvals for our facilities, product candidates and processes;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gain reimbursement by third-party payors, such as private health insurers, managed-health organizations, and state-sponsored health insurance plans for each jurisdiction in which our products are offered;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">educate physicians and change physician behavior to secure clinical adoption of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promote awareness of our products to increase market penetration; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publish in peer-reviewed journals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is no assurance that we will be successful in these areas. Any failure or delay in such areas could have a material adverse impact on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for PMN310, PMN267, PMN442 and future product candidates, if approved, may be smaller than we anticipate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to seek approval for product candidates for various neurodegenerative diseases and other misfolded protein diseases. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and market research and may prove to be incorrect. Even if we obtain significant market share for our product candidates after FDA approval, the potential target populations may be too small to consistently generate revenue, and we may never achieve profitability without obtaining marketing approval for additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if one or more of our product candidates receive FDA or other regulatory approvals, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy of our product as compared to other available therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement from governmental healthcare plans or third-party payors for any of our product candidates that may be approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proper training and administration of our product candidates by physicians and medical staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public misperception regarding the use of our therapies, if approved for commercial sale;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue and profitability that our products may offer a physician as compared to alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the FDA-approved labeling for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any FDA requirement to undertake a REMS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales, marketing and distribution efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity about our products or favorable publicity about competitive products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot assure that our current or future product candidates, if approved, will achieve broad market acceptance among physicians, patients, healthcare payors and others in the medical community. Even if we receive regulatory approval to market any of our product candidates, we cannot assure that any such product candidate will be more effective than other commercially available alternatives or successfully commercialized. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS.&#160;Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our reputation, ability to raise additional capital, financial condition, results of operations and business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process to commercialize our potential products, which may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our third-party manufacturers will be successful in establishing a larger-scale commercial manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition, there is no assurance that any third-party manufacturers will be able to manufacture our product candidates to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of such products or to meet potential future demand. Our failure to properly or adequately scale up manufacturing for commercial scale would adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. For more information regarding the risks related to insurance coverage and reimbursement please see &#8220;<i style="font-style:italic;">Business&#160;&#8212; Government Regulation&#160;&#8212; Pricing and Reimbursement</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safe, effective and medically necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appropriate for the specific patient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the U.S., the European Union or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the U.S., third-party payors, and governmental healthcare plans, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the U.S. for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the U.S. and foreign jurisdictions, if approved, or generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">We currently do not have a marketing or sales organization. In order to commercialize our product candidates in the U.S. and foreign jurisdictions, if approved, we intend to make arrangements with third parties to perform these services, and we may not be successful in doing so. If we are unable to enter into such arrangements on acceptable terms or at all, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">we may not be able to successfully commercialize our product candidates, if approved. If we are not successful in commercializing our product candidates or any future product candidates, if approved, either on our own or through arrangements with third parties, we may not be able to generate any product revenue and we would incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will rely on third parties to supply components, research, develop, test, and manufacture our product candidates and market these product candidates, if approved. The loss of any of these third-party relationships or the failure of any of them to meet their obligations to us could affect our ability to develop and obtain approval of our product candidates in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our activities will require us to enter into various arrangements with corporate and academic collaborators, licensors, licensees and others for the research, development, clinical testing, manufacturing, marketing and commercialization of our products. We intend to attract corporate partners and enter into additional research collaborations. There can be no assurance, however, that we will be able to establish such additional collaborations on favorable terms, if at all, or that our current or future collaborations will be successful. Failure to attract commercial partners for our products may result in substantial clinical testing, manufacturing and commercialization costs prior to realizing any revenue from product sales or result in delays or program discontinuance if funds are not available in sufficient quantities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should any collaborative partner fail to develop, manufacture, or successfully commercialize any product to which we have rights, or any partner&#8217;s product to which we will have rights, our business may be adversely affected. Failure of a collaborative partner to continue to participate in any particular program could delay or halt the development or commercialization of products generated from such program. In addition, there can be no assurance that the collaborative partners will not pursue other technologies or develop alternative products either alone or in collaboration with others, including our competitors, as a means for developing treatments for the diseases targeted by our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, we will hold licenses for certain technologies and there can be no assurance that these licenses will not be terminated, or that they will be renewed on acceptable conditions. We intend to negotiate additional licenses in respect of technologies developed by other companies and academic institutions. Terms of license agreements to be negotiated may include, <i style="font-style:italic;">inter alia</i>, a requirement to make milestone payments, which may be substantial. We will also be obligated to make royalty payments on the sales, if any, of products resulting from licensed technology and, in some instances, may be responsible for the costs of filing and prosecuting patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We intend to rely on CROs and other third parties to conduct, supervise and monitor a significant portion of our research and nonclinical testing and clinical trials for our product candidates, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to engage CROs and other third parties to conduct our planned nonclinical studies or clinical trials, and to monitor and manage data. We expect to continue to rely on third parties, including clinical data management organizations, medical institutions and clinical investigators, in the future. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience. If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative third parties or to do so on commercially reasonable terms, if at all. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, any third parties conducting our clinical trials will not be our employees, and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">resources to our clinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to rely on these parties for execution of our nonclinical studies and clinical trials and generally do not control their activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCPs, which are standards for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMPs conditions. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process, or may result in fines, adverse publicity and civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval for PMN310 or any other product candidate we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If any of our third-party manufacturers encounter difficulties in production of PMN310, PMN267, PMN442 or any future product candidate we develop, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or, if approved, for commercial sale could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The processes involved in manufacturing PMN310, PMN267, PMN442 and any other product candidate we may develop are highly-regulated and subject to multiple risks. As product candidates are developed through nonclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our third-party manufacturers, such facilities may need to be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to conduct clinical trials of our product candidates, or supply commercial product candidates, if approved, we will need to manufacture them in both small and large quantities. We currently rely on third parties to manufacture our product candidates, and our manufacturing partners will have to modify and scale-up the manufacturing process when we transition to commercialization of our product candidates, if approved. Our manufacturing partners may be unable to successfully modify or scale-up the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale-up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the manufacturing process for any product candidates that we may develop will be subject to FDA, EMA and foreign regulatory requirements, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including complying with cGMPs on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce product candidates in accordance with the requirements of the FDA, EMA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such product candidates. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our third-party contract manufacturers will be able to manufacture the approved product in accordance with the requirements of the FDA, EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods and have an adverse effect on our business, financial condition, results of operations and growth prospects. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will likely seek collaborations with third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates, including PMN310, PMN267 and PMN442. Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will likely seek third-party collaborators for the commercialization of PMN310, PMN267, PMN442 and any of our future product candidates, in the U.S. and may enter into collaboration agreements for the development and commercialization of any of our product candidates outside the U.S. In the U.S., commercialization partners are likely to include large biotechnology or pharmaceutical companies. Our likely collaborators outside the U.S. would most likely include regional and national pharmaceutical companies and biotechnology companies. If we enter into such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Collaborations involving our product candidates would pose the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or similar regulatory authorities outside the U.S., the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates, and other proprietary technologies if approved, may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on our ability to obtain and maintain a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates, and other proprietary technologies we develop. If we are unable to obtain or maintain patent protection with respect to our product candidates, and other proprietary technologies we may develop, our business, financial condition, results of operations, and prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies is highly uncertain and involves complex legal, scientific, and factual questions and has been the subject of frequent litigation in recent&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued that protect our product candidates and other proprietary technologies we may develop or that effectively prevent others from commercializing competitive technologies and products. Further, no consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the U.S. or in many jurisdictions outside of the U.S. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in the patents that may be issued from the applications we may own or license from third parties. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators will be successful in protecting our product candidates and other proprietary technologies and their uses by obtaining, defending and enforcing patents. These risks and uncertainties include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications may not result in any patents being issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or may otherwise not provide any competitive advantage;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use and sell our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other parties may have designed around our claims or developed technologies that may be related or competitive to ours, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications and/or patents, either by claiming the same composition of matter, methods or formulations or by claiming subject matter that could dominate our patent position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any product candidate that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">because patent applications in the U.S. and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates and other proprietary technologies and their uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an interference proceeding can be provoked by a third-party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of any application with an effective filing date before March&#160;16, 2013;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">U.S. courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates in those countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, or maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection for such output. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and other proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to file patent applications for these inventions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patents that we obtain may not provide us with any competitive advantages;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights or where patent protection is weak and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third-party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition or invalidity proceedings before U.S. or non-U.S. patent offices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot be certain that claims in an issued patent covering our product candidates will be considered patentable by the USPTO, courts in the U.S., or by patent offices and courts in foreign countries. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property internationally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The strength of patents in the biotechnology and pharmaceutical fields involves complex legal and scientific questions and can be uncertain. Patent applications that we file or in-license may fail to result in issued patents with claims that cover our product candidates in the U.S. or in foreign countries. Even if such patents do successfully issue, third parties may challenge the ownership, validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. If the breadth or strength of protection provided by our patents with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For U.S. patent applications in which claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For U.S. patent applications containing a claim not entitled to priority before March&#160;16, 2013, there is greater level of uncertainty in the patent law. In September&#160;2011, the Leahy-Smith America Invents Act, or America Invents Act, was signed into law. The America Invents Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is developing regulations and procedures to govern the administration of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and in particular, the &#8220;first to file&#8221; provisions, were enacted on March&#160;16, 2013. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. It remains unclear what impact the America Invents Act will have on the operation of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">business. As such, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the U.S., provided all maintenance fees are timely paid, a patent generally has a term of 20&#160;years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. When the terms of all patents covering our product candidates expire, our business may become subject to competition from competitive products, including biosimilar version of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates are protected by certain patents or patent applications, which expire at varying times. We cannot be certain that we will file and, if filed, obtain patent protection for our product candidates beyond our rights in our current patent portfolio. If we are unable to obtain additional patent protection on our product candidates, our primary protection from biosimilar market entries will be limited to regulatory biologic exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extension for our product candidates our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration, and specifics of any FDA marketing approval of our product candidates, one or more of patents issuing from U.S. patent applications that we file or license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term, or PTE, of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate, or SPC. If we encounter delays in our development efforts, including our future clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the license agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense intellectual property rights to third parties under collaborative development relationships;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms and/or to secure our rights to the licensed intellectual property, our business, results of operations, financial condition, and prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ outside counsel to pay these fees due to foreign patent agencies. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market with similar or identical products or technology earlier than should otherwise have been the case, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Our patent rights may be affected by developments or uncertainty in United States or foreign patent statutes, patent case law, USPTO rules&#160;and regulations or the rules&#160;and regulations of foreign patent offices. Obtaining and enforcing patents in the biotechnology and pharmaceutical industry involve both technological and legal complexity, and is therefore costly, time- consuming and inherently uncertain. In addition, the United States &#160;may, at any time, enact changes to its patent law and regulations, including by legislation, by regulatory rule-making, or by judicial precedent, that adversely affect the scope of patent protection available and weaken the rights of patent owners to obtain patents, enforce patent infringement and obtain injunctions and/or damages. For example, the scope of patentable subject matter under 35 U.S.C. 101 has evolved significantly over the past several&#160;years as the Court of Appeals for the Federal Circuit and the Supreme Court issued various opinions, and the USPTO modified its guidance for practitioners on multiple occasions. Other countries may likewise enact changes to their patent laws in ways that adversely diminish the scope of patent protection and weaken the rights of patent owners to obtain patents, enforce patent infringement, and obtain injunctions and/or damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Further, the United States and other governments may, at any time, enact changes to law and regulation that create new avenues for challenging the validity of issued patents. For example, the America Invents Act created new administrative post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes</i> review, and derivation proceedings that allow third parties to challenge the validity of issued patents. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents are of national or regional effect. Filing, prosecuting, and defending patents on our product candidates, and other proprietary technologies we develop in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The requirements for patentability may differ in certain countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval for a drug and its patent status. In addition to India, certain countries in Europe and developing countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third-party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology or pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an interest in our patents rights, trade secrets, or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. For example, we may have inventorship disputes arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through in-licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Presently we have intellectual property rights to our product candidates through a license from the UBC. Assuming this agreement remains in place, we could be required to pay a low to high single digit royalty on revenues to UBC in the future. Because our program may require the use of additional proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license, on reasonable terms, proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidates. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain or enforce the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. If any of our licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, or in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, we will likely have obligations under our current or future licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical or similar to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For example, we have collaborated and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate an exclusive license to any of the institution&#8217;s proprietary rights in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">technology resulting from the collaboration. Regardless of such option to negotiate a license, we may be unable to negotiate a license within the specified time-frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. In addition, disputes may arise under our existing or future license agreements with these institutions or with other counterparties, which may, among other things, lead to the termination or renegotiation of these agreements, or otherwise require us to incur significant financial obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition, and prospects for growth, could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including <i style="font-style:italic;">inter partes</i> review, interference and reexamination proceedings before the USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. The America Invents Act introduced new procedures including <i style="font-style:italic;">inter partes</i> review and post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future and the outcome of such challenges. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product candidates may give rise to claims of infringement of the patent rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure you that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third-party might assert are infringed by one of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents of which we are currently unaware with claims to materials, compositions, formulations, methods of manufacture or methods for treatment related to our product candidates, or the use or manufacture of our product candidates. Because patent applications can take many&#160;years to issue and may be confidential for 18&#160;months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our product candidates, and other proprietary technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of management and other employee resources from our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any claims of patent infringement asserted by third parties would be time-consuming and could:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">result in costly litigation;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">divert the time and attention of our technical personnel and management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cause development delays;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent us from commercializing our product candidates until the asserted patent expires or is finally held invalid, unenforceable, or not infringed in a court of law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be willfully infringing; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to enter into royalty or license agreements, which may not be available on commercially reasonable terms, or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do either. Proving invalidity or unenforceability is difficult. For example, in the U.S., proving invalidity before federal courts requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity or enforceability of the patents in court. Patent litigation is costly and time- consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid or unenforceable, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from developing, manufacturing or selling our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. We cannot be certain that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the U.S., Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction, because:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">some patent applications in the U.S. may be maintained in secrecy until the patents are issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications in the U.S. and elsewhere can be pending for many&#160;years before issuance, or unintentionally abandoned patents or applications can be revived;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or their uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications in the U.S. are typically not published until 18&#160;months after the priority date; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publications in the scientific literature often lag behind actual discoveries.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies or product candidates are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates or future products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over one of our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a third-party prevails in a patent infringement lawsuit against us, we may have to stop making and selling the infringing product, pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing a third-party&#8217;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates, and other proprietary technologies. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third parties including competitors may infringe, misappropriate or otherwise violate our patents, patents that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may need to or choose to file infringement claims, which can be expensive and time- consuming. We may not be able to prevent, alone or with our licensors, infringement, misappropriation, or other violation of our intellectual property, particularly in countries where the laws may not protect those rights as fully as in the United States, or if we require, but do not receive, the consent or cooperation of our licensors to enforce such intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we choose to go to court to stop another party from using the inventions claimed in our patents, that individual or company has the right to ask the court to rule&#160;that such patents are invalid, unenforceable, or should not be enforced against that third-party for any number of reasons. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness, lack of written description, indefiniteness, or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution, i.e., committed inequitable conduct. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we or our licensors hold now or in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our future clinical trials, continue our research programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Common Shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to enforce our patent rights depends on our ability to establish standing in a court of competent jurisdiction. Whether a patent holder or licensee of a patent has standing can be uncertain and the considerations complex. However, if a licensor is required to be joined, and they are unwilling to do so, we may be unable to proceed with an infringement action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent or patents that may issue from patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and/or other advisors, and inventions agreements with employees, consultants, and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer, or third-party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company or academic to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors, and/or consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our trademarks or trade names, once registered, may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, any names we may propose to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. Similar requirements exist in Europe. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of the date of this Annual Report on Form 10-K, neither our patents nor our product candidates are subject to march-in rights. However, some of &#160;our future patents may be generated through the use of &#160;U.S. government &#160;funding, and we may acquire or license in the future intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third-party if it determines that: (1)&#160;adequate steps have not been taken to commercialize the invention; (2)&#160;government action is necessary to meet public health or safety needs; or (3)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). If the U.S. government exercised its march-in rights in our future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Legal and Regulatory Compliance Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third- party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations promulgated under such laws. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs, and other interactions with healthcare professionals. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. For more information regarding the risks related to these laws and regulations please see &#8220;Business&#160;&#8212; Government Regulation&#160;&#8212; &#8220;U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices could, despite efforts to comply, be subject to challenge under current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In Loper Bright Enterprises v. Raimondo, for example, the court overruled Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., which for 40 years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency such as the FDA acted within its statutory authority under the Administrative Procedure Act (APA). Additionally, in Corner Post, Inc. v. Board of Governors of the Federal Reserve System, the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision, Securities and Exchange Commission v. Jarkesy, overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and CMS, that we rely on. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Finally, with the change in presidential administrations in 2025, there continues to be substantial uncertainty as to the extent and manner in which the current administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. This uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates. Also, state governments may seek to address or react to changes at the federal level with changes to their regulatory frameworks in a manner that could impact our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and could materially adversely impact our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for PMN310, PMN442, PMN267 or any future product candidates, they will remain subject to ongoing regulatory oversight, which may result in significant additional expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Even if we obtain any regulatory approval for PMN310, PMN442, PMN267 or any future product candidates, such product candidates will be subject to ongoing regulatory requirements applicable to research, development, testing, manufacturing, labeling, packaging, storage, advertising, promoting, sampling, record- keeping and submission of safety and other post-market information, among other things. Any regulatory approvals that we receive for PMN310, PMN442, PMN267 or any future product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">drug may be marketed or to the conditions of approval, or requirements that we conduct potentially costly post-marketing testing and surveillance studies, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the drug. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. We will further be required to timely report any serious and unexpected adverse events and certain quality or production problems with our products to regulatory authorities along with other periodic reports. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to comply with applicable regulatory requirements following approval of a product candidate, a regulatory authority may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue a Form&#160;483, an untitled letter or warning letter asserting that we are in violation of the law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue a safety alert, Dear Healthcare Provider letter, press release or other communication containing warnings or safety information about the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandate corrections to promotional materials and labeling or issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any ongoing clinical trials;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve a pending marketing application or supplement to an approved application or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrict the marketing or manufacturing of the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain the drug or otherwise require the withdrawal of the drug from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to permit the import or export of products or product candidates; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to allow us to enter into supply contracts, including government contracts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize a product candidate, if approved, and harm our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to or affected by federal, state and foreign data protection laws and regulations which address privacy and data security. In the U.S., numerous federal and state laws and regulations, including HIPAA, as amended by HITECH, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section&#160;5 of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of any future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative, civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, various states have implemented similarly comprehensive privacy laws and regulations. For example, the California Consumer Privacy Act, or CCPA, &#160;established a comprehensive privacy framework for covered businesses and gives California residents certain privacy rights, including the right &#160;to access and delete their personal information, opt out of certain personal information sales or transfers, receive detailed information about how their personal information is used and limit the use and sharing of sensitive personal information. The CCPA provides for civil penalties, as well as a private right of action for certain data breaches, and created an agency specifically tasked with enforcing the CCPA, which may increase the risk of litigation. &#160;Similar consumer privacy laws have passed in numerous other U.S. states with several more expected to pass in the coming years. Like the CCPA, these laws grant consumers rights in relation to their personal information and impose new privacy and data security obligations on regulated businesses. These comprehensive privacy laws in different states in the country vary in their scope, application and enforcement, which may complicate compliance efforts. In addition some states have passed or proposed laws specifically regulating consumer health information. For example, Washington&#8217;s My Health My Data Act (MHMDA), requires regulated entities to obtain consent to collect health information, grants consumers certain rights, including to request deletion, and provides for robust enforcement mechanisms, including a private right of action for consumer claims. At the federal level, the FTC has used its authority over &#8220;unfair or deceptive acts or practices&#8221; to impose stringent requirements on the collection and disclosure of sensitive categories of personal information, including health information. Moreover, the FTC&#8217;s expanded interpretation of a &#8220;breach&#8221; under its Health Breach Notification Rule could impose new disclosure obligations that would apply in the event of a qualifying breach. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulators and legislators in the U.S. are increasingly scrutinizing and restricting certain personal data transfers and transactions involving foreign countries. The federal government has taken steps to restrict data transactions involving certain sensitive data categories &#8211; including health data, genetic data, and biospecimens &#8211; with persons or entities affiliated with countries of concern. For example, the Department of Justice&#8217;s January 8, 2025, Rule on Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons prohibits transfers of data including health data, genetic data, and biospecimens, to countries of concern, including China. The rule also prohibits covered businesses from granting access to certain investment agreements, employment agreements and vendor agreements involving such data to countries of concern, absent specified cybersecurity controls. Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions, may result in exclusion from participation in federal and state programs and may restrict our ability to use certain vendors, sites, investigators, or service providers in global clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Foreign data protection laws may also apply to health-related and other personal information we process. For example, the collection and use of personal information (including health data) in Europe are governed by the provisions of the EU General Data Protection Regulation (EU GDPR) as well as other national data protection legislation in force in relevant EU Member States, with respect to the European Economic Area (EEA), and the U.K. General Data Protection Regulation (the U.K. GDPR, together with the EU GDPR the GDPR) and the U.K. Data Protection Act 2018 with respect to the United Kingdom (U.K.). These laws impose a broad range of strict requirements on companies subject to the GDPR, such as including requirements relating to having legal bases or a condition for processing personal data relating to identifiable individuals and transferring such information outside the EEA or the U.K., providing details to those individuals regarding </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the processing of their personal data, implementing safeguards to keep personal data secure, having data processing agreements with third parties who process personal data, providing information to individuals regarding data processing activities, responding to individuals&#8217; requests to exercise their rights in respect of their personal data, obtaining consent of the individuals to whom the personal data relates, reporting security and privacy breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments, and record-keeping. The GDPR may impose additional responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the EEA and U.K. data protection regimes. This may be onerous and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The GDPR prohibits the international transfer of personal data to countries outside of the EEA or the U.K. ("third countries") which are not deemed as adequate for the transfers of personal data by competent authorities, unless a derogation exists or adequate safeguards (for example, the European Commission approved Standard Contractual Clauses ("EU SCCs") and the U.K. International Data Transfer Agreement/Addendum ("U.K. IDTA")) are implemented. Where relying on the EU SCCs or U.K. IDTA for data transfers, we may also be required to carry out transfer impact assessments on a case-by-case basis to ensure the law in the data importer&#8217;s country and the data importer can ensure sufficient guarantees for safeguarding the personal data. These international transfer restrictions will require significant effort and cost and may result in us needing to make strategic considerations around storage and transfer of personal data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EU Commission has adopted its adequacy decision for the EU-U.S. Data Privacy Framework ("Framework") agreed with the U.S., which entered into force on July 11, 2023. This Framework provides a further avenue to transfer European personal data to U.S. companies which self-certified with the Framework, without the need for further safeguards. However, the Framework&#8217;s validity has already been challenged in European courts and the Framework could subsequently be invalidated like its predecessors Privacy Shield and Safe Harbor frameworks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the U.K. is regarded as a third country under the EU&#8217;s GDPR, the European Commission has issued an adequacy decision recognizing the U.K. as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the U.K. remain unrestricted. In December 2025, the European Commission adopted a decision to extend the validity of the U.K. adequacy decision for six years until December 2031, determining that the U.K. continues to offer a level of data protection that is &#8220;essentially equivalent&#8221; to the EU standards. This follows the U.K.&#8217;s adoption of the Data (Use and Access) Act 2025 (the DUAA) on 19 June 2025. Like the EU GDPR, the U.K. GDPR restricts personal data transfers outside the U.K. to countries not regarded by the U.K. as providing adequate protection. The U.K. Government has confirmed that personal data transfers from the U.K. to the EEA remain free flowing. The respective provisions and enforcement of the EU GDPR and U.K. GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of the respective provisions and enforcement of the EU GDPR and U.K. GDPR further diverging in the future creates additional regulatory challenges and uncertainties for us. The lack of clarity on future U.K. laws and regulations and their interaction with EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of European personal data and our privacy and data security compliance programs and could require us to implement different compliance measures for the U.K. and the EEA. In addition, EEA Member States have adopted national laws to implement the EU GDPR that may partially deviate from the EU GDPR and competent authorities in the EEA Member States may interpret the EU GDPR obligations slightly differently from country to country. Therefore, we do not expect to operate in a uniform legal landscape in Europe </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If we are investigated by a European or U.K. data protection authority, we may face fines and other penalties, including bans on processing and transferring personal data. EEA and U.K. data protection authorities have the power to impose administrative fines for violations of the GDPR of up to a maximum of &#8364;20 (&#163;17.5 under the U.K. GDPR) million or 4% of our total worldwide global turnover for the preceding fiscal year, whichever is higher, and violations of the GDPR may also lead to damages claims by data controllers and data subjects. Such penalties are in addition to any civil litigation claims by data controllers, clients, and data subjects. Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">could result in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The use of new and evolving technologies, such as artificial intelligence (AI), in our offerings may result in spending material resources and presents risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, and as a result we may be exposed to reputational harm and liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Artificial intelligence presents risks and challenges that can impact our business including by posing cybersecurity risks to our confidential information, proprietary information, and personal data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We continue to build and integrate artificial intelligence (AI) into our offerings, including in our own development and implementation of AI through the adoption of commercially available tools. Our use of AI presents risks and challenges that could adversely affect our business and reputation, including cybersecurity, data privacy, IT, confidentiality, regulatory, legal, operational, competitive, reputational, intellectual property and other risks. Specifically, risks related to accuracy, bias, AI hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks (including model poisoning or data poisoning), surveillance, data leakage, bias and inequality, environmental and other harms may flow from our development or use of AI technologies. Certain AI tools may increase the risk of unauthorized disclosure of confidential information, compromise of proprietary intellectual property, or inadvertent inclusion of third-party intellectual property or other protected material, which could result in disputes or claims of infringement. Development, use, and deployment of these technologies could pose cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, reputational, and other risks and challenges that could affect our business. Specifically, risks related to bias, AI hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks such as model poisoning or data poisoning, surveillance, data leakage, loss of consensus reality, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government and supranational regulation related to AI is evolving as new laws and regulations are implemented globally and could increase the burden and operational cost of compliance in this area, including through requirements related to transparency, accountability, risk management, human oversight, and data governance. We expect to see increasing regulation related to AI governance, use and ethics, which may also increase the burden and cost of research, development and compliance. For example, the EU&#8217;s Artificial Intelligence Act (AI Act) entered into force on August 1, 2024, with important sections scheduled to come into effect in August 2026. As currently enacted, the AI Act imposes significant obligations on providers and deployers of high-risk AI systems and general purpose AI models, and encourages providers and deployers of AI systems to account for EU ethical principles when developing and using AI technology. The scope of requirements depends on legal and risk determinations that rely on legal provisions that have not yet been fully interpreted by courts or regulators, and non-compliance can lead to significant fines. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the U.S., the regulatory environment is complex and uncertain. Over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI governance and regulation, including on deployment of AI in healthcare settings. At the federal level, the current administration has endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. In addition, there is continued uncertainty regarding the application of existing federal and state legal frameworks to uses and development of AI, and legal norms and market standards regarding AI continue to evolve. For example, various federal and state regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The U.S. Food and Drug Administration, for example, issued guidance on the use of AI in medical devices, requiring detailed risk management and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">review processes to obtain approvals. If we develop or use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality, transparency, and human oversight, and we would need to adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements, with the potential for significant enforcement or litigation in the event of any perceived non-compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain our products and services to help ensure that AI is implemented in accordance with applicable law and regulation, in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising confidential or proprietary intellectual property, or by undermining our ability to assert or defend ownership rights in intellectual property created with the assistance of AI tools. Our vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain FDA or EMA approval any of our product candidates in the U.S. or European Union, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Approval by the FDA in the U.S. or the EMA in the European Union does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional nonclinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government- paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Additional changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules&#160;regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the ACA and the passage of additional laws and regulations may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program. For more information regarding the risks related to recently enacted and future legislation please see &#8220;<i style="font-style:italic;">Business&#160;&#8212; Government Regulation&#160;&#8212; Healthcare Reform Measures.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: &#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for our product candidates, if we obtain regulatory approval; &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to set a price that we believe is fair for our approved products; &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenue and achieve or maintain profitability; &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that we are required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital. &#160; </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business activities may be subject to the Foreign Corrupt Practices Act of 1977 (FCPA) and similar anti-bribery and anti-corruption laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business activities may be subject to the FCPA, U.S. domestic bribery statutes, and similar anti- bribery or anti-corruption laws, regulations or rules&#160;of other countries in which we may operate, including the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">U.K. Bribery Act of 2010. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. There is no certainty that all of our employees, agents, contractors or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our product candidates in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards, FCPA and similar anti-bribery and anti-corruption laws, and requirements and insider trading, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with health care fraud and abuse laws and regulations in the U.S. and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, products liability and directors&#8217; and officers&#8217; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of PMN310 or any other product candidate. Any &#160;significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations. We may in the future operate beyond the United States and, if approved, we may sell our products in countries throughout the world. Significant political, trade, or regulatory developments in the jurisdictions in which we may sell our products, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on us. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. For example, on February 1, 2025, the U.S. imposed a 25% tariff on imports from Canada and Mexico, which were subsequently suspended for a period of one month, and a 10% additional tariff on imports from China. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective than ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The development and commercialization of new drugs is highly competitive. Moreover, the AD field is characterized by strong competition and a strong emphasis on intellectual property. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If approved, PMN310 will likely compete with therapies currently approved for the treatment of patients with AD, which have primarily been developed to treat the symptoms of AD rather than the underlying cause of the disease, such as memantine and cholinesterase inhibitors. PMN310 may also compete with one or more potentially disease-modifying therapeutics that target A&#946; or amyloid plaques. Biogen&#8217;s aducanumab (Aduhelm) was approved by the FDA in June&#160;2021 under the Accelerated approval pathway but commercialization was discontinued in January 2024. &#160;Lecanemab (Leqembi) from Eisai and Biogen received traditional approval from FDA in 2023, and donanemab (Kisunla) from Lilly received approval in 2024. Other companies known to be developing therapies with A&#946;/amyloid plaque-related targets include Alzheon,&#160;Inc., Alzinova AB, Chugai Pharmaceutical Co.&#160;Ltd., Cognition Therapeutics,&#160;Inc., Eisai Co.,&#160;Ltd., Eli Lilly and Company, Grifols, S.A., KalGene Pharmaceuticals,&#160;Inc., Neurimmune AG, Novartis AG, Acumen Pharmaceuticals&#160;Inc., Prothena Biosciences,&#160;Inc., Roche Holding AG (including Genentech, its wholly owned subsidiary) and Wren Therapeutics,&#160;Inc. Additionally, PMN310, if approved, may also compete with other potential therapies intended to address underlying causes of AD that are being developed by several companies, including AbbVie&#160;Inc., AC Immune SA, Alector,&#160;Inc., Anavex Life Sciences Corp., Annovis Bio,&#160;Inc., &#160;Athira Pharma,&#160;Inc., Biohaven Pharmaceuticals,&#160;Inc., Cassava Sciences,&#160;Inc., Cortexyme,&#160;Inc., Denali Therapeutics,&#160;Inc., Johnson&#160;&amp; Johnson (including Janssen, its wholly-owned subsidiary) and Takeda Pharmaceutical Co.&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved product candidates than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any product candidates that we may develop. Furthermore, currently approved product candidates could be discovered to have application for treatment of AD, which could give such product candidates significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours from the FDA, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, product candidates or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our competitors market product candidates that are more effective, safer or less expensive than our product candidates, if approved, or that reach the market sooner than our product candidates, we may not achieve commercial success. In addition, the pharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or product candidates developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, particularly our CEO, Neil Warma, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our current or any future product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may explore strategic collaborations that may never materialize or may fail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may attempt to broaden the global reach of our platform by selectively collaborating with leading therapeutic companies and other organizations. As a result, we may periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. In the event we do form such collaborations, we intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Ownership of Our Common Shares and Our Status as a U.S. Public Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Common Shares are currently listed on Nasdaq. We cannot assure you that we will be able to maintain a listing of our Common Shares on any such trading venue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On January 8, 2025, we received written notice from Nasdaq stating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because, for the 30 consecutive business days prior to the date of the deficiency letter, the closing bid price for our Common Shares was trading below the minimum $1.00 per share requirement. We subsequently regained compliance as of December 12, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">If Nasdaq delists our Common Shares, investors may face material adverse consequences, including, but not limited to, a lack of trading market for the Common Shares, reduced liquidity, decreased analyst coverage of the Company, and an inability for us to obtain additional financing to fund our operations. While a listing on an over-the-counter exchange could maintain some degree of a market in our Common Shares, we could face substantial material adverse consequences, including, but not limited to, the following: limited availability for market quotations for our Common Shares; reduced liquidity with respect to and decreased trading prices of our Common Shares; a determination that shares of our Common Shares are &#8220;penny stock&#8221; under the SEC rules, subjecting brokers trading our Common Shares to more stringent rules on disclosure and the class of investors to which the broker may sell the Common Shares; limited news and analyst coverage for our Company, in part due to the &#8220;penny stock&#8221; rules; decreased ability to issue additional securities or obtain additional financing in the future; and potential breaches under or terminations of our agreements with current or prospective large stockholders, strategic investors and banks. The perception among investors that we are at heightened risk of delisting could also negatively affect the market price of our securities and trading volume of our common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investment in the Company&#8217;s Common Shares is speculative, involves risk, and there is no guarantee of a return.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is no guarantee that the Common Shares will earn any positive return in the short term or long term. A holding of Common Shares is speculative and involves a high degree of risk and should be undertaken only by holders whose financial resources are sufficient to enable them to assume such risks and who have no need for immediate liquidity in their investment. A holding of Common Shares is appropriate only for holders who have the capacity to absorb a loss of some or all of their holdings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our share price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The trading market for our Common Shares will be influenced by the research and reports that equity research analysts publish about us and our business. As a relatively new public company, we anticipate having only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our Common Shares, and such lack of research coverage may adversely affect the market price of our Common Shares. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">company or fails to publish reports on us regularly, demand for our shares could decrease, which in turn could cause our shares price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of ownership of our Common Shares among our existing executive officers, directors and principal shareholders may prevent new investors from influencing significant corporate decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on their shareholdings as of December 31, 2025, our directors, executive officers and beneficial owners of greater than 5% of our outstanding shares and their respective affiliates will beneficially own, in the aggregate, approximately 60% of our outstanding Common Shares. As a result, these persons, acting together, would be able to significantly influence all matters requiring shareholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets or other significant corporate transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Some of these persons or entities may have interests different than yours. For example, because many of these shareholders purchased their shares at prices substantially below the estimated public offering price and have held their shares for a longer period, they may be more interested in selling our Company to an acquirer rather than other investors, or they may want us to pursue strategies that deviate from the interests of other shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our constating documents permit us to issue an unlimited amount of additional Common Shares or Preferred Shares, which may prevent a third-party takeover or cause our shareholders to experience dilution in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our constating documents authorize us to issue an unlimited&#160;number of Common Shares and an unlimited&#160;number of&#160;Preferred Shares. Our Board has the authority to cause us to issue additional Common Shares and Preferred Shares and to determine the special rights and restrictions of the shares of one or more series of our Preferred Shares, each without consent of our shareholders. The issuance of any such securities may result in a reduction of the book value or market price of our Common Shares. Given the fact that we have not achieved profitability or generated positive cash flow historically, and we operate in a capital-intensive industry with significant working capital requirements, we may be required to issue additional Common Shares or other securities that are dilutive to existing shareholders&#160;in the future in order to continue our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, on September 22, 2023, we filed a registration statement on Form S-3 (File No. 333-274658) with the SEC, which was declared effective on September 29, 2023 (2023 Shelf Registration Statement), in relation to the registration of Common Shares, preferred shares, subscription receipts, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our Common Shares, debt securities or other equity securities in one or more offerings. On January 5, 2024, we entered into an At The Market Offering Agreement with BTIG, LLC to provide for the offering, issuance and sale of up to an aggregate amount of $25.0 million of our Common Shares from time to time in &#8220;at-the-market&#8221; offerings under the 2023 Shelf Registration Statement and subject to the limitations thereof, including the rules applicable to us if our public float as of a measuring date preceding the Annual Report is less than $75 million. On July 21, 2025, the At The Market Offering Agreement was terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 13, 2025, we filed a registration statement on Form S-3 (File No. 333-289577) with the SEC, which was declared effective on September 4, 2025 (2025 Shelf Registration Statement), in relation to the registration of Common Shares for the purposes of selling, from time to time, our Common Shares in one or more offerings. On August 13, 2025, we entered in an At The Market Offering Agreement with H.C. Wainwright &amp; Co, LLC to provide for the offering, issuance, and sale of up to an aggregate amount of $18.0 million of our Common Shares from time to time in &#8220;at-the-market&#8221; offerings under the 2025 Shelf Registration Statement and subject to the limitations thereof, including the rules applicable to us if our public float as of a measuring date preceding the Annual Report is less than $75 million, which rules we are currently subject to. Sales of Common Shares, debt securities or other equity securities by us may represent a significant percentage of our Common Shares currently outstanding. If we sell, or the market perceives that we intend to sell, substantial amounts of our Common Shares under the 2025 Shelf Registration Statement or otherwise, the market price of our Common Shares could decline significantly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our efforts to fund our intended business plan may result in dilution to existing shareholders. Further, any such issuances could result in a change of control or a reduction in the market price for our Common Shares. Additionally, the rights of the holders of Common Shares&#160;will be subject to, and may be adversely affected by, the rights of holders of any Preferred </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Shares that may be issued in the future. For example, Preferred Shares typically rank senior to Common Shares as to dividend rights, liquidation preference or both and may be convertible into Common Shares. Lastly, our ability to issue Preferred Shares could make it more difficult for a third-party to acquire a majority of our outstanding voting shares, particularly in the event we issue Preferred Shares with special voting rights, the effect of which may be to deprive our shareholders of a control premium that might otherwise be realized in connection with an acquisition of us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions in our governing documents and under Canadian Law could prevent or delay transactions that shareholders may favor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provisions of our governing documents and the OBCA may discourage, delay or prevent a merger or acquisition that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium for their Common Shares, and may also frustrate or prevent any attempt by shareholders to change the direction or management. For example, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require a 66 </span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">2</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">/3% majority of shareholder votes cast in favor of a resolution to effect various amendments to the Articles of Incorporation of the Company, as amended (the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">articles</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that in the event of shareholders of the Company vote via written resolution, that such resolution must be signed by all shareholders of the Company entitled to vote on that resolution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to the Board at any annual or special meeting of shareholders of the Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any transaction in which a third-party seeks to acquire our voting securities or equity securities that would result in the acquiror holding greater than 20% of the securities of that class may be governed by Multilateral Instrument 62-104&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Take-Over Bids and Issuer Bids </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(the &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Takeover Bid Rules</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) promulgated by the Canadian Securities Administrators. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation and these differences may make our Common Shares less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are incorporated under the provincial laws of Ontario, Canada, and, therefore, certain of the rights of holders of our shares are governed by Canadian law, including the provisions of the OBCA, and by our articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations and these differences may make our Common Shares less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our Common Shares may be less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot predict if investors will find our Common Shares less attractive because we will rely on these exemptions. If some investors find our Common Shares less attractive as a result, there may be a less active trading market for our Common Shares and our share price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of the last day of the fiscal&#160;year (i)&#160;following the fifth anniversary of the filing of our Form 10 Registration Statement, (ii)&#160;in which we have total annual gross revenue of at least $1.235 billion, or (iii)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our Common Shares that are held by non-affiliates exceeds $700 million as of the prior June&#160;30th, and the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide herein may be different than the information you may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our Common Shares less attractive as a result of these elections, which may result in a less active trading market for our Common Shares and higher volatility in our share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal&#160;year following the determination that our voting and non-voting Common Shares held by non-affiliates is more than $250 million measured on the last business day of &#160;our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal&#160;year and our voting and non-voting Common Shares held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never paid dividends on our capital shares and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our Common Shares will likely depend on whether the price of our Common Shares increases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any dividends on our Common Shares and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our Board. Accordingly, investors must rely on sales of their Common Shares after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We incur increased costs and demands upon management as a result of being a public company in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a public company listed in the U.S., we incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We continue to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to comply with these rules&#160;might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, on committees of our Board of Directors or as members of senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;margin:18pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public health crises, such as a pandemic, epidemic or outbreak of other highly infectious or contagious diseases, could seriously harm our research, development and potential future commercialization efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Public health crises, such as a pandemic, epidemic or outbreak of other highly infectious or contagious diseases, could adversely impact our business, the business operations of third parties on whom we rely and our ongoing or planned research and development activities. Additionally, timely enrollment in our ongoing and planned clinical trials is dependent upon clinical trial sites which may be adversely affected by global health concerns. Public health crises could result in increased adverse events and deaths in our clinical trials. Some factors from public health crises that could delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include:</p><div style="margin-top:6pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:25.2pt;margin-top:0pt;padding-left:23.75pt;text-align:justify;text-indent:-23.75pt;"><span style="display:inline-block;min-width:23.75pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">&#9679;</span>the potential diversion of healthcare resources away from the conduct of clinical trials to focus on public health crises, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials and the need for drugs and other supplies that clinical trial sites must have on hand to conduct our clinical trials to be used to address such public health crises;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:25.2pt;margin-top:6pt;padding-left:23.75pt;text-align:justify;text-indent:-23.75pt;"><span style="display:inline-block;min-width:23.75pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">&#9679;</span>limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials;</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:25.2pt;margin-top:6pt;padding-left:23.75pt;text-align:justify;text-indent:-23.75pt;"><span style="display:inline-block;min-width:23.75pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">&#9679;</span>interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and other supplies used in our prospective clinical trials; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:25.2pt;margin-top:6pt;padding-left:23.75pt;text-align:justify;text-indent:-23.75pt;"><span style="display:inline-block;min-width:23.75pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">&#9679;</span>interruptions in operations at third-party manufacturers, which could result in delays or disruptions in the supply of our current product candidates and any future product candidates; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:25.2pt;margin-top:6pt;padding-left:23.75pt;text-align:justify;text-indent:-23.75pt;"><span style="display:inline-block;min-width:23.75pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">&#9679;</span>business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, product manufacturing and supply, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:24.5pt;margin:0pt;">Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operations and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The elimination of monetary liability against our directors, officers, and employees under Canadian law and the existence of indemnification rights for our obligations to our directors, officers, and employees may result in substantial expenditures by us and may discourage lawsuits against our directors, officers, and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our by-laws provide that, subject to the OBCA, we may indemnify a director or officer or a former director or officer or a corporation of which the we are or were a shareholder or creditor and their heirs and legal representatives of such person against all costs, charges, and expenses including and amount to be paid to settle an action or satisfy a judgment, reasonably incurred in respect of any civil, criminal or administrative action or proceeding to which they are made a party by reason of being or having been a director or officer of us or a director or officer of any such corporation. Each director and officer upon being elected and appointed shall be deemed to have contracted with us on the terms of this indemnity. The failure of a director or officer to comply with the provisions of the OBCA or the articles or the by-laws shall not invalidate any indemnity to which they are entitled under the by-laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also have contractual indemnification obligations under any future employment agreements with our officers or agreements entered into with our directors. The foregoing indemnification obligations could result in us incurring substantial expenditures to cover the cost of settlement or damage awards against directors and officers, which we may be unable to recoup. These provisions and the resulting costs may also discourage us from bringing a lawsuit against directors and officers for breaches of their fiduciary duties, and may similarly discourage the filing of derivative litigation by our shareholders against our directors and officers even though such actions, if successful, might otherwise benefit us and our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">There may be difficulty in enforcing judgments and effecting service of process on directors and officers that are not citizens of the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are incorporated under the OBCA and some of our directors and officers reside outside of the U.S., in Canada. Consequently, it may not be possible for an investor to effect service of process within the U.S. on us or those persons. Furthermore, it may not be possible for an investor to enforce judgments obtained in U.S. courts based upon the civil liability provisions of U.S. federal securities laws or other laws of the U.S. against us or those persons. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities based upon U.S. federal securities laws and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions of the U.S. federal securities laws. Therefore, it may not be possible to enforce those actions against us and certain of our directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The rules&#160;dealing with federal, state and local income taxation are constantly under review by persons involved in the legislative process and, in the case of U.S. tax laws, by the Internal Revenue Service and the U.S. Treasury Department, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and in the case of Canadian tax laws, by the Canada Revenue Agency and the Department of Finance. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our Common Shares. For example, under Section 174 of the code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on our cash flow. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional changes to U.S. federal income tax law are currently being contemplated, and future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2017, the U.S. Congress and the Trump administration made substantial changes to U.S. policies, which included comprehensive corporate and individual tax reform. In addition, the Trump administration called for significant changes to U.S. trade, healthcare, immigration and government regulatory policy. Since the start of the Trump Administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. For example, on July 4, 2025, the One Big Beautiful Bill Act was signed into law and made significant changes to U.S. federal tax law. Changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are characterized as a passive foreign investment company (PFIC), U.S. Holders may be subject to adverse U.S. federal income tax consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on our current operations, income, assets and certain estimates and projections, including as to the relative values of our assets, including goodwill, which is based on the expected price of our Common Shares, we were not a PFIC for the 2024 taxable&#160;year and do not expect to have been a PFIC for the 2025 taxable&#160;year.<b style="font-weight:bold;"> </b><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"><a style="vertical-align:super;" href="#footnote-2">1</a></sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">However, we must make an annual determination as to whether we are a PFIC based on the types of income we earn and the types and value of our assets from time to time, all of which are subject to change. Therefore, we cannot assure you that we will not be a PFIC for our current taxable&#160;year or any future taxable&#160;year. A non-U.S. corporation generally will be considered a PFIC for any taxable&#160;year if either (1)&#160;at least 75% of its gross income is passive income or (2)&#160;at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable&#160;year) is attributable to assets that produce or are held for the production of passive income. The market value of our assets may be determined in large part by the market price of the Common Shares, which is likely to fluctuate. In addition, the composition of our income and assets will be affected by how, and how quickly, we use any cash that we raise. If we were to be treated as a PFIC for any taxable&#160;year during which you hold Common Shares, certain adverse U.S. federal income tax consequences could apply to U.S. Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of Common Shares, and who is: (i)&#160;an individual who is a citizen or individual resident of the U.S.; (ii)&#160;a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the U.S., any state therein or the </p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a id="footnote-2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> NTD: Please confirm that Company has not performed PFIC analysis for FY 2025, i.e., ensure that this sentence should not instead read &#8220;we were not a PFIC for the 2025 taxable year and do not expect to be a PFIC for the 2026 taxable year.&#8221; If not, fine to leave as-is.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">District of Columbia; (iii)&#160;an estate the income of which is subject to U.S. federal income taxation regardless of its source; or (iv)&#160;a trust if (1)&#160;a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2)&#160;the trust has a valid election in effect to be treated as a U.S. person under applicable U.S. Treasury Regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity posture or a natural disaster.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, we, like others in our industry, have experienced and expect to continue to experience cybersecurity incidents, data breaches, and similar threats related to our infrastructure. We, like other organizations, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, including via attachments to emails, the theft, fraud, and subsequent misuse of employee credentials, wrongful conduct by insider employees or vendors, denial-of-service attacks, attacks enhanced or facilitated by AI, ransomware attacks, business email compromises, breakdown, wrongful intrusions, data breaches, and social engineering (including phishing attacks). Attempts to disrupt or gain unauthorized access to our and our third-party service providers&#8217; information systems from malicious third parties or insider threats may incorporate widely varying and frequently changing tactics, which may be enhanced or facilitated by AI. The risk of a security incident or breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident or breach was to result in a loss of or damage to our data or applications, systems, or infrastructure, or inappropriate disclosure or misuse of confidential or proprietary information, we could incur material legal claims and liability (including litigation and regulatory actions), financial costs, and damage to our reputation, and the further development of our product candidates could be delayed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While we have not directly experienced any material system failure, accident or cybersecurity incident or breach to date, like others in our industry we and our vendors have, and may in the future continue to experience, threats and cybersecurity incidents relating and other attempts to disrupt or gain unauthorized access to our and our third-party vendors&#8217; information systems. We cannot guarantee that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, or cybersecurity incidents or breaches in or compromises of our systems or those of third-party CROs, vendors, contractors, consultants and/or third parties with whom we do business. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the regulatory environment surrounding information security is increasingly demanding, with the frequent imposition of new and changing requirements. Compliance with changes in information security laws and with rapidly evolving industry standards may result in our incurring significant expense due to increased investment in technology and the development of new operational processes related to cybersecurity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or biologics to be reviewed and approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, including most recently from October 1, 2025 to November 12, 2025, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions of our current or future clinical trials may be conducted outside of the U.S. and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, a severe or prolonged economic downturn, including a recession or depression resulting from potential public health crises, weather catastrophe, acts of terrorism, war (such as the military conflict between Russia and Ukraine), threats of terrorist attacks or war, political disruption or other events outside of our control could result in a variety of risks to our business, including, among other things, weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. Any of the foregoing could seriously harm our business, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Rising inflation rates may result in increased operating costs and reduced liquidity, and affect our ability to access credit</span><span style="font-style:italic;font-weight:bold;">. </span><span style="font-style:italic;font-weight:bold;"><br/><br/></span>Increased inflation may result in increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve System has repeatedly raised, and may continue to raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_115f8f17_e8e3_428e_8aea_f4d2d0bc1bb7"></a><a id="Item1BUnresolvedStaffComments_71850"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None</p><a id="_7aa198f6_f106_4ae8_aa46_39a3cfec7135"></a><a id="Item1CCybersecurity_537304"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1C. Cybersecurity</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_UvxTE3zB5kKCT4XUsm_41Q" continuedAt="Tb_UvxTE3zB5kKCT4XUsm_41Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk Management and Strategy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_5ggNGiLjzEaA9YGuiE6Tfw" escape="true">We recognize the importance of assessing, identifying, and managing risks to the security, confidentiality, integrity, and availability of our business systems and confidential information, including personal information and intellectual property. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_-vRyu-H_e0a7lx6FPuuXmg">We have developed a cybersecurity risk management program in accordance with our risk profile and business.</ix:nonNumeric> </ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_tVxSije9qEai91gaL-pt7w">Leveraging the support of a third-party</ix:nonNumeric> information technology provider, our cybersecurity risk management program includes cybersecurity awareness training for employees and periodic systems monitoring and vulnerability scanning.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UvxTE3zB5kKCT4XUsm_41Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_cEZdpTR2UE6AWMB6QIXIrg">We have not identified cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us</ix:nonNumeric>, including our business strategy, results of operations, or financial condition. However, like other companies in our industry, we and our third-party vendors may from time to time experience threats that could affect our information or systems. For more information, please see the section entitled &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_X_bd_VgXnUacFuVQtlhfdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Governance Related to Cybersecurity Risks </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_o-P92Ubsd0qKx80s4j5GPw">Our <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_LSD1-mUP3EqiPAhvn72MHQ" escape="true">Vice President, Finance and Chief Executive Officer</ix:nonNumeric></ix:nonNumeric>, with the assistance of the Company&#8217;s third-party information technology provider, are responsible for the strategic leadership and direction of the Company&#8217;s cybersecurity program.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_N5pk2lmgCEWqA95Ave7V-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Board exercises oversight of risks from cybersecurity threats primarily through its <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_iR5m5FsAmku60g9iZwyfBQ" escape="true">Audit Committee</ix:nonNumeric>. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_rwcbg8e5gEOQ7r6efMrTmA" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_1wC55z_faUCkT7Ph8l-zGA" escape="true">Our Vice President, Finance, with input of other members of Company management and the Company&#8217;s information technology provider, periodically makes presentations to the Audit Committee on the Company&#8217;s enterprise risk management program, which may address cybersecurity risks and related cyber strategy, as applicable.</ix:nonNumeric></ix:nonNumeric> </p></ix:nonNumeric><a id="_b959f57f_bd1f_47b6_b261_a9162ce3ffc0"></a><a id="Item2Properties_166556"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company does not own or lease any material properties.</p><a id="_1ed209e2_17f9_4c82_8b38_ce5d55a3dc26"></a><a id="Item3LegalProceedings_235845"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:normal;">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </span></p><a id="_0e6d5d07_17d4_47a9_842e_2c898c8c565f"></a><a id="Item4MineSafetyDisclosures_791437"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Not applicable.</p><a id="_89461dce_b77a_4ce2_8c89_676be162975f"></a><a id="PARTII_149212"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="color:#231f20;font-style:italic;">Market Information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#231f20;">Our Common Shares are listed on the Nasdaq Capital Market. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Shareholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of March 23, 2026 there were 152 holders of record of our Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Dividends </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">There are no restrictions in our articles, by-laws or elsewhere which would prevent us from paying dividends. No dividends have been declared or paid on the Common Shares in the last five fiscal&#160;years, and it is not expected that dividends will be declared or paid in the immediate or foreseeable future. Consequently, to date there have been no distributions made by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The policy of our Board is to reinvest all available funds in operations. The Board will reassess this policy from time to time. Any decision to pay dividends on the Common Shares will be made by the Board based on the assessment of, among other factors, earnings, capital requirements and our operating and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Securities Authorized for Issuance under Equity Compensation Plans</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The information required by this item will be set forth in the 2025 Proxy Statement under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance under Equity Compensation Plans&#8221; and is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><i style="color:#231f20;font-weight:normal;">Ownership and Exchange Controls</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">There is no limitation imposed by Canadian law or by our Constating Documents on the right of a non-resident to hold or vote our Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 54pt 8pt 0pt;"><i style="font-style:italic;">Recent Sales of Unregistered Securities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following information represents securities sold by us during the year ended December 31, 2025, and through the filing of this Annual Report on Form 10-K, which were not registered under the Securities Act. Included are new issues, securities issued in exchange for property, services or other securities and new securities resulting from the modification of outstanding securities. We sold all of the securities listed below pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act, or Regulation D or Regulation S promulgated thereunder. </p><div style="margin-top:8.44pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:37.95pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On April 4, 2025, we granted 3,800 Stock Options with an exercise price per Stock Option of $18 to certain directors, advisors, executives and employees. No consideration was received by us for this issuance.</span></td><td style="width:54pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:8pt;margin-top:8.44pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:37.95pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June 12, 2025, we granted 4,000 Stock Options with an exercise price per Stock Option of $12.50 to certain directors, advisors, executives and employees. No consideration was received by us for this issuance.</span></td><td style="width:54pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:8pt;margin-top:8.44pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:37.95pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On July 22, 2025, we completed a PIPE Offering of 504,673 Common Share Warrant Units to Selling Shareholders for gross proceeds of approximately $2.4 million before deducting placement agent fees and other offering expenses.</span><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;In conjunction with the proceeds from the exercise of existing warrants, the total gross proceeds inclusive of the PIPE Offering were approximately $9.2 million.</span></td><td style="width:54pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:8.44pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:37.95pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On July 28, 2025, we completed a PIPE Offering of 624,654 PIPE Common Share Warrant Units to Selling Shareholders for gross proceeds of approximately $3.0 million before deducting placement agent fees and other offering expenses.</span><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;In conjunction with the proceeds from the exercise of existing warrants, the total gross proceeds inclusive of the PIPE Offering were approximately $11.6 million.</span></td><td style="width:54pt;"/></tr></table><div style="margin-top:8pt;"></div><div style="margin-top:8.44pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:37.95pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On September 22, 2025, we granted 47,600 Stock Options with an exercise price per Stock Option of $11.25 to certain directors, advisors, executives and employees. No consideration was received by us for this issuance.</span></td><td style="width:54pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;margin-bottom:0pt;margin-top:8.44pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:37.95pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 30, 2026, we completed a PIPE Offering of an aggregate of approximately $75.5 million of (i) 6,815,296 Common Shares, no par value, (ii) Common Share Warrants to purchase 6,915,296 Common Shares or Pre-Funded Warrants in lieu thereof, and (iii) 100,000 Pre-Funded Warrants to purchase Common Shares before deducting placement agent fees and other offering expenses. There is an additional $100 million available tied to the exercise of the Common Share Warrants and Pre-Funded Warrants.</span></td><td style="width:54pt;"/></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:8.44pt 54pt 8pt 0pt;"><i style="font-style:italic;">Purchases of Equity Securities by the Issuer and Affiliated Purchases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:8.44pt 54pt 8pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Material Canadian Federal Income Tax Considerations </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following is, as of the date hereof, a summary of the material Canadian federal income tax considerations generally applicable under the <i style="font-style:italic;">Income Tax Act</i> (Canada) and the regulations promulgated thereunder, collectively the &#8220;Tax Act&#8221;, to a purchaser who acquires as beneficial owner Common Shares under this offering, and who, for purposes of the Tax Act </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">and at all relevant times, (i) is not, and is not deemed to be, resident in Canada for purposes of the Tax Act and any applicable income tax convention, (ii) holds the common shares as capital property, (iii) deals at arm&#8217;s length with, and is not affiliated with, the Company or the underwriters, and (iv) does not use or hold and will not be deemed to use or hold, the common shares in a business carried on in Canada, hereinafter a &#8220;Non-Resident Holder&#8221;. Special rules, which are not discussed in this summary, may apply to a Non-Resident Holder that is an &#8220;authorized foreign bank&#8221; within the meaning of the Tax Act or an insurer carrying on an insurance business in Canada and elsewhere. Any such Non-Resident Holder should consult its own tax advisor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">This summary is based upon the provisions of the Tax Act in force as of the date hereof, all specific proposals to amend the Tax Act that have been publicly announced in writing by or on behalf of the Minister of Finance (Canada) prior to the date hereof, or the &#8220;Proposed Amendments&#8221;, the Canada-U.S. Tax Treaty, or the &#8220;Treaty&#8221;, and an understanding of the current administrative policies and assessing practices of the Canada Revenue Agency, or the &#8220;CRA&#8221;, published in writing by it prior to the date hereof. This summary assumes the Proposed Amendments will be enacted in the form proposed. However, no assurance can be given that the Proposed Amendments will be enacted in their current form, or at all. This summary is not exhaustive of all possible Canadian federal income tax considerations and, except for the Proposed Amendments, does not take into account or anticipate any changes in the law or any changes in the CRA&#8217;s administrative policies or assessing practices, whether by legislative, governmental or judicial action or decision, nor does it take into account or anticipate any other federal or any provincial, territorial or foreign tax considerations, which may differ significantly from those discussed herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">This summary is not applicable to a Non-Resident Holder who reports its &#8216;&#8216;Canadian tax results&#8217;&#8217; in a currency other than Canadian currency; or that has entered or enters into a &#8216;&#8216;derivative forward agreement&#8217;&#8217; with respect to the common shares (each as defined in the Tax Act). Any such Non-Resident Holder should consult its own tax advisor with respect to an investment in the common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">This summary is of a general nature only and is not intended to be, nor should it be construed to be, legal or tax advice to any prospective purchaser or holder of the common shares, and no representations with respect to the income tax consequences to any prospective purchaser or holder are made. Consequently, prospective purchasers or holders of the common shares should consult their own tax advisors with respect to their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Currency Conversion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Generally, for purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the common shares must be converted into Canadian dollars based on the exchange rates as determined in accordance with the Tax Act. The amounts subject to withholding tax and any capital gains or capital losses realized by a Non-Resident Holder may be affected by fluctuations in the applicable exchange rate (such as the Canadian-U.S. dollar exchange rate).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dividends paid or credited or deemed to be paid or credited on the Common Shares to a Non-Resident Holder by the Company will be subject to Canadian withholding tax under the Tax Act at the rate of 25%, subject to any reduction under the provisions of an applicable income tax convention. For example, under the Treaty, the rate of withholding tax on dividends paid or credited or deemed to be paid or credited to a beneficially entitled Non-Resident Holder who is resident in the U.S. for purposes of the Treaty and who is fully entitled to the benefits of the Treaty is generally limited to 15% of the gross amount of the dividend. Non-Resident Holders are urged to consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dispositions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A Non-Resident Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common Share, unless the Common Share constitutes &#8216;&#8216;taxable Canadian property&#8217;&#8217; (as defined in the Tax Act) of the Non-Resident Holder at the time of disposition and the Non-Resident Holder is not entitled to relief under an applicable income tax convention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Generally, the Common Shares will not constitute taxable Canadian property of a Non-Resident Holder at a particular time provided the common shares are listed at that time on a &#8216;&#8216;designated stock exchange,&#8217;&#8217; as defined in the Tax Act (which </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">currently includes the Nasdaq Stock Market), unless at any time during the 60-month period that ends at that time the following two conditions are satisfied concurrently: (i) (a) the Non-Resident Holder; (b) persons with whom the Non-Resident Holder did not deal at arm&#8217;s length; (c) partnerships in which the Non-Resident Holder or a person described in (b) holds a membership interest directly or indirectly through one or more partnerships; or (d) any combination of the persons and partnerships described in (a) through (c), owned 25% or more of the issued shares of any class or series of the shares of the company; and (ii) more than 50% of the fair market value of the common shares was derived directly or indirectly from one or any combination of: (a) real or immovable property situated in Canada, (b) &#8216;&#8216;Canadian resource properties&#8217;&#8217;, (c) &#8216;&#8216;timber resource properties&#8217;&#8217; (each as defined in the Tax Act), and (d) options in respect of, or interests in or for civil law rights in, such properties, whether or not such properties exist. Notwithstanding the foregoing, in certain circumstances set out in the Tax Act, the common shares could be deemed to be taxable Canadian property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A Non-Resident Holder contemplating a disposition of Common Shares that may constitute taxable Canadian property should consult a tax advisor prior to such disposition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_168afd9f_57ef_4461_a36d_2971944ae077"></a><a id="Item6_513958"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;6. [Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9a4a2ff0_7c88_479d_abcc_bdc9d4f0051f"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">All references in this management&#8217;s discussion and analysis of financial condition and results of operations, or MD&amp;A, to the &#8220;Company&#8221;, &#8220;ProMIS&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221; refer to ProMIS Neurosciences&#160;Inc., unless otherwise indicated or the context requires otherwise. The following MD&amp;A is prepared as of March 25, 2026 for the&#160;years ended December&#160;31, 2025 and 2024 and should be read in conjunction with the audited consolidated financial statements for the&#160;years ended December&#160;31, 2025 and 2024 (collectively, the &#8220;</i><span style="font-style:italic;font-weight:bold;">Financial Statements</span><i style="font-style:italic;">&#8221;), which have been prepared by management in accordance with United States generally accepted accounting principles (&#8220;</i><span style="font-style:italic;font-weight:bold;">U.S. GAAP</span><i style="font-style:italic;">&#8221;) as issued by the Financial Accounting Standards Board (&#8220;</i><span style="font-style:italic;font-weight:bold;">FASB</span><i style="font-style:italic;">&#8221;). All dollar amounts refer to United States dollars, except as stated otherwise.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are applying our patented technology platform to build a portfolio of antibody therapies and therapeutic vaccines in neurodegenerative diseases and other protein-misfolding diseases, with a focus on Alzheimer&#8217;s disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS). We believe these diseases share a common biologic cause&#160;&#8212; misfolded versions of proteins, that otherwise perform a normal function, becoming toxic and killing neurons, resulting in disease. ProMIS&#8217; technology platform enables drug discovery through a combination of protein biology, physics and supercomputing. We believe this platform provides a potential advantage in selectively targeting the toxic misfolded proteins with therapeutics or detecting them with diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing a pipeline of antibodies aimed at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative diseases without interfering with the essential functions of the same properly folded proteins. Our product candidates are PMN310, PMN267, and PMN442. Our lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is our second lead product candidate targeting ALS. It has been shown in preclinical studies to selectively recognize misfolded, cytoplasmic TDP-43 aggregates without interacting with normal TDP-43. Misfolded TDP-43 is believed to play an important role in the development of ALS. In light of research suggesting that misfolded toxic a-syn is a primary driver of disease in synucleinopathies such as MSA and Parkinson&#8217;s disease, our third lead product candidate, PMN442 has shown robust binding to pathogenic a-syn oligomers and seeding fibrils in preclinical studies, with negligible binding to a-syn monomers and physiologic tetramers which are required for normal neuronal function. We also have earlier stage preclinical programs and a project to refine our discovery algorithm using machine learning as highlighted in the &#8220;Other Key Projects&#8221; section below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were incorporated on January 23, 2004 under the Canada Business Corporations Act (CBCA). On July 13, 2023, we continued our existence from a corporation incorporated under the CBCA into the Province of Ontario under the Business Corporations Act (Ontario) (OBCA) (Continuance). The Continuance was approved by our shareholders at our 2023 Annual Meeting of Shareholders held on June 29, 2023. We have a wholly-owned U.S. subsidiary, ProMIS USA, which was incorporated in January&#160;2016 in the State of Delaware. ProMIS USA has had no material activity and has no material financial impact on our Financial Statements. Since our inception, we have devoted substantially all of our resources to developing our platform technologies and the resultant antibody product candidates, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. We have principally financed our operations through public and private placements of Common Shares and warrants and convertible debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our product candidates and any future product candidates. We had an operating loss of $40.2 million and $16.8&#160;million for the&#160;years ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, we had an accumulated deficit of $130.4 million. W<span style="background:#ffffff;">e had negative cash flows from operations of $28.1 million for the year ended December 31, 2025. In July 2025, we received gross proceeds of $21.6 million from discounted warrant exercises, the sale of additional warrants in private placements, and the sale of pre-funded warrants to purchase Common Shares in a registered direct offering, less transaction costs of $1.4 million. Refer to additional discussion in Note 6.</span> </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;">In January 2026, we received gross proceeds of $75.5 million from the sale of Common Shares, Common Share warrants, and pre-funded warrants to purchase Common Shares to external investors and certain of our directors and management in a private placement. Fees and other expenses are currently not estimable, as they are still being determined. Refer to additional discussion in Note 14.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on our current operating plan, we expect that our existing cash, including the proceeds from January 2026, will be sufficient to fund our operating expenses and capital expenditure requirements through 2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, including based on our decision to initiate other clinical trials or programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">However, we expect to continue to incur losses for the foreseeable future and, if able to raise additional funding, would expect our research and development expenses, general and administrative expenses and capital expenditures to increase. In particular, if we are able to raise additional funding we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as continue and initiate new clinical trials, hire additional personnel, and pay fees to outside consultants, lawyers and accountants. In addition, if we obtain marketing approval for any product candidates, we may incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection with the in-licensing or acquisition of additional product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, our &#8220;at-the-market&#8221; program, or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Operating Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of our products in the near future, if at all. If our product candidates are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of our platform technologies, as well as unrelated discovery program expenses. We expense research and development costs in the periods in which they are incurred. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, related benefits and share-based compensation expense, for employees engaged in research and development activities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (CROs), and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of acquiring, developing, and manufacturing clinical study materials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with clinical and preclinical activities and regulatory operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We enter into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including our clinical sites. These costs consist of direct and indirect costs associated with our platform technologies, as well as fees paid to various entities that perform certain research on our behalf. Depending upon the timing of payments to the service providers, we recognize prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. We monitor each of these factors and adjust estimates accordingly. See Item&#160;1A -<i style="font-style:italic;">&#8220;Risk Factors</i>&#8221; in this document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development activities account for a significant portion of our operating expenses. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to implement our business strategy, which includes advancing our platform technologies through clinical development as well as other product candidates into clinical development, expanding our research and development efforts, including hiring additional personnel to support our research efforts, our clinical and product development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. Our direct research and development expenses consist primarily of external costs, including fees paid to consultants, contractors and CROs in connection with our development activities and the cost of acquiring, developing, and manufacturing clinical study materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development and protection of intellectual property, professional service fees, and other general overhead and facility costs, depreciation, and amortization. We expect our general and administrative expenses to increase substantially for the foreseeable future as we increase our administrative function to support the growth of the business and its continued clinical development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other expenses consist primarily of interest expense on certain deferred accounts payable and the loss on issuance of common shares, warrants and pre-funded warrants in the July 2024 Private Placement. Other income consists of changes in the fair value of our warrant liabilities and interest income earned on our cash balances.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Result of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Years Ended December&#160;31, 2025 and 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the years presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,379,321</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,637,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,741,345</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,787,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,189,502</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 598,485</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,167,308</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,827,478</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,339,830</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40,167,308)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,827,478)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,339,830</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 448,161</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,606,351</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,158,190</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39,719,147)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,778,873</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42,498,020</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the year-over-year changes in research and development expenses for the years presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct research and development expenses by program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">PMN310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,226,059</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,275,268</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,950,791</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ALS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,850</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,850)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Platform and other programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 685,113</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 632,003</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,110</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indirect research and development expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee salaries and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,100,417</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,540,802</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 559,615</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 166,938</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49,405</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,533</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Consulting expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 149,083</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83,062</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other operating costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,711</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,627</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,916)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,379,321</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,637,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,741,345</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by $22.7 million, or 214%, for the&#160;year ended December&#160;31, 2025 compared to the&#160;year ended December&#160;31, 2024. This increase is primarily attributable to a $22.0 million increase in spending on our lead program, PMN310, as our Phase 1b clinical trial of PMN 310, which began in late 2024, continued to progress. &#160;Employee salaries and benefits also increased by $0.6 million as we hired additional personnel in 2025 to support the Phase 1b study. Consulting expenses increased by $0.1 million while other operating costs remained consistent during the year ended December 31, 2025 compared to the year ended December 31, 2024. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the year-over-year changes in general and administrative expenses for the years presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee salaries and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,093,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 969,970</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,123,261</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 690,691</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 776,403</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (85,712)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,291,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,985,899</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (693,923)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 286,265</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 304,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,335)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility-related and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 425,824</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 152,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 273,194</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,787,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,189,502</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 598,485</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $0.6 million, or 10%, for the&#160;year ended December&#160;31, 2025 compared to the&#160;year ended December&#160;31, 2024. Employee salaries and benefits increased by $1.1 million, primarily due to the recognition of $0.5 million in severance costs in 2025 and the hiring of additional employees in 2025. The $0.7 million decrease in professional and consulting costs included a $0.3 million decrease in external investor and shareholder relations, a $0.2 million decrease in legal fees, and a $0.2 million decrease in insurance costs. Facility-related and other costs increased by $0.3 million due to higher business development, internal investor relations, and conference activity in 2025. Share-based compensation costs decreased by $0.1 million and patent fees stayed consistent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income (expense) decreased by $19.2 million for the&#160;year ended December&#160;31, 2025 compared to the&#160;year ended December&#160;31, 2024. The decrease was primarily attributable to a decrease in gain on change in fair value of financial instruments of $22.6 million in 2025, which was driven in 2024 by the gain on the change in the July 2024 Private Placement warrant liability, a decrease of $0.2 million in interest income due to higher average cash balances and interest rates during the year ended December 31, 2024, and a decrease of $0.1 million in interest expense, offset by a $3.5 million one-time loss in 2024 on the issuance of common shares, warrants, and pre-funded warrants in issued in the July 2024 Private Placement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">We are a clinical-stage development company as we have not generated any product revenues to date and do not expect to have significant revenues until we are able to sell a product candidate after obtaining applicable regulatory approvals or we establish collaborations that provide funding, such as licensing fees, milestone payments, royalties, research funding or otherwise. Operations have been financed since inception through the sale of equity and debt securities and the conversion of common share purchase warrants and share options. Our objectives, when managing capital, are to ensure there are sufficient funds available to carry out our research, development and eventual commercialization programs. When we have excess funds, we manage our liquidity risk by investing in highly liquid corporate and government bonds with staggered maturities to provide regular cash flow for current operations. We do not hold any asset-backed commercial paper and our cash is not subject to any external restrictions. We also manage liquidity risk by frequently monitoring actual and projected cash flows. The Board reviews and approves the Company&#8217;s operating and capital budgets, as well as any material transactions not in the ordinary course of business. The majority of our accounts payable and accrued liabilities have maturities of less than three&#160;months. We are dependent on our ability to generate revenues from our future products or secure additional financing in order to continue our research and development activities and meet our ongoing obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATM Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In September 22, 2023, we filed a registration statement on Form S-3 with the SEC, which was declared effective on September 29, 2023 (Shelf Registration Statement), in relation to the registration of Common Shares, preferred shares, subscription receipts, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our Common Shares, debt securities or other equity securities in one or more offerings. In January 2024, we entered into an At The Market Offering Agreement with BTIG, LLC (2024 ATM Agreement) to provide for the offering, issuance and sale of up to an aggregate amount of $25.0 million of our Common Shares from time to time in &#8220;at-the-market&#8221; offerings under the Shelf Registration Statement and subject to the limitations thereof, including limitations related to the amount we are able to sell pursuant to such ATM Program based on our public float as of a measuring date preceding the filing of our Annual Report. During the year ended December 31, 2024 we sold 3,034 shares for net proceeds of approximately $0.2 million, after deducting sales commissions. We did not sell any Common Shares in 2025 pursuant to the 2024 ATM Agreement and the 2024 ATM Agreement was terminated in July 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In August 2025, we filed a new shelf registration statement with the SEC. In conjunction with the shelf registration, we entered into an&#160;<span style="color:#191c1f;">At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC (2025 ATM Agreement) to offer </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;">up to $18.0 million of our Common Shares. During the year ended December 31, 2025, we sold 40,795 Common Shares for net proceeds of $0.7 million, after deducting sales commissions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">July 2024 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In July 2024, we completed a private placement for aggregate gross proceeds of $30.3 million to sell an aggregate of (a) 390,307 common share units (Common Share Units) sold at $2.15 per Common Share Unit, each consisting of one Common Share and certain accompanying warrants to purchase Common Shares (Tranche A, B and C) and, for certain investors, (b) 174,841 pre-funded units (the Pre-Funded Units and together with the Common Share Units, the Units) sold at $2.14 per Pre-Funded Unit, each consisting of one pre-funded warrant to purchase one Common Share &#160;and certain accompanying warrants to purchase Common Shares (Tranche A, B and C), totaling 565,148 each of Tranche A, B and C warrants (July 2024 PIPE). The Common Shares issuable upon exercise of the warrants and pre-funded warrants are referred to herein as the &#8220;2024 Warrant Shares.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The pre-funded warrants have an exercise price of $0.25 per 2024 Warrant Share, are immediately exercisable and will expire when exercised in full. The Tranche A Common Share purchase warrants have an exercise price of $50.50, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) 18 months or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with multiple ascending doses of PMN310. The Tranche B Common Share purchase warrants have an exercise price of $50.50, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) 30 months or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with multiple ascending doses of PMN310. The Tranche C Common Share purchase warrants have an exercise price of $62.50, are immediately exercisable and will expire on July 31, 2029. Pursuant to Nasdaq Listing Rule 5635(d), the exercise of the Tranche A and Tranche B Common Share purchase warrants is subject to shareholder approval (Shareholder Approval). We received Shareholder Approval for the Tranche A and Tranche B warrants on October 23, 2024 at a Special Meeting of Shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="color:#191c1f;font-style:italic;">July 2025 Registered Direct Offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;">On July 22, 2025, we entered into a securities purchase agreement to issue and sell pre-funded warrants to purchase 39,389 Common Shares (RD Offering). The RD Offering pre-funded warrant was sold at an offering price of $0.8124 per share, which represents, if it were applicable, the per share offering price for the Common Shares of the Company, less a $0.0001 per share exercise price for such pre-funded warrant. &#160;The gross proceeds from the RD Offering were $0.8 million before deducting offering expenses of $0.1 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="color:#191c1f;font-style:italic;">July 2025 Discounted Exercise of Warrants and Private Placements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;">Additionally, in July 2025, across multiple transactions dated July 22 and 28, 2025, we accepted discounted exercise offers for 752,885 Common Share warrants, distributed ratably amongst the Tranche A, B, and C warrants from the July 2024 PIPE for aggregate gross proceeds of approximately $15.5 million (Discounted Exercise) and sold 1,129,327 new warrants in two private placements for aggregate gross proceeds of $5.3 million (July 22, 2025 PIPE and July 28, 2025 PIPE). The total aggregate gross proceeds across the RD Offering, discounted warrant exercises, and sales of new warrants was $21.6 million, before deducting fees and offering expenses of $1.4 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="color:#191c1f;font-style:italic;">January 2026 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#191c1f;">On January 29, 2026, we completed a private placement for aggregate gross proceeds of &#160;$75.5&#160;million to sell </span>an aggregate of (i) 6,815,296 Common Shares, (ii) Common Share purchase warrants (Common Share Warrants) to purchase 6,915,296 Common Shares, (iii) Pre-Funded Warrants (Pre-Funded Warrants) to purchase 100,000 Common Shares (January 2026 PIPE). The Common Shares issuable upon exercise of the Common Share Warrants and Pre-Funded Warrants are referred to herein as the &#8220;2026 Warrant Shares&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">6,090,075 Common Shares were sold at a price of $10.77 per Common Share, 100,000 Pre-Funded Warrants were sold at a price of $10.77 less an exercise price $0.0001 per 2026 Warrant Share and 725,221 Common Shares were sold at a price of $12.13 per Common Share. The Common Share Warrants have an exercise price of $14.40, are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants have an exercise price of $14.40 per 2026 Warrant Share, are immediately exercisable and will expire when exercised in full. For purposes of the foregoing, the &#8220;Milestone Event&#8221; means the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310. <span style="color:#191c1f;">Fees and other expenses are currently not estimable by the Company, as they are still being determined.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Current Capital Position</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We incurred an operating loss of $40.2 million in the year ended December&#160;31, 2025, had an accumulated deficit of $130.4 million as of December 31, 2025, <span style="background:#ffffff;">had negative cash flows from operations of $28.1 million for the year ended December 31, 2025</span> and finished the year ended December 31, 2025 with negative working capital of $1.2 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">However, following the closing of the January 2026 Private Placement for gross proceeds of $75.5 million, and based on our current operating plan, we expect that our existing cash will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through 2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, including based on our decision to initiate other clinical trials or programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional funding will be necessary to fund future clinical activities. We will seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. Although we have been successful in raising capital in the past, there is no assurance of success in obtaining such additional financing on terms acceptable to us, if at all, and there is no assurance that we will be able to enter into collaborations or other arrangements. If we are unable to obtain funding, it could force us to delay, reduce or eliminate research and development programs and product portfolio expansion or commercialization efforts. These potential delays, reductions and eliminations could adversely affect future business prospects, and the ability to continue operations.<span style="background:#ffff00;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our sources and uses of cash for the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,118,579)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,182,095)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (936,484)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (702)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (693)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,944,670</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,875,809</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,931,139)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net (decrease) increase in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,174,611)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 693,021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,867,632)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash Flows from Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities was $28.1 million for the&#160;year ended December&#160;31, 2025, which consisted of a net loss of $39.7 million offset by $0.9&#160;million in non-cash charges and a net change of $10.7&#160;million in our net operating assets and liabilities. The additive non-cash activities primarily consisted of non-cash charges for share-based compensation of $0.9 million. Changes in cash flows related to operating assets and liabilities primarily consisted of a $7.4 million in accrued liabilities and a $2.6 million increase in prepaid expenses and other current assets, primarily related to the PMN310 Phase 1b clinical trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;background:#ffffff;">Cash used in operating activities was $27.2 million for the&#160;year ended December&#160;31, 2024, which consisted of net income of $2.8 million offset by $18.2&#160;million in non-cash charges and a net change of $11.7&#160;million in our net operating assets and liabilities. The additive non-cash activities primarily consisted of a gain on the change in fair value of financial instruments of $22.6 million, offset by non-cash charges for share-based compensation of $0.8 million and a $3.5 million loss on the issuance of common shares, warrants, and pre-funded warrants in the July 2024 Private Placement. Changes in cash flows related to operating assets and liabilities primarily consisted of a decrease of $6.1 million of accounts payable, a decrease of $1.0 million in accrued liabilities and a $4.6 million increase in prepaid expenses and other current assets, primarily related to the PMN310 Phase 1b clinical trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash Flows from Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities was nominal during the years ended December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash Flows from Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash provided by financing activities during the year ended December 31, 2025, was $20.9 million, which included $8.4 million from the July 22, 2025 Discounted Exercise (as detailed in our notes to the financial statements) and July 22, 2025 PIPE, $11.1 million from the July 28, 2025 Discounted Exercise (as detailed in our notes to the financial statements) and July 28, 2025 PIPE, $0.7 million from the sale of Common Shares under the 2025 At The Market Offering Agreement, and $0.7 million from the issuance of pre-funded warrants in the July 22, 2025 RD Offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities during the year ended December 31, 2024 was $27.9 million which included $27.7 million from the common shares, pre-funded warrants, and common share warrants sold in the July 2024 PIPE and $0.2 million of proceeds from the sale of common shares from the 2024 ATM offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MD&amp;A is based on our Financial Statements, which have been prepared in accordance with U.S. GAAP and on a basis consistent with those accounting principles followed by us and disclosed in Note&#160;2 to our audited consolidated financial statements for the&#160;year ended December&#160;31, 2025. The preparation of these Financial Statements in conformity with U.S. GAAP requires our management to make certain judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the Financial Statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgement about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not limited to, accruals for research and development expenses. Accordingly, actual results may differ from these judgments and estimates under different assumptions or conditions and any such difference may be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the following critical accounting estimates discussed below are most important to understanding our historical and future performance, as these estimates relate to the more significant areas involving management&#8217;s judgments and estimates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accruals for Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Substantial portions of the Company&#8217;s clinical and preclinical trials and drug substance manufacturing are performed by third-party laboratories, medical centers, and other vendors. These vendors generally bill monthly for services performed, or bill based upon milestone achievement. For clinical and preclinical studies, the Company recognizes and, if necessary, accrues expenses based upon estimated percentage of work completed and the remaining contract milestones. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. Sometimes the actual timing of performance or the level of effort varies from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.5pt 0pt;">The percentage of work completed is inherently subject to estimation uncertainty, and the Company uses third-party invoices, contract terms, and support provided directly from third parties, when available, to establish the percentage of completion at each measurement date. &#160;A hypothetical difference in estimated percentage of work completed compared to actual percentage of work completed of 10% for a $1.0 million contract at the measurement date could have a $0.1 million impact on accrued liabilities and research and development expenses. The Company had $7.4 million of accrued research and development costs and $2.6 million of prepaid upfront research payments, which had not yet been recognized at December 31, 2025, and which are from multiple contracts. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8.5pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.5pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our audited consolidated financial statements in Item 8 &#8211; &#8220;<i style="font-style:italic;">Financial Statements and Supplementary Data</i>&#8221;.</p><a id="_97f0b4a3_92fa_40f6_a14c_056b9531bd66"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8.5pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.5pt 0pt;">In the normal course of business, we are exposed to a number of financial risks that can affect our operating performance. These risks are credit risk, liquidity risk and market risk. Our overall risk management program and prudent business practices seek to minimize any potential adverse effects on our financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8.5pt 0pt;">Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.5pt 0pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and short-term investments. We manage our exposure to credit losses by placing our cash with accredited financial institutions, which at times, may exceed federally insured limits, and when we have excess funds, such funds are invested in high-quality government and corporate issuers with low credit risk. Cash held is not subject to any external restrictions. As of the&#160;year ended December&#160;31, 2025, a hypothetical 10% relative change in interest rates would not have a material impact on our Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8.5pt 0pt;">Liquidity Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.5pt 0pt;">Our exposure to liquidity risk is dependent on purchasing obligations and raising funds to meet commitments and sustain operations. We are a pre-revenue clinical-stage development company, and we rely on external fundraising to support our operations. We also manage liquidity risk by continuously monitoring actual and projected cash flows. Our Board reviews and approves the Company&#8217;s operating budget, as well as any material transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8.5pt 0pt;">Foreign Currency Exchange Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.5pt 0pt;">We are exposed to foreign exchange risk on our non-U.S. dollar denominated cash and non-U.S. dollar denominated liabilities. We do not believe that foreign exchange impacts had a material effect on our business, financial condition or results of operations during the years ended December 31, 2025 or 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8.5pt 0pt;">Inflation Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.5pt 0pt;">Inflation generally affects us by increasing our cost of labor, outside consultants and CROs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the&#160;years ended December&#160;31, 2025 or 2024.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_caae93b8_0760_4790_8b05_98ec42e62d12"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PROMIS NEUROSCIENCES&#160;INC.</p><a id="INDEXTOCONSOLIDATEDFINANCIALSTATEMENT"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:92.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:92.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:4.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:92.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#INSERTREPORTOFINDEPENDENTREGISTEREDPUBLI"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:AuditorFirmId" id="Narr_Qd2HoPq5kEimLDkRGOsldw">23</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-2</p></td></tr><tr style=""><td style="vertical-align:bottom;width:92.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ConsolidatedBalanceSheets_857069"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024</span></a></p></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-3</p></td></tr><tr style=""><td style="vertical-align:bottom;width:92.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ConsolidatedStatementsofOperationsandCom"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the Fiscal Years Ended December 31, 2025 and December 31, 2024</span></a></p></td><td style="vertical-align:top;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-4</p></td></tr><tr style=""><td style="vertical-align:bottom;width:92.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Shareholders&#8217; Deficit for the Fiscal Years Ended December 31, 2025 and December 31, 2024</span></a></p></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:92.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_552360"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the Fiscal Years Ended December 31, 2025, and December 31, 2024</span></a></p></td><td style="vertical-align:top;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-6</p></td></tr><tr style=""><td style="vertical-align:bottom;width:92.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements_8"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="INSERTREPORTOFINDEPENDENTREGISTEREDPUBLI"></a><a id="_e10cafda_b74a_4d81_846a_5c9817a8d5a8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Shareholders and Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ProMIS Neurosciences Inc. and Subsidiary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of ProMIS Neurosciences Inc. and Subsidiary (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations, shareholders&#8217; (deficit) equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;<b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><a id="_ed0160a2_ef91_4b88_af8d_7dabae8268da"></a><a id="Tc_S2bUZqQSlEyyV9StTkt3Jg_1_0"></a><a id="Tc_b40OLR2OKU6MRpViHewEcg_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:AuditorName" id="Narr_xAIV4WQswkSuYcUfBODYPA">Baker Tilly US, LLP</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="dei:AuditorLocation" id="Tc_2f0yLWobTUiw5akyrJ5lvw_2_0">Tewksbury, Massachusetts</ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">March 25, 2026</p></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2021.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dd3ed306_c8d0_4197_8082_44bb5b416215"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PROMIS NEUROSCIENCES&#160;INC.</p><a id="ConsolidatedBalanceSheets_857069"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(expressed in U.S. dollars, except share amounts)</b></p><a id="_5b98ba39_ef61_473c_8b47_4083d4242a66"></a><a id="Tc_YXAV1ZBBnUSMhdcwF7SYkw_1_2"></a><a id="Tc_Bjk0wVwG70aav0lTGwzThA_2_2"></a><a id="Tc_E_dPWqPc1U6nACTr6scG4w_2_5"></a><a id="Tc_XwSLSCK8b0-6tAQyAHGh8Q_3_0"></a><a id="Tc_tSjvgxaZUEuaHpdbKjHTOQ_4_0"></a><a id="Tc_c2-CIqx3j0ChDWA3Uzl15A_5_0"></a><a id="Tc_9NoyRTEWaEuIbhonvcL2Eg_5_2"></a><a id="Tc_nEUZx7ZJ5UuICVa_mDzrWw_5_5"></a><a id="Tc_oP500Ttj_kyDVSH3TfLcmA_6_0"></a><a id="Tc_38TGNJZCAEaFT8KjhFs6dQ_7_0"></a><a id="Tc_TOPgPTv3NU2ORsv-pzd-Nw_8_0"></a><a id="Tc_yp4fQqqNakeo8pj-J4-new_9_0"></a><a id="Tc_rfZARcIpbEmx3YiehQoYwg_9_2"></a><a id="Tc_njQK9JVrCEmZrsJDPrjmHQ_9_5"></a><a id="Tc_dVOI_bK_10e4PG1OYRcAxg_10_0"></a><a id="Tc_T7AKtK3dKUe3VFxHBRBKrg_11_0"></a><a id="Tc_fpVRW7JC1U2am19qumvoIw_12_0"></a><a id="Tc_AgBdhTXSsEC56G0nSSdlkw_12_2"></a><a id="Tc_mh1BAAxm2UCIWfZ-XZYueg_12_5"></a><a id="Tc_7lNGPyCpPEmhDbA2ePwAzQ_13_0"></a><a id="Tc_OrbpLPsQ8UeqMGGkXL3zsA_14_0"></a><a id="Tc_lH2xbTISy0uqV3vZ4-_Pog_15_0"></a><a id="Tc_NGwXdMz4TUqvk1Y-5g3d1Q_16_0"></a><a id="Tc_3fvgaX1sv0-48OpO1Azc8w_16_3"></a><a id="Tc_lMPsZKcMaEqCAIAwaBrWsA_17_0"></a><a id="Tc_27R7FfEALkS5EcFEPSBxqg_19_0"></a><a id="Tc_x1Nhe_7gHkWjrMWnvi4TuQ_20_0"></a><a id="Tc_BMRJXCz1Z0K2jsU7MLfNmQ_21_0"></a><a id="Tc_owz3nvIUek-GqbLoqM-kWg_22_0"></a><a id="Tc_t8ddkIPZfk2gYrTMBqkzlw_23_0"></a><a id="Tc_YFlS_UCx7U2vraSBcjr8qw_24_0"></a><a id="Tc_gyn1aE1TsECTVPtLpK6L7w_25_0"></a><a id="Tc_tlcjR19E2U-zYk3SydP04w_26_0"></a><a id="Tc_udFgNopHYk2_QgAeacUpQg_26_2"></a><a id="Tc_SJA9lVaUQEKMijfbbVnVXw_26_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_7ERVIdDYXk27TXvB09VGRA_5_3">6,116,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_Sah5tPdCmEGLrIuCILRSqw_5_6">13,291,167</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" id="Tc_XWazV78_ikOTahHu0JYMIg_6_3">33,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" id="Tc_i62IDcz_cUiplPHX0Y1uVA_6_6">33,051</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_2S59zcyaQEGdo8L6DKI6ow_7_3">3,032,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_f2lc9FUwxkCOjYNf-l_qVQ_7_6">5,587,238</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_QTfuyt_9P0yPTkVXOaVooA_8_3">9,182,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_s_PtR5gwo0mYuVwKh7UQuQ_8_6">18,911,456</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_-nHntwpsNUu300EP0J-vbw_9_3">9,182,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_99e-YEyALkeOH7nZBC6mUQ_9_6">18,911,456</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Shareholders' (Deficit) Equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_1OhUnY7jdUKpTbGbx7klxw_12_3">2,543,415</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_UgvHxTfP0UCQ921rJ0GEhw_12_6">1,737,463</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_hTLxFa-zlUWh8Yj4aXwsKA_13_3">7,868,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_oOaN0_ZQokmNy5uhcbLEIQ_13_6">480,962</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_QcZfUE4fS0yubP_UqnnUWQ_14_3">10,411,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_JquoDogL30Cmvdc3rwoGJw_14_6">2,218,425</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="0" id="Tc_LIqbT4W3UESIwx6WFbgFYw_15_3">29,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="0" id="Tc_gkqcabY3iEGk_8VfSjzyNA_15_6">199,263</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_cBrEbxVWwkyBtB2VUVzaYA_16_6">5,592</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_dYyfzY3mjk6awi42shmOrw_17_3">10,441,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_k1oFm9aJoEuoYekciKCtiQ_17_6">2,423,280</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shareholders' (deficit) equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common Shares, <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="Narr_CksMGDZvj0OksiQ4ycY_Gg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="Narr_yJK8f9BxvUq6AU08aSZBpQ">no</ix:nonFraction></ix:nonFraction> par value, <span style="-sec-ix-hidden:Hidden_SdkTB3HWa020CccPjwzO6Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unlimited</span></span> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_18Zx0HJVbUOEOeM_r2e5XA"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_lHLrl63an0uwPfq1JYBkTA">2,152,397</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_AxZZl6nn102iRNUhiUJ29A"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_REcqZVmzLUKOLqlDcWDFsw">1,307,520</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31,&#160;2025 and December&#160;31,&#160;2024, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_6oppxBhmXEeEh4xZRJJ3vQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_b4hNM_E66Ua0TaTRWn1_tA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_DbnIPB14lEe_KPHcfU8RQA_22_3">129,518,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_EK-jlW81gEaQObw-rrOogQ_22_6">107,546,433</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_tLUzD3CR2k-2YR7863bR1g_23_3">371,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_W0KWaIYy1k6fhwSlTknj1Q_23_6">371,184</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_dM7BP7ScLkGaV8Ai0AFtxA_24_3">130,406,220</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_x9R7eJykdUWIo7DovMm9AA_24_6">90,687,073</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shareholders' (deficit) equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_AtKZVGsftk-FpeJIqSJj8w_25_3">1,258,592</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_VgI6AKNAG0eqXQ-Svn5YrA_25_6">16,488,176</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and shareholders' (deficit) equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_BnjG2V9J1kCMvJ5XbzLHSA_26_3">9,182,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_4AgT5tsaD0yrW40eZ1uZdw_26_6">18,911,456</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ee9a1d91_2d78_488b_86d4_a7c72ed4244a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PROMIS NEUROSCIENCES&#160;INC.</p><a id="ConsolidatedStatementsofOperationsandCom"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(expressed in U.S. dollars, except share amounts)</b></p><a id="_78386ef6_9ff6_468c_920d_7a46da6d3485"></a><a id="Tc_vrIsV4C0r0mw0I1FsRNCOw_3_2"></a><a id="Tc_1MInOfO3f0Kj8hoBwIQdGA_4_2"></a><a id="Tc_X-l_d3ltq0e58LXvGtP_zQ_4_5"></a><a id="Tc_wZxr-WYkykWz4YLo3S6xag_5_0"></a><a id="Tc_iIN3ktWs5kOAQ5S3IjhSsQ_6_0"></a><a id="Tc_59FgSg2pSEO6z2M9kKhRXA_6_2"></a><a id="Tc_6jX82yb7W0GZXxT8YXmtKw_6_5"></a><a id="Tc_v3BES4bOVUOFCeXLN1_Nfw_7_0"></a><a id="Tc_V1iaOI-4RECyivu8X4ytZQ_8_0"></a><a id="Tc_grxdCgMW2ECU4TwE2_9MaA_9_0"></a><a id="Tc_aRnULwH8qEuTQZPtwvtuoQ_11_0"></a><a id="Tc_zSMSviCA-0-gRcMSmOSe7g_12_0"></a><a id="Tc_fe_eLrOZFk-_s2GNr3M1Qg_13_0"></a><a id="Tc_JiQ1PvAkc0OWfDvObvDACA_13_3"></a><a id="Tc_dfQpdFeg9EWQrKuonxJquw_14_0"></a><a id="Tc_-IjaC4zZiEaA_vQ1Oe51FA_15_0"></a><a id="Tc_LM0FJtbCOE6Amkn_P-tqow_15_3"></a><a id="Tc_E9UHXus9k0-QkcIUiRGBzg_16_0"></a><a id="Tc_pgQqrAa0q0iEgKNHQrAMfw_18_0"></a><a id="Tc_lCCejLnQXUeXu_MslOViOg_18_2"></a><a id="Tc_dRD7ehUXU0mld396ohQivw_18_5"></a><a id="Tc_eWcCXjsHNUmc9VdrKz71Dg_20_0"></a><a id="Tc_Yck766xtqUqD4kQyHmHEbQ_20_2"></a><a id="Tc_6brrO5-p40qyDOlva1Svkg_20_5"></a><a id="Tc_qq7ok7fA5UGvvfIFcat9mQ_21_0"></a><a id="Tc_wgEr8WBu7USA324s0Om2eA_21_2"></a><a id="Tc_2j2YUekCTkyZTHvyhve-Pw_21_5"></a><a id="Tc_GjCwSDCVTEKRLuNPxWIVLw_23_0"></a><a id="Tc_FXfGsBdhVkiiSuXTR8-B8Q_24_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_wKX8w5Cd10iXbKOCTcsPRg_6_3">33,379,321</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_4Nh05Ec3_k-mhhUcosn-GQ_6_6">10,637,976</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_Q-T0H1Ana0urRZaNxHlzVg_7_3">6,787,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_IQtjfD7I-EeMbixd8ttw_A_7_6">6,189,502</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_NkFW4y-AEEyZh4R51PWNkg_8_3">40,167,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_H_Wr_Z1BG0qGjCZNUIjpkw_8_6">16,827,478</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_NKqafxcFpEKaY2H9Msi3Ng_9_3">40,167,308</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_2FIIjV-zGkufeQRSGmMvfw_9_6">16,827,478</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of financial instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:GainLossFromChangeInFairValueOfFinancialInstruments" scale="0" id="Tc_BgRy3-gbZ0OYA6luuok2dQ_12_3">5,592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:GainLossFromChangeInFairValueOfFinancialInstruments" scale="0" id="Tc_cIfZx0D25E-V2Nrn1rtK9A_12_6">22,581,477</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" id="Tc_-gMM02HAZ0O5xM_tflsAZQ_13_6">76,775</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_vY7rarEFlECh-MTwiO3Mfg_14_3">442,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_P444iAYIvEKZXGkkYH9d5Q_14_6">626,184</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:LossOnSaleOfCommonSharesAndWarrants" scale="0" id="Tc_-bTjUbaqdkW9Ti12mDOEJQ_15_6">3,524,535</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_NPz9dHJXqkevhzB2ZK75SQ_16_3">448,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_P4T5CCjsuUeiItougF9_Pg_16_6">19,606,351</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_8As-ig1CsUG7CIXX0_LZ6A_18_3">39,719,147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_BVxqf_hdXkCPtoGS90KfsQ_18_6">2,778,873</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income per share, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_-n6IEwpotkCToK4omvUoUw_20_3">22.61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_trMHJeo260y1zb89cLqPWQ_20_6">2.68</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income per share, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_3pkyBextj02F6FemepMvQQ_21_3">22.61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_gOZTIrMYWEa-SYhLA7HqXg_21_6">2.63</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average outstanding Common Shares, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_dC0fYgQcZ0qsLVZe50Ohdg_23_3">1,756,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4TeDjd4TdE29LdSMri9FrA_23_6">1,036,799</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average outstanding Common Shares, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_RJ90_QWqU06_oe8UHrBdNg_24_3">1,756,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_RK7gyVOkcEa_BvypE9MNHw_24_6">1,058,469</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_80e9698e_d248_41e0_9bd1_3d4be0e62782"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">PROMIS NEUROSCIENCES&#160;INC.</p><a id="Equity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Shareholders&#8217; (Deficit) Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(expressed in U.S. dollars, except share amounts)</b></p><a id="_1eddf437_0f0b_4c4c_a02f_cb76ee28d6e3"></a><a id="Tc_5_XLdZbo1UWu7mmJwWFLEg_1_16"></a><a id="Tc_7dpaathGhEq3NImEhfWJLA_2_13"></a><a id="Tc__rLzxSyJwUq91hrQe0CgVw_2_16"></a><a id="Tc_A1616RhVlE2g-Bwn5xA5Ew_3_3"></a><a id="Tc_oxNSTyVsgkm91dyn3tGiCA_3_8"></a><a id="Tc_1RH6xqVH2UOp9av7yrbUIA_3_13"></a><a id="Tc_uRYv5mNMjkKgT1RVtuwLlQ_3_16"></a><a id="Tc_TT-rSFmHs0iqizpenyeTdQ_3_19"></a><a id="Tc_PtqWrV3UPEuCrDnnnlAb6w_4_3"></a><a id="Tc_FpegAenoJEKxDm-bBJV66A_4_5"></a><a id="Tc_MUl2WLuMsEunntGfc-iqdw_4_8"></a><a id="Tc_CGwWfoXwMUyYI-BgLOgPcw_4_10"></a><a id="Tc_R2HFrU3M60KHKzey_JhEfA_4_13"></a><a id="Tc_TRwqOgL_Hk-AEqhFuZHDaA_4_16"></a><a id="Tc_mbX_T1Cft0mxFeEY74K3Tg_4_19"></a><a id="Tc_DSriYFNz5UORvJ8pu1PPXQ_4_22"></a><a id="Tc_aZwiSOniDEy0YZeK02trWA_5_0"></a><a id="Tc_xiddXdCOUEycITsIzVbhdA_5_6"></a><a id="Tc_CloD_jSxw0qgZLP7q7NTRw_5_11"></a><a id="Tc_ruvFlT8XFUGRgYIOZHr8jg_6_0"></a><a id="Tc_w_JsluxWB0i0j1lr9VYFSw_6_3"></a><a id="Tc_EXQggVaW4kmgDrwzJ5p9Pw_6_6"></a><a id="Tc_IcutKOE7ok-LYemFir9eRw_6_8"></a><a id="Tc_VdwC93KGWkOJPt1wlO6mBQ_6_11"></a><a id="Tc_GEr7FVvsQ06aLHtLjBFdeQ_6_17"></a><a id="Tc_I1SrBZ5YTEqXrrdr2Qn8dA_7_0"></a><a id="Tc_Ejll1_H9pUyMsxVbsvrlWg_7_6"></a><a id="Tc_n73Y9P4hYkCvVu9I0aRT6w_7_11"></a><a id="Tc_lOwsLx3bzUyNqRmeTC3MMA_7_14"></a><a id="Tc_i9NfthibJUeLPGI0iWcDNw_7_17"></a><a id="Tc_XFSti6FoVku7i4go-lp6MQ_7_20"></a><a id="Tc_1SRIRp92m0KJGQGMdDElZg_7_23"></a><a id="Tc_EWGaJBubVUieskakrYz1Wg_8_0"></a><a id="Tc_rPg3NPu9UkiwG4_f_FLq1Q_8_3"></a><a id="Tc_kcP8UPCPQ0eIAFWF9cJQSw_8_6"></a><a id="Tc_NAjmv0NmlEyXQRbqpJv58w_8_11"></a><a id="Tc_xA9m756Cb02AvWTmQd5-HA_8_17"></a><a id="Tc_GUsgILhiVkClK_CMW-pHsg_8_20"></a><a id="Tc_zEbg_9sOsk6E9wBbihww9w_9_0"></a><a id="Tc_DaZZytugskWQs0-tOOnohQ_9_3"></a><a id="Tc_BNUY4vfMjkSSm8xrl843bQ_9_6"></a><a id="Tc_9JBMWsWiZUeqgwWdIp-agA_9_11"></a><a id="Tc_TqeMi61xEkGEbaK5D9Lszg_9_14"></a><a id="Tc_aIZnpyrnA0ubjpADQj-YGg_9_17"></a><a id="Tc_uQISsaHR4EWuRTUCYoiBiA_9_20"></a><a id="Tc_2g1F3Ezxs0uCR2NcrF51xg_9_23"></a><a id="Tc_K3aqar2c1kyqRyCAB-yiqQ_10_0"></a><a id="Tc_-ljwx_ulgk-dRD08nkbyug_10_3"></a><a id="Tc_oFbfSFYnDkyJV9aOGK5Yug_10_6"></a><a id="Tc_eNwJTsXdOk-saaVAxJSdWg_10_8"></a><a id="Tc_Po3T4L925EWHZ4mGYM_UZg_10_11"></a><a id="Tc_XHgWHlg_o0aNQQ7fXa62XA_10_17"></a><a id="Tc_G5f-E0pS50O9J1ARVGgCSA_10_20"></a><a id="Tc_Ja_pVTJXS0eV8v4LOiezkA_11_0"></a><a id="Tc_EiyryHzBtkuu2EN7iSFEpQ_11_3"></a><a id="Tc_z0g6suLdQEC4HhpzsnUhjw_11_6"></a><a id="Tc_U7ZG9IzLlkWhufejmRAYsA_11_8"></a><a id="Tc_Zv5IQa7oOEOpvIFEbaKzZQ_11_11"></a><a id="Tc_28z7n4hgNUq_YNiBhfak0g_11_17"></a><a id="Tc_OG2OoBrR60yGvhm_EpdOpA_11_20"></a><a id="Tc_5q0i0gvoO0KRCJ4Zr0goZw_12_0"></a><a id="Tc_AgfKUimXTkqes7YvvlOByQ_12_3"></a><a id="Tc_QlqVUXCMI0qwwN8Xk1layw_12_6"></a><a id="Tc_yTwkN06meEWabMgIJ1H8jw_12_11"></a><a id="Tc_25GOORAciE2s7gTS-uXl3Q_12_17"></a><a id="Tc_MJG_lzBtgkimbIHC_nVL9A_12_20"></a><a id="Tc_mxOrY1R5KUWdhMMaXZu8yg_13_0"></a><a id="Tc_Q5g4xh1Ce06yHjPCMKZLtQ_13_3"></a><a id="Tc_sGydkvL1QEeNo4MkNGQJUQ_13_6"></a><a id="Tc_CsHAODYu3kOYZQNn2J80lg_13_8"></a><a id="Tc_SRMNaX2COUW44ITJCF3MNA_13_11"></a><a id="Tc_zb-rYu73pUy01sHNti7BIA_13_14"></a><a id="Tc_OEmJ3EbfiU-pOTPtZbm6dA_13_17"></a><a id="Tc_1GRHBHhOlUizrShzGLJdZg_14_0"></a><a id="Tc_X5bN6eokDECsfPZo-8vYVw_14_3"></a><a id="Tc_ALWZKYuin0CvSKM5Ovuihw_14_6"></a><a id="Tc_GWz4YdpDD0SzjYmLQscgsg_14_11"></a><a id="Tc_WU_UHpf-ok6N1dQ-qOwoiQ_15_0"></a><a id="Tc_FSKr6o3PB06hAulpvpLcZg_15_3"></a><a id="Tc_JH3IC13sj0KxxUC1iRvT6Q_15_6"></a><a id="Tc_9h_fl2zR-ECejgaMWc3mNQ_15_8"></a><a id="Tc_0FAOCuQdM0a4s0lV1Jczxg_15_11"></a><a id="Tc_9pDhGEBDDUO1qsnKNEoJhg_15_17"></a><a id="Tc_H7GuAKkhxk6wqF2QMXDR_Q_15_20"></a><a id="Tc_6O0w1jov_EG3UsHOleSI6g_16_0"></a><a id="Tc_0gmHYIZQ70ScU2EM9tkXfA_16_3"></a><a id="Tc_3Y7YO991GEi1bsPXj_OK8Q_16_6"></a><a id="Tc_Zp28cBPFvkadcMUH31TK1w_16_11"></a><a id="Tc_JMdoetosKkqd2dOoXT7uhA_16_17"></a><a id="Tc_RACTUa5KTEi3VeBVnqm28Q_16_20"></a><a id="Tc_eszh0dES0EiHPWhFqbIT-Q_17_0"></a><a id="Tc_-5Wc7V842EeaAcbR0FiBkQ_17_3"></a><a id="Tc_Yw0dr8qqFUKBrHwtGUvz7Q_17_6"></a><a id="Tc_4ptbVmORIkGDmmSm7YfQvw_17_8"></a><a id="Tc_YUKfM5tWDUKKr3YVMRmugw_17_11"></a><a id="Tc_q52pn0pNM0Kd21b0TF1fJw_17_17"></a><a id="Tc_6L_JDLlrtEG1urfJSfHc8g_17_20"></a><a id="Tc_xkIiEKMSmESiUxBg-rq5pg_18_0"></a><a id="Tc_FCtp3IdYa0q_EjoqbY93bg_18_3"></a><a id="Tc_E7sDDu6GZUm14-rEBJEPRQ_18_6"></a><a id="Tc_LxyKVCJBK0Wy6jNCXxUqvw_18_11"></a><a id="Tc_Uu6q0-m7y0CcSl2oIRz2jA_18_17"></a><a id="Tc_qLsj8QVnCUun0z0P7UAM7g_18_20"></a><a id="Tc_LIOQnxyLUEuNZROpuPljVg_19_0"></a><a id="Tc_btMK1HgnyECu4txF5qB7yg_19_3"></a><a id="Tc_BeOGwa2Xe0SxF7UMdLGRlg_19_6"></a><a id="Tc_rHL7gxc2VUixysa24EfPiQ_19_11"></a><a id="Tc_7jqUpkOCSUea4UPEAKc7-w_19_17"></a><a id="Tc_oVvP_8Ll6UCr2FSgppoJhw_19_20"></a><a id="Tc_6fJ8-roMoE2J2kG3quKt1g_20_0"></a><a id="Tc_znTcW3Hhr0STWXGX5zwsag_20_3"></a><a id="Tc_LL9d6OmKxEO6Y4d9tBv9nA_20_6"></a><a id="Tc_GT4T8rb49k-N7KGkcx5enA_20_11"></a><a id="Tc_TR-IVRzfP0O_YEPxBOXnwA_20_17"></a><a id="Tc_fxtzzNwO20aegDbH4M8i-Q_20_20"></a><a id="Tc_KcTcY2bgjkaUiY4Df2m41Q_21_0"></a><a id="Tc_ykrXNP79ykiuLIqJwRxVCQ_21_3"></a><a id="Tc_0igS4WCdIEaB1XL1WdjdYg_21_6"></a><a id="Tc_RJBEZi1LMESZdux0dUfvOA_21_8"></a><a id="Tc_kJ9XilaBok20TkCnyaD9uQ_21_11"></a><a id="Tc_5QidYlVo_kyLdQTvHFx10Q_21_17"></a><a id="Tc_Eq18QC-eRUeta0zCcdfgWA_21_20"></a><a id="Tc_7ZGrC6a7Hkq_mp0NaBNu3g_22_0"></a><a id="Tc_t23vQMpAwEyLC39RyyQbZA_22_3"></a><a id="Tc_mQcqJHwltkSz6hNC8pcrdg_22_6"></a><a id="Tc_vVWOiJNof0Kuta6vQwOsYA_22_8"></a><a id="Tc_GB50H6358Ueflom9MBsFGQ_22_11"></a><a id="Tc_l43KKJt0qUWNQ1Tb2K7jOQ_22_14"></a><a id="Tc_DHYJLg-4_EenOzSsgrwFFw_22_17"></a><a id="Tc_AhnfV7EWnEehlp63H7ty_w_23_0"></a><a id="Tc_BPVJwxpcTUirJFDQqQMrpA_23_3"></a><a id="Tc_o8_JkUsG-kGhJAcBaVKU4Q_23_5"></a><a id="Tc_7Ey-mmABv0SUscCxgmb0tw_23_6"></a><a id="Tc_9Po5qutK9E6Wfowe0R-P5A_23_10"></a><a id="Tc_3TBXC745eUqUHWgyI_xGkQ_23_11"></a><a id="Tc_4binFcbDuU6ALJtqHgCVCA_23_13"></a><a id="Tc_udMZ_SGMAEyZIqwqcKkFnw_23_16"></a><a id="Tc_PB_H7ZwuCka-HIGF6HVg-A_23_19"></a><a id="Tc_77zuP43VqUSRYGxCb3-gBg_23_22"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Series 2 Preferred Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Common&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">Balance, January 1, 2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_a3Lixc5gK0udx4DuG-SYdw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_jZ2krpr580-JcqOLJWk1kw_5_3">46,667</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w7-zVhUC1kKywOJd7lAuXQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_UrBgRHXU50evNnjXcayWrw_5_8">755,362</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMw169EA8Uy88PupRPJN3g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_VQntC5AdsUqATsmycwVMFQ_5_14">97,590,426</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bZ9SGI8L40et_WctpSEuqg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_sGy-2EGl60uIVSgUI0WpzA_5_17">371,184</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EQwMMLg4YEGiDu7FMobu8Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_dKWf1-SESUWsZXhVrzG5yA_5_20">93,465,946</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_8SNyrcTlAkOgR3eFOTKOtA_5_23">3,753,296</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_gwu655bnAkKM8BGo-gswoA_6_14">825,808</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc__LQlRB4NzEiBEgUyd99_Hg_6_23">825,808</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Conversion of Series 2 Convertible Preferred Shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zYsxCnpXe0KHopuDgqbqvw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_keWLALwzJ0auZNSAlObIgA_7_3">46,667</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T2FBENRGJ0aV_HOn6Nz-tQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_LRtRVM-w2kCyrTvewOrkVg_7_8">46,667</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Issuance of Common Shares from 2024 ATM Offering, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_jzjohLSy8kiD2BCrS5ZH6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc__uacrnc1tUS0zKBB6kHW3A_8_8">3,034</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_x5pcthNFT0ihjd4LzbTnhw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_53dhx027F0yi7lXGY0yJtA_8_14">190,274</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_APUegcHFdk-_60hGUyzvGA_8_23">190,274</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Issuance of Common Shares, pre-funded warrants and accompanying Common Share warrants in July 2024 PIPE, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_bj8OdyKOgkSN2xamZTJ45w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_zKNnQ1G-fUC-2NvpyV0pvA_9_8">390,307</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Reclassification of July 2024 PIPE warrant liability to additional paid-in capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_l20P0yuK7EitX_A64oUA5w_10_14">8,689,148</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_ixgf7acZtkOCqbmsIiqgew_10_23">8,689,148</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Re-measurement of liability-classified CAD stock options as of December 31, 2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw" decimals="0" format="ixt:num-dot-decimal" name="pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" scale="0" id="Tc_T3s1PZBvjEaU1RDl3Mc9TQ_11_14">222,739</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" scale="0" id="Tc_ZQ7iFMny00Waepxd-MG8Mw_11_23">222,739</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Issuance of Common Shares from exercise of pre-funded warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4P_Kz5oy5k-CBSt-JdWqyg" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_K-NoE2o2Q0qUfAcIAngsKg_12_8">112,150</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_DsT4wG0uBEKSwe4JmOup9w_12_14">28,038</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_F1gtESWVq0iBG5SZmQUWsA_12_23">28,038</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Net income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GFBuNQasRUSBVwbZTVEbuA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_xV8ZjmbFJECUbx5wDMo8jQ_13_20">2,778,873</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_xd0_Z9l1tU2lfqnjEqesUQ_13_23">2,778,873</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">Balance, December&#160;31,&#160;2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__rxEw1kCCEqZzbbgn51WGA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_vaWW3u9FGk-CGjeFzj7MdA_14_8">1,307,520</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5FgCE8zX30-mupqCfqO9Hg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_zFrooetCs02d18O1XOSqHQ_14_14">107,546,433</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEDCy0IDbk6AIgd9hmwmxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_vcAiO2tkyUapruIMc2jt0Q_14_17">371,184</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L4zZj1oYT0W-2XHWII1COQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Of3FV2Df3kys5gDR9ilqsg_14_20">90,687,073</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Ssta3XbgOk2xw6OU11qxlw_14_23">16,488,176</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_-TuSlafAuk2WDUYsZoGD1A_15_14">857,628</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_ALJ-EsdugEShi4KeFMDXjA_15_23">857,628</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Issuance of Common Shares from 2025 ATM Offering, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_B_WytrX9uEGjxCiY6yXfMw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_2HTYr7loQUSiAuW3R32NDA_16_8">40,795</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_Nk1_WvPkJUiSujdxjoOzOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_GxtZQnDHFUmz3M1arsdNQA_16_14">708,468</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_AqnySAykYkO61LUixXLCyw_16_23">708,468</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Issuance of pre-funded warrants from July 2025 Registered Direct Offering, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_jqrojhglskGaEskFutBHoQ_17_14">697,658</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_VL4qG-7hxkqM0y7YpOhjWQ_17_23">697,658</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Issuance of Common Shares from exercise of pre-funded warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KTeicbzkpEaKVTYwByBWeQ" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_y_JojzdgAky0VA7BjX4e7g_18_8">51,197</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_s2O7CqfX2k6HBO1-izXJhQ_18_14">3,050</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_inqInsDLmk-gy7dKCJeQRg_18_23">3,050</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Proceeds from issuance of Common Shares and warrants from July 22, 2025 discounted warrant exercise and PIPE, net of issuance costs&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_1g3BSYKGr0uWzgGWV2G3HQ" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_A3F1hWgi8E6FGM6iF9Xy4Q_19_8">336,449</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_8DzdAeeke06K0IAuzwW1iA" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_DKnfLxhOnUi0nkMBon3iXw_19_14">8,391,027</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_BTV6VUnnSUmguppxmUji_w_19_23">8,391,027</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Proceeds from issuance of Common Shares and warrants from July 28, 2025 discounted warrant exercise and PIPE, net of issuance costs&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_vATcI-2w8ku4HaP9mKA02A" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_hmR2JTWdCUyf62bS-ByxQQ_20_8">416,436</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_ywYEmzxlq0GiCBn4u9aJUg" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_YMEXOQlhM0ym5LTxwkJGCg_20_14">11,144,467</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA" decimals="0" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_slO6g3r9wE2_fCdfYFgFrA_20_23">11,144,467</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Re-measurement of liability-classified CAD stock options as of December 31, 2025</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ" decimals="0" format="ixt:num-dot-decimal" name="pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" scale="0" id="Tc_woaaV_Oq6kujub5yyFHf5g_21_14">170,081</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" scale="0" id="Tc_zMrOAk92LU2MYigeqpSLtQ_21_23">170,081</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nE9oOriQukSZ_Xm8_Ompeg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_SusXUqVTkkaknKPbyW1e2Q_22_20">39,719,147</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_bR6Whf_DwUm1lAOnF0lvzA_22_23">39,719,147</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:23.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">Balance, December&#160;31,&#160;2025</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Oh5tArIfbUWmdvd8QxM1uA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_G8h9tPWzQkGru3PzLDf40g_23_8">2,152,397</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 1.8pt 0pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r75dt_d2N0-jq-dK5XbpKA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gzSwYdZ9A067vRQoWkZ4Rw_23_14">129,518,812</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1hHfoCkg_ky9CLByNbJgvQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_4XTqpKNVr0-EifutfOHCFA_23_17">371,184</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__TYAGjaVLEGvdKi8ag1ZZg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Qb8cfYZBY0KNss_7bBG6dg_23_20">130,406,220</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="font-size:6.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_uPg4Z6U5MEGirdnhJ456cQ_23_23">1,258,592</ix:nonFraction>)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_778cec05_ae9f_4a37_b663_06046d708fa5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PROMIS NEUROSCIENCES&#160;INC.</p><a id="ConsolidatedStatementsofCashFlows_552360"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(expressed in U.S. dollars)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9bc8c5ce_f0bd_4cb9_bf55_98ad9fa8c737"></a><a id="Tc_sFCj7UTkikWzNrQtIiLEhw_2_2"></a><a id="Tc_K1GRRlXJTkiRXVyz-PhtkQ_3_2"></a><a id="Tc_UADCIvXsD06MLGbKiLlXUA_3_5"></a><a id="Tc_om3qRT7LAU-dHTCPgK4r8A_4_0"></a><a id="Tc_OAsvh9ebOUqqAhveHWMPPg_5_0"></a><a id="Tc_MvtUTZlzE0-t03iCcRF67A_5_2"></a><a id="Tc_Esl2Lf80s0u9okaTzxkzng_5_5"></a><a id="Tc_LAwrEbF7ZEGHzCYG268lfg_6_0"></a><a id="Tc_cDFXDc58nkqbhsF_wmeyFQ_7_0"></a><a id="Tc_GgRaRp2zUUCIq910jVO-Gw_8_0"></a><a id="Tc_cMtMrW7t50yurcJCG_XAog_8_3"></a><a id="Tc_EU4SkVUvXEuX5QYLtcJ_6w_9_0"></a><a id="Tc_8N4eWzMEuEWYLnvOT6-DXQ_10_0"></a><a id="Tc_I5ZdfrXIvE2bjYCQ3ynvIA_11_0"></a><a id="Tc_RYm0C3R70kajSfi1oLbHyg_12_0"></a><a id="Tc_AwUfS56p1kyd6rnv5SVMyw_13_0"></a><a id="Tc_TFRS-s5NdkuzCO68fEeCtg_14_0"></a><a id="Tc_4peN1u3L9EilRGmfB2gksQ_16_0"></a><a id="Tc_Y0ue15fHKkKOK1fEztb__g_17_0"></a><a id="Tc_wP_IIijPE0-_8eUCd9ahTg_18_0"></a><a id="Tc_fvomM-ADzEuK21B8eXUVtw_19_0"></a><a id="Tc_ILWl7BuTD0qkqGEgS9a9VA_21_0"></a><a id="Tc_XtawZ704-UqWboMrZaOnuA_22_0"></a><a id="Tc_NkomlKBZNkCEUBCdwk0gkg_23_0"></a><a id="Tc_BRf5DHa84kGCIwF9sV_yMw_24_0"></a><a id="Tc_u02qWEC3PU-M8hIpAJppHw_24_6"></a><a id="Tc_EIKC9XKeCke4lL7M13SwWA_25_0"></a><a id="Tc_dTvXxy2R1UKYEPKP9j7ycw_25_6"></a><a id="Tc_Nmr7gdo7wEmjLO0HNohghg_26_0"></a><a id="Tc_lx36bdFWSkmaxJgwbZMW4Q_27_0"></a><a id="Tc_C2z7spvDZE6hVhOqk4vbfw_28_0"></a><a id="Tc_YXJrQaPC6UqxT8dtcaGJjw_29_0"></a><a id="Tc_69LHS1evW0qZE0fEsBxh1g_31_0"></a><a id="Tc_z8lckAUI70q3Vnv5IUWX6g_32_0"></a><a id="Tc_oAinjNNfF0qmUd7gEXVg1A_32_2"></a><a id="Tc_rHY2i48t_EqnLSmb6S6l-g_32_5"></a><a id="Tc_-QBZ3uVcKkWIEgvn-HBQjw_34_0"></a><a id="Tc_pJJfIiXIlkmjROqnaqGYcQ_35_0"></a><a id="Tc_YJXavMCASk-yxzVtK3dJSg_35_2"></a><a id="Tc_xS1x6B_EnkSy_eRbE9e92w_35_3"></a><a id="Tc_Vl2s34XG1kuRTEmnzXYfNw_35_5"></a><a id="Tc_P34obzbHD0mM1vyL_m2kzg_36_0"></a><a id="Tc_ISxquSy4CkumqoVVZMn5Lw_36_2"></a><a id="Tc_4G_KQzn-yk2g5a84Wzp6DA_36_5"></a><a id="Tc_NvrlUnnq2kyUpiFQOr5NrQ_37_0"></a><a id="Tc_eUhPqBUeJ0avT3-talL48g_37_2"></a><a id="Tc_njyzL67RiUmaYfo1a3vg0w_37_5"></a><a id="Tc_nsVL9HH3GEe7xPW-YYSjVg_37_6"></a><a id="Tc_FqTXEWEXkUWF2sqxG4uufQ_38_0"></a><a id="Tc_Xpjv-W-HtkGT7XKo0vMz-w_38_2"></a><a id="Tc_l1btFX1-VUSi3pflWfnO3A_38_5"></a><a id="Tc_eGnkQTF_QEiX3uNUKQXCjw_38_6"></a><a id="Tc_861-dVPgxkO8PB5k0Q431A_39_0"></a><a id="Tc_GWFlkk6swESBY6eULxw0fA_39_2"></a><a id="Tc_TvyofOcRgEqBdGAzFXM0DQ_39_5"></a><a id="Tc_p6QyIfN7ykeVcMH5Jr2pmQ_39_6"></a><a id="Tc_QL31mrklf06LqRpi559FOQ_40_0"></a><a id="Tc_5qP1eephDk-naobWx08kzA_40_2"></a><a id="Tc_gkmebiTHjUSqL160IoQwVA_40_5"></a><a id="Tc_2dzIQLJwTUuM2q3RpDymlQ_40_6"></a><a id="Tc__d3iQROY_kCz9hpi690fKA_42_0"></a><a id="Tc_pxfWfNuJ2UKcFi6A_YOU4A_43_0"></a><a id="Tc_omtFvfXU6E2iN6xvXE4Vjg_43_2"></a><a id="Tc_sPjUgPyWAEuvnzxKaN2ihQ_43_3"></a><a id="Tc_bsF0nX0zcUKXFKl_46Ts5A_43_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Years Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Net (loss) income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_LjQJ0rTZeEieGtKgZ7c-Tg_5_3">39,719,147</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" id="Tc_7eLiG_aX5EOuLLi8PjQJrA_5_6">2,778,873</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Adjustments to reconcile net (loss) income to net cash used in operating activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Share-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_9Ay8YtQYpUSAE92x2qxCLQ_7_3">857,628</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_BLIvVwO92kuaqPDerUJaGg_7_6">825,808</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Loss on issuance of common shares, warrants, and pre-funded warrants in July 26, 2024 PIPE</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:LossOnSaleOfCommonSharesAndWarrants" scale="0" id="Tc_3q14u4lThkCKlPz-zpf3ZQ_8_6">3,524,535</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Change in fair value of financial instruments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="Tc_p0FUpeNRlUqTDrImV3IOtQ_9_3">5,592</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="Tc_yaAHABFLSUub9mOWubnFNA_9_6">22,581,477</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8.5pt;">Changes in operating assets and liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Prepaid expenses and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_SHefCp0Ly0yqJtdBbfNBbg_11_3">2,555,126</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_034ze3MNq0CE-IWn3DwTLw_11_6">4,598,597</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_LBvG8EnKckefO47R-I9Trg_12_3">805,952</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_Fh4UxFFTF0CetOXis4L6eQ_12_6">6,105,673</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accrued liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_nnNlSayGm0OJVX_lKLg_wg_13_3">7,387,454</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_giBRbHP80k-Z73uyOVgknA_13_6">1,025,564</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_hpnht7Qhx0qZ9te4_pBV-g_14_3">28,118,579</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_RQMobzzv6UydQFTN7SHoxA_14_6">27,182,095</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Cash flows from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Purchase of short-term investments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_qD9UuQUb2UaKSCayo_twQg_17_3">33,753</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_wPu8xo396kiDNd0z3yM8iw_17_6">33,051</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Maturity of short-term investment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="0" id="Tc_ruWp8oLPAky5BVdDCCgWVA_18_3">33,051</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="0" id="Tc_GD47rcWOyECo1St_j8hhrw_18_6">32,358</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Net cash used in investing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_Nuc29AN3cUy3s2d4_kqNDQ_19_3">702</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_2hKldCsOY0iHfvUnetdKoQ_19_6">693</ix:nonFraction>)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Proceeds from issuance of Common Shares pursuant to 2025 and 2024 ATM offering, respectively, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_ELQCpRScyUmIRQ60-S-JLw_22_3">708,468</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_Ritc5jnKuUu9KYH7SgB6pw_22_6">190,274</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Proceeds from issuance of pre-funded warrants from July 22, 2025 Registered Direct Offering, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfWarrants" scale="0" id="Tc_kqzR5HKjakm0ijGDp3Dh9g_23_3">697,658</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Proceeds from issuance of Common Shares and warrants from July 22, 2025 discounted warrant exercise and PIPE, net of issuance costs&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Tc_BzsILihyo0S2jPkm1Xb_VA_24_3">8,391,027</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Proceeds from issuance of Common Shares and warrants from July 28, 2025 discounted warrant exercise and PIPE, net of issuance costs&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Tc_oi_GSpxqFkiPPJ4aBlfF8w_25_3">11,144,467</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Proceeds from issuance of Common Shares, pre-funded warrants, and accompanying warrants from July 26, 2024 PIPE, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_JaWdR8WEoEu-vtz5zRuEhA" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Tc_ylku8hFBUkWEmflCAaVrLQ_26_6">27,657,497</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Proceeds from exercise of pre-funded warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_eHiFHTKNZ0Gnq0Fmm0gvdw_27_3">3,050</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_kgN16U0d60uiKx_KGxAk9Q_27_6">28,038</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Net cash provided by financing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_tuUWJuQ8PkKFlkvQK0IXzg_28_3">20,944,670</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_Rx7vx96H6k2Gmc8mCvbXRQ_28_6">27,875,809</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Net (decrease) increase in cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_kxnxCH67EEG3BQthjLJBRA_29_3">7,174,611</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_VKwzxryZ90qx-ptAqSkDUQ_29_6">693,021</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash at beginning of period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_rd9Ck1AvAE-EQLuGSCU9Nw_31_3">13,291,167</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_HS9HUhdhG0eL5L2LV56_Kg_31_6">12,598,146</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash at end of period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_U9zNm-Njq0GsyZh3NNNhWA_32_3">6,116,556</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_oGoXne08yEqlMh_ziJ4T-w_32_6">13,291,167</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Noncash financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;">&#160;&#160;&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Reclassification of July 2024 PIPE warrants from liability to equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:ReclassificationOfPipeWarrantsFromLiabilityToEquity" scale="0" id="Tc_SHJQQv0o2kesi07LUWz2mQ_35_6">8,689,148</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Decrease in share-based compensation liability on CAD denominated share options increasing additional paid-in-capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" sign="-" scale="0" id="Tc_yhCRRVjkd02Hp2nS_cc4pQ_36_3">170,081</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" scale="0" id="Tc_4rYS8sypGUqyF63xVLbnXw_36_6">222,739</ix:nonFraction></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">July 22, 2025 deferred discount for fair value modification of warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredDiscountForFairValueModificationOfWarrants" scale="0" id="Tc_TaVQpOs2M0O35thowt0M9g_37_3">930,841</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">July 22, 2025 deferred discount issuance cost recognized on completion of PIPE</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredDiscountIssuanceCostRecognized" sign="-" scale="0" id="Tc_ESCrH0NZ0UKgVNtauG1Pyg_38_3">930,841</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">July 28, 2025 deferred discount for fair value modification of warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredDiscountForFairValueModificationOfWarrants" scale="0" id="Tc_xKHW1yff0UWH08V9P1VWVA_39_3">1,794,146</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">July 28, 2025 deferred discount issuance cost recognized on completion of PIPE</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredDiscountIssuanceCostRecognized" sign="-" scale="0" id="Tc_ZNlwVJMwf0mcsCIoW13H1Q_40_3">1,794,146</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Supplemental disclosure of cash flow information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash paid for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_SDIrC4uQHkmR0l5iOzZXVQ_43_6">76,775</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_26ed4af8_6b90_4555_a868_6a699e1f9495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PROMIS NEUROSCIENCES&#160;INC.</p><a id="NotestoConsolidatedFinancialStatements_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(expressed in U.S. dollars, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span>DESCRIPTION OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Business Description</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">ProMIS Neurosciences&#160;Inc. (the &#8220;<b style="font-weight:bold;">Company</b>&#8221; or &#8220;<b style="font-weight:bold;">ProMIS</b>&#8221;) is applying its patented technology platform to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody-based therapies in neurodegenerative diseases and other protein-misfolding diseases, with a focus on Alzheimer&#8217;s disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS). The Company believes these diseases share a common biologic cause&#160;&#8212; misfolded versions of proteins, that otherwise perform a normal function, becoming toxic and killing neurons, resulting in disease. ProMIS&#8217; technology platform enables drug discovery through a combination of protein biology, physics and supercomputing. ProMIS believes this platform provides a potential advantage in selectively targeting the toxic misfolded proteins with therapeutics or detecting them with diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company is developing a pipeline of antibodies aimed at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative diseases without interfering with the essential functions of the same properly folded proteins. The Company's product candidates are PMN310, PMN267, and PMN442. The lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is our second lead product candidate targeting ALS. It has been shown in preclinical studies to selectively recognize misfolded, cytoplasmic TDP 43 aggregates without interacting with normal TDP 43. Misfolded TDP 43 is believed to play an important role in the development of ALS. In light of research suggesting that misfolded toxic a-syn is a primary driver of disease in synucleinopathies such as MSA and Parkinson&#8217;s disease, our third lead product candidate, PMN442, has shown robust binding to pathogenic a-syn oligomers and seeding fibrils in preclinical studies, with negligible binding to a-syn monomers and physiologic tetramers which are required for normal neuronal function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company was incorporated on January 23, 2004 under the Canada Business Corporations Act (&#8220;<b style="font-weight:bold;">CBCA</b>&#8221;). On July 13, 2023, the Company continued its existence from a corporation incorporated under the CBCA into the Province of Ontario under the Business Corporations Act (Ontario) (&#8220;<b style="font-weight:bold;">OBCA</b>&#8221;) (&#8220;<b style="font-weight:bold;">Continuance</b>&#8221;). The Continuance was approved by the Company&#8217;s shareholders at the Company&#8217;s 2023 Annual Meeting of Shareholders held on June 29, 2023. The Company is located at 1920 Yonge Street, Toronto, Ontario. The Company&#8217;s Common Shares are traded on the Nasdaq Capital Market (&#8220;<b style="font-weight:bold;">Nasdaq</b>&#8221;) under the symbol PMN. The Company has a wholly-owned U.S. subsidiary, ProMIS Neurosciences (U.S.) Inc. (&#8220;<b style="font-weight:bold;">ProMIS USA</b>&#8221;), which was incorporated in January&#160;2016 in the State of Delaware. As of December 31, 2025, ProMIS USA has had no material activity and has no material financial impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The accompanying consolidated financial statements were prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. To date, the Company has not generated revenues from its activities. The Company had an operating loss of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="6" id="Narr_VYV7oKNr6k2vFlKGUGsCpg">40.2</ix:nonFraction> million for the&#160;year ended December&#160;31, 2025, an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_8UptSvUH7EauS2AGoRIlfw">130.4</ix:nonFraction> million as of December&#160;31, 2025, and negative cash flows from operations of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="6" id="Narr_3aGPD-tO8E20WfROR4E2ow">28.1</ix:nonFraction> million for the year ended December 31, 2025. In January 2026, the Company received gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qb681Op0wU2HNAyg8TBGWA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_-C9JrjuIt0eObyH9bJqqIw">75.5</ix:nonFraction> million from the sale of Common Shares, Common Share warrants, and pre-funded warrants to purchase Common Shares to external investors and certain of the Company&#8217;s directors and management in a private placement. Fees and other expenses are currently not estimable by the Company, as they are still being determined. Refer to additional discussion in Note 14.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Based on the Company&#8217;s current operating plan, the Company expects that its existing cash, including the proceeds from January 2026, will be sufficient to fund the Company&#8217;s operating expenses and capital expenditure requirements through 2027. The Company based this estimate on assumptions that may prove to be wrong, and the Company could exhaust its available capital resources sooner than it expects, including based on its decision to initiate other clinical trials or programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Future capital requirements will depend upon many factors, including the timing and extent of spending on research and development and market acceptance of the Company&#8217;s products, if approved for commercial sale. The Company will require additional funding to conduct future clinical activities. The Company expects to seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. Although the Company has been successful in raising capital in the past, there is no assurance of success in obtaining such additional financing on terms acceptable to us, if at all, and there is no assurance that the Company will be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding or other arrangements, it could force delays, reduce or eliminate research and development programs, and/or reduce product portfolio expansion or commercialization efforts, which could adversely affect future business prospects, and the ability to continue operations.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Tb_Zkqq4guoxEai-3tecnFYYg" continuedAt="Tb_Zkqq4guoxEai-3tecnFYYg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_ayCCt6AhDkicdpA0qT83vg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;<b style="font-weight:bold;">GAAP</b>&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;<b style="font-weight:bold;">ASC</b>&#8221;) and as amended by Accounting Standards Updates (&#8220;<b style="font-weight:bold;">ASU</b>&#8221;) of the Financial Accounting Standards Board (&#8220;<b style="font-weight:bold;">FASB</b>&#8221;).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On November 17, 2025, the board of directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of&#160;<span style="-sec-ix-hidden:Hidden_EKVA16217E2dxeEyM3doRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>:1, effective November&#160;28, 2025 (the &#8220;<b style="font-weight:bold;">Reverse Share Split</b>&#8221;). All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Share Split, unless otherwise stated.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_Gk7CXTze9kGmrII1Q2gKvA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:UseOfEstimates" id="Tb_sGXXyHF6xE6TCGbLAJb0Rw" continuedAt="Tb_sGXXyHF6xE6TCGbLAJb0Rw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of financial instruments. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zkqq4guoxEai-3tecnFYYg_cont1" continuedAt="Tb_Zkqq4guoxEai-3tecnFYYg_cont2"><ix:continuation id="Tb_sGXXyHF6xE6TCGbLAJb0Rw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_0WbdHHUb00madA1jH5vOCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (&#8220;<b style="font-weight:bold;">CODM</b>&#8221;), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_oypYvD2ghEaW7a5qy0yn3g">one</ix:nonFraction> operating segment and its Chief Executive Officer serves as the CODM. Substantially all of the Company&#8217;s assets are located in Canada. Refer to additional Segment Information in Note 10.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_yj6hakUydUSDoVicDsmKTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Foreign and Functional Currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company determines its functional currency as the currency of the primary economic environment in which the Company operates. To determine the primary economic environment, the Company considers salient economic factors, including cash flow indicators, expense indicators and financing indicators. Functional currency is a matter of fact, not a policy election and the Company will only reevaluate its functional currency if there is a significant change in facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Prior to July 1, 2023, the Company&#8217;s functional currency was the Canadian dollar (&#8220;<b style="font-weight:bold;">C$</b>&#8221;). Translation gains and losses from the application of the United States dollar (&#8220;<b style="font-weight:bold;">US$</b>&#8221;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative foreign currency translation adjustment, which is reported as a component of stockholders&#8217; (deficit) equity as accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Following the Company&#8217;s voluntary delisting from the Toronto Stock Exchange in July 2023, the Company determined there was a significant change in its facts and circumstances, and completed a reassessment of its functional currency. The Company determined that, as of July 1, 2023, the Company&#8217;s functional currency had changed from the C$ to the US$. The Company reassessment included analysis of various factors, including: the Company&#8217;s cash flows and expenses denominated primarily in US$, the primary market for the Company&#8217;s Common Shares trading in US$ and a majority ownership by U.S. shareholders from financings denominated in US$. The change in functional currency was accounted for prospectively from July 1, 2023 and consolidated financial statements prior to and including the period ended June 30, 2023 were not restated for the change in functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">For periods commencing July 1, 2023, monetary assets and liabilities denominated in foreign currencies are translated into US$ using exchange rates in effect at the end of the reporting period. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after July 1, 2023 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations within operating expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_4ksIyqdDXkSWLVoqY4SC1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2025 and 2024, the Company did not have any material cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:ShortTermInvestmentsPolicyPolicyTextBlock" id="Tb_FS83Mjirl0y8xqJAdjjaNA" continuedAt="Tb_FS83Mjirl0y8xqJAdjjaNA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Short-term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Short-term investments consist of guaranteed certificates of deposit with a maturity greater than 90&#160;days and up to one&#160;year at the time of purchase. Accordingly, all short-term investments are classified as current assets in the accompanying consolidated balance sheets. The short-term investment is being held as collateral for the Company&#8217;s credit cards.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zkqq4guoxEai-3tecnFYYg_cont2" continuedAt="Tb_Zkqq4guoxEai-3tecnFYYg_cont3"><ix:continuation id="Tb_FS83Mjirl0y8xqJAdjjaNA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_4Y1tuQ2idEm-Zg9Qe0GtFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="2" format="ixt:num-dot-decimal" name="pmn:PercentageOfOriginalAmountInvested" scale="-2" id="Narr_aRSELsFjJ0KZnyO9mUIVcA">100</ix:nonFraction>% of the original amount invested. As of December&#160;31, 2025, the Company has not experienced any losses on its cash or short-term investments as a result of credit risk.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_CvbauMNShECUh4yWS7gnHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures, </i>(<b style="font-weight:bold;">&#8220;ASC 820&#8221;</b>) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, as established by ASC 820, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; Observable inputs, such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; Inputs (other than Level 1 quoted prices) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s warrant liabilities were classified as Level 3 financial instruments for the&#160;year ended December&#160;31, 2024. The Company&#8217;s share-based compensation liability was classified as a Level 3 financial instrument for the&#160;years ended December&#160;31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The carrying amounts of prepaid and other current assets, short-term investments, accounts payable, and accrued expenses are generally considered to be representative of their fair value based on the short-term nature of these financial instruments.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_p-0IbYd0HU2rsFb1cRo4Jg" continuedAt="Tb_p-0IbYd0HU2rsFb1cRo4Jg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company historically evaluates its long-lived assets, which consist of property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not have any material long-lived assets as of December&#160;31, 2025 and 2024.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zkqq4guoxEai-3tecnFYYg_cont3" continuedAt="Tb_Zkqq4guoxEai-3tecnFYYg_cont4"><ix:continuation id="Tb_p-0IbYd0HU2rsFb1cRo4Jg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb__Y-c6YH340yHoxTf3AFhVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Property and equipment, net are historically stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Laboratory and equipment are depreciated over <span style="-sec-ix-hidden:Hidden_NcV6rL8tMk-QI6TxetjyIg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_DFTrDh2oYk6khT-4RADKcQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_UltyNtgivUiN3AQ6ctFkRg">five&#160;years</ix:nonNumeric>. Computer equipment is depreciated over <span style="-sec-ix-hidden:Hidden_xwYBGyVeBki9Pw78B3ou9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__MZVg_HiDUGOdFb43rdmsQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_3VAFIMMmJ0KWzfE1nAdE9A">three&#160;years</ix:nonNumeric>. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accompanying consolidated balance sheets and any resulting gain or loss is included in loss from operations in the accompanying consolidated statements of operations. Expenditures for repairs and maintenance are expensed as incurred. The Company did not have any material property and equipment as of December 31, 2025 and 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="Tb_hvcf7Xynf0WSQJU7p9MGNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Definite-lived intangible assets are historically stated at cost less accumulated amortization and any accumulated impairment losses. An intangible asset&#8217;s carrying amount is assessed for impairment whenever there is an indication that the asset may be impaired. The Company&#8217;s definite-lived intangible assets consist of acquired rights and patents. Intangible assets are amortized on a straight-line basis over the lesser of the life of the intangible asset or its estimated useful life, which is <ix:nonNumeric contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_kA2C8Gjlo0CykAN4cbaCig">15&#160;years</ix:nonNumeric>. The Company did not have any material intangible assets as of December 31, 2025.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="Tb_VTc_80r2sUiSzn-xy5tKpA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Collaboration Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company may enter into collaboration arrangements with pharmaceutical and biotechnology partners. The Company analyzes its collaboration arrangements to assess whether they are within the scope of FASB ASC 808, <i style="font-style:italic;">Collaborative Arrangements, </i>(<b style="font-weight:bold;">&#8220;ASC 808&#8221;</b>), to determine whether such arrangements involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. ASC 808 does not provide guidance on the recognition of consideration exchanged or accounting for the obligations that may arise between parties. The Company concluded that ASC Topic 730, <i style="font-style:italic;">Research and Development, </i>should be applied by analogy to payments between parties during the development activities of its collaboration arrangements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Tb_LXwoGEFaNkWXJmI9fNwpKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">General and administrative expenses consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development and protection of intellectual property, professional service fees, and other general overhead and facility costs, including rent, depreciation and amortization, which relate to the Company&#8217;s general and administrative functions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_NxLbbdd7FkW3YqxkEhrWTg" continuedAt="Tb_NxLbbdd7FkW3YqxkEhrWTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of the Company&#8217;s platform technology, as well as discovery program expenses. The Company expenses research and development costs as incurred. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, related benefits and share-based compensation expense, for employees engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CROs</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of acquiring, developing, and manufacturing clinical study materials; and</span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zkqq4guoxEai-3tecnFYYg_cont4" continuedAt="Tb_Zkqq4guoxEai-3tecnFYYg_cont5"><ix:continuation id="Tb_NxLbbdd7FkW3YqxkEhrWTg_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Costs associated with preclinical and clinical activities and regulatory operations.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" id="Tb_y3GH4SerG0SnZ1b4zzpdgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Prepaid and Accrued Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Substantial portions of the Company&#8217;s pre-clinical development, manufacturing and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors. These vendors generally bill&#160;monthly for services performed, or bill based upon milestone achievement. For preclinical and clinical studies, the Company accrues expenses based upon estimated work completed and the remaining contract milestones. At times, the Company is obligated to make upfront payments upon execution of research and development agreements. Upfront payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses until such goods are delivered or the related services are performed. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. The actual timing of performance or the level of effort may vary from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:PatentCostsPolicyTextBlock" id="Tb_HW8vG-Xljkuck6qK3nJMWA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company issues warrants, including pre-funded warrants, on its common shares in connection with financings as well as for compensation of intermediaries and advisors. The Company accounts for warrants as either equity instruments or as liabilities depending on the specific terms of the warrant agreements in accordance with FASB ASC Topic 815, <i style="font-style:italic;">Derivatives and Hedging </i>and Topic 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i>. When classified as equity, warrants are recorded within additional paid-in-capital at the time of issuance and are not subsequently remeasured. Warrants identified as meeting the definition of a liability are recognized as a liability and treated in accordance with the derivative liability accounting policy described above. The Company periodically reassesses the appropriateness of the classification of its financial instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Share-based compensation expense related to share awards granted to employees, directors and non-employees, excluding awards with market conditions in which the award does not vest unless the market condition is met, is recognized based on the grant-date estimated fair values of the awards using the Black- Scholes option pricing model (&#8220;<b style="font-weight:bold;">Black-Scholes</b>&#8221;). The value is recognized as expense ratably over the requisite service period, which is generally the vesting term of the award. The Company adjusts the expense for actual forfeitures as they occur. Share-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Black Scholes requires a number of assumptions, of which the most significant are expected volatility, expected option term (the time from the grant date until the options are exercised or expire) and risk-free rate. Expected volatility is determined using the historical volatility for the Company. The risk-free interest rate is based on the yield of U.S. government treasury bonds with a remaining term equal to the expected life of the option for C$ options and based on the yield of U.S. government treasury bonds for US$ options. Expected dividend yield is zero because the Company has never paid cash dividends on common shares and the Company does not expect to pay cash dividends in the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">For awards with market conditions in which the award does not vest unless the market condition is met, the Company will incorporate the market condition into the award&#8217;s grant date fair value calculation and derive the expected service period using a Monte Carlo simulation. The estimated expense is recognized on a straight-line </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zkqq4guoxEai-3tecnFYYg_cont5" continuedAt="Tb_Zkqq4guoxEai-3tecnFYYg_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">basis over the derived service period. If the market condition is satisfied during the derived service period, the remaining unrecognized expense is recognized during the period the market condition is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'TimesNewRomanPSMT';">Awards of options that provide for an exercise price that is not denominated in: (a) the currency of a market in which a substantial portion of the Company's equity securities trades in, (b) the currency in which the employee's pay is denominated, or (c) the Company's functional currency, are required to be classified as liabilities. The change in the Company&#8217;s functional currency, effective July 1, 2023, resulted in the reclassification of outstanding stock options that were previously denominated in C$ from equity-classified to liability-classified options (see Note 8), which are accounted for as a share option modification in accordance with FASB&#8217;s ASC 718 &#8211; </span><i style="font-family:'TimesNewRomanPSMT';font-style:italic;">Compensation </i><i style="font-family:'TimesNewRomanPSMT';font-style:italic;">&#8211;</i><i style="font-family:'TimesNewRomanPSMT';font-style:italic;"> Stock Compensation</i><span style="font-family:'TimesNewRomanPSMT';"> (&#8220;</span><b style="font-family:'TimesNewRomanPSMT';font-weight:bold;">ASC 718</b><span style="font-family:'TimesNewRomanPSMT';">&#8221;). Under ASC 718, when an award is reclassified from equity to liability, if at the reclassification date the original vesting conditions are expected to be satisfied, then the minimum amount of compensation cost to be recognized is based on the grant date fair value of the original award. Fair value changes below this minimum amount are recorded in additional paid-in capital. For each reporting period after the modification date, the stock option liability is adjusted so that it equals the portion of the requisite service provided multiplied by the modified award&#8217;s fair value at the end of the reporting period. Increases in the fair value of the liability in excess of the minimum grant date compensation cost described above are recognized as share-based compensation in operating expenses in the consolidated statement of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Share Issuance Costs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Common share issuance costs are incremental costs directly associated with an offering of securities. These costs typically include fees paid to bankers or underwriters, attorneys, accountants, as well as printers and other third parties. Prior to the effective date of an offering of equity securities, specific incremental costs directly attributable to a proposed or actual offering of securities may be deferred and charged against the gross proceeds of the offering. &#160;The Company capitalizes these deferred financing costs as prepaid expenses and other current assets in the accompanying consolidated balance sheets until the completion of the offering, unless the offering is abandoned, at which time the deferred financing costs will be recognized in the consolidated statements of operations. &#160;The Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="Narr_MgTC0qfUMk6NTDxe3VGh5g">32,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="Narr_MJ79MF_qgUCdb9epWNVS1Q">0</ix:nonFraction> in deferred financing costs as of December 31, 2025 and December 31, 2024, respectively, which was recorded in prepaid expenses and other current assets on the consolidated balance sheets.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_ECsTgg-Fm0mEHyIoeXeM2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company is a taxable entity under the Income Tax Act (Canada). Deferred income tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the respective income tax bases of assets and liabilities, measured using substantively enacted income tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are recognized to the extent it is more likely than not that taxable income will be available against which the deferred tax asset can be utilized. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company follows the provisions of ASC 740-10, <i style="font-style:italic;">Uncertainty in Income Taxes</i> (&#8220;<b style="font-weight:bold;">ASC 740-10</b>&#8221;). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_iftQj32S7ECE8gh6m9AHPQ">no</ix:nonFraction> unrecognized benefit since the date of adoption. The Company has <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_E_qockheUkWMIiCkBgKwtQ">no</ix:nonFraction>t recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_o4IAhor000qbm850TUmfcA" continuedAt="Tb_o4IAhor000qbm850TUmfcA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Basic and Diluted Net (Loss) Income Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Basic net (loss) income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net (loss) income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zkqq4guoxEai-3tecnFYYg_cont6"><ix:continuation id="Tb_o4IAhor000qbm850TUmfcA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">dilutive shares result from the assumed potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. The proceeds of such exercises or conversions are assumed to have been used to repurchase outstanding stock using the treasury stock method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Both basic and diluted net (loss) income per share calculations include financial instruments that allow for the purchase of common shares issuable for little to no consideration, including pre-funded warrants.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:EmergingGrowthCompanyStatusPolicyTextBlock" id="Tb_nqUSKCzv7kezRNua2wHzyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company is an Emerging Growth Company, as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (&#8220;<b style="font-weight:bold;">JOBS&#160;Act</b>&#8221;). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740):</i> <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 became effective for the annual period starting on January 1, 2025. The Company&#8217;s income tax disclosures are disclosed in Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires public entities, among other items, to disclose in a tabular format, on an annual and interim basis, purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion for each income statement line item that contains those expenses. ASU 2024-03 becomes effective for the annual period starting on January 1, 2027 and interim periods starting on January 1, 2028. The Company is in the process of analyzing the impact that the adoption of ASU 2024-03 will have on its disclosures.</p></ix:continuation><a id="_0fe26b7f_7171_413c_9591_caf59291cd0c"></a><a id="Tc_3G-xzrTQeU6n2CqP_xHHxA_1_2"></a><a id="Tc_uxshWKcZfkKtP2gRZudl-Q_2_2"></a><a id="Tc_vSwkh3XQK0O_IeFeUsd-FQ_2_5"></a><a id="Tc_uRYLRio4Z0mUJnNx4Rb-rQ_2_9"></a><a id="Tc_7pApuEL8NESDqyF8ltTi-A_2_11"></a><a id="Tc_9cpoMZPcJESkxxLs6Aj1_A_3_0"></a><a id="Tc_tQ9QPr4fz0GGPDERSO6thQ_4_0"></a><a id="Tc_tOEGVPmkTk2iKf8q-tRbQg_4_2"></a><a id="Tc_JIgmi-Mor0WwxWS10-LTSA_4_5"></a><a id="Tc_gEDl0KGRMESzfwOfg3ZAgA_4_6"></a><a id="Tc_29Fu6_y4AUyvqEQ_5h-tHw_4_8"></a><a id="Tc_cIZ6zLWN2UGrWD130hUhNQ_4_9"></a><a id="Tc_2MD3JvBXl02_zKd_1vdxZQ_4_11"></a><a id="Tc_NkoMxswzyU6HI7780axeYg_5_0"></a><a id="Tc_Ohhwpl2mwE6ei_nFkcZUtg_5_2"></a><a id="Tc_A9Qx8jr3g0uacogzu9MYKQ_5_5"></a><a id="Tc_BCD6bARZLkCXew36KsxwOg_5_6"></a><a id="Tc_0KB6rPS5QUevoKdbZA4WjA_5_8"></a><a id="Tc_MaZsKzlXYE6vnfiXQrgX1A_5_9"></a><a id="Tc_c7tOgN-vCU2tWxea4moTHA_5_11"></a><a id="Tc_7QoMUDsF_kiT4OODi0ZBnw_6_0"></a><a id="Tc_g0kkYGMxVEiF-lnC6Jn_6w_7_0"></a><a id="Tc_iwpSE_6_SkOpmMe0yDDb1A_7_2"></a><a id="Tc_0zoqHJcYv0SysphDY4ct5w_7_3"></a><a id="Tc_gFzfQnYgW0iyIk0RVtCMxg_7_5"></a><a id="Tc_FcUCm7NoIkeIK-xeWYnk8A_7_6"></a><a id="Tc_u469nQQmCkKEcxpQcbKR5w_7_8"></a><a id="Tc_mBlnYH05gEWnEqgKLt_zDw_7_11"></a><a id="Tc_tLtAC2x7IkakLR86nUHlfw_8_0"></a><a id="Tc_r_iNPtzKkEegufq7IOMv7A_8_2"></a><a id="Tc_On40x8tP40KUY-Cu4gtnPg_8_3"></a><a id="Tc_jmDbAWEWgEW1ObU4XhSftw_8_5"></a><a id="Tc_ugk2850vREGtKzTAxXth_A_8_6"></a><a id="Tc_vAbbFaerEEqHKljP721D8A_8_8"></a><a id="Tc_KcMLCqzPxkmCMbYGkNiMVA_8_11"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_OyzvrtepFUyz8_cMfMJ1iw" continuedAt="Tb_OyzvrtepFUyz8_cMfMJ1iw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span>FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following are the major categories of assets measured at fair value on a recurring basis as of December&#160;31, 2025 and 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_e6am47peVke6xlI4BN627g" continuedAt="Tb_e6am47peVke6xlI4BN627g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2BUfm8XxKEiVAOa9cCeI-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="Tc_emqaHLqKZ0iO4D6qVFVP3Q_4_3">33,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="Tc_xzQkw8xs_EuPbErJ_qu7lA_4_12">33,753</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2BUfm8XxKEiVAOa9cCeI-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_-YOnvviF-UGadM-3ICypeA_5_3">33,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_Ok-Y6u0lAEOtmtOBEsahiA_5_12">33,753</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6VYWxtDOn0yRARELn8NX6Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="Tc_D9pkfAGnQUOh0kFfq17AWw_7_9">29,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="Tc_0cAFYc1AaUaOS7T_OSkAVw_7_12">29,182</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6VYWxtDOn0yRARELn8NX6Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_YngQpf6BwEq2yiZRg1fnYw_8_9">29,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_9Jfu0fIH40e4jk5FIlHwog_8_12">29,182</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a1de8ec0_8fef_4dfb_acbf_5e14790aa6ae"></a><a id="Tc_KpvWMCH9dkmFMQ-3aEc95Q_1_2"></a><a id="Tc_qQEc6QH0PUqi8wQy1gMwbQ_2_2"></a><a id="Tc_d9HKQxMLr0CEl_FY050_Uw_2_5"></a><a id="Tc_mJyXJcZcN0eT83thIrVHGw_2_9"></a><a id="Tc_xaZOo0CmzUmUdWaSwRGAZw_2_11"></a><a id="Tc_q9pToN30sk2PnQchmp7Neg_3_0"></a><a id="Tc_CN7tpEffFUqlflVX7n9mew_4_0"></a><a id="Tc_Sfj5Q-abHUim-xNxFKtFEQ_4_2"></a><a id="Tc_qWvqPd9DV0iZu3Pm4uIUqA_4_5"></a><a id="Tc_dgrkncaoVUWduvaMVNS91g_4_6"></a><a id="Tc_a16b4ibrt0q1Hm7V-oiwrQ_4_8"></a><a id="Tc_4UwFW0g4XEqy5YBjqnLZMg_4_9"></a><a id="Tc_al6OoS14DkS-5B0rtL4wuA_4_11"></a><a id="Tc_-vNcz-OT60ikbXDzwYndpg_5_0"></a><a id="Tc_T9lMQ64hUEWVJrWpkLVB7w_5_2"></a><a id="Tc_QliNxWOxHkuwMBRYtebcEg_5_5"></a><a id="Tc_T9tjjvPs0Eig7wCr-TUkQw_5_6"></a><a id="Tc_4pEyVmwon0KetZx71Cod6A_5_8"></a><a id="Tc_8n2Am_6ixkqnHl0QEOZ1IA_5_9"></a><a id="Tc_7POHBRShBkuJsdCB6y6o9A_5_11"></a><a id="Tc_-vq7hoa21UCea7K3JMpnjA_6_0"></a><a id="Tc_rPfNpJ2R90adoAE76DBWHw_7_0"></a><a id="Tc_iMgAhkQqLEi75cnYrVXLqg_7_2"></a><a id="Tc_Kfa2vRqUE0GKxfvWTBdjaQ_7_3"></a><a id="Tc_5-VBsOs6KkiSJ14JfpHMWg_7_5"></a><a id="Tc_xziMwQlcyEeBtBdxFzCaMQ_7_6"></a><a id="Tc_kBn4F3qXwE6moIKIqZQ95w_7_8"></a><a id="Tc_q8f2j0_nA0WHUgjFbfIgTw_7_11"></a><a id="Tc_BNzkN6hNCkuNULG5Quwt7g_8_0"></a><a id="Tc_YFJZh20B1EqFVPYAc31ONA_8_3"></a><a id="Tc_eE4oKs6tSUqJm5EHgJCLlg_8_6"></a><a id="Tc_PGA3NlHak0WGuCq_4he3WQ_9_0"></a><a id="Tc_nqERogrWOEeUe5lBZ-JWzQ_9_2"></a><a id="Tc_IR4Fuy_7eECbEBbdI5_jBA_9_3"></a><a id="Tc_mHyxJHjpg06n9eyj2Ej4lA_9_5"></a><a id="Tc_06v7Hu0It0-iL3b2HuzFpw_9_6"></a><a id="Tc_FPyqs1zE9k-p16I668FATw_9_8"></a><a id="Tc_omeegGAyn0yVMGcbHj5Etw_9_11"></a><a id="_e3e658df_23a0_4e85_a0cd_4b1369859917"></a><a id="_e3e658df_23a0_4e85_a0cd_4b1369859917_2"></a><a id="_e3e658df_23a0_4e85_a0cd_4b1369859917_3"></a><a id="_5c9190d3_c348_48de_90a2_7c0b969ef34a"></a><a id="_5c9190d3_c348_48de_90a2_7c0b969ef34a_2"></a><a id="_5c9190d3_c348_48de_90a2_7c0b969ef34a_3"></a><ix:continuation id="Tb_OyzvrtepFUyz8_cMfMJ1iw_cont1"><ix:continuation id="Tb_e6am47peVke6xlI4BN627g_cont1"><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Aptos Narrow';font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b><b style="font-weight:bold;">Level&#160;3</b><b style="font-family:'Aptos Narrow';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qm2HZYqej0K6tZkucd3Jzw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="Tc_gm9gOZtUxkKZIXittAh-MQ_4_3">33,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="Tc_DVSgnyzI-kKCorjNQfovjQ_4_12">33,051</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qm2HZYqej0K6tZkucd3Jzw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_JwVxyatDbUupZEI1cLHnYA_5_3">33,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_Teb6XgUwFEGiWg7hDB01Mg_5_12">33,051</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="Tc_YXsn_eVgT0aQKJhPA83oGQ_7_9">199,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="0" id="Tc_AgIb_iUJBk6iWsyTEJ2dBQ_7_12">199,263</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_EJS0vbsJkUGo-vHYJKmxOg_8_9">5,592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" scale="0" id="Tc_cKjjD-rkIkWD7x4xYo6sDQ_8_12">5,592</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_fhoUG8L-N0aAqstck86gPg_9_9">204,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_zaXUK9Vt-U26nQoQaaYqdg_9_12">204,855</ix:nonFraction></p></td></tr></table></div></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt-sec:numwordsen" name="pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount" scale="0" id="Narr_yRgUIlbHBkuILETN6Tx8rw"><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt-sec:numwordsen" name="pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount" scale="0" id="Narr_0NBrG3k840SJgNpmCNCUmA"><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt-sec:numwordsen" name="pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount" scale="0" id="Narr_0EBQT-lUz0i_kDRhXXX7mg"><ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt-sec:numwordsen" name="pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount" scale="0" id="Narr_kip-2bfXI0WvE-_TDU8tSg">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between levels have occurred in either reporting period presented. Refer to Note 6 for disclosures related to the warrant liability and Note 8 for disclosures related to share-based compensation liability.</p></ix:continuation><a id="Tc_DF1gvMOkUUypaAztxjIkfw_1_2"></a><a id="Tc_3535hYGx7EKRCTNVn26c0A_2_2"></a><a id="Tc_y7UtqLRv-0-q7bMnNgGadw_2_5"></a><a id="Tc_Qji3amulckaMFmFHrJWe9g_3_0"></a><a id="Tc_1ixaU3PGSkCzyVgc4X_vhg_3_2"></a><a id="Tc_9yf6BOPprEGZ7Wcj1qhDGw_3_5"></a><a id="Tc_yquU1__CM02aAADS1pqY0A_4_0"></a><a id="Tc_MO-Z4x4nqEKgqGqmJwAKmQ_5_0"></a><a id="Tc_nls0XxaJbUKGNOIdpbmunA_6_0"></a><a id="Tc_b2Lzy5fj8UqJfh2hKl66pA_7_0"></a><a id="Tc_91HSljFXdkWAPPzgy08cnQ_7_6"></a><a id="Tc_fYpMHTyGIkCL81CkOus8Ng_8_0"></a><a id="Tc_CVlV-QZgq0KVKXpv9YN1Dw_9_0"></a><a id="Tc_cpj4GhHa_0e6J7TNQQw8MQ_9_2"></a><a id="Tc_0cqoLNTPzE2efcmNpPt7Pw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="Tb_WtqWzt7_mkeB2oJWBNsl9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span>PREPAID EXPENSES AND OTHER CURRENT ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Prepaid expenses and other current assets consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_2BAazFr3tkKkydKhG3eAzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Upfront research payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="pmn:PrepaidUpfrontResearchPaymentsCurrent" scale="0" id="Tc_DwmxF8eEf0yYxbmCRiU5mA_3_3">2,625,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="pmn:PrepaidUpfrontResearchPaymentsCurrent" scale="0" id="Tc_jQAQpCwayU6a-hEe44CHug_3_6">5,087,692</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="0" id="Tc_Yo3sEGskikOvDNX3iUGGhw_4_3">36,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="0" id="Tc_Jbt8WcLtJkel3SD8yjPsEw_4_6">78,034</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_yMyKoxBJtUapyObMdDqFPw_5_3">238,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_W-5QDg81eU-wS4a5EadgeA_5_6">335,976</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="pmn:PrepaidLicenseFeeCurrent" scale="0" id="Tc_B7N1HraYs02GO3uJoGBkAg_6_3">62,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="pmn:PrepaidLicenseFeeCurrent" scale="0" id="Tc_2PD_sORBu0uMDMgSeh15JA_6_6">38,255</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredFinancingCostAssets" scale="0" id="Tc_Cvh3S2qgPkqYRWA9BjZNUg_7_3">32,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_oNWA0bc6IUipMCmjDVN3rw_8_3">38,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_m09qTOnlzUKLBfYmnLXltw_8_6">47,281</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_vTwnXRumyEK9hn5az0u4Vw_9_3">3,032,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_QBJ1htP2MECjiU7azVaXKw_9_6">5,587,238</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_lZOHNx__JU22FGl0X-GJpw_1_2"></a><a id="Tc_WMYk2kPah0ulvkbF6vSleg_2_2"></a><a id="Tc_eg0nErmmU0-04srSLApcTg_2_5"></a><a id="Tc_X4LQSLpLUUWxsVEbs61Xxw_3_0"></a><a id="Tc_U2ZV9kRj8ku-rr33Qm4R8Q_3_2"></a><a id="Tc_RwB-ieWwkUqSWMeAjyK1cg_3_5"></a><a id="Tc_Y90pDwyMQU-dKjw_6m8HhA_4_0"></a><a id="Tc_mH5j2iCvhEO9-6RgVkYf_w_5_0"></a><a id="Tc_oIK2vGx3nEmOKvhvlQYnMA_6_0"></a><a id="Tc_g1nsMx_PcU-uAOCfvXU3sg_7_0"></a><a id="Tc_SkFi_EIDQkaDUxXTgGsU4g_8_0"></a><a id="Tc_5eNmvqsTtEmn4pW1FX-P_w_8_2"></a><a id="Tc_3HU9PL70B0GdiTqN_7Mq4w_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:AccruedLiabilitiesTextBlock" id="Tb_1e5ACMxLDEuWLcRrX1mF8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span>ACCRUED LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Accrued liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb__68yCvVA-E650rXTLTd8vg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Legal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="pmn:AccruedLegalFeesCurrent" sign="-" scale="0" id="Tc_5YFECuUJ2Eqkf4i2VwSL9g_3_3">88,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="pmn:AccruedLegalFeesCurrent" sign="-" scale="0" id="Tc_Uj99HdFki06JaQQ4GS4agg_3_6">44,610</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_wTydNU5GSEmFrnHqEj-hFQ_4_3">159,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_UMOHNvbnDk-_aF3cCoQ9sA_4_6">95,182</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="pmn:AccruedResearchAndDevelopmentCurrent" sign="-" scale="0" id="Tc_PPVsaaxJRE6JMhoD-UsJVw_5_3">7,460,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="pmn:AccruedResearchAndDevelopmentCurrent" sign="-" scale="0" id="Tc_C9pbtwsXoUqpzS7uw2jQFA_5_6">223,559</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="0" id="Tc_pc7eyBcoikSkfdn2T3bb7Q_6_3">79,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="0" id="Tc_wCEtsf4wVE6KkNssbszlPg_6_6">38,328</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_doJNxA02OUOpEGBTySTPdA_7_3">79,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_UM59a4ePVUe-1QoM50XViA_7_6">79,283</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_LDHkBETXDkOJ_nzlwZc9vA_8_3">7,868,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_n2sFF0e_6kOwPZ_oXzuDnA_8_6">480,962</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_FqsUdyaRykOXCQ9is13ZaQ" continuedAt="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">EQUITY </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has authorized an unlimited number of both Common and Preferred shares. As of December&#160;31, 2025 and 2024, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_4EMfl319XEiTIKNxei-UNA"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_fiL9aTGuS0uHQFzmrO1WWQ">2,152,397</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_3o2iQxOWbUK-qJXfhKzQUQ"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Vp_CCNsj5Eqk3jYacsEx-Q">1,307,520</ix:nonFraction></ix:nonFraction> issued and outstanding Common Shares, respectively. All share classes have <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="Narr_TiETkOKDCEe1vgjd8BMxqw">no</ix:nonFraction> par value.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_YcVQur1EMki2bpsa9tJhKA_1_2"></a><a id="Tc_iloj7_Ss4UaJm79PDX2gRw_2_2"></a><a id="Tc_FWUsbnZUckS_bPj1xMX66A_3_0"></a><a id="Tc_ZO_7Ce6npkitm9UITg1lnA_4_0"></a><a id="Tc_Lp7ZNSutwUGD8JfI4NaQdQ_5_0"></a><a id="Tc_TkpJrZTwwEaGDuWvvw9bCw_6_0"></a><a id="Tc_pkn242x06k-QdNECO5xb5A_7_0"></a><ix:continuation id="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont1" continuedAt="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Common Shares reserved for future issuance consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="Tb_uy2WEp5WZk-f07rhk088mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_DO_fwCZQ6Uu2JP2XTJqahw_3_2">2,639,005</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_f9QUE4-tFkGUM69b1vTyBg_4_2">180,827</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred Share Units granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="pmn:DeferredShareUnitsOutstanding" scale="0" id="Tc_T9gqqUOjjEKRaz7y50KsEQ_5_2">42</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Shares available for grant under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_AqlYf8unu0q50_dys2tn5w_6_2">80,686</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Common Shares reserved for future issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_wE8wT6Jh4EGCkv2V-rwq-A_7_2">2,900,561</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preferences, privileges, and rights of the Common Shares are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Voting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Subject to any special voting rights or restrictions, holders of common shares entitled to vote shall have <ix:nonFraction unitRef="Unit_Standard_Vote_I7wc_r8nuUinrT38wY9WLA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfVotesPerCommonShare" scale="0" id="Narr_22ccacN7ZkGkXau8JwZnpw">one</ix:nonFraction> vote per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s board of directors may from time to time declare and authorize payment of dividends, if any, as they may deem advisable and need not give notice of such declaration to any shareholder. Subject to the rights of common shareholders, if any, holding shares with specific rights as to dividends, all dividends on common shares shall be declared and paid according to the number of such shares held and paid in Canadian dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Liquidation Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In the event of the liquidation, dissolution or winding-up of the Company or any other distribution of the Company&#8217;s assets for the purpose of winding up the Company&#8217;s affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled <i style="font-style:italic;">pari passu</i> to receive any remaining property of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 2024 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On July 26, 2024, the Company entered into a Unit Purchase Agreement (the &#8220;<b style="font-weight:bold;">Unit Purchase Agreement</b>&#8221;) to raise $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA" decimals="0" format="ixt:num-dot-decimal" name="pmn:AggregateGrossProceeds" scale="0" id="Narr_TtE73sctiUGEx196lIEmwg">30,332,984</ix:nonFraction> in aggregate gross proceeds for the Company (the &#8220;<b style="font-weight:bold;">July 2024 PIPE</b>&#8221;) before deducting $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA" decimals="0" format="ixt:num-dot-decimal" name="pmn:OfferingCostsAndAgentFee" scale="0" id="Narr_yBbxudVbwEeHywIEQ--H0A">2,675,487</ix:nonFraction> in placement agent fees and other expenses. All gross proceeds were received by the Company as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Pursuant to the terms of the Unit Purchase Agreement, the Company agreed to sell to PIPE Investors in the Offering, an aggregate of (x) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_WoxRD2BhjUizfdZS0HDjoA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:UnitsIssuedDuringPeriodSharesNewIssuance" scale="0" id="Narr_KX055QAIEU6Fv-xoB9MxmQ">390,307</ix:nonFraction> common share units (the &#8220;<b style="font-weight:bold;">Common Share Units</b>&#8221;), each consisting of (i) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_8p18K6uLmk6qW32n10mbgw" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfCommonSharePerUnit" scale="0" id="Narr_-QNOh-cVEUiAz23w9o1emw">one</ix:nonFraction> Common Share, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_3sNvUqnERk29CoEwJ1LNig" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfWarrantsPerUnit" scale="0" id="Narr_l2TzWT_2MkKygEc_0rhPnw">one</ix:nonFraction> Tranche A Common Share purchase warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_3sNvUqnERk29CoEwJ1LNig" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_SJGJa1tNhE28P1al23fJ_g">one</ix:nonFraction> Common Share, (iii) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_6T695C591UiyeQbCleHuxg" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfWarrantsPerUnit" scale="0" id="Narr_lxP21pU4TUS-yNErs0j2pA">one</ix:nonFraction> Tranche B Common Share purchase warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_6T695C591UiyeQbCleHuxg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_XK-Qo83vcEqGYyOw3DxNug">one</ix:nonFraction> Common Share and (iv) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OX19e1OjNUi2f5RsX_WMag" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfWarrantsPerUnit" scale="0" id="Narr_WF2o5HbHGUiQKA1yrxl9tg">one</ix:nonFraction> Tranche C Common Share purchase warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OX19e1OjNUi2f5RsX_WMag" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_Ye9l14bArkqcxzEh0bjuJw">one</ix:nonFraction> Common Share (each, a &#8220;<b style="font-weight:bold;">Warrant</b>&#8221;, collectively, the &#8220;<b style="font-weight:bold;">Warrants</b>&#8221;) and, for certain investors, (y) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_w1RADThn2Uar_4m_e19qyQ" decimals="INF" format="ixt:num-dot-decimal" name="pmn:UnitsIssuedDuringPeriodSharesNewIssuance" scale="0" id="Narr_j9dt9_yCWkeuFx8Vf6cn-g">174,841</ix:nonFraction> pre-funded units (the &#8220;<b style="font-weight:bold;">Pre-Funded Units</b>&#8221; and together with the Common Share Units, the &#8220;<b style="font-weight:bold;">Units</b>&#8221;), each consisting of (i) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_Cj0bmR9KNU-gOSr3An81OQ" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfWarrantsPerUnit" scale="0" id="Narr_zwU5aYOm3UeaDSdCSWMaWA">one</ix:nonFraction> Pre-Funded Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_Cj0bmR9KNU-gOSr3An81OQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_3iOiaYUOK0i-OcRZP94wZA">one</ix:nonFraction> Common Share (each, a &#8220;<b style="font-weight:bold;">Pre-Funded Warrant</b>&#8221;, collectively, the &#8220;<b style="font-weight:bold;">Pre-Funded Warrants</b>&#8221;, and the Common Shares issuable upon exercise of the Warrants and the Pre-Funded Warrants, the &#8220;<b style="font-weight:bold;">2024 Warrant Shares</b>&#8221;), (ii) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_sO-pqyxjMUuCAIj5bfCXDw" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfWarrantsPerUnit" scale="0" id="Narr_-YsPeUl2Wkiy556MY9Kxag">one</ix:nonFraction> Tranche A Common Share purchase warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_sO-pqyxjMUuCAIj5bfCXDw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_-PrkjlTDxU6cEbM65YMXxg">one</ix:nonFraction> Common Share, (iii) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_bpZRccBbfUmU6W3r5YkXHA" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfWarrantsPerUnit" scale="0" id="Narr_WjcPYmmT8UeMPL_FWO0vmA">one</ix:nonFraction> Tranche B Common Share purchase warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_bpZRccBbfUmU6W3r5YkXHA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_0hXPoZGFn0GIKRJeFH8ecg">one</ix:nonFraction> Common Share and (iv) <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_v_5AQ8INOEWby_KGMYOsxQ" decimals="INF" format="ixt-sec:numwordsen" name="pmn:NumberOfWarrantsPerUnit" scale="0" id="Narr_QURm-2QwdUGDUAfW87qvpg">one</ix:nonFraction> Tranche C Common Share purchase warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_v_5AQ8INOEWby_KGMYOsxQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_Ot77decOm062HUEJXc2NhA">one</ix:nonFraction> Common Share. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont2" continuedAt="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The purchase price for each Common Share Unit was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_WoxRD2BhjUizfdZS0HDjoA" decimals="2" format="ixt:num-dot-decimal" name="pmn:PricePerUnit" scale="0" id="Narr_NAGJjxth20Kib5IyBmGK7g">53.75</ix:nonFraction> per Common Share Unit, and the purchase price for each Pre-Funded Unit was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_w1RADThn2Uar_4m_e19qyQ" decimals="2" format="ixt:num-dot-decimal" name="pmn:PricePerUnit" scale="0" id="Narr_0_eEXHT1s0OEFrGtgqXmmw">53.50</ix:nonFraction> per Pre-Funded Unit. The Pre-Funded Warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_26_2024_YRF1DtgvqEykJgtUIbZvgA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_IjdjAeweG0exjhCOOkb_Hw">0.25</ix:nonFraction> per 2024 Warrant Share, are immediately exercisable and will expire when exercised in full. The Tranche A Common Share purchase warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OTZaBhXrTk-ATiBJ5MN0xg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_P2wL__-tOE28hJuAm6_R8w">50.50</ix:nonFraction>, for aggregate gross proceeds of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_AXkBdGaKv0Sxf5BYb0bqKw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_NlHNp7lBv0aNMDtxn7Eg9g">28.5</ix:nonFraction> million, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) <ix:nonNumeric contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OTZaBhXrTk-ATiBJ5MN0xg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_kiBzp2TOu0-_20u-FSBMfQ">18 months</ix:nonNumeric> or (ii) within <ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_FcVZtKmJ30yeYVCm5Ilgeg" format="ixt-sec:durwordsen" name="pmn:ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" id="Narr_k6dt44k9E0KnHjh61P91ww">60 days</ix:nonNumeric> of the Tranche A Milestone Event (as defined below). The Tranche B Common Share purchase warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_SKI98Sng40qCm1MAstf_uw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_a3ZbNaMEckOhcJiyEu6t8Q">50.50</ix:nonFraction>, for aggregate gross proceeds of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_anrOgR3un0mVCIt8ZEvpkg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_VJxFl-6qtUiZY2Vs5gTrRg">28.5</ix:nonFraction> million, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) <ix:nonNumeric contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_SKI98Sng40qCm1MAstf_uw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_LFSTvmk0VkSONpng8RSu0Q">30 months</ix:nonNumeric> or (ii) within <ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA" format="ixt-sec:durwordsen" name="pmn:ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" id="Narr_PLnGOguXiUONVRcwdCvtdw">60 days</ix:nonNumeric> of the Tranche B Milestone Event (as defined below). The Tranche C Common Share purchase warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_7IREftZcLkyg0wHsVKlqFQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_6nvOw9QZ40ukiKz-t6HLIQ">62.50</ix:nonFraction>, for aggregate gross proceeds of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_47_m4S0qR0iRJtAX5RQLIg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_pHdQP3b7f0ePXQ1vCVfjuw">35.3</ix:nonFraction> million, are immediately exercisable and will expire on July 31, 2029. For purposes of the foregoing, &#8220;<b style="font-weight:bold;">Tranche A Milestone Event</b>&#8221; means the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with multiple ascending doses of PMN310, and &#8220;<b style="font-weight:bold;">Tranche B Milestone Event</b>&#8221; means the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with multiple ascending doses of PMN310. Pursuant to Nasdaq Listing Rule 5635(d), the exercise of the Tranche A and Tranche B Common Share purchase warrants is subject to shareholder approval (&#8220;<b style="font-weight:bold;">Shareholder Approval</b>&#8221;). The Company agreed to convene a shareholders&#8217; meeting, or otherwise obtain written Shareholder Approval, on or before <ix:nonFraction unitRef="Unit_Standard_D_JjSvLYrH-EWdNko9j1YiTg" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ThresholdDaysToGetShareholdersApproval" scale="0" id="Narr_fx4HDXHTx0ChlNgEUmxnsg">90</ix:nonFraction> days following the Closing Date, to obtain such approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Tranche A and Tranche B Warrants (&#8220;<b style="font-weight:bold;">AB Warrants</b>&#8221;) were classified as liabilities (&#8220;<b style="font-weight:bold;">AB Warrant Liability</b>&#8221;) and recorded at fair value utilizing level 3 inputs at issuance due to the requirement for Shareholder Approval. Under the applicable accounting guidance, the requirement for Shareholder Approval precludes a financial instrument from equity classification, as it cannot be considered indexed to the Company's own stock. &#160;The preclusion is because of the potential of the settlement amount differing than a fixed for fixed option on the Company's shares. The fair value of the AB Warrant Liability at issuance was determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_Ec-PTVWrHU6jtSro-6pQ3g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="0" id="Narr_zjgZYVwiWEejgVTkME4xLQ">31,182,033</ix:nonFraction>, calculated using a Black Scholes calculation on July 26, 2024 with the following weighted average assumptions: share price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OBE-rahe30mjEaB9k6wKdQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_mKvByLX4LUyCTDZgDTZt5Q">50.50</ix:nonFraction>, the most currently available Nasdaq Official Closing Price for the Company&#8217;s Common Shares when the Company entered into the purchase agreements, exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_oIAjV4RAJk26fwCLgDL5rw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_lOeJu9G3IUiLJz0V1RwmZQ">50.50</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SMlc3z5xwU2h8j7yM4L-sQ" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_jPj238l4CU2Ci0fTExQjUQ">102.5</ix:nonFraction>%, risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0ulmsA0VAkKV0dAMZCrDbA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_ZP0wcUS4f0G-iV5D51BrOA">4.34</ix:nonFraction>%, and a term of <ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_irrRYii8eE21ooTnYfcNCA" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_c4vnot842U-tcafdBTa3bA">2.1</ix:nonFraction> years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company incurred offering costs totaling $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_oZFjvhH-JUix4Fgqj1x1hQ">2,675,487</ix:nonFraction> that consisted of placement agent fees and direct incremental legal, advisory, accounting and filing fees relating to the July 2024 PIPE, resulting in net cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="Narr_sA2WpImO-UG5hOv2SfAxlg">27,657,497</ix:nonFraction>. The value of the AB Warrants exceeded the net proceeds received. As a result, the entire proceeds and offering costs were allocated to the AB Warrant liability, and also resulted in a loss on issuance of common shares, warrants, and pre-funded warrants of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg" decimals="0" format="ixt:num-dot-decimal" name="pmn:LossOnSaleOfCommonSharesAndWarrants" sign="-" scale="0" id="Narr__kQPJ6FYGEGwnL18ME2OTg">3,524,535</ix:nonFraction>, which was recorded in other income (expense) in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On October 23, 2024, Shareholder Approval for the AB Warrants was obtained during the Company&#8217;s Special Meeting of Shareholders. Following Shareholder Approval, the Company determined that the AB Warrants met the criteria for equity classification. The Company re-measured the fair value of the AB Warrant Liability at October 23, 2024 to $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_qo_eeZpMdkKWqiKn5hBbMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="0" id="Narr_2Gy2SZQcIU2Y-CFtLbdW7g">8,689,149</ix:nonFraction>, calculated using a Black Scholes calculation with the following weighted average assumptions: volatility of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hE5JvZ3pGkuLwiBtavfN2w" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_x5xtLG3LSEmd-RJU50NLkw">100.9</ix:nonFraction>%, share price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_sgCMr1pSoUC2ePK4kj1p-A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_yjlGB6hzkkqHv1ImqLNIrA">23.75</ix:nonFraction>, exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_C7t5pUTfOU2-H7yBZeKMnA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_nZxGU0-hV0G4xe-8eK486g">50.50</ix:nonFraction>, risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qIdSELbVFkaYdmFaMjb2AA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_-IqeEK-evkWbBl3EEFC6gg">4.10</ix:nonFraction>%, and a term of <ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RbMHvC0yfUeVN1ARzZnBIQ" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_GJDbnFy6VEKX8rTovDMAWg">1.9</ix:nonFraction> years. The change in fair value of the AB Warrant Liability of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_RQMPznxiJUaeXSv1Kr1dkg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="0" id="Narr_Fraq6R2ISEmoawtm_R1WGQ">22,492,884</ix:nonFraction> was recorded in other income (expense) in the consolidated statements of operations and the remaining fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_RQMPznxiJUaeXSv1Kr1dkg" decimals="0" format="ixt:num-dot-decimal" name="pmn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" scale="0" id="Narr_ItI50JdJwEKWRxbsQKCnVg">8,689,149</ix:nonFraction> was reclassified from liability to additional paid-in-capital in the consolidated balance sheets. As of December 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_n8K5Hi-d6EKuzXBWSyVZug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_kIRXiXdXxU2BD67ktUW2WQ">942,510</ix:nonFraction> warrants issued with the <span style="-sec-ix-hidden:Hidden_YqiLGZ_RnUeciaPL5_1Scw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">July 2024</span></span> PIPE are <span style="-sec-ix-hidden:Hidden_zqmpoD10K0mYm-cj5Mnc8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_JIhTf2m0-0KabLXPYhKDMQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_zYPlRvRpq0-bIaZjD109Fg">314,170</ix:nonFraction> each from Tranche A, Tranche B, and Tranche C).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2781d5e8_5529_44ac_b1de_6cd917d49082"></a><a id="Tc_Ipan84jB40aD_eAks2fLww_1_2"></a><a id="Tc_mSbpBQ0sFEyAwtMBGVUIbw_2_2"></a><a id="Tc_xUmKJNdytUyxuLMJItu27A_3_0"></a><a id="Tc_BsiAZemEL0GOuG7MsK5NQg_3_2"></a><a id="Tc_yD_jcnqERkeB7hJcl8gp8w_5_0"></a><a id="Tc_WNNR1mgYZU-bdXKBvYQVNA_5_2"></a><a id="Tc_q0XrhC7a_EeUtuvQOaZ8VA_5_3"></a><a id="_ac8df274_2aba_46a0_ad52_9d4bcc9d197a"></a><a id="Tc_l5AWFSrUj0qxrKVNVZJAQA_1_2"></a><a id="Tc_S92knWwWx0qNAIVNHc46uQ_2_2"></a><a id="Tc_86slbxzqzUW9ms0sOxne-Q_3_0"></a><a id="Tc_ylpHcAniIEKkuXudRt_4Cg_3_2"></a><a id="Tc_R7nSOOVxNUuEUdfRPExo5Q_4_0"></a><a id="Tc_Zjxlz1jACkCk-6f3cQPhxw_6_0"></a><a id="Tc_MhxjOnqDTk-iZ4V0E6viIg_8_0"></a><a id="Tc_xa_n17tUSEyj23WGyaXHTQ_8_2"></a><ix:continuation id="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont3" continuedAt="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">A summary of warrant liability activity, which is based on level 3 inputs, for the years ended December 31, 2025 and 2024 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_YoanmoqTME6ncgb6u864pQ" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_H2NEwcf350aPFyKmsq_uqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_xaU9LQGLVkuHu1Sq5gLwdw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_P0sV5IiJgE63t8wDPYj-xg_3_3">5,592</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TkWIfmwCtk2L1o77RyTsVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of C$ warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_PmbPPIZSikyMOvx6yPh_Ag" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_1VRYM3t8N06ETI8wD8QjkQ_4_3">5,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_eoUbqM8EvkG5L47UIBVk4A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_GSzWSiYCz0STeeqLtIBQaA_3_3">94,185</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 2024 PIPE AB Warrant Liability at issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_T8HONw3a-0-21izjx6PztQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="0" id="Tc_1Y3yHK8JoEe61FChxaHhHA_4_3">31,182,033</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_K9LLXyDMFk2irW-0jw4rvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of 2024 PIPE AB Warrant Liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_iNpkjm-HZkCwVepJ2_piAQ_5_3">22,492,884</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reclassification of 2024 PIPE AB Warrant Liability to equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw" decimals="0" format="ixt:num-dot-decimal" name="pmn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" sign="-" scale="0" id="Tc_wUCZv97Gykumvul765uxaA_6_3">8,689,149</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NKYPClXPwkOL6W5cM2Ychw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of C$ warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_aET_q1kz20eyyiAplvmU3A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc__31mpY62jEaNVom0iCq3cg_7_3">88,593</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_JgwQ5vRSwU6dCCuhwG_xZA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_PMlvC65jm0eqYLkjCwD95Q_8_3">5,592</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 2025 Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;">On July 22, 2025, the Company entered into a securities purchase agreement relating to the issuance and sale of a pre-funded warrant to purchase </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_xDeT03pBJ0eMB1_ES1k0mg">39,389</ix:nonFraction></span><span style="color:#191c1f;"> Common Shares (the &#8220;</span><b style="color:#191c1f;font-weight:bold;">RD Pre-funded Warrant</b><span style="color:#191c1f;">&#8221;) to such investor (the &#8220;</span><b style="color:#191c1f;font-weight:bold;">RD Offering</b><span style="color:#191c1f;">&#8221;). The RD Pre-funded Warrant was sold at an offering price of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_alrUEPuhgkiIhHg83YFJIw">20.31</ix:nonFraction></span><span style="color:#191c1f;"> per share, which represents, if it were applicable, the per share offering price for the Common Shares of the Company, less a </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_-oIAjuFbI0KbGr2MPGxL5g">0.0025</ix:nonFraction></span><span style="color:#191c1f;"> per share exercise price for such Pre-funded Warrant. &#160;The gross proceeds from the RD Offering were </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_c27Fx9k4pkmbZZyNSQSBcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_bLgFh8VaOk6O0nb05al6nQ">800,000</ix:nonFraction></span><span style="color:#191c1f;"> before deducting offering expenses of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_c27Fx9k4pkmbZZyNSQSBcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_XVna9MbfD0yu9Ym_74UmYA">102,342</ix:nonFraction></span><span style="color:#191c1f;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 22, 2025</span><span style="color:#191c1f;text-decoration-color:#191c1f;text-decoration-line:underline;text-decoration-style:solid;"> Exercise of Discounted Warrants and PIPE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">On July 22, 2025, the Company accepted a discounted warrant exercise offer from a healthcare-focused institutional investor for certain July 2024 PIPE warrants (&#8220;<b style="font-weight:bold;">July 22, 2025 Discounted Exercise</b>&#8221;). Related to the July 22, 2025 Discounted Exercise, the Company also entered into a securities purchase agreement (the &#8220;<b style="font-weight:bold;">July 22, 2025 PIPE</b>&#8221;) with the same existing healthcare-focused institutional investor. The Company raised $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g" decimals="0" format="ixt:num-dot-decimal" name="pmn:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr_mVb_zUnbWk-uGMwLDJ2W4Q">9,199,765</ix:nonFraction> in aggregate gross proceeds from the July 22, 2025 Discounted Exercise and July 22, 2025 PIPE before deducting $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_WF7AxAk1uUa0Qd1Ics3PTw">808,738</ix:nonFraction> in transaction costs paid by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In the July 22, 2025 Discounted Exercise, the Company <span style="-sec-ix-hidden:Hidden_sIX-I_ihFUyckByqXSCcEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise" scale="0" id="Narr_Ijaq2raQPUm51ifFqt-VnQ">336,449</ix:nonFraction> Common Shares in exchange for the exercise of <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" scale="0" id="Narr_yMCXNrtBTEitQAGSur5QIg">336,449</ix:nonFraction> of the <span style="-sec-ix-hidden:Hidden_rAT-TO71IkG83cETElUNVQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">July 2024</span></span> PIPE warrants (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_T1JrdAuH_EGgMvUA5bYqhA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" scale="0" id="Narr_A8UchikPuU6NAuUwb0y0CQ">112,150</ix:nonFraction> each from Tranche A, Tranche B, and Tranche C) for $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_IxRv2RxvLk-C6APbD0vZoA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_SgN6e2T4CkuE_5kJ2kzV2g">20.31</ix:nonFraction> per warrant. The Company determined that discounting the exercise price represented a modification of the July 2024 PIPE warrants. In accordance with <i style="font-style:italic;">ASC815 &#8211;</i> <i style="font-style:italic;">Derivatives and Hedging </i>(&#8220;<b style="font-weight:bold;">ASC 815</b>&#8221;), the Company accounted for the incremental fair value of the modification as the difference between the pre-modification fair value and the post-modification fair value of the July 2024 PIPE warrants, as calculated using Black-Scholes. The modification date incremental fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredDiscountForFairValueModificationOfWarrants" scale="0" id="Narr_MLyLZCb3yUqmSwbiSn3dtA">930,841</ix:nonFraction> was initially recorded as a deferred financing cost, as the discount was directly attributable to a proposed offering, and was subsequently recognized as an equity issuance cost upon the closing of the July 22, 2025 Discounted Exercise and July 22, 2025 PIPE. The range of valuation inputs used in the pre-modification fair value Black Scholes calculation of the July 2024 PIPE warrants included a share price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Gqt906yAIEyMV9y-5GtbIg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_buhpGw_SMU-6DcQYwfdu9g">14.70</ix:nonFraction>, exercise prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_dJb2jjHN40ybk15--NzTxA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_BbfReSUmZ06TsjwGCtVFDw">50.50</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_-BYZBHNW00qP6PIyK-XiTw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_n9iPRc7kbUKoWpOCrJx3vg">62.50</ix:nonFraction>, time to maturity of <ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DuvCQ_GM9UKztjhwWQu6pA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_8E-RNcBwT0e96nW3577_Sg">0.53</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DRD7WoeXBU-JH-rKWT9PFg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_KllCQtgsWU20SyvbS3Fhyw">4.02</ix:nonFraction> years, risk free rate of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_GvLUVdGT7kKjraQdVt5bsQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_bF1hvBALEkGK-MUP_OEkJg">3.9</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y-QIx4_sEUmBnP424eXzYw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_ZfQadL056U6NkElVsMc0Aw">4.3</ix:nonFraction>%, and annualized volatility of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_wj2kZqXnhEOGN-1dq0Xllg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_v-5-113XmEajY50xVEvWmQ">106.5</ix:nonFraction>%. The post-modification fair value Black Scholes calculation used the same <span style="-sec-ix-hidden:Hidden_vE8nknvrREuwISKkbV-t1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair</span></span> value inputs <span style="-sec-ix-hidden:Hidden_sDMpaTJpt02AivVLsCelvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span></span> <span style="-sec-ix-hidden:Hidden_UiLMq0ECGUuuIc3ZT61PGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span></span> <span style="-sec-ix-hidden:Hidden_bE979HFoxkSnleUqfJBh_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pre</span></span>-<span style="-sec-ix-hidden:Hidden_qaJfvU25ukC0j9SFajVEUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modification</span></span> <span style="-sec-ix-hidden:Hidden_z2jv6MWYFkOFbHtRCJPIPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value</span></span> calculation apart from the modified exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_neufGN5uEk2IUYIIK5t4qA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_Q5gxx1ZlvEq2J1rTgKfaWw">20.31</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont4" continuedAt="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Pursuant to the terms of the July 22, 2025 PIPE, the Company agreed to sell a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_vJ4I8MQi4ke1JEx6u_Z6hg">504,673</ix:nonFraction> Common Shares (the &#8220;<b style="font-weight:bold;">July 22, 2025 Warrant</b>&#8221;). The July 22, 2025 Warrant was sold to the investor at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_afA6-KFkzEeagiznlWW-BA">4.69</ix:nonFraction> per share and has an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8Ba_Fme1X0OPttUKx5p_0A">31.25</ix:nonFraction> per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The July 22, 2025 Warrant is immediately exercisable and will expire <ix:nonNumeric contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_Z2tbndalY0aUxxvUd49peg">five years</ix:nonNumeric> after the date of issuance. The holder of the July 22, 2025 Warrant may not exercise it if the holder, together with its affiliates, would beneficially own more than <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_iEMqWL4XT0SxMr2o3-qqIQ" decimals="4" format="ixt:num-dot-decimal" name="pmn:BeneficialOwnershipLimitation" scale="-2" id="Narr_-eUeDOiRjkGlfuY1nYfnew">4.99</ix:nonFraction>% (or, at the election of the holder, <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y36YA1aV8EG9tI8Bg4zyLw" decimals="4" format="ixt:num-dot-decimal" name="pmn:BeneficialOwnershipLimitation" scale="-2" id="Narr_AO4_tHuztkuSlhKlPDLGkQ">9.99</ix:nonFraction>%) of the number of Common Shares outstanding immediately after giving effect to such exercise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company determined the July 22, 2025 Warrant met the permanent equity criteria classification. The July 22, 2025 Warrant is classified as a component of permanent equity because it is a freestanding financial instrument, is immediately exercisable, does not embody an obligation for the Company to repurchase its shares, and permits the holders to receive a fixed number of common shares upon exercise. In addition, the July 22, 2025 Warrant does not provide any guarantee of value or return. The Company used a Black-Scholes calculation to determine the fair value of the July 22, 2025 Warrant at issuance and allocated a share of the net proceeds based on the relative fair value of the July 22, 2025 Warrant. Net proceeds allocated to the July 22, 2025 Warrant were $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_0I2NUUyQSkuP1T4GHvUZvA" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr_c4O7aqFrYkOlMKj9zbBHag">4,284,557</ix:nonFraction>, with the remaining net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr_0CqbP3kanUqq2L0O3Be3Jw">4,106,470</ix:nonFraction> allocated to the Common Shares issued in the July 22, 2025 Discounted Exercise. The aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr_nxGCATDmTUSlZ-uYOVDvCQ">8,391,027</ix:nonFraction> are recorded in additional paid-in-capital. The valuation inputs used in the Black Scholes calculation of the July 22, 2025 Warrant at issuance included a share price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_y4m6ZNV0Q0Kp3hRUT7r-aA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_dzNaRJ-T2kqCntTMnl6DNg">14.70</ix:nonFraction>, exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_AD1d2zJY0Ue1O3lheBiTPg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_iNVU4gAodkW5P-TMmfJGpw">31.25</ix:nonFraction>, time to maturity of <ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_aepTXAELwE2v1b_eEMAxzg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_EU7RY5dTdEKRRQvmCRQM5w">5</ix:nonFraction> years, risk free rate of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_xEmsDgSeNU-j_EYzMwwGPw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_Ytr3Xf12RUit2GMVo9hZTg">3.9</ix:nonFraction>%, and annualized volatility of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_YtOhhYng_UGNJq2bFO6jYw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_yaiFsI08pE2P0Em3seuO5Q">106.5</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 28, 2025</span><span style="color:#191c1f;text-decoration-color:#191c1f;text-decoration-line:underline;text-decoration-style:solid;"> Exercise of Discounted Warrants and PIPE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">On July 28, 2025, the Company accepted discounted warrant exercise offers for certain July 2024 PIPE warrants (&#8220;<b style="font-weight:bold;">July 28, 2025 Discounted Exercise</b>&#8221;). Related to the July 28, 2025 Discounted Exercise, the Company also entered into a securities purchase agreement (the &#8220;<b style="font-weight:bold;">July 28, 2025 PIPE</b>&#8221;) with the same existing investors. The Company raised $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw" decimals="0" format="ixt:num-dot-decimal" name="pmn:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr__ef28c9RDEGJK9ZPE3l_bg">11,623,047</ix:nonFraction> in aggregate gross proceeds from the July 28, 2025 Discounted Exercise and July 28, 2025 PIPE before deducting $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_JtMdqQiCDkK-5IMWo0f0UA">478,580</ix:nonFraction> in transaction costs paid by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In the July 28, 2025 Discounted Exercise, the Company <span style="-sec-ix-hidden:Hidden_2uiJ2Xl62UWXxUyC2yNBhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise" scale="0" id="Narr_rXjncVEk70eefuki4snF7Q">416,436</ix:nonFraction> Common Shares in exchange for the exercise of <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" scale="0" id="Narr_mCStJj_PzEaDgr9A8cRocQ">416,436</ix:nonFraction> of the <span style="-sec-ix-hidden:Hidden_u1jGCHE0JUyEOMipzgeTYA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">July 2024</span></span> PIPE warrants (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_qwFZGwi9q0GjlBqTpS8zEg" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" scale="0" id="Narr_wcaQGBYZjUKLrc7LA3jsTw">138,812</ix:nonFraction> each from Tranche A, Tranche B, and Tranche C) for $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_TP3g5_42vkuIAbWzNvhidg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_-n7VupHmv0qNsE-4aOVvow">20.88</ix:nonFraction> per warrant. The Company determined that discounting the exercise price represented a modification of the July 2024 PIPE warrants. In accordance with ASC 815, the Company accounted for the incremental fair value of the modification as the difference between the pre-modification fair value and the post-modification fair value of the July 2024 PIPE warrants, as calculated using Black-Scholes. The modification date incremental fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredDiscountForFairValueModificationOfWarrants" scale="0" id="Narr_nw2qoup9oEWxg69CLhD6AQ">1,794,146</ix:nonFraction> was initially recorded as a deferred financing cost, as the discount was directly attributable to a proposed offering, and was subsequently recognized as an equity issuance cost upon the closing of the July 28, 2025 Discounted Exercise and July 28, 2025 PIPE.<b style="font-weight:bold;"> </b>The range of valuation inputs used in the pre-modification fair value Black Scholes calculation of the July 2024 PIPE warrants included a share price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_e9DEwqxr8EKiOrKOtaJIGA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_QGCWxH7fC02ayZF7gNhtyw">20.88</ix:nonFraction>, exercise prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_VQxtOloCU0Kve5DNgHGdOg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_PTMOd77GVUeWkFjX7xWMKg">50.50</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_uFsROG-NVU2k94DCS0QXRA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_f90nSjWCkEawg5qRnN_34w">62.50</ix:nonFraction>, time to maturity of <ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_cyhzjHJjgkSJTrqFS2S_jw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_efVOiKlqpUq20PbyF65oUw">0.52</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_rc0mwg3aNEm7zVK6UJmkYA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_uBgRPtDI-UGakIqi_fvfPA">4.01</ix:nonFraction> years, risk free rate of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_jgbAwglzZ0mcOj7IwSXxRw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_aqIUIccb10mMQPvS6GXNSA">3.9</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_Gcz0PPFqSkCFQ8-TE6lbgw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_hOlu3NSa_0WdCnudCWpZTw">4.3</ix:nonFraction>%, and annualized volatility of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_FP_FrTOu2Uu1Wd6byIXwSQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_Zhfs21s9uUeL58Ebg2ciAw">107.4</ix:nonFraction>%. The post-modification fair value Black Scholes calculation used the same <span style="-sec-ix-hidden:Hidden_88CXrfs02k61Q4fWLfzeFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair</span></span> <span style="-sec-ix-hidden:Hidden_XdTVGA3HiEy71yJOaEE4tg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">value</span></span> <span style="-sec-ix-hidden:Hidden_Dh34ZOTg80WsRg6qGMRmNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inputs</span></span> as the pre-<span style="-sec-ix-hidden:Hidden_p37SpWW4dk6Jm7sLGseshg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modification</span></span> <span style="-sec-ix-hidden:Hidden_fQaxwlZiKkGwEDVd1NMCVQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value</span></span> <span style="-sec-ix-hidden:Hidden_DM6veFeJkkWgBQ6DbhWYUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">calculation</span></span> apart from the modified exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_aHA4MFp8MUyKpl5PvcxEWA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_9j0I2-DBsEa00h-b25JT8w">20.88</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Pursuant to the terms of the July 28, 2025 PIPE, the Company agreed to sell warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_XsO5YafoN0KHB7621GOn-w">624,654</ix:nonFraction> Common Shares (the &#8220;<b style="font-weight:bold;">July 28, 2025 Warrants</b>&#8221;). The July 28, 2025 Warrants were sold to the investor at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_IcN6jcp4bkG-W7YDcxzp-w">0.1875</ix:nonFraction> per share and has an exercise price of $<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA" decimals="2" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice" scale="0" id="Narr_d0rPN9gnu0K3H_3s-sdO3Q">31.25</ix:nonFraction> per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The July 28, 2025 Warrant are immediately exercisable and will expire <ix:nonNumeric contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_FXNeUmhVSUu6h2t4_mjpdg">five years</ix:nonNumeric> after the date of issuance. Certain holders of the July 28, 2025 Warrants may not exercise it if the holder, together with its affiliates, would beneficially own more than <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_SWJwnPT2MUWAT21zy7PWMg" decimals="4" format="ixt:num-dot-decimal" name="pmn:BeneficialOwnershipLimitation" scale="-2" id="Narr_NWQK2ylHMEyp9880EPF34w">4.99</ix:nonFraction>% (or, at the election of the holder, <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_wj_YaF2jk02-OwZm2Ww4xw" decimals="4" format="ixt:num-dot-decimal" name="pmn:BeneficialOwnershipLimitation" scale="-2" id="Narr_zd_0YlACVEKsN7hZPoL4ug">9.99</ix:nonFraction>%) of the number of Common Shares outstanding immediately after giving effect to such exercise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FqsUdyaRykOXCQ9is13ZaQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company determined the July 28, 2025 Warrants met the permanent equity criteria classification. The July 28, 2025 Warrants are classified as a component of permanent equity because they are a freestanding financial instrument, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, the July 28, 2025 Warrants do not provide any guarantee of value or return. To determine the fair value of the July 28, 2025 Warrants at issuance, the Company used a Black-Scholes model and allocated a share of the net proceeds based on the relative fair value of the July 28, 2025 Warrants. Net proceeds allocated to the July 28, 2025 Warrants were $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr__JY84CpgMEenElsLpEub8A">5,885,032</ix:nonFraction>, with the remaining net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr_TRc4AOPqz0GmECcOgF1bWQ">5,259,435</ix:nonFraction> allocated to the Common Shares issued in the July 28, 2025 Discounted Exercise. The aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw" decimals="0" format="ixt:num-dot-decimal" name="pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="Narr_iOKqh8C2WEiuwL5WqRZ8IQ">11,144,467</ix:nonFraction> are recorded in additional paid-in-capital. The valuation inputs used in the Black Scholes calculation of the July 28, 2025 Warrant at issuance included a share price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_sQgJPaD0DE-aVvUQ9j8Tng" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_9Xgkft5rnUavimICYj4ZZA">20.88</ix:nonFraction>, exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Ywf0QSn_MU67VjykM1HpRw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_0sraNU6Zo0WJhWcHk4yvnA">31.25</ix:nonFraction>, time to maturity of <ix:nonFraction unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ" contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Okge8-wzBU2jlOsUJvycVQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_sOaZ8SOE5EqpS64R8tZrrQ">5</ix:nonFraction> years, risk free rate of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_PVYYZPfc3UauSC4uMd_VJw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_1LC9cTTD8E2yxhyoG92Wrg">4.0</ix:nonFraction>%, and annualized volatility of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_nNyk22XD9EK1oyNQIa_tUQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_Y08rEXbNNEG81sFcfWXWZw">107.4</ix:nonFraction></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">November 2025 Reverse Share Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">On November 28, 2025, the Company filed articles of amendment to effect a <span style="-sec-ix-hidden:Hidden_bzJ1h69P5Uu2r6edpFDPOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five reverse share split of its Common Shares (the &#8220;<b style="font-weight:bold;">Reverse Share Split</b>&#8221;). As a result of the Reverse Share Split, every <span style="-sec-ix-hidden:Hidden_uNKYSpxl1EOc5rSnKnyhFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span> Common Shares issued or outstanding were automatically reclassified into one validly issued, fully paid and non-assessable new Common Share, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportional adjustments were made to the number of Common Shares awarded and available for issuance under the Company&#8217;s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company&#8217;s outstanding stock options and other equity securities under the Company&#8217;s equity incentive plans. All outstanding warrants were also adjusted in accordance with their terms, which resulted, among other changes to the warrant terms, in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise prices of such warrants. The Common Shares outstanding following the Reverse Share Split remain fully paid and non-assessable. The Reverse Share Split did not affect the number of authorized Common Shares or the par value of the Common Shares. All share and per-share amounts have been retroactively adjusted to reflect the Reverse Share Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">At-the-Market Offerings (ATM)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In September 2023, the Company filed a shelf registration statement with the SEC. In conjunction with the shelf registration, the Company entered into an ATM agreement in January 2024 (the &#8220;<b style="font-weight:bold;">2024 ATM Agreement</b>&#8221;) to offer up to $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_9_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_Kfapro2AwUiDsFbp7-NsnQ" decimals="-5" format="ixt:num-dot-decimal" name="pmn:CommonStockCapitalSharesReservedForFutureIssuanceAmount" scale="6" id="Narr_75V63rDUo0idwS4C3_iyUg">25.0</ix:nonFraction> million of the Company&#8217;s Common Shares. During the year ended December 31, 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_o2FOGoUStEKfFdyR_UAHiA">3,034</ix:nonFraction> Common Shares for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_b3_QaciH5kKnv7WOMgLvvg">190,274</ix:nonFraction> after deducting sales commissions. The 2024 ATM Agreement was terminated in July 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In August 2025, the Company filed a shelf registration statement with the SEC. In conjunction with the shelf registration, the Company entered into an <span style="color:#191c1f;">ATM Agreement with H.C. Wainwright &amp; Co., LLC (the &#8220;</span><b style="color:#191c1f;font-weight:bold;">2025 ATM Agreement</b><span style="color:#191c1f;">&#8221;) on August 26, 2025 to offer up to </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_8_1_2025_To_8_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_TnDWza_UfEC6NE6VKGF_Kw" decimals="-5" format="ixt:num-dot-decimal" name="pmn:CommonStockCapitalSharesReservedForFutureIssuanceAmount" scale="6" id="Narr_jQyJQB6tlkWQxXllsBXVMQ">18.0</ix:nonFraction></span><span style="color:#191c1f;"> million of its Common Shares. During the year ended December 31, 2025, the Company sold </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_c9Q8wvQ2E0u_9zglb7JLCQ">40,795</ix:nonFraction></span><span style="color:#191c1f;"> Common Shares for net proceeds of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_YpjJbWMTe0O2ypP-h012wg">708,468</ix:nonFraction></span><span style="color:#191c1f;"> after deducting sales commissions pursuant to the 2025 ATM Agreement.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;"> </span><span style="color:#191c1f;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_pusrZoIvpUyLtGYT5BRg6g_1_0"></a><a id="Tc_4get5ZLsG0udNQ7HusMY-g_1_2"></a><a id="Tc_ss5FjoXkdkqckpcl6C3qOA_2_0"></a><a id="Tc_-8GVzptRUUeJWJBaYlW7iw_2_2"></a><a id="Tc__hvrgkymq0idGB2Lo6yEgg_2_4"></a><a id="Tc_3peDt-lyJESFgczLjNU7Hw_3_0"></a><a id="Tc_M5FU0n9Y30qX5GBT4lXiSw_3_4"></a><a id="Tc_3caxwtYcQkugDEoIqVplQw_4_0"></a><a id="Tc_nyLX4IcoikO-_6p3SJ9xQw_4_4"></a><a id="Tc_RrfNIjxfTEGCIl4G6h2p9g_5_0"></a><a id="Tc_B64iDoNbGE6oPUPpJsHbUQ_5_4"></a><a id="Tc_62NchEphqUWVUvcvxTIxng_6_0"></a><a id="Tc_UyV6jMcHHUui-NJwhb0big_6_4"></a><a id="Tc_IefeEc6nXEa7L5jHvLUoqw_7_0"></a><a id="Tc_2xwgrg7zPEqTIc6W34WhQQ_7_4"></a><a id="Tc_WbP5KoS1W0O8h7kumqU2Cg_8_0"></a><a id="Tc_HJurl3jm00q6jYuabT2o0g_8_4"></a><a id="Tc_9p5xymqRbkemeXwNSs1Wkg_9_0"></a><a id="Tc_kSX5EdwTQEi1vyxH2GI7sA_9_4"></a><a id="Tc_UfTzw_Tko0G6KADbBHmcuQ_10_0"></a><a id="Tc_PZ372IZluUSwqemOjn8wnA_10_4"></a><a id="Tc_jeVwWpxta0S7PUMLx77pgg_11_0"></a><a id="Tc_suMtkhSMYEOVAkQTmwXm2Q_11_4"></a><a id="Tc_zr9ERZ24Okim3TehdyRGPA_12_0"></a><a id="Tc_M3SFyYEpkEyGROWStIGV0Q_12_4"></a><a id="Narr_mVmG14QxxU6UXYyVkzzGWw"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:WarrantsAndRightsDisclosureTextBlock" id="Tb_GCFoFqM9akeDDqPTiz48kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span>WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, outstanding Common Share warrants and exercise prices related to unit offerings are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:ScheduleOfWarrantExercisePriceTableTextBlock" id="Tb_dT9eDbDciUOBim-VNKI0Cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:50%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price $</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiry&#160;date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_BLU4_tV9gUySljXY2fjsag" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Sp5YyUbc20eQjAVbG4Z1uw">50.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_BLU4_tV9gUySljXY2fjsag" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_v88j2VsvxEaO-5nbvtibqA_3_2">314,170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">January 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd31500Member_xOPbGlUKKEeb6s_MpQYu2w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_b48yznLxcEmgEgHN2HHVig">315.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd31500Member_xOPbGlUKKEeb6s_MpQYu2w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_rdgwFIpCjU6PQKKYP1dljw_4_2">20,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">August 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd24000Member_3gS1r2Q7ikiBMcspRxwhdA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_gTKCeWFhuEOXG3bFY6sk-Q">240.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd24000Member_3gS1r2Q7ikiBMcspRxwhdA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_lLhyc3q9J0qVGicYBPXWiA_5_2">5,868</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">August 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2027Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_OxC1c99JokOfGf-9JXcpPQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_vHcKU1vnYkauui6a5Hy3Hw">50.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2027Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_OxC1c99JokOfGf-9JXcpPQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_GOLRe8yVsEyNRVQBTWSSow_6_2">314,170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">January 2027</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd18750Member_DceMNtnvik6aFW0Sn6WY3Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_qLWtZs21IEeGWSzCsRBLbw">187.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd18750Member_DceMNtnvik6aFW0Sn6WY3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_2HjMFyqnzkuSozQk45anSg_7_2">13,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">April 2028</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd15250Member_M2aoRgqepE2Z5hmL4ieMNg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_CtXptywRhki_hfFv7k_dZA">152.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd15250Member_M2aoRgqepE2Z5hmL4ieMNg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_bXOnEXzTOUSjuwYff3Ov6Q_8_2">2,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">April 2028</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_February2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd4375Member_96PtobwXOEKcI7qN4vYumA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8NzIww5PP06g8d7ezellEQ">43.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_February2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd4375Member_96PtobwXOEKcI7qN4vYumA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_zrlqx30BxUGOjIrq1bB9LA_9_2">449,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">February 2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd6250Member_ZBhfqWXuAEO3TU5tCv6HmA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_FtHqsavNx02psNhoVqUrEw">62.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd6250Member_ZBhfqWXuAEO3TU5tCv6HmA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_TWMfexqlC0CKZ72zlQsOKQ_10_2">314,170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">July 2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2030Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd3125Member_BEwiO-eDbUWWmJRIGGfGtQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_eUR1_etU3UWl1oszfj4WRg">31.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2030Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd3125Member_BEwiO-eDbUWWmJRIGGfGtQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Vmi1atTcl0KY07SrrMxALA_11_2">1,129,324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">July 2030</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd025Member_QbxyhQijfEureNNbf38Kiw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_whD9EXyNIECGlQf0rPNEZg">0.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd025Member_QbxyhQijfEureNNbf38Kiw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_wVHW91rM6U2ehyg2Is2d1Q_12_2">74,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">None</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_dPj0_188x0mojcXyFmA0Tw_13_2">2,639,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">During the year ended December 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_lXO6kxQzJUamKXpLjwBijA">51,197</ix:nonFraction> pre-funded warrants, including <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_RegisteredDirectOfferingMember_CC8gh5SgoE2iWhbtumf2UA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_a5-nCMgvlk2kNlyKx7qRlw">39,389</ix:nonFraction> issued in the July 2025 RD Offering, were exercised for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:ProceedsFromPreFundedWarrantExercises" scale="0" id="Narr_s1gAcVqI-katDKUtjlECRw">3,050</ix:nonFraction>. Refer to Note 6 for discussion on the discounted exercise of <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise" scale="0" id="Narr_J-doWVwbSUKADzQwFeAeRQ">336,449</ix:nonFraction> July 2024 PIPE warrants on July 22, 2025, discounted exercise of <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise" scale="0" id="Narr_csopjPqpbkWJAiE244EAww">416,436</ix:nonFraction> July 2024 PIPE warrants on July 28, 2025, issuance of <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_0I2NUUyQSkuP1T4GHvUZvA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightIssued" scale="0" id="Narr_d9iLWqHDvEaWKsZvlAb-0A">504,673</ix:nonFraction> new warrants in the July 22, 2025 PIPE, and issuance of <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightIssued" scale="0" id="Narr_auLBB2dQVUiyRZvs--703A">624,654</ix:nonFraction> new warrants in the July 28, 2025 PIPE. During the year ended December 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExpired" scale="0" id="Narr_KWy1we1d4E6U1bE0FQ2j1w">11,184</ix:nonFraction> warrants expired without being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">During the year ended December 31, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExpired" scale="0" id="Narr_1sc0Lqf9sEudRmXmWtcvtA">16,319</ix:nonFraction> warrants expired without being exercised, and <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_yEzxtOjj-EyFV6MUX2x0TQ" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightExercised" scale="0" id="Narr_yLFZ8UGcUU2hLrMsm8lfmA">112,150</ix:nonFraction> pre-funded warrants were exercised for an equivalent number of common shares for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_yEzxtOjj-EyFV6MUX2x0TQ" decimals="0" format="ixt:num-dot-decimal" name="pmn:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" scale="0" id="Narr_ch6QSwbgIkyiWZ4Bif88fg">28,038</ix:nonFraction>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_nac5xMpRDkC5Lgfgl4BtBg" continuedAt="Tb_nac5xMpRDkC5Lgfgl4BtBg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span>SHARE-BASED COMPENSATION </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">2025 Stock Option Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">At its June 2025 Annual Meeting of Shareholders, the Company&#8217;s 2025 Stock Option and Incentive Plan (<b style="font-weight:bold;">&#8220;2025 Option Plan&#8221;) </b>was approved by the shareholders. The 2025 Option Plan replaces the 2015 Stock Option Plan (<b style="font-weight:bold;">&#8220;2015 Option Plan&#8221;</b>), originally referred to as the 2007 Option Plan. <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_lzS6k88pCESIdR5eDOhhpw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_NEgvDBBIFEmsmhowSpHm2g">No</ix:nonFraction> new awards can be issued under the 2015 Option Plan. &#160;The Company reserved <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionAndIncentivePlan2025Member_8TYcGUAhwU2A4TqH-py3Vw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_zvA365Qs-UCR0teATRDrWw">117,868</ix:nonFraction> Common Shares for issuance under the 2025 Option Plan at the time of adoption. As of December 31, 2025 and 2024, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionAndIncentivePlan2025Member_8TYcGUAhwU2A4TqH-py3Vw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_tg4bPNbwvkuBDnODry1K8w">80,686</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_HkhKPStIm06ybEXHIFwi_Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_H1FhTdyo_kexcMBIeIh-hQ">118,535</ix:nonFraction> options available for grant under the 2025 Option Plan and 2015 Option Plan, respectively. The Common Shares underlying any awards under the 2025 Option Plan and 2015 Option Plan that are forfeited, canceled, or otherwise terminated (other than by exercise) are added back to the shares available for issuance under the 2025 Option Plan. Share options are granted in either USD or CAD. Upon the change in the Company&#8217;s functional currency, effective July 1, 2023, CAD share options previously classified as equity were reclassified as liabilities. All grants following the Company&#8217;s change in functional currency are in USD.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_H-5QJI3JSkqOaM0iPEoSfw_1_7"></a><a id="Tc_txtbWbrn90-Zj_d5wRumkA_2_4"></a><a id="Tc_FSo9NMVtrkGc435tmpIpUw_2_7"></a><a id="Tc_9O_lATM8eEGd4DIgVfEuBQ_3_4"></a><a id="Tc_GifGK8ZZlkCP5oioEcswBw_3_7"></a><a id="Tc_Fob5f06i0kalEk9ES0XKYA_4_2"></a><a id="Tc_bwkliFsOdUq-6GepYWmAag_4_4"></a><a id="Tc_-luGA-st10uqgURuhNtQMg_4_7"></a><a id="Tc_BGxeKnV6CESYER7H9Lefcg_4_9"></a><a id="Tc_Xv8bLEWhGEOLWu0eCZiDWw_5_2"></a><a id="Tc_IL7KzxpklUW1tBmTqI6ONQ_5_4"></a><a id="Tc_T8jnjEm7m0eBP9uKevdtlg_5_7"></a><a id="Tc_65_LrkA5Ikm8G7IIVX1fFA_5_9"></a><a id="Tc_VpbbBaqMvk-otP0wQT-cFA_6_2"></a><a id="Tc_vo6VuTY_e0acQFPqt17TCA_6_4"></a><a id="Tc_a5BipKqAv0SGcbK04t2kLQ_6_7"></a><a id="Tc_7BI3bEC1Skm9qDCp_mZcAg_6_9"></a><a id="Tc_isbrT6bLb0ygoFqC2LCEWA_7_0"></a><a id="Tc_lcAaxKYao0amCnYaz2ft3A_7_4"></a><a id="Tc_AOdH8bEOn0yqM4lUJ8SqEg_7_9"></a><a id="Tc_MGQBKY6UH0qtu66nC7DPEA_7_10"></a><a id="Tc_Y2Vnzb6gTkmQI4SA6iyigA_8_0"></a><a id="Tc_ZFt5MAj25EGKYXKfa0SGfQ_9_0"></a><a id="Tc_jbuOpG63W0arPgV2eBKgPw_9_10"></a><a id="Tc_3i9KjP9CNUe-Ynbv8k_mfw_10_0"></a><a id="Tc_kVM6hiV6LE6ngOQuZ-SurQ_10_7"></a><a id="Tc_KIKQrJo3bUyR3zLDrWl7_Q_10_10"></a><a id="Tc_ng2lftEJI0OKXFgmChGqMw_11_0"></a><a id="Tc__6O_Ib1800SmH5x6H-bBQw_11_7"></a><a id="Tc_FRcL7okh8Eit97EjhwW7Xg_11_10"></a><a id="Tc_CtgKqiks7kmJplBlIXAXFg_12_0"></a><a id="Tc_06qT3Vd6XUWCzfCitRKyMg_12_4"></a><a id="Tc_C4dPeSrpfUS5qzrcg5ETdQ_12_10"></a><a id="Tc_IPEjvywr3k69h0Zz5a7HbA_13_0"></a><a id="Tc_K0QpV8zJm0S63k3nrFxsFA_13_4"></a><a id="Tc_0_Eu6KmaDEmrrIsl1C3RRQ_13_9"></a><a id="Tc_6pH4XTR5fkql9ePk6QHO0Q_13_10"></a><a id="Tc_eRc8SWq63EO-Ticg8uqwJw_1_2"></a><a id="Tc_GE__kP2Lq0KE0DnyzFvaIQ_2_2"></a><a id="Tc_pPTkwTF_w0mum8JcwA7GdQ_3_0"></a><a id="Tc_EfGjqT0uwUWgEjhWPPf-IQ_3_2"></a><a id="Tc_J-zzIhyK6UuBJ0guffFTGQ_4_0"></a><a id="Tc_IaZW7y2MxkaN1lWpa-eylA_5_0"></a><a id="Tc_YORb7A0MdkaAAx-jx4H2_g_5_2"></a><a id="Tc_svQ8biCKiEKihVwdTq_PDw_1_2"></a><a id="Tc_iA4D4rXZrUKM81Daa1uT4A_2_2"></a><a id="Tc_Y67vrCS-sUqzR-uKDcdPHQ_3_0"></a><a id="Tc_yMY7o6rclUysBL4uRMdRGw_3_2"></a><a id="Tc_mKE27Ky36EudxQXYpI_hkw_4_0"></a><a id="Tc_HOdp1-pwVEar-0lRKY8HGw_5_0"></a><a id="Tc_j_28aTGFO0Cwv88LFaTgLg_5_2"></a><ix:continuation id="Tb_nac5xMpRDkC5Lgfgl4BtBg_cont1" continuedAt="Tb_nac5xMpRDkC5Lgfgl4BtBg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Canadian Dollar Share Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following table summarizes the activity of the C$ share options under the 2015 Option Plan for the&#160;years ended December&#160;31, 2025 and 2024. All amounts are denominated in Canadian dollars, except&#160;year and share amounts:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Group_tLNDCx_EFkiSFThoL1Ez9A" continuedAt="Group_tLNDCx_EFkiSFThoL1Ez9A_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_DAPNYxdYn0qZikf9-Z1Hkg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_jmMZQ65o70mOqMteriQGKA_7_2">35,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_DAPNYxdYn0qZikf9-Z1Hkg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_vCpSmde4fEGLkmK39DlIFg_7_5">189.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_LlWSStT2D0-0Npx7XslrPA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc__wSvSSsqNk2X-64fUoNc3w_7_7">6.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_wCcWIsgxl0eD0SvPPl8YWg_8_2">3,191</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ZTxY8GGwtk-TMzVgc7iQNA_8_5">229.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_535wZCcGeEeaUhW6qrPQIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_YKHrbsa4eESR2He3hsND7Q_9_2">32,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_535wZCcGeEeaUhW6qrPQIg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8imK05adYU2qzsCS_i6efw_9_5">184.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_RerLel3NbkGo6owWvYAoZg_9_7">6.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_ZmIjYZq6i0eEoWPRjGNWHA_10_2">2,346</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ZfzhPMbcDEKqGgNsdyHEvw_10_5">209.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_PUcWi2oKWkqVZsbJE9Ks6g_11_2">14,704</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_IVzCSGU6qU6TBuZi06Q9DQ_11_5">54.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_bZ2qusZjsEOCEEruftmMLw_12_2">15,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc__52-STRrIUqwDeCF6n6Q7w_12_5">170.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_1xTwZTJF_kKnCqWvu8e0yw_12_7">6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_-jTsP-ZbF0yUl7-ZwStWRA_13_2">15,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc__uLY1kDyWkWE4n6JBtTX-g_13_5">170.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_DZXQ4ip7AkCngvVU6WuOVA_13_7">6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The aggregate intrinsic value of options outstanding, exercisable, and vested and exercisable is calculated as the difference between the exercise price of the underlying options, and the fair value of the Company&#8217;s Common Shares. There were <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_je7wft_cJkGadaaTOxkMkQ"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_GVPyzleTEEKNj-TGWJZRmg">no</ix:nonFraction></ix:nonFraction> C$ share options granted during the years ended December 31, 2025 or 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Upon the change in the Company&#8217;s functional currency effective July 1, 2023 C$ share options previously classified as equity were reclassified as liabilities. The C$ options were re-measured as of December 31, 2024 and had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ" decimals="0" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" scale="0" id="Narr_LewLvYF8mU2FkH8YHjYxCw">199,263</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">A summary of share-based compensation liability activity, measured using level 3 fair value inputs, for the year ended December 31, 2025 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="pmn:ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock" id="Group_yNEShZzVVk6qJN3YCBIryA" continuedAt="Group_yNEShZzVVk6qJN3YCBIryA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="0" id="Tc_qdx-huCIX0yk99CnRJD2IA_3_3">199,263</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" scale="0" id="Tc_6X98GCSw50-drtKI7E_hbw_4_3">170,081</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="0" id="Tc_Jx6e2gLI_E-C0JZ8MfbY6A_5_3">29,182</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">A summary of share-based compensation liability activity for the year ended December 31, 2024 is as follows:</p><ix:continuation id="Group_yNEShZzVVk6qJN3YCBIryA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="0" id="Tc_1kSoBchZN0my0ocbv8-iyA_3_3">422,002</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" scale="0" id="Tc_p_3KCKPx0EmKx01GBhoHCg_4_3">222,739</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="0" id="Tc_bXNntBgcu0m8zYW-ojbUNw_5_3">199,263</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_BvnKgavrwEWPFu_8bSh8VA_1_2"></a><a id="Tc_oVzLd64rBk-jGcSfZzeAGw_2_2"></a><a id="Tc_XW7wbG7LTU-PQ2VfK96Wsw_2_5"></a><a id="Tc_zi-08KLynEejMTzWDLdlyw_3_2"></a><a id="Tc_6D3UbFpBhkWZtYINvHBjtQ_3_5"></a><a id="Tc_Twyiin8v6kyYZ_TAv0wKnw_4_0"></a><a id="Tc_Atv5c02VvUW5pITGX2Rppg_4_2"></a><a id="Tc_t4aCuHNI70KLtYMcbwq4Og_4_5"></a><a id="Tc_YbOiUI8Unk-FKMIKyEN7-Q_5_0"></a><a id="Tc_SXjDnOhjY0ONN3i5J0f8uw_5_4"></a><a id="Tc_KVQkef5ddECSLBzTGCT8zw_5_7"></a><a id="Tc_ZCSH5mD4mEa1_ilwmqQPrA_6_0"></a><a id="Tc_WZ58qXEYtUC11zFTyHK_3g_6_4"></a><a id="Tc_hSC0HXEKgUywDci3FnzzZQ_6_7"></a><a id="Tc_oLrbwNW3l0ii0VAo4YAfdw_7_0"></a><a id="Tc_042hWvvT-0K-AEcDnujBTg_7_3"></a><a id="Tc_z4Wzxv7T6UGLx74VKlem-Q_7_4"></a><a id="Tc_VNsch-0LtEOsIsdiOlHeag_7_6"></a><a id="Tc_EXJZGe6CyEuldi7-zMo3sQ_7_7"></a><a id="Tc_8rMCuvuTiEy6XLRZpv03Ug_8_0"></a><a id="Tc_UEy1K3Ed5kudNl-UmlqVDw_1_7"></a><a id="Tc_rEt-0EPIk0W0EwjgKu89mA_2_4"></a><a id="Tc_z7WuiwSYV0SZnZJMvsSsvQ_2_7"></a><a id="Tc_g6g5msvlvkiBJLb-YjOnTw_3_4"></a><a id="Tc_5yHUpq9wOUmntjZmu0fzxg_3_7"></a><a id="Tc_J6n02v4CFEage5zA9_ZRNg_4_2"></a><a id="Tc_V7lBhJswGky8n2ujRA6pWQ_4_4"></a><a id="Tc_HipOKUem6Eiik-LDfjUyXg_4_7"></a><a id="Tc_m_C_9pgIpkqIrUuGsDlGtQ_4_9"></a><a id="Tc_ampOC1T98Ea11n8WosXo1A_5_2"></a><a id="Tc_54_0K89U-0GlDvXIRdDORw_5_4"></a><a id="Tc_E4vQsl_buUWBCDQwJbBjbw_5_7"></a><a id="Tc_KaZwvTvWY0OjKa-QoFfoYQ_5_9"></a><a id="Tc_Xjm1ENAh8E-XSBrjJ17dAQ_6_2"></a><a id="Tc_uP2Vlbj53EWtOZ4aADmi1Q_6_4"></a><a id="Tc_izeijPZTL0C6ijIYywGbHA_6_7"></a><a id="Tc_mpgYPrF16Eyhd-5wuMo09A_6_9"></a><a id="Tc__FOKCM4hx0qyryGOsBM-pw_7_0"></a><a id="Tc_5FwuS7MbxESyTGAa7tgFrg_7_4"></a><a id="Tc_5afoYC5txUu7_j3PpVHshA_7_9"></a><a id="Tc_9mFL5Oj_J0SCYCHxa7lXHA_7_10"></a><a id="Tc_k9x4-876YE-12neL0Rgxqw_8_0"></a><a id="Tc_FGj_ChEbyEybF5W_EDQaVA_9_0"></a><a id="Tc_VT8k0O7udEi59rCaQD3Xfw_9_10"></a><a id="Tc_-dKNOXlQskK1mG-0n4gt2Q_10_0"></a><a id="Tc_iuZwUHq-CUihQD3hnXkN8w_10_10"></a><a id="Tc_beOb1L5URkKqvhDnWDbjHQ_11_0"></a><a id="Tc_o2nw2eAyo0uQjz4VIdythQ_12_0"></a><a id="Tc_XOtu42JgaEq2w6GOqw5mCQ_12_10"></a><a id="Tc_TyYmn7N3YkKMbHvVyyTXvg_13_0"></a><a id="Tc_bVJTKIfuSkSW4eakomACMQ_13_4"></a><a id="Tc_AOAfKfN-9UG1YmQPi9PgUQ_13_9"></a><a id="Tc_tcuP9LONkUSViXms4qPlAg_13_10"></a><a id="Tc_LfcJ3Jzd3kamBRJj3jEQhA_1_2"></a><a id="Tc_AVTB83YeG0CVFB7M3xktAQ_2_2"></a><a id="Tc_7MO5poNU80CE-dzTou4Vmw_2_5"></a><a id="Tc_YvdLprnyskqIb9KmQMS1tw_3_2"></a><a id="Tc_RiwZTmIdQkGwofCAKMd1Aw_3_5"></a><a id="Tc_qpWvCDGUQ0mlK8XTFCIajA_4_0"></a><a id="Tc_4XlUDk0y4U-ZS2GhyXCXcA_4_2"></a><a id="Tc_4pED6tfpLEqfXwS_f-uxbg_4_5"></a><a id="Tc_gif4fJhzzEaqHG3EN_jBGA_5_0"></a><a id="Tc_oOnu-__T60i0wzeKLIklkQ_5_4"></a><a id="Tc_yGkZTrIhPUuUG_eoIaYJSA_5_7"></a><a id="Tc_rgVY2feWhk68jxwLBAJfrg_6_0"></a><a id="Tc_3XnXKcOfJEa3wNLkSzWwAw_6_4"></a><a id="Tc_O1xVF6M2p0SiFP9CjcRgkA_6_7"></a><a id="Tc_Aspi3cFX6ESkW8fddT7dyA_7_0"></a><a id="Tc_-qwzkDhhq0-gxYtesxbe7A_7_3"></a><a id="Tc_z_ov5lNl6EG3GZ2W9cwiRA_7_4"></a><a id="Tc_qSFADQ_CFkWBHXM6GU_e_A_7_6"></a><a id="Tc_JJmcpS5uAk2TSrfwFls_Dg_7_7"></a><a id="Tc_64CB1BTUdUSpZYpIbzr9dQ_8_0"></a><ix:continuation id="Tb_nac5xMpRDkC5Lgfgl4BtBg_cont2" continuedAt="Tb_nac5xMpRDkC5Lgfgl4BtBg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following table summarizes the weighted average of significant assumptions used to calculate the fair value of C$ share options using the Black Scholes option pricing model:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Group_I0KqKkFkfEWNA0_IZvqoPA" continuedAt="Group_I0KqKkFkfEWNA0_IZvqoPA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value of C$ Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="2" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" scale="0" id="Tc_hrdChYBSKUu9QNPTAtef2A_4_3">0.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" decimals="2" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" scale="0" id="Tc_MZmfpVQeXUmPqkoL7KJXgw_4_6">0.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_nLl38PK4bUqr0JU5mdWK1Q_5_3">106.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_eEZthdYrhUiAg0iegkhy_g_5_6">99.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_85Omm_3s0U-W3zreDldNkg_6_3">3.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_aFernyEWUUacKvFbUju2pw_6_6">4.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_avpPx_kPH0SHPIcej8mK9A_8_3">6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_l1NkQyuAVkWD8u8RcbwqgA_8_6">6.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Expected volatility is based on historical volatility of the Company&#8217;s Common Shares over the expected life of the option, as the Company&#8217;s options are not readily tradable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S. Dollar Share Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company began making share option grants denominated in US$ following the Company&#8217;s change in functional currency in July 2023. The following table summarizes the US$ share options outstanding under the 2015 Option Plan for the years ended December 31, 2025 and 2024. All amounts are denominated in US$, except&#160;year and share amounts:</p><ix:continuation id="Group_tLNDCx_EFkiSFThoL1Ez9A_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_ZnKVIeo_bUW1r1sdCiTiBg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_bEykVHUzBkOWLzjkJ02J9g_7_2">2,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_ZnKVIeo_bUW1r1sdCiTiBg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_b-WJPf8CSUGbLQAIxVAD9Q_7_5">46.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_9DIop6bIQ0aP7inIriiC6Q_8_2">107,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_fFUV3NktDECPN_hYKT5tHg_8_5">27.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_oUDs-NDYv0qB68laQ04sGA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_rMt1A-1etEW-k3lpaVq7ZA_9_2">110,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_oUDs-NDYv0qB68laQ04sGA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_hOKC63czHUaX8vzD8KTLeQ_9_5">28.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_xRbUnpfMBEuzk5MzhCdVhg_10_2">55,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_hlOuk0OEQ0icNckJafDDPQ_10_5">11.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_qh8ETLVb4ku0NbQjTKJgkA_11_2">501</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_KGFwPn2Da0mb7lz29Z4Q5w_11_5">46.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_F2BLtdt0pkO7HhDa-7XctA_12_2">165,137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_kaN-IG0GYEmLP9EGvDBoyg_12_5">22.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_gLkEIQy4mEGA1Wp1AwRuwA_12_7">9.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_iLevyS990UyiykI8YXCx4Q_13_2">47,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_dLgBiUaRDE6w3pnWIO2Mhg_13_5">28.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_ryAxBRZnekC1WJsiPBGpLA_13_7">8.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The grant date fair value of <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="0" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" scale="0" id="Narr_0MFr0l0MC0ui-0J9pR6SIQ">55,400</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ" decimals="0" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" scale="0" id="Narr_W6tZwUNL2EafCUOeJH1Q_w">107,478</ix:nonFraction> US$ share options granted during the years ended December 31, 2025 and 2024, respectively, was estimated using Black Scholes with the following assumptions:</p><ix:continuation id="Group_I0KqKkFkfEWNA0_IZvqoPA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:88.88%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value of US$ Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="2" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" scale="0" id="Tc_b8tLqvpeC0S3k9W_f3Nnig_4_3">9.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ" decimals="2" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" scale="0" id="Tc_-D14VugVKU-xg36FyAkglg_4_6">22.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_FHwoK_Hhf0SWnDXZklPRsw_5_3">107.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ZiQR89iezkW49Bsz5TuMAA_5_6">101.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_7PpkaZ2D8Eqws36BwCiVUQ_6_3">3.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_XgxyiNx-U0qa1q8Gll68xA_6_6">3.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_qPJTbG988kasZ78LclcyYA_8_3">6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_zKGm4EmBAUevapgCBd6oOA_8_6">5.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In October 2024, the Company granted its Chief Executive Officer <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_hlDapgXK7kiWM6q4c2AMIg">19,614</ix:nonFraction> options with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_-5Or6TjPZE2TCHjWH7cmCg">28.75</ix:nonFraction>, which will begin vesting if and when the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_D_JjSvLYrH-EWdNko9j1YiTg" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q" decimals="INF" format="ixt:num-dot-decimal" name="pmn:VolumeWeightedAveragePriceThresholdTradingDays" scale="0" id="Narr_gaD3FSUEJkWnYGhml5kIaw">10</ix:nonFraction>-day VWAP of its Common Shares trading on the Nasdaq Capital Market meets or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_cuRNgn1GhEKPKyrtju0bxw" decimals="2" format="ixt:num-dot-decimal" name="pmn:ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" scale="0" id="Narr_CgYWAt6oh0u0LgQpsKw2mQ">86.25</ix:nonFraction>. The Company determined the share price requirement to begin vesting represented a market condition and performed a Monte-Carlo simulation to determine the fair value of the award, discounted for the likelihood of achieving the market condition. The resulting fair value of the option award was $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4m9O5GYGnEyywiNYhqVX6A" decimals="0" format="ixt:num-dot-decimal" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" scale="0" id="Narr_AlKcldAaV0al1IZe7AnK6A">383,000</ix:nonFraction>, with $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_8kidyz1Xz0e1GRFRPcmD0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_NSw1Ri5PGE-cKMir0S5_xw">168,946</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_bAqN9UYOfk6qG8Vt8Q_g7A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_ZJJkIEUVHUazMSG2RByorg">39,344</ix:nonFraction> recognized during the years ended December 31, 2025 </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Z4JL9MbKuEOwkHo53ZICEA_2_2"></a><a id="Tc_N8NxTGocDUS6RHpwVL4zTA_3_2"></a><a id="Tc_XL44afI5mEG_eq0jkgoc7g_3_5"></a><a id="Tc_3U27vLbV20Gg9s7TOFNSIQ_4_0"></a><a id="Tc_--D_70xuYkGgfVWpkwovpg_4_2"></a><a id="Tc_JOMQJ6BIEEKhOrzEjZN6oA_4_5"></a><a id="Tc_MRa2gV6OSku3_5IPOee3EA_5_0"></a><a id="Tc_VzrKrhZJiEqaMIzoTCe7Hw_6_0"></a><a id="Tc_XtSK2m7Kt0OS85fkb_hmbw_6_2"></a><a id="Tc_WqBqIsSISUq9QDO4wYnHFg_6_5"></a><ix:continuation id="Tb_nac5xMpRDkC5Lgfgl4BtBg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">and 2024 in the accompanying consolidated statement of operations, with the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4m9O5GYGnEyywiNYhqVX6A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_MsbMQdAri0-WwA0Cy0xH2g">174,710</ix:nonFraction> expected to be recognized over approximately <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_8kidyz1Xz0e1GRFRPcmD0g" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_lpzCNUJvs02Uu2bmiCeCpA">1.4</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">DSU Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has a Deferred Share Unit plan (&#8220;<b style="font-weight:bold;">DSU Plan</b>&#8221;) for senior officers. Under the DSU Plan, rights to the Company&#8217;s Common Shares may be awarded on a deferred payment basis up to a maximum of <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_43Sf9jwGKE-gVcgtsZ09GQ">667</ix:nonFraction> common share units. Each common share unit will fully vest upon cessation of employment with the Company and then can be redeemed for <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ" decimals="INF" format="ixt-sec:numwordsen" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" scale="0" id="Narr_c2OplC1spEiFAKfvsiO1Uw">one</ix:nonFraction> common share of the Company by the unitholder. The Company has <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_LFOfEBmVZ0KXodBvDDRA8w">42</ix:nonFraction> units outstanding as of December&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">S<b style="font-weight:bold;">hare-based Payment Expense</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following table summarizes total share-based compensation for both the C$ and US$ share options included in the Company&#8217;s accompanying consolidated statements of operations:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb__jqDPdsDiUen-kpVC8uBNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lI1_7YZGDkiVsD04bzBKuA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_IQ_AqZi2qUysHfp-Ezrtzg_4_3">37,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-qWN91AyB0iMTTieOzW1eQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_rJp8WAWRE0i9WHQVdd8Ltw_4_6">49,405</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rhZmPGlkfEOEJZUvfYbOgw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_y73omf4juU2qOgHccp4K1g_5_3">819,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4me8oDqyvUC5VCBKaBFb0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_vM-L-Y32SE60S-09WlJUCw_5_6">776,403</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_9DB9jBjlkEGaklDNhqL6SA_6_3">857,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_8qt8OcE6KECPQ1WlwNVMnQ_6_6">825,808</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_srt_CurrencyAxis_currency_USD_AW-HI8NCBUijoCTjKG1Vyw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_Sk6Tvi12xESurRmVSiycxw">1,265,556</ix:nonFraction> of unrecognized share-based compensation related to US$ options outstanding, which is expected to be recognized over a weighted-average remaining service period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_srt_CurrencyAxis_currency_USD_2N501AziF0iBtEVWWSNtGA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_1K90xuSF5kSHl6ehyFz9CA">2.7</ix:nonNumeric>&#160;years. There was no material liability yet to be recognized for C$ share-based compensation as of December 31, 2025.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_J9mRzhAVEkG88PU-LFdpOg_1_2"></a><a id="Tc_QEAbN2jw6kKY7_8tIaaBqQ_1_5"></a><a id="Tc_Zay2dL2ZrEGVcknVn5hcRA_2_0"></a><a id="Tc_s8W_gKTpBku6VZjMAEJIPw_2_2"></a><a id="Tc_oLe8w5vfEkyWPw8wllEnOA_2_5"></a><a id="Tc_9aGHL3laQkeuVorcvgOalg_3_0"></a><a id="Tc_PbiLAumSNk6_Y4sao2sfrg_4_0"></a><a id="Tc_XY3B294YnkeXbJpZ0bD2cw_5_0"></a><a id="Tc_F9WFj6j9qk-WXMhwB1_meQ_6_0"></a><a id="Tc_EmzLPKX7kEyE9xdy68wGZw_7_0"></a><a id="Tc_2N2yfqpdykWvAfQGvSyySg_7_3"></a><a id="Tc_hP0WCPuW9kSmYi6W81PIkw_8_0"></a><a id="Tc_SQrFIaLZQE296JppPSygEw_8_3"></a><a id="Tc_HN1QtQCSW0mSCsif-MUaIQ_9_0"></a><a id="Tc_4WRNGaHJ2kiT2pWODuVIOQ_10_0"></a><a id="Tc_uRJIIQ_UgUOO0MDQo6fdWA_11_0"></a><a id="Tc_z3R16crCjUeZLpVCO99ABw_11_2"></a><a id="Tc_oRrdm0MtcEmzh6_3fHaxTw_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_BYf3ujcjCE2PlLSkBM6-5A" continuedAt="Tb_BYf3ujcjCE2PlLSkBM6-5A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span>INCOME TAXES </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025 and 2024, the net deferred tax assets have not been recognized in the accompanying consolidated financial statements. A valuation allowance is recognized to reduce the deferred tax asset as it is more likely than not that a tax benefit will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following are the significant components of the Company&#8217;s deferred taxes as of December&#160;31:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_yRnhAGtSCkadCH0-xSXXyw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_7GX3ca-3hki07P5a0ocZrw_2_3">34,810,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_iAsrMVmcoUOrHLvVDFEtIA_2_6">24,850,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_zOgn9luOZkyPTxPDexTlbQ_3_3">3,022,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_Vld610eOtEymMMTlCtCUCw_3_6">3,175,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="Tc_un1wZpKCpEqrjE_BsZWCGg_4_3">1,944,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="Tc_qFhCLgm2RUe_88kBLkaGSw_4_6">2,043,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax value of technology rights and property and equipment in excess of accounting basis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" scale="0" id="Tc_ijndJg2H9Uar-thKkIljhQ_5_3">160,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" scale="0" id="Tc_1PqlKKVGLEqMtbJ_Q-6zwg_5_6">193,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issue costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_euw3mWxumE2eYJTl9y1V3w_6_3">1,066,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_BqW-2hfWLUSpxsAfCw3eEg_6_6">1,275,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" id="Tc_HB7TFwVV0UWCE_roO2HywA_7_6">10,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted interest and financing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="pmn:DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" scale="0" id="Tc_jZUYdE2a30iAnGo99nyEFA_8_6">337,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_6TlbyoBJlEWmrbfAqmuOFQ_9_3">41,005,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_bRRLmX0rOEik0WzbxfXJNw_9_6">31,883,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_hHPWuAMSBUa2uH329-8tLQ_10_3">41,005,721</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_SPJbAehcN06of5sBV6W55g_10_6">31,883,000</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc__jTw6h_2eUm95-sYB9JTxw_11_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g" decimals="0" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_CLiX67AilEGOw3A7O32QxQ_11_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, the Company has available research and development expenditure credits for income tax purposes of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="Narr_xnEVTHOZx0SevxirmKzu_A">11,407,000</ix:nonFraction>, which may be carried forward without expiration to reduce future taxable income.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aadcfc24_f770_49e6_8f55_e8ac1700dc63"></a><a id="Tc_8IzXHt6hFkms3yEQcXxpLw_1_2"></a><a id="Tc_K0S8R8UWm0ynb67Qbt1rnQ_2_2"></a><a id="Tc_fR2nsgn9xEK4qn91E1_CDQ_3_2"></a><a id="Tc_bgdWq4yQ-kSytQO-rr8Vqw_3_3"></a><a id="Tc_cIX3I6KVWU-2PN4PJFI_5A_4_0"></a><a id="Tc_Q-mOIInBbkGrkJTZkKbH2A_4_4"></a><a id="Tc_ZJBUmi1xAEeuVkT9vD9F2g_5_0"></a><a id="Tc_vj2HTmqROEWmSFNi4Nsdrw_5_2"></a><a id="Tc_2AnjhJcAYkqh6q-2b9Xj9w_6_0"></a><a id="Tc_vhI3Nj74PESZPmLxC2f68g_7_0"></a><a id="Tc_230w1DYKqE6dWVxsZNBusw_8_0"></a><a id="Tc_JcSvEsNf3kqa0xu5xhCfNw_9_0"></a><a id="Tc_dnvgs0n9g0qPlTr6CJyLZg_10_0"></a><a id="Tc_HbHEALSpjEikXbgNFPPtVA_11_2"></a><a id="Tc_TVZj8unw5kiYkLtXw1ZLwQ_11_3"></a><ix:continuation id="Tb_BYf3ujcjCE2PlLSkBM6-5A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, the Company has non-capital income tax loss carry-forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_pmn_NonCapitalLossCarryforwardMember_i2OXSaXBF0CPpT0LBRI-Mw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="Narr_Mjz6hzMWC06zmsaXxziEiQ">131,360,190</ix:nonFraction> available to reduce future income for income tax purposes. The income tax loss carry-forwards have expiry dates between the&#160;years 2026 and 2046.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, the Company has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember_QgKzyfBAJkiVQVpxeqeEuA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="Narr_9lqGFBpY4E6tZ528UmNDWg">2,553,000</ix:nonFraction> of non-refundable investment tax credits available to offset future income taxes. The non-refundable investment tax credits have expiry dates between 2025 and 2035. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">A reconciliation of the combined federal and provincial statutory income tax rate applied to the net (loss) income for the&#160;year to the income tax recovery as of December&#160;31 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount ($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent (%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Canadian federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_xlAyWLbLAk6hcp9kDDptwQ_4_2">5,960,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_h4tUodCrnUO2v81qcP6KVg_4_3">15.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provincial taxes (Ontario)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_9_31SV197ESWcWqOSUz_Kg_5_3">11.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_PwxYmnAsKECHRbUJNsnu1w_6_2">127,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_7HLgK9SwkEyzCWCHplg3Dw_6_3">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issue costs recorded, net of equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" sign="-" scale="0" id="Tc_Ti6q2hwVYEee5ReE4dupJg_7_2">372,011</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="Tc_CXYeAW3LuE-sdo3w60ISCg_7_3">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_Z4iHHxH_fEaYzNspXbZyZg_8_2">6,027,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_TS8c-PEOQEuL38E1-bPR7A_8_3">26.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Return to provision adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" scale="0" id="Tc_an6qKRYU60amIVAtfOXltA_9_2">15,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="3" format="ixt:num-dot-decimal" name="pmn:EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" sign="-" scale="-2" id="Tc_EvpRPARpWEKbFYgzDkr58Q_9_3">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="Tc_fTW44-id70CZIaPw59AVaw_10_2">161,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_i8IR4ydLKEKP9DqSFY0zsQ_10_3">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ek1qQB57M0uiwz7O77M-zA;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Effective Tax Rate</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company does not expect a significant change in the amount of unrecognized tax benefits over the next 12&#160;months. However, any adjustments arising from certain ongoing examinations by tax authorities could alter the timing or amount of taxable income or deductions and these adjustments could differ from the amount accrued. The Company&#8217;s federal and provincial income tax returns files for all&#160;years remain subject to examination by the taxation authorities.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb__IGS5wsrAUevQnCkhQazCg" continuedAt="Tb__IGS5wsrAUevQnCkhQazCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span>Segment Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_i48rermic0m7T3ssgZo9kw">one</ix:nonFraction> reportable segment: life science. The life science segment consists of the development of clinical and preclinical product candidates. The Company&#8217;s chief operating decision maker (&#8220;<b style="font-weight:bold;">CODM</b>&#8221;) is the chief executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the life science segment based on net (loss) income, which is reported on the income statement as consolidated net loss (income). The measure of segment assets is reported on the balance sheet as total consolidated assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As such, the CODM uses cash forecast models in deciding how to invest into the life science segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss (income) is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management&#8217;s compensation, along with cash forecast models.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Oc0NICVUDUiOuiJMysuYEw_1_2"></a><a id="Tc_7mSIlaM1JEy9DOxEZtsSbg_2_2"></a><a id="Tc_dSlVIaHCZ0WDuphOzX8o-w_2_5"></a><a id="Tc_ygoOtKRkPkeoVy1ywTIJAw_3_0"></a><a id="Tc_VhiJ-DdC0kiieL4SP1I8cQ_4_0"></a><a id="Tc_Iz2Z1SdjEEWVRsU5X-lGeQ_4_2"></a><a id="Tc_OaySmArRP0G1OOYYRfE10A_4_5"></a><a id="Tc_vrlHp9N_PEqBpRSfHzIziQ_5_0"></a><a id="Tc_A29PZt-pQEa5B0At3vlm-A_6_0"></a><a id="Tc_4bfIg0T7C0CILd2z0KyMhg_7_0"></a><a id="Tc_3C7G5roIDUq9LaHSxOEGrw_8_0"></a><a id="Tc_ids4xz7ky062hoyanbM9kg_8_2"></a><a id="Tc_EpqRTJQGQ0Cx1mNy3LHpGw_8_5"></a><a id="Tc_O0nk-rGDkkeRywCvZODOqA_9_0"></a><a id="Tc_IbHfvC6BhEmWOH_uZp1YrA_10_0"></a><a id="Tc_QbnoA3xM3U-uEZtG9u-UeQ_10_2"></a><a id="Tc_LkRicq_lOUeeNSX_iIa4Vw_10_5"></a><a id="Tc_oYas99pRp02-0H7jKcpL2w_12_0"></a><a id="Tc_HiSyATtB8EGHVS2UtIZtig_13_0"></a><a id="Tc_8YrXdxO5RESqacoi5kPtQg_13_3"></a><a id="Tc_UdOngqVNw02SdDqo5P1eBg_13_6"></a><a id="Tc_yt2_5U_RQUObvbeqD7kyAQ_14_0"></a><a id="Tc_86kAJXWVT0qapcEoVMrh8g_14_2"></a><a id="Tc_nHV0yxhx20O9GuAYXECOIg_14_5"></a><a id="Tc_NAW7ehq8-0mTuq_4sdsrdg_16_0"></a><ix:continuation id="Tb__IGS5wsrAUevQnCkhQazCg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025, and 2024: </p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Tb_DBP0yMWEfUaid8z8ez0f0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:45pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:89.6%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">PMN310 development program costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_K_opEzrTEU-k6e90ZUfyuA_4_3">30,226,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_zgbdxIbjLE6rrXi3Z5IUpw_4_6">8,275,268</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other non-employee research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw" decimals="0" format="ixt:num-dot-decimal" name="pmn:SegmentReportingOtherSegmentItemAmount" sign="-" scale="0" id="Tc_imZqBtuJ2UWmt2IYK2NYZQ_5_3">885,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A" decimals="0" format="ixt:num-dot-decimal" name="pmn:SegmentReportingOtherSegmentItemAmount" sign="-" scale="0" id="Tc_-z3Oh2Sn7kOtayw7_1hKYA_5_6">772,501</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Employee costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="Tc_EmkT1VEDnUyEsmzY8t1DuQ_6_3">5,051,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="Tc_C5i05UXRAkSNnGXT6qrZKA_6_6">3,336,580</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other general and administrative costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" id="Tc_71jP0Vue3Eip6Ia7iG2DxQ_7_3">4,004,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" id="Tc_ZrwNCgZoZEO7VtN6Q_sieA_7_6">4,443,129</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Operating Loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_ePWpK_9je0SNhuyw9hr54w_8_3">40,167,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_wvN1vZ2cH0iHX2Gt0XTJzw_8_6">16,827,478</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw" decimals="0" format="ixt:num-dot-decimal" name="pmn:OtherNonEmployeeResearchAndDevelopmentCosts" sign="-" scale="0" id="Tc_TbWf-HebFkWxt5lUpmUYKA_9_3">448,161</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A" decimals="0" format="ixt:num-dot-decimal" name="pmn:OtherNonEmployeeResearchAndDevelopmentCosts" sign="-" scale="0" id="Tc_aMFP_m3tLEy2xvkn43Gl-g_9_6">19,606,351</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss (Income):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw" decimals="0" format="ixt:num-dot-decimal" name="pmn:Pmn310DevelopmentProgramCosts" scale="0" id="Tc_WC3o25owN0i-TWrYoSLQXg_10_3">39,719,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A" decimals="0" format="ixt:num-dot-decimal" name="pmn:Pmn310DevelopmentProgramCosts" sign="-" scale="0" id="Tc_TjZ_0EzvCUWrDo2fSV0Lww_10_6">2,778,873</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reconciliation of Profit or Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated Net Loss (Income):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_WdhANRd9JEuHez3tjsdkRg_14_3">39,719,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_880keX0zlUKFOILQTaDj5Q_14_6">2,778,873</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_5K2QM90CL0O9ZruQSaCdTA"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_i6PFWvwQFE-SOfJE2EAIyg">Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense</ix:nonNumeric></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_71g2nnudmUm1nA1r9X0dNg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span>RELATED PARTY TRANSACTIONS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">UBC Collaborative Research Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">In April&#160;2016, the Company entered into a collaborative research agreement (&#8220;<b style="font-weight:bold;">CRA</b>&#8221;) with the University of British Columbia (&#8220;<b style="font-weight:bold;">UBC</b>&#8221;) and the Vancouver Coastal Health Authority in the amount of C$<ix:nonFraction unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA" contextRef="As_Of_4_30_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_DdNjmpvgs0aZ4rzq8r7w_g" decimals="0" format="ixt:num-dot-decimal" name="pmn:RelatedPartyTransactionFundingCommitment" scale="0" id="Narr_5KxcwUcby0i1UYNyjfNh_Q">787,500</ix:nonFraction>, with the Company&#8217;s Chief Scientific Officer, as principal investigator at the UBC. In January 2022, the UBC CRA was amended to extend the project for an additional three years, and in December 2024, for an additional 1 year. Aggregate funding under the agreement was increased to a total of C$<ix:nonFraction unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA" contextRef="As_Of_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_yUl-HCLG1kqLzAcQbh7uGA" decimals="0" format="ixt:num-dot-decimal" name="pmn:RelatedPartyTransactionFundingCommitment" scale="0" id="Narr_N2fA1B8TVUKFLycumtKoVQ">5,830,000</ix:nonFraction> through February 2026. During the&#160;years ended December&#160;31, 2025 and 2024, the Company made cash payments of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="pmn:CashPaymentsRelatedParty" scale="0" id="Narr_KEyF3bjgSkeduvPNVoJwhw">428,860</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="pmn:CashPaymentsRelatedParty" scale="0" id="Narr_nYQWc8URWkWX9Q_N3MGRgQ">587,000</ix:nonFraction>, respectively, and incurred costs of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iyRZGqr_Ek6zR0Ofkljmjg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" id="Narr_lQ9Qg2L8skmscUNxycXKSg">573,187</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v5tCRtG69EORGsNwZgNgJg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" id="Narr_pi2sToRii0iTJ9umwMcU9g">584,226</ix:nonFraction>, respectively, which are included in research and development expenses in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Neil Warma Employment Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In October 2024, in connection with Mr. Neil Warma&#8217;s appointment to the role of CEO, he entered into an employment agreement with the Company (the &#8220;<b style="font-weight:bold;">CEO Employment Agreement</b>&#8221;) providing for an annual base salary of $<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ" decimals="0" format="ixt:num-dot-decimal" name="pmn:EmploymentAgreementAnnualBaseSalary" scale="0" id="Narr_2QdZgMj1vEWUyMxkbbVCIA">500,000</ix:nonFraction> and annual discretionary bonus with a target of <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ" decimals="2" format="ixt:num-dot-decimal" name="pmn:EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" scale="-2" id="Narr_37ocxLYcAkOsdW8ji790qg">50</ix:nonFraction>% of his base salary. Mr. Warma was also provided (i) severance in the amount of <ix:nonNumeric contextRef="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_TerminationWithoutCauseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Wm0yqUihf0aj0uy8QZAwtg" format="ixt-sec:durwordsen" name="pmn:EmploymentAgreementSeveranceAmountCalculationTerm" id="Narr_NnNPMI_9akmcDOAiwrEIMg">12-months</ix:nonNumeric>&#8217; salary, a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a termination without cause and (ii) severance in the amount of the sum of <ix:nonNumeric contextRef="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_ChangeInControlOfCompanyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ce9A_GawfUqwocEsnGglEA" format="ixt-sec:durwordsen" name="pmn:EmploymentAgreementSeveranceAmountCalculationTerm" id="Narr_kSzkREZkq0WgMkJsajc5kA">18-months</ix:nonNumeric>&#8217; salary and a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a change in control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In connection with his appointment, Mr. Warma was also granted (i) an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Pm7NX9q6C0GTLtp_fVq02Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_uLkUUC9_g0yd-GXfd2aBXA">45,765</ix:nonFraction> of the Company&#8217;s common shares (the &#8220;<b style="font-weight:bold;">Initial Award</b>&#8221;) and (ii) an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_DNu7rAGff0iie8PDPBHJ2w">19,614</ix:nonFraction> of the Company&#8217;s common shares (the &#8220;<b style="font-weight:bold;">Performance Award</b>&#8221;). Per the Company&#8217;s 2015 Stock Option Plan, the exercise price of each of the Initial Award and the Performance Award is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Pm7NX9q6C0GTLtp_fVq02Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_UrBS_l8y50uR8ofr-Hz3QQ">28.75</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_VGlBM7hgKUyWd-Dp-bhCdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per</span></span> share, the <ix:nonNumeric contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_I6q6e-G_hkObQ4WrMKNO1g" format="ixt-sec:durwordsen" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" id="Narr_fiphv2wvNUCkR9_5k5M65A">5-day</ix:nonNumeric> volume-weighted average price (&#8220;<b style="font-weight:bold;">VWAP</b>&#8221;) as of October 8, 2024. The Initial Award is <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hegnycuWWk64ZdX1vlM55g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_aCoWtDGz4k2ulx_j4lnsxg">25</ix:nonFraction>% vested upon grant with the remaining shares vesting ratably over <ix:nonNumeric contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1Gx3t3xx065WtYKYn1A9w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_f3mz0MAqY02TTKV_NeG2RA">thirty-six months</ix:nonNumeric>. &#160;The Performance Award shall vest <ix:nonFraction unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YXkmIVrXsUao5mEA8VBliw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_-chveniyd0-eNtQAaGMy6g">25</ix:nonFraction>% on the date that the <ix:nonNumeric contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A" format="ixt-sec:durwordsen" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" id="Narr_709Klji1HkexmLdk58iK9Q">10-day</ix:nonNumeric> VWAP of the Company&#8217;s common shares on the Nasdaq Capital Market exceeds <ix:nonFraction unitRef="Unit_Standard_item_ETwbko2pdkCFGeE5avOMiw" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A" decimals="INF" format="ixt-sec:numwordsen" name="pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" scale="0" id="Narr_yMq2IkX6TUCaJ84sZdf9SQ">three</ix:nonFraction> times the exercise price, with the remainder vesting ratably over the following <ix:nonNumeric contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CgSeHaCH60uJVtf2HXDdBQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ZSPl9u12cUqPlhs3W1ls0Q">thirty-six months</ix:nonNumeric>. &#160;Refer to Note 8, Share-Based Compensation, for further discussion on the Performance Award.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_6FnWdys2tEqQnjMCdDcJ1w" continuedAt="Tb_6FnWdys2tEqQnjMCdDcJ1w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></span>COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Research, Development and License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company enters into research, development and license agreements with various parties in the ordinary course of business where the Company receives research services and rights to proprietary technologies. The agreements require compensation to be paid by the Company, typically, by a combination of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fees comprising amounts due initially on entering into the agreements and additional amounts due either on specified timelines or defined services to be provided;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">milestone payments that are dependent on products developed under the agreements proceeding toward specified plans of clinical trials and commercial development; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">royalty payments calculated as a&#160;percentage of net sales, commencing on commercial sale of any product candidates developed from the technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Milestone and royalty related amounts that may come due under various agreements are dependent on, among other factors, preclinical safety and efficacy, clinical trials, regulatory approvals and, ultimately, the successful development and commercial launch of a new drug, the outcomes and timings of which are uncertain. Amounts due per the various agreements for milestone payments will accrue once the occurrence of a milestone is likely. Amounts due as royalty payments will accrue as commercial revenues from the product are earned. Through December&#160;31, 2025, <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q" decimals="0" format="ixt-sec:numwordsen" name="pmn:CollaborativeArrangementAccrualsForRoyaltyPayments" scale="0" id="Narr_pQZrKOIloEW3JgpPqlTuUA">no</ix:nonFraction> events have occurred that require accrual of any milestone or royalty related amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">UBC and the Vancouver Coastal Health Authority Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In April&#160;2016, the Company entered into a <ix:nonNumeric contextRef="Duration_4_1_2016_To_4_30_2016_pOn31i6lLEW5JuoImgoy_w" format="ixt-sec:durwordsen" name="pmn:RelatedPartyTransactionTermOfAgreement" id="Narr_gajVAtcbFE-qQblWEUlNQg">three-year</ix:nonNumeric>, CRA with the UBC and the Vancouver Coastal Health Authority. The agreement was amended various times through November&#160;2021. Refer to Note&#160;11 Related Party Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">UBC Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In February&#160;2009, the Company entered into an agreement with UBC to further the development and commercialization of certain technology developed, in part, by the Company&#8217;s Chief Scientific Officer. The agreement was amended and restated in October&#160;2015. Under the amended and restated agreement, the Company is committed to make royalty payments based on revenue earned from the licensed technology. An annual license fee is payable over the term of the agreement. The agreement remains effective unless terminated under the provisions of the agreement. The Company made annual license payments of C$<ix:nonFraction unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA" contextRef="Duration_1_1_2024_To_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_Oi4UAzx7LkqdsUQQKfYJbQ" decimals="0" format="ixt:num-dot-decimal" name="pmn:AnnualLicensePayment" scale="0" id="Narr_bFG9dOSUb0OPb-WrCCk5hQ">25,000</ix:nonFraction> during each of the years ended December 31, 2025 and 2024. Through December&#160;31, 2025 <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_4lfKtp945kqn9mXeMmjskQ" decimals="-5" format="ixt-sec:numwordsen" name="pmn:CollaborativeArrangementAccrualsForRoyaltyPayments" scale="6" id="Narr_PepBElkpuUeKWiK6eWo3IQ">no</ix:nonFraction> accruals for royalty payments have been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Indemnification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6FnWdys2tEqQnjMCdDcJ1w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 36pt;">against liabilities that may arise by reason of their status or service as directors or officers. The Company currently has directors&#8217; and officers&#8217; insurance.</p></ix:continuation><a id="Tc_FhUeqSRvjkee9KPI-FVl8A_1_2"></a><a id="Tc_ec5mX7-ZkkWMmrLAse4W1g_2_2"></a><a id="Tc_05gEJ_KUn0OMxe7euAXXEw_2_5"></a><a id="Tc_1WKLS3cb3USCHngblieILw_3_0"></a><a id="Tc__ovIHU-b1ka9YJTgziXKvw_4_0"></a><a id="Tc_NaUtttVG40iuKQkpyLkJUQ_4_2"></a><a id="Tc_5IPiZytXbEOVdZK7ZqvhBg_4_5"></a><a id="Tc_C2n6S86CFkWR8i_bcgb_nw_5_0"></a><a id="Tc_7E77Hze170eOH-Nzq97UDQ_6_0"></a><a id="Tc_czni2YonsUOXUyTz3SUoDA_7_0"></a><a id="Tc_76RdyxCpiEqq2C-tgbwEKQ_8_0"></a><a id="Tc_dQeXurg3MUCl1AosYbv0mQ_8_3"></a><a id="Tc_PLma1QrSPU-q8ajWRqHgrg_9_0"></a><a id="Tc_K7B-S1wYPU-rVKDYL6Br6w_9_3"></a><a id="Tc_vwuTz7a6iEu7l5rVjpR8cw_10_0"></a><a id="Tc_SQbmvIYU_0ODDgIJ_vZB_A_12_0"></a><a id="Tc_jOgx1Ix9Q0Kz_y8baoPtHw_12_2"></a><a id="Tc_8K5gd-vsFkWudPYBD_1O-Q_12_5"></a><a id="Tc_SKLAxnIw702YDT1gC2pUKA_13_0"></a><a id="Tc_f-R2u1cPuEeRzP9M0gu5xg_13_2"></a><a id="Tc_DswvNCcre0mHxH7Fo_x9-Q_13_5"></a><a id="Tc_RWUGikzJgEGNhop1mU47iA_1_2"></a><a id="Tc_nQmnieLbyEylkzQDxLmMsw_2_2"></a><a id="Tc_x_j1MfbZtE20w3dNGk2XSg_3_2"></a><a id="Tc_A5Q39PBg7Ey0AnzB_1lxUg_3_4"></a><a id="Tc_d9--SrOFeU2EHw9zLrfLiQ_4_0"></a><a id="Tc_wlUCk5g9JEW5ECHVnie7Sw_5_0"></a><a id="Tc_IfnePSB-GEu2t8Wq3S0HNg_6_0"></a><a id="Tc_l51EO9QLB0Klhh46WeGDUQ_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:EarningsPerShareTextBlock" id="Tb_MKBzRI5vFkOjsa3HksAiJw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">NET LOSS PER SHARE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common shareholders by the weighted average shares outstanding during the period, without consideration for common share equivalents. Diluted net earnings per share applicable to common shareholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common share equivalents outstanding for the period, determined using the treasury-stock method and the if-converted method. For purposes of the calculation of dilutive net (loss) income per share applicable to common shareholders, stock options, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share applicable to common shareholders when their effect would be anti-dilutive or would not add additional Common Shares to the denominator of the calculation due to being out-of-the-money.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">As of December 31, 2025 and 2024, respectively, <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_igRnDfASGkG63gecqvoxGA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_3J8xfroNZEe4tPLyxr30bg">74,673</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_YLC21hJnUUecfOnIoqyf6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_fzv-B_RE90q2oN0ofe_P5g">86,481</ix:nonFraction> Pre-Funded Warrants to purchase common shares for little to no consideration, issued in connection with the August 2023 Private Placement and July 2024 Private Placement (see Note 6), were included in the basic and diluted net (loss) income per share calculation. The following table sets forth the computation of basic and diluted net loss (income) per share attributable to common shareholders:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_nft6V7-qhEmkEUxiUSr1Cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_KwyOB1TRekua5J7zJUHniQ_4_3">39,719,147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="Tc_18WCTTcRakaTCbXYt1vFZQ_4_6">2,778,873</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_I8x7AN8xQU-Pi4tAU-Cd_A_6_3">1,756,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_7SDnWwRNtky63qEEh6GLhw_6_6">1,036,799</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Effect of potentially dilutive securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">          Warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Tc_RIS6dJwmREiyefXyjmor0A_8_6">20,882</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">          Stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_1C8LvcOfXUeGyxN1ojO2hw_9_6">789</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Diluted weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_4Ed5hkdXY06Uu_aoSUe_Ow_10_3">1,756,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_bIIlXlZvwkWcQgfJnhfU-Q_10_6">1,058,469</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income per share attributable to common shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_imb4lRdXkUOJ9fmr-QtdzA_12_3">22.61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_glBl5cjXG0K7a6ej4emZCA_12_6">2.68</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share attributable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_n2XD9d7ebkG9x2lUOQH2Mw_13_3">22.61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_4cUPOTeojUifcYjJKXW2KA_13_6">2.63</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been antidilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_is4mbi_jiEynqsqkqLlBWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options issued and outstanding under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DtZmtuC1ykum9CataBZk8g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_A1_7mCOFC06Serdxf3V61Q_4_2">180,827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a-CEo9VCBE-UkGXp15OLEg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_xovsJHYPTkebVKiobN7cZw_4_4">142,978</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I1pUDf-UVkWE1fMJu2oIPg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_d-7saYtRmUqwVmIeFIYH3A_5_2">2,564,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I_iDsTdFrk6-anUo_VHT0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_q8B7QEa6HkW7bcyZkHr5gg_5_4">2,199,175</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_-Oj0jlKSiEGQv00Y8TYf4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_rpJZZkWiCEW72woPi6a7KQ_6_2">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_fsghA6bgmEe7eA6MOqoAlg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_m02OFtOCREKlW4U15ekWTA_6_4">42</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_N_nLjQZTTUOJRl_CYaGG0g_7_2">2,745,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_RRDLxFDytUGJw2nM0Hhojg_7_4">2,342,195</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" name="us-gaap:SubsequentEventsTextBlock" id="Tb_Hs6uJgLiR0Sm52NjXkJOOA" continuedAt="Tb_Hs6uJgLiR0Sm52NjXkJOOA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></span>SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;">On January 29, 2026, the Company completed a private placement &#160;for aggregate gross proceeds of &#160;</span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_VJQcwaFCd0a0jZupEeCuog">75.5</ix:nonFraction></span><span style="color:#191c1f;"> million to sell an aggregate of (i) </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kYdgWN5wP02-mAaUlx9HGA">6,815,296</ix:nonFraction></span><span style="color:#191c1f;"> Common Shares, (ii) Common Share purchase warrants (&#8220;</span><b style="color:#191c1f;font-weight:bold;">Common Share </b></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Hs6uJgLiR0Sm52NjXkJOOA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><b style="color:#191c1f;font-weight:bold;">Warrants</b><span style="color:#191c1f;">&#8221;) to purchase </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_NrDzHyxGB0mKB6zttI9Mtw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr__-UC8U2i7keh9U3cgah7Hg">6,915,296</ix:nonFraction></span><span style="color:#191c1f;"> Common Shares, (iii) Pre-Funded Warrants (&#8220;</span><b style="color:#191c1f;font-weight:bold;">Pre-Funded Warrants</b><span style="color:#191c1f;">&#8221;) to purchase </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_4AS1X6aDQkuCNq0ZGYhBVg">100,000</ix:nonFraction></span><span style="color:#191c1f;"> Common Shares (collectively the &#8220;</span><b style="color:#191c1f;font-weight:bold;">January 2026 PIPE</b><span style="color:#191c1f;">&#8221;). </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_6VuupOYBAkOYhCWeJHRGrg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_qNrqCFhB1EOozQ0L1DVyCA">6,090,075</ix:nonFraction></span><span style="color:#191c1f;"> Common Shares and </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceOneMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_Q86c3TOUPUerZkUpsynvOQ" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightIssued" scale="0" id="Narr_CHxclR1QKU2beAOulyZDsA">6,090,075</ix:nonFraction></span><span style="color:#191c1f;"> Common Share Warrants were sold at a price of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_C9tRwMO6rE-LT1JzUAMX2g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_QrLOk3QCb0W_qt-6TWmtXA">10.77</ix:nonFraction></span><span style="color:#191c1f;"> for one Common Share and </span><span style="-sec-ix-hidden:Hidden_g2-t6Gg1-USHvtLxsXmEHw;"><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="color:#191c1f;"> Common Share Warrant. </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_br3i9uDnNUeb1G3P44Ok7A" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightIssued" scale="0" id="Narr_7C6uk0Fguk6wZ0UDCFh3hA">100,000</ix:nonFraction></span><span style="color:#191c1f;"> Pre-Funded Warrants and </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_MI2T6mOoo0yiJyx9T1pfEg" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightIssued" scale="0" id="Narr_39Wn1rYpR0WqJ75AsHwMkA">100,000</ix:nonFraction></span><span style="color:#191c1f;"> Common Share Warrants were sold at a price of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_atViPoIYo0CLfKm49OwGMA" decimals="2" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightPricePerWarrant" scale="0" id="Narr_pZpbAuD-EkqcsKbBLzkAxg">10.77</ix:nonFraction></span><span style="color:#191c1f;"> for one Pre-Funded Warrant and </span><span style="-sec-ix-hidden:Hidden_z_3eEpwo3UirEsenSR7Cow;"><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="color:#191c1f;"> Common Share Warrant, less an exercise price of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lZRuz0TFckyJ2QplU-KoIA">0.0001</ix:nonFraction></span><span style="color:#191c1f;"> per Pre-Funded Warrant. </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_hIXk7T7AhEypKsAQMXXglg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_LhwaTHZo0E2V_7RsaSS7nA">725,221</ix:nonFraction></span><span style="color:#191c1f;"> Common Shares and </span><span style="color:#191c1f;"><ix:nonFraction unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ" contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_p9u06d6usECaMSjjXOcQkA" decimals="INF" format="ixt:num-dot-decimal" name="pmn:ClassOfWarrantOrRightIssued" scale="0" id="Narr_LpxucblqcU-8ugfEn4CYLg">725,221</ix:nonFraction></span><span style="color:#191c1f;"> Common Share Warrants were sold to certain of our directors and management at a price of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_Y-LkZ-hLQ0uB5SljT10LcA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_bKFm5JPCcU2scxznNsxX1g">12.13</ix:nonFraction></span><span style="color:#191c1f;"> for one Common Share and </span><span style="-sec-ix-hidden:Hidden_bKWVPXSjm0mG5YAXBCSUsw;"><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="color:#191c1f;"> Common Share Warrant. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;">The Common Share Warrants have an exercise price of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_NrDzHyxGB0mKB6zttI9Mtw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_48KMq7GmIkiCOENTCIHFYg">14.40</ix:nonFraction></span><span style="color:#191c1f;">, are exercisable immediately and will expire upon the earlier of (i) within </span><ix:nonNumeric contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g" format="ixt-sec:durwordsen" name="pmn:ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" id="Narr_kYknIZKDa0Sm7Gx0IJitlA"><span style="color:#191c1f;">60 days</span></ix:nonNumeric><span style="color:#191c1f;"> of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants have an exercise price of </span><span style="color:#191c1f;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg" contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_OtzEHgzjV0eUQYldB3VUmA">0.0001</ix:nonFraction></span><span style="color:#191c1f;"> per Pre-Funded Warrant, are immediately exercisable and will expire when exercised in full. For purposes of the foregoing, the &#8220;Milestone Event&#8221; means the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with multiple ascending doses of PMN310. Fees and other expenses are currently not estimable by the Company, as they are still being determined.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_506d532d_f91e_4e40_bd4b_c375a05fa13a"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure0</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None. </p><a id="_55967520_bd20_4f45_851c_b3495a8a0a99"></a><a id="Item9AControlsandProcedures_177201"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of December 31, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance of the reliability of financial reporting and of the preparation of financial statements for external reporting purposes, in accordance with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included extensive documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Based on management&#8217;s processes and assessment, as described above, management concluded that our internal control over financial reporting was effective as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Remediation of Previously Identified Material Weakness</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As previously disclosed in our 2024 Annual Report on Form 10-K, management identified a material weakness in the Company&#8217;s internal control over financial reporting related to the fair value calculations related to certain financial instruments, specifically the calculation over the fair value of the July 2024 PIPE Warrant Liability. the Company did not design and maintain effective controls over the review of certain fair value calculations, which could have resulted in a material misstatement of the Company&#8217;s financial statements that would not have been prevented or detected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Remediation of Material Weakness</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To address the material weakness described above, the Company implemented a number of measures to remediate the material weakness, including enhancing review controls over the calculation of the fair value of its financial instruments, engaging qualified third-party specialists to assist in the valuation when necessary and improving the documentation and review of management&#8217;s accounting analyses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These remediation measures were implemented and have been in operation for a sufficient period of time during the year ended December 31, 2025. Management has performed testing of the design and operation of these controls and based on the results of such testing concluded that the controls are operating effectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, management concluded that the material weakness described above has been remediated as of December 31, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Control Over Financial Reporting</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except for the remediation measures in connection with the material weakness described above, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, that occurred during the twelve months ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inherent Limitations on Effectiveness of Internal Controls</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</p><a id="_bcc53a71_b959_4bd2_a6dc_6377e3d5e534"></a><a id="Item9BOtherInformation_880196"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the twelve months ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A" format="ixt:fixed-false" name="pmn:Rule10b51ArrModifiedFlag" id="Narr_XeYUkNMxskqstmRa9awcFQ"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA" format="ixt:fixed-false" name="pmn:Rule10b51ArrModifiedFlag" id="Narr_NiOf2wMS2E-TlOagnYWznA"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg" format="ixt:fixed-false" name="pmn:Rule10b51ArrModifiedFlag" id="Narr_n2Yv7CoTLUOeeyG5j1VwfA"><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q" format="ixt:fixed-false" name="pmn:Rule10b51ArrModifiedFlag" id="Narr_SW4yVuwKx06U2iyH_OGwwQ">modified</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> a <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_iL9ZEQgGpEqjT4YH9eOQhA"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_wzQG6LI9UE294eM_yOpS1g"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_QWcDm83JVEmrp0BQMHnhWw"><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_nF5u_6t-SkyG4T49X71Q6Q">Rule</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_N7LQkcXJik24RNEQtDcAUw"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_kDKig7FWMUuKseDUWopxEg"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_eWDq575M-UCQ2BQ0NyJw8Q"><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_n-2L09_yK0qaZEh7qPbkeQ">10b5-1</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> trading arrangement or <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_jwolPkF9WEytmb2ZjSAGAg"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_Wh3sR-xU502qgv7D9Dj6JQ"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_Ky0shOVAuk2oyL6_dpDBag"><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_7c1c8whtIk-i3ioGOt0uVg">non-Rule</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_aYJEBgTnuECQrqJ705bOog"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_y122uXZWg0ebg5EGoIUIqQ"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr__eAunmpV2E2u5n7oNXNgyg"><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_oPbbRLLHK0qoVKfHKYcogw">10b5-1</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> trading arrangement (as such <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A" format="ixt:fixed-false" name="pmn:NonRule10b51ArrModifiedFlag" id="Narr_1t543gD8TkKaZtIX4nP7uw"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA" format="ixt:fixed-false" name="pmn:NonRule10b51ArrModifiedFlag" id="Narr_0xfz56Qcx0utvmnMD-ZKtA"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg" format="ixt:fixed-false" name="pmn:NonRule10b51ArrModifiedFlag" id="Narr_XnD47_sgO0maKIF2YsscvQ"><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q" format="ixt:fixed-false" name="pmn:NonRule10b51ArrModifiedFlag" id="Narr_0rcuqlG1a02ej3N58t-pYQ">terms</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> are defined in Item 408 of Regulation S-K).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cd0dd5f9_befc_419f_9bac_75014f727d02"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_f66b8565_0b2e_4d3e_82f1_8a7e7b8bdec6"></a><a id="PARTIII_789338"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="_Item_10._Directors"></a><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;10. Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The information required by this item will be contained in our 2026 Proxy Statement, to be filed with the SEC not later than 120 days after the end of our fiscal year ended December 31, 2025 and is incorporated in this report by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.75pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. The Code of Business Conduct and Ethics is posted on our website at https://www.promisneurosciences.com/investors/corporate-governance/governance-documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;background:#ffffff;margin:0pt;">We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Business Conduct and Ethics by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of Nasdaq, by filing a Current Report on Form 8-K with the SEC, disclosing such information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_e1ZHRG95Z0OiNLEXg2amng">The Company has an insider trading policy</ix:nonNumeric> governing the purchase, sale and other dispositions of the Company&#8217;s securities that applies to all Company&#8217;s directors, officers, employees and other covered persons. The Company believes that its insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. It is also the policy of the Company to comply with all insider trading laws and regulations. A copy of the Company&#8217;s insider trading policy is filed as Exhibit 19.1 to this Form 10-K. <br/><span style="visibility:hidden;">&#8203;</span></p><a id="_efb8120c_61c7_49a8_bb90_88ee442b1a45"></a><a id="Item11ExecutiveCompensation_175783"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be contained in our 2026 Proxy Statement, to be filed with the SEC not later than 120 days after the end of our fiscal year ended December 31, 2025 and is incorporated in this report by reference.</p><a id="_17309d5b_b8b9_454c_999f_ab8f1dfedebd"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:10pt;">The information required by this item will be contained in our 2026 Proxy Statement, to be filed with the SEC not later than 120 days after the end of our fiscal year ended December 31, 2025 and is incorporated in this report by reference</span>.</p><a id="_Item_13._Certain"></a><a id="_d54aa611_b500_49b8_a80d_977ebe365977"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be contained in our 2026 Proxy Statement, to be filed with the SEC not later than 120 days after the end of our fiscal year ended December 31, 2025 and is incorporated in this report by reference.</p><a id="_Item_14._Principal"></a><a id="_296a4e30_297a_4c2c_8689_0606106540f1"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountant&#8217;s Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by this item will be contained in our 2026 Proxy Statement, to be filed with the SEC not later than 120 days after the end of our fiscal year ended December 31, 2025 and is incorporated in this report by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our independent public accounting firm is Baker Tilly US, LLP, Tewksbury, Massachusetts, PCAOB Auditor ID 23.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4d55b827_28db_41b2_9e6a_7af6fff02eee"></a><a id="PartIV_782813"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Part&#160;IV</p><a id="_Item_15._Exhibits"></a><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:32.05pt;background:#ffffff;margin:0pt;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;text-indent:32.05pt;background:#ffffff;margin:0pt;">(1) Financial Statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;text-indent:32.05pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#INSERTREPORTOFINDEPENDENTREGISTEREDPUBLI"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ConsolidatedBalanceSheets_857069"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ConsolidatedStatementsofOperationsandCom"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the Fiscal Years Ended December 31, 2025, December 31, 2024</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Shareholders&#8217; Equity for the Fiscal Years Ended December 31, 2025 and December 31, 2024</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_552360"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the Fiscal Years Ended December 31, 2025, and December 31, 2024</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements_8"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:32.05pt;background:#ffffff;margin:0pt;">(2) Financial Statement Schedules:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:32.05pt;background:#ffffff;margin:0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:32.05pt;background:#ffffff;margin:0pt;">(3) Exhibits. The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Item_16._Form"></a><a id="_1e5bc062_ec10_455c_a4a2_9a076e2a6bbe"></a><a id="Item16Form10KSummary_886180"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_062c6c79_4f78_4aa9_b7ea_4892d26290a9"></a><a id="EXHIBITINDEX_801361"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT&#160;INDEX </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:top;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br/><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:85.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles. (incorporated herein by reference to Exhibit 3.1 to ProMIS&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10 Registration Statement filed June 22, 2022, as</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Articles dated </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">July </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">8, 2015. (incorporated herein by reference to Exhibit 3.1.1 to ProMIS&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10 Registration Statement filed June 22, 2022, as</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-1d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">dated</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">June</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">17,</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2022.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(incorporated</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">herein</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">reference </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to Exhibit 3.1.2 to ProMIS&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10 Registration Statement filed June 22, 2022, as</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1.3</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922076352/tm229830d7_ex3-1d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.5pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">dated</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">June</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">21,</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2022.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(incorporated</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">herein</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">reference </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to Exhibit 3.1.3 to ProMIS&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10 Registration Statement filed June 22, 2022, as</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1.4</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837023011879/pmn-20230713xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Continuance. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 14, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1.5</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/pmn-20231204xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Articles dated December 4, 2023. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1.6</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465925115182/pmn-20251124xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Articles dated November 28, 2025. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 24, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated By-law No. 1. (incorporated herein by reference to Exhibit 3.2 to ProMIS&#8217; Form 10 Registration Statement filed June 22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex3-2d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">By-law</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">No.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(incorporated</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">herein</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">by</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">reference</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.2.1</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ProMIS&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">Form</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Registration </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Statement filed June 22, 2022, as</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">amended)</span></a><span style="color:#231f20;">.</span></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837023011879/pmn-20230713xex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated By-law No. 1. (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 14, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2.3</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837023011879/pmn-20230713xex3d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated By-law No. 2. (incorporated by reference to Exhibit 3.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 14, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">of Amended and Restated Unsecured Convertible Debenture dated June 17, 2022. (incorporated herein by reference to Exhibit 4.1 to ProMIS&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10 Registration </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Statement </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">filed June 22, 2022, as</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922109341/tm2228219d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">PIPE</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Warrant.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(incorporated</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">herein</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">reference</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.2</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ProMIS&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Current Report</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">8-K</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">filed</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">October</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">17,</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2022).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922109341/tm2228219d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">of</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Placement</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agent</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Warrant.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(incorporated</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">herein</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">by</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">reference</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.3</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.6pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">to</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-1.55pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ProMIS&#8217; Current</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Report</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">on</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Form</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">8-K</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">filed</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">October</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">17,</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2022).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.4*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="pmn-20251231xex4d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Registrant&#8217;s Securities</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465923094126/tm2324315d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant. (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 22, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465923094126/tm2324315d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant. (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 22, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837024010224/pmn-20240726xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant. (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 26, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837024010224/pmn-20240726xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Tranche A Warrant. (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 26, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837024010224/pmn-20240726xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Tranche B Warrant. (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 26, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837024010224/pmn-20240726xex4d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Tranche C Warrant. (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 26, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.11</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025009380/pmn-20250722xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 22, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.12</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837025009380/pmn-20250722xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 22, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.13</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837025009636/pmn-20250728xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 28, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.14</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000110465926008325/pmn-20260129xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Share Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed January 30, 2026).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.15</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000110465926008325/pmn-20260129xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed January 30, 2026).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.1+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Joint Venture Agreement dated July&#160;7, 2020 by and between ProMIS Neurosciences&#160;Inc. and BC Neuroimmunology Lab&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.1 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.2+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Joint Venture Agreement dated July&#160;8, 2020 by and between ProMIS Neurosciences&#160;Inc. and BC Neuroimmunology Lab&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.2 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.3+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences&#160;Inc. effective April&#160;1, 2016. (incorporated herein by reference to Exhibit&#160;10.3 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.3.1+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;1 dated February&#160;13, 2017 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.3.1 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.3.2+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;2 dated July&#160;5, 2018 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.3.2 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.3.3+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;3 dated February&#160;13, 2019 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.3.3 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.3.4+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-3d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;4 dated September&#160;9, 2019 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.3.4 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.3.5+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922113573/pmn-20220630xex10d3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No. 5 dated January 11, 2022 to the Collaborative Research Agreement by and between the University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc.</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.3.6+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922113573/pmn-20220630xex10d3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Memo dated November 24, 2021 confirming increase of ProMIS Neurosciences Inc. SRA with the University of British Columbia.</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.4+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amended and Restated License Agreement dated October&#160;6, 2015 by and between The University of British Columbia and ProMIS Neurosciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.4 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.5+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">License Agreement dated August&#160;3, 2006 by and between Amorfix Life Sciences&#160;Ltd. and an Affiliate of Biogen Idec&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.5 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.6+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Exclusive License Agreement dated July&#160;14, 2010 by and between Amorfix Life Sciences&#160;Ltd. and Biogen Idec MA&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.6 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.7+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">License Agreement dated April&#160;4, 2006 by and between University Health Network and Amorfix Life Sciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.7 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.7.1</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment dated July&#160;13, 2006 to the License Agreement dated April&#160;4, 2006 by and between University Health Network and Amorfix Life Sciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.7.1 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.7.2+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;2 dated July&#160;11, 2007 to the License Agreement dated April&#160;4, 2006 by and between University Health Network and Amorfix Life Sciences&#160;Ltd. (incorporated herein by reference to Exhibit&#160;10.7.2 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.7.3+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-7d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;3 dated November&#160;4, 2013 to the to the License Agreement dated April&#160;4, 2006 by and between University Health Network and Amorfix Life Sciences&#160;Ltd. (incorporated herein by reference to Exhibit&#160;10.7.3 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.9&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Advisory Consulting Agreement dated May&#160;26, 2021 by and between ProMIS Neurosciences&#160;Inc. and David Wishart. (incorporated herein by reference to Exhibit&#160;10.9 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.10&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Consulting and Advisory Agreement dated March&#160;1, 2005 by and between Amorfix Life Sciences&#160;Ltd. And Neil Cashman. (incorporated herein by reference to Exhibit&#160;10.10 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.11&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Consulting Agreement dated June&#160;29, 2015 by and between Amorfix Life Sciences&#160;Ltd. and Virtua, LLC. (incorporated herein by reference to Exhibit&#160;10.11 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.12&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Consulting Agreement dated October&#160;17, 2016 by and between ProMIS Neurosciences&#160;Inc. and Danforth Advisors, LLC. (incorporated herein by reference to Exhibit&#160;10.12 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.12.1&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;1 dated March&#160;27, 2017 to Consulting Agreement dated October&#160;17, 2016 by and between ProMIS Neurosciences&#160;Inc. and Danforth Advisors, LLC. (incorporated herein by reference to Exhibit&#160;10.12.1 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.12.2&#8224;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;2 dated December&#160;12, 2017 to Consulting Agreement dated October&#160;17, 2016 by and between ProMIS Neurosciences&#160;Inc. and Danforth Advisors, LLC. (incorporated herein by reference to Exhibit&#160;10.12.2 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.12.3&#8224;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;3 dated August&#160;28, 2018 to Consulting Agreement dated October&#160;17, 2016 by and between ProMIS Neurosciences&#160;Inc. and Danforth Advisors, LLC. (incorporated herein by reference to Exhibit&#160;10.12.3 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.12.4&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-12d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No.&#160;4 dated March&#160;27, 2017 to Consulting Agreement dated October&#160;17, 2016 by and between ProMIS Neurosciences&#160;Inc. and Danforth Advisors, LLC. (incorporated herein by reference to Exhibit&#160;10.12.4 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.13</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Finder&#8217;s Warrant Certificate dated April&#160;30, 2018. (incorporated herein by reference to Exhibit&#160;10.13 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.14</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-US Warrant Certificate dated April&#160;30, 2018. (incorporated herein by reference to Exhibit&#160;10.14 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.15</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Employee Stock Option Commitment. (incorporated herein by reference to Exhibit&#160;10.15 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.16+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for Non-U.S. Subscribers dated February&#160;25, 2020. (incorporated herein by reference to Exhibit&#160;10.16 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.17+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for Non-U.S. Subscribers dated June&#160;17, 2019. (incorporated herein by reference to Exhibit&#160;10.17 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.18+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for U.S. Subscribers dated November&#160;27, 2018. (incorporated herein by reference to Exhibit&#160;10.18 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.19+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for U.S. Subscribers dated October&#160;21, 2019. (incorporated herein by reference to Exhibit&#160;10.19 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.20+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for U.S. Subscribers dated April&#160;13, 2018. (incorporated herein by reference to Exhibit&#160;10.20 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.21+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for Non-U.S. Subscribers dated April&#160;13, 2018. (incorporated herein by reference to Exhibit&#160;10.21 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.22+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for Non-U.S. Subscribers dated November&#160;27, 2018. (incorporated herein by reference to Exhibit&#160;10.22 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended). </span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.23+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Unit Subscription Agreement for Non-U.S. Subscribers dated October&#160;21, 2019. (incorporated herein by reference to Exhibit&#160;10.23 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.24+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Finder&#8217;s Warrant Certificate dated November&#160;2020. (incorporated herein by reference to Exhibit&#160;10.24 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.25+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-U.S. Finder&#8217;s Warrant Certificate dated January&#160;2019. (incorporated herein by reference to Exhibit&#160;10.25 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.26+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-U.S. Warrant Certificate dated January&#160;2019. (incorporated herein by reference to Exhibit&#160;10.26 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.27+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-U.S. Warrant Certificate dated June&#160;2019. (incorporated herein by reference to Exhibit&#160;10.27 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.28+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of U.S. Warrant Certificate dated January&#160;2019. (incorporated herein by reference to Exhibit&#160;10.28 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.29+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of U.S. Warrant Certificate dated November&#160;2020. (incorporated herein by reference to Exhibit&#160;10.29 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.30</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-30.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Special Warrant Certificate dated November&#160;4, 2020. (incorporated herein by reference to Exhibit&#160;10.30 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.31</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of U.S. Special Warrant Certificate dated November&#160;4, 2020. (incorporated herein by reference to Exhibit&#160;10.31 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.32+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Warrant Certificate dated November&#160;2020. (incorporated herein by reference to Exhibit&#160;10.32 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.33+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Technology License Agreement dated February&#160;1, 2006 by and between Dr.&#160;Neil Roy Cashman and Amorfix Life Sciences&#160;Ltd. (incorporated herein by reference to Exhibit&#160;10.33 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.34+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Service Agreement dated September&#160;1, 2020 by and between The University of Saskatchewan and ProMIS Neurosciences&#160;Inc. (incorporated herein by reference to Exhibit&#160;10.34 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="letter-spacing:0.2pt;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.35+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-35.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Assignment Agreement dated February&#160;18, 2005 by and between Neil R. Cashman and Marty Lehto and the Governing Council of the University of Toronto and Amorfix Life Sciences&#160;Ltd. (incorporated herein by reference to Exhibit&#160;10.35 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="letter-spacing:0.2pt;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.35.1</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-35d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment Agreement dated April&#160;1, 2005 to the Assignment Agreement dated February&#160;18, 2005 by and between Neil R. Cashman and Marty Lehto and the Governing Council of the University of Toronto and Amorfix Life Sciences&#160;Ltd. (incorporated herein by reference to Exhibit&#160;10.35.1 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="letter-spacing:0.2pt;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.37&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-37.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Executive Employment Agreement of Gavin Malenfant dated December&#160;31, 2021. (incorporated herein by reference to Exhibit&#160;10.37 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.38&#8224;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922113573/pmn-20220630xex10d38.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">ProMIS Neurosciences&#160;Inc. 2015 Stock Option Plan.</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.39&#8224;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-39.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amorfix Life Sciences&#160;Ltd. Deferred Share Unit Plan for Canadian Senior Officers. (incorporated herein by reference to Exhibit&#160;10.39 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.40</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-40.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-U.S. Finder&#8217;s Warrant Certificate dated November&#160;2019. (incorporated herein by reference to Exhibit&#160;10.40 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="letter-spacing:0.2pt;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.41</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-U.S. Warrant Certificate dated November&#160;2019. (incorporated herein by reference to Exhibit&#160;10.41 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.42</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of U.S. Warrant Certificate dated November&#160;2019. (incorporated herein by reference to Exhibit&#160;10.42 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.43</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-43.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-U.S. Warrant Certificate dated November&#160;2020. (incorporated herein by reference to Exhibit&#160;10.43 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.44</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-44.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Broker Warrant dated August&#160;2021. (incorporated herein by reference to Exhibit&#160;10.44 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.45</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-45.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Non-U.S. Warrant Certificate dated August&#160;2021. (incorporated herein by reference to Exhibit&#160;10.45 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.46</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922073200/tm229830d4_ex10-46.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of U.S. Warrant Certificate dated August&#160;2021. (incorporated herein by reference to Exhibit&#160;10.46 to ProMIS&#8217; Form&#160;10 Registration Statement filed June&#160;22, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.47*&#8224;+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20251231xex10d47.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">E</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">mployment agreement by and between ProMIS Neurosciences&#160;Inc. and Larry Altstiel. Effective March 1, 2025.</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.48</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/tm2225652d1_ex10-48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Strategic Services Agreement, dated September&#160;12, 2022, by and between ProMIS Neurosciences&#160;Inc. and Eugene Williams, effective September&#160;19, 2022. (incorporated herein by reference to Exhibit&#160;10.48 to ProMIS&#8217; Current Report on Form&#160;8-K filed September&#160;13, 2022).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="letter-spacing:0.2pt;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.50+</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922113573/pmn-20220630xex10d50.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Unit Purchase Agreement by and between ProMIS Neurosciences&#160;Inc. and various investors (incorporated herein by reference to Exhibit 10.50 to ProMIS&#8217; Registration Statement on Form S-1 filed on November 1, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.51</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922113573/pmn-20220630xex10d51.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Registration Rights Agreement by and between ProMIS Neurosciences&#160;Inc. and various investors (incorporated herein by reference to Exhibit 10.51 to ProMIS&#8217; Registration Statement on Form S-1 filed on November 1, 2022, as amended).</span></a></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#8203;</p></td></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">10.52&#8224;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="http://www.sec.gov/Archives/edgar/data/1374339/000110465922113573/pmn-20220630xex10d52.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Executive Employment Agreement of Neil Cashman dated January&#160;21, 2022, effective February&#160;1, 2022 (incorporated herein by reference to Exhibit 10.52 to ProMIS&#8217; Registration Statement on Form S-1 filed on November 1, 2022, as amended).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.53</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922109341/tm2228219d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Placement Agent Agreement, dated September 22, 2022, by and between ProMIS Neurosciences Inc. and Ceros Financial Services, Inc. (incorporated herein by reference to Exhibit 1.1 to ProMIS&#8217; Current Report on Form 8-K filed October 17, 2022).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.54</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922109341/tm2228219d1_ex1-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Amended and Restated Placement Agent Agreement, dated October 5, 2022 by and between ProMIS Neurosciences Inc. and Ceros Financial Services, Inc. (incorporated herein by reference to Exhibit 1.2 to ProMIS&#8217; Current Report on Form 8-K filed October 17, 2022).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.55</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465923094126/tm2324315d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Unit Purchase Agreement. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 22, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.56</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465923094126/tm2324315d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 22, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.57</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/pmn-20231204xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Share Exchange Agreement between the Company and holders of Series 1 Preferred Shares dated December 4, 2023. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2023).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.59<span style="letter-spacing:0.2pt;">&#8224;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837024013244/pmn-20241008xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement with Neil Warma, dated October 8, 2024. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 10, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.60</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837024013244/pmn-20241008xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 10, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.61</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837024010224/pmn-20240726xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Unit Purchase Agreement. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 26, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.62</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837024010224/pmn-20240726xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 26, 2024)</span></a>.</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.63</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025007255/pmn-20250331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No. 6 dated December 2, 2024 to the Collaborative Research Agreement by and between the University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the Securities Exchange Commission on May 12, 2025)</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.64</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837025004068/pmn-20241231xex10d47.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Employment agreement by and between ProMIS Neurosciences Inc. and Larry Altstiel. Effective March 1, 2025 (incorporated herein by reference to Exhibit 10.47 to ProMIS&#8217; Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.65</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025007255/pmn-20250331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Separation agreement by and between ProMIS Neurosciences Inc. and Gavin Malenfant. Effective February 14, 2025 (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the Securities Exchange Commission on May 12, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.66</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025008600/pmn-20250612xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">ProMIS Neuroscience Inc. 2025 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 13, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.67</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025009380/pmn-20250722xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 22, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.68</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025009636/pmn-20250728xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 28, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.69</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465925095032/pmn-20250926xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amended and Restated Employment Agreement with Neil Cashman (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 30, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.70</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000110465925109719/pmn-20250930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amended and Restated Employment Agreement with Johanne Kaplan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 12, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.71</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025009380/pmn-20250722xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 22, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.72</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000155837025009636/pmn-20250728xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 28, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.73</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000110465926008325/pmn-20260129xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 30, 2026).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.74</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001374339/000110465926008325/pmn-20260129xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 30, 2026).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.75*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="pmn-20251231xex10d75.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amendment No. 7 dated February 12, 2026 to the Collaborative Research Agreement by and between the University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s &amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc.</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">16.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000110465922083899/tm2221748d1_ex16-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Letter from PricewaterhouseCoopers LLP dated July 28, 2022 to the Securities and Exchange Commission regarding change in certifying accountant. (incorporated herein by reference to Exhibit 16.1 to ProMIS&#8217; Current Report on Form 8-K filed July 29, 2022).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">19.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837025004068/pmn-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Insider trading policy adopted March 27, 2025 (incorporated herein by reference to Exhibit 19.1 to ProMIS&#8217; Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">21.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20251231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of the Registrant</span></a> </p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="pmn-20251231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Baker Tilly US, LLP, independent registered public accounting firm</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20251231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Rule&#160;13a-15(e) or Rule&#160;15d-15(e)</span></a>&#160;</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20251231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Rule&#160;13a-15(e) or Rule&#160;15d-15(e)</span></a>&#160;</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">32*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="pmn-20251231xex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer and Chief Financial Officer of Periodic Report Pursuant to 18 U.S.C. Section&#160;1350 </span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">97.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1374339/000155837024004532/pmn-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ProMIS Neurosciences Inc. Clawback Policy. (incorporated herein by reference to Exhibit 97.1 to ProMIS&#8217; 10-K filed April 1, 2024).</span></a></p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.INS*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.SCH*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.CAL*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.DEF*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.LAB*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.PRE*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">104*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cover Page&#160;Interactive Data File (formatted as Inline XBRL and contained in Exhibit&#160;101*).</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.62%;"><tr style="height:18.25pt;"><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:2pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">&#8224;</span></p></td><td style="vertical-align:top;width:93.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:2pt 0pt 0pt 0pt;">Management Contract or compensatory plan or arrangement.</p></td></tr><tr style="height:16.85pt;"><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:2pt 0pt 0pt 0pt;">+</p></td><td style="vertical-align:top;width:93.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:2pt 0pt 0pt 0pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10) of Regulation S-K.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.62%;"><tr style="height:11.15pt;"><td style="vertical-align:top;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:2pt 0pt 0pt 0pt;">*</p></td><td style="vertical-align:top;width:93.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:2pt 0pt 0pt 0pt;">Filed herewith.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b79c8251_0864_40a2_afd1_23bb77e9d218"></a><a id="SIGNATURES_18917"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 25, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PROMIS NEUROSCIENCES&#160;INC.</p></td></tr><tr style=""><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Neil Warma</p></td></tr><tr style=""><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Neil Warma</p></td></tr><tr style=""><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 25, 2026 by the following persons on behalf of the registrant and in the capacities indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Signature</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:47.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Neil Warma</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer and Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Neil Warma</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Daniel Geffken</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer </p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Daniel Geffken</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Financial Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Max Milbury</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Vice President, Finance</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Max Milbury</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Accounting Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Eugene Williams</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Eugene Williams</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Neil Cashman</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Science Officer and Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Neil Cashman</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Patrick Kirwin</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Patrick Kirwin</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Joshua Mandel-Brehm</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Joshua Mandel-Brehm</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Maggie Shafmaster</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Maggie Shafmaster</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ William Wyman</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">William Wyman</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Slanix Paul Alex</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Slanix Paul Alex</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>pmn-20251231xex4d4.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:17 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:413.3pt;margin:0pt 0pt 12pt 59.05pt;"><b style="color:#131313;font-weight:bold;">Exhibit 4.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 59.05pt;"><b style="color:#131313;font-weight:bold;">DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="color:#131313;font-style:italic;">The following description of the capital stock of ProMIS Neurosciences Inc</i><i style="color:#494949;font-style:italic;">. </i><i style="color:#131313;font-style:italic;">(the &quot;Company&quot;) is intended as a summary only and therefore is not a complete description of the Company&#8217;s capital stock</i><i style="color:#494949;font-style:italic;">. </i><i style="color:#131313;font-style:italic;">This description is based upon, and is qualified by reference to, the Articles of the Company, as amended (the &quot;Articles&#39;&#39;), and its Bylaws, as amended (the &quot;Bylaws&quot;, together with the Articles, the </i><i style="color:#2f2f2f;font-style:italic;">&quot;Constating </i><i style="color:#131313;font-style:italic;">Documents&#39;&#39;), which are filed as exhibits to the Annual Report on Form 10-K, of which this Exhibit 4.4 is a part.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#131313;font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">The Company&#39;s authorized share capital consists of an unlimited number of common shares, no par value (the &quot;Common Shares&quot;), and an unlimited number of preferred shares, no par value, issuable in series (the &quot;Preferred Shares&quot;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#2f2f2f;font-weight:bold;">Common Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#2f2f2f;font-style:italic;">Voting </i><i style="color:#131313;font-style:italic;">R</i><i style="color:#2f2f2f;font-style:italic;">ight</i><i style="color:#494949;font-style:italic;">s</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">The holders of Common Shares shall be entitled to receive notice of all meetings of shareholders, and to attend, vote and speak at such meetings, except those meetings at which only holders of another specified class or series of shares of the Company are entitled to vote separately as a class or series. A quorum for a meeting of Shareholders shall be two shareholders, or two proxyholders representing shareholders, or any combination thereof, holding not less than thirty-three and one-third percent (33 1/3%) of the issued shares entitled to be voted at the meeting. On all matters upon which holders of shares are entitled to vote, each Common Share is entitled to one vote per Common Share. Unless a different majority is required by law or the Constating Documents, resolutions to be approved by holders of shares require approval by a simple majority of the total number of votes of all shares cast at a meeting of Shareholders at which a quorum is present.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#2f2f2f;font-style:italic;">Dividend Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">There are no restrictions in the Company&#39;s Articles or elsewhere, which would prevent the Company from paying dividends. No dividends have been declared or paid on the Common Shares of the Company in the last five fiscal years</font><font style="color:#494949;">, </font><font style="color:#131313;">and it is not expected that dividends will be declared or paid in the immediate or foreseeable future. Consequently, to date there have been no distributions made by the Company. The policy of the Board of Directors of the Company (the </font><font style="color:#2f2f2f;">&quot;Board&quot;) </font><font style="color:#131313;">is to reinvest all available funds in operations. The Board will reassess this policy from time to time. Any decision to pay dividends on the Common Shares of the Company will be made by the Board based on the assessment of, among other factors, earnings, capital requirements and the operating and financial condition of the Company, subject to any rights of the holders of Preferred Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#2f2f2f;font-style:italic;">Liquidation Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">In the event of the liquidation, dissolution or winding-up of the Company or any other distribution of the Company&#39;s assets for the purpose of winding up the Company&#39;s affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled </font><i style="color:#131313;font-style:italic;">pari passu </i><font style="color:#131313;">to receive any remaining property of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#2f2f2f;font-style:italic;">Preemptive, Redemption and Other Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">Holders of Common Shares do not have any preemptive, conversion, sinking fund or redemption rights. The rights, preferences and privileges of the holders of the Company&#39;s Common Shares are subject to, and may be adversely affected by, the rights of the holders of shares of any series of the Company&#39;s Preferred Shares that currently exist or that we may designate and issue in the future.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#2f2f2f;font-weight:bold;">Preferred Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#111111;">The Preferred Shares of the Company may be issued in one or more series and the directors are authorized to fix the number of Preferred Shares in each series and to determine the designation, rights, privileges, restrictions and conditions attached to the Preferred Shares of each series. The special rights or restrictions which the directors may create, define or attach to any series of Preferred Shares may allow the directors to declare dividends with respect to </font><font style="color:#131313;">the Common Shares only or with respect to any series of Preferred Shares only or with respect to any combination of two or more such classes or series of classes. Where Preferred Shares or one or more series of Preferred Shares are entitled to cumulative dividends, and where cumulative dividends in respect of the Preferred Shares or a series of Preferred Shares are not paid in full, the shares of all series of Preferred Shares entitled to cumulative dividends shall participate ratably in respect of accumulated dividends in accordance with the amounts that would be payable on those shares if all the accumulated dividends were pain in full.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">The Company does not currently have any outstanding Preferred Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#131313;font-weight:bold;">Registration Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">Certain of the Company&#39;s holders are entitled to piggyback registration rights provided under the terms of a registration rights agreement between the Company and certain holders of the Company&#39;s Common Shares, entered into in connection with PIPE Offerings to effect the filing of resale Registration Statements. We are not required to register any securities pursuant to such registration rights agreement if such shares are eligible for resale pursuant to Rule 144 or that are the subject of a then-effective registration statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#131313;font-weight:bold;">Anti-Takeover effects of the Company&#39;s Constating Documents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">Provisions of the Company&#39;s Constating Documents and the Business Corporations Act (Ontario) (the &quot;OBCA&quot;) may discourage, delay or prevent a merger or acquisition that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium for their Common Shares, and may also frustrate or prevent any attempt by shareholders to change the direction or management. For example, these provisions:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#131313;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require a 66 2/3% majority of shareholder votes cast in favor of a resolution to effect various amendments to the articles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#131313;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that in the event of shareholders of the Company vote via written resolution, that such resolution must be signed by all shareholders of the Company entitled to vote on that resolution;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#131313;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to the Board at any annual or special meeting of shareholders of the Company; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#131313;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any transaction in which a third party seeks to acquire the Company&#39;s voting securities or equity securities that would result in the acquiror holding greater than 20% of the securities of that class may be governed by NI 62-104 promulgated by the Canadian Securities Administrators (&quot;CSA&quot;), as more fully described below.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#131313;font-weight:bold;">Advance Notice Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">Under our advance notice provisions in our Bylaws, a shareholder wishing to nominate a director would be required to provide the Company with notice, in a prescribed form and within prescribed time periods. These time periods include, (1) in the case of an annual meeting of shareholders (including annual and special meetings), not less than 30 days prior to the date of the annual meeting of shareholders; provided that if the first public announcement of the date of the annual meeting of shareholders, which we refer to as the notice date, is less than 40 days before the meeting date, not later than the close of business on the 10th day following the notice date, and (2) in the case of a special meeting (which is not also an annual meeting) of shareholders called for any purpose which includes electing directors, not later than the close of business on the 15th day following the notice date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#131313;font-weight:bold;">Takeover Bid Provisions of Canadian Securities Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">All provinces of Canada have adopted NI 62-104 and related forms to harmonize and consolidate take-over bid and issuer bid regimes nationally. The CSA have also issued National Policy 62-203 entitled &#8220;Take-Over Bids and Issuer Bids&#8221; (the &#8220;National Policy&#8221;) which contains regulatory guidance on the interpretation and application of NI 62-104 and on the conduct of parties involved in a bid. The National Policy and NI 62-104 are collectively referred to as the &#8220;Bid Regime.&#8221; The National Policy does not have the force of law, but is an indication by the CSA of what the intentions and desires of the regulators are in the areas covered by their policies.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">A &#8220;take-over bid&#8221; or &#8220;bid&#8221; is an offer to acquire outstanding voting or equity securities of a class made to any person who is in one of the provinces of Canada or to any securityholder of an offeree issuer whose last address as shown on the books of a target is in such province, where the securities subject to the offer to acquire, together with the securities &#8220;beneficially owned&#8221; by the offeror, or any other person acting jointly or in concert with the offeror, constitute in the aggregate 20% or more of the outstanding securities of that class of securities at the date of the offer to acquire. For the purposes of the Bid Regime, a security is deemed to be &#8220;beneficially owned&#8221; by an offeror as of a specific date if the offeror is the beneficial owner of a security convertible into the security within 60&#160;days following that date, or has a right or obligation permitting or requiring the offeror, whether or not on conditions, to acquire beneficial ownership of the security within 60&#160;days by a single transaction or a series of linked transactions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">Offerors are also subject to early warning requirements, where an offeror who acquires &#8220;beneficial ownership of&#8221;, or control or direction over, voting or equity securities of any class of a reporting issuer or securities convertible into, voting or equity securities of any class of a target that, together with the offeror&#8217;s securities, would constitute 10% or more of the outstanding securities of that class must promptly publicly issue and file a news release containing certain prescribed information, and, within two business&#160;days, file an early warning report containing substantially the same information as is contained in the news release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">In addition, where an offeror is required to file an early warning report or a further report as described and the offeror acquires or disposes of beneficial ownership of, or the power to exercise control or direction over, an additional 2% or more of the outstanding securities of the class, or disposes of beneficial ownership of outstanding securities of the class below 10%, the offeror must issue an additional press release and file a new early warning report. Any change in material fact in a previously filed early warning report also triggers the issuance and filing of a new press release and early warning report. During the period commencing on the occurrence of an event in respect of which an early warning report is required and terminating on the expiry of one business day from the date that the early warning report is filed, the offeror may not acquire or offer to acquire beneficial ownership of any securities of the class in respect of which the early warning report was required to be filed or any securities convertible into securities of that class. This requirement does not apply to an offeror that has beneficial ownership of, or control or direction over, securities that comprise 20% of more of the outstanding securities of the class.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">Related party transactions, issuer bids and insider bids are subject to additional regulation that may differ depending on the particular jurisdiction of Canada in which it occurs. For additional information on Shareholder Nominations and Proposals, Amendments to Constating Documents, Votes on Mergers, Consolidations and Sales of Assets, Transactions with Directors and Officers and other provisions, please see the section below entitled &#8220;</font><i style="color:#131313;font-style:italic;">Comparison of Canadian and Delaware Law</i><font style="color:#131313;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#131313;font-weight:bold;">Comparison of Canadian Law and Delaware Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#131313;">There are significant differences between the OBCA and the Delaware General Corporate Law (the &quot;DGCL&quot;) which governs companies incorporated in the State of Delaware, including:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:-0.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:18pt;"><td style="vertical-align:middle;width:50.95%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="color:#131313;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.04%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="color:#131313;font-weight:bold;">Canada</b></p></td></tr><tr style="height:18pt;"><td style="vertical-align:middle;width:50.95%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#131313;font-style:italic;font-weight:bold;">Capital Structure</font></p></td><td style="vertical-align:middle;width:49.04%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:35.7pt;"><td style="vertical-align:top;width:50.95%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">Under the DGCL, the certificate of incorporation must set forth the total number of shares of stock which the corporation shall have authority to issue and the par value of each of such shares, or a statement that the shares are to be without par value.</p></td><td style="vertical-align:top;width:49.04%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">Under the OBCA, the articles of incorporation may but are not required to set forth the maximum number of shares that the corporation is authorized to issue.</p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.95%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Dividends</font></p></td><td style="vertical-align:top;width:49.04%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:167.95pt;"><td style="vertical-align:top;width:50.95%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">The DGCL generally provides that, subject to certain restrictions, the directors of a corporation may declare and pay dividends upon the shares of its capital stock either out of the corporation&#39;s surplus or, if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Further, the holders of preferred or special stock of any class or series may be entitled to receive dividends at such rates, on such conditions and at such times as stated in the certificate of incorporation.</font></p></td><td style="vertical-align:top;width:49.04%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, dividends may be declared on the common shares at the discretion of the board of directors. Any dividends declared shall be subject to the rights, if any, of shareholders holding shares with special rights as to dividends.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Dividends may not be declared if there are reasonable grounds for believing that the corporation is, or would after the payment be, unable to pay its liabilities as they become due or the realizable value of the corporation&#39;s assets would thereby be less than the aggregate of its liabilities and stated capital of all classes.</font></p></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.95%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Number and Election of Directors</font></p></td><td style="vertical-align:middle;width:49.04%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:372.2pt;"><td style="vertical-align:top;width:50.95%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, the board of directors must consist of at least one person, and the number of directors is generally fixed by, or in the manner provided in, the by&#173; </font><font style="color:#111111;">laws of the corporation, unless the certificate of incorporation fixes the number of directors, in which case a change in the number of directors shall be made only by amendment of the certificate. The board of directors may be divided into three classes of directors, with one-third of each class subject to election by the stockholder each year after such classification becomes effective.</font></p></td><td style="vertical-align:top;width:49.04%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, an offering corporation shall have no fewer than three individuals on the board of directors and at least one third shall not be officers or employees of the corporation or its affiliates. The articles of incorporation will commonly set out the number of initial directors and, if applicable, the minimum and maximum number of directors of the corporation. The shareholders may amend the articles to increase or decrease the number of directors or the minimum or maximum number of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">In the case of an offering corporation, shareholders may by ordinary resolution elect directors to hold office for a term ending not later than the close of the third annual meeting of shareholders following the election. A director that is not elected for an expressly stated term shall cease to hold office at the close of the first annual meeting of shareholders following his or her election.</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Canada</b></p></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Removal of Directors</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:107.8pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, any or all directors may be removed with or without cause by the holders of a majority of shares entitled to vote at an election of directors unless the certificate of incorporation otherwise provides or in certain other circumstances if the corporation has cumulative voting.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, the shareholders of a corporation may by ordinary resolution remove any director or directors from office</font><font style="color:#3b3b3b;">. </font><font style="color:#111111;">If the holders of any class or series of shares of </font><font style="color:#282828;">a </font><font style="color:#111111;">corporation have an exclusive right to elect one or more directors, a director so elected may only be removed by </font><font style="color:#282828;">an </font><font style="color:#111111;">ordinary resolution at a meeting of the shareholders of that class or series.</font></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Vacancies on the Board of Directors</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:180.05pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under &#160;the &#160;DGCL, &#160;vacancies &#160;and &#160;newly &#160;created directorships resulting from an increase in the authorized number of directors, may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, vacancies on the board may be filled by a quorum of directors, except a vacancy resulting from an increase in the number of directors (otherwise than in accordance with the provisions under the OBCA on the appointment of directors subsequent to an annual meeting) or the maximum number of directors or a failure to elect the number directors required to be elected at any meeting of shareholders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">If there is not a quorum of directors or if there has been a failure to elect the number of directors required by the articles or by the OBCA, the directors then in office shall forthwith call a special meeting of shareholders to fill the vacancy and, if they fail to call a meeting or if there are no directors then in office, the meeting may be called by any shareholder.</font></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Qualifications of Directors</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:83.8pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, directors are not required to be residents of Delaware or the United States. The certificate of incorporation or by-laws may prescribe other qualifications for directors.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, there is no residency requirement for directors. The articles of incorporation may prescribe other qualifications for directors.</font></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Board of Director Quorum and Vote Requirements</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:168.05pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, a majority of the total number of directors shall constitute a quorum for the transaction of business unless the certificate or by-laws require a greater number. The by-laws may lower the number required for a quorum to one-third the number of directors, but no less.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, subject to the articles or by-laws, a majority of the number of directors or minimum number of directors required by the articles constitutes a quorum at any meeting of directors. Where a corporation has fewer than three directors, all directors must be present at any meeting of directors to constitute a quorum. Subject to the articles or by-laws, where there is at least one vacancy in the board of directors, the remaining directors may exercise all the powers of the board so long as a quorum of the board remains in office.</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Canada</b></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Transactions with Directors and Officers</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:312.05pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">The DGCL generally provides that no transaction between a corporation and one or more of its directors or officers, or between a corporation and any other corporation or other organization in which one or more of its directors or officers, are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee which authorizes the transaction, or solely because any such director&#39;s or officer&#39;s votes are counted for such purpose, if (i) the material facts as to the director&#39;s or officer&#39;s interest and as to the transaction are known to the board of directors or the committee, and the board or committee in good faith authorizes the transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum (ii) the material facts as to the director&#39;s or officer&#39;s interest and as to the transaction are disclosed or are known to the stockholders entitled to vote thereon, and the transaction is specifically approved in good faith by vote of the stockholders; or (iii) the transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the board of directors, a committee or the stockholders.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, a director or an officer of a corporation who (i) is a party to a material contract or transaction or proposed material contract or transaction with the corporation; or (ii) is a director or an officer of, or has a material interest in, any person who is a party to a material contract or transaction or proposed material contract or transaction with the corporation, shall disclose in writing to the corporation or request to have entered in the minutes of meetings of directors the nature and extent of his or her interest.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Directors with a conflict of interest shall not attend any part of a meeting of directors during which that particular contract or transaction is discussed and shall not vote on any resolution to approve the contract or transaction unless the contract or transaction is one relating primarily to his or her remuneration as a director of the corporation or an affiliate, one for indemnity or insurance under the OBCA or one with an affiliate.</font></p></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Limitation on Liability of Directors and Officers</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:240.05pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">The DGCL permits a corporation to include a provision in its certificate of incorporation eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for a breach of the director&#39;s or officer&#8217;s fiduciary duty as a director or officer, except for liability:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 12pt 7.2pt;"><font style="display:inline-block;min-width:18.15pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">for breach of the director&#39;s or officer&#8217;s duty of loyalty to the corporation or its stockholders;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 12pt 7.2pt;"><font style="display:inline-block;min-width:18.15pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 12pt 7.2pt;"><font style="display:inline-block;min-width:18.25pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">for directors, under Section 174 of the DGCL, which concerns unlawful payment of dividends, </font><font style="color:#343434;">stock </font><font style="color:#111111;">purchases or redemptions; or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 0pt 7.2pt;"><font style="display:inline-block;min-width:18.2pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">for any transaction from which the director or officer derived an improper personal benefit.</font></div><div style="margin-top:12pt;"></div></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">No provision in a contract, the articles, the by-laws or a resolution may relieve a director or officer from the duty to act in accordance with the OBCA or the regulations or relieve him or her from liability for a breach thereof.</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Canada</b></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Indemnification of Directors and Officers</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:368.9pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, a corporation may indemnify any person who is made a party to any third-party action, suit or proceeding on account of being a director, officer, employee or agent of the corporation (or was serving at the request of the corporation in such capacity for another corporation, partnership, joint venture, trust or other enterprise) against expenses, including attorney&#39;s fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with the action, suit or proceeding through, among other things, a majority vote of a quorum consisting of directors who were not parties to the suit or proceeding, if the person:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 12pt 7.2pt;"><font style="display:inline-block;min-width:18.25pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">acted in good faith and in a manner he or she reasonably believed to be;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 12pt 7.2pt;"><font style="display:inline-block;min-width:18.25pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">in or not opposed to the best interests of the corporation;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 12pt 7.2pt;"><font style="display:inline-block;min-width:18.25pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">or, in some circumstances, at least not opposed to its best interests; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 7.2pt 0pt 7.2pt;"><font style="display:inline-block;min-width:18.3pt;white-space:nowrap;">&#9679;</font><font style="color:#111111;">in a criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">The DGCL permits indemnification for derivative suits against expenses (including legal fees) if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and only if the person is not found liable, unless a court determines the person is fairly and reasonably entitled to the indemnification.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">Under the OBCA, a corporation may indemnify a director or officer of the corporation, a former director or officer of the corporation or another individual who acts or acted at the corporation&#8217;s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the corporation or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">A corporation shall not indemnify an individual unless the individual (i) acted honestly and in good faith with a view to the best interests of the corporation (or, as the case may be, to the best interests of the other entity for which the individual acted as a director or officer or in a similar capacity at the corporation&#8217;s request); and (ii) in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds for believing that the individual&#8217;s conduct was lawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">An individual is entitled to indemnification if he or she fulfills the conditions above and was not judged by the court or other competent authority to have committed any fault or omitted to do anything that the individual ought to have done.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">The OBCA also permits indemnification for derivative suits with the approval of the court.</p></td></tr><tr style="height:17.95pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Call and Notice of Stockholder Meetings</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:143.8pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, an annual or special stockholder meeting is held on such date, at such time and at such place as may be designated by the board of directors or any other person authorized to call such meeting under the corporation&#39;s certificate of incorporation or by-laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">If an annual meeting for election of directors is not held on the date designated or an action by written consent to elect directors in lieu of an annual meeting has not been taken within 30 days after the date </font><font style="color:#131313;">designated for the annual meeting, or if no date has been designated, for a period of 13 months after the later of the last annual meeting or the last action by written consent to elect directors in lieu of an annual meeting, the Delaware Court of Chancery may summarily order a meeting to be held upon the application of any stockholder or director.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the by-laws.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, the directors are required to call an annual meeting of shareholders not later than 18 months after the corporation comes into existence, and subsequently, not later than 15 months after holding the last preceding annual meeting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Subject to the articles and any unanimous shareholder agreement, a meeting of shareholders shall be held at such place in or outside Ontario as the directors determine or, in the absence of such a determination, at the place where the registered office of the corporation is located. A meeting held by telephone or electronic means shall be deemed to be held at the place where the registered office of the corporation is located.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">The directors may at any time call a special meeting of the shareholders. The holders of not less than five per cent of the issued shares of a corporation that carry the right to vote at a meeting may requisition the directors to call a meeting of shareholders for the purposes stated in the requisition.</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#131313;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#131313;font-weight:bold;">Canada</b></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#131313;font-style:italic;font-weight:bold;">Stockholder Action by Written Consent</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:59.8pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Under the DGCL, a majority of the stockholders of a corporation may act by written consent without a meeting unless such action is prohibited by the corporation&#39;s certificate of incorporation.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Under the OBCA, shareholders may act by written resolution signed by all the shareholders entitled to vote on that resolution at a meeting of shareholders.</font></p></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#131313;font-style:italic;font-weight:bold;">Stockholder Nominations and Proposals</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:215.95pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Under the DGCL, the by-laws of a corporation may include provisions respecting the nomination of directors or proposals by stockholders, including requirements for advance notice to the corporation.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Under the OBCA, a registered holder or beneficial owner of shares that are entitled to be voted at a meeting of shareholders may submit to the corporation notice of any matter that the person proposes to raise at the meeting (a &#8220;proposal&#8221;) and discuss at the meeting any matter in respect of which the registered holder or beneficial owner would have been entitled to submit a proposal. &#160;However, the by-laws of a corporation may include requirements for advance notice to the corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">A proposal may include nominations for the election of directors if the proposal is signed by one or more holders of shares representing in the aggregate not less than five per cent of the shares or five per cent of the shares of a class or series of shares of the corporation entitled to vote at the meeting to which the proposal is to be presented. This does not preclude nominations made at a meeting of shareholders.</font></p></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#131313;font-style:italic;font-weight:bold;">Stockholder Quorum and Vote Requirements</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:131.8pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Under the DGCL, quorum for a stock corporation is a majority of the shares entitled to vote at the meeting unless the certificate of incorporation or bylaws specify a different quorum, but in no event may a quorum be less than one-third of the shares entitled to vote. Unless the DGCL, certificate of incorporation or by-laws provide for a greater vote, generally the required vote under the DGCL is a majority of the shares present in person or represented by proxy, except for the election of directors which requires a </font><font style="color:#111111;">plurality of the votes cast.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Unless the by-laws otherwise provide, under the OBCA, the holders of a majority of the shares entitled to vote at the meeting, present in person or represented by proxy, constitute a quorum for a meeting of shareholders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#131313;">Unless the OBCA, articles of incorporation or a unanimous shareholder agreement provide for a greater number of votes, generally the required votes under the OBCA is a majority of the votes cast by the shareholders who voted in respect of that resolution.</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Canada</b></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Amendment of Governing Instrument</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:413.9pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><i style="color:#111111;font-style:italic;">Amendment of Certificate of Incorporation. </i><font style="color:#111111;">Generally, under the DGCL, the affirmative vote of the holders of a majority of the outstanding stock entitled to vote is required to approve a proposed amendment to the certificate of incorporation, following the adoption of the amendment by the board of directors of the corporation, provided that the certificate of incorporation may provide for a greater vote. Under the DGCL, holders of outstanding shares of a class or series are entitled to vote separately on an amendment to the certificate of incorporation if the amendment would have certain consequences, including changes that adversely affect the rights and preferences of such class or series.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><i style="color:#111111;font-style:italic;">Amendment of By-laws.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><font style="color:#111111;">Under the DGCL, after a corporation has received any payment for any of its stock, the power to adopt, amend or repeal by-laws shall be vested in the stockholders entitled to vote; provided, however, that any corporation may, in its certificate of incorporation, provide that by&#173; </font><font style="color:#111111;">laws may be adopted, amended or repealed by the board of directors. The fact that such power has been conferred upon the board of directors shall not divest the stockholders of the power nor limit their power to adopt, amend or repeal the by-laws.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><i style="color:#111111;font-style:italic;">Amendment to Articles of Incorporation.</i><font style="color:#111111;"> Under the OBCA, a corporation may amend its articles to add, change, or remove any provision permitted by the OBCA to be, or that is, set out in its articles. A registered holder or a beneficial owner of shares that are entitled to be voted at an annual meeting of shareholders may also make a proposal to amend the articles.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><font style="color:#111111;">Generally, under the OBCA, an amendment to the articles requires approval by special resolution of the shareholders. A special resolution is a resolution passed by not less than two-thirds of the votes cast by the shareholders who voted in respect of the resolution or signed by all shareholders entitled to vote on that resolution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><font style="color:#111111;">The holders of the shares of a class or a series (if such series is affected by an amendment in a manner different from other shares of the same class) are entitled to vote separately as a class or series on an amendment to the articles if such amendment would have certain consequences in respect of that such class or series, including increasing or decreasing the number of shares of such class, creating a new class or series equal or superior to such class or series or changing the rights, privileges, restrictions or conditions attached to such class or series.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><i style="color:#111111;font-style:italic;">Amendment to By-Laws.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 10pt 7.2pt;"><font style="color:#111111;">Under the OBCA, a registered holder or a beneficial owner of shares that are entitled to be voted at a meeting of shareholders may make a proposal to make, amend or repeal a by-law. Unless the articles, by-laws or a unanimous shareholder agreement otherwise provide, the directors may, by resolution, make, amend or repeal any by-laws that regulate the business or affairs of the corporation. The directors shall then submit such by-law, or amendment or repeal of such by-law, to the shareholders at the next meeting of shareholders, and the shareholders may, by ordinary resolution, confirm, reject or amend the by-law, amendment or repeal.</font></p></td></tr><tr style="height:16.1pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Votes on Mergers, Consolidations and Sales ofAssets</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:83.8pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">The DGCL provides that, unless otherwise provided in the certificate of incorporation or by-laws, the adoption of a merger agreement requires the approval of a majority of the outstanding stock of the corporation </font><font style="color:#262626;">entitled </font><font style="color:#111111;">to vote thereon.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, the adoption of an amalgamation agreement requires approval by special resolution of the shareholders of each amalgamating corporation by special resolution of the holders of the shares of each class or series entitled to vote thereon. A special resolution is a resolution passed by not less than two-thirds of the votes cast by the shareholders who voted in respect of the resolution or signed by all shareholders entitled to vote on that resolution.</font></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Dissenter&#39;s Rights of Appraisal</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;">Under &#160;the &#160;DGCL, a stockholder &#160;of &#160;a &#160;Delaware corporation generally has the right to dissent from and request payment for the stockholders shares upon a merger or consolidation in which the Delaware corporation is participating, subject to specified procedural requirements, including that such dissenting stockholder does not vote in favor of the merger or </font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">Under the OBCA, a shareholder may dissent from a transaction and obtain a right of appraisal when the corporation resolves to:</p><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend its articles to add, change or remove any provisions restricting or constraining the issue, transfer or ownership of shares of that</font></div><div style="width:7.2pt;display:table-cell;"></div></div></div><div style="margin-top:12pt;"></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:59.8pt;"><td style="vertical-align:top;width:50.93%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">consolidation.However, the DGCL does not confer appraisal rights, in certain circumstances, including if the dissenting stockholder owns shares traded on a national </font><font style="color:#262626;">securities </font><font style="color:#111111;">exchange and will receive publicly traded shares in the merger or consolidation. Under the DGCL, a stockholder asserting appraisal rights does not receive any payment for his or her shares until the court determines the fair value or the parties otherwise agree to a value. The costs of the proceeding may be determined by the court and assessed against the parties as the court deems equitable under the circumstances.</font></p></td><td style="vertical-align:top;width:49.06%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 36pt;">class;</p><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend its articles to add, change or remove any restriction on the business or businesses that the corporation may carry on or upon the powers that the corporation may exercise;</font></div><div style="width:7.2pt;display:table-cell;"></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amalgamate with another corporation;</font></div><div style="width:7.2pt;display:table-cell;"></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be continued under the laws of another jurisdiction, the </font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Co-operative Corporations Act</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or the </font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Not-for-Profit Corporations Act, 2010</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; or</font></div><div style="width:7.2pt;display:table-cell;"></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e)</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, lease or exchange all or substantially all its property.</font></div><div style="width:7.2pt;display:table-cell;"></div></div></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">Further, the holders of a class or series of shares entitled to vote as a separate class on an amendment to the articles of incorporation may dissent from such amendment (with certain exceptions, including where the amendments involve certain changes to such class or series where the articles provide that the holders of shares of such class or series are not entitled to dissent). This right to dissent applies even if there is only one class of shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">A shareholder asserting dissent rights is entitled, subject to specified procedural requirements, including sending a written objection to the resolution and providing sufficient notice, when the action approved by the resolution from which the shareholder dissents becomes effective, to be paid by the corporation the fair value of the shares in respect of which the shareholder dissents, determined as of the close of business on the day before the resolution was adopted. A corporation shall not make a payment to a dissenting shareholder if there are reasonable grounds for believing that, (i) the corporation is or, after the payment, would be unable to pay its liabilities as they become due; or (ii) the realizable value of the corporation&#8217;s assets would thereby be less than the aggregate of its liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;">Where a corporation fails to make a written offer of payment or a notification that it is unable to lawfully offer payment to the dissenting shareholder, or the dissenting shareholder fails to accept an offer, the corporation or the dissenting shareholder, as the case may be, may apply to a court to fix a fair value for the shares. The court may in its discretion allow a reasonable rate of interest on the amount payable to each dissenting shareholder from the date the action approved by the resolution is effective until the date of payment. </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:-0.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.93%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.06%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Canada</b></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.93%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Anti-Takeover and Ownership Provisions</font></p></td><td style="vertical-align:middle;width:49.06%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:155.95pt;"><td style="vertical-align:top;width:50.93%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Unless an issuer opts out of the provisions of Section 203 of the DGCL, Section 203 generally prohibits a public Delaware corporation from engaging in a &quot;business combination&quot; with a holder of 15% or more of the corporation&#39;s voting stock (as defined in Section 203), referred to as an interested stockholder, for a period of three years after the date of the transaction in which the interested stockholder became an interested stockholder</font><font style="color:#484848;">, </font><font style="color:#111111;">except as otherwise provided in Section 203. For these purposes, the term &quot;business combination&quot; includes mergers, asset sales and other similar transactions with an interested stockholder.</font></p></td><td style="vertical-align:top;width:49.06%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">The OBCA contains no restriction on adoption of a shareholder rights plan. The OBCA does not restrict related party transactions; however, in Ontario, takeover bids and related party transactions are addressed in through the provincial securities legislation and policies.</font></p></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.93%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Inspection of Books and Records</font></p></td><td style="vertical-align:middle;width:49.06%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:59.8pt;"><td style="vertical-align:top;width:50.93%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, any holder of record of stock or a person who is the beneficial owner of shares of such stock held either in a voting trust or by a nominee on behalf of such person may, upon written demand, inspect the corporation&#8217;s books and records during business hours for a proper purpose and may make copies and extracts therefrom.</font></p></td><td style="vertical-align:top;width:49.06%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, registered holders of shares, beneficial owners and creditors of a corporation, their agents and legal representatives may examine the records of the corporation, other than a register of individuals with significant control over the corporation, during the usual business hours of the corporation, and may take extracts from those records, free of charge, and, if the corporation is a offering corporation, any other person may do so upon payment of a reasonable fee.</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:17.8pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Delaware</b></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><b style="color:#111111;font-weight:bold;">Canada</b></p></td></tr><tr style="height:17.7pt;"><td style="vertical-align:middle;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;"><font style="color:#111111;font-style:italic;font-weight:bold;">Derivative Actions</font></p></td><td style="vertical-align:middle;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:420.3pt;"><td style="vertical-align:top;width:50.94%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the DGCL, a stockholder may bring a derivative action on behalf of a corporation to enforce the corporation&#39;s rights if he or she was a stockholder at the time of the transaction which is the subject of the action</font><font style="color:#3d3d3d;">. </font><font style="color:#111111;">Additionally, under Delaware case law, a stockholder must have owned stock in the corporation continuously until and throughout the litigation to maintain a derivative action. Delaware law also requires that, before commencing a derivative action, a stockholder must make a demand on the directors of the corporation to assert the claim, unless such demand would be futile. A stockholder also may commence a class action suit on behalf of himself or herself and other similarly situated stockholders where the requirements for maintaining a class action have been met.</font></p></td><td style="vertical-align:top;width:49.05%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">Under the OBCA, a &#8220;complainant&#8221;, which includes a current or former registered holder or beneficial owner of a security of a corporation or any of its affiliates, a current or former director or officer of a corporation or any of its affiliates and any other person who, in the discretion of the court, is a proper person to do so, may make an application to the court to bring an action in the name and on behalf of a corporation or any of its subsidiaries, or intervene in an action to which any such body corporate is a party, for the purpose of prosecuting, defending or discontinuing the action on behalf of the body corporate (a &#8220;derivative action&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">No derivative action may be brought unless the complainant has given fourteen days&#8217; notice to the directors of the corporation or its subsidiary of the complainant&#8217;s intention to apply to the court to bring a derivative action and the court is satisfied that (i) the directors of the corporation or its subsidiary will not bring, diligently prosecute or defend or discontinue the action; (ii) the complainant is acting in good faith; and (iii) it appears to be in the interests of the corporation or its subsidiary that the action be brought, prosecuted, defended or discontinued.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 12pt 7.2pt;"><font style="color:#111111;">In connection with a derivative action, the court may make any order it thinks fit, including an order requiring the corporation or its subsidiary to pay reasonable legal fees and any other costs reasonably incurred by the complainant in connection with the action</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#0f0f0f;font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#0f0f0f;">The transfer agent and registrar for the Company&#39;s common shares is Computershare Trust Company of Canada and Computershare Trust Company, N.A. The transfer agent and registrar&#39;s address in the United States is 150 Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) 962-4284.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#0f0f0f;font-weight:bold;">The Nasdaq Capital Market</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#0f0f0f;">The Company&#39;s Common Shares are listed on Nasdaq under the symbol &quot;PMN.&quot;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>3
<FILENAME>pmn-20251231xex10d47.htm
<DESCRIPTION>EX-10.47
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="pmn-20251231xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:131.98pt;"></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><b style="font-weight:bold;">Exhibit 10.47</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ProMIS Neurosciences (US) Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Larry Alstiel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#0c0c0c;">31 Water Street,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#0c0c0c;">Stonington CT, 06378</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">BY EMAIL</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">March 1, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employment Offer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Dear Larry:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On behalf of ProMIS Neurosciences (US), Inc. (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), I am pleased to offer you employment as Chief Medical Officer (&#8220;<b style="font-weight:bold;">CMO</b>&#8221;). The new terms of your employment are set forth below in this Employment Offer (the &#8220;<b style="font-weight:bold;">Employment Agreement</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><b style="font-weight:bold;">Position. </b>Effective as of March 1, 2025 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), you will serve as the Company&#8217;s CMO and you will report to the Company&#8217;s Chief Executive Officer (&#8220;<b style="font-weight:bold;">CEO</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><b style="font-weight:bold;">Salary. </b>The Company will pay you a base salary at the rate of $35,416.67 per month ($425,000 when annualized), payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings, which shall be retroactive to the Effective Date. Your base salary will be subject to periodic review and adjustments at the Company&#8217;s discretion. The base salary at any given time shall be referred to as the &#8220;Base Salary.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><b style="font-weight:bold;">Annual Bonus. </b>You will be eligible to receive an annual performance bonus targeted at 20% of the Base Salary, as determined by the CEO and Board in their sole discretion. The actual bonus is discretionary and will be subject to the CEO and Board&#8217;s assessment of your performance as well as business conditions at the Company. In order to receive the bonus payment, you must be employed by the Company on the date such bonus is paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><b style="font-weight:bold;">Equity</b>. You were previously granted stock options, which shall remain subject to the ProMIS Neurosciences Inc. Stock Option Plan (the &#8220;<b style="font-weight:bold;">Option Plan</b>&#8221;) and stock option agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><b style="font-weight:bold;">Benefits. </b>You will be eligible to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. Details of such benefits programs, including mandatory employee contributions, if any, and waiting periods, if applicable, will be made available to you when such benefit(s) become available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><b style="font-weight:bold;">At-Will Employment; Accrued Obligations. </b>Your employment will be &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the forgoing and except for termination in the event of your death, any termination of your employment by the Company or by you shall be communicated by written Notice of Termination to the other party hereto. In the event of your resignation without Good</p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1px solid #000000;margin:0pt;">One<font style="letter-spacing:-0.45pt;"> </font>Broadway,<font style="letter-spacing:-0.4pt;"> </font>Cambridge,<font style="letter-spacing:-0.4pt;"> </font>MA,<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">02142</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="pmn-20251231xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:131.98pt;"></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reason, you agree to provide the Company with at least 30 days&#8217; notice which may be waived by the Company in its discretion. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary as accrued but not paid, through your last day of employment (the &#8220;<b style="font-weight:bold;">Date of Termination</b>&#8221;), and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed (the &#8220;<b style="font-weight:bold;">Accrued Obligations</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><b style="font-weight:bold;">Termination Benefits. </b>In the event the Company terminates your employment for any reason or you resign for any reason, the Company shall pay you the Accrued Obligations. In the event that the Company terminates your employment without Cause (and other than by reason of your death or Disability) or you resign for Good Reason, then provided you enter into, do not revoke and comply with the terms of a separation agreement in a form satisfactory to the Company, which shall include a general release of claims against the Company and related persons and entities (the &#8220;<b style="font-weight:bold;">Release</b>&#8221;) and such Release becomes irrevocable within the time period set forth in the Release but in no event more than 60 days after the Date of Termination, the Company will provide you with the following &#8220;Termination Benefits&#8221;:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">i.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a payment that is equivalent to the sum of nine (9) months of your Base Salary (the &#8220;<b style="font-weight:bold;">Salary Continuation Payment</b>&#8221;); and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">ii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#8220;<b style="font-weight:bold;">COBRA</b>&#8221;), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the Date of Termination until the earlier of (i) twelve (12) months; and (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Salary Continuation shall be paid out in accordance with the Company&#8217;s payroll practice commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Employment Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section l.409A-2(b)(2). For the avoidance of doubt, in the event your employment is terminated as a result of death, Disability, or for any reason other than a termination by the Company without Cause or your resignation for Good Reason, you will be entitled to the Accrued Obligations but you will not be entitled to any of the Termination Benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of this Employment Agreement, the term &#8220;<b style="font-weight:bold;">Cause</b>&#8221; means: (i) conduct by you constituting a material act of misconduct in connection with the performance of your duties, including, without limitation, (A) willful repeated failure or refusal to perform material responsibilities that have been requested by the Company; (B) dishonesty to the Company with respect to any material matter; or (C) misappropriation of funds or property of the Company or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1px solid #000000;margin:0pt;">One<font style="letter-spacing:-0.45pt;"> </font>Broadway,<font style="letter-spacing:-0.4pt;"> </font>Cambridge,<font style="letter-spacing:-0.4pt;"> </font>MA,<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">02142</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="pmn-20251231xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:131.98pt;"></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by you of acts satisfying the elements of (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) any misconduct by you, regardless of whether or not in the course of your employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if you were to continue to be employed in the same position; (iv) a breach by you of any of the provisions contained in the Employment Agreement or the Restrictive Covenants Agreement, which remains uncured following 30 days&#8217; notice from the Company to you; or (v) your material failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of this Employment Agreement, &#8220;<b style="font-weight:bold;">Disability</b>&#8221; shall mean Disability shall mean you are unable to perform the essential functions of your position under this Employment Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.3pt;margin:0pt 0pt 12pt 0pt;">For purposes of this Employment Agreement, &#8220;<b style="font-weight:bold;">Good Reason</b>&#8221; means: (i) a material adverse change in your duties and responsibilities; (ii) a material reduction in your Base Salary without your prior consent except for across-the-board salary reductions based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; or (iii) a requirement that you relocate your principal place of employment more than 30 miles. To terminate your employment for Good Reason you must (i) provide notice to the Company of the event giving rise to the Good Reason within 60 days after such event occurs, (ii) provide the Company with at least 30 days to cure (the &#8220;Cure Period&#8221;), and (iii) if not cured, resign for Good Reason within 30 days following expiration of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><b style="font-weight:bold;">Restrictive Covenants Agreement</b>. As a condition of your employment, you will be required to execute a Non-Solicitation, Confidentiality and Assignment Agreement in the form attached as Exhibit A (the &#8220;<b style="font-weight:bold;">Restrictive Covenants Agreement</b>&#8221;), as a condition of employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which restricts your engagement in any business in any way, other than confidentiality restrictions (if any). You represent to the Company that your execution of this Employment Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1px solid #000000;margin:0pt;">One<font style="letter-spacing:-0.45pt;"> </font>Broadway,<font style="letter-spacing:-0.4pt;"> </font>Cambridge,<font style="letter-spacing:-0.4pt;"> </font>MA,<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">02142</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="pmn-20251231xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:131.98pt;"></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. During and after your employment, you shall cooperate reasonably with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were employed by the Company, (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information and (iii) transitioning your duties. Your reasonable cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your employment, you also shall cooperate reasonably with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. Any reasonable costs incurred by you as part of the foregoing shall be reimbursed by the Company. In addition, you will be compensated (at the Base Salary as applied to a 32-hour week) for your time performing services in accordance with this Section in respect of any period after your employment with the Company ends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><b style="font-weight:bold;">Section 409A. </b>All in-kind benefits provided and expenses eligible for reimbursement under this Employment Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Employment Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. The parties intend that this Employment Agreement will be administered in accordance with Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). To the extent that any provision of this Employment Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Employment Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A 2(b)(2). The parties agree that this Employment Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Employment Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><b style="font-weight:bold;"> Withholding; Tax Effect. </b>All forms of compensation referred to in this</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1px solid #000000;margin:0pt;">One<font style="letter-spacing:-0.45pt;"> </font>Broadway,<font style="letter-spacing:-0.4pt;"> </font>Cambridge,<font style="letter-spacing:-0.4pt;"> </font>MA,<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">02142</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="pmn-20251231xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:131.98pt;"></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Employment Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><b style="font-weight:bold;">Entire Agreement. </b>This Employment Agreement, together with the Restrictive Covenants Agreement, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font><b style="font-weight:bold;">Governing Law; Jurisdiction. </b>This Employment Agreement will be governed by the laws of the Commonwealth of Massachusetts, excluding laws relating to conflicts or choice of law. You and the Company each submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts with respect to any dispute, controversy or claim arising out of or in connection with this Agreement, including the validity, invalidity, breach or termination thereof, and including tort claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</font></font><b style="font-weight:bold;">Assignment; Successors and Assigns. </b>Neither you nor the Company may make any assignment of this Employment Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Employment Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further that (without limiting the provisions of Section 7 of this Employment Agreement) if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments or benefits pursuant to Section 7 of this Employment Agreement solely as a result of such transaction. This Employment Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and the Company&#8217;s respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.</font></font><b style="font-weight:bold;">Waiver; Amendment. </b>No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Employment Agreement, or the waiver by any party of any breach of this Employment Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.</font></font><b style="font-weight:bold;">Enforceability. </b>If any portion or provision of this Employment Agreement (including, without limitation, any portion or provision of any section of this Employment Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Employment Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1px solid #000000;margin:0pt;">One<font style="letter-spacing:-0.45pt;"> </font>Broadway,<font style="letter-spacing:-0.4pt;"> </font>Cambridge,<font style="letter-spacing:-0.4pt;"> </font>MA,<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">02142</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="pmn-20251231xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:131.98pt;"></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">unenforceable, shall not be affected thereby, and each portion and provision of this Employment Agreement shall be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18.</font></font><b style="font-weight:bold;">Other Terms. </b>The provisions of this Employment Agreement shall survive the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Employment Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Employment Agreement. This Employment Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[SIGNATURE PAGE FOLLOWS]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1px solid #000000;margin:0pt;">One<font style="letter-spacing:-0.45pt;"> </font>Broadway,<font style="letter-spacing:-0.4pt;"> </font>Cambridge,<font style="letter-spacing:-0.4pt;"> </font>MA,<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">02142</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><img src="pmn-20251231xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:131.98pt;"></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To accept the terms of this Employment Agreement, please sign it and return it to the Company.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">s/ Neil K. Warma</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Neil Warma</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I have read and accept this employment offer:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">s/ Larry Altstiel</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Larry Altstiel, M.D., Ph.D</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1px solid #000000;margin:0pt;">One<font style="letter-spacing:-0.45pt;"> </font>Broadway,<font style="letter-spacing:-0.4pt;"> </font>Cambridge,<font style="letter-spacing:-0.4pt;"> </font>MA,<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">02142</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.75
<SEQUENCE>4
<FILENAME>pmn-20251231xex10d75.htm
<DESCRIPTION>EX-10.75
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:17 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:bold;">Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.75</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pmn-20251231xex10d75001.jpg" alt="Graphic" style="display:inline-block;height:74.24pt;width:357.7pt;"></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 12, 2026</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">UBC File: F16-05805 / 2026-2011</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VIA EMAIL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neil K. Warma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and CEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ProMIS Neurosciences, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suite 200, 1920 Yonge Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Toronto, ON M4S 3E2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Re:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Collaborative Research Agreement between The University of British Columbia and Vancouver Coastal Health Authority (collectively the &#8220;Institution&#8221;) and ProMIS Neurosciences, Inc. (the &#8220;Sponsor&#8221;), effective as of April 1, 2016 and amended on December 13, 2017, July 5, 2018, February 13, 2019, September 9th, 2019, January 11, 2022 and December 2, 2024 (the &#8220;Agreement&#8221;); Amendment No. 7</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-left:36pt;text-indent:-36pt;border-bottom:1px solid #000000;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Institution and Sponsor have executed the Agreement and hereby agree to amend the Agreement as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Any reference in the Agreement to Schedule &#8220;A&#8221; shall be understood to also include a reference to Schedule &#8220;A-2&#8221; as attached to this Amendment No. 7.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The first two paragraphs of Article 4.1 will be replaced with the following:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Parties understand and agree that, subject to Article 4.3 and excluding any intellectual property related costs under Section 7, the total costs to the Sponsor hereunder will be CAD $6,630,000. The Parties acknowledge that any budget categories that may be described in the Project are estimates only and that changes from category to category may be made at the Institution&#8217;s discretion.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">As of February 9, 2026, the Sponsor has already paid an amount of CAD $5,630,000. The Sponsor will pay the remaining amount of CAD $1,000,000 in five equal installments, each within 30 days of receipt of an invoice (to be) sent in accordance with the following invoicing schedule:</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:50%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:62.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:25.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">i.</p></td><td style="vertical-align:bottom;width:62.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 15, 2026</p></td><td style="vertical-align:bottom;width:25.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$200,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ii.</p></td><td style="vertical-align:bottom;width:62.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 1, 2026</p></td><td style="vertical-align:bottom;width:25.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$200,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">iii.</p></td><td style="vertical-align:bottom;width:62.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 1, 2026</p></td><td style="vertical-align:bottom;width:25.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$200,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">iv.</p></td><td style="vertical-align:bottom;width:62.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">September 1, 2026</p></td><td style="vertical-align:bottom;width:25.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$200,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">v.</p></td><td style="vertical-align:bottom;width:62.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 1, 2026</p></td><td style="vertical-align:bottom;width:25.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$200,000</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">Each invoice will contain the required payment details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:bold;">Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles 16.0 (Notices) will be deleted in its entirety and replaced with the following:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All legal notices will be sent electronically using the email address below, or to such other address that a Party may designate. A notice will be deemed delivered at the time of successful transmission.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Institution: [***], with a copy to [***]</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Company: [***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All other terms and conditions of the Agreement will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment No. 7 will be read together and constitute one agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Amendment to the Agreement may be signed in counterparts either through original copies or electronically each of which will be deemed an original and all of which will constitute the same instrument.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed for and on behalf of</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed for and on behalf of</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">THE UNIVERSITY OF BRITISH COLUMBIA</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROMIS NEUROSCIENCES, INC.</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">by its authorized signatory:</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">by its authorized signatory:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John-Paul Heale</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neil Warma</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Dr. John-Paul Heale</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Neil Warma</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Managing Director, UILO</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: CEO</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 2/17/2026</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 2/12/2026</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed for and on behalf of</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed for and on behalf of</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">THE UNIVERSITY OF BRITISH COLUMBIA</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">VANCOUVER COASTAL HEALTH AUTHORITY</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">by its authorized signatory:</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">by its authorized signatory:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jennifer Lynett</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ James Johnson</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jennifer Lynett</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Dr. James Johnson</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Associate Director Sponsored Research</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Professor, Faculty of Medicine, UBC</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 2/13/2026</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: 2/17/2026</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acknowledged by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Neil Cashman</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dr. Neil Cashman</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Investigator</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:bold;">Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SCHEDULE &#8220;A-2&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">[***]</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>pmn-20251231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUBSIDIARIES OF THE REGISTRANT</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">Company Name</p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jurisdiction</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">ProMIS Neurosciences (US), Inc.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>pmn-20251231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:26 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-274656, 333-274658, 333-281841, 333-289577, 333-290039 and 333-294408), Post-Effective Amendment on Form S-3 to Registration Statement on Form S-1 (File No. 333-268103) and Form S-8 (File No. 333-267319 and 333-289579) of our report dated<b style="font-weight:bold;">&#160;</b>March 25, 2026, relating to the consolidated financial statements of ProMIS Neurosciences Inc., appearing in this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:99.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:99.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ BAKER TILLY US, LLP</p></td><td style="vertical-align:bottom;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:99.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:99.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tewksbury, Massachusetts</p></td><td style="vertical-align:bottom;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:99.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 25, 2026</p></td><td style="vertical-align:bottom;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.8" width="88.0%" style="background-color:#000000;color:#000000;height:1.8pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>pmn-20251231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:27 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Neil Warma, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K for the year ended December 31, 2025 of ProMIS Neurosciences Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;">to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:38.8pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 74.8pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:40.5pt;text-indent:-40.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 27.8pt 0pt 0pt;">Date: &#160;March 25, 2026</p></td><td style="vertical-align:top;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">/s/ Neil Warma</p></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><b style="font-weight:bold;">Neil Warma</b></p></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p></td></tr><tr style=""><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>pmn-20251231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:27 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Daniel Geffken, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K for the year ended December 31, 2025 of ProMIS Neurosciences Inc. (the &#8220;registrant&#8221;);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;">to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">. JK</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 25, 2026</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">/s/ Daniel Geffken</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Daniel Geffken</b></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer </b></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>pmn-20251231xex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 01:44:27 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS REQUIRED BY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of ProMIS Neurosciences Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 25, 2026</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neil Warma</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neil Warma</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:13.95pt;"><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 25, 2026</p></td><td style="vertical-align:top;width:35.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Daniel Geffken</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Daniel Geffken</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to ProMIS Neurosciences Inc. and will be retained by ProMIS Neurosciences Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>pmn-20251231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &T Z@# 2(  A$! Q$!_\0
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MMO\ "O3Z*GVTNR^Y?Y&GU:'>7_@4O\SS#_A ?B-_T5!__!';?X4?\(#\1O\
MHJ#_ /@CMO\ "O3Z*/;2[+[E_D'U:'>7_@4O\SS#_A ?B-_T5!__  1VW^%'
M_" _$;_HJ#_^".V_PKT^BCVTNR^Y?Y!]6AWE_P"!2_S/,/\ A ?B-_T5!_\
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M1[:79?<O\@^K0[R_\"E_F>8?\(#\1O\ HJ#_ /@CMO\ "C_A ?B-_P!%0?\
M\$=M_A7I]%'MI=E]R_R#ZM#O+_P*7^9YA_P@/Q&_Z*@__@CMO\*/^$!^(W_1
M4'_\$=M_A7I]%'MI=E]R_P @^K0[R_\  I?YGF'_  @/Q&_Z*@__ (([;_"C
M_A ?B-_T5!__  1VW^%>GT4>VEV7W+_(/JT.\O\ P*7^9YA_P@/Q&_Z*@_\
MX([;_"C_ (0'XC?]%0?_ ,$=M_A7H6M:O;Z!I%YJ5V66UM8FFE*C)"@9.!7
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M?F*EH]M+LON7^0?5H=Y?^!2_S/,/^$!^(W_14'_\$=M_A1_P@/Q&_P"BH/\
M^".V_P *]/HH]M+LON7^0?5H=Y?^!2_S/,/^$!^(W_14'_\ !';?X4?\(#\1
MO^BH/_X([;_"O3Z*/;2[+[E_D'U:'>7_ (%+_,\P_P"$!^(W_14'_P#!';?X
M4?\ " _$;_HJ#_\ @CMO\*]/HH]M+LON7^0?5H=Y?^!2_P SS#_A ?B-_P!%
M0?\ \$=M_A1_P@/Q&_Z*@_\ X([;_"O3Z*/;2[+[E_D'U:'>7_@4O\SS#_A
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MB@ HHHH **** "BBN;^(_C*+X?>!]9\0RQ&X6PMVF$0.-[ <+GW.* .1^/\
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MG%I)$R;;E5ZLN>U>NUYKXS\$:MK/Q=\&:_:11MIVF0W"7$C2 %2X^7"]3^%
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MAOO_  41?_'*/^%-_$3_ *+#??\ @HB_^.4>QI_\_5]TO\@^LU_^@>7WP_\
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M&0PZ8L8!MY1(&_UAW%L8))ZG/M71?\*;^(G_ $6&^_\ !1%_\<H_X4W\1/\
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M "#ZS7_Z!Y??#_Y(]HHKQ?\ X4W\1/\ HL-]_P""B+_XY1_PIOXB?]%AOO\
MP41?_'*/8T_^?J^Z7^0?6:__ $#R^^'_ ,D>T45XO_PIOXB?]%AOO_!1%_\
M'*/^%-_$3_HL-]_X*(O_ (Y1[&G_ ,_5]TO\@^LU_P#H'E]\/_DCVBBO%_\
MA3?Q$_Z+#??^"B+_ ..4?\*;^(G_ $6&^_\ !1%_\<H]C3_Y^K[I?Y!]9K_]
M \OOA_\ )'M%%>+_ /"F_B)_T6&^_P#!1%_\<H_X4W\1/^BPWW_@HB_^.4>Q
MI_\ /U?=+_(/K-?_ *!Y??#_ .2/3/'&A3>)_!^LZ1;R1Q3WMK) CRYVJ6&
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MH_\ CM'U>'_/Q?=+_(/KM7_GQ+[X_P#R1\S4JNR,&4E6!R"#@BOIC_ABH?\
M0Y/_ ."T?_':/^&*A_T.3_\ @M'_ ,=H^KP_Y^+[I?Y!]=J_\^)??'_Y(^:9
M[B6ZE,DTCRR'J\C%B?Q-,KZ9_P"&*A_T.3_^"T?_ !VC_ABH?]#D_P#X+1_\
M=H^KP_Y^+[I?Y!]=J_\ /B7WQ_\ DCYFKK?"?_(H>,/^O:#_ -'"O;/^&*A_
MT.3_ /@M'_QVK=I^QS<6MG>00^.)(X;A569!I@PX!R ?WOK1["'_ #\7W2_R
M#ZY5_P"?$OOC_P#)'RW17TS_ ,,5#_H<G_\ !:/_ ([1_P ,5#_H<G_\%H_^
M.T?5X?\ /Q?=+_(/KM7_ )\2^^/_ ,D?,U%?3/\ PQ4/^AR?_P %H_\ CM'_
M  Q4/^AR?_P6C_X[1]7A_P _%]TO\@^NU?\ GQ+[X_\ R1\S45],_P##%0_Z
M')__  6C_P".T?\ #%0_Z')__!:/_CM'U>'_ #\7W2_R#Z[5_P"?$OOC_P#)
M'S-17TS_ ,,5#_H<G_\ !:/_ ([1_P ,5#_H<G_\%H_^.T?5X?\ /Q?=+_(/
MKM7_ )\2^^/_ ,D?,U%?3/\ PQ4/^AR?_P %H_\ CM'_  Q4/^AR?_P6C_X[
M1]7A_P _%]TO\@^NU?\ GQ+[X_\ R1\S45],_P##%0_Z')__  6C_P".T?\
M#%0_Z')__!:/_CM'U>'_ #\7W2_R#Z[5_P"?$OOC_P#)'B?PU_Y"VK?]@74/
M_29ZY*OJ33?V.KC3I97M?'$D#R0R0N5TP<HRE67_ %O<$BJG_#%0_P"AR?\
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M.U6X\<22K!$(X@=,'R*.@_UM'U>'_/Q?=+_(/KE7_GQ+[X__ "1\MT5],_\
M#%0_Z')__!:/_CM'_#%0_P"AR?\ \%H_^.T?5X?\_%]TO\@^NU?^?$OOC_\
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M*A"M?FZ'SF;8NIA7%T^M_P!#VP_''P\/^65]_P!^E_\ BJ8?CMX<7_EE?_\
M?E?_ (JO!WJO)UKU?J-'S/G?[8Q/E]Q[\?CUX;'_ "RO_P#ORO\ \53&^/\
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M7QF_0U7DZ4GEF'\_O&L_QOE]Q]I']L?P(/\ EWUG_P !4_\ CE,/[9G@)?\
MEWUG_P !4_\ CE?%+U7DZU/]F4//[S19]C/+[C[</[:'@$?\N^M?^ J?_'*8
M?VU/ "_\NVM?^ L?_P <KX>?I4,G>H_LZAYFBSS%OM]Q]R']MGX?KUMM;_\
M 6/_ ..4T_MO?#T?\NVM_P#@)'_\<KX5DZ57D[U/]GT/,U6=8M]ON/O)/VY/
MAW&23;:YRI'%I'Z?]=*A/[<_PZ'_ "[:[_X"1_\ QRO@MZ@>I>7T?,T6<XI]
MON/OD_MU_#D=;77?_ 2/_P".4P_MX?#@?\NNO?\ @''_ /':^ 9.M5WZ5#P-
M%=S19OB7V^X_0,_MZ?#8?\NNO?\ @''_ /'::?V^/AJ/^777_P#P#C_^.U^>
M\G>H'J7@J7F6LVQ/E]Q^NWPU^)>A_%?PQ#KN@3O+:.Q1HY5"RQ,.JNH)P>AZ
M]ZZJOR^_9B^.\_P7\;I]JD=_#FH,L5]".=GI*!ZK^HR*_3NSO(-0M(+JVE6>
MVGC66*5#E75AD$'T(->3B*/L96Z'T>#Q2Q-.[W6Y-4DO1/\ =J.I)>B?[M<I
MZ/0CHHHH$%%%% !1110 5)#U?_=-1U)#U?\ W328UN1T444Q!1110 4444 %
M%%% '%_%G_C[^'/_ &,5O_6BCXL_\??PY_[&*W_K12J?#'Y_F.C_ !*GR_)&
M/^U3_P B#=_]<G_]!->B?"?_ ))EX5_[!EO_ .BQ7G?[5/\ R(-W_P!<G_\
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M$QW\GXK_ #/EF3O5>3O7U4W[&UBW_,SW'_@&O_Q=1M^QC8M_S--Q_P" :_\
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M]C%;_P!:*53X8_/\QT?XE3Y?DC'_ &J?^1!N_P#KD_\ Z":]$^$__),O"O\
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M+)C=@$Y([UJX12NS&-6<FDE?^D?2NNZ[I_AC1KS5M6O(K#3;.)IKBYG;:D:
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MC_S]P_\ ?8H_MBQ_Y^X?^^Q19AS1[ERBJ?\ ;%C_ ,_</_?8H_MBQ_Y^X?\
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M^5/^T:OE_7S(_L/#/K+[_P#@'R?)^S]XS;I96_\ X$I_C5=_V>/&K=+&W_\
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M)^AZ@UZ17FRBXMQ>Y[T)QJ14XO1A1114EDD'WF_W6_E4=20?>;_=;^51TA]
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MIIZ7ZKO/RJ]R",?AC\Z[71?&NJVWB?X<^$_$+R+J>AZB[M-DXGMFARC9[_\
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MM<+Y+G;N_6O-+SX?:Q83>'=.\06UWH?AC6_&-LEIH4NI-.T$(M9O,W2#& [
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MC\_S'1_B5/E^2,?]JG_D0;O_ *Y/_P"@FO1/A/\ \DR\*_\ 8,M__18KSO\
M:I_Y$&[_ .N3_P#H)KJO"7AD>*_@_P"%;,ZGJ.E#^SK=O/TV812_ZL<9*GC\
M*%_"^?Z%))XI7_E_5'HM%>8_\*+3_H>O&7_@RC_^-4?\*+3_ *'KQE_X,H__
M (U65EW/2Y*7\_X'IU%>8_\ "BT_Z'KQE_X,H_\ XU1_PHM/^AZ\9?\ @RC_
M /C5%EW#DI?S_@>G45YC_P *+3_H>O&7_@RC_P#C5'_"BT_Z'KQE_P"#*/\
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M  HM/^AZ\9?^#*/_ .-4?\*+3_H>O&7_ (,H_P#XU19=PY*7\_X'IU%>8_\
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MXJ_\#T_^-T?\*RE_Z'/Q5_X'I_\ &Z.=]P_LVG_,ON/4_P#A%]&_Z!%A_P"
MR?X4G_"*Z(?^8/8?^ J?X5Y;_P *RE_Z'/Q5_P"!Z?\ QNC_ (5E+_T.?BK_
M ,#T_P#C='.^X?V;3_F7W'J/_")Z&?\ F#:?_P" J?X4G_"(Z%_T!=._\!8_
M\*\O_P"%92_]#GXJ_P# ]/\ XW1_PK*7_H<_%7_@>G_QNCG?<7]FT_YE]QZ>
M?!^@G_F":=_X"1_X4G_"&Z ?^8'IO_@)'_A7F/\ PK*7_H<_%7_@>G_QNC_A
M64O_ $.?BK_P/3_XW1SR[A_9M+^9?<>F_P#"%^'C_P P+3/_  #C_P *>G@G
MPZ8Y,Z!I9X'_ "YQ^O\ NUY?_P *RE_Z'/Q5_P"!Z?\ QNIX/A;(]O<,?&GB
MO* $8U!/7_KG1SR[A_9M)?:7W'HG_"#^'#_S -+_ / */_XFD_X07PV?^9>T
MK_P"C_\ B:\U_P"%92_]#GXJ_P# ]/\ XW1_PK*7_H<_%7_@>G_QNCG?</[-
MI?S+[CTH^!/#1_YE[2O_  "B_P#B:3_A O#)_P"9=TG_ , 8O_B:\V_X5E+_
M -#GXJ_\#T_^-T?\*RE_Z'/Q5_X'I_\ &Z.=]Q_V;3_F7W'I'_" >%S_ ,RW
MI'_@#%_\32?\*^\+?]"UI'_@!%_\37G'_"LI?^AS\5?^!Z?_ !NC_A64O_0Y
M^*O_  /3_P"-T<[[A_9U/^9?<>C'X>>%3_S+.C_^ $7_ ,33H/ /ABVF2:'P
MYI,4J$,LB6,092.A!"\&O-_^%92_]#GXJ_\  ]/_ (W1_P *RE_Z'/Q5_P"!
MZ?\ QNES/N/^SJ?\R^X]FHKQG_A64O\ T.?BK_P/3_XW1_PK*7_H<_%7_@>G
M_P ;I71?U%?S_@SV:BO&?^%92_\ 0Y^*O_ ]/_C='_"LI?\ H<_%7_@>G_QN
MBZ#ZBOY_P9[5!]YO]UOY5'7D%G\+9)I) ?&GBL8C=N-03LI/_/.H/^%92_\
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M+_T.?BK_ ,#T_P#C=%T'U%?S_@SV:BO&?^%92_\ 0Y^*O_ ]/_C='_"LI?\
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MFWCM\_:2$]>./K7O]>-W?[-.E7/B'QGJJ:O>6Y\0VSP1PQ !;!G(,KQ$'JY
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MX3_\DR\*_P#8,M__ $6*/^77S_0E_P"\K_"_S1U=%%%8'6%(0#U&:6B@ I
M.@Q2T4 %%%% !1110 4444 %%%% !137;8I8@G'8#)J+[6O_ #SE_P"_9I-I
M;C2;V)Z*@^UK_P \Y?\ OV:/M:_\\Y?^_9I<R'RLGHJ#[6O_ #SE_P"_9H^U
MK_SSE_[]FCF0<K)Z*@^UK_SSE_[]FC[6O_/.7_OV:.9!RLGI,#.<<^M0_:U_
MYYR_]^S1]K7_ )YR_P#?LT<R#E9-@9SCGUI:@^UK_P \Y?\ OV:/M:_\\Y?^
M_9HYD'*R>BH/M:_\\Y?^_9H^UK_SSE_[]FCF0<K)Z*@^UK_SSE_[]FC[6O\
MSSE_[]FCF0<K)Z*@^UK_ ,\Y?^_9H^UK_P \Y?\ OV:.9!RLGHJ#[6O_ #SE
M_P"_9H^UK_SSE_[]FCF0<K)Z*@^UK_SSE_[]FC[6O_/.7_OV:.9!RLGHJ#[6
MO_/.7_OV:/M:_P#/.7_OV:.9!RLGHJ#[6O\ SSE_[]FC[6O_ #SE_P"_9HYD
M'*R>BH/M:_\ /.7_ +]FC[6O_/.7_OV:.9!RLGHJ#[6O_/.7_OV:/M:_\\Y?
M^_9HYD'*R>BH/M:_\\Y?^_9H^UK_ ,\Y?^_9HYD'*R>BH/M:_P#/.7_OV:/M
M:_\ /.7_ +]FCF0<K)Z*@^UK_P \Y?\ OV:/M:_\\Y?^_9HYD'*R>BH/M:_\
M\Y?^_9H^UK_SSE_[]FCF0<K)Z*@^UK_SSE_[]FC[6O\ SSE_[]FCF0<K)ZK2
M:;:RW\-\]O&UY"C1QSE?G56QN /H<#\J=]K7_GG+_P!^S1]K7_GG+_W[-',N
MX<K[$]%0?:U_YYR_]^S1]K7_ )YR_P#?LT<R#E9/14'VM?\ GG+_ -^S1]K7
M_GG+_P!^S1S(.5D]%0?:U_YYR_\ ?LT?:U_YYR_]^S1S(.5GE_Q+1I?&T*("
MS-I,@ '<[VKX#O\ X)>/);ZY=?"VHLK2,01%U&37Z$^+[5[[Q]9RH414T\J1
M*P1C^\/0'DBG?V;)_P ](?\ OZO^-;PE9:'M8'%RPL6DMS\[?^%'>/?^A5U+
M_OU1_P *.\>_]"KJ7_?JOT2_LV3_ )Z0_P#?U?\ &C^S9/\ GI#_ -_5_P :
MT]H>E_:T^R/SM_X4=X]_Z%74O^_5'_"CO'O_ $*NI?\ ?JOT2_LV3_GI#_W]
M7_&C^S9/^>D/_?U?\:/:!_:T^R/SM_X4=X]_Z%74O^_5'_"CO'O_ $*NI?\
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M_C1_9LG_ #TA_P"_J_XU%SS.9%2BK?\ 9LG_ #TA_P"_J_XT?V;)_P ](?\
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M>%?^P9;_ /HL4?\ +KY_H2_]Y7^%_FCJZ***P.L**** "BBB@ HHHH ****
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M]F\T"6MI,BR7#(P!5KI@%52S >U?5GAWP;H_AC1K33;&PMXX+=(D!$*@L8P
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M' ! _*H8_#^EPRW$D>FVB27((F98%!E!ZACCG\:/:+JA^QE?21Y-^S'X\O\
MQEHOB.VU*_NM2N=,U!8?.FGBNHPK0HVV.XB55E&23DC(W8/2O::JZ=I5EI%O
MY%C:06<.=WEV\81<^N!5JL9.[NCHBG&-FSR;XG?\CG'_ -@B3_T)J_,[4_\
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M?DBA^U3_ ,B#=_\ 7)__ $$UW_PNN8K7X7^%7FD6)?[-M^7.!_JQ7 ?M4_\
M(@W?_7)__037:> =!L?$/PG\*VVH0"X@_LVW.PDCGRQZ4?\ +KY_H2_]Y7^%
M_FCKO[:L/^?R#_OX*/[:L/\ G\@_[^"N=_X5+X4_Z!*?]_'_ ,:/^%2^%/\
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M^?R#_OX*/[:L/^?R#_OX*YW_ (5+X4_Z!*?]_'_QH_X5+X4_Z!*?]_'_ ,:
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M =%_;5A_S^0?]_!1_;5A_P _D'_?P5SO_"I?"G_0)3_OX_\ C1_PJ7PI_P!
ME/\ OX_^- '1?VU8?\_D'_?P4?VU8?\ /Y!_W\%<[_PJ7PI_T"4_[^/_ (T?
M\*E\*?\ 0)3_ +^/_C0!R_C?4+:7X@V,B7$;1C3BI8,",^8>*C_M"V_Y^(_^
M^A3=6^'^@6_CNWL(]/5;1K S&/>W+[R,]?2M/_A6GAO_ *!B?]]M_C5)V-X5
M>16L9W]H6W_/Q'_WT*/[0MO^?B/_ +Z%:/\ PK3PW_T#$_[[;_&C_A6GAO\
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M[=]C._M"V_Y^(_\ OH4?VA;?\_$?_?0K1_X5IX;_ .@8G_?;?XT?\*T\-_\
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M3T<]=/A_*FGP?HK==.@/X4 >"SUGW%?0Y\%:&W73(#^%,;P)X?;KI5N?^ T
M?,]SUK*NNIKZJ;X>^&VZZ/;'_@-1M\-?"[==$M3_ ,!/^- 'R!==ZQ;SO7VH
MWPL\)OUT&T/_  $_XU$WPB\&O][P]9'_ ( ?\: /F/X)_"EOB)XC%Q>QG^P[
M)@TY(XE;J(Q]>_M]:^S;:)(+9HXU"(BA551@ #M6=HF@:=X;L19:79Q65J&+
M"*(8&3U-:<?^KD^@_G0!'1110 4444 %%%% !1110 4444 %%%% $D'WF_W&
M_E4=20?>;_<;^51T %%%% !1110 4444 %23?=C_ -VHZDF^['_NT 1T444
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M]_\ UZ/*G_Y[K_W[_P#KU/10!!Y4_P#SW7_OW_\ 7H\J?_GNO_?O_P"O4]%
M$'E3_P#/=?\ OW_]>CRI_P#GNO\ W[_^O4]% $'E3_\ /=?^_?\ ]>CRI_\
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M7I'[/OPH;Q3KRZ_J$9&F63YB4_\ +60?T% 'UC1110 5)'_JY/H/YU'4D?\
MJY/H/YT 1T444 %%%% !1110 4444 %%%% !1110!)!]YO\ <;^51U)!]YO]
MQOY5'0 4444 %%%% !1110 5)-]V/_=J.I)ONQ_[M $=%%% !1110 4444 %
M20]7_P!TU'4D/5_]TT 1T444 %%%% !1110 4444 <9\6?\ C[^'/_8Q6_\
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M'G2_\^[?]]"@">BH/.E_Y]V_[Z%'G2_\^[?]]"@">BH/.E_Y]V_[Z%'G2_\
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M\]1_WR:/+C_YZC_ODT 1T5)Y<?\ SU'_ 'R:/+C_ .>H_P"^30!'14GEQ_\
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M_P#6BCXL_P#'W\.?^QBM_P"M%;3^"'S_ #.2E_%J>J_)&-^U3_R(-W_UR?\
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MZ/\ AHKQ/_T3U_\ P/H]D^Z^]!]9C_++_P !?^1](45\W_\ #17B?_HGK_\
M@?1_PT5XG_Z)Z_\ X'T>R?=?>@^LQ_EE_P" O_(^D**^;_\ AHKQ/_T3U_\
MP/H_X:*\3_\ 1/7_ / ^CV3[K[T'UF/\LO\ P%_Y'TA17S?_ ,-%>)_^B>O_
M .!]'_#17B?_ *)Z_P#X'T>R?=?>@^LQ_EE_X"_\CZ0HKYO_ .&BO$__ $3U
M_P#P/H_X:*\3_P#1/7_\#Z/9/NOO0?68_P LO_ 7_D?2%%?-_P#PT5XG_P"B
M>O\ ^!]'_#17B?\ Z)Z__@?1[)]U]Z#ZS'^67_@+_P CZ0HKYO\ ^&BO$_\
MT3U__ ^C_AHKQ/\ ]$]?_P #Z/9/NOO0?68_RR_\!?\ D?2%%?-__#17B?\
MZ)Z__@?1_P -%>)_^B>O_P"!]'LGW7WH/K,?Y9?^ O\ R/H\C-&T;<8&/2OG
M#_AHKQ/_ -$]?_P/H_X:*\3_ /1/7_\  ^CV3[K[T'UF/\LO_ 7_ )'TA17S
M?_PT5XG_ .B>O_X'T?\ #17B?_HGK_\ @?1[)]U]Z#ZS'^67_@+_ ,CZ/P,Y
MQS69X>\,Z=X6M9[?3;<6T,]Q)=2*.\DC;G;\2<UX'_PT5XG_ .B>O_X'T?\
M#17B?_HGK_\ @?1[*7=?>@^L0_EE_P" O_(^D*3 )SCFOG#_ (:*\3_]$]?_
M ,#Z/^&BO$__ $3U_P#P/H]D^Z^]!]9C_++_ ,!?^1](4F!G..?6OG#_ (:*
M\3_]$]?_ ,#Z/^&BO$__ $3U_P#P/H]D^Z^]!]9C_++_ ,!?^1]$66GVVFQR
M1VL*0))*\SA!C<[L69C[DDG\:L5\W_\ #17B?_HGK_\ @?1_PT5XG_Z)Z_\
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M6/\ "C_AI'Q3_P!$\'_@6/\ "CV3[K[T'UF/\LO_  %_Y'M-%>+?\-(^*?\
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MY'M-%>+?\-(^*?\ HG@_\"Q_A1_PTCXI_P"B>#_P+'^%'LGW7WH/K,?Y9?\
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MG_HG@_\  L?X4>R?=?>@^LQ_EE_X"_\ (]IJ2;[L?^[7B7_#2/BG_HG@_P#
ML?X4?\-)>*C_ ,T\_P#)L?X4>R?=?>@^LQ_EE_X"_P#(]IHKQ;_AI'Q3_P!$
M\'_@6/\ "C_AI'Q3_P!$\'_@6/\ "CV3[K[T'UF/\LO_  %_Y'M-%>+?\-(^
M*?\ HG@_\"Q_A1_PTCXI_P"B>#_P+'^%'LGW7WH/K,?Y9?\ @+_R/::*\6_X
M:1\4_P#1/!_X%C_"C_AI'Q3_ -$\'_@6/\*/9/NOO0?68_RR_P# 7_D>TU)#
MU?\ W37B7_#2/BG_ *)X/_ L?X4?\-)>*A_S3S_R;'^%'LGW7WH/K,?Y9?\
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M]8O^^11_8-A_SZQ?]\BBB@ _L&P_Y]8O^^11_8-A_P ^L7_?(HHH /[!L/\
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MP;#_ )]8O^^11_8-A_SZQ?\ ?(HHH /[!L/^?6+_ +Y%']@V'_/K%_WR***
M#^P;#_GUB_[Y%']@V'_/K%_WR*** #^P;#_GUB_[Y%']@V'_ #ZQ?]\BBB@
M_L&P_P"?6+_OD4?V#8?\^L7_ 'R*** #^P;#_GUB_P"^11_8-A_SZQ?]\BBB
M@ _L&P_Y]8O^^11_8-A_SZQ?]\BBB@ _L&P_Y]8O^^11_8-A_P ^L7_?(HHH
M /[!L/\ GUB_[Y%']@V'_/K%_P!\BBB@ _L&P_Y]8O\ OD4?V#8?\^L7_?(H
4HH GM]-MK1LPPI&?]D8HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pmn-20251231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "- 7$# 2(  A$! Q$!_\0
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MG12))5+;R&7D8-?0/[17A^YU#PG:?$3P79PS>"[.'9J6GV.I"/[/;/->->1
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M,@40ZC%<A/M"7"*"I4@']RWFL% (),>&4;4S0C]98_\ @M'\$I#@>%O'^?\
ML'67_P F5*__  6=^"*E OAOQW(&7.X:?9 #VR;L<_2OQA:7=+&V$0*2>!SZ
M@8Z?_KII?S(HSN*QEF^54^5&./N_AC^5 '[-?\/I?@CNQ_PB_C_Z_P!GV/\
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M.V"Q,RB4$.,YW#V]_7Z?A7J7AOXAKXW\/6/@?Q!I5M<S*@ATO6)91&UO. 1
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M*JJKR5SN93D@,-V<-D@MR >.>*?$K^*=3:]FAMK=R"A6",ID;F**0./E5@N
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M':XLYP6*[)$4Y0E5,B@@.K-PK@,L7@*]T#7+L:!XE1;*PN+.2&VU6%I2]E<
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MV_,J[=YZA>"!FZWI>H^-_&&K_P!@Z1?W=O S^1#;VLLDD%I$/+C,@4$C;&J
MENX.3UKL7\(_%WQU:^'M#C\.ZE!96SC[$(]-33[=7=EQ(T@5%('RMN<X0EVX
MRQ-KX@>&_B'_ ,)HJ:[82:1J.G7;BYUJ;4_)L+B92H>:*7<L6W=N.8#_ !C&
M21D XCPCMT7P=XJUR9VCO!$FCV0Y5Q)<A_.8888 @293D,#YH&,D&OJ72-/T
M#6/^"</@.Q\1+?BSN/B5=)Y^G&/S8 +9FDDQ(RH0(UD'S$ 9W9XP?GZW\/7O
MQ"_LSPCH-[<^*]9:[N-4U+48S*UK#E8XU^:4!L*L>3*^ 3*J8^7<?H_XN7S^
M#?\ @G;X"?0T@T.[B\>7,$MM8OYC64AL9 ZF9F9C,1\SME2KO(BA4510!\HZ
MO>/\,M2M[CP9XBU5+.\M(Q-=1NUJUP=N).(VP82^\*&)8A6W <BG^$AI/B$7
M:W'AV.6,6C7%Y>6L<TDMBT?'G"-6CB\MV9%*8/7@@XJIH?Q)UZ&UL='B-A_9
MT4AF:W.E02+=D,9%28;,S*&R%1\JFX[=NXY] ;QYX>T/29I=.\!VGA+Q'K-G
M*)#<[+BUAMI <W%LERK30N4+;0DF#@;<YVT >P_#5?#.C>&='BACM/"VKWUM
M]GEU@1RVEOJSK.LXL8Q\S3 I^[+%B&9H05*@@>):[X5N/'EQJ?VJ2TT!K=YK
MJ26ZN(XK%7-Q%;QVX=XD:/:SR;L[@2K,=H#..*\4^-_M?B/3-9T:\OX)K13]
MG2=RYLMLTC1"(LQ.%# @$G:20":V_&_Q*\0?$K7-/\2F]DO?$5LB63PB/S99
M(85B$<\J%-CM(S?-QEF3<P))9@#F;N6]>[FM=3N&M[^"X=-3O[F=YI96!QY;
M $ET'E#''4\G&W'N_P )OC%<PZE':^$]#N]3\0VU^;S35:98VM2\@1S"7)$!
M=OL\CRH!(Y!C8&,$U\[ZYX?UO0;HPZWIU_I-TRDE-0A:"1A@$\. 3D$>N<CU
M%=]\$;LZ'XMTG6Q:W^I3PW#--'96WVHM&8L>6^YD4[@S+M$F[(SQ@9 /W)^$
MWQ ?XF>!+?7-.O<3.JV4CV#;HC)GYFCSM"_*01N ;U Z5^<__!1[X+WFG_%"
MX\0W,>DVFD/:6WV>SNK&?S+@V\(CE\JYMXF"H<!CYS1KEF(^ZS&S\,OVF?BK
M\*M=^'NHZ+%X6L_"OBE-'&I:1IUE&UQ;66XV<?GKL60O@?NWWMA(X%X4;3Z1
M\8/&6H^+/&'@[78K?4)-3UG3XKB[\.7%^RW,5C<PKY=[;6_F$7,ZK(7$,6=D
MD4#,D98@@'Y?:_ D-_>PP);R6L=R^V6U):/9D 8;)!&,<]\]361M:0[CP@Y9
M@!Q_G%?4/Q!_9ZU+Q1X<O?%MAI6HWTB7$D>I:@J7+I:(D7F&68SNTA.$ \P9
MCQ)L^\N!X#<V5II$#VUYI=TM]);HT;7CM&T*N$DCF"?+C<A4#=N!#;AGB@"]
M\-99QXJT38[!/[1LXI""WS@W,;!6'0_,N?3CU(KZ#_X*@K ?VRO'9$C?:_.M
M Z;>%C^P6NQL]\DR#';;[U\\?#R\GD^(GA2-UQ#!J=K&8, *!YR9R..2><GG
M-?0O_!3"Z2U_;?\ B.9-S'98[?*(0C_08.K8X_\ U^M 'R[;0.S1P3!VAR76
M(]L@;B/0';R?:H[>=;<.\94N0=K[<X..@],^M/MM1FMD=H]H.[).Q6XP.,D9
MYX_(=:WM"\-P2Z??ZGJYEAL+?+P1[L/<N,DQ _>R0,%PI5<9;' (!:\(:5K%
M[K%C>VEE>.DC-+$]DJF0E7"B1AGD+*T9^;'/ (ZC0^)OBDZXL"6NJS:A9VKB
M S7#%96D"*789.=K,[<$GIQP!B[X8L=6OM>@CTN2WL-*B6'_ $IE\JWF=$4A
M"^T,X8H3P.[-@ DE-)^&FF7U_J\,7BJ!K*U@EN%BLHC=W,X"DJ%5<#+ -DY^
M7.2,<T <181V\T-PE_?&RC1/,0B+S!,Q)P&PV<G)YP< $>Q^CO#^D2?#_P"'
M&DZY<ZAI]R8K9KMXWA3;('2.=4=]N68K*%V$9.6Z@''G&A?"73M6U+2KS^WH
MM%LY[E2\$I190@"'=&&;#,=V!_#NS@D*:[[]H^QU!X])TB0K-9QPW$Q"20PM
M+=,ZL@2)L'**$4 ?,%<@9R0P!Y1\0KE/$-O!K^EV#6=CJ.8)YH[D'=]S$<Z]
MGWHS LY#+M( V$UP/E7$4_SAY'4'.1N  &!UX. ,?E[5KV=W>^';W4K!HT::
MX1K:X@E )5SD?,#T8$G@'(Z'N*UQ!%X]NY%T.&/2M8GDVOI"2>7#< 9):)F.
MT-G)*':!@;<Y( !S"RK'' ''G9)<EF#X)/ P1D'CGGGBGO:V\MO]HCE6-6+#
M8!F1,%<9YP <\<]C[9282"X:.\MS&R2F-\ORK'CZG&W/7'(Z=2L<UM!*A8&9
M9"0L1D \L#N>..>_!XSQU(!]?_\ !-KPU<V?Q1^*=KJ5C)%!>_"_5V4;'(EC
M=[;.W9ECP>B_-Z#/%<Q\8OA'X4T;0M F\::YJO@CQ9I^F_V-+9/9/JJ7<MNR
MF!_/41[0;26)$1^4$*(Q4*<='_P3GBEB\<_%N)[K[%Y?PPUQ!+=EMMN=UL2S
M !F '4@ G@X!XKD/AKKOCSQSX.GTFRTVW^+&FP>)[&&"SU&U,D*H8[O>06"M
M:1RL48ONCRP_B(>@#$\>?\(ZGPHTUOAY>?VO;:=8_P!BZ]JEQ:O::L0UQ),F
MV 3.JVLC3K$74LQ,8#!00&H>.],T7PYX6\,ZZ;?_ (KJ]@$>JZ>T(-FD99D$
MSQCY(W<*8O)89Q'YN%\Q#7U_X)\#>"/A5HVM-#%86_CZ_P!(GEM]%T1K+4+F
M&.3>##!:M'#]N+ *P:8%0?DC1E(9_E;Q[X<T[0_$]M9ZWXGAT^TU.*W>PN--
M2ZU"YE;S52:^GC65!%<$1N#& ^61%"A"DU '/^"OC]J'AS6[2#5)&U7PO%$U
MK/9WL%O=F&-CY>Z-9HV/[M/+"H&4,8ERP&0*6N^,M>T;Q3XC\,>-=1O?$^AW
MUX+FZWW/FO(P7$-_:22!U#M$1M8<.C!3QM*]Q:? SP;=W_AVQ6\,JQK+<:JS
MZW:17J1QOO9VMXQ,4V0K+E<YR%9BHW$8VL_$'P!?Z19W8^&VL7.FP6YT^PEU
M/5]R0K'$"")(D1F=I'#NA;"JS8!W+L /'-.UB]\-ZH;_ $F_FLKI0T=O<QOY
M<R*>#T/5ER",D88CFOM7]F#X4:U\2?$+P^/M-2]\.R6)N[>/5WCAF:\\L0E6
M6!1(8W:10R2,FY$B)8E,+XUH/Q/T+PSI;MI<>E>"5GLXXXY='MSJNN@+,02D
MS[(X)3F0[V8,J%0HP17L?[,/Q2OC?6D6CZKX@L;"2]O;>XFU76);Z>^AB@$H
MB>/(CL@A:)@ZG,I1ESM#"@#T3Q-XX\3:AK&B:%H-BEI-HT)MK71-(TJ$K JR
M@A8HH@P4DD;AM R203V]+N;NR\5>";^*\L[7PW->:9*TDGDA8[&Z\E_/9DE5
M592S9,<NX;<CL<^L_ 34]!L_!'B#XBZ>MG!XDV)'/:J5596B&U48[P#DE@K
MXY;E_E(X7XP>/]1\53>*_$&F:).^L/IZZ9IVDK?+;R7,TA:,YE>/:CE9'97)
MY6!5' &0#XZT#X7:TFK746I?%2QU[0VE,EU$]A'<+;O'(%4HDZR(OR(?FC_@
MW+D[6 \G_:%T"R\&Z:VF7,LD'BIM10WUF\DLZ*R+,))HI#$BK$P> )$"Y4*<
M[3D5R7B?P]J][K][9^*[J?PQ:VMZ;F[&L;Y)HEFF&9F0*&N)/F9@0 S*I.<
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MA3\NP$L\<3Z;XF\/V?B#3H+33[F.1;+4+**!("DQ,LOF*!DR(X. Q)8>400
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ME49]7_;X\/WFN?MO_$6/1]=@TK4 MEY\\3312QP-8VX?S'7&4549B%SPPZ]
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MJUU'/.MU.)6$LH! 9\G.,\D9]A2VNJ7-G<>?#<S6LH4Q-- QW!&&"O;UQUH
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M#913BTNEU.TUUC&;-U^S,'BD69T5DE5$BV'+D7+X7*$5YAXD\*:#XGL+W7_
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MX/(-90)48''N":O:B\;)!)'&45XA\K-GH2G)P,\+G\:IRR;V/RJ.. HQTXH
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896>-HXF#$9;:58E6(H _H&Q13J* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pmn-20251231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #E ?L# 2(  A$! Q$!_\0
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M?X._\']K_P#'*/\ AHKX4?\ 13_!W_@_M?\ XY6W_P *F\$?]"?H'_@L@_\
MB:3_ (5/X(_Z$_0/_!9!_P#$T?N_,/=,7_AHKX4?]%/\'?\ @_M?_CE'_#17
MPH_Z*?X._P#!_:__ !RMO_A4W@G_ *$_0/\ P60?_$T?\*F\$?\ 0GZ!_P""
MR#_XFC]WYA[IB?\ #17PH_Z*?X._\']K_P#'*/\ AHKX4?\ 13_!W_@_M?\
MXY6U_P *G\$?]"?H'_@L@_\ B:7_ (5-X(_Z$_0/_!9!_P#$T?N_,/=,3_AH
MKX4?]%/\'?\ @_M?_CE'_#17PH_Z*?X._P#!_:__ !RMK_A4_@C_ *$_0/\
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M%5T^Z>!WW119E>56\I-_SHJMAMC&D@_9CFM_'=IKR>)8S9VOB*X\0K;-IO\
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MX>TC0M*LM%TJV\8^%%@L=-M4@MXE_P"$AT_A$3"K7MI&:\"^*7CW0OB9\%=
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MOV1JJ[MJ*-W^S7TD#Q7WF"Q,,90CB(JRD=D9<\>8?1117>6%%%% !112'I0
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M]9*\P\^XN)//=9I]\OF[G\U_[S9^ECTJF3$C'WJ_$KXJ?\EC^)G_ &.&N?\
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MD,_J0****TI_&O4B?PL^P?V4O^37O@__ -B=H_\ Z115ZK7E7[*7_)KWP?\
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M+2?B%X;TZ]BFU59;021:O87;M%<2I%N7[+NF/RKM5'S]QJ]*/[6/P1_Z+)X
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M7<KV<^S/4J0]*\M_X:H^"W_17_ ?_A36/_QVF-^U?\$@2#\8_ (/H?%%C_\
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M&H-<16L4<IRJEVQOV[DWX_N[U_WJ\#?]JWQJEMNB>TFN]G^H;P\Z*S?^!O\
M[/7K'[6W_)+[3_L+VO\ Z$U?+-?G?$&;8G 8J-*A+[)^E\-Y-A,PP<ZM>/O<
MQ]R_"GQC<>/OASH/B&[M5LKJ_M5FEMXWW*C=P#7E7[1WQX\1_"KQ'X>T?0K"
MV=+VWFN[F]GMOM31*KJJJL7GP^OWMS?[M=W^SC_R1'PG_P!>G_LS5X;^V1Q\
M1_#/_8)G_P#1J5^L<.8>.88FA2K_ &O\C\ZQJ5"K54?L\QD6?[8GC*SU?3-U
MK::O92W44%U"^CO9.J.ZKN65[KY>O_/)J^U,Y45^9S_\?%E_U^6__HU:_2\'
M'X"O>XHRVAE=:E&A]HX*%3VL22BBBOC3I"D/2EI#TH \5\9_\G6?#+_L :Y_
MZ'95[3V->+>,_P#DZSX9?]@#7/\ T.RKVGL:NI]DICJ***@D**** /'/VDM'
MU/7/!6F6MKX:U#QCIG]KVK:QH.FM!YU]9KO9XML\L2.I8)N1F^9<UP_PZT>2
M3XUZ#JOASX,ZY\+-*&GWEMJ]Q=0Z9;6]Y_JC;JT5G=2[V1D?:S+\N]_[]?3=
M%*/NBE[QRWC_ ,'6_P 0?"UWH5W=W6G17#1,MW9;//@EC=98I8]Z,N]71&&Y
M67Y>E<:WP$@?PKJ.B7/BWQ%>OJ%P][>:G+]A%U/>>9$\5W\EJJ+)%Y$2(JJL
M6W[R/UKUJEIC/GSXI>!(_ ?PFLK?^U;_ %V]O?'GA>]OM6U00"XNI6U_34WN
M((HH_NJB_*B_*BU]!UY/^TK_ ,D\TC_L<O"7_J0Z?7K% "8I"BDY*@_A3J*
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MM'H*6BBR ****8!1110!X=:_\GJ:E_V(%K_Z<;BO;Z\0M?\ D]34O^Q M?\
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MW5D?<8FWMYFY59=N6#I]45Y/^TK_ ,D\TC_L<O"7_J0Z?7K%,84444 %%%%
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M_P# :[ \5#7*6>4_\-8_!'_HLG@#_P *BQ_^.T?\-8?!'_HLG@#_ ,*BQ_\
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M5OXOENM*BBEBW,Z:E_KUBWKM9?-W*SJOFK]VMB3Z5N/@_P"%+SQ4?$4VD_\
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M0+?Q5X=U71[MGCM=0M9;.5HFPRI(A1MI['YJVLBCI]*B45)<LA)V=T>5:G\
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M%Z+_ /+&C_A:7B7_ *)#XS_\"]%_^6-'*PLSTC(HR*\W_P"%I>)?^B0^,_\
MP+T7_P"6-'_"TO$O_1(?&?\ X%Z+_P#+&CE869O^)? 6B>+[G2YM8MY;\Z=,
MMU!;_:I5@\Y7#([Q*X23:R@KO5MM7O$OAJP\5Z)=Z5JEK]LL;E"DD19DS_P)
M#N4_[2UR7_"U/$O_ $2+QE_X%Z+_ /+&C_A:GB7_ *)%XR_\"]%_^6-'*PY9
M'HR *N*=D5YO_P +2\2_]$A\9?\ @7HO_P L:/\ A:7B7_HD/C/_ ,"]%_\
MEC1RL.4](R*Q+GPW87?B&RUJ>W,FH6<$L%O*TS8C60KO&W[O.Q?F^]Q7)?\
M"TO$O_1(?&?_ (%Z+_\ +&C_ (6EXE_Z)#XS_P# O1?_ )8T<K#E/2,BC(KS
M?_A:7B7_ *)#XS_\"]%_^6-'_"TO$O\ T2'QG_X%Z+_\L:.5A9GI&11D5YL_
MQ0\3!6V_"/Q@S=@;O1AG_P J%8&I?%+XHR^3!HGP8OQ-+\IN];\0:=!;Q?[3
M^1+,[?\  5I\C#E9[%/.D$322,$15W,S?PU\V^)=>N_VK=?F\(>&7E3X5VDP
M'B'Q'"61=6=&_P"0?:O_ !)N7][*O\/R=_FV!\#_ !I\651OB[XKAFT<-O;P
M?X55[;3W_P!FXG;][<+_ +/R+7MFBZ+8^']+MM,TNSAT[3[6-8H+2UB6*&)5
M_A15^Z*KW:?^(?PEBRL+?3+."TMH8[>V@18XHHUVJBK]U5%7:**R("BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K(30--37Y]:BL+5=7DMTM)=06%?/>%69TB:3[Q16=
MVV]/F^M:]% !1110 4444 %%%% !1110 4F*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** #%&*** #%+110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pmn-20251231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "] H<# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!17GW[05_?Z7\#_'5WI?B.W\(:E%H]RUOKUWGRK"3RSMF<A6("GDL%)'7!Q7
MPOX=_:9\1? "W\1Z=&FLZEXQO+'2);.QUCQBOBG0R+F\$!U!+AGCEAW-+DP.
M\:ME2"!\U 'Z4T5\ >-_V\_BGX8\!BY&A^$K?Q3IL&KWVHVCH]TMU:6;0JDR
M)%=^7:JQE*,LEQ+(K@*L<F[-=1JW[8WQ.-GX_P!;T[1/",'AW2M5TC0-,DU
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M-RW.APRPVMTL44$JRK'+)(R$B?!!=N5SGG%>R4 %%%% !1110 4444 %%%%
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MJ@OPE\#I?6]ZO@SP^MY;VT5E#<#2X/,B@BD62*)6V9"(ZJZJ.%900 17644
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M-6^E1R6<^J:K<7/BJ_E6W%K;M;JL2./]4#YK%GY6(*#M;?QREM^U'XN\-?\
M"2Z9INCOXGN](N]?UFZEO?.D5K2/6+Z"WM8Y4!6$*ELP\V3*(H3@@DJ ?8E%
M0VEP+RTAG5602HKA6QD9&<''%34 %%%% !1110 4444 %%%% !117)Z]\4_#
M'AKQCI7A74-2:/7M3026]I%;3380OL5Y'1"L2LX*JTA4,P(!)&* .LKRK]F_
M_D2_$?\ V.?B;_T\W==#\,OC+X-^,=G>W7@_6X]9ALG1)BL,L) ==T;A9%4M
M&Z\K(H*, 2I.*Y[]F_\ Y$OQ'_V.?B;_ -/-W0!ZK1110!^.WPQ^)%QX)_;P
MO]3OTMYM*M]9N8)'AN%*!%>=?,5L]#F4@M@#*ERBY8?K[I&KVFNZ=#?6,PGM
MI@2K@$$$'!!!Y5@005(!!!! (KY_3]B#P?IGQ G\=:7J=]%XF:62XC6YL[!K
M$NRLI5X$MDRA#$-M*L<D[MWS5'X.UJ_^$_B=].6UECTN>9;=M*DDWM;RGA(
MYQN+!?\ 1IC@3(OD/MEC3=ZF*KX?'.,L+AU1E"$8N*^VH14>?>3<[+WEUBE;
M6+YO4QV P.$BJF65'.%KSOO&3?317CLK]][72/I"BJFE:K::YIT%]8SK<6LR
M[DD7([X((/(((((."""" 15NO*335T>7N%%%%, HHHH **** "BBB@ HHHH
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MCE.]AT+8)&0*[.B@ HHHH **** "BBB@ HHHH H:[I;ZWHM_I\=_=Z6]U \
MO;!E6X@W*1OC+*P##.02#@@<5^:L^I?#"/XZQ>%K7P-J+:K;>)3X?U'Q2?'^
MIKK41EOQ8VLH*R;FGDE6YN?)8@?9X1(,AAC]*M?THZ[HE_IPO;O33=P/ +RP
MD$=Q!N4C?&Q! 89R"0>1T-?/I_9_^*,OB )+\<;%X49+C[4/!&G?VR6"O&DA
MN"3'O",ZB00#JPQ@D$ ^@?#^DOH.A:?ILFH7FJO9V\<!OM0=7N+C:H'F2,JJ
M"YQDD 9)/%>+?%?]E_\ X61\;-!\?V^O)I,EI;V-I>*MO(UR\-K=R7 C@E69
M%C$HGEBEW(^4;  /->U:%I1T/1;#3C>7>HFT@2 WE_)YEQ/M4#?(V!ECC).!
MR3P*OT ?.OP=_9%A\%^';O2_%^O/XB_T+2M)M)-&>ZT@I9:=;O!:B1HKC<\A
M$LC.=P4DC"_**ZG]E?2;;0?AMK&FV8E%I:>+?$<$0FF>9PBZQ=@;G<EF.!U8
MDGJ2:]AKRK]F_P#Y$OQ'_P!CGXF_]/-W0!ZK1110 5QWQ'^'=KXYTR0!(5U%
M8FB5IP?*GC;EH)MO)C8@'(^9&"NN&45V-%&J::=FM4UNGT:\T;4JLJ,^>'_
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M%6$W9/7ML_N(4D]"]1116Q04444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@"KJHG.F7@M8(KJY\E_*@FE,22/M.%9PK%03@$[3C.<'I7P%\"O\
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MR1DV&FO':.<,&R'+(!@C)YYK"_9K^&:?"WP4VF-X<N= OY!%)>O->I<+=3A
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M88F\J#YE)D?"+N&7KUR">*Z@CFAD2:&10Z21L&5E(R"".H(H DHHHH ****
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MO[,&J^"]0&J>%/&ZZ5J[QW%K+=7>D"Z MYK:QA;RT\Y0DJMI\<BN=R_,P9'
M&/?Z* /FOQ-^QI%J^NW>KV?B.T^V7[WR7AUK11J"F"YF\[]TOG1JLR$N [B1
M&W?-$<"OHG2M-AT;2[.PMP%M[6%((P%5<*JA1PH ' Z  >@JW10 4444 %%%
M% !1110 4444 %%%% !114-ZTZ6<[6R+)<B-C$CG 9L< GTSB@":O*OV;_\
MD2_$?_8Y^)O_ $\W=>)_LG^//BYKOA/69HH;GQC>)::-)<+XZO)](6WU22VD
M;58(I5LI6*Q2B ",1[5WMAAC!]!^'&D?&_X?:+J6G_\ "%?#^_\ MFLZGJ_F
M?\)M?1;/M=Y-<^7C^QVSL\[9NS\VW.!G  /H"BO*O^$C^-__ $3SX?\ _A>7
MW_RFH_X2/XW_ /1//A__ .%Y??\ RFH ]5HKPJR^+/QAO_'^L^$(_AOX'&I:
M5IECJL\K>.KSR6BNI;N*-5/]CY+!K*4L"  &3!.2!T'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U<_X9^+/QA\5:UXLTRT
M^&_@>.X\-:FFE7C3>.KP+)*UE;7@:,C1R2OEW<8R0#N5QC !(![K17E7_"1_
M&_\ Z)Y\/_\ PO+[_P"4U'_"1_&__HGGP_\ _"\OO_E-0!ZK17E7_"1_&_\
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M::+<7EW+K>B:C=>*O#/Q8$*SM<O.RI>V.KV^]1([HP163:#&J[#&8B#]G44
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910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pmn-20251231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &  LH# 2(  A$! Q$!_\0
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M^<_YQ_\ Q5 %JBJOVR7_ )\Y_P X_P#XJC[9+_SYS_G'_P#%4 6J*J_;)?\
MGSG_ #C_ /BJ/MDO_/G/^<?_ ,50!:HJK]LE_P"?.?\ ./\ ^*H^V2_\^<_Y
MQ_\ Q5 %JBJOVR7_ )\Y_P X_P#XJC[9+_SYS_G'_P#%4 6J*J_;)?\ GSG_
M #C_ /BJ/MDO_/G/^<?_ ,50!:HJK]LE_P"?.?\ ./\ ^*H^V2_\^<_YQ_\
MQ5 %JBJOVR7_ )\Y_P X_P#XJHY=0DB3<UE/C('#1]20!_%[T 7J*J_;)?\
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M1LTGV_ FHJ'ST/\ $OYT>?'_ 'U_.IYD/FCW(],_Y!MI_P!<E_D*M53TM_\
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MN5.YI&/+$$NS9+2/DBO0M,TFTT:SCM;*VBM;:,82*) JJ/8"N?FJ5/AT7?\
MX'^?W'-S5:K]SW8^>_W?Y_<>-Z?\$[GQ WVCQOX_\7:XQSBPM]9DT^%5/\+_
M &!+991[E!Z'/)/2:;\"?A1I)+6_@'PSYY&'N)M)BEG?_?D=2['@<L2>*]-'
M6EZUK&FHKN;PIJ"MOZG GX2?#0_\R/X8_P#!+!_\;JK<_!#X4W<F^?X>^$IG
MP%S)H-LQ !R!DQ].2<>YKTC/%'45IHS2R/,_^%#_  CQC_A7'@[_ ,)^V_\
MC=!^ OPB;K\-_!Q^OA^V_P#C=>F<^M'/K2Y5V%RQ['EG_#//P;VA?^%:>#=H
MZ#_A'[;_ .-U!=_L\_!Q("5^&?@T'<HR/#]L."PS_P L_2O6L55U#_CV/^^G
M_H0I<D>Q/LX=CS1OV=_@\<;/AUX4@(R0UOHT,1Y]U0$]OR]J8_[.?P?EQO\
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M !JU10!5_M"S_P"?J'_OX/\ &@:C9_\ /U#_ -_!_C5JB@"K_:-I_P _4/\
MW\'^-']HV?\ S]0?]_!_C5JB@"J-0L_^?J'_ +^#_&D_M"S_ .?J'_OX/\:M
MT4 5?[0L_P#GZ@_[^#_&@:A9C_EZ@_[^#_&K5% &=<R:9>Q>7<O:7$>0=DI5
MAD=#@T:3';I'.ELL:0+*0JP@!>@SC''7/XYK1JK9_P"MNO\ KJ?_ $%: +5%
M%% !1110 4444 %%%% !116;K][>Z=H]W<:?9)J%[&A:&VEG$"2-V#2$':O<
MG!( . 3@4 :54/W@UABQ4Q>0-JA2&!W'.3GD'C P,8.2<C'@J_M<P2^&#K4/
MAQ+VTL;/4=7U>XLM466VBTZRN?L\MU:2^6/M0<AWC!6,,L4F2IV!_?1_R$A_
MUQ/_ *%0!<HHHH JR?\ (3@_ZXR?S2K55).-3@_ZXR?S2K= #<TE!/&*\1^/
M_BFYU_4],^%FAR2'4=>A,^L&V;9)!I?S*4$@R8GN&5HP^-RQQW3I^\B4'.<E
M!<S,YSC3BY29D:SXD;XV^)HUAB_M3P+:3$:9I*\)XCN8F^:\G8@@:?"X CX(
MG=2X#H(?-]AT#PI]AO9-4U"4:AK<R;)+HJ55%Z^7$F3L3/.,DD@%B3BF>"?!
M=IX/TU8H8H1<2*BRO#$(D"JNU(XT'$<2* J(/N@=222>G48K&$7-\]3[NW_!
M,(0E4?M*OR7;_@BJ,"G445U'6%%%% !1110 4444 %5=0_X]3_OK_P"A"K55
M=0_X]3_OI_Z$* +5%)G-+0 4444 %%%% !1110 4444 %%%% %73/^0;:?\
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M30K 02W#+)=WTS&6ZO7 P'GF;+2$#"J"<*H"J%50HZO JO\ 88_[\W_?Y_\
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M#WF?_&B2J?9:&N3JCQQOVR_A:I .H^(AD\9\':S_ /(E20?MA?#&X;"7WB$
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M@Y65+0#(*R2#K:TO]F?P[=NMYXXN[OXBZCU;^W"/L*-@ E+- (B0<[9)1+,
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M?BG\44RI_P"$ T63&+G48E>^D3INBM(Y"(25((:XFDP01): \#K?!OP1\/\
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ME2YP!EBH)QTKLAAZ-+6_,_ZZ_P# -FY/9V1*GQN^(OBR2-?!GP?OA [[#?\
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M>/)D*GXW>,@#_=M-#4C\1I8Q39/A1XYMK?YOC/XMF VC$UGHI_B')(TT9/\
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M*NBO;@'<L?A(*Y/;!-T0/R-,_P"$%^-'V_/_  M;0_L.?]7_ ,(E^]QCIO\
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MX;_XNCR;S_GX@_[\-_\ %T_:+I%?B/G2VB>#?\+)_:)\[/\ PIGPYY6<[?\
MA,5W8],_9\9]\?A6XOQ+^,IL03\%[+[;N ,?_"8P>5M]=_D9S[;<>]>O>7>?
M\]H/^_+?_%TGEWA_Y;V__?AO_BZB4T^A+E?H>3V_Q*^+[2#[1\&+:-.<F'Q=
M;N>^.#"O7C//&>])#\2OC ;@B;X,VR0XX:/Q=;LV>>-IA QTYSZ\<<^M^5>?
M\]X/^_!_^+I/+O?^?B#_ +\-_P#%U-_(D\H3XD?%LO%N^#<(0KF0CQ9;DJWH
MH\H9'3DD=^/6I>_%/XJ6-XS1?!"[OV:-01:^*-/&W!;&?,9/?IFO8]EY_P ]
MX/\ OPW_ ,7598[O^T)OW\'^JC_Y8GU?_;I?(#QF3XX?%J,X/[/.MGME?$NE
MGL/^FWO^AIT?QL^+3IN_X9[UE1N"X;Q-I8/U_P!=TKVKRKS_ )[P#_M@W_Q=
M'E7O_/> _P#;%O\ XNKYHV^$KF78\8N/C/\ %J!<_P##/VKR_-M C\3:621Z
MX\WI^OM2P?&;XM2Q;_\ AG_5H_FV[7\3Z8&^N/-QC\<^@->S^5>?\_$'_?AO
M_BZ/*O!_R\0?]^&_^+HYE;85UV/)C\8_B/#A9?@-XGEDYRUIKNBO'U/0O>(Q
MZ9Y4<$=\@5IOCMX_M]F[]GWQL=S;1LU31&Y]\7YQ]>GO7L>R\'_+Q!_WY;_X
MND\F\_Y[P?\ ?AO_ (NI378$UU/"X_VE?&DEP\ _9Z^(8D7(),VEA3CKAC>!
M3[8)SVK7/QN^(0C#_P##/WC,CT&L:%G\OM]>NB&\/_+>#_OPW_Q='DWG_/>#
M_OPW_P 73;B]D/3L>/7/QV\?VB;G_9^\;,/^F>J:(Y_);\U2N_VC?'%E"LLO
M[/?C\JW0176DR-^*K>$CIZ>GK7MWEWG_ #W@_P"_+?\ Q='E7A_Y;P?]^6_^
M+IIQ6Z!-=4>"S_M0^+K9]DO[/OQ&5B 5"+82YZ<92Y8#KW(_0X]9^&_BJ?QK
MX6AUF[T+4?#-S=2.7TK5XPEU;E3MPX!(Y"[A@D$,#70>3>'_ );P?]^&_P#B
MZ2P5P;D2%6;S3DJI4'Y5[$FB3BUHK VFM$7J***@D**** "BBB@ HHHH ***
M* $(S58_\A0?]<3_ .A59S5$0JNL-(-VYH IRQ*\,<8&< \G) YXR3@8 +]%
M%% %609U.#_KC)_-*M55D_Y"<'_7&3^:5:H **** "BBB@ HHHH **** "BB
MB@ HHHH *JZA_P >I_WU_P#0A5JJNH?\>I_WU_\ 0A0!:HHHH **** "BBB@
M HHHH **** "BBB@"KIG_(-M/^N2_P A5JJNF?\ (-M/^N2_R%6J "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!",U2O98TGLE9E5I)L(&."Q"L< =S@
M$_0$]JNY%5;S!DM.G$P_]!:@"W2$9I:* *MW_K+7_KK_ .RM5G&*KW?^LM?^
MNO\ [*U6: "BBB@ HHHH **** "BBB@ HHHH **** "JJ?\ (2F_ZY1_S>K5
M54_Y"4W_ %RC_F] %JBBB@ HHHH **** "BBB@ HHHH *JV?^MNO^NI_]!6K
M55;/_6W7_74_^@K0!:HHHH **** "BBB@ HHHH *R]8FOFC-KI\?EW,\4HBO
MY8EEM[:0+\AEC\Q'<$G[JD9 (++D&M2J6IZ99ZYIMUI^H6L-_I]W$UO<6EU&
M)(IHV!5T=&!#*P)!!!!!(- 'R-K/QN\>O\)?"OB >)Y-.U:V^&#^-)%AL[8+
MKFH(+?\ <NCQMMB)<*4A*-_I2X8$*:^LVN6357!MY]BQ "0)N5B3G (R<C'.
M0.W6L.S^$G@C3K#2;&T\&^'[:RTBZ-]IMM#I<"1V5R229H5"8CD)).]0&R3S
M77 8 H K?;T_YY3_ /?IO\*/MZ?\\I_^_3?X5:I"<"@#)DU*(:M;(4GWM!*P
M'DMT#1YYQ[C_ "#5W[>G_/*?_OTW^%>!>*OB?XIL?B]>BVU<P:3I?B;1O#@\
M.BVA9+Z&]@1Y+II"AF#H9B5V,$Q:N&5LDK]##I0!6^WI_P \I_\ OTW^%'V]
M/^>4_P#WZ;_"K5% %7[>G_/*?_OTW^%'V]/^>4__ 'Z;_"K5% %7[>G_ #RG
M_P"_3?X4?;T_YY3_ /?IO\*M44 4(M4BEW%8Y^&9?F@<<@D'@CID=>AZ@D&I
M?MZ?\\I_^_3?X5:HH J_;T_YY3_]^F_PH^WI_P \I_\ OTW^%6J* *OV]/\
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M_A5JB@"KIRLEA;*P*LL2@@]0<#(-6J** "BBB@ HHHH **** "BBB@ HHHH
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M:?X[\(65\;43Z5K-BD_V6\C5M\,T8.R1<E3E6P1R.HY%8G_"E?A\?#B>'O\
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MU_\ (='_  W#\(O^@IXB_P#",UK_ .0Z^3**/]7:7_/Q_<']OS_Y]_B?6?\
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MF45?^KM+_GX_N(_M^?\ S[_$^L_^&X?A%_T%/$7_ (1FM?\ R'1_PW#\(O\
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MPH^AOB/XTO5A70?#W_D?O#?_ &$K;_T:M<_4EO<2V=Q'/!(\,T3!XY8V*LC
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M)(ZBO&OB-^U%;6/B6Z\%_#C1I_B)XWMW,-Y%IZLUAI#@XQ=W"@JK@Y A!#9
M$C0J=XY[2?V<O%'Q'U.UUWXHZRMW?131SQ0#,CVP#!BMJBL(+$'E"46:X*%@
M;MP0%S<[.R5V8RJ6TBKL],_X:@^#F,_\+:\"X]?^$DLO_CM/A_:9^$%U/Y,/
MQ6\$2S8SY<?B.S9L?029]:L_\*#^'[G=<^%;'4F/5M34WAZ8ZRECP.!Z<@8S
M45Q^SM\,KN#RI_ /AZX4D,QFTZ)V<_[;$$L/9B<CBE>IV7W_ / %>K_*OO\
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M2".18E4YSE<$\'\J[/QM\+=&\3>-]$O-+L;33M(M[R>RUB*W0111>06?<P4
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M81&&VM+"(QQQJ3DX!)//'?'' %-^'5QIEEXWT:ZUBY^R:=;7"W$LOEL_W#N
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M6\*_#*/PGIGB:XU347\2ZOKEVNHW][=VT<:O)';Q01!(E&U0J6\9[DL68$9
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M_P"_8_PH_LZS_P"?6'_OV/\ "O+O^&N/@?\ ]%A\"?\ A1VG_P <H_X:W^"
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M['^%']G6?_/K#_W['^%><_\ #47P: !_X6YX%QV/_"2V7_QRC_AJ+X- ;O\
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MO'-<A6ACG<!2$=U9BR[5^909CCJTFDIO77?SM^HW@J"7P+3R.,_X9?\ '?\
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M=4NKC5M9_LV&"!(PXPXAE+.P)(!4( K%G7@%_7ZUF^=Z?U^@?4:%^7D7]?\
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M%4D?ZU02IR0!4K'5W9<[U&\%05_W:T.)_P"&7_'?_11/#O\ X24__P L:/\
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M4L\CS,JJ .223P, Y)KQ.7QSK_QWN6L?AC<RZ'X,60Q7OQ"D0N;@#[\>E12
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M ,DI!(VJ!WW_  O3P_\ ] 3QW_X;_7?_ )"H_P"%Z>'_ /H">.__  W^N_\
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M_P -_KO_ ,A4TX73OM^FWW6%:3OIN>A45Y[_ ,+U\/\ _0$\>?\ AO\ 7?\
MY"H_X7KX?_Z GCS_ ,-_KO\ \A5?/'N3R/L0:_\ \G'>!O\ L5/$'_I7H]<Q
M\6?@]XH\0^)?%=]X8CT&YMO%_AU/#NJ?VY<2QFS"--LGB1(9!/\ +<R9C9H@
M2B_/R<9FN?&;0Y/C[X,O1H_C,10^&=<B9&\$:TLK%[G2B"L9M [J!&=S*I52
M5#$%U!]!_P"%Z>'_ /H">.__  W^N_\ R%63Y);O^K6-%S+9?UN6-:TOQOX?
MT;1=.\&'0;R*RTZ:WG?Q!).CR3+ %M2#$" ID&9,@G;]WFO.-!^"_C'Q!\-_
M&WACQE;Z+9:OXHM)#>^*-/UF;4)Y[PKM1C!):0+'#&  D:N0%4#DEG/?_P#"
M]?#_ /T!/'G_ (;_ %W_ .0J/^%Z>'_^@)X[_P##?Z[_ /(54W&3;<MR5&44
MDEL<K)\+O&?C"'QGJ7B8:'IFMZIX7;PUI]GI=]/=6R B5FGDD>&,@L\BC:L9
MVJF=SEL"S\)?A&_AC0]1T6]\ >$? ]M=V<5O<:AX&U::*[O60$;G>.TM70C+
M$,LA8%CC&23T/_"]?#__ $!/'?\ X;_7?_D*C_A>OA__ * GCO\ \-_KO_R%
M27)%W3_K5_JP:DUM_6G^2.6^)7PT\8.O@O3?!>GZ9J.D>']6AUEKCQ1XIOGN
MY9%\X&$N]O<NRD2 AVD)&-H4  U>^,?A?X@>+[WP8V@:/X:EAT;4[;6;AM2U
MVXMV:9%E5H$"64@*X<$2$@G!!C'6MO\ X7KX?_Z GCO_ ,-_KO\ \A4?\+U\
M/_\ 0$\>?^&_UW_Y"H]SOUO\]/\ (>O;I;^OO9WUJTS6T)N42*X* R1Q.756
MP,@,0"0#D D D<X'2I*\]_X7KX?_ .@)X\_\-_KO_P A4?\ "]?#_P#T!/'G
M_AO]=_\ D*K<X]R%&78]*_9/_P"36O@[_P!B=H__ *115ZM7E/[)O_)K7P=_
M[$[1_P#TBBKU:O%/1(IX_.AD17,992H=>JD]Q[BO&?@C^SW<?!_6I;V35=)U
M2.2S2T06^C/;2PX2)7,;FYD5!*T1EE"H#+*V]B=H ]KHH *H:Q(T>EW)6-I3
ML(VH0#@\$\D# !)/? XR< \UKOQ=\(^&=8UG2]3UJ&TO=&T>37]11U?;:V,?
MWIG8 @  $XSN(!.,4OA?XA:5\0=$UF33DO;>;3I39WMEJ-I):W-K,8DF59(W
M ()BFB<=1AQWR  =G1110!4U4_\ $MN_^N+_ /H)KP3Q-&/$G[9?@?3V(,6@
MZ%J.N 'DK+^[M%^F4O9?K@^E>]:K_P @Z[_ZXO\ ^@FO#/A;C7?VJ/C%K'E[
MHM.T_1]&BE8<J^+B:91]0\!([X!],\E;6<%Y_HSBKZSIKS_1_J>I?$;QF?!/
MATW%M:?VEJ]W*MEI>FA]IO+M\^7'NP=J\%G;!VHCL00IKQ^Y\+R>(]0/PBL[
M]M16X5=7^(WB&(F.2X$P&+)2IS')<A-I4$F&TCVC:9('%CQU\0F3Q3?^*K6R
M_MN;1KEO"WA#1P^T:IKDPQ.^<':D04QM( 3%'%?,05!SZA\*OAX/AOX46QGO
M3K&MW<S:AK.LO&(Y-2OY /.G903M!P%1,D1QI'&ORHH&L?>;ET-H^_+G^XZR
MTM8=/M8;:UA2WMH4$<4,2A415& J@<     <<5D>-/&^A_#WP[<ZYXAU&+3-
M-MRJF60%F=V(5(XT4%I)&8A5C0%F8A5!) KFOBE\9-,^&IT_3DM;GQ#XMU9F
MCTCPSIA#7=\X R<$@11+D%YG(1 <L1QG'\$?";4;KQ'!XZ^)5]:Z]XO@0_V=
M96RG^R_#R,#O6T5P"\I!*O=. [C(41(3'34^:5HG1:RNS$B\$>(/VB9;?4OB
M!8W'ASX>Y$MIX#F8"YU+!RLFKE<@+P&%FK%>?WQ<DQ1^W6UM%901001)#!$H
M2..-0JHH  4 <  <8]JXN3XG?VY(T'@S3'\4RJ2K7PE^SZ9&0<'-T582=P1"
MLI!!#!:P?&BVOAS07UCXI_$*'2-%+A'L[:==+L6<@[8A(29Y6." @D <\>7@
M[1NJ2CK+3\R.>^B.LUGXH:!H^H3::EU+JNK18#Z=I5N]W/&3T#K&#Y>?5RHQ
MDDX!-<SXO\?>-M&\+ZIXA70-.T'3=-MWNY%UB[$]S(B#)4QPGRX\@'Y_.?'=
M36+H?BWQ/K]C%I?PL\ P>$O#:<1Z]XNLI-.@0$@EK?2U"7$Q'S9$QM 200S"
MKR?LVZ/XH'VCXE:I??%"]8?\>^N%4TN$X/\ J=/C"P J2=LDBR3+Q^])&:UC
M.G%KW;^I+C)[L[W_ (61X27@^*-%S[ZC#_\ %4?\+(\)XS_PE&C8]?[0A_\
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M8B0E8;M9=RK7U/K;6]<TWPUI-UJNKZA:Z5IEI&9;B]OIUAAA0=6=V(50.Y)
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MF$;L0L"MWC@6./T45Z129%9EE;[!'_>F_P"_\G^-'V"/^]-_W_D_QJSD49%
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M /0;\>?^' UW_P"3:/9R#G1[E17AO_"BO#__ $&_'G_AP-=_^3:/^%%>'_\
MH-^//_#@:[_\FT>RD'.CW*BO#?\ A17A_P#Z#?CS_P .!KO_ ,FT?\**\/\
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MFT?\**\/_P#0;\>?^' UW_Y-H]G(.='N5%>&_P#"BO#_ /T&_'G_ (<#7?\
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M,OLX)\N3^Q-1WMSQE?MF!_WT?QKV'[+-_P _DWY)_P#$T?99O^?R;\D_^)H
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M0UY_\N*]XHH]K/N/DB>#_P#"HOC!_P!%'\$?^$->?_+BC_A4?Q@_Z*/X(_\
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MO%%/VU3N')'L>#_\*C^,'_11_!'_ (0UY_\ +BC_ (5'\8/^BC^"/_"&O/\
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M>2H._<=@^JJ *OD7/_/T/^_8_P :/(N?^?H?]^Q_C5JB@"KY%S_S]#_OV/\
M&CR+G_GZ'_?L?XU:HH J^1<_\_0_[]C_ !J-(+Q6D+72LN1L"Q8(&!D$Y.3G
M)R ."!CC)O44 5?(N?\ GZ'_ '['^-'D7/\ S]#_ +]C_&K5% %7R+G_ )^A
M_P!^Q_C3);.:9=CW&5R"0$ Z$'U]JNT4 (.!2T44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (1FEHHH **** "BBB@ HHHH **** $/ KY\\>?'
M'Q7X,^(&N:7'IUAJ-O:W\"Z?8I+)#/- ^F2S>9,?)D A-Q$R"2/D%2"#M*M]
M"4@% 'R[XG_:R\9>$K*]^T_#FVO+R&Z\A'@UM(+3"S:A QDGN4A5"\FG8C&2
M2+F/@L K]K\5/BIK?P_UWQ1J-KMO;#1]$TJXCTFYN(+6!I+J]N8I99)G7<"B
M0J54.H8AEP692/; N*SSX?TPZX-9_LVT_M<0"U&H>0OVCR0Q;R_,QNV;B3MS
MC))QF@#B_A'XIU#Q/<^*WO+R>YMXKZV>RCN;<0O;0S6%M<>5M\J-\*TS@>8N
M\#ACD8'HN,UG:7H.F:+-?2Z=IUK82W]P;J[>VA6-KF8@*9)" -SD*HW')PH&
M>!6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pmn-20251231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "M BT# 2(  A$! Q$!_\0
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M,PVO-<DS2M,^W"C+*J@=.F,?Q/\ LJ_\)'?>-+G_ (2C[/\ \)'X@T[7=O\
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M/^'H_P"T[_T4W_R@:7_\C4?\/1_VG?\ HIO_ )0-+_\ D:OF.72]@&)-Y)P
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MY0-+_P#D:C_AZ/\ M._]%-_\H&E__(U?./AO1IM8GFBM[8W,BQ,X51D@ 9)
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M2<*H 'X=!39+<JQ!7 SV%',M@YUL?3W_  ]'_:=_Z*9_Y0-,_P#D:C_AZ/\
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M_P!BUX@_],]Y6T7S*YO&7,KGMO\ P]'_ &G?^BF_^4#2_P#Y&H_X>C_M._\
M13?_ "@:9_\ (U?*ZC@UT'A'19M:U%H(+7[5)Y3L(P,G@9X'<\=*T275V0Y2
M4$Y/8^B/^'H_[3O_ $4S_P H&E__ "-1_P /1_VG?^BF?^4#2_\ Y&KP^*S@
MA!4VT!)Z[H@2/IQQ2R643L6%K"!CM$N/Y5]H^&)J'.ZJMZ,Q]LCV_P#X>C_M
M._\ 13/_ "@:9_\ (U'_  ]'_:=_Z*9_Y0=,_P#D:O%+?3;5$<&WA)QRQC'Z
M4IL;8 J+2 ]LB,=/6NFGPC6E3C.55*_D]#&6+BG:Q[7_ ,/1OVG?^BF?^4#3
M/_D:D_X>C?M.Y_Y*;_Y0-+_^1J\-NK2UBL+W?;0DM'\C", A@1@@]OZ\UR/V
M5^2$)'J17R6/P-7+Z\J%7IL^Z.V$E.*E%_\  /J$?\%1OVG?^BF_^4#2_P#Y
M&I/^'HW[3O\ T4S_ ,H&E_\ R-7@UA-IVEVD$RV\,MPB[B)XA*'?KRK C'3M
MSS65$HU&[DN9$A1W<ML2-40$G/"@  >PXKS87D[6LCKJT/9V7,G<^CO^'H_[
M3O\ T4S_ ,H&F?\ R-1_P]&_:=_Z*9_Y0-,_^1J\">R@^7$,?/7Y!2P:2)9-
MD=LKL3@*(\FOKHY#&5)5OK$>7OV.%S:=K'O@_P""H_[3N?\ DIG_ )0-,_\
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M/$5AK%@"EU9S)+&^W(W Y&?8TL33G/#SC3W:=K[7)KQE.E*,=VCT7XF^#U\
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M1TA+B+S(P5EQPP7 KT[]G?6=/\(:V_B(6NEZQJMA"XCTK5(&G'FA21(8UQN
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MW4_9ZE=8S(\5'VEJ/NMZ*][^[Y^6GY'D18\\<9Z4 !^W-2Q/$CY?YUS@_2K
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MSUVZGJ1PL:BNI)KO?3>WYGE<IS*_U-?47[&O_('\3_\ 7>#_ -!>OEZ<!9G
M.0&//XU]0_L:_P#('\3_ /7>#_T%Z_+Y_$QGB?QR_P"2V_$'_L8=0_\ 2F2H
MH%Q9H21]T?RJ7XY_\EM^(/\ V,.H?^E,E<\^JS- $4K&-H!QWK])X*SC#9//
M$U,0F[Q227?4X\33=1)(>R*LC; .2:>BCKBH+.02)M8X8>M755@!C&*^JP$8
M8J*K4UH];+H82]W1D) SGO[U#/&9$8,.1R*N2J, CEO054N[G9%@KAB,?2C,
M:=*C1J>V=E;[_P#@CA=M6,MA@T;C2MS2$#%?C=FFW%G>)DD59BT^:4 X"C_:
M.*LZ99"2,RLN<=*TX8/,4EO2OO\ ).%IX^$:V(O:2NDM-.[?^1RU*ZB[(PI[
M*6TP7'!/!%3:?=%'\L\J3Q[&M7RU=&1SN'H:Q;JV-K,,'@\@TL?E=3(:T,=A
M&_9WU3=VNZ?=,<:BJKE>YM%B%&.*@DB)D##G%0V]V)8RK$;JL1.-P4L"37VT
M<7A\QA!WNG;KLSEY7!BDG(SG/M3@A./7UI00DF.H'4#O4L<L:E@S 5[-"E3G
M.U6=O4AM]$4]8C$=GC&/F%;/Q!_Y%/X9_P#8O3?^G;4*Q]9:-K'"ON;<*V/B
M#_R*?PS_ .Q>F_\ 3MJ%?CW&JA'-;4VK<L=G?N=^'OR:G(VZY3\:DF4C@9/&
M:CAE*PXP,9ZT@D=C@\U^>6U/94DH)"#D4I(8^E#*R'D$4TC-49O30!4D@#(O
MTI5BW"G!"1MQR*FYJH.UF/MKV6SX4YQV/-/U76[K5BOVA]P7H,5 D83&?UI'
M5,,Q!![8Z5/+%RYK:FOM:RI.DIM1>ZN0 9J6%VA;<C%6]J9T/O0!DUHSCC[K
MNB2XN//<,1@]Z(V^8<5+9K [,)F*K@\CUI]G9/=&3R@&V*6)+ <#ZU#:6AU0
MA.I)26K?WD>W<PXSS5Z'2[E[(SA (0<$DCM_^NH5A9P,@*O<TY[B1D,9<^6.
M-N:R;;T1VTX4XWE43VTZ:_Y%M'\J/8VW(Y&WFJMS>/(X()4KT.:6WMGG=4)V
M@]">*@G@:-V1B!M[FE%*YM5J5'3NE9'2_#3FP\<_]B]-_P"CX*P-*D\NP)Z'
M>?RP*W_AI_QX>./^Q>F_]'P5R5NP%L^<?>Z5T37-&Q\I5CS*Q<NQ'*"1)DCM
M5+C'/7K1'&SL6480=?0#WJT;"5HGD3:R(NYL,.F0/YD5*]U6N0K05KE9BI([
M4X+NR%X'OTH"%B#LP!Z<YJ=( -S*I8*1D=J&[ W8C=2\0Q\Q'I42#@,F0>YJ
MTL;SF3*\GDD# '/:H@(XAZ^H!H3!/H57+LQR2QSUJ6.UW8YP?>IH\!&78#O(
M.XYR![5,BF0!5&>W'-#E8<IVV(3:!AT X[55EA:-L-R1[UK&)4+)N+8]*@E4
M%=V!QVJ5/N1&H[ZC+";'!-:$JJL:G=N)&?I68L6P@'/'M5V-6,7S*<]LU,UK
M<SJ+6Z$)W CH/3-.9VD55=FP@PB=<<_IWH^SR26QF\MQ&I"F0#@'TS488]-I
M)[5!"+4*#*LP[XQFMGX)?\CGJ/\ V+7B#_TSWE8JR?=!SUZ>E;7P2_Y'/4?^
MQ:\0?^F>\K6EU-J&[(OA]<I;6%\[LJ@2)]X@<8-6-8OK?4)RD4RML!P!W^E<
MII+!;6X.1U7 />I;>*5YS-& JKRV>BC..:_3,-Q!7AEM# 62IQ>O=J[8_8KG
M<UNS2BC!'S'&.<5)+@@;>U3I:B>!I8V1D5=Q 8=/ZTB LN53&!VYS7VV#J86
MM2YH5%9]M_N,9*2=K$"P!\X.&'KTJG?)YL7R8?;UQ6PU@ZI(8XG<XR??UK-6
MVEGGE5TY8%C@8 KX7B/$Q48T%'7=L[*%.7Q&7"NX@P[@>A/?-0S)/),0VYV)
MQD\YK05(K4<@,0>0#S]*LZ4RI<C=&K++]TL#E1[5\?@Z$<5B:=%NW,TK_,Z9
M/EBV1V6A+D>?AI#_  YX%:!TJW=&C>%4;'!7@BM*" %@RC.1C &>:EGAVR8W
M;RN.GTK]XI9%A<'AW'D37FD[KNV?/O$3E+1G&W^G3V;JC'S$ ^4@Y&*V/#MZ
M2 FXAU/KV[5J3%4(=D5M@R%/<CL:Y^R\E;M6E=[>,DL2B;L=^E?GV+IKAK,5
M4I:TI+;\U\MT>K22Q=-)OWK_ -,ZP^68U).\$D@8[58M[2R-K*TTKQ-G*!>?
MS_2LBUN1)&Y*LP'W>>_O5P2&Z@9TCR(P"[+_  CW]*]O#YGA,9S15176OGZ#
MA2>&?/**?K^>A=@E4)&"7!P=H;GTZ>F:F4;F (R <*/05F>>MN\8DRXWY8#L
M/_K\U<NM0"S84[DSG;WYZ?A7T&%S'+TY4HN\EO;4SKTZWLE)Z+MM^!Y1/_KI
M/]X_SKZA_8U_Y _B?_KO!_Z"]?+TQS*Y]S_.OJ']C7_D#^)_^N\'_H+U^ U/
MC9T(\3^.7_);?B#_ -C#J'_I3)7*!-R9KJ_CG_R6SX@_]C#J'_I3)7(J^4 S
M7IY=*,92YNQ,AI)5@1U%6(KZ4X488].:@8BI+#:+D9KVL'5K0Q4*=*HXJ32=
MC.25KM&FF\K\PY'I5:\MX_*+AOF!_.KF,]Z1[#[4GS':%&0%%?J.*P$\9AY4
M:4.>5M+]^]_ZN<49).[T,)B.U"J3SVJT]C()?+ SWS5M-*7&7D.>X K\RP^1
M8[%5)*-/X='T5_GO\CL=2*6X:3*R;H_Q%:<DH09QR:QI;&6V8R(V57G(ZTG]
MI2$#?@U][EV=RR;#_4<;%QDOA>ZL<LZ?M'SQ-/S@#N. 36;J4BNRJ!DCK2&_
M9^%3YJDBC"8W %SR2:Y<;F/]L4GAJ$O=ZNW]:LJ,?9OF90$3XR%;'KBG1NT;
M @D.*U]KE<@X&*I7A50IX#UX6)R58"'MHU'IKKI]VIK&ISZ6&F^E ., GN!S
M44=P\;%NN>N::PR..M-5"QX!->5/%8F<X^^VUL6DNQ+=70F@"[<'.:ZGX@_\
MBG\,O^Q>F_\ 3KJ%<M=6;00!V/)(XKJ?B#_R*?PR_P"Q>F_].VH5XN<?65B%
M];7O67W=#2G:WNG%ASLV]LT]9"%P!R>]1#I2C@BO":.A2:+<<[,/+<=?6I"T
M:KA4!8]ZKK_K4)YJ;RSNXY':LFDCT(2DT/2X8=\?A3FFVDD?-FH'PK#O31D$
MU-D:>TDM 4,Y.X_+Z5))M*;<#(Z&HF?^[1ORO-68*22:&;233EB8DC&:4!BI
M(&0.IIRERP .#1=D**&K"6<*%.[..*ZB/P?$NA_VA-JD%M,6^2V<?.Z]V&*E
M\/\ @J]NECNKD"TCD^:,W *"11U(X_#\:N:_X:FTL%I8E)E;*,'/S#KG;]#^
M>:\^IB(RFH0G9GV>!R:I3P\\5B,.Y1:TNVK7V>FOIT,2'2Y9I&@C=9SDLC(<
MDCW'45%-8R6CYECW-UY'!J_I5C>)>^=IZRNR+EFB4_*/>O2K3X9W.MVX.IZB
M&<1;80C;O+/4?ASR/>N6OC(89IU):?B>[E7#>)SJ#CA*3<UZ<MO5_/N>/R-(
M[C: 2>@455NHG+MOSGJ1TQ6A??:/#^KSVY8+- Y1F4Y!(XJK=7)N7#DAG89.
M!C!KTX-NS6S/A\1&*4J<VU-.S7H=!\-/^0?XX_[%Z;_T?!7$J>*[;X:?\>'C
MG_L7IO\ T?!7$#I78?,DJLWW,X!(J4AH652^1Z"J_2K(5F9&4<"H9FR5'\W
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M! 52#]_.&)X'4<\8KGO"7@Z#QAK<&F0W\5A/,&VM>N$A7:I;!?MTP*RBC2N
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M)69N'+,0-FTX"MR,@U@Z!\')O#;N_B6.6._),36$61-; ,,ESM*C.>F>,Y/
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MV&&[T^M?-^JVESIMQ*9HR)"Q#;U(.?<'Z5W7PQ\4:7<ZU91ZOJ#:3H\,322
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M>E'5K[45^MNYNJRJQY>I?*_+@8Y[55O,+;R!NE1#5DV_ZLAAZ&J=S=R77!&
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M PRLK$KN/7CUS_GO6<(J$;&$(*$+'H?P-\2:9H/Q#TN?Q!#'<:*S,+J*2-I
M4VM_".OTZ4[Q_P",[#4?$FJ?\(Q8KI.@/-OM['K\HXR0<]>N,UQ>EZ7+>NQM
MU=]JDD@=\>U%NCF5F*MOC&6(_A'3_"O,EA:3Q+Q%W>R5KZ;WO;OYGDSP5%XM
MXJ[YN5*U]-[WMW\SH+.30M5TK4+?5K);349 9+/4K3("2#G8\8X*'D< %2<\
MCBN0FM9--G:*=0<=\Y'(K4B'VEF3.YCPI!P,U7CY#[AO!!&&&:ZZ?N-ZZ/\
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MINJ6VMZ:+'5)T:2QU>P)0P3#!"20CY6C;!7@ J6R"0-M95J);N=B1(7B7>[
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MO5K<8^UJ<\,,HI[I2_X!FL/9:L_)1U1<JSJ21ZBLEPN2.#7[ _\ #DCX<?\
M10O%/_?JV_\ B*/^')'PX_Z*%XI_[]6W_P 17@YCG:Q_+^Z4;>=_T-84^7J?
MCUD#N*E%U\FW K]@/^')'PX_Z*%XI_[]6W_Q%'_#D?X<?]%"\4_]^K;_ .(K
MQ88VI2O[/2YIRI[GX]M(3&1GJ178_$'_ )%/X9_]B]-_Z==0K]4_^')'PX_Z
M*%XI_P"_5M_\16MK?_!&KX?:YIN@64OCWQ+''H]BUC$R16^75KF>X+-\G7=<
M,/H!7+4J.HTWT&E8_&2)PJ\FI6E0X.X5^P'_  Y'^''_ $4'Q3_WZMO_ (BC
M_AR1\./^BA>*?^_5M_\ $5@U<WC5<58_($3H!C<#4MM>Q0R9=5E7H0<U^O/_
M  Y(^''_ $4+Q3_WZMO_ (BC_AR1\./^BA>*?^_5M_\ $5/(F:K$SBTT?D*T
MT!4LKJK'^$@\<]JB$Z \G(K]?_\ AR1\./\ HH7BG_OU;?\ Q%'_  Y'^''_
M $4'Q3_WZMO_ (BGR(3Q$GT/R&BOTC4C"D]BPSBHKN=)F1@PSC!P,5^OW_#D
MCX<#_FH7BG_OU;?_ !%'_#DCX<?]%"\4_P#?JV_^(H4$G<<L3.4>5GX_N\8"
M[6&?6FB12?O8K]@O^')'PX_Z*%XI_P"_5M_\11_PY'^''_10O%/_ 'ZMO_B*
M?*9.JWT/R!Q"<8F&>^1Q0947@2 @_6OU^_X<C_#C_HH/BG_OU;?_ !%'_#D?
MX<?]%!\4_P#?JV_^(I<I?MWT1^06^+8/W@SZ<\5'),IR-V?>OV!_X<D?#C_H
MH7BG_OU;?_$4?\.1_AQ_T4+Q3_WZMO\ XBCE0G7;Z'X\[AZU8L;H07"ECE,\
MBOU^_P"')'PX_P"BA>*?^_5M_P#$4?\ #DCX<?\ 10O%/_?JV_\ B*;5]"85
M90DI(_*WX:\V/CG_ +%Z;_T?!7%QS&,8 %?LYH/_  1J^'^@0ZO'#X^\3.-2
ML6L9"T5M\JLZ/D?)UR@_.LG_ (<C_#C_ **#XI_[]6W_ ,15&+UW/R ?4#(<
MM&I.,"D^WD#[@SZU^P'_  Y'^''_ $4'Q3_WZMO_ (BC_AR/\./^B@^*?^_5
MM_\ $5/*B.2)^2>@^--1\-Z@M[8R>3.JE05.,J1@@CN".".])>^+;K4I)IKE
M5EN96+-,/E)R2<8'&,FOUM_X<C_#C_HH/BG_ +]6W_Q%'_#D?X<?]%"\4_\
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M_P#$4<J#DCV/Q_-\6!RBGC ]JA,['H  >PK]AO\ AR/\./\ HH/BG_OU;?\
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M=WY+_(MPB^A^2%QXHDN,;K=,CH2QJH^L-)@-$A'/'-?KU_PY(^''_10O%/\
MWZMO_B*/^'(_PX_Z*#XI_P"_5M_\17F5:]2M)SF[MEK161^/IO7SP /IWJSI
MFNW&DZA!>6Y"3PN'4^XK]>?^'(_PX_Z*#XI_[]6W_P 11_PY'^''_10?%/\
MWZMO_B*Q<G)6>P'X[R.9)&<]6.37U%^QK_R!_$__ %W@_P#07K[F_P"'(_PX
M_P"B@^*?^_5M_P#$5Z'\+/\ @E?X+^%5MJ$-CXU\0W:WKH[>?';C:5! QA/>
$I __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pmn-20251231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $W NX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU?G-^T]X<\1?M5_'7XBZ)X8\(2>,]'\#^&O^$;MKF+4H;5-/UJX*W$LZ%_\
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MONGFODKXY_LG1>/_ -H+PIX@M;-1H&J,3XA51A=T(W*QQT\U?D/0?*.[5Z6
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MUS]J35_#/B@V6IZ5;P66F:HTVMEU99K32)Q;QV,A&<+*TU[$6).T):W/0@8
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M?^+&0$@Z5X2O=CX./E>5$4Y['.*].\'_  8\ _#V 1>%_!'A[P\F=Q&FZ7#
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M] <BIH8W#XF3C2FF_(4*M.H[1E<^F**0<"EKM-0HHHH **** "BBB@ HHHH
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MJKJ&'XY]VHH ^;_ '[#WA/P!KWA2X'BKQ=KWA_PE=R7WASPOK%]%+I^ESL&
M= L2R.4#L$\QVVY/4\U>7]C'P:O@S2/#*ZSXA6QTOQD?&\,PFM_-:],KRF-C
MY./)W.>  V,?-7T%10!\W2_L.>$Y;'Q/I9\6>+5\/ZYXCC\4_P!C+=6QM[*]
M6Y%RQ@S 6"NX (8M\HP""2:V_BM^R?I'Q,\<WWB^R\9>+? FN:GI8T;59O#%
MY#$NH68)VI(LL,@#*&8!TP1D]>,>[44 >/>#_P!F#P;X"\7>"->T$ZA8'PAX
M?E\-Z;IZS*UN;:1U=GDW(7:0L@.[>!R<@YKUZ//-/HH **** "BBB@ HHHH
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M#'_@U@_^*HYX]Q?5ZW\C^YGI/F #H3]*;Y@_I7FS?M(?"G@?\+%\,_AJL/\
M\57FWP\_;5\'ZGJ]YH/BK4+32+ZUN9+>#6(I ^F7Z*Q"2I*I(CW* VUR "<
MD\"95H1:N]SHIY?BZT)2ITV^75Z/8Z']N+_DT7XM'M_PC]Q_*OG*V_X];?O^
MY3_T$5]$_MLW45Y^QY\59X)%FAE\.W#I(AR&4J""#W%?/EA#FSMV;A1"A))P
M -@S7PG%B<J=%+N_T/E,T5U%#<$#OS]:] _8CS_PMKX^9_Y^] _]-4=?,?@7
MXJZ-KGQI\8Z?'KK7-A>I:1:,)2_V>62!'6Y6$GY<EG4\?>QD9XKZ=_8C/_%V
M_CY_U]Z!_P"FF.LN'\#5P&.E"IUA?[VCGRY6JOT/KM!Q3Z:M.K]%1](%%%%,
M HHHH X'XZZYJGAWX8:Q?Z+=:G::I$J_9Y-'T:;5;DMN&%2"*.1CNZ%MA"@D
MG@9KG?C)X[EC^'$LVCW/C32]3=;66&Y\/^&;JXN%,V[;OB:RF.P;&,JB,R(-
MH(0NN?7V&1UQ3?+..O>@#,TJ>YN_#UG/&YENY;1'#W<#P%G* @O$P#)D]5(!
M'0@$5SF@:QXOUZPDN8XM$B$=U<VI5FF/,,[PD_0F,G\:[8#:17-_#K_D7[O_
M +"^J?\ I?<4 )CQE_U OSGHQXR_Z@7YSUU%% '+X\9?]0+\YZ,>,O\ J!?G
M/7444 <OCQE_U OSGHQXR_Z@7YSUU%% '+X\9?\ 4"_.>C'C+_J!?G/7444
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M37]TSPT.2L_0^CM5^&7A/6K^6^O_  YI=Y>2',D\]G&[N?<D9-4_^%0>!_\
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M (_7644 <G_PK/2?^?SQ!_X4>H__ !^C_A6>D_\ /YX@_P#"CU'_ ./UUE%
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ML9D"0$L [,JG !YH ^28+35K+Q9K-U8:M)X/F6S^( AUVZM7>.T9]8T4QLP
MSA@K8(YP"PSMKTR?Q;K.J_LW^'M5L[?4['4/[?M( T]V^I2R1KJ8C::.>2)'
MEAD0%TD:-&\ME)"GIZYX*^*.E^-(+>1(I]+-Q!9S6Z7[QJ9S<6WVA4CPYW,J
M!\CU1L9 S6W>^+=#TVW-Q=ZWI]K#O>,RSW<:*&201NN2<95V5".S$ \G% 'S
MW\-];\7Q>._!]]>ZSKE[#KGB;Q=IE]97K,]K%:6U_>BR*)@"/"11!7S\RG&2
M,8^GJSK+6M/U.[O;:TO[:ZN+)Q%=103*[P.1D+(H)*G'."!6C0 ASCBH;B>*
MTA>:>1((4&6DD8*JCU)/2IZX3X[>%+_QU\'/&/A[2H4N=1U/3)K6WAD<(KNR
MD %CP/K0!TMMXGT:\>U2#5K">2[,@MUCN48S%&*N$P?FVD$''0@YJM-XX\.0
MI<O)XATJ-+55>=GO8@(E8X4L=WR@G@$]:^>+C]G35K3XLV-TL&JKX5?^QIK1
M/#\^G6\6E/9LSR12+-$9A&TC/(3;N"_GS!@,!FD^%W[-$NB3_#5]=\*Z,PTR
M+Q -9#K#,)&NKKS+?<,?O1M9SSD+N(XS0!]'W>OZ7I]W96MUJ5G;75Z=MK#-
M<*CSGCA%)RW4=,TEK?:7"L;6]Q9)'<SNJ-$Z 2S?,S@8/S/\CD]_E;/2ODC2
M?V>_'=M\,(/#>J^&++7==U?P=I6A1ZU<ZA$S>'+NWMS%))O;+LJN1,K099G7
M!"\-73>*/V;/%>O:_P"--.L[Z'3O#\=KJ.H>&;PS#S$U;48ECN)"@4B/R@MT
M%;:P*ZB^!\E 'TKI6LZ?KD#SZ;?VVH0(YC:2UF65588RI*D\C(X]ZJ?\)?H(
M&H$ZWIN-.;9>?Z7'BV;.,2<_(<C'S8KR+X*_"?5= TOQI<7'_"1>&=9URT@L
M%_M&XTR6*W:&*54N+=+"*)-P\X NX#N(8@<!17"2?!SQ>_P[\%Z3:>#G\.7W
MA.> :BNBW>FN=>*6TD!GA>Y217(=O, ND5B';D..0#V+Q[\>=&\!:R^FW%A>
M7Y6WTJY$]FT;(ZWVHI818)89VNX<_P"R.,GBNJ\>^/-*^'?AR_U;5+B)!;VT
MUQ%:F:..:Z,:%S'$'8!F('3W%?.6I_LX>)+;1],L=$L[N6SM].\/PHFLW]N]
MU&UMXA2_N(W:("/$<.[:$ 7"JB]!76_'SX5:_P"+?$GB6[L?"EEXRM]=\*-H
M%D;RZBB&CW(:=FE(DY\N7SHMS1[G!@7Y<8( /5KJ?PW\1_#VG:=JWDNFLVL5
M]'ID]QY=P5(#@@*P;*^JG^$UA?!;Q[X,USX>6,OAR&U\-Z=#'<3'2)IHDFM8
MUGD5Y9%5C@.RM(7)YWY)R37E&E? 7Q/;?%2SO]8&M7>E276D:C;W6EW>G+#8
MM:6<$+6TPFB-SL\V&1\6\FQQ<,"JG<7XL_LV^-[SX8-X8A\':;HVLV6D>)%;
M6HKZ!AJDFH0W:P6V1\X^:XC:0R (IC^0L,&@#ZO3Q]I!UJ\LS+MM+.U-U-JQ
MEB%DNV5HWC,F_(=&4[@0 ,]<\5OV5_;:I:Q75G<17=M*H>.>"0/&ZGH58<$5
M\X>,?V?II!!#9^&II-&MO"]A8QVN@W-K;W"7\%^ER'43_N7VLBN1*&23!#*V
M2#[1\)].\0:3\.M!L_%"6,>NPP;+A-/B6*(?,=F53Y ^S;OV83?NV +@4 ><
M?MU?\F@?%C_L!3?TKYWTZ4QV%K_UPC_]!%?0_P"W5_R:!\6>W_$BF_I7SK9_
M\>-K_P!<(S_XX*_/>+_X=&W=_H>'F>T/F6Y)RXQ7>?L,#'Q!^.G_ &%=,_\
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MPLKP]_S]S_\ @%/_ /$4?\+*\/?\_<__ (!3_P#Q% '3T5S'_"RO#W_/W/\
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M.M#\2Z!XEATNUU&?0;WP_>BQ^VK&]V+?2+S3[E5<C"LK7@==W#;".,UH:+\
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M<9_Y&'P__P""&?\ ^3: .KHKD_[.\<?]##X?_P#!#/\ _)M']G>./^AA\/\
M_@AG_P#DV@#K**Y/^SO''_0P^'__  0S_P#R;1_9WCC_ *&'P_\ ^"&?_P"3
M: .LHKD_[.\<?]##X?\ _!#/_P#)M']G>./^AA\/_P#@AG_^3: .LHKD_P"S
MO''_ $,/A_\ \$,__P FT?V=XX_Z&'P__P""&?\ ^3: .LHKD_[.\<?]##X?
M_P#!#/\ _)M']G>./^AA\/\ _@AG_P#DV@#K*:3MY)P*Y7^SO''_ $,/A_\
M\$,__P FUE^)X?&]CH-_.?$.A92!V&S0IP<[3T/VV@#N3>0@_P"N4?4TGVV#
M_GLGYU_.,?VS_CLQR?BUXN)]3JLI_K2?\-G?'7_HK/BW_P &LO\ C0!_1W]M
M@_Y[)^=*+N%N%D4GV-?SA_\ #9WQU_Z*UXM_\&LO^-20_MH_'=)%*_%SQ<IS
MU&JR_P"- ']'@.3[8KC_ (PZE<Z/\,?%%[9S-;W=OI=U-#,GWD=8796'N" :
MD33_ !OSCQ#H&!D?\@&?_P"3:X[XSV'C!/A1XO-SKNA2Q#1[S*IH<ZL1Y#Y
M/VS@^^#]#0!^$S_MN_'9V+-\3M=+'J3*O_Q--_X;;^.O_13==_[^K_\ $UXB
M>U% 'MW_  VW\=?^BFZ[_P!_5_\ B:VO!?[:WQRN?%VB6\OQ,UQX)KZ".1#*
MN&4R*"#\OH:^=ZV_ P8^-O#X0A7_ +0M\%AD ^8O49&?S% ']06FMNM4/KFK
M=<78Z?XT:V0QZ_H"KSP=!G_^3:L?V=XX_P"AA\/_ /@AG_\ DV@#K**Y/^SO
M''_0P^'_ /P0S_\ R;1_9WCC_H8?#_\ X(9__DV@#K**Y/\ L[QQ_P!##X?_
M /!#/_\ )M']G>./^AA\/_\ @AG_ /DV@#K**YBVL/&*W,)NM=T.6V#J98XM
M$FC=TS\P5C=L%)&0"0<'G!Z5T:9W<],4 24444 %%%% !1110 4444 %%%%
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M#TW_ ,!(_P#"@"S_ &_I?_02M/\ O^O^-']OZ7_T$K3_ +_K_C5;_A#= _Z
M>F_^ D?^%'_"&Z!_T ]-_P# 2/\ PH L_P!OZ7_T$K3_ +_K_C1_;^E_]!*T
M_P"_Z_XU6_X0W0/^@'IO_@)'_A1_PAN@?] /3?\ P$C_ ,* +2:YITKJD=_:
MN[$*JK,I))Z <U<#ACCO67%X2T."5)8M&T^*5&#I(EJ@96!R"#C@@]ZU H4Y
M% #J*** "BFMTXKS/XI_M*?"[X*"1/&WCO1= O$57_LZ:Z$EZRMT9;9-TK ^
MH0T >G45\[']KJ\\1O-%X%^#/Q*\6N%#075WHXT6QG4]&6>]:+(Y_NY]JG/C
MS]H[66BET_X6>#M!MI.=FN^*I);B,=@RP6[+GZ.: /H*BOGNXT;]I_4]CQ^*
M?AEH>[EX$T:^O"GH YG3/0]JEA\#?M'3P.MS\6/!=O(QP&M?!\I*CU&^[//U
M!H ]_HKP&3P)^T9!;JEM\6?!UQ(O\=WX.D!8=>=EV!GMP*K0Z%^U%IQ>0^,/
MAEK(7E8)-#O;4O[;Q</CZX- 'T/17SZOCC]I#1I9'U#X8>"M>MD&X)HGBF6&
M>3ID*L]N%SUZL!TYJ'_AK74/#9AC\=?!;XD^%792TMU8Z2NMV<*@G+/-9/(0
M/JH/M0!]$45Y=\+_ -IOX5_&>5(/!OCS1M:OVW#^S/M'D7PV_>)M9-LH ]2@
M%>HT %%%% !1110 4444 %%%% !1110 45D^)O%6B^"](GU?Q!K%AH.DP#,U
M_J=TEM!'Z;G<A1^)KP^]_;I^%=S=W]EX1NM?^)VI63;9K7P'H-WJX'TFBC\D
MCOGS,4 ?0U%?/4/Q^^+'B-\^'/V?->@LY ##>>*=;LM-Z_WX5:21?H1GVJ6/
M7_VF=5ED1?"/PW\/PL?DFN=<O+UE7U*K!&#V[T ?0%%?/TVC_M.S1G9XI^&%
MK)TQ_8U_*!Z?\MUJM%X<_:E20%_'7PPE7.2A\.7R_@#]JH ^BJ*^?S:_M/6&
M)%U+X7:P%(S";6_M"_\ P+>^/R--B^(/[1>C*[ZI\(_"FN(K?<T#Q:R2LOLM
MQ;HN?JU 'T%17SQ_PUCJWAMH(O''P2^)'AEY"=USINF)KMI&H/+-)9/(RCZH
M#[5U'P\_:U^$'Q3OAI_AWX@Z/-J[2FW72;^4V%^9!U46UP(Y21[+0!Z_135S
MGG-.H **** "BBB@ HHHH **** $]:PO%W_(LZQ_UYS?^@&MWUK"\7?\BSK'
M_7G-_P"@&IELRZ?\2/JOS/.?V1?^3<O '_8-3^9KV,=*\<_9%_Y-S\ _]@U/
MYFO8QTJ*7P+T.O'_ .]U?\3_ #%HHHK4X0HHHH **** $(#=>:0H#VIU% #<
M %0.E<KX$_Y%>_\ ^PMJO_I?<5U1^\*Y7P)_R*]__P!A;5?_ $ON* /PZ_X*
MD_\ )W6M?]@VR_\ 15?)%?6__!4G_D[K6O\ L&V7_HJODB@ HHHH _H%_P""
M:7_)F?PV_P"O.X_]+)Z^D]=_Y!5Q_NU\V?\ !-+_ ),S^&W_ %YW'_I9/7TG
MKO\ R"KC_=H _G#_ &NO^3H?BI_V,=[_ .CFKR.O7/VNO^3H?BI_V,=[_P"C
MFKR.@ HHHH _IK^!'_)'O!G_ &!K+_TG2NRU([;21@<$*>:XWX$?\D>\&?\
M8&LO_2=*[+4_^/.3Z&@#^;/]J@EOVG_B^2<D^,=8.?\ M]FKRZO4/VI_^3G?
MB]_V.&L?^ELU>7T %%%% ']1'@,EO"6E$G)^S1?^@"E\=?\ (JZE_P!>\G_H
M!IO@'_D4=*_Z]HO_ $ 4[QU_R*NI?]>\G_H!H _EVHHHH *5?O#ZTE*OWA]:
M /ZHX?NG_>;^9KA_CI_R2+QC_P!@>]_]$/7<0_=/^\W\S7#_ !T_Y)%XQ_[
M][_Z(>@#^9.BBB@ K<\"?\CQX>_["-O_ .C5K#K<\"?\CQX>_P"PC;_^C5H
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M_=?$#]HW5?$&F6FKZEJOC34=*N;+48EG2.P9A.L6QLKLE$P<C'/&>@QTUO\
M!'Q]\$F)^#_B>'4_"Z_=\ ^,IY)K:V7CY;*^^::W7 P$?S$&3QDBOA\US-RG
M+"T9\C75]?GT_K4[J=.WO/4]R\/^'M*\(Z5#IFA:79Z+ID*A([33[=8(D4#
M 50!5\G&<5X(_P"UI:^"(RGQ9\#>)OA?L^5]6N;-M1T<G.!B\M@ZKN/0.%/3
M->K>"?B/X3^)=D;KPAXHT?Q/;JH9GTB^CN3&#_>",2IYZ, 1WKX6OA<5%\TT
MWY[K[U<[(SB=(S'BFEB?_P!=(RLIP003VQ4;<GK7+"DY,IRL2;\>@^E)YON#
M4.><8Y]*4$YKT8Y?*2YKF#K).Q,)*7<>WZ5 #[X]Z<K9!Z],UQU,.X&L:B:)
MP3]13HW*'@X/K3%C?87VD*!DL> /7FO)/&?[67PD\#7T>G77CC3=4UN5C'%H
MOA]CJE]+)@8C$-N'8,<C ;&:FGAJ]1VI1;]$4Y174V_B7^S[\/OBVR7/B3PU
M;2:M%S;ZW8%K/4K9AR&CNHBLBD'G&<''((XKR/Q9\;_&/[#ME;O\0M=D^*7P
MUNFDATS4YVCC\36DBQEDAF7*I>I\H!F4*ZEBSC'3HY/BC\8_B>1#X#^':^ ]
M)EQ_Q4?Q%S'.%(SF/38F\PMU&)63L<'D5TOPU_9WT?P9XCD\7>(]5O\ XA_$
M">)H9/$GB$HS0QG.Z&TMUQ%:Q')RD8&=Q!)!Q7U6!QM;+?\ >*EU_+N_^!]_
MR.:<%4^%'.?L ZEJOB;P7\0O$WB%+)?$FN>+;B^OFTZ=9X!O@@:)$D7A@D1C
M3(_NGO7??'S]IC1O@7$D%QI6H:EJ<Z9MTB@9+<L>@:=AM!_V1D^U<-^PMX?L
M/ Z?&;P9HUD++0M!\=7<-BB]%CDAAFV#V0R%1[ 5]):UX>T[Q'ITVGZI96^H
M6,ZE);:ZB62-U/4%6!!K]&YG6I*4':ZN8X:5&E7C+$1YHK=)V/FWX)_M2PZW
MX7NM:\9SZA)J>H7<C0V6E:+=36ME;H=B1*Z(P=B59V8DDE\<!0H]'_X:;\%Y
MSY7B#_PG[W_XU73?#7X4:3\*-/U#3-!>>+1KBZ:\AL9G,BVC,!O2,DY"$C<%
M.<%FYP<#LC".3U_"G3C-12D]3?%5<+4K2E1@U%O17Z?<>3_\-/>"_P#GEX@_
M\)^]_P#C5'_#3W@O_GEX@_\ "?O?_C5>K>6O<#\JP-4\;Z%HFMVNDWUZEM>W
M+*D2NC;-S$A%9\;59B"%5B"QX&:NS6YSQ=.6B@_O_P" <1_PT]X,_P">7B#_
M ,)^]_\ C5'_  T]X,_YY>(/_"?O?_C5:-[\9M&/CS0O#>G7%M?O>7-U;W<P
M<@6_DP/(VTXVN5951P#\A8!L'BG>%_B_I?C/Q_)H>C-;W^FII7]H?;HV8%B9
M0B[5(&Z-AEED!PV."1S4<ZZ,Z/8I+F=-VM??I]QF_P##3W@P?\LO$'_A/WO_
M ,:K-\0?M&^$=0T/4K6"'Q TLUM)&@/A^]Y)4@#_ %7O74:'\;/">N:'>ZLM
MQ<65I:WK:>1>V<L4DLX8KLC0KND8E3A5!;CD Y%;TWC[PW!X5'B1]8LUT$J'
M.H>8/* +;>6[8;@YZ'@XP:=[K<GD5.:3I.]^_7[CB_V5M/N])_9^\"6=_:S6
M5W'IR!X+B,QNAR>&4@$'V->N5Q;_ !7\+1Z*VK_VJLEC'<-:NT<,C/'*H+,C
M1A=RD*"QR.%YZ<TEO\4=(E\2-ISWUCY$T5I)8SQ7'F&Y,_G;!@# !\AMIR=V
M&Z8Y<7&,4KF595*U6=5QM=MG:9I:X^7XL>%8)A%+K5JCFY>S()/R2I+Y+!CC
MY0)?W>XX7=A<YXKK!(2.E:)I['-*,H?$K$E%(#D4M,D**** "BBD8D=!F@!#
M]X5RO@3_ )%>_P#^PMJO_I?<5U(;=M-<KX%/_%+W_P#V%=5_]+[B@#\._P#@
MJ3_R=UK7_8-LO_15?)%?6_\ P5('_&76M_\ 8-LL?]^J^2* "BBB@#^@7_@F
ME_R9G\-O^O.X_P#2R>OI/7?^05<?[M?-G_!-/C]C/X;?]>=Q_P"ED]?2>N_\
M@JX_W30!_.'^UU_R=#\5/^QCO?\ T<U>1UZY^UU_R=#\5/\ L8[W_P!'-7D=
M !1110!_37\"/^2/>#/^P-9?^DZ5V6I_\><GT-<9\!_^2/>#/^P-9?\ I.E=
MGJ?_ !YR_P"Z: /YLOVI_P#DYWXO?]CAK'_I;-7E]>H?M3?\G._%[_L<-8_]
M+9J\OH **** /ZA_ /\ R*.E?]>T7_H IWCK_D5=2_Z]Y/\ T TWP#_R*.E?
M]>T7_H IWCH9\*ZG_P!>\G_H)H _EVHHHH *5?O#ZTE*OWA]: /ZHX?NG_>;
M^9KA_CI_R2+QC_V![W_T0]=Q%T/^\W\ZXCXY\_"+QC_V![W_ -$/0!_,E111
M0 5N>!/^1X\/?]A&W_\ 1JUAUN>!/^1X\/?]A&W_ /1JT ?U :3_ ,>,?XUY
MG^U9_P FX_$__L5=6_\ 2*:O2]*.+*.O-/VK/^3<?B?_ -BKJW_I%-0!_-?Z
M4444 %=O\"_^2V_#W_L8=/\ _2F.N(KM_@7S\;?A[_V,6G_^E,= '],VF?\
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M^7[-<)+GZ;6-<3Q./IW52+?K'_-%\M-['B/_  KK]H.W;]U\9_"\Z9SBZ\%
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MK(&*MY>\EMN5XSS5"O<F\.^!-8\*Z%IVCV/BEQ96%O%:PA]/B+;$0(N3GDX
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M/I!2T#/,?CG\*[WXP6'AK0CJ'V'PY#K,&I:TL%S-;W5Q#;[I88H9(L,A^T+
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MCK_@:#Q7XRU62YN-6C5[#3U010VMJ/N': /F<?,2<\;:\'VB]LZ:1]E]3?\
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MI,B@-]TY'/TKCG^+VA7(TB31EO/$UKJ.I-I?VO0[<W4-K*N0S3.O"1J007Z
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ME>9YJ&/.-^X8_.OBKPS\&OB-#XTU+4[[PIJ>BQ:CINK6>J+H-[9P+.TC9MC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX-Y"R ;A'N ;8#MR <5C^'?A!X#\(>);WQ%H/@GP[HGB"]5UNM6T[2H+>[N
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pmn-20251231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #) E@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "N*\?_ !8T'X;ZYX0TO67N5N_%6IC2=.%O 9%:?8SX<C[J
MX4\UVM>$_M&_#;Q)X[^(/P0U+0M-^WV7ASQ8-3U67SXX_LUM]GD3?AV!?YF
MP@)YZ4 >S#Q!I9O8K,:E9F[E9TCMQ.GF.R?? 7.25[CMWKG?!WQB\%>/CJHT
M#Q+I^HG2[]],NQ', 8KE3S'SC)],<'!QTKX[U;]CKQ#=:AXF\61^"H#X[F^,
M"Z_8:N+Z!;G^P//0N5?S?E1HVFS"<,Q()4D CG;C]BWQ)%-XK\+Q_"C3/[$U
M'XFZ;KCZ[8W]I$M_H7V@M/;E-Z2HL2,^4ZMO.P$T ?H%'XHT:XNK2VCU>PDN
M+N,2V\*W*%YD.<,@SEAP>17%_"OXW:/\4[GQ-;002:3=:)XCO_#HM[V:/S+M
M[0J))8E#$E#N'N,<XKXQ^./[*/Q1U7]HK3KWP3\//#^G>!](U319])U#0;?2
MK22*S@9/M"2RR8NT=<,!'"5B* #!).77W[*/Q%N_BOKT]K\+=.T[4-3^)DGB
MFT^*']NP"ZTW3%N0_DBW4F3]XBL BY4^;\X5ES0!^@XUW3CJATP7]J=2"[S9
MB9?.V^NS.<?A7"?&;XXZ+\&M)L;R\B?5;FYU2QTS[!9S1B>,W4PB25E8@[ 3
MD_I7Q]H7[*/Q('Q=T=[SP'86VL67Q!;Q7=?&-=;B:YO=-$S2?8O('[_YXV6'
MRV'E#&>E4?B+^R?\1]5^+'B*\C^%FF>([^[^(UKXJLOB.VNV\=Q;Z4)H6%BL
M#D2?ND1AM)"'JN2!D _0F/7M,:VBG&HVC023?9XY1.NQY,D; <X+9!&.N16A
M7P3\/?A=J]S^VQK?PY$L<_PL\#:Q+\1XX$RWEZCJ$2K;6K\_*(Y/MLZ#ON.>
M-N/O:@ HHHH **** "BBB@ HI*6@ HI*6@ HHIN?FH =12'BD#9- "D@?6O+
MOB1^T3X0^%WQ,\!^!M;NVBUOQE-)#8*N-L>Q<AI,G@,V$!]37ISGYL&O@KXS
M_!7XA?%E?BOJ>J?"WQ)+XYU#4X?^$,UFSO\ 1FMM*M;&3=9,K/J"2*96WRRC
M9QY@&&V#* ^E=._:I^'^J^-?B)X4BO;Q=;\"6LEYJUO):LNZ*-0TC0G_ ):;
M0R9QT\Q/6M7P'^T'X0^(WBVR\.:-+?/J=YX?MO$\0GM6C0V4YQ&2QZ-ZKVKY
M.E_9O^+7B7P'\0O&Q\(P>'OBQ<>(;G4].TB?4;5TU.PO-+M+._LGFBD9%5S&
M[(6(VR0Q-P.:W?!GP^^,/P0^*WA3Q+I7PIN/&UE'\/=)\,7BVWB#3[-K2Y@;
M,O$LG[S _N\$]#3 ]_\ "/[4G@SQQ\0[CPCHUMK]S)#?7.F?VS_8\PTM[J#/
MG0K<XV%E((]"1P:L_'C]I/PQ^SK8VM_XKTWQ#/ILT;2/?Z3I4EW!;@.B 2NO
M"%F=0 >O-?/6A? SXGR?M$R:KX>\&7OP<\/7VHWTOBG4](\9)=:;KT,BNBS6
M]B%+0W+$I()"D>T[B02<UW?QP_9K\1C]D+QO\./"OB#Q3\2-?U2>&XMKCQAK
M$=Q=MBX@9HQ.XC58U6(L%/<MU)H ZG6?VR/!WA_0_">H7GA_QFMQXHN+JWTO
M2AX?F-_*T"JTC&#[P7:P(/<9/:H=0_;=^&-IX#T3Q5;S:UJMKJVKMH,6GV&E
M2RW\5^J%VMI;? =) !R"*POVB?!_Q"C^(OP+\9^#? TWCEO![:@=1TZ#5[6P
M=?/M$A7$D[A6^;)(&<XZC(->-:_^R3\4_'5KI.LZK;2^%]<\3?$I?%NLP>$]
M9BAN?#EE]C,"^7<L ))Q@;FC5LEC@$<T ?3,'[7'PYE^#NN_$F34+VTT/0[M
M]-U&TNK-XK^VO5=4^RM;MAO.+.@"_P"T*SO%W[9W@#P;X)T+Q;=V?B>[T#5=
M+76?MNGZ%/<1V=HS;5EN&48BR>Q.>.E><_$+]B?6=*T7P[;_  RUZS>/2)]3
MUJ^M_&T<^IRZWK-U (5U">031@W"+OV,PVHS[@N0,>4^.OV9?BMXB_9G^'OP
M^U;X6P^*?%6FZ$;*SUW2?%_]DQ>'[@NNPW-MYK)=^6%1RZ[]Q5@JID$@'Z&Z
M7J-MJ^GVU_9S"XL[J))X95SAT8!E8?4$&K=8?@>RUC3?!NA6?B+4(M6\0V]A
M;PZE?P((X[FY6-1+*J@ *&<,P&!C/05N4 %%%% !1110 444TM@T .HIF^@R
M>U*Z ?12!LTM%P"N$^-?QD\.? 3X>7WC/Q6UVFBV4D,<ILK<SR[I)%C3"#D_
M,PKNZ\1_;"^'?B'XH_!AM"\,:8-7U0ZUI5T;4SQPAH8;V&24[I&5>$5CC.3C
M !-,"+XB_MC?#+X9?"#PS\2M6U6ZF\,^(RG]FFQMC-/-NB:0GRP<@*J-N/\
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MB@#]V?\ A[9^SI_T'-:_\$TW^%'_  ]M_9TQ_P AW6O_  33?X5^$PZTX#-
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MQ"ZUK)(XQ_8\PI#_ ,%5/@ & .LZT2?^H/-BOQF;P]";8&YE6T:,$&0GK_\
M7JAI]E8W=P\%OJ2,%&?WRE0?H?6OH<MQ&0UH*.-52$NLEJONM='GK&N2;CT\
MC]J3_P %-OV??$<$]E)>ZM?Q%2SV\NA22*X'/W2"#TK/M_\ @JY^SCI<$=I#
MJNKVD,/RK!%H4J*@] H&!7Y"6.LZ=X9C@D0O'-&X8RQOM;/L1TQ_6N3\=^*(
M_&FLK=PV$=K.5VRO%G]^1_&W^T>Y[UY^+GA*V+5+*XRE"V[WOY+L&'Q=6M4:
ME#W>Y^U\'_!6/]GBX)6/7-:)[G^QIJL'_@JE\ %4$ZSK6#R,:/+7X=Z3%+8/
M(98656'!9:U(+I/+P8L/V'8BOUC(>#,OQ^&C+'U)4ZCOI9JUO5=3>KB)P?NK
M0_:U?^"K7[/K9*ZUK?'7.CS<5&__  5C_9YA4,VMZT >_P#8TU?B7?.67;#\
MJG[QZ?A72^#_  ;%=WMGJ.LVK#0K=P\N]MGG?[([X]>*^:XCR7+<CHU)*HW*
M*TU7O-O9+=Z;FU*I4J[(_9[0_P#@HU\!_BK?VNBV2:SKLEQ+^[BG\/R/$&'\
M1+#:,9ZGU]Z]!\;_ +8GPV^&5S;V6LS:G:AHPT7V?3)'C"#@8V]!V[#BOSD^
M%?QK^&/AQK.6+PI';75M&8I)8HU,8W'YB(CD'"A<<=S7I/Q2^/?AV:6TUK3]
M!2]GGMI+1$FM?(0(0"TH8=]PX# ].*_F;%\59I#'1I4<*U3UWW;Z:WLCFK5,
M7"=HP^__ #/I#6_^"I/P$\-SB&_UC6XI>I4Z+."/;D5FC_@K=^SJ%Q_;NM?^
M"::OQC^+NL?VQXKNFCW>3O; V[1G/IV[=:X0@@D=:_4<+4E5HQG45FT>GKU/
MW9/_  5O_9U/_,=UK_P33?X4?\/</V=?^@YK7_@FF_PK\).E'6NH#]V_^'N'
M[.O_ $'-:_\ !--_A1_P]P_9U_Z#FM?^":;_  K\),8HH _=O_A[A^SK_P!!
MS6O_  33?X4?\/</V=?^@YK7_@FF_P *_"2B@#^B?X ?MR?"K]ICQ=>>&_ V
MHZA>:I:V9OI4N]/D@41!U0D,W4Y=>**_-O\ X(L_\G*>)_\ L69?_2B"B@#O
M?^"XW_(S?"+_ *\]3_\ 0[:OR_K]0/\ @N-_R,WPB_Z\]3_]#MJ_+^@ HHHH
M **** "@=>:**  \FBCK2XH !C/-=3H-GHMGISWNJF2XD;(AM8FVY/JQ]/I7
M-VMNUQ,L:CDU->2L90K'E!M&.U8U%S^ZG8]+"5%A[UY04NBOM?O\C0?7F2=C
M!&MM$>/+0=J274TE8,Y8C&:Q2V3[T!CU%'LHC6/K6:;T.MTW7HXAE%4R 8#$
M8(_^O1JCFYB01X+OR37)Y/)!Q6[I,C7$!+](_P"(US3HJ#YT>WA<RJ8J/U:I
MV,RYB, *L &/>J9K0U-F,N7_  )%9]=<-5<^;Q*4:CBN@H!)P.34TEJ\29=2
MGU%0KUK;M?$L\%C]BG1+JU+9*2*-WX-U%5)M6LKDT8TI7525NVES#[T5).R/
M,YC39&6)"DYP.PS4=48,****!"K]X?6ON3_@K-_R53X3_P#9/=/_ /1]S7PV
MOWA]:^Y/^"LW_)5?A/\ ]D]T_P#]'W- 'PZ!@]*=%PVX#)["B/YG"^M;$T-O
M:I%&"Q8X8MCOW_6LY2Y=#*<^70SKA)%V2/& 6Y!Q@'%2W6MW%S"D3;$51@"-
M N!^%3:_,'>!(^$1.N>2<\D_Y[5DGFE&TTFT*"4XJ31=BU:ZC4A;B10>>&I6
MU*2]Q'=3/(I/#-SMJCF@57)'>Q7LX[I%R:&>Q8E9,QG@2(>&JJ\C2-EV+'WJ
MW8/YJO Y.QN< 9.:9?Z?+83&.4>X([T)I.SW$FE*SW*N12@BFTY 68*.IXJ[
MFIZ!\(]$\+:AK$][XRN+B/0K2/<T-HP$T[GA47.0/<TOBKQ5H_\ :DC>&=*&
MB6"L1$F_S)2/5G/.?I@>U<K=++8P16[G9CYR.G)K-:<Y/>O/]A[2JZKDVNBO
MI]QY?U;VM9UY2;6R5]/N[LUKO4WO,222,^&Z$\_6M;PGXF31[H.P#8.[]YW(
MKD/,.<YII8GDUM/#QG#D>QO/"PJ0=.2T9ZUXB\=3^*+::>X(>Z;"H>H"@8P*
M\VU"&6(EIE(ST.!S6GX1M;K5KV/3X(7NGD/RQH,D#N?85I^-?#-YI4$<LL$B
M6Y.Q9&SM8CK@]ZXJ,:>$J>QCI<\ZA&E@JJP\+*YQ)<XP*0 FAACZT+UKUT>\
M7I-$O8+*.[DM94M9.4F9#M;Z'I5%UPQKK/#'Q)UKPQ:7%C!.MSIMP4,UE=()
M(I-C9 *GI^%8OB'4;;5=4ENK33TTR-^?LT3%E4]\9Z#/;M647/F:DM.YA"53
MF:G'3HT9=%!ZT5J;A2C%)13 ^UO%X)_X)T?!@J0&'B75B"QXZU\J>(M6'V<6
MZE7D8?/CM7TE\5)&C_X)N_!$JQ7_ (JC5^0<5\C%LGDYK]%PG&-? 9#+)L-&
MSES<TKZ6;OHN_2_8XY8=2J^T8  OQ5H0RSH"(LKT! JW#;V]O9-(Y)DD!&/[
MO2M&V9/L42)U)#9;]*^#P-!X[%T\.OM-()UK?"B&-Y+:T^RJZHG4X0 D^N>M
M6+>Y6RAVPR,9#U?-5KR'80)750QX4=:DM&A@RB-YA/;%?M^"RG!87$3HJE"/
M1N5G+[G?5G)-<RNQTVLJ\1CN=TD9&-I]^]9=_IKV)6:VE,MN1N5UX*^Q'8UH
MSPPS2 L"?I2FV:-V\L,8MO)/2O)SOA^IB*4ZE.,/<VY59M>=OZ15.4:>D58Q
M[2-[^4"21BJ\DD]JUHKU-/XMH "/XVY-0+:MIL@E()MI1C=Z<UHV\_G7 1HE
M8#[K@=:K@NA0J4(O#5%"NY6ORW:[>B\RZTT]5JA3,]U'YKR,AQ]W'!KHOAQX
M8TSQ)XYTVSUW56T?00C7&H7*8+I$G)" _P 3<*/<U@7.8KQ!P8QRQ["IPMW;
MV$LFTA;L!AD8.T9"X/?UKZGBV4HT/J,*DEB9RY5)7YM%>4U\M%TOZ&="-[R:
M]U(]$^(GB[P"FH-!\/- GT;3;<X6_P!1G^T7MPW]YF(VH/9 /<FN"O\ Q'<:
MS;S&:ZDG<$$AGY;UQ_.N8^W".4QA-R]^>35A$CVB4OY>1QMK\OP^2X3,*<:;
MESRA\4I2;E?O=_\  .VG7J8?X7HSI_#7B*+2+X-)'N0_*3(.GOZYKU._^*I\
M61&*]\I;6WB,5M#&<1QC\<#^M> ->22.5(WJ#]_'6M[13/;\QD.)1M,1&<D]
M,#UKP\QX&H8VE4Q>";;I*[OV6]F=<<:G->W2*GB"UO+B66[G0&)V+#:!QFN5
MD?;(V %YZ"O8O%W@K5=.T1V%E<((HQ+.'0D1;N@?CAO8]Z\>E7YR">1Z<U\5
M@:JJPO'H:5)TYOW'<A/.:NVFB7][93WEO9SS6L&!+-'&65/J1TJCFNE\$?$/
M7OAYJT>HZ#J$EG<(&!7 >-U888,C95@0>A%>C/F4?<W\S!WZ'.%""*;76>-?
M&5MXS-M=MHEEIFK#(NKBP'E17 VJ%)B'RJW!)*]=W2N3[T1;E&\E9C"BBBJ
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MI*WV/*;<G=@#@T9-%% @HHHH **** %7[P^M?<?_  5G_P"2J?"C_LGNG_\
MH^YKX<7[P^M?<G_!6<?\74^%'_9/=/\ _1]S0!\06O\ KT)['FMR2T&'.0W)
M'2L>WCV@$CD]*O*\[QR2  J@R>0!_P#7KGFFWH<M2[>C*UQ8W+NQV,V!GUXJ
MFR%?O"I#=S;\^8V<8SFAKDR(58#/J !^=;*ZW-XJ2T9#T-%:MGHDFI0J;;+S
M%L%.@K8?X9Z[;R6B7%G);FY&4\P8R/;UK*5>E#24DC&>)HT])R2,WPWI\\]Q
MY\) \OELG%=MINA1:U"\4B!HT1F(_O'MS_6L;6[23P=:)IL6?M,GSS.1R/0"
ML&#Q->62NB2, XPP+<5P3C4Q/OTGZ'F5(U<6O:47;L5];T6;1=1>UE"LXP1L
M.1@\UWWP@^#.M_$#4!<6^G33V<)^=E' /;)Z5YW<ZM<W,HD>4EAT([5[Q^RM
M\=X_AMXAOK36KF9M(O8UR-V0DBGAN?;BL<UJ8RE@)SPJ4JB6W?T.?.ZF84,L
MJ5,$E*JEMW[V.8^-_P -+CP7>6\NQOL[C80RD,K>AKR1AACD5^A>H?%CX8_'
M*.X\,:G!)Y<T9,=R\6&5QGYE8=,=>>#7QU\7/@[J'PSUIU5EU/1I26L]2MR&
M29/PZ$=#7C9!F]2O!87'0=.JN_5>3_0\#A?/:N)IK!YE3=*NM;/:2\GW\MSS
ME1S[4]$#'GY:?#:R3N%2-I'/ "C)S7K?A_X8:+X2\/#Q+X_NY+))%9M/T* @
MW=XXZ,X_Y9QYZDX)[5]97Q$*"UU;V2W?R/M\1BJ>'2YM6]DM6_1?TA/A7JC?
M".RN/%.I:>LZWMN]O817&5WE@07 [@<?G7FNM>)KK6)W>1SL+%E4GI5OQIXX
MU#QMJ"7%]*#%!&(;6W3(CMXAT1!V KG"0<XK"AADIO$55[\OP71'-AL&E4>*
MK+]Y+\$MD!;-)FBBO0/5%R:3)-%% !1110 4448H ^O/BQ_RC;^"/_8T:O7R
M*/F.*^N?BQS_ ,$V_@C_ -C1J]?)5O$2=W84MD)NR-J"!7CC.0#M!P>GN326
M]K(9R$!.?NX/&>XJO"99&6.,98C!Y P/<U2FNY3,?F*X/0$XK; 5YX/$QKQU
ML<:A*5[,UKVQGN+L!T,<BC#*31:6AMR[R2;0. <=#5"UUF:%\L1(.Y/7\ZW+
M2)M9@E4/ARNY%4<$YQSZ5^M9=F&78J4\:T_;+6S>CT\K&53GIJTMB."5$N 0
M=S'N>]3RI->SK#$ 68[0 < 5?;X?:_'I4=\;)TM@^WSB,+^?3\*GO=(G\'Z6
M;F==UW,N(\] #R3[TLXXNIX?+ZF"HM*<]K>:UOZ=3SW6I2DE3DF]B?3--:^N
M!;,JF20A21@@#O6+XDTZY\*:AOA5?LDC$QINW;:QXO$%W97 F65UE'3#8JM>
M:Y=WO$DI(SFOQW+L1CLMQ2Q.%J\K78Z:6&K1J7;3B]T>B_"CX6^)OC3XIM[#
M3M-GNH597G$*'[G^''6O8OCW^S]J'P^\+6U_%;E&MQBYAD&V1"."1V(Y7D5Y
MY^R;^T%?? _XOZ5J\]_<C1I0UM?0JVX-&PZX.1P<&OT.U3]MSX*_$VX7PKK6
MD-J-G?EH9;B6VW1;L *,CD$\\CI@=<\?#\0<6\48#B;#YDZ4J]*.LFM7;52O
M?2]M4>K'DA&5-Z*Q^2+V6Z5F7&T_ABIIT>VMA&.2._K7T)^TE^RTWPRUF[U7
MPG?CQ%X+N'/D7D+!I+5L\PS*.0PZ9QS7@5M"9-L5P6# X&!S]*_HO(<7@,ZP
MOUK+W954];I6?6,D]8OU..;:2;(]-G*Q'@YSD\<8[UZC\+=._LV^A\7:K$8O
M#^F.)&:0[$GD4AA'GOG'05>\"_"+2[C19/%'CG5F\'^"[9_+\\)OO-0EQD0V
MT)Y8^KD;%[GM7G/Q!^)5QXO2VTJS5].\+Z<S?V?I8<LL0/5W/\4A[M^6!7D\
M09W5AAYY#@ZW.OAG-?#;K%/J^FFWX'/#]_/W5IU-#XP?%RX^(_C;7-6@@33[
M.^NI)EM(23&@))P,UYRSEB23DGN:0G-)7Y]0P]/#4U2I*R1ZL(1@K1049HHS
M706&31110 4444 ?H'_P19_Y.4\3_P#8LR_^E$%%'_!%G_DY3Q/_ -BS+_Z4
M044 =[_P7&_Y&;X1?]>>I_\ H=M7Y?U^H'_!<;_D9OA%_P!>>I_^AVU?E_B@
M HQ110 4444 .4[02*3%)10 HI\QC,A\H,$]&.34>:,T#'*=IZXJU:WLMH"%
M<A2<D#O5,$TN<4FE+1EPJ3IOF@[,[0>+;*XTT6]Q!YTXP!(W&!65=>('B21;
M(+ C8!"KS^=8*GGGIWKHH]%AN;6$E3;B3.V9NA]JX_94Z+N?2K'X[,H\J:O%
M;[/[SGWD9R23D^III[5V5M\--0U&5H["2&^ 4-O1P/PYZFH?$?P[O_#L<!E
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M;_D9OA%_UYZG_P"AVU?E_7Z@?\%QO^1F^$7_ %YZG_Z';5^7]  !1Z\T44
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MW>I/3VK3@D4HT;.P0 X Z@^]<M6[W/H,"J4%[NYT#W=C<1227J,UP5PASN4
MCC'ICTK%O-(C?2DD2X=H5SYC!>%&>./SJL"+B%MY(Z+M''XU!?7LEO9O;@ML
M8C=D8+?7VK&G!Q=HL]/%8N%:#=:"M9ZK>_F<[/$%R0<C)P:@QQ5ZY43 E3A5
M'&>]4B,5[$7='YO6CRRT$HHHJC 5?O#ZU]Q_\%9_^2J?"C_LGNG_ /H^YKX<
M7[P^M?<?_!6?_DJGPH_[)[I__H^YH ^&Z***  4=:** "BBB@ I<C/' I**
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M%*M)2@\4T!]I>,V"_P#!.;X,$C=_Q4NKX_.OER218XRTX!&,Y]*^D_B6)_\
MAV]\$V@)#+XGU<G'UKY$N+N:<_O'8X]:_5\GXL63Y/'#.BW*\K/3E=WU[V.&
MI0]I4O<6^G%Q<.Z\+G JO^M&:3-?E]>M+$5959[R=_O.U))61(A.X;2=W:MV
MV2[= I>-G'W0W:LK30INEW'CMFM^-8R@8$C!^8#O7Z?P?EWUBG.JZC2OLI6^
M9QXB?*[6,*_^T&0B?.X=/2J1XS7621^9(S, \1&-K=<5SVI6RVURR+RO4?0U
MY'$W#]7+Y/%*;E&3M[V_D_-,THU5-<I5X(&.#W-6+=AC&-V>O-0+$S=!GCM7
M0:3HXBA6:6(R,X^4'H!ZUX.29%BL^Q'L,.MM6];)?(UJ5%17,S)N+(MF2(93
M&=N<D>M5%'-=A<Z;!=?N618Y5Y5T&/>N4N(C!/(C<LIQFO1S_A;%\/.,JLE*
M$M$UW6Z:[D4J\:VVYZQ\*=)CO?"FIPVLX_MN\?RX8<8;RE&6PQX&3_+FN&N]
M,DAN;B,QD-$2#T(Z]<CC'O4WAKQ_<:$(8Y8!=PPL\D:AS&RLR[2=PYZ =*ZH
MQ^$->TIIK?4C87RQHIM;E,1F3'S$-UYYZ\<U\!AL77RVO.HUS0ETW/>4Z6(I
MPI/1Q.&*LL8&[&,X%$6X$Y!8CG%=!J_@R\TB-;GRXKJTF \F:VD$B$]<$]C6
M+';&,-(REE4G*YZ5];1S_#\RJ*&WF<\L%/:^A86%FC#,#M8\'U]A6YI&C27<
M8:./RG(*KSDY&"2,'K@_E6'+))_H[E0'?!)?OVZGMP*T[*_F8B0'R)8B8O-X
M(?/.#[X[UX^<9QB<QC;X8_UN>EA*%*B[=3MO#^M+I\4FF7L<CZ;Y@-P+60AY
M5S]T\_,,_P ..:VM/T[P_P"*_&VGVFG7HTBU,9MF<1;6D?DE\MPB9P"#RH'X
M5YOJ$OVJ6)1(ZI*@61F4X5CUR<=*>9#87\]RC/*$<AQ*F]"PXR2>U?%O#7O*
M,K2:^1[%5^TI\DDGYE3XB>#6\+^(9;2XNM^I N;B!E(\G!^7GOD<UP;+M<C.
M?I72ZKJ\NI7=U<W4S27LA W/G+#I7/7$!MY2I8-[BOH,-S1IJ-1W=CY"M#E;
M(:*,45UG*?H'_P $6?\ DY3Q/_V+,O\ Z4044?\ !%G_ ).4\3_]BS+_ .E$
M%% '>_\ !<;_ )&;X1?]>>I_^AVU?E^*_4#_ (+C?\C-\(O^O/4__0[:OR_H
M 4FDSQBBB@ S0*** %Z4H;:00.1WIM% $I=I0!G/M221,GX=:2-@KBK$A\U1
M@87&<FH>C-XI23;W*E&:M);[H'8 D@9JJ:I.YG*+C:X[/I2K(5((.*913)3L
M:<&K.4,4W[Q,@AF/*X[5O6']FWC+&EVZR2(0L>,;6XXR>U<=3U8J<@X(Z5A.
MDI;.QZF&S"5%^_%27F=J^@1Z80PNU?<I)&SH>, @]N>M47+Q1>6Z[) <888;
MFJBZU=7,*S3$S/  JL1G [5LG4++6K6V#,S7_)D<<$<?K7$XSC\>I]3"IAJ]
MUA_<TT3Z[?B50K"(_-LY'+G&:2]E$7EAXD8G&3DG<*806+&[!X^567H<#VIE
MRK-#$X7,8;:KCH?8^]"6I,ZGN-+^OD5;Z%3$\42@?-D 5BNC(Q5A@@UL7".B
MX&<9)''.:R[@[SD_>[GN:[:3TL?-8Y)N]K,@HHQ16YY J_>'UK[C_P""L_\
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M . 3D?ETKJ4U>S.U5$GRM&*:*FNTBCG=869H_P"$MUJ'FM4;;GV!\4)WMO\
M@F]\$63&3XGU>OD%Y"[$L<D]2:^NOBQ_RC;^"/\ V-&KU\AULZU25-4G+W5L
MO45E>X$YHHH%8C"E(K?T72$FLWEN  DH*H<9/'<51US2AI=PJH_FQ.NY7QP?
M6O1>7XJ.&^MNF_9WM<Q5:$IN"W,VBC-%><;!T-2PW#VYRAQG@U%3D0OP!FMJ
M3J1FG3O?R MRZM/, '8G'K5-F+$D]:5T9#A@0?>FU5:=6I-RK-N7GN5S-JP4
M445SDB[3TJ66TDMVVRH\;XSM=2#7HW[.^G^%=8^+.@Z?XON_[/T>ZF$+73*K
M)&Y^[N# C!.!D],YK]4_AO\ #GP/XT\#OIGQ<^&6DV\VG&&V@O[[28X2ZL2@
MVW,>&.2,\,!C!YZU\5Q!Q13X>E%U:,IQ?\MK]M$]_.QU0I4YQUG:78_(3P!X
M?N?$?B[2[&U5F=Y@S$#(11R2?;%>B_%#PC:!C/:P^5.LF&FW=AW'M_\ 7K]
M/B+HO[//@+P?J-MX8M]+\(NQ>.6ZTQ/.N9@IP5$\C,VS/]TD''?BOC/XA>+/
MA]JMB;41ZA<0N2J3VF P Z2OO^\W'*C QBJR3$YEQ356*P.$J0IQ_F5O5]OS
M.BE&G&,E.2LSQ!-,\3I;K8007,UL4.!$F59<Y)!J*XUB]T]H+"ZA%ND+;<30
M8*]B?7TXKZ.^ 7P[T3Q,D]C_ ,)9:V]M. D2W+&*2.7J-P[*<GG.,BJ'Q?\
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MHBI//&,YKTZ<KQ2/8I2O%(CHHHK8W/KSXL?\HVO@C_V-&KU\B*,FOKOXL?\
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MF\3_ /@$?\:/^&&?C]_T2;Q/_P" 1_QK^C6BF,_G+_X8:^/W_1)O$W_@$?\
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M> =<MM8\/_#CQ;IFH6[AXYH;0]1Z@\'J>H[UZ3<> ?VK-7+)K'PFUZ_MI?\
M7)'IYA+\@DY4]<CTK]SJ3O7GU\#A<5+GK4TVNMM?O+4Y)63T/P+\0?LS_'S6
MRX7X.>*HD$C21G[+EU!/ +=ZY"__ &,/V@K^0N_PF\3ER<[C9G/\Z_HC'2EK
M:EAZ5%6@K&DJ]2:LV?E#_P $I/V=/B=\(?C[XAU;QKX'UGPUIL_A^6WCN]0M
8_+C:0SPD(#ZD*Q_ T5^KC=117287/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pmn-20251231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $! 7P# 2(  A$! Q$!_\0
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MIZ%X#\-^%M0O=0T7P]I6D:A>QQ175U8V44$LZ1+MB61T4%@B\*"3@<#%;]%
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M&=IYBK/M4*">$1V)Z!48D@ FM6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!K'&/K7S;>?MEKIG[6VF? V_\ :[8
M3:H\@L/$ET?+L[Q$M6N&DB!4&105,9*D@,#SVKZ2;I7YZ_%?Q!XJU7_@J_\
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M3P_\8Y/!@\*ZW>:%9ZU:>&]2\70>7]BLM3N@##;LA;>P.] S@84L,UX!\5O
M=_X7_P""K_P7UJZ\3ZIK=KX@AU*YM=,OI&:WTI8]/EC:*W!8@*S N0 O+=.]
M 'Z%CI2T@Z4M !1110 4F1ZT'I3"1FDW8!^:,BF;J,U/,.P_-&:9FC-',%CX
M+\4^//V@OVA?VJ?BCX!^&?Q(TWX8Z+X!2SA*2:7'>-?&92YD9I$8A@01@8&
M."<D[?\ PSO^V7_T<YI/_A-6W_QFOHSP'^S[X8^'7Q9\??$32I=1?7O&IMSJ
M:7,ZO ODJ53RE"@KP><L?PKTW-.X6/B;_AG?]LO_ *.=TC_PFK;_ .,T?\,[
M_ME_]'.Z1_X35M_\9K[9S1FES!8^)O\ AG?]LO\ Z.<TG_PFK;_XS1_PSO\
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M-!\$Z"]U)H^BVXM;5KV023% 2?F8  G)/0"NNH **** "BBB@ HHHH ****
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M:_U-X>_Z :?_ (!'_(\7ZQ5_F9]$_P##PO\ :%_Z*1<_^"RQ_P#C%'_#PO\
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M ">A\./][4?_ $VW5?-M?27_  3E_P"3T/AQ_O:C_P"FVZKXCC;_ ))O'_\
M7J?Y'3AOXT?4_<8=*<O2FCI3EZ5_G#$^O%HHHJ@"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD!!Z4;AZT (_2OS
MU^*W@/4/"_\ P5?^"^M7?BC5-;M/$$.I7-IIEZ[-;Z4L>GRQM%;@L0%9E+D
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M_4Q_[HK^G/!#_>,=Z0_.1XN9;1^8^BBBOZV1X(4444P"BBB@ HHHH *^DO\
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MU.6:Q?PW)9RWK,$Q/%*UPP6,G! "." 0&[CE_P!J_5=+T?\ :4^!T^K^._\
MA6UDMIKP;7_M5E;F,^1  N^\CDB^;('*YYX(KZY/7IFAT5Q\P!^HHUO%]O\
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210 4444 %(:**  TM%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pmn-20251231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "A L<# 2(  A$! Q$!_\0
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M]Q!?6=KIMJNF*C;L^;82Q>>OW?W%XK?WTJE'F?*#]T^Y:***0PHHHH ****
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M=?$<D;:K</;003Z9>12QNLB1GSXWBW6RAY8EWS!%_>IS\ZU<^,A_XN'\"O\
ML<[G_P!1[6:^?G_8X^(&I^(M6\17FH^';6_\6R"#7[6&\GFAL8%GLG1K1F@7
MS6V66W8Z1?ZW[_R?-ZG\0O"&KZ7\:_@]JMUXXU_6["Y\97HBT._@T]+2SW:'
MJ[+Y306L<^57Y%\R5_E;YMS885+EMH<T92^T?0U%%%2:A1129H 6BBD- #3^
M5&<5YO\ %CX[^$/@M<>'8O%5[-9G7[T6%BT4#RJTAV_>V_=^]]ZD;XP66O2M
M;>#]-O?&-RO/VNQ3RM/3Y]OS7C_NVP5^98O,<?W*Z8X+$.G&MR/EEM+I]^PK
MQ/216;KGB#3?#5A)?:OJ%KI=G$,O<7LZQ1K]6:N)A\.?$#Q.B/KOB2V\-6[*
MC-IWAB+S94?^)&O)U^=?]V")JM:-\&O"6AZG'J!TE=7U>+>4U77)7O[Q S;F
M"33LS(N?X5POW>/EH]G1IKWYW]/\W9?F*[(#\;=!OV:+0+/6/%;K'YJ/HNGR
M/:RK_L73[;=O^_M']N_$G6Y%%IX8TCP]:/'N\_5]2:>Y1O[IMX4V?^1Z]%P
M.E&,XH]M3C\%/[]?\D%F>;Q>"/&>IQ6HUCXA7-O-&^Z5?#VE06<4O^S^_P#M
M#[?]U^U?/O[8NM^*?V;]!T#QEX&L[GQ=JEQJL5A<V_B"XU+445F3]Q+'%'=+
M%$=X*8\OYFE3^[\WV2>.2<5R/C3X7>#_ (D?9#XK\*Z)XG-GO%M_;&GQ70@+
M[=VP2*VW=M7./[JUZ&7YC&ABJ=7%0YH+XHI*-_+2WYDSAS+W38\.OJ$NAZ>V
MI20S:B;>/[1+;PM#&TNT;V5&=V5=W1=[8'\3=:V<UEZ3I-GH6F6FG:=:0V%A
M9QK!;VEM&L45O&JA51%7Y555Z+6GCK7C3E&4I.)J.HHHH$%%%% !1110 444
M4 >3_M ?'K2/V>O!=MXDUVUN[ZVFNOLB0VI179_+DEY9V51\D+XY^9BJKRU:
MOP5^*T7QC^']KXECTV71W>XN+6:RFG2?RY8)6B<+*GRNNY#\PKPC]NS5KS1M
M.\-ZK)X@\4>'- TB\CNKJ72X=&:RN96WI"CMJ,J+YJ-\X^^O^SNVLGI/[(>I
MZ?K?P)T34-*U/5=8LKJ>\F^U:K<64DSNUQ*7_P"/-V@1-V=J1?=I0]Z,I%5/
M=Y3W =*6BBF2%>4?M9?\FL_&/_L3=9_](I:]6KRG]K+_ )-9^,?_ &)NL_\
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M1?4;RXUQI5U:]\'ZA+=P3^5C['%JWF_9UE7KLV_[%3#^+$)_PI'W..E>:_M
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M"^4S02LK[]WW?D^;Y?7*S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^3/V^YXX_"GA6!= U+4M0NKZ2WL[[3+VYM'M963
MY%9H$;<COL9E?Y=D3M]Y$KU_]F]XG^!O@MHM+?1HWL586CRRS,?F;]X7E_>-
MO_UFY_F^?YN:\H_;G\-:=KFB>#WOETN_FM]0D:#1=5\-WGB!+\M%AMMG:NKD
MI][?_#C_ &J]E^!"6,?P@\)#3)-*;3TT]/).B6<ME9;>O[J"5F>)?]ACN7D4
MJ?PR_P 0I_%'T(/CQXQUCP!\/KWQ!H^JZ!H:Z>PEO-1\3+-+;06_.[;%$Z-+
M*S;41=Z\OWQM;YC\4?MW^-O!FAR^)-7\'Z=865E:P6E]H,J3_;DU&72)=2W>
M;NVI$FU(F3RF;YF;?\FROJ[XH_"+PO\ &/0K+2?%MC/?VEI=QW\"VVH7-FT=
MQ'G9)O@E1LKG^]6#=?LU_#O4]5CU+4?#TFJWWV+^SY)-3U"ZNQ<1>2\&Z999
M6667RI73SI=TNQV7=BG'^]_7]?\ !->:/N_U_7](^?W_ &QO'VF>(]5\/7EE
MX:NKSPE*)M?NH;2XAAOH&N+)42U5KAO*DVWOWG>7YHON?/\ +ZE\0OB3I/B+
MXU_![P_:6NOPZA8^,KTR2ZAX=U"SM&V:'JZ-Y5U- L$OS-\OENVY?F7<H+5T
M=I^RQ\,;5=$1?#DDC:5</<P3SZG>2RR.TB2GSY'EW7*EXHFV3%U_=)Q\BU<^
M,@_XN'\"O^QSN?\ U'M9JY<MM#FC&7VCUBBBD) !).*@U,W6]=L/#>E76J:E
M=1VEA;1^;+<2M\JKZUP'ASP_?>/M0M/%/BBREM+6&3SM&T"X'_'M_=N+A?XI
M_P"ZO_++_?W-5;2(6^,/BA-8G8OX*T6Y9-,@/*ZG>1O\UTP_BBB==L7]YE:3
MH(FKUGI7;*V%CR+XWOY>7KW^[N+<7%+117$,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^9/V\;JP@^"\#7WAK4O$AEO_ "8O[)N9;:XM
M6:WN%W*T2.W[U2]O]THWVCYOES74?L?&0? W2/-TN32YUN[Q9VENKBX-Y+]I
MDWW7F7"K*_FME_F'\587[;N@:=X@^%^CQZC+8.L.M02Q:9J6C76LQ:D_E2H(
M/L5LRRSM\V_C[OE;_P"&NJ_94M]/M/@AH<.EIHMO9HUPODZ!I4^EVT#?:'WQ
M?99V>6*17W*ZN<[]U.'PS'/:F>S4444A!7E'[67_ ":S\8_^Q-UG_P!(I:]7
MKRC]K+_DUGXQ_P#8FZS_ .D4M 'J]%%% !1110 4444 %%%)0 M%)FD9@JDD
M@"@!C<@^E4[_ %&UTNQFN[N:.VM8DWR2RMM55]S7(:E\09+N]ETOPO8MX@U%
M&VS2H_E6EF?^F\Q_BZ?(@9_F4[=IW4FG?#][^_AU7Q5?OKM_$V^&W,?EV5LW
M_3.$?>;C[\FYA_#MW$5'/S+0[(X=4X\]>7+Y?:^[IZO[F,/BW7/&;%/"]LME
MIH8A]=U&-MK_ /7"#Y6D_P!]MJ]U\RI(/A-I#:==17TVHZCJ5U$L5SK)OI;>
M^E"MN \Z%D:-=W.R+:HR?EQ7<B$1\+A0>HQ3B>H[#MFER=]12Q4H^[1]V/X_
M-_TO(Y3P+X$TOX<Z+'HVB+=Q:?%@1Q75]/<B-55554:9V95"JORCY?S-=8.I
MH_&@D*M5&*BN6)S2G.I-U)RNV/'2EI*6J)"BBB@ HHHH **** &GI7YY^)_%
M3^"OVJ;_ %K5)==;PU9^*/-E\)V7AW6[JRW?9PG]JK/%O@>7>?\ 5)%][_:^
M>OT,/2O@A//NOVV9I[GQGK+V,'B!5LW\B]%HK.CK+:[O-\K[\44'W/*_[:O4
MT_XJ_K^OZZBG_"D?>-K<+=6\<T>=DB[E#+BK%(.E+5#"BBB@#R?]FK_DGFK_
M /8Y>+?_ %(=0KUBO)_V:O\ DGFK_P#8Y>+?_4AU"O6* "BBB@ HHHH ***0
MT ,QS2[<&JE_.UO9W$R_?CC9EW?3-?.#_M)>)Q^Q/9_&#[%I/_"2SZ=;WCVG
ME2?8MSW"1-\OF;MNUL_?J/\ @?CH*W]?B?3M%>6_%GXBZKX/F\(:!X?BL?\
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MO ?[-/B+PW\+KWX8:_XOT;Q#\/;RVO[26TM_#LUKJ6RZ>5_^/K[;+'E&E/\
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M#G]E]OA_\1;+Q2/$WV_[+?\ B"]^R"P\K=_:=S%.5W>:W^J\K;G;\V[^&O?
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M!VE:/J&J2ZU>6=ND4NH3;MT[#^/YF8_K72@5K'WH^\6+1116@!1110 4444
M,W8KQ7]HOQ#;>$]>^$&MWY$=EIWBF]NIV]$3PYK3-^@IOQY_:,'P5U73;*+0
M5UZ1].NM<U%VO?LOV33;9X5FE3]V_FR_OUV1?+NVM\RXKYX_;R_:H\ >'[[X
M>Z58:U!XGU3P_P"*?[1U33=(NHK@Q016MU:W%K.V_P#=2-YY38WS?>KULIRS
M$YMBZ>'P\>;F[>6YG4J1I_$?8/PH\.3>%/ .D6%ZD2:G)&]WJ'DC:CWD[M/<
M,!_M2RR-^-=D!UKQC1/VN?@SJNC6%W<_%7P/IT]Q;Q2R6ESXELED@9E#;&_>
M_>7I^%:?_#6'P1_Z+'X _P#"HL?_ ([7F5O:.K)U%[UV4CU>BO*/^&L?@C_T
M63P!_P"%18__ !VC_AK'X(_]%D\ ?^%18_\ QVH*/5Z*\H_X:Q^"/_19/ '_
M (5%C_\ ':/^&L?@C_T63P!_X5%C_P#': /5Z*\I_P"&L?@C_P!%D\ ?^%18
M_P#QVD_X:Q^"/_19/ '_ (5%C_\ ': /5Z*\H_X:Q^"/_19/ '_A46/_ ,=H
M_P"&L?@C_P!%D\ ?^%18_P#QV@#U>BO*/^&L?@C_ -%D\ ?^%18__':/^&L?
M@C_T63P!_P"%18__ !V@#U>BO*/^&L?@C_T63P!_X5%C_P#':7_AK'X(_P#1
M9/ '_A46/_QV@#U:BO*/^&L?@C_T63P!_P"%18__ !VC_AK'X(_]%D\ ?^%1
M8_\ QV@#U;%%>4_\-8_!'_HLG@#_ ,*BQ_\ CM'_  UC\$?^BR> /_"HL?\
MX[0!ZO17E'_#6/P1_P"BR> /_"HL?_CM'_#6/P1_Z+)X _\ "HL?_CM 'J]%
M>4?\-8_!'_HLG@#_ ,*BQ_\ CM>KT %%%% !1110 444AH :<;<=J\G_ &KN
M?V7?C'D8/_"&ZP,_]N4U:/QV^(5[\+_AAJ>OZ7;PW>IQRVMG:+=*[1++<7$4
M"O)M^;8K2!F]EKY]^*O[26C>(?V7_B)H'BWQ!H-IX\O]/UKPVND6-RL4MVPF
MN+ 74%K)(THBW(S-R^T+)\S;*AR48RE+:)O2H5<14IT:,>:527+'U/L5Y-O!
MP,\5R'CWXG^&?AC'9/XAU5+%KZ3R;.#RWEEGD_NHBJS,WS+7QCXE_;HU7XL:
MB-!\+^(/#GP@>%C>#7/%VM6\"W$2@+Y&UXV7<S/NXS\L;5Z_;^-?V;=3CTR]
M\4?%3P)XC\06KQW#:IJ/BRSDE\Y<'>O[U51=W\**J_[-<5/$_68_[/\ ?T/I
M<3DD<GJ1AG$K/K"-I37:_P!E7]6]]$>NBU\3^.'/VPS^%-$<8%O!*IOYEQ_%
M(ORPCK\J;F_VUY6N-TC]E;0O#?Q57QYIOB'7+/55=A]G1;3R#&S[VB8>1N96
M^[NW>9C^+=\U;S?M5_!1@ /C)X"&.P\36/\ \=I3^U;\$LG_ (O'X"/M_P )
M/8__ !VNIT82]Z6IY%/-,3AE.&&ER1DN5I?R^=[W/6@.!2UY1_PUC\$?^BR>
M /\ PJ+'_P".T?\ #6/P1_Z+)X _\*BQ_P#CM;'E'JV!2UY1_P -8_!'_HLG
M@#_PJ+'_ ..TO_#6'P1_Z+)X _\ "HL?_CM 'JU%>4?\-8_!'_HLG@#_ ,*B
MQ_\ CM'_  UC\$?^BR> /_"HL?\ X[0!ZO17E'_#6/P1_P"BR> /_"HL?_CM
M'_#6/P1_Z+)X _\ "HL?_CM 'J]%>4?\-8_!'_HLG@#_ ,*BQ_\ CM'_  UC
M\$?^BR> /_"HL?\ X[0!ZO17E'_#6/P1_P"BR> /_"HL?_CM'_#6/P1_Z+)X
M _\ "HL?_CM 'J]%>4?\-8_!'_HLG@#_ ,*BQ_\ CM'_  UC\$?^BR> /_"H
ML?\ X[0!ZO17E'_#6/P1_P"BR> /_"HL?_CM'_#6/P1_Z+)X _\ "HL?_CM
M'J]%>4?\-8_!'_HLG@#_ ,*BQ_\ CM=SX1\7:+XYT"UUOP]K-AK^CW1?R=1T
MRY2YMY=KLC[)4^5@KJR\?W: -ZBBB@ HHHH **** (GC#C!Y!KP[PS^Q_P##
M3PY!J,6L:5%XSTV40I;67BVVMK^WTV"![AXHK=6B^55^U3_,^Y_G/S5[GU%4
MM5L%U'3KNT9BBW$;1;E_AW+MK-\T;M#^+1GR'\&_V>O@%\8/A?XRT"T\+>$;
MZZN=0UF-M:TOPY';W=G:7UY=2V3VLL]JK?N[:6-8I45HOW7R,ZI7KNL?L;?!
M/5M2T*Z_X5?X1LAI=ZUWY%GX?L8XKS=;S0>5<+Y/[R(>?Y@7_GI%$W\.*R?V
M8?@/XB^#<-^?$EYIMU<)I&E^';3^S)9)4EM;%)52XEWQ(4EE\YMR#<J[1\[5
M]!X K::C%^Z9QN>)Z/\ L;?!/2M1UVZ_X5?X1O1JEZMYY%[X?L9(K/;;PP>5
M;KY/[N(^1YFW_GI+*W\6*Q]-_86^">FZ1X)T\> - N1X7\H?:KC1;%[C5MEG
M+:_Z>WD?O]WF^:WW?WL:/_#BOH:BI+/$+7]C7X)V_BO4=:_X5=X1E%Y9VUG_
M &?+X?L6M(/)>X?S8H_)^65_/VNW\2Q0_P!RLC_AA'X*?\(__9/_  K_ $#;
M_;7]L_;O[&L?M?\ R$/MOV7?Y'_'M_R[^5C_ %'[O/\ %7T-10!\N^.?@9^S
MEX,^(GA:34_AGH)U6[L;ZUL]"TCP0M_;W*-+:;[F>*VM)-OE;(U65]JJMQ+_
M '^/+8?AY^S#JNB?&0:EH?A.+2M6U5;73+C1?"1.H6$$^G6]DOV!?L>YF^U6
MM[*CVJRQ[MS;MV_;[G^TA\"]7^,DVFPZ3IWA1'CB\I?$&I6\B:SHC^:C^?87
M"HW\*E?+_=\E6W\;6\FT']CKX@>&_P"QM3M]1\/WNL>$SIUIH5O-=SI;W]K:
MO>_/=/\ 9V:"5TO_ +B+*JM%][Y_EB/VOZ_K^NQ7N_U_7]?,]<A_94^ WQ!M
M/"GB/2OAQX,.F1R_VK;-IN@62P:C%):RQHDZ^5^\BQ.)0O'[R*)OX:OVO[&O
MP3M_%>HZS_PJ[PC*+RSMK/\ L^7P_8M:0>2]P_FQ1^3\LC^?M=OXEBA_N5VG
MP8\!R_"WX4>$O"-Q=+?SZ)ID%E)<(NQ9&1 K,H]*[D]*TFU%OE,XGSW!^PM\
M$[;P1H'AAO .@2C2?[-_XF\FBV/]H7GV26*3]_-Y'[WS_)VS\#>DDH^7=6O=
M?L:_!.X\5Z=K7_"KO",0L[.YL_[/B\/V*VD_G/;OYLL?D_-*GD;4;^%99O[]
M>W4M(H^>)_V%O@G<>"-?\,+X!T"(:M_:7_$WCT6Q_M"S^URRR?N)O(_=>1YV
MR#@[$CC'S;:P/&WP8_9?T[Q2EMJW@[P-HE_X1@;Q/J-C;>'[..,V30SVP^UX
M@(>+,ID6+AO,BB;G;7U*>E?._P 8_P!FNZ^(>N^,;S1I=)T=-=\+G2O-\MEF
M:_6[6=)9=B_,GR*K-NW5'V@/+O WA7]F.R\5:_+J?A/P)<V_BS7DFT*TD\'8
M?38$M;*R:"Y22U7[#NO(KCY)=BLTO]]V6N@^$_[.?[,_Q+\.^&;;PGX8T'78
MO!,L*2WEWX;@CFU;_0I;='O&EM4^U12B3S_-3Y'EB1U8[,5SE_\ L7>-_$.N
M:U?ZCJ>B6O\ PF=Y#<>)(K>\G?\ LY8-2^VQ)9,T"^?N5?*??Y7]_P#V:]8_
M9A^ _B+X-PWQ\2WFFW5PFDZ7X=M/[,EDE26UL4E5+B7?$A267SF+(-RKM'SM
M6JC'E]X)?W?Z_K^MS6M?V-?@G;^*]1UG_A5WA&47EG;6?]GR^'[%K2#R7N'\
MV*/R?EE?S]KM_$L4/]RLC_AA'X*?\(__ &3_ ,*_T#;_ &U_;/V[^QK'[7_R
M$/MOV7?Y'_'M_P N_E8_U'[O/\5?0U%2!XA=?L:_!.X\5Z=K7_"KO",0L[.Y
ML_[/B\/V*VD_G/;OYLL?D_-*GD;4;^%99O[]9&I?L+?!/4M(\;:>? &@6P\4
M>8/M5OHMBEQI.^SBM?\ 0&\C]QM\KS5^]^]D=_XL5]#4AH ^8O&_P)_9JT_Q
MCH6FZKX'\$Z/JVE0W7B/^S+3P_9J+JTB@D@E^TJL#;H%^TK)M.W]Y'&R[MA%
M9GPQ\5?"#X4_$_5-:\.V=CX&\/>--+TK3M.TJW\*7FC/+<VUQ>>;=2P-:Q*D
M#_VC91+<.=K/\F[A<^@_%#X(W7BSXDV/BC2;'PWG_A'M7TJ]BUJQ:XBNY;H6
MJQ>?$NWSXMMNR,C.ORD5X59?L5>-K36M2O[>7PIX=TOQ#_H-]X9TF:?^S]"L
M_M%I.WV >0JN[O:RLR,D2[I_O?)\[C;[7]:A/W8^Z?4O@GXQ>$/B!K.L:3X<
MUG^T;[2)-MVAMIHU/SO%NB=U594\V*5-\6Y-R.OWJ[[N:^>O@%^S_P"(OA=X
MNOK[6+_3I].M+&?2M(-C+*TLT$M_->-+.K(HC?\ >HFQ6?[C-N^?:OT+W-3T
MB3]ICJ***904AI:* /*/BW^S]X=^,E]I5UK-WJ5A+9PS6<O]GR1HM[9RO$\M
MI/O1LQNT,9.S:XV_*RUQO[1.@_"G5/B!\,6\=_V4NJV.I-<6]I>Z.U]]LMWA
MEM5BD=598(?M5U:R;Y/D\R.)?O,I'T-GVQ7SY\?O@'XB^)_C6PU71+[3;>PN
MM-71=66_DE2:"!;V"Z$MOM5E=_W3IM;9]]6W_)M;6A5G1J1E"3C_ (=")ZQD
MSV71/#&EZ'J.O7NGVWV:[UF]2^U!_,9O/G6WAME?YL[?W5O"GRX^Y_>+5F0_
M##PQ:>!]!\%Q:7Y?AS0O[/.G67GR_N/L,L4MI\^_<VQ[>)OG8[MGS;LM79CI
M2UD68-KX4TVU\5WWB*&U*:O?6EK8W-SYK?O(('N'B4KG;\K74_\ WW_LK63-
M\,/#%WX'U[P7+I?F>'-=_M ZC9>?+^_^W2RRW?S[]R[WN)6^1AMW_+MPM=I1
M0!@W?A73;KQ78^(IK4OJ]C:75C;7/FM^[@G>W>50N=OS-:P?]\?[35S'B37?
M"'P835M?OH+RUD\2:K%+<_8+*ZU&>\O?L\-NGEP0+*^[RK6)=J)TB+8^\U>B
M$5Y/\?\ X;WOQ-\'0:=:>&_!OBU4N?-ETWQO;,]N5\MTWQ2JDGD2INW!_*?(
M#+\N_>L/R*C;[1Y\_CCX2V4_@+1-.\3-X8T_X6 ZP-/O].O$$5E%I,]F+9Y9
MU79+%%?P.R,6E7Y5= 7W5TVD_'7X1S>,[/6;35Y(_$?BF&#2 TEE>)(4MKF=
M(8KB)X_]$/GW5PG[Y8F9WV_-\M>$:=^PKXXA\+WOA>_\8:=JUG!!>75IK=S+
M.U[=:C/;VL>VXBV_)$C6[MO65F99%^7Y/FV;7]D#QY<>-+S7[W4=!A?Q/JEK
M?^(8(;R=Q8+;:HM[$EF[0+Y^Y$\I]_E?WO\ 9K>,8\W+]G^OZ_X?3+WK?U_7
M]>1]1?\ "K_#/_"-_P!A_P!F?\2O^VO^$A^S^?+_ ,?_ /:']H^;NW;O^/K]
M[M^[_#MV_+6E=>%--NO%=CXBFM2^KV-I=6-M<^:W[N"=[=Y5"YV_,UK!_P!\
M?[35NTM9EG%ZO\+?"^LZ1XTTR\T[S;#QEYO]O1&>5?MF^SBLW^8/F/,$$2?)
MM^YN^]EJU-:\,Z9K>I:!?7]L;F[T:]>^T^3S&4P3M;S6S/\ +C=^ZN)D^;/W
M_P"\%KH** //=7UCP7X.^)ED;R^@T[QKXKMETVV2265WO(+/[5<*NS[J+'Y]
MPV_Y?O[=Q^45XOKWQ6^"ES\'M \/:)XM?1?#/AW5="6Q5=+OKIS!IMS;WL2Q
MHR^;+ T%DW^E#=%M#R;V"-7IOQ1^#I\=?$+P)XBLH=/MY='N;HW]W(-EU-!)
M8W-NB(RIEMKW&[:S*/O5\VZ=^Q+\1M,M]+U&#5O#3:]I.BQ>$[2%KRY^R3:<
MEA<6GVIW\C<D^9_,\K:Z_+M\WYMU'V?Z_K^K]!2_K^OZ[=3Z!O\ XV_"-_&M
MWK%UXAC.N>$]+O(9;XP77E):RRVK7"1-L\JX;S(K,,L6]T;8OR[]K;WA+1/
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MGA;PC%/]J71=,M[#SCUD,2*C-^)%=?1.W.^78S6WO#L4M%%24%%%% !1110
M4444 %%%% !1110 4444 %%%% !1112 1>E+113 0]#0.IHHH#H+1112>PD%
M%%%'470****.I04444""BBBF,**** "BBB@ HHHH **** "BBB@ HHHH ***
M*3 ****8""EHHH 0T=Z**D0-TH'2BBJ&+1112Z"ZA1112[#"BBBJ **** "B
MBB@ HHHH **** "BBB@ HHHH 0T#I110)BT444#"D-%% "T444@$[T#O111U
B 6BBBF AZ4AZ444A"BEHHH *0]***!BT444P"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pmn-20251231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $% 7P# 2(  A$! Q$!_\0
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M-2P?\%!OV.;9$2'Q1I$2IY6U4\)7P \K=Y6,6G\'F/M_N[VQC)KX\Z#UV/\
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M8= ^(OC/1=,L_ Z:;H_B#4M*M?M>CWDLQBMKR6!&=UOD!8K&"2%49)P!7O\
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MJ\NY5BA@B12SR.[$!55026)  !)KS7_AK'X(?]%D^'__ (5%C_\ ':/VL?\
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M?EDXWM=VO:]KNW<\J_:Q_P"36/C)_P!B9K/_ *0S4?LG?\FL?!O_ +$S1O\
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M=IZ(4444 %%%% !1110 5X/^V[_R;OJ/_8>\._\ I\L:]XKP?]MW_DW?4?\
ML/>'?_3Y8UQ8[_=:O^&7Y,[,%_O-+_$OS1\R4445_&A_6@5X-^W;_P FU_L:
M?]B,_P#Z1Z17O->#?MV_\FU_L:?]B,__ *1Z17]5_1W_ .2HA_CI_E4/Q3Q,
M_@8?TG_[8?&%%%%?[ '\Y'H7[.?_ "<9\)/^QST3_P!.$%?7'[8'Q)\;:?\
MM4_$S3M/\>^,-(TVRN[&*VL-+\27UG;PJVEV4C!(HI51<O([' Y+$GK7R/\
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M)?XG^2/UKA+_ '&?^-_E$****^J/M@HHHH **** "BBB@ KP?]MW_DW?4?\
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M_P#37IU?9E?&?_!+?_DC_P 0?^QSE_\ 37IU?9E?KV!_W6E_AC^2/\W>*_\
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M KP?]MW_ )-WU'_L/>'?_3Y8U[Q7@_[;O_)N^H_]A[P[_P"GRQKBQW^ZU?\
M#+\F=F"_WFE_B7YH^9****_C0_K0*\&_;M_Y-K_8T_[$9_\ TCTBO>:\&_;M
M_P"3:_V-/^Q&?_TCTBOZK^CO_P E1#_'3_*H?BGB9_ P_I/_ -L/C"BBBO\
M8 _G(]"_9S_Y.,^$G_8YZ)_Z<(*^F/VR?^3N_BS_ -?^G_\ IGL*^9_V<_\
MDXSX2?\ 8YZ)_P"G""OIC]LG_D[OXL_]?^G_ /IGL*_@CZ1/_(TH_P#7J'_I
MRH<N;?\ (HE_B1Y!1117\9GYB>C? W_FMW_9&?%?_ME7GU>@_ W_ )K=_P!D
M9\5_^V5>?5[^)_Y%^%_[?_\ 2C_1'Z-G_(KQG_</_P!*K!1117BG]E'Z'_\
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M** "BBB@ HHHH *\'_;=_P"3=]1_[#WAW_T^6->\5X/^V[_R;OJ/_8>\._\
MI\L:XL=_NM7_  R_)G9@O]YI?XE^:/F2BBBOXT/ZT"O!OV[?^3:_V-/^Q&?_
M -(](KWFO!OV[?\ DVO]C3_L1G_](](K^J_H[_\ )40_QT_RJ'XIXF?P,/Z3
M_P#;#XPHHHK_ & /YR/0OV<_^3C/A)_V.>B?^G""OIC]LG_D[OXL_P#7_I__
M *9["OF?]G/_ ).,^$G_ &.>B?\ IP@KZ8_;)_Y.[^+/_7_I_P#Z9["OX(^D
M3_R-*/\ UZA_Z<J'+FW_ "*)?XD>04445_&9^8GHWP-_YK=_V1GQ7_[95Y]7
MH/P-_P":W?\ 9&?%?_ME7GU>_B?^1?A?^W__ $H_T1^C9_R*\9_W#_\ 2JP4
M445XI_91^A__  2W_P"2/_$'_L<Y?_37IU?9E?&?_!+?_DC_ ,0?^QSE_P#3
M7IU?9E?KV!_W6E_AC^2/\W>*_P#DH,P_Z_5?_2Y'E7[6/_)K'QD_[$S6?_2&
M:C]D[_DUCX-_]B9HW_I##1^UC_R:Q\9/^Q,UG_TAFH_9._Y-8^#?_8F:-_Z0
MPUVGRQZK1110!\A?M=_%GQ?X2\<-I.F74_\ 9*Z?820:+<^"[G6]+U5YKJ:.
MZ-Y)!!(ZK!$L4JQQO&Y;LX8 >^_ 6\:^^%&A3-KEWXB)1Q_:%YH+Z(SXD8;4
MLGCC:&-<;4# G:JDLV=QP?VE[CQW:>$M$G\"WNOZ>R:M&=7N/#&GV5_?K9&*
M4'RX+L%'_>F'.T%P,D @$'GOV5+SXOW*^(U^)TFL75B/)DTNY\066G6MXQ9I
M2R[+([ HB%LQ#KN61Y5W,$!H ]_K)\6>%M+\<^%=9\-ZW:_;=%UBRFT^^MO,
M:/SH)4,<B;D(9<JQ&5((SP0:X#]ISXMZS\%/@[K?B?P]H,_B#6X(RMK EE<W
M4$+;68S7"VZM(L*!2688[ LN=P\L\-?M0_$/Q3JGCR#PUX,TSQQJ6E017&F>
M%;>X;1K^-3<QQ#[;-=,1&98FDN8U:*,A(RIW$AB <E^Q-\+?#'P6_:Q_:F\&
M^#=,_L;PWIO_  BWV2R^T2S^7YEA/*_SRLSG+R.>6.,X'  K[5KXJ_8F\1>)
M_%?[6/[4VJ^,O"/_  @GB2X_X1;[7X?_ +3BU'[+ML)U3_2(@$?<BH_ XW[3
MR#7VK0 4444 %%%% !1110 5^>W_  51_P"1Q^#_ /UX:]_Z,TROT)K\]O\
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M 6G_ /R;1_P^&^$7_0F_$#_P"T__ .3:_)"BO['_ .(*\/?\_P"M_P"!0_\
ME9\]_:57LOQ_S/UO_P"'PWPB_P"A-^('_@%I_P#\FUP7_!0[QK8_$JQ_9Z\7
MZ9%<0:;K_AW5=5M8KM569(IQI,J*X5F 8*X! )&<X)ZU^9M??O[4'_)"?V._
M^R>R_P#I+HU?@'B[P5EW!^"H_4)SE[55+\[B_AY+6Y8Q_F=[WZ'+C\3/$9=B
M.=+1'S[1117\='XX='\+O^2P_#+_ +'/0/\ TZ6U?M[7XA?"[_DL/PR_['/0
M/_3I;5^WM?HW#G^Z2_Q/\D?K7"7^XS_QO\HA1117U1]L%%%% !1110 4444
M%>#_ +;O_)N^H_\ 8>\._P#I\L:]XKP?]MW_ )-WU'_L/>'?_3Y8UQ8[_=:O
M^&7Y,[,%_O-+_$OS1\R4445_&A_6@5X-^W;_ ,FU_L:?]B,__I'I%>\UX-^W
M;_R;7^QI_P!B,_\ Z1Z17]5_1W_Y*B'^.G^50_%/$S^!A_2?_MA\84445_L
M?SD>A?LY_P#)QGPD_P"QST3_ -.$%?3'[9/_ "=W\6?^O_3_ /TSV%?,_P"S
MG_R<9\)/^QST3_TX05],?MD_\G=_%G_K_P!/_P#3/85_!'TB?^1I1_Z]0_\
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M)$&+! Q&=H+,<>K'UKJ?!G@G0/AWX=M= \,:19Z%HMKN\BPL(A%#'N)8[5'
MR22?<T ;=9/BS7_^$4\*ZSK?]FZAK/\ 9ME->_V=I,'GWEUY:%_*@CR-\K;=
MJKD98@9YK6HH ^*OV)O'_P#PM#]K']J;Q/\ \(YX@\)?;O\ A%O^)-XIL?L6
MHV^RPGC_ 'L.YMN[9O7DY5E/>OM6OE7]GC_D^S]KG_N4?_37)7U50 4444 %
M?+W_  4S_P"3)OB#_P!=M)_].MG7U#7R]_P4S_Y,F^(/_7;2?_3K9UZN4_\
M(QP_^.'_ *4B)_ _0_$6BBBO]/CXH*^_?VH/^2$_L=_]D]E_])=&KX"K[]_:
M@_Y(3^QW_P!D]E_])=&K^0/I$?[E@O2M_P"XAXC_ )%V)]$?/M%%%?Y]GY,=
M'\+O^2P_#+_L<] _].EM7[>U^(7PN_Y+#\,O^QST#_TZ6U?M[7Z-PY_NDO\
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M_P#IKTZOLROC/_@EO_R1_P"(/_8YR_\ IKTZOLROU[ _[K2_PQ_)'^;O%?\
MR4&8?]?JO_I<CRK]K'_DUCXR?]B9K/\ Z0S4?LG?\FL?!O\ [$S1O_2&&C]K
M'_DUCXR?]B9K/_I#-1^R=_R:Q\&_^Q,T;_TAAKM/ECU6BBB@ HHHH \R_:+^
M'FI?%+X6WWAW2M(T/7+NYFB/V3Q%=RV]F4#?.S;(9@[!<E%>-TW[696"[3Y#
MX4_9<^(/AB^\<7GAOQ5I/P\UK6;2&"S\2649UR[.+B.4+<Q744:RB"%'M8V+
ML2LC.0AP@^JZR?%GBG2_ WA76?$FMW7V+1='LIM0OKGRVD\F")#)(^U 6;"J
M3A02<< F@#Y _8F\.^)_"G[6/[4VE>,O%W_"=^)+?_A%OM?B#^S(M.^U;K"=
MD_T>(E$VHR)P>=FX\DU]JU\5?L3?%+PQ\:?VL?VIO&7@W4_[9\-ZE_PBWV2]
M^SRP>9Y=A/$_R2JKC#QN.5&<9'!!K[5H **** "OE[_@IG_R9-\0?^NVD_\
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MG_D[OXL_]?\ I_\ Z9["OF?]G/\ Y.,^$G_8YZ)_Z<(*^F/VR?\ D[OXL_\
M7_I__IGL*_@CZ1/_ "-*/_7J'_IRH<N;?\BB7^)'D%%%%?QF?F)Z-\#?^:W?
M]D9\5_\ ME7GU>@_ W_FMW_9&?%?_ME7GU>_B?\ D7X7_M__ -*/]$?HV?\
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MQ9_Z_P#3_P#TSV%?,_[.?_)QGPD_['/1/_3A!7TQ^V3_ ,G=_%G_ *_]/_\
M3/85_!'TB?\ D:4?^O4/_3E0Y<V_Y%$O\2/(****_C,_,3T;X&_\UN_[(SXK
M_P#;*O/J]!^!O_-;O^R,^*__ &RKSZO?Q/\ R+\+_P!O_P#I1_HC]&S_ )%>
M,_[A_P#I58****\4_LH_0_\ X);_ /)'_B#_ -CG+_Z:].K[,KXS_P""6_\
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M^>_^U++_ )^X/^_J_P"-']J67_/W!_W]7_&OZ$/^&3O@A_T1OX?_ /A+V/\
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M:?<7=OMWR:797>H6YW*&&R>WADB?AAG:QP<@X(('H'_#)WP0_P"B-_#_ /\
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MX(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =H_X9.^"'_1&_A_\
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M<@VL <HP[&OU;_X9.^"'_1&_A_\ ^$O8_P#QJC_AD[X(?]$;^'__ (2]C_\
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M+H]E#I]C;>8TGDP1((XTW.2S850,L23CDDUL>::U%%% !1110 4444 %%%%
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pmn-20251231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "X B(# 2(  A$! Q$!_\0
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M_P#A!WW_ ,N: /5:*\J_X1SXW_\ 10_A_P#^$'??_+FC_A'/C?\ ]%#^'_\
MX0=]_P#+F@#U6BO*O^$<^-__ $4/X?\ _A!WW_RYH_X1SXW_ /10_A__ .$'
M??\ RYH ]5HKRK_A'/C?_P!%#^'_ /X0=]_\N:/^$<^-_P#T4/X?_P#A!WW_
M ,N: /5:*\J_X1SXW_\ 10_A_P#^$'??_+FJFD^#_CKIVE65I<?%+P/JEQ!"
MD4E]=^ ;I9KEE4 R.(]71 S$9(1%7).% P  >P45Y5_PCGQO_P"BA_#_ /\
M"#OO_ES1_P (Y\;_ /HH?P__ /"#OO\ Y<T >JT5Y5_PCGQO_P"BA_#_ /\
M"#OO_ES1_P (Y\;_ /HH?P__ /"#OO\ Y<T >JT5YI^SCXM\5?$'X+^$O%_B
M^\T>YU+Q'IEIK,<6B:=+90VL5Q;12B B2XF,C*S./,RH88^1<$GTN@ HHHH
M**** /*O$?\ R=/\//\ L3/$O_I=H5>JUY5XC_Y.G^'G_8F>)?\ TNT*O5:
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M&?4-%%%?F!^RA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO/\ TQ:K7+B^'_JM"5;VM^5;6_X)VX'BGZYB88?V-N9VOS7_ /;3[4HHHKY
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MO+RB@[-W.WIGF@#D/V3O^36/@W_V)FC?^D,->JUY5^R=_P FL?!O_L3-&_\
M2&&O5: /G?\ ;&Z?"#_L<W_],>K5YY7H?[8W3X0?]CF__ICU:O/*_2.&_P#=
M)?XG^2/R/B[_ 'Z'^!?G(****^K/B KJOV7?^2Z_$_\ [%OP[_Z5:S7*UU7[
M+O\ R77XG_\ 8M^'?_2K6:^;X@_W%^J/KN%O^1BO1GU#1117Y@?LH4444 ?,
MW[<__(&^%'_8YG_TRZK7A%>[_MS_ /(&^%'_ &.9_P#3+JM>$4 %%%% !79_
MLT_\G3Z/_P!B9K?_ *7:17&5V?[-/_)T^C_]B9K?_I=I% 'V[1110 4444 %
M%%% !1110 4444 %%%% 'BG[%_BS0_%?[+'PM_L36=/UG^S?#.E:;??V?=)/
M]ENH[&#S+>783LE7<-R-AAD9'->UUY5^R=_R:Q\&_P#L3-&_](8:]5H ****
M /G']M?3[7Q!X0\-Z/)?:''</J1O6LM9O[: 2V\4;>;*$GFC5EB+1NS L5'\
M+!B*^BH.(8^%'RCA6W <=CWKQ+]H_P '>";JYT+Q1XLU;7M,FTUF^RKH< N&
M<Q9N?,:'R92WE^47W8PN,UZ[X7\1:?XM\.Z=K.E3M=:;>PK-!,\;1LR$<$JP
M# ^H(!H \^\1_P#)T_P\_P"Q,\2_^EVA5ZK7E7B/_DZ?X>?]B9XE_P#2[0J]
M5H **** /BO6_P#DN_QJ_P"QDL__ $Q:55FJVM_\EW^-7_8R6?\ Z8M*JS7Z
M[E7^XTO0_",[_P"1C6]0HHHKUCPPHHHH *K:)_R7?X*_]C)>?^F+5:LU6T3_
M )+O\%?^QDO/_3%JM>3FO^XU?0]S)/\ D8T?4^U****_(C]W"BBB@ HHHH *
M^ /B/_R<1\9?^P_9?^F/3*^_Z^ /B/\ \G$?&7_L/V7_ *8],H SJ*** "BB
MB@ HHHH [/\ 9I_Y.GT?_L3-;_\ 2[2*^W:^(OV:?^3I]'_[$S6__2[2*^W:
M "BBB@#RKPY_R=/\0_\ L3/#7_I=KM>INZQHSNP5%&2S'  ]:\L\.?\ )T_Q
M#_[$SPU_Z7:[7IFHV,>J:?=6<Q80W$30N4.&VL"#@]CS0!\\?LIZ=;1^-_BE
MJMO?:%J4>K:BMW!=Z3?VUT\]N9KCRI&,,TA*'YD5I-A+12?(#NKZ0KYM_9LU
M+PSX/\=>)/ _AZT\57!\R2:YO=6DM)H8YHF,1$GDXDCD950XE7.SRB,!EW?2
M5 'E7[)W_)K'P;_[$S1O_2&&O5:\J_9._P"36/@W_P!B9HW_ *0PUZK0!\[_
M +8W3X0?]CF__ICU:O/*]#_;&Z?"#_L<W_\ 3'JU>>5^D<-_[I+_ !/\D?D?
M%W^_0_P+\Y!1117U9\0%=5^R[_R77XG_ /8M^'?_ $JUFN5KJOV7?^2Z_$__
M +%OP[_Z5:S7S?$'^XOU1]=PM_R,5Z,^H:***_,#]E"BBB@#YF_;G_Y WPH_
M[',_^F75:\(KW?\ ;G_Y WPH_P"QS/\ Z9=5KPB@ HHHH *[/]FG_DZ?1_\
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MZC_AFGPC_P!!?X@?^''\0_\ R=7Y$?NYZK17E7_#-/A'_H+_ ! _\./XA_\
MDZC_ (9I\(_]!?X@?^''\0__ "=0!ZK17E7_  S3X1_Z"_Q _P##C^(?_DZC
M_AFGPC_T%_B!_P"''\0__)U 'JM? 'Q'_P"3B/C+_P!A^R_],>F5]5?\,T^$
M?^@O\0/_  X_B'_Y.KX_U[PS9^#_ (U?%S2+";4+BTM]?M-DFJ:E<:A<'=HV
MFL=\]Q))*_+'&YC@8 P   "6BBB@ HHHH **** .S_9I_P"3I]'_ .Q,UO\
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M7H?[8W3X0?\ 8YO_ .F/5J\\K](X;_W27^)_DC\CXN_WZ'^!?G(****^K/B
MKJOV7?\ DNOQ/_[%OP[_ .E6LURM=5^R[_R77XG_ /8M^'?_ $JUFOF^(/\
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M 'J: /,O$?\ R=/\//\ L3/$O_I=H5>JUY5XC_Y.G^'G_8F>)?\ TNT*O5:
M"BBB@#XKUO\ Y+O\:O\ L9+/_P!,6E59JMK?_)=_C5_V,EG_ .F+2JLU^NY5
M_N-+T/PC._\ D8UO4****]8\,**** "JVB?\EW^"O_8R7G_IBU6K-5M$_P"2
M[_!7_L9+S_TQ:K7DYK_N-7T/<R3_ )&-'U/M2BBBOR(_=PHHHH **** "O@#
MXC_\G$?&7_L/V7_ICTROO^O@#XC_ /)Q'QE_[#]E_P"F/3* ,ZBBB@ HHHH
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M90HHHH ^9OVY_P#D#?"C_L<S_P"F75:\(KW?]N?_ ) WPH_[',_^F75:\(H
M**** "NS_9I_Y.GT?_L3-;_]+M(KC*[/]FG_ ).GT?\ [$S6_P#TNTB@#[=H
MHHH **** /D__@HG_P B-\,O^QS'_IHU.OD2OKO_ (*)_P#(C?#+_L<Q_P"F
MC4Z^1*_?_#__ )%=3_KX_P#TF!Y>*^->@4445^F'&%>P?L6?\G3VW_8F:O\
M^EVE5X_7L'[%G_)T]M_V)FK_ /I=I5?&<8_\B/$?]N_^EQ.C#_Q$?H71117\
MSGL'E7[)W_)K'P;_ .Q,T;_TAAKU6O*OV3O^36/@W_V)FC?^D,->JT %%%%
M!6!XY\'6GC[PQ=:)>W-U9P3M%(+BR=5EC>.19$92RLN0R*<$$>HK?HH \IU;
M]F7P1K>N6>LW4OBJ/5+.R&G6]Q8>,=7L1#;[(5:...WNHTC5_L\#.$50[1JS
M L,TO_#-/A'_ *"_Q _\./XA_P#DZO5:* /*O^&:?"/_ $%_B!_X<?Q#_P#)
MU'_#-/A'_H+_ ! _\./XA_\ DZO5:* /#W_8R^%TM_>WSV_BQ[V^D$UU<MXZ
MUTR7$@C2,/(WVW+,$CC0$Y.U%'0"E_X8T^&'_/'Q;_X7>N__ ";7M]%;*M5B
MK*3MZF$L/1D^:4$WZ(^-?$VA?LQ>#=2UFRUS5_'.EMI+2QW5S<^(/%BVN^,H
M)$CN/.\J9U\Q2RQNQ R2,*Q"ZCX!_9KU?3;JRMO&'C'2+BZO=1T&"_A\7>(5
MEBOK6W:6?RO.F:-WC0;U+*Z.1@!_NGVS5/V5_AYJX\5SS:+ NL>)KT7FH:Y'
M;6XU!@)HIA )_+W&'= GR-GCOT(YV#]B;X?Q>!(?";7>N3:;$DVV9KM%N/-E
MMHH&G\Q8P1*#"LH8?\M"Q.0=M/V];^=_>R?JM#_GVON1PVJ> _V9]%M/$5S>
M^)?$5O!X=TRUU?56;QOXB_T2VN03;LP^U9W2#&(QE_F7Y?F7.WX;^!GP'\6^
M*]2\-Z5>>+[K5]/B$T\1\8^(XXRIVY\N5KH1RE2Z!PC,4+J'"D@5KZC^PE\+
MM3AU>.8^*%_M.SBM9C#XFOHPLB"0"X1%E"B3]X<KCR^.(QEMWHG@+X.0^ /%
MFK:Y#XHU_6%O[6"S6PUB2VGCM(H458UBE$ N,  DAY7!:21R-S%J/;UOYW][
M#ZK0_P"?:^Y')?\ #&GPP_YX^+?_  N]=_\ DVD3]C+X717]E?);^+$O;&0S
M6MROCK71);R&-XR\;?;<JQ221"1@[78=":]PHI.M5DK.3MZE1P]&+O&"3]$>
M5?\ #-/A'_H+_$#_ ,./XA_^3J/^&:?"/_07^('_ (<?Q#_\G5ZK16)N>5?\
M,T^$?^@O\0/_  X_B'_Y.H_X9I\(_P#07^('_AQ_$/\ \G5ZK10!Y5_PS3X1
M_P"@O\0/_#C^(?\ Y.H_X9I\(_\ 07^('_AQ_$/_ ,G5ZK10!Y5_PS3X1_Z"
M_P 0/_#C^(?_ ).KG[G]B?X3WFHWNH7%CXHGO[V19;JZD\<:XTL[JBQJSL;S
M+$)&B G/RHHZ 5[K10!\W^,?V4O@AX!\,ZAX@UNV\5VVE6*>9/)#XN\07#@$
M@#;'%=,[DD@!54DYZ5RV@_"3]F'Q MJL>MZQIMW<RW$$6FZYXXU[2[\O  TZ
MFUNKN.8%%(9LH,*P/0@UZM\1/B#\*?B9X>\5>"/$/B>UM["*>?3M9%P/)CMV
MMHX[F=)7F3RU01LA+-\I5B 20<<5XJ^"7P+\6^(_A\MEXHT;PW$;64^&O#WA
MZZTVWM+U91(S3VD)B9BS!Y,O;E0XQNW;5P 9.I?LY?LX:O\ #Z[UZS\9WNG:
M!<[[&+Q19?$K4'@MYV)C!CEDO'A,JN>%<,-P *GD'8U?]F+]GWP_::1=:IJ=
M_IMMK$T=MILUY\1=7B2^ED&8XX6:^ D9ARJKDD=*C\1^#/@_I*ZQ\,[WQIJ'
MAW4K$CQ;<7TGEQ"PC6T6TDD-S+;FV4& -O5\N!*S_+E6$^J^&O@WKFD^$]*7
MXH7FG/I.K6-WI>J_\)(-UW<36^(8;:6?=$5FB4D1VNT#YM@3<<@&;=? ']FF
MQM;&ZN?$LEO;7]PEI:32_$S5%2XG=4=(HR;_  [LLD;!1DD.I PPKKO^&(OA
M+_T#O$W_ (6^N?\ R97FNM:9\$M)\,:9X7\2_$+3;^\N=4UFUGG\,R1"-+R7
M!FA:$O<.CPIY,:(69EVKD;1\OTIJ'Q>\":3/IT-]XU\.V<VI.D5C'<:K!&UT
M[NT:+$"_SEG1U 7.65@.0: /.],_8P^%NBZJFIZ?;>*[#4DA>V6\MO'6NQS+
M$[(SQAUO00K-'&2N<$HI/W16Y_PS3X1_Z"_Q _\ #C^(?_DZO5:* /*O^&:?
M"/\ T%_B!_X<?Q#_ /)U'_#-/A'_ *"_Q _\./XA_P#DZO5:* //_ OP+\*?
M#KQ5?>)-(;Q!-K5[9)I]Q<ZSXGU/5/,@1VDC0K=7$J_(SR%3C*^;)@@2/GT"
MBB@ KS!_@M.?BMXA\:0>(Y-.EU33)+"'['91_:K-WC@3S5EE\Q'"_9T=(VB*
MAF8MO!*UZ?10!XIX3_9RUKP-X5T;PWHGQL^(%EHNCV4.GV-M]ET"3R8(D$<:
M;GTLLV%4#+$DXY)-:W_"F_%W_1=OB!_X ^'O_E57JM% 'A'C']EJ_P#'_P#8
M_P#;WQG^(%__ &1>G4++_1]"C\J<P2P%_DTL;OW5Q*N&R/FSC(!' :S\&/ ?
MASQ,?#FK?M*Z]I?B$0&Y_LF]U'PY#=^4%+F3RFT\/M"JS;L8PI/05];5XMX[
M_9<T#XA^)O%^NZM?WLM[K-FEO90_:KD6EA*EM)"L[6JS"&>13(75G3<A VL#
M@CII8FO17+2J.*\FT<E;!X;$2YZU.,GW:3_,\XLO@;X*U*1H[3]H[Q%=.LMK
M;LL%]X=<B2Y4-;(0-/\ O2J08QU<$%<U)H'[-6ES6.D6MY^T+XEU+6+BR:X:
M2P&@Q1W?E;5N)X8C8R,L2N>1O?9N +$\F?PS^PAI&A^';[1;KQ-+?6EYJ%C>
MN5L1$\:6C3BWCB/F'88XI8$1A]TVRM@D\5]._8*C26QN+_XJ>*);L>'YO#]_
M+96EA#]HAD=7;R_,@D,2L0Y>,EU8N<;1E6U^OXO_ )_2_P# G_F8?V9@?^?$
M/_ 5_D/TO]G_ ,):YJECIFF_M#^)]0U*^L1J=I9VMWX>EFN+0G N(T73B6B)
MXW@%<]ZZSPM^R;<^"]=U36=&^,GQ L]2U.VMK2[G\C0G\R*!IGA7:VF$#:US
M,<@ G?R3@8D^$G[-.J?"W7_"4TGBK3->T?P]I"Z;%#/X=6WO7E",GVCSX9UC
MR(RL2AH7*1J55@7D9O>JSJ8K$5H\M2HVNS;9K2P6%H2YZ5*,7W22?X(\J_X4
MWXN_Z+M\0/\ P!\/?_*JC_A3?B[_ *+M\0/_  !\/?\ RJKU6BN4[3RK_A3?
MB[_HNWQ _P# 'P]_\JJ/^%-^+O\ HNWQ _\  'P]_P#*JO5:* /G_P"(G[+<
MGCS3]/?Q9\:O'ES9Z)=-JEO)+%H,"6\H@FA:5F33%X$4\P.[*_-G&0".$\$_
MLO> OB5I\U_X0^/_ (F\56,,GDRW6B7V@7D4<F =C-'I[ -@@X//-?2'CS5M
M!N=&UCPYJ7B'3M'N[[2YB1=7$:R10/B'S]C,"4#R(N>!N91G)%>%>,?V%="U
MS0/"&G:3KDMC<:-?6VHWFHZM]KU6ZO)X(T2%XYI;L2P>7M;9&':("1QY9R"
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M,AFMHQ)"QBA:3?(3&5D#2R;9%#D444 ?0M%%% !1110 4444 %%%% !1110
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7QM'F;(QL3;S]"T44 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>pmn-20251231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "Z >\# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7=]HL]+\)75C<2?*0NR9]3F5,-M)S&V0"."=PRO^&L?@A_T63X?_ /A46/\
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MN/\ D^SX9?\ <3_]-=W0!^_U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45\07W_!07XBZAXV\<Z-X1_9__ .$ITWPMXBOO#DFJ?\)G;6?G2VTF
MPMY4D&5RI1L98#=C<<&G?\-T_&[_ *-=_P#,@V/_ ,8KLA@\34BI0I2:?9,X
M)X_!TI.%2M%-='))_F?;M%?$7_#=/QN_Z-=_\R#8_P#QBC_ANGXW?]&N_P#F
M0;'_ .,57U#%_P#/F7_@+_R(_M/ _P#/^'_@2_S/HC]FG_DG6K_]CGXL_P#4
MAU&O5:_/CX:?M7_&[X=^'+S2O^&:_P"T/M&M:MJ_G?\ "=V,6W[;J-Q>^7CR
MFSL^T;-V?FV;L+G ZK_ANGXW?]&N_P#F0;'_ .,4?4,7_P ^9?\ @+_R#^T\
M#_S_ (?^!+_,^W:*^(O^&Z?C=_T:[_YD&Q_^,4?\-T_&[_HUW_S(-C_\8H^H
M8O\ Y\R_\!?^0?VG@?\ G_#_ ,"7^9]NT5Y5^RY\=/\ AI3X$^&?B/\ V)_P
MCG]M?:O^)9]K^U>3Y-U+!_K=B;L^5N^Z,;L<XR?5:X3T@HHHH ^;OVA_V[/!
MO[-_Q(LO ^L^%/&?B76[O24UE1X8TZ&[1+=II(1NW3HP(:(Y^7'S+SDX'G'_
M  ]8\"?]$G^+W_A.0?\ R57DO[<G_)^FD_\ 9-(?_3I<5PU?IW#_  C0SG!+
M%5*KBVVK)+H<=6NZ<N5(^D_^'K'@3_HD_P 7O_"<@_\ DJC_ (>L>!/^B3_%
M[_PG(/\ Y*KYLHKZ3_B'N%_Y_P ON1C]:EV/7M)_X*1^$K#XT>*O%\GPL^*Q
MTW5?#^D:5!$OAZ'SEEM;G4I9&8?:,!2M[$%())*OD# )[7_AZQX$_P"B3_%[
M_P )R#_Y*KYLHH_XA[A?^?\ +[D'UJ78^D_^'K'@3_HD_P 7O_"<@_\ DJC_
M (>L>!/^B3_%[_PG(/\ Y*KYLHH_XA[A?^?\ON0?6I=C[U_9E_;!\*?M3WWB
MVR\.^'_$_AV\\,?9/MUOXFLHK60_:1*8]JI+(>D+$[MO#+C.>/=J_/K_ ()D
M_P#);OVD/^Y;_P#2:ZK]!:_&\?AU@\76PT7=0E*-_1M'H1?-%,****X2@HHH
MH **** "OD[Q;\$_BK>6'C;P1IV@>#[_ ,/>*==FUEO&%_K5W'?6Q>=98G-J
ML)W36_EQK%ME"?NHB0/F%?2WC;P[+XO\':YH<.I76C3:E936D>HV3%9[5G0J
M)4((^92<CGM7PC8>+O'/P]\;'X>Z_P#MNZ';^*!J,D;V5SX)AN]CS3.\<4ET
M\H2)V4C$3-^[R$7*A20#]!XT,<:J69RH W-U/N:=38U9(U5G+L  6( )/KQ7
MS]\6?VKY?AA\:M&\ IX334S?FP E?5!;WMT+JX:$FQM3$WVH0["\Q\R/8O/-
M 'T'7RK_ ,Y3?^Z,_P#N<KL/A7^U3#\2OB'8Z$= CL-&UR/5)O#NK1:CY[WR
M:?="WN#-#Y2B'+'='M>7<H).PX!X_P#YRF_]T9_]SE 'U51110 5^5?_  7.
M_P":)_\ <;_]L*_52ORK_P""YW_-$_\ N-_^V% 'Y5T444 %%%% !1110 5]
M5?\ !+C_ )/L^&7_ '$__37=U\JU]5?\$N/^3[/AE_W$_P#TUW= '[_4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'YK? 3_ )'+]H'_ +*OX@_]
M&1UZ]7D/P$_Y'+]H'_LJ_B#_ -&1UZ]7Z[E7^XTO0_",[_Y&-;U"BBBO6/#"
MBBB@ HHHH Z'_@EQ_P F)_#+_N)_^G2[KZJKY5_X)<?\F)_#+_N)_P#ITNZ^
MJJ_##^DPHHHH _,W]N3_ )/TTG_LFD/_ *=+BN&KN?VY/^3]-)_[)I#_ .G2
MXKAJ_HO@?_D3Q_Q2/)Q/\0****_0#E"BBB@ HHHH ]F_X)D_\EN_:0_[EO\
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M"_F$*,OQ\WOQ3Z /!/A3^RG;?##XA66NKKXO]'T2/4X?#^DKIXA>Q2_N1<7
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M)_R?II/_ &32'_TZ7%<-7]%\#_\ (GC_ (I'DXG^(%%%%?H!RA1110 4444
M>S?\$R?^2W?M(?\ <M_^DUU7Z"U^?7_!,G_DMW[2'_<M_P#I-=5^@M?R;G7_
M "-,5_U\G_Z4SW*?P1] HHHKQC0**** "BBB@ K\[O%'CC]GGXH>.M;A^/GQ
M?U#7]1T3Q#J%I;>";^X:UTRP\JZ=(<1V<2><VP)\SRR9!P>0PK]$:_/?XO\
MBGQ9_P )WXJL_#7B'X[R:\NI31V5A:^ [:72F<2G;&ER]N<P8X$S.0%PQW 8
M(!^@L001((P%C"C:%& !VXI]1P B",,6+!0"7ZD^]24 %?*O_.4W_NC/_N<K
MZJKY5_YRF_\ =&?_ '.4 ?55%%% !7Y5_P#!<[_FB?\ W&__ &PK]5*_*O\
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MG?\ R,:WJ%%%%>L>&%%%% !1110!T/\ P2X_Y,3^&7_<3_\ 3I=U]55\J_\
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M=(T3YH<LTC2 !<1L:^T*SM8\.:3XB^Q?VKI=EJ?V*Y2\M?MENDOV>=,[)4W
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M5?\ !+C_ )/L^&7_ '$__37=U\JU]5?\$N/^3[/AE_W$_P#TUW= '[_4444
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M*W.[ (P2#Q71_K)B_P"6/W/_ #.7_5' _P \_O7_ ,B?$'_#<OP1_P"AV_\
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EHX# $ 5]U44 (!@ >GK2T44 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>pmn-20251231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #% 4T# 2(  A$! Q$!_\0
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MNHRT3$88\$=#P/0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTNZ^JJ^5?^"7'_)B?PR_[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH ****
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M5?\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@
MHHHH **** "BBB@ HHHH *_(G]CO_DW+PC_V^?\ I9/7Z[5^1/['?_)N7A'_
M +?/_2R>@#U/Q!X=M?$UDEK>2WT,22"4-I^H7%E)D C!>%T8CD_*3CH<9 QS
M_P#PJ70_^?[Q-_X56J?_ "379T4 <+:?!CPWI\316L_B&VB:1Y2D/B?4T!=W
M+NV!<=69F8GN22>35VR^&&CZ?>V]U%>>(6E@D655G\2ZC+&2#D!D>X*L..58
M$'H0176T4 %=%_P3U_Y.-_::_P"Y8_\ 2.YKG:Z+_@GK_P G&_M-?]RQ_P"D
M=S0!]W4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_&/6/[)^&^
MOI!XBT_POJMY93VNF:CJ5VEM&EVT3^5AV(P01GC)&"<'%?'_ .S'9^'(_C1X
M4/@KP??^ +](;D^)[G5/'UOJJZQF!B(HX4NYS<OYSB7SRD>U8V_O;1]7_'_P
M]X;UOX4Z_=^)_!VG>.[31K2?5H-&U.U2XCEGBA<KA65L'!(R 3AC@'I7Q1^R
MUXDLT_:#\*61\#_ #1+N>ZO+8_\ "#64CZW$@LWGBN8LXVVTL91A. P(?80I
M)P ?HY1110 445Y_\:_A#_PNGPK:Z)_PFOC#P)]GO4O?[1\%:K_9UY)M21/*
M>38V8CYFXKCED0YXH \5_P""7'_)B?PR_P"XG_Z=+NOJJOE7_@EQ_P F)_#+
M_N)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ K\B?V._^3<O"/_;Y_P"E
MD]?KM7Y$_L=_\FY>$?\ M\_]+)Z /9J*** "BBB@ KHO^">O_)QO[37_ '+'
M_I'<USM=%_P3U_Y.-_::_P"Y8_\ 2.YH ^[J*** "BBB@ K \;^/?#WPV\/S
MZYXGU>VT;2X>&N+E\;FP2%4#EV(!PJ@DX.!6_6%XU\#:'\1O#\VA>)-/35M&
MG9&GL9G813A6#!9%4@.F0,HV5/<&@#3TO5;+6[""^TZ\M[^RG7=%<VLJR1R#
MU5E)!'TJU5/1])M= TBRTRR1X[.SA2W@1Y&D9410J@LQ+-P!R22>YJY0 444
M4 %%%% !1110 4444 8GB#Q?8>&]5\/:?=^:;C7;UK"T$:AAYBP2SDMSPNR%
M^1GG'UJ#PS>>&_%,TWB'1X+:XN4DGTM]1%KY<I,$S121;V4,561'''RG&1D8
M->>?M'>$K'QW+\/=!N=<\2>&;N[U]C9:OX6O(K>ZMI4L+MR3YD4@92BNI 4$
M;@<@9!Y']G3X!:?X<O4\2Z)\5/BAK&G6FK:I#+HOB+4[22RNKE;F:&XE=(K=
M2X:4/(K;P<D$@'(H ^DZ*** "BBB@#Y5_P""7'_)B?PR_P"XG_Z=+NOJJOE7
M_@EQ_P F)_#+_N)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ K\B?V._^
M3<O"/_;Y_P"ED]?KM7Y$_L=_\FY>$?\ M\_]+)Z /9J*** "BBB@ KHO^">O
M_)QO[37_ '+'_I'<USM=%_P3U_Y.-_::_P"Y8_\ 2.YH ^[J*** "BOBS_@J
M=H5CXH^&'PAT;4X/M.FZC\3M'M+J#>R>9%)!=HZ[E((RI(R"".QKQ#_AAKX(
M_P#0D_\ E6OO_C]>Q@<KK9A&4J32MWO^B9X&99UA\KG&%:,FY*^B7ZM'Z!>*
M?V>OA9XYUVZUOQ)\-/!_B#6KK;]HU'5-!M;FXFVJ$7?(\99L*JJ,G@*!T%>/
M_M-_LR?![0/V;?BOJ>F?"CP/IVI67A+5KFUO+3PY9Q302I9RLDB.L8*LK $,
M""" 17R[_P ,-?!'_H2?_*M??_'ZY+XN_L;?!_PO\)_&NLZ9X0^S:EIVB7MW
M:S_VG>/Y<L<#NC;6F(.& .""#W%>A/AW%PBY.4=/-_Y'E4^*\%4FH*$[MVV7
M_P D?HU_PR=\$/\ HC?P_P#_  E['_XU75>!?A/X'^%_V[_A#?!OA_PE]NV?
M:_["TN"R^T;-VSS/*1=VW>^,YQN;'4U^='_##7P1_P"A)_\ *M??_'Z/^&&O
M@C_T)/\ Y5K[_P"/U?\ JWB_YH_>_P#(C_6[ _R3^Y?_ "1^H5%?DA\7?V-O
M@_X7^$_C76=,\(?9M2T[1+V[M9_[3O'\N6.!W1MK3$'# '!!![BOT:_9._Y-
M8^#?_8F:-_Z0PUX^.R^KE\HQJM._:_ZI'OY;FE'-(2G132B[:V_1L]5HHHKS
M#V HHHH **** /!/VP/#.G^-_"7A3PW/X,3QQJVJZZD.EV,^OW.C06\ZVUQ*
MUQ+<6Y\P*D4<HVJ&)+ 8YR.._92_9V\ >'-7O];7P!+X-\?>%]3GT^[AM?%N
MI:M8F1X%?S8S/+M</#<*3OC#*21U ->@_M6P_!V?P-I8^-5V++PVE^9;64ZA
M=V>VY2VF?[]LZ.3Y2S +D[B0 "2!7%_!?X0?LP^%_B)I^K_#G6](NO%[>8UJ
MEKXWN=1EE)B96/D27<BR$1EN2IP!GC&: /I^LWQ'XETCP?HEWK.O:K9:)I%H
MH>XU#4;A+>WA7( +R.0JC) R3W%:5>-?M;>&)?&'P9N=,4ZZMH^IZ?+>2>&]
M)35+U(([J.1V6V=OW@&T%@$E.,D12_=(!UT?QR^'$VCZ3JT?Q \+/I6K71L=
M.OEUJV,%[< X,,+[]LDF>-JDG/:NWK\Z?B+HGQ;\<:'JNJ>)-!\3>)(=;\(>
M(_"'A^5]!:.^DDFO(FLKF]MH8U^R--$@!=TA11$"_EDXKZ8^(=C^TIIDGAZS
M^%[_  OET>WT>WAOW\:G43>-?+N$A3[-\GE;1'C/.[?VQ0!R?_!+C_DQ/X9?
M]Q/_ -.EW7U57RK_ ,$N/^3$_AE_W$__ $Z7=?55 !1110 454U;5K'0-*O=
M3U.]M].TVRA>YNKR[E6*&")%+/([L0%55!)8D  $FO-?^&L?@A_T63X?_P#A
M46/_ ,=H U_AK\;O"_Q7UCQ-I>@27S7GAV]-A?I=V$MOLD"JV/G4;3\V-K;7
M^4G;MP3WU>*Z-^T/^SKX<DF?2?B9\,-+>8!9&LM?TZ$N-[OABL@S\TDC<]W8
M]2:U?^&L?@A_T63X?_\ A46/_P =H ]5HJII.K6.OZ59:GIE[;ZCIM["ES:W
MEI*LL,\3J&21'4D,K*00P)!!!%6Z "BBB@ K\B?V._\ DW+PC_V^?^ED]?KM
M7Y$_L=_\FY>$?^WS_P!+)Z /9J*** "BBB@ KHO^">O_ "<;^TU_W+'_ *1W
M-<[71?\ !/7_ ).-_::_[EC_ -([F@#[NHHHH ^._P#@I?\ \B;\#_\ LJ^A
M_P#HNZJ"I_\ @I?_ ,B;\#_^RKZ'_P"B[JH*_0>&OX-3U7Y'Y;QA_'I>C_,Y
M+7?A%X%\4:K/J>L^"O#NK:E/M\V\OM*@FFDVJ%7<[(2<* !D\  =JH?\*#^&
M/_1.?"7_ (([7_XW7>45]6Z%)N[BON1\,L16BK*;MZLX/_A0?PQ_Z)SX2_\
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MK\ ?^"H__)]GQ-_[AG_IKM* /5?^'U?QO_Z%;X?_ /@NOO\ Y,H_X?5_&_\
MZ%;X?_\ @NOO_DRO@"B@#[?O?^"NWQAO_'^C>+Y/#?@<:EI6F7VE01+87GDM
M%=2VDLC,/M>2P:RB"D$ !GR#D$=!_P /J_C?_P!"M\/_ /P77W_R97P!10!]
M_P#_  ^K^-__ $*WP_\ _!=??_)E>U?L9_\ !4#XI_M$_M)^#_A[XDT#P?9:
M+K'VS[1/I=G=1W"^59SSKL9[EU&6B4'*G@GH>1^2U?57_!+C_D^SX9?]Q/\
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M_P GV?$W_N&?^FNTK]_J_ '_ (*C_P#)]GQ-_P"X9_Z:[2@#Y5HHHH ****
M"OJK_@EQ_P GV?#+_N)_^FN[KY5KZJ_X)<?\GV?#+_N)_P#IKNZ /W^HHHH
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M .Q,T;_TAAK\^XF_C4_1_F?J?!_\"KZK\CU6BBBOC3] "BBB@ HHHH ****
M"BBB@ HKYP_:9_:0\1?"?Q'=:3X7M])DFT7PC?>-=3_M:VEF%S:VTT48M862
M6,122;Y#YK>8%V#Y&S7I>L?M"?#;PG!I/_"4^//#'A*]U*PBU*"QUS6;>SG:
M"0':X25U8KE6&[&,JP[&@#QG_@EQ_P F)_#+_N)_^G2[KZJKX5_X)P_M"_"S
MP-^QC\/-$\2?$OP?X?UJU_M'[1IVJ:]:VUQ#NU&Y==\;R!ERK*PR.0P/0U]*
M_P##6/P0_P"BR?#_ /\ "HL?_CM 'JM?@#_P5'_Y/L^)O_<,_P#37:5^U/\
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MKZG>:I):_$#6[2V>\N'F\JW28>7%'N9ML:@X"J=H[4 ='_PR=\$/^B-_#_\
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M/_\ PE['_P"-4?\ #)WP0_Z(W\/_ /PE['_XU7JM% 'E7_#)WP0_Z(W\/_\
MPE['_P"-4?\ #)WP0_Z(W\/_ /PE['_XU7JM% 'E7_#)WP0_Z(W\/_\ PE['
M_P"-4?\ #)WP0_Z(W\/_ /PE['_XU7JM?%_[1H\;^+/VBO$_ACPBOC2_U-/
M=O/HR>'/%!TJSTK4'NKI$O+J(WD*3("$ROES$JF"A&,@'O?_  R=\$/^B-_#
M_P#\)>Q_^-5XI^V9^Q3X3\8?LV>,-(^%/PA\'V_CZX^Q_P!FR:7I-AI]P-MY
M TNR<B,)^Y67/S#(R.<X/C?B/XY?$KX*_'7XB76I>(]7\1KJSKX-L=-$TLNG
MVNO-IEC-:2P0](1)+)<;MH48ZX(->#VGQR^,'PY\/_$.2;Q_XJ\1:1I6C7N@
M7=W=:S<37-I=2:IJ$-G?*Q?*NKVT<;,NT[95[+P ?J/_ ,,G?!#_ *(W\/\
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M%0!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4
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EI%L-(LX[6!68Y9A'&H4$GJ<<UM444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>pmn-20251231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $I ?T# 2(  A$! Q$!_\0
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MQ5@&(P=IQT-?"'A30OCOHWP[\/W&C7GCV7Q9J_PVU*341KUS=W AU:.>'[.
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M\V=V$P6(QT^3#QNUOLDO5NR7;5K73<K_ /#)WP0_Z(W\/_\ PE['_P"-4?\
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M_%?CSPQX8U.>,3166LZQ;VDTB$E0RI(ZD@D$9 QD&@#GO^&3O@A_T1OX?_\
MA+V/_P :H_X9.^"'_1&_A_\ ^$O8_P#QJO3++4[/4Q,;.[@NQ!(89?(D#^6X
M )5L'@X(.#SR*LT >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_
M  E['_XU7IMWJ-KIYMQ=7,-L;B400B:0)YDA!(1<]6(!X'/!KF[?XM>!KOQM
M+X-@\9^'IO%\1(D\/QZI U^F%WG-N'\P87YON].>E '+?\,G?!#_ *(W\/\
M_P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM9][XATK3;Z"RN]3L[6\GQY5
MO-<(DDF6"C:I.3EB ,=SB@#SK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\
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M^3J\BMOVL?%,NM6$ ?PQ=73V%O<0^&;>&8:GKHD6?=<61:<;85$*3<QRG9(
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M0"1+''5E*RPRR-D*5VQ8D$DJQX%I:0:?:0VMK#';6T"+%%#"@1(T PJJHX
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M_K]#SLYPRQ6#==_%22U[Q;2L_1M->LKWTMZ=XHLYM1\-:M:6Z>9<3VDT4:9
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M,:2' <R90J4#8!Z]O@QX,D>T:31$E^R@K$LD\KJ 7D<@J6PP+32G# _>QT
MJ>'/@/X)\*Q!+#2[EF!D(FO=4N[N;#P^24\R:5WV",E53.U ?E"T >;#]IOP
MZ=53Q+<_#OQ?87*6(A^W7SZ?!&EO-$;J#=OO@JB81-@M@QE#YIB!!+M/_:[L
M?%NEZ=J7A_0+[^R+RQU"ZDU4SV%]%:26MQ%"4(M[PI,&,O#12L.5Y^]M])U[
MX%>"?$ND/IE_I$K6K"U \C4+F"1#;(R6[))'(KHR!CAE(.<'.0"*UK^SUX%M
M+.WM5TV^ECA%R-UQK-[-)-]H*&8S.\Q:8NT2,3(6.X;A\Q)(!QJ_M!^'=,U+
M4M7L/ GBN[U36'M8; 0+:!M>B\XV\<UMYETJ)&K.,^<86VNK;2,&G:O^UQX=
ML=4\-Z0NE7UMJ7B33FO=/%Y>:<I1Q'*_ER6XN_M+;3"RL\43Q@_\M.I'<:/\
M"/!&@ZI-J-GI,RW,ES'=IYVHW,R6[I(956"-Y"L$>]BQBB"H3R5.!5+_ (9Q
M\ ?VK;Z@-*O4DMU4);IK-\MKN52JR&W$WE-($9D\PJ7VG;NV\4 4=0^/]MX<
MT[PLVI:!JVH3ZGH\6L7UUI,4/V73H"8UDFE,LRML5I!\J"1R,D*V#7+Z'^VS
MX%\4WFK6.@V6HZ]J=E=1VL&GZ7=:=<W%Z9)O)5U1+L^0-^T$77DL P)4 ,1V
MWB#X!>'/$WBGP_J5\;O^SM$TT:=:Z7;WMS!&ZK)&ZB8QRJ)X_P!VH,4H=&P"
M02*S]?\ V9_"^JV4EI97FO:9:W&HP7\UO'XAU)H8Q'*9=EK']I"V9+'AK<(5
MXQT H YBY_:TMHO%T%BWAC6+?3&TY+M6:.VDFN+EVGC^Q "Y BE66 Q[B'C9
ML_.JX<Y__#;/ASPO?6>G^-]/F\-ZK>ZE<VPL;J\T^":Q@CG\E6F5[S,[EL@B
MT\\G:2%P1GTFY_9R^']V]J\NBW#/;:=_9<3C5+L,(<N=Q(ERTP,CL)SF4,Q8
M/GFF6?[.?@C35T[[%%KUC-8RR3K<VOBC5(KBX9Y!(_VF5;D/<@O\VV9G&6;C
MYCD ] UC1[/7]-FL+^'S[2;&^/<5S@AAR"#U J[110 4444 %%%% !1110 5
M0U_0K'Q1H6I:-J<'VG3=1MI+2Z@WLGF12*4==RD$94D9!!'8U?J)FF%S&JQQ
MFW*,7D+D.&RNT!<8((W9.1C X.20-*2LRHSE3DIP=FMFMTSYE\#WM]?>%--.
MJOOUJWC^R:EPHVWL),5ROR_*<3)(,K\IQE21@UN5:\>>%O\ A7?B,7-LC_\
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MB@ HHHH **** "BBB@ HHHH **** "BBJL_VPWMJ(?(6T&]KAI-QD/&%5 ,
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MJ-)=VPS@N]O!&\3XY8(MP-PP"T9)V^A:W\&=%UZ7Q!)<75^C:W?6.H7'E2(
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M%HVR[')=GR25+'Z/M5F2VA6XDCEN @$DD2%$9L<E5)) )Z DX]3UJ6DW]E;
MEU>YYM';6WQV^&NB:NDT6G7ZR&^L+NV+W$5O<J)(2<,L?FQE7D1A@95R48'9
M(. T34IM1L\7MH=-U6W(AO\ 3G?<]G<!06B)P-V-P*N!M=65URK*3]!W5PEI
M;33R"1DB0NPBC:1R ,G:J@ECZ  D]A7(>+/AC8>.?LNH7DEUH7B&.!8O[1T:
MY^=!G)C(=#'.@+2!?.B;;YCLH1F)KOPV(]FN6?P_E_P/Z]>+$4/:N\=SSNBJ
MGB'0?'/@O2;_ %74])T?5=)TZ-Y9Y]*U)DNIHU',BV\T2QIQ\Q0W!VC(#2$
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M0XY%<G_POCPA_P ]-;_\)S4?_D>IOBW:R6WP<^(;2R^;+-HVHR$@N% ^SN$
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M**** "BBB@ HHHH **** .7\7:4(HWU6!0IC&Z[ /WXPI^?'=EP/JH(Y(4#
M1UD171@Z,,AE.01ZUZ/6!JOA*"\D:>SD&GW+$L^R,-'*Q.2SKQD]>003QG(
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MGUO1;W6/MWVL*T @DB0)Y.TEM_F,0VX8\L\'G'I->.>L%%%% !1110 4444
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M$MMWOPM\?:]H4,5SI'B]="@O;>]L]"OO%(DU.%(]2MI=DMR+UA))L2X=29V
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MM],3DDPQ\^7Q=W^T)XM\-Z%I]O86T-S;I?K973FXAM#;VP2\9!:HMHZA@+9
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M0-'D2J)D<HT8:.7DKY3#;@^92;Y8MK=?CU7R=U\C)TU&3BNCW_)_-6?S//\
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MD=2S$<FO_!6XU3X+6_@2TUV.UNK9X)(M3FL3*FZ*X68;H1*I(.W;@..N<]J
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M_%,BZEXJ\0:[I5X8[65I;.S>:SW2!%\EK:T650YD DD)/EJF_='AGKY1\4_
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MF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!RWQ#\!V_Q T:"SEOKO3+FUG^U6MY9R8:&78\>XH<I(-DCC;(K+DAL;
ME4CRC2KGQ)\-/*L?$>D01:)=RHC"R5YK>WF:*)F=+E0-J+B= 9HHO-<QJ-I/
M[SWYJIZOI%CK^DWNEZG9P:AIM[ ]M=6EU&)(IXG4JZ.IX964D$'@@FLY03=^
MIVT<5.E%TWK%ZV_5/HSRK5/"<"V2'3M$L-:T&ZNA>S^7&NX2[S*9C$5.^3S@
MC<X((+%@5 /G&O\ CC0?!D>J>+_$E@-)TBP;$RR/&)IXHW(C48)!,CL?+C!R
M?-485W*CTKP/^RC\-/AGX=_L+PEI6J^&]+W._DZ7XCU.W.YSECO6X#<_7C Q
MT%>>^/?A9;2_#Z[L/'&G:AK/B,+-ID?BN[1KN.=5BCG2[<P_\>]OFW1I(9##
M&95D4;U=)'PG3>Y[F!Q]-SY)K?33?7[E?[O0^*_'OQV\!?%?XA>(;2S\/7NC
M^&[Y)+V'6[J\O#?Z5/C[;([6SW<EM.JSF=O(A500V5>/AZZ?X3?$6T^'7Q!M
M/!_C=-'M"MW;W=MXOM+Q;-3#(OGQ[Y7D2-;6X5X2X*;FB=T:-Y'3R[7[0OP3
MNOAQ\'1J,>B>$K.U^6*:XM(62]-F\Q16?Y GF2.R*V"Q(+@LP.6\;@UZ;QU\
M%RT-V]EXE^'<Z7=G=P/Y5P^EW$ZJ0KH@8-;W<D;(3)D?;'P!LK6%I^]8_8Z.
M"PV8Y7.C!WINU-7;O&22Y9>:YK*4;)-MNRM8_0KX;>']4\26J/H=]>Z'X?&A
M6DFG'2;*&-+Z"\A5+2YV3-(-MK$BJ5=VE=X&PB1%$N)I+;6/#&L:S:27=OXP
MN-%TVUM&N]*M[:VU6U^T22M-/-/*4MA&L=O%*8(D9Q\N48;&DK?LN_%E?B!X
MMU&VT:&/1/#2V-G/'X>C#SQ0SOINGR2"TF*QQ1VMMO2%H8P[F:X>1Q$K*&]0
M\>+HVBB^T6XTB^3_ (2A[UXYM(??)/<+8'<G+*8)9(HI@KJ53,7S2H\JJ]\J
M/P"5:K3FU)V:T:]#.^%GQ%O/B+X<\)ZM93Z2NF:KIT=T&M98@\TQ42?*OF2;
M%.'5H_G9<GY\J2;]QJ>F^(M&MK+4M#BN]&UVX?3I]&@6.>.XF9W-RLI#"/8H
MCNC,K%ED VKO=O+=NI>!=,TSPYX:LYGL/#NH6-M:Z?'J&EJME:@E! L,432$
MB-I/*B"-YA E15.X[U/"7@'Q58>'_!6CZI)I$$NG6L%UK&M:?L:>YU% @F$4
M+6PC5)P9@\V5<)(Z*BEQ+&)-,*E6G.-TK2^?ZMG=^"(-;MO!F@P^)9X+KQ%'
M80)J4]L (I+H1J)60 #"E]Q' X["MND' I:LX@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &[:-M.HH ;MHVTZB@!NVO"?B'^Q3\+_BE\:K#XF^
M(M*>^UFV@CAET]TA-A>[%D57N8FC)E;:ZKEFZ0Q#&%P?>**!IM;'%3?!/X>W
M,OFR^!/#4LGGBZWOI%N3YPQB3)3[_ ^;KP*[,)@<<4ZB@0W;7%_$E?&:0PS>
M$"KRPVMRTEL_E 3R%5$2AG^ZP)=A_"2H#$ YKMJX3XI:=X\U"/3!X'U73-+E
M60_:CJ)/[Q=T9PG[I_FV"49(P,C@\%4U<:=CEIO$/QDABN)H?"UC=2!+<)!+
M<0Q*6\IVF(Q*Q.)=B#+ %?0Y:N[DAUZ]\1>'+O$]I8"WG.HVPDCVB3">4" 2
M3R7^Z2.!GM7GL&G?%@70MI_%_AUIS ZB&&78[3!#M8!H&(0-)$Q7D]BS!QB5
M/#/QABUS2+A?%&CM:!;6/4(IY"XF9)0UPT2BW7;OCW@ L<>O0HQ$-QK'QKM/
M#%K;PZ#I^H:H8@DUXT\,4BL88/GV;RA*R/<#C _=J<$'#(_C/XS7/A.QOM-\
M&Z=/J$\)=H+YQ:NC&.'&Z(S' WM/P7#81<@'AI=/\*_%.RT[2++_ (3#3A.;
MI9)YFN/-=[47,C2*GF0$NQA>!0Q(VE??)D\2Z?\ $O68+32-!\;Z';:W:Z6B
M:O"2AE%PRLHE4"(LBMDL#A>8UP,$T :6O^*/B7I&I7RQ>&[2\TM%MEM[RT'F
MRRN\ENLG[CS5(QYEP<EMH$8). =W/_\ "4?&G2_"FL7]WX:M+G58FN)K>TB6
M*5-BF/RE54G#D%?..,LY8*![[7A_P3X[LK34TU#Q-%<VMYITD('VR1_*F^RV
M\<<J2&,,@WI<.2#_ !J<$YQB1?##X@0Q:C+?_$*?3F^PO DMK?%A\J&.%G\Z
M)@FX*'=T ?>S[6[D U+3Q1\7Y&U?S?"&G"%8V;3G^TQH\QW1;%D3S6$;%6ER
M0S ; <$_*[=;\3_&1==M8-)\(:2^FM9&6>ZN[A/EN!;*XB"K/D SEDW?, !T
MP-S:NF^#O$EMX2O;)Y[,:U*ENAO$U6Y9;]DD+2%\J# 9(^"4WD!L9(C7.3!X
M2^)FE^(KB72]7T?3_#;/*[:=)?37+P9MW"+&\D)V#S?*?&-JC(5<9#@&K%XH
M^(@_X1J"?PW;PWMV]R;]%Q+%!&D\2H6F$@"EHGD8 !B2H^4885AR>*/C;"\*
M_P#"':-<AHXW>2&Z1 &*1EUVM,2"',@R"P8(/NYW5J>&?#'Q./AK5K+Q/XAT
MRYU.6Y@DL;C37DB$<2S[I%8^6#S&%7OUP23EVHZOX,^(UU#X8L(_$>F'1(4B
MCUO[1<2F>ZVO(T@1_+SR!&#EAD*PX&=P!%8^(?C5>7"+>^%M+T^W%S:*YM;B
M*1VB.]KAU9I< *5C4 IG#MC)&ZM'PCKOQ8U+Q#91>(_#ECH^EK,IFELIXIMZ
M^1*7!8R;@!+Y0&U">N3@9,7@_0?B9HMU86_B3Q;I,EG]N3"VYS//"%N#Y6Z6
M/+,?]'Y&"1&YR#DM6AL/BI>:_=6-[KFEP6<^G*;9X+I/WKB%XY651 L@;S6A
MD+ [4#*!NR10!L>&M;^)]SXGABUC0-/M="S LLRE!+\T,K3,-L[_ "I*L2KQ
MDJY)'&1@76L_&O2G5K/0+'6XI6^>.\F@A>$+:PD;620!MTYF!!'0=5&#61X?
M\-?&N74=4NY/'?AFZ0+!8I!#(\L<#HP,I?\ =C]X273C:3O!ROEJE=/KL'Q*
M>\T2RL?%?AVTO/[,,-_%*P\V2]:WN-KQ(8C\OF")^1RL3X4 $, :GB/Q%\1[
M#Q#=QZ5X6MM1TA;?,,PGB#O-Y1.W#3)\HD*@L<97=@# 9N;U+6?C1IFEQ7UC
MX;T_6-9NQ#Y]E)<1PVUH D.X(#-D_,\^?F).Q3D !6O0:3\2+"\\0_:O$=GJ
M=TECJ!TBTMYXTF#2;/LF^,PJA8&*3YW+#DC!&XUEV\'Q/U%]7L[+QQHS:OYD
MK6MHSQM]CC!A4;\6P,I4B=&Z#+IR",  Z?3M=^)CZGK$5SX=L5L([.9]/NI)
M45Y9PJ>4DD:S-C+&0$AL$*#E#P<Z^U7XJ6&@:YJ-CX?AU+6WOO*L--N;B&*/
M[*D3['.)<*S/MW#<2=W\(P5SM<L?BM8ZDDD/C+PY8Z=<3)';17\P,A+!=D8?
MR%$A8K(5P >1GS I!LZ3X5^, \2"\O/%NDMIBJB_98?F#$7*,V[, Y\GS4)4
MKEBO"@#: )/X@^+\-GIEW-H5DDD23R7T%L$=#_H*R(NWS6=B+G?& AR0!V(:
MJ%CXW^-NJ7-PT'@O3K>P$UXL,U[MAE9(T?R T/VD[2\@5=P9E*G=\M;ND6'Q
M2O?#-XEY>06&L"Y4P-<3P,&B^Q@9S';D+_I!W%"K'"D;RI&8[_X>^.XM)T>'
M2/$45E>6=JOG3&ZE*2W0BNMS,C(P=6EFA8[N2$/&0,@$\/BCXHWFI:E;+X:T
MRT^SS01JY=I8-K&V+LDK/$TVU)+@G$: % H+$'=CQ>+/C@2JR>!]'#?*&(U"
M,+SM+%3YA/=P,KQ@9#YR.AT70OBA#X3,&I^(=(FU\7L1%S;0D1&V**LO#1G#
M@F211C!94!(4D#'T?PU\9%FOCJWB31YHFF@-JMF^S9$,>>K[K4[F?G##&WJ!
MCY: ,^Y\0_'2;2)+A/#.F0:D+-I(K2.2$Q^?]JP(Y"TY)'D+NRK*,N1G( &S
MH_C+XES:[K.FWOAJ!3;07S65R+8I;W#IY7V4&7SVP7WMN7:!Q]X%6 R9/!WQ
MN@,K6GC+1R'O;J58;T"4+ RKY"!UMT.Y7\PDXQC:-I'RCTGQ?I>N:WX.O;.Q
M>W@U=F3RF%TT4;A9%8[G$;%-R@@C8X&<?,* .&U76/B[=)K-M9Z%:VL8A#:?
M?K) LS.'A^5HVE= 2IFYR00H/RG@WFUGXIS^&=-E30K&UUHZW'#=0N\;H-.*
M_/-@3?>!.=H8D$8^8<M7C\)?$^S\/V=I9:_I\%W%"BEYYWG4-Y\C/O9H=TFZ
M(Q*"IBVLI*J!\M=)\-_#WBO18#)XJU:'4[R2W59/L\KM&)O/G=BJLJ@#9)$H
MP!]S&  * .B\-W&IW7A[3)M:MH[/5WMT:[MX2"D<I4;U4@G@'/<_4U!X8T";
MP_8R0W&J76K32S2SM+<D80R2-(8XU_AC7?M126*HJJ6;&:VB,T;:!)65AM%.
MVT;:!G)0_";P1;02P0^#M AAELY=.DCCTN!5>UEYE@("\QO_ !)]T]P:^+_V
MA_V>],_9-\0:7\7_  +X?N-4\"P/)9>,_#+W?G(NFSJL#F&)\-*I#R%EDE8*
MYA8*$5ROW[MJO?Z=:ZK8W-E>V\5Y9W,;0SV\Z!XY8V&&1E/!4@D$'@@T'HX3
M,,3@7+V$VE)--7T::MJMNNG9ZK4_,_\ 8H\5^#OA?\6OB;\.M7\4Z#K&B6.K
M6^M>'M=CO;86'F<Q?:()U<C[6UO, ZJK K%(CN%4AOL/P;XL\*^(/$5E?6GC
M[4?B5-<W$D^G:?=6%K/'I3R(VQR;6Q66U C=XUDN& ,<[_,^ZNZ^%7P*\!_!
M'2Y=/\$>&K70;:65YG\HO([.P0,2\C,V"(TXSCY1Z5W>T4')7JRKU959.[D[
MOU>_XG">$_"]WJVKV_B[Q)9M9:J(&CL-'D:*7^RHW/S%I$SON9$6)96#NB^6
M$B)&^2;N<T[;1MH,0'2EI.E+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5Y_P#%WX-Z?\7=,2WN]2O],G@@FAAD
MM)!Y?[S83YD9&) #&O!QQGD9R/0** /)%_9K\/"*0'5-5$DMS<W4CK]GPTD\
M"P280PE5&U<@*!@DFJ=M^R[H7_"-Z7IEWK>L--9QA&GLY([=)<)"O,(0IC%N
MG4$]<DGFO9Z* /+M6_9X\.:WH_A[3;R]U6:'0XKV&VDDFC>1Q=(RNTC-&=S*
M&RK<'(!.ZK.O? ;P_P"(_$.I:S=7>I+>7\$=O(89D38B6\UO\K!-PRMPY//W
ME4\ $'TBB@#RV;]GC0)M.MK0ZKK8$"2*)OM2&5BT_G*Y8H3N0M(JL,$+*_5B
M&%6Z_9G\-W?AY='DU/5GMUM1:>;*;:64K]D%J26>$Y)C ./N[OFVY QZY10!
MY0_[-_AH^*+;7H[_ %BVO()3-Y=O<I'%*3=-=$.H3YOG;;R<A0,$'FJ^J?LQ
M>&-8\6:IX@NM4UUKV_!&Q;M$2V)N1<9AQ&"AW#'7D$YR237K]% 'E.J?L[Z+
MK=WH_P!NU&]GL-*M+"W@@9(C)(UK+(ZO+*4)8-YF"B[1U]1BA>?LL^&;S0[/
M26UOQ)';6E['?1O'?J)=R>3M0OLSL_<)\N>IS_"FWV6B@#R>3]FSPS(8F.H:
MPLB6[VK2K<1B21&M8K4[F$><[(5(P1AF8CC $_A[]GGP_P"'$U9(=2UBZ74[
M:[MIS=3QN^VX$8<B3RP^0(E R2!R2"237J-% 'BI_9.\)&YU:Z_M/6TN]2F$
M\EQ#-#"T9"RKM01Q* I$S94@@X7CCG7U;]G[2;XZE/;:MJ-I>W3&6*=A$_V>
M7=<.L@(0.Q5KEV&YS@JG8$'U.B@#A=7^#VC:OK6E:B;F]M6TZTALH8+=HQ'Y
M44R3*,LA93NC495E....M1P_!O2XM4\27IU+4G&NV]Q;3P P1I$LS;G*LD2N
MQ!)VF1GV[F P":[ZB@#RE?V<O#H\4VVO'4]8-W!=+>"!98DMVD79@^4L04?Z
MM<[<9R2<GFNM\!_#^U^'ME<VECJ%_>6T\S3F.]:-MKD ':512!A0 O0#@
M5U-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>pmn-20251231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $? 6H# 2(  A$! Q$!_\0
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M.?7  /1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&" DD*"QQDDX[FNGK@/V??\ D@OPV_[%K3?_ $ECKOZ "BBB@ HHHH ****
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M2)K.WFBM@!;Q9CBCG3#XR[R3,54DL_9VMC'J?QK\=6<S3)#<>%=&A=K>9X9
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M-EN);]%LR?+>#'G,GV@,Q"!>#SA0.U6_V??^2"_#;_L6M-_])8Z@_P";=_\
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M 9ZBOEKX?>$4TZ\T;0T_9Q\>:)ILOB"VUB[U/5/%5K=[[B/"0RW;F^DFGCA
M1EC.X Q+A3W /L*BBB@ KQ3]J_[9_P (7X*^S?VAY/\ PL#PK]J^Q?9_*\O^
MV;7'VCS?G\K?Y>/(_>>9Y6?W7FU[77BG[5\/F^"_!3?8]0N?+^('A5O-LKOR
M8K?_ (G-J/,N$\Q/.B.=@3;)B1XGV#9YD8![71110 4444 %%%% !1110 44
M44 %%%% !117DGQ[^ G_  O#^PO^)[_8O]E^?_RY^?YOF>7_ --%QCR_?.>V
M*RJRG"#E3CS/M>WXG?@*.&Q&)C2Q=;V5-WO+E<K:.WNK5W=EY7N>MT445J<
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M_P G*>._^Q2\/?\ I9K5>F5YGH'_ "<IX[_[%+P]_P"EFM5W8+^!BO\  O\
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MQ!_Z>+RCXW?\B9IW_8R^'_\ T\6='P1_Y$S4?^QE\0?^GB\H^-W_ ")FG?\
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MFEMI5D598M0T>*6,E20&21'1EZJRL#@@BMK6?^2Z^$/^Q;UK_P!*M*K/U_\
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MDK&&$ [D\OS Y0;37T%I^GVND6%M8V-M#965K$L,%M;QB..*-0 J(HP%4
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M$_B3X)TSX<_%77Y_%&G:K':GQ'>^$TBM;N]^TR2R;K6\C;:\URSMD/M  15
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M0L!V)(R0,D9O[:/Q%\1_"[P=9:SX=\=7&@:M+YEEHWAG2]'M[Z]\0ZK(5%M
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MXB^%L?Q6T7Q#J4?C>[\)ZWIUAI>J:Q-;Z:]VM]!%(D4[6\&UI(R[\00-(ZE
M(F8Y.+IW[?BS^#;;Q!>> Y;2.[TO5Y+2'^TF#7.JV%TMN=.59;>-P9"\;*[(
MK#+ Q@H:VIUITHSA'::L_2ZE^:1YS5SO-/\ 'OCBT^)FO^(G^!OCHV5_I&G:
M?%&NH>'_ #%DMYKZ1RP_M3&TBZCQ@DY#9 P,]/\ \+D\7?\ 1"?B!_X'>'O_
M ):T?&_XWQ?!'X1#Q1K4>G:=K=T(+*TLK_4%CLQJ$PPD<ERVU5B5MQ:0[?D1
MCC.!7Q7#^V%\4?%'P0\%ZKHGCRVU+Q-!X>UO6O$4GA^SL;AK>2VNU2*:\22/
M:EBL;?,L"_:6&TH&Y-8#/JWX7>/?''@GX9^$?#M]\#?'4M[I&D6FGSR6^H>'
MVC:2*%(V*$ZH"5)4XR <=A6CX2^)WC30?"FC:9<? OQZ\]E90VTC17_AXJ62
M-5)!.J@XR/05Z]HE^-4T:PO1+',+FWCF$L*LJ/N4'*AN0#G@'GUJ[6;IQ=15
M.J37WVO^2-%-J#I]&T_NO_FSQ36OB=XTU'4M!N(_@7X]5+"]:YE#W_A[)4VT
MT6%_XFO7=*IYQP#]#VW@KQ_KOBK59;34_AKXH\'6Z0F5;[6[G2I(9&#*!&!:
M7L[[B&)R4"X4Y8' /:T40IQ@Y27VG=_<E^202FYJ*?167WM_J%%%%:&84444
M %%%% !1110 4444 %%4===XM$U!XW,<BV\A5U."IVG!SVKX@\ :VM]\)_AW
MK'@ZZ^+]]\2Y(=*N[JZUB;Q-)I$R_NVOGF?4,V+1-#Y^"N>2IBRVV@#[MKCO
MB/\ "7PS\6+?28O$=M?2-I-W]OL+C3=5N].N+:?RVCWI-;2QN#LD=?O8PQKR
M6[_:RN=$^#GA#QMXBT+P]X5N/&-Q#'HMMK?BC[)8I%);FX\R]O'M@+<[$D 5
M(YMS>6 ?G)3H?!7[4'@CX@?#_2KZ7Q/H&@Z_K:7=M9:4=<@D>YN89'AD^QOE
M3<Q^8AV21K\RE3@$X !LZC^S)\-M3\->'M!E\/R16&@7$]UI[6FI7=O<1RSA
MQ<,UQ'*LLAF$DGF>8[>9O._=FN?TC]E;0M%^*'P]\0V<EI;>&_A_I-SIOAO0
MX[21Y[9IU1'>6[EG<RJJJ0B;%*[B=QZ5Y_X5_:2\6>%OA3X;CM/"\?C"?2?A
MSI_B_6-5UCQ UK-+$8Y1(BYMY6DG/D;EWE5?+;I%P"_5ZM^U'KOANR\1-J_@
M"*+4+*TTG4]-L;/7%F:\M+^]^RQB5C"BP3HW+1@R(3PLI'S4 >M?$;X6^&?B
MOI-MIWB?3Y+V"UG%U;2V]W-:7%O+M9-T<T+I(A*NRG:PRK$'()%;GA_0--\*
M:'8:-H]E#INE6$"6UK9VZ!(X8D "JH'0  5X/-^TMXST;4=7M];^'>DVMOX=
MUO3]'UV[L?%#7"1B]^S^1):*UG&TY7[2OF)((-N!L,F3MZ.Q_:(:]T_PO='P
M\(_[<U_5M#"_;2?)%BMXWFY\KYM_V/&WC:9!\QQR >RT5\V^&OVO+[_A'[?Q
M%XR\$)X:T&^\'7'C*QDL=8^W7+6\'D^9#+$T$*QR$3H4VNZL 2Q3&*ZK]G_]
MI&Q^-VJ>(-(SX;;5-(AMKMY/"?B1-=L7AGWA0;A8HMLJM%('C*\#8P9@W ![
M11110 445X;\4)O&=A\?OA1,OB@6OA&\U:YL_P"P;"V>-[EO[-N9#)=3;R)%
M5D^2,(J@_,S,=NP ]RK@/B/\"_!_Q6UC2]5\0VNIMJ6F6\]I:W6EZY?:9(D,
M^SSHR;6:/>K^6F0V1\M/\??%:#X=>)M%L]5L2FAZA97]S)JXEXMY;:(3>48]
MO.^)9V#;ACR2,'<*\G^+O[6NK?"#PMHNM:QX7\,:6;S0QK$UAK_C:'3;J9\
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M\/\ 3O'T7C.'0Y/^$ABE^TK/+J%U)";CR1!]I:!I3$UP8@$,Y0R$=6KBK_\
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M>2>XG6/R0UO.)888X7)N$*L)'4J"6*=* /?8((K6".""-(88U")'&H554#
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KJ'PP]S ^G/=VQ5H)1OA,\05TC?RX98XRR9*'<^[U&B@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>pmn-20251231xex10d47001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231xex10d47001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# + # 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>pmn-20251231xex10d75001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20251231xex10d75001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !C =T# 2(  A$! Q$!_\0
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M?M6_\C[^SS_V/\'_ *175>=_\$]_$.K:[XY_:*CU/5+[4H[3QG+#;)>7+S+
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M@?:NL^#GPM\8^"?@=+X#\5^);3Q+?6MO<:;IVK1PM&[690I;B<'K(JD E>"
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M_P!G_P >ZQ\9=,^)_P 8/$^BZUK6@V4UCH.C^&K22"PLO.&)IV,I+O(R_+Z
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M#ZC\$]*\5W6O:Y;Z]XF\5ZS)K>J3:?:?9+..5E5 D$63A0%&23DD\UA_![X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>pmn-20251231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 1:44:30 PM-->
<!--Modified on: 3/25/2026 1:44:30 PM-->
<xsd:schema targetNamespace="http://www.promisneurosciences.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2024" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:pmn="http://www.promisneurosciences.com/20251231" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>99940401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetails">
        <link:definition>99940501 - Disclosure - ACCRUED LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails" id="DisclosureEquityFutureIssuancesDetails">
        <link:definition>99940602 - Disclosure - EQUITY - Future issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" id="DisclosureIncomeTaxesDeferredTaxesDetails">
        <link:definition>99940901 - Disclosure - INCOME TAXES - Deferred taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>99940903 - Disclosure - INCOME TAXES - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" id="StatementConsolidatedStatementsOfShareholdersDeficitEquity">
        <link:definition>995200300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityTables" id="DisclosureEquityTables">
        <link:definition>99930603 - Disclosure - EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails" id="DisclosureDescriptionOfBusinessDetails">
        <link:definition>99940101 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>99940202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>99940203 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>99940301 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityDetails" id="DisclosureEquityDetails">
        <link:definition>99940601 - Disclosure - EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityRightsOfCommonSharesGrossProceedsDetails" id="DisclosureEquityRightsOfCommonSharesGrossProceedsDetails">
        <link:definition>99940603 - Disclosure - EQUITY - Rights of the common shares gross proceeds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails" id="DisclosureEquityEquityTransactionsDetails">
        <link:definition>99940604 - Disclosure - EQUITY - Equity transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails" id="DisclosureEquityWarrantsLiabilityDetails">
        <link:definition>99940605 - Disclosure - EQUITY - Warrants liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails" id="DisclosureEquityAtMarketOfferingAtmDetails">
        <link:definition>99940606 - Disclosure - EQUITY - At-the-Market Offering ATM (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails" id="DisclosureEquityRegisteredDirectOfferingDetails">
        <link:definition>99940607 - Disclosure - EQUITY - Registered Direct Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails" id="DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails">
        <link:definition>99940608 - Disclosure - EQUITY - Exercise of Discounted Warrants and PIPE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsDetails" id="DisclosureWarrantsDetails">
        <link:definition>99940701 - Disclosure - WARRANTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>99940702 - Disclosure - WARRANTS - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>99940801 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails" id="DisclosureShareBasedCompensationShareOptionsDetails">
        <link:definition>99940802 - Disclosure - SHARE-BASED COMPENSATION - Share options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails" id="DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails">
        <link:definition>99940804 - Disclosure - SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>99940805 - Disclosure - SHARE-BASED COMPENSATION - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails" id="DisclosureShareBasedCompensationStatementsOfOperationsDetails">
        <link:definition>99940806 - Disclosure - SHARE-BASED COMPENSATION - Statements of operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails" id="DisclosureIncomeTaxesCreditCarryforwardsDetails">
        <link:definition>99940902 - Disclosure - INCOME TAXES - Credit carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails" id="DisclosureSegmentReportingSignificantExpenseCategoriesDetails">
        <link:definition>99941002 - Disclosure - Segment Reporting - Significant expense categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails" id="DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails">
        <link:definition>99941101 - Disclosure - RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails" id="DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails">
        <link:definition>99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99941201 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>99941301 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails" id="DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails">
        <link:definition>99941303 - Disclosure - NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941401 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995210301 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995210401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
        <link:definition>995210501 - Disclosure - ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureEquity" id="DisclosureEquity">
        <link:definition>995210601 - Disclosure - EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>995210701 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>995210801 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995210901 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995211001 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995211101 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211201 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211301 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211401 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99930303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>99930403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
        <link:definition>99930503 - Disclosure - ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>99930703 - Disclosure - WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>99930803 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99930903 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>99931003 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931303 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>99940302 - Disclosure - FAIR VALUE MEASUREMENTS - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails" id="DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails">
        <link:definition>99940803 - Disclosure - SHARE-BASED COMPENSATION - Share-based compensation liability activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReportingDetails" id="DisclosureSegmentReportingDetails">
        <link:definition>99941001 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" id="DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails">
        <link:definition>99941302 - Disclosure - NET LOSS PER SHARE - Computation of basic and diluted net income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <xsd:element name="PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmergingGrowthCompanyStatusPolicyTextBlock" id="pmn_EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidUpfrontResearchPaymentsCurrent" id="pmn_PrepaidUpfrontResearchPaymentsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PrepaidLicenseFeeCurrent" id="pmn_PrepaidLicenseFeeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AccruedLiabilitiesTextBlock" id="pmn_AccruedLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedLegalFeesCurrent" id="pmn_AccruedLegalFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredShareUnitsOutstanding" id="pmn_DeferredShareUnitsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfVotesPerCommonShare" id="pmn_NumberOfVotesPerCommonShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UnitsIssuedDuringPeriodSharesNewIssuance" id="pmn_UnitsIssuedDuringPeriodSharesNewIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PricePerUnit" id="pmn_PricePerUnit" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfCommonSharePerUnit" id="pmn_NumberOfCommonSharePerUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfWarrantsPerUnit" id="pmn_NumberOfWarrantsPerUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ClassOfWarrantOrRightPricePerWarrant" id="pmn_ClassOfWarrantOrRightPricePerWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsAndRightsDisclosureTextBlock" id="pmn_WarrantsAndRightsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="August2026Member" id="pmn_August2026Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" id="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DeferredShareUnitPlanMember" id="pmn_DeferredShareUnitPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" id="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="UbcAgreementMember" id="pmn_UbcAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionTermOfAgreement" id="pmn_RelatedPartyTransactionTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionFundingCommitment" id="pmn_RelatedPartyTransactionFundingCommitment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborativeArrangementAccrualsForRoyaltyPayments" id="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborativeResearchAgreementMember" id="pmn_CollaborativeResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredShareUnitsMember" id="pmn_DeferredShareUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentCurrent" id="pmn_AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="GainLossFromChangeInFairValueOfFinancialInstruments" id="pmn_GainLossFromChangeInFairValueOfFinancialInstruments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShortTermInvestmentsPolicyPolicyTextBlock" id="pmn_ShortTermInvestmentsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" id="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentCostsPolicyTextBlock" id="pmn_PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="pmn_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="pmn_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightIssued" id="pmn_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExercised" id="pmn_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExpired" id="pmn_ClassOfWarrantOrRightExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" id="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" id="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NonCapitalLossCarryforwardMember" id="pmn_NonCapitalLossCarryforwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfWarrantExercisePriceTableTextBlock" id="pmn_ScheduleOfWarrantExercisePriceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="April2028Member" id="pmn_April2028Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfOriginalAmountInvested" id="pmn_PercentageOfOriginalAmountInvested" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AnnualLicensePayment" id="pmn_AnnualLicensePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CashPaymentsRelatedParty" id="pmn_CashPaymentsRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="February2029Member" id="pmn_February2029Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredFinancingCostAssets" id="pmn_DeferredFinancingCostAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NetProceedsFromIssuanceOfCommonStockAndWarrants" id="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" id="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Series2PreferredSharesMember" id="pmn_Series2PreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" id="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreFundedWarrantsMember" id="pmn_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarketOfferingMember" id="pmn_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnitedStatesDollarDenominatedWarrantsMember" id="pmn_UnitedStatesDollarDenominatedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CanadianDollarDenominatedWarrantsMember" id="pmn_CanadianDollarDenominatedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" id="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueAssetsLiabilitiesLevel1TransfersAmount" id="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueAssetsLiabilitiesLevel2TransfersAmount" id="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Rule10b51ArrModifiedFlag" id="pmn_Rule10b51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonRule10b51ArrModifiedFlag" id="pmn_NonRule10b51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LossOnSaleOfCommonSharesAndWarrants" id="pmn_LossOnSaleOfCommonSharesAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="July2024PipeFinancingMember" id="pmn_July2024PipeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock" id="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" id="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" id="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CanadianDollarShareOptionsMember" id="pmn_CanadianDollarShareOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UsDollarShareOptionsMember" id="pmn_UsDollarShareOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" id="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="January2026Member" id="pmn_January2026Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="January2027Member" id="pmn_January2027Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July2029Member" id="pmn_July2029Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" id="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EmploymentAgreementAnnualBaseSalary" id="pmn_EmploymentAgreementAnnualBaseSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" id="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TerminationWithoutCauseMember" id="pmn_TerminationWithoutCauseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChangeInControlOfCompanyMember" id="pmn_ChangeInControlOfCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockOptionPlan2015Member" id="pmn_StockOptionPlan2015Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArrangementOptionInitialAwardMember" id="pmn_ArrangementOptionInitialAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementOptionPerformanceAwardsMember" id="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" id="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementSeveranceAmountCalculationTerm" id="pmn_EmploymentAgreementSeveranceAmountCalculationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" id="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="Pmn310DevelopmentProgramCosts" id="pmn_Pmn310DevelopmentProgramCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherNonEmployeeResearchAndDevelopmentCosts" id="pmn_OtherNonEmployeeResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SegmentReportingOtherSegmentItemAmount" id="pmn_SegmentReportingOtherSegmentItemAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReclassificationOfPipeWarrantsFromLiabilityToEquity" id="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="VolumeWeightedAveragePriceThresholdTradingDays" id="pmn_VolumeWeightedAveragePriceThresholdTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" id="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" id="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AggregateGrossProceeds" id="pmn_AggregateGrossProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OfferingCostsAndAgentFee" id="pmn_OfferingCostsAndAgentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="July2024PrivatePlacementMember" id="pmn_July2024PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonShareUnitsMember" id="pmn_CommonShareUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheaAndBWarrantsMember" id="pmn_TrancheaAndBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheaCommonShareWarrantMember" id="pmn_TrancheaCommonShareWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheBCommonShareWarrantMember" id="pmn_TrancheBCommonShareWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheCCommonShareWarrantMember" id="pmn_TrancheCCommonShareWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedUnitsMember" id="pmn_PreFundedUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" id="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdDaysToGetShareholdersApproval" id="pmn_ThresholdDaysToGetShareholdersApproval" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" id="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" id="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarketOffering2024Member" id="pmn_AtMarketOffering2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarketOffering2025Member" id="pmn_AtMarketOffering2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetProceedsFromIssuanceOfWarrants" id="pmn_NetProceedsFromIssuanceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredDiscountForFairValueModificationOfWarrants" id="pmn_DeferredDiscountForFairValueModificationOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredDiscountIssuanceCostRecognized" id="pmn_DeferredDiscountIssuanceCostRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RegisteredDirectOfferingMember" id="pmn_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July2030Member" id="pmn_July2030Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd50.50Member" id="pmn_WarrantExercisePriceUsd50.50Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd315.00Member" id="pmn_WarrantExercisePriceUsd315.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd240.00Member" id="pmn_WarrantExercisePriceUsd240.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd187.50Member" id="pmn_WarrantExercisePriceUsd187.50Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd152.50Member" id="pmn_WarrantExercisePriceUsd152.50Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd43.75Member" id="pmn_WarrantExercisePriceUsd43.75Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd62.50Member" id="pmn_WarrantExercisePriceUsd62.50Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd31.25Member" id="pmn_WarrantExercisePriceUsd31.25Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExercisePriceUsd0.25Member" id="pmn_WarrantExercisePriceUsd0.25Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockCapitalSharesReservedForFutureIssuanceAmount" id="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="July222025DiscountedWarrantExerciseOfferMember" id="pmn_July222025DiscountedWarrantExerciseOfferMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July222025DiscountedWarrantExerciseOfferTrancheMember" id="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July222025DiscountedWarrantExerciseOfferTrancheBMember" id="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July222025DiscountedWarrantExerciseOfferTrancheCMember" id="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July222025PipeOfferingMember" id="pmn_July222025PipeOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July282025DiscountedWarrantExerciseOfferMember" id="pmn_July282025DiscountedWarrantExerciseOfferMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July282025DiscountedWarrantExerciseOfferTrancheMember" id="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July282025DiscountedWarrantExerciseOfferTrancheBMember" id="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July282025DiscountedWarrantExerciseOfferTrancheCMember" id="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="July282025PipeOfferingMember" id="pmn_July282025PipeOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockAndWarrants" id="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodSharesDiscountedWarrantExercise" id="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BeneficialOwnershipLimitation" id="pmn_BeneficialOwnershipLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantJuly222025Member" id="pmn_WarrantJuly222025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreModificationMember" id="pmn_PreModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PostModificationMember" id="pmn_PostModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantJuly282025Member" id="pmn_WarrantJuly282025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightExercisedDiscountedExercisePrice" id="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromPreFundedWarrantExercises" id="pmn_ProceedsFromPreFundedWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" id="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" id="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="January2026PrivatePlacementMember" id="pmn_January2026PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="January2026PrivatePlacementIssuePriceOneMember" id="pmn_January2026PrivatePlacementIssuePriceOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="January2026PrivatePlacementIssuePriceTwoMember" id="pmn_January2026PrivatePlacementIssuePriceTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="January2026PrivatePlacementIssuePriceThreeMember" id="pmn_January2026PrivatePlacementIssuePriceThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonShareWarrantsMember" id="pmn_CommonShareWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonShareWarrantsIssuePriceOneMember" id="pmn_CommonShareWarrantsIssuePriceOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonShareWarrantsIssuePriceTwoMember" id="pmn_CommonShareWarrantsIssuePriceTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonShareWarrantsIssuePriceThreeMember" id="pmn_CommonShareWarrantsIssuePriceThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DirectorsAndManagementMember" id="pmn_DirectorsAndManagementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" id="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockOptionAndIncentivePlan2025Member" id="pmn_StockOptionAndIncentivePlan2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>pmn-20251231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 1:44:30 PM-->
<!--Modified on: 3/25/2026 1:44:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityFutureIssuancesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639100430687249571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_639100430687249571" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100430687249571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639100430687249571" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100430687249571" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_639100430687255256" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639100430687249571" xlink:to="us-gaap_ShortTermInvestments_639100430687255256" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100430687255256" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639100430687249571" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100430687255256" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639100430687255256" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_639100430687255256" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639100430687255256" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100430687255256" xlink:to="us-gaap_AdditionalPaidInCapital_639100430687255256" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639100430687255256" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100430687255256" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639100430687255256" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639100430687255256" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100430687255256" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639100430687255256" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639100430687260957" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100430687255256" xlink:to="us-gaap_CommonStockValue_639100430687260957" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639100430687260957" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_639100430687260957" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639100430687260957" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_639100430687260957" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_639100430687260957" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639100430687260957" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_639100430687260957" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430687260957" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639100430687260957" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430687260957" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639100430687260957" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639100430687260957" xlink:to="us-gaap_LiabilitiesCurrent_639100430687260957" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639100430687266549" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100430687260957" xlink:to="us-gaap_AccountsPayableCurrent_639100430687266549" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639100430687266549" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100430687260957" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639100430687266549" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639100430687266549" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_639100430687266549" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639100430687266549" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639100430687266549" xlink:to="us-gaap_OperatingExpenses_639100430687266549" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639100430687272201" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639100430687266549" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639100430687272201" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639100430687272201" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639100430687266549" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639100430687272201" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_639100430687272201" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_639100430687272201" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_GainLossFromChangeInFairValueOfFinancialInstruments" xlink:label="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_639100430687272201" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639100430687272201" xlink:to="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_639100430687272201" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639100430687272201" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639100430687272201" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639100430687272201" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430687272201" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639100430687272201" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430687272201" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther_639100430687272201" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_639100430687272201" xlink:to="us-gaap_InterestExpenseOther_639100430687272201" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639100430687277796" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" xlink:to="us-gaap_ProfitLoss_639100430687277796" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639100430687277796" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" xlink:to="us-gaap_ShareBasedCompensation_639100430687277796" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430687277796" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430687277796" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_639100430687277796" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_639100430687277796" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100430687283604" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100430687283604" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639100430687284085" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639100430687284085" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100430687284085" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430687277796" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100430687284085" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100430687284085" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100430687284085" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_639100430687284085" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100430687284085" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_639100430687284085" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_639100430687284085" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100430687284085" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_639100430687284085" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430687289346" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430687289346" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430687289893" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430687289346" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430687289893" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_639100430687289893" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430687289346" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_639100430687289893" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfWarrants_639100430687289893" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430687289346" xlink:to="pmn_NetProceedsFromIssuanceOfWarrants_639100430687289893" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639100430687289893" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430687289346" xlink:to="us-gaap_ProceedsFromWarrantExercises_639100430687289893" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430687289893" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430687289346" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430687289893" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_639100430687296720" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_639100430687296720" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredFinancingCostAssets" xlink:label="pmn_DeferredFinancingCostAssets_639100430687296720" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pmn_DeferredFinancingCostAssets_639100430687296720" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidLicenseFeeCurrent" xlink:label="pmn_PrepaidLicenseFeeCurrent_639100430687296720" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pmn_PrepaidLicenseFeeCurrent_639100430687296720" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_639100430687296720" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_639100430687296720" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_639100430687296720" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivable_639100430687296720" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidUpfrontResearchPaymentsCurrent" xlink:label="pmn_PrepaidUpfrontResearchPaymentsCurrent_639100430687296720" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pmn_PrepaidUpfrontResearchPaymentsCurrent_639100430687296720" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - ACCRUED LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639100430687302304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639100430687302304" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_639100430687302304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_639100430687302304" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedResearchAndDevelopmentCurrent" xlink:label="pmn_AccruedResearchAndDevelopmentCurrent_639100430687302304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pmn_AccruedResearchAndDevelopmentCurrent_639100430687302304" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639100430687302304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639100430687302304" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedLegalFeesCurrent" xlink:label="pmn_AccruedLegalFeesCurrent_639100430687302304" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pmn_AccruedLegalFeesCurrent_639100430687302304" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - EQUITY - Future issuances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639100430687308518" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639100430687308518" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430687308518" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430687308518" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitsOutstanding" xlink:label="pmn_DeferredShareUnitsOutstanding_639100430687308518" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="pmn_DeferredShareUnitsOutstanding_639100430687308518" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100430687308518" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100430687308518" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - INCOME TAXES - Deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639100430687308518" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639100430687308518" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639100430687314186" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_639100430687314186" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100430687314655" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100430687314186" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100430687314655" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_639100430687314655" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100430687314186" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_639100430687314655" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" xlink:label="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_639100430687314655" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100430687314186" xlink:to="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_639100430687314655" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" xlink:label="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_639100430687314655" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100430687314186" xlink:to="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_639100430687314655" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments_639100430687314655" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100430687314186" xlink:to="us-gaap_DeferredTaxAssetsInvestments_639100430687314655" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639100430687314655" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100430687314186" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639100430687314655" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100430687320302" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100430687314186" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100430687320302" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - INCOME TAXES - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100430687320302" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100430687320302" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639100430687320302" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639100430687320302" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639100430687320302" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639100430687320302" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639100430687325485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639100430687325485" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430687326427" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430687326427" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_639100430687326427" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_639100430687326427" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639100430687326427" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639100430687326427" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100430687326427" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100430687326427" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639100430687326427" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639100430687326427" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639100430687332091" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639100430687332091" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430687332091" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430687332091" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_639100430687332091" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_639100430687332091" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_639100430687332091" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_639100430687332091" order="6" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>pmn-20251231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 1:44:30 PM-->
<!--Modified on: 3/25/2026 1:44:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedStatementsOfShareholdersDeficitEquity" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityTables" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureDescriptionOfBusinessDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityFutureIssuancesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityEquityTransactionsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityWarrantsLiabilityDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityAtMarketOfferingAtmDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityRegisteredDirectOfferingDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureWarrantsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureWarrantsAdditionalInformationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationShareOptionsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationStatementsOfOperationsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxesCreditCarryforwardsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSegmentReportingSignificantExpenseCategoriesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:roleRef roleURI="http://www.promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain" xlink:title="definition: AwardDateAxis to AwardDateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="ExtinguishmentOfDebtAxis" xlink:title="ExtinguishmentOfDebtAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="ExtinguishmentOfDebtTypeDomain" xlink:title="ExtinguishmentOfDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ExtinguishmentOfDebtAxis" xlink:to="ExtinguishmentOfDebtTypeDomain" xlink:title="definition: ExtinguishmentOfDebtAxis to ExtinguishmentOfDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" xlink:title="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_1" xlink:title="us-gaap_LegalEntityTypeOfCounterpartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1 To us-gaap_LegalEntityTypeOfCounterpartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_1" xlink:title="srt_CurrencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_1" xlink:title="currency_AllCurrenciesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CurrencyAxis_1" xlink:to="currency_AllCurrenciesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CurrencyAxis_1 To currency_AllCurrenciesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: IncomeStatementAbstract to FairValueAdjustmentOfWarrants" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="UnrealizedGainLossOnDerivatives" xlink:title="UnrealizedGainLossOnDerivatives" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementAbstract" xlink:to="UnrealizedGainLossOnDerivatives" xlink:title="definition: IncomeStatementAbstract to UnrealizedGainLossOnDerivatives" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="DerivativeLiabilitiesNoncurrent" xlink:title="DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="DerivativeLiabilitiesNoncurrent" xlink:title="definition: LiabilitiesNoncurrentAbstract to DerivativeLiabilitiesNoncurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_GainLossFromChangeInFairValueOfFinancialInstruments" xlink:label="pmn_GainLossFromChangeInFairValueOfFinancialInstruments" xlink:title="pmn_GainLossFromChangeInFairValueOfFinancialInstruments" />
    <link:definitionArc xlink:type="arc" xlink:from="IncomeStatementAbstract" xlink:to="pmn_GainLossFromChangeInFairValueOfFinancialInstruments" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:IncomeStatementAbstract To pmn_GainLossFromChangeInFairValueOfFinancialInstruments" order="3" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639100430687337750" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_639100430687337750" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639100430687343442" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_639100430687343442" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Series2PreferredSharesMember" xlink:label="pmn_Series2PreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmn_Series2PreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687350963" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687350963" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PipeFinancingMember" xlink:label="pmn_July2024PipeFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July2024PipeFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2024Member" xlink:label="pmn_AtMarketOffering2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_AtMarketOffering2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2025Member" xlink:label="pmn_AtMarketOffering2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_AtMarketOffering2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pmn_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pmn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="pmn_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" xlink:label="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687377985" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687377985" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PipeFinancingMember" xlink:label="pmn_July2024PipeFinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July2024PipeFinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pmn_NetProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" xlink:label="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" xlink:label="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountForFairValueModificationOfWarrants" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pmn_DeferredDiscountForFairValueModificationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountIssuanceCostRecognized" xlink:label="pmn_DeferredDiscountIssuanceCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pmn_DeferredDiscountIssuanceCostRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityTables" xlink:type="extended" xlink:title="99930603 - Disclosure - EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430687468834" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430687468834" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - DESCRIPTION OF BUSINESS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639100430687475826" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_639100430687475826" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100430687481575" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100430687481575" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100430687487329" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_639100430687487329" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687493545" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687493545" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PercentageOfOriginalAmountInvested" xlink:label="pmn_PercentageOfOriginalAmountInvested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_PercentageOfOriginalAmountInvested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_639100430687508954" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_639100430687508954" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100430687508954" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100430687508954" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - EQUITY - Future issuances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687526913" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687526913" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PrivatePlacementMember" xlink:label="pmn_July2024PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July2024PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687526913" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687526913" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaCommonShareWarrantMember" xlink:label="pmn_TrancheaCommonShareWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheaCommonShareWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheBCommonShareWarrantMember" xlink:label="pmn_TrancheBCommonShareWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheBCommonShareWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheCCommonShareWarrantMember" xlink:label="pmn_TrancheCCommonShareWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheCCommonShareWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitsOutstanding" xlink:label="pmn_DeferredShareUnitsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_DeferredShareUnitsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - EQUITY - Equity transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430687544348" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430687544348" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639100430687545388" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_639100430687545388" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100430687551895" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_639100430687551895" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687558178" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687558178" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PrivatePlacementMember" xlink:label="pmn_July2024PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July2024PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOfferingMember" xlink:label="pmn_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639100430687563928" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_639100430687563928" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareUnitsMember" xlink:label="pmn_CommonShareUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmn_CommonShareUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedUnitsMember" xlink:label="pmn_PreFundedUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmn_PreFundedUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687569587" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687569587" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarDenominatedWarrantsMember" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_CanadianDollarDenominatedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaAndBWarrantsMember" xlink:label="pmn_TrancheaAndBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheaAndBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaCommonShareWarrantMember" xlink:label="pmn_TrancheaCommonShareWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheaCommonShareWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheBCommonShareWarrantMember" xlink:label="pmn_TrancheBCommonShareWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheBCommonShareWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheCCommonShareWarrantMember" xlink:label="pmn_TrancheCCommonShareWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheCCommonShareWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UnitsIssuedDuringPeriodSharesNewIssuance" xlink:label="pmn_UnitsIssuedDuringPeriodSharesNewIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_UnitsIssuedDuringPeriodSharesNewIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PricePerUnit" xlink:label="pmn_PricePerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_PricePerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfCommonSharePerUnit" xlink:label="pmn_NumberOfCommonSharePerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_NumberOfCommonSharePerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfWarrantsPerUnit" xlink:label="pmn_NumberOfWarrantsPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_NumberOfWarrantsPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" xlink:label="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysToGetShareholdersApproval" xlink:label="pmn_ThresholdDaysToGetShareholdersApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_ThresholdDaysToGetShareholdersApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightPricePerWarrant" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_ClassOfWarrantOrRightPricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AggregateGrossProceeds" xlink:label="pmn_AggregateGrossProceeds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_AggregateGrossProceeds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_OfferingCostsAndAgentFee" xlink:label="pmn_OfferingCostsAndAgentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_OfferingCostsAndAgentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightIssued" xlink:label="pmn_ClassOfWarrantOrRightIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_ClassOfWarrantOrRightIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails" xlink:type="extended" xlink:title="99940605 - Disclosure - EQUITY - Warrants liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430687640312" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430687640312" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687646420" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687646420" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UnitedStatesDollarDenominatedWarrantsMember" xlink:label="pmn_UnitedStatesDollarDenominatedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_UnitedStatesDollarDenominatedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarDenominatedWarrantsMember" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_CanadianDollarDenominatedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaAndBWarrantsMember" xlink:label="pmn_TrancheaAndBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_TrancheaAndBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails" xlink:type="extended" xlink:title="99940606 - Disclosure - EQUITY - At-the-Market Offering ATM (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687659009" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687659009" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2024Member" xlink:label="pmn_AtMarketOffering2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_AtMarketOffering2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2025Member" xlink:label="pmn_AtMarketOffering2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_AtMarketOffering2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" xlink:label="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails" xlink:type="extended" xlink:title="99940607 - Disclosure - EQUITY - Registered Direct Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687672113" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687672113" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails" xlink:type="extended" xlink:title="99940608 - Disclosure - EQUITY - Exercise of Discounted Warrants and PIPE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687683881" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687683881" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025PipeOfferingMember" xlink:label="pmn_July222025PipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:to="pmn_July222025PipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025PipeOfferingMember" xlink:label="pmn_July282025PipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:to="pmn_July282025PipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100430687713611" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_639100430687713611" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687720141" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687720141" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantJuly222025Member" xlink:label="pmn_WarrantJuly222025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantJuly222025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantJuly282025Member" xlink:label="pmn_WarrantJuly282025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantJuly282025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639100430687725369" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_639100430687725369" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="us-gaap_MeasurementInputMaturityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputMaturityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639100430687733085" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_639100430687733085" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreModificationMember" xlink:label="pmn_PreModificationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pmn_PreModificationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PostModificationMember" xlink:label="pmn_PostModificationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pmn_PostModificationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" xlink:label="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountForFairValueModificationOfWarrants" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_DeferredDiscountForFairValueModificationOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_BeneficialOwnershipLimitation" xlink:label="pmn_BeneficialOwnershipLimitation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_BeneficialOwnershipLimitation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - WARRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687762876" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687762876" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd50.50Member" xlink:label="pmn_WarrantExercisePriceUsd50.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd50.50Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd315.00Member" xlink:label="pmn_WarrantExercisePriceUsd315.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd315.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd240.00Member" xlink:label="pmn_WarrantExercisePriceUsd240.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd240.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd187.50Member" xlink:label="pmn_WarrantExercisePriceUsd187.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd187.50Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd152.50Member" xlink:label="pmn_WarrantExercisePriceUsd152.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd152.50Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd43.75Member" xlink:label="pmn_WarrantExercisePriceUsd43.75Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd43.75Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd62.50Member" xlink:label="pmn_WarrantExercisePriceUsd62.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd62.50Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd31.25Member" xlink:label="pmn_WarrantExercisePriceUsd31.25Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd31.25Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd0.25Member" xlink:label="pmn_WarrantExercisePriceUsd0.25Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_WarrantExercisePriceUsd0.25Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_639100430687772247" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_639100430687772247" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_August2026Member" xlink:label="pmn_August2026Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="pmn_August2026Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_April2028Member" xlink:label="pmn_April2028Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="pmn_April2028Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_February2029Member" xlink:label="pmn_February2029Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AwardDateDomain" xlink:to="pmn_February2029Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026Member" xlink:label="pmn_January2026Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AwardDateDomain" xlink:to="pmn_January2026Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2027Member" xlink:label="pmn_January2027Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AwardDateDomain" xlink:to="pmn_January2027Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2029Member" xlink:label="pmn_July2029Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AwardDateDomain" xlink:to="pmn_July2029Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2030Member" xlink:label="pmn_July2030Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AwardDateDomain" xlink:to="pmn_July2030Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - WARRANTS - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430687789684" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430687789684" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687790124" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430687790124" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RegisteredDirectOfferingMember" xlink:label="pmn_RegisteredDirectOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_RegisteredDirectOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025PipeOfferingMember" xlink:label="pmn_July222025PipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July222025PipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025PipeOfferingMember" xlink:label="pmn_July282025PipeOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_July282025PipeOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromPreFundedWarrantExercises" xlink:label="pmn_ProceedsFromPreFundedWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_ProceedsFromPreFundedWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightIssued" xlink:label="pmn_ClassOfWarrantOrRightIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_ClassOfWarrantOrRightIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExpired" xlink:label="pmn_ClassOfWarrantOrRightExpired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_ClassOfWarrantOrRightExpired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExercised" xlink:label="pmn_ClassOfWarrantOrRightExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_ClassOfWarrantOrRightExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:label="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100430687807576" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_639100430687807576" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionPlan2015Member" xlink:label="pmn_StockOptionPlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmn_StockOptionPlan2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionAndIncentivePlan2025Member" xlink:label="pmn_StockOptionAndIncentivePlan2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmn_StockOptionAndIncentivePlan2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - SHARE-BASED COMPENSATION - Share options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430687814534" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430687814534" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarShareOptionsMember" xlink:label="pmn_CanadianDollarShareOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmn_CanadianDollarShareOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UsDollarShareOptionsMember" xlink:label="pmn_UsDollarShareOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmn_UsDollarShareOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430687844959" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430687844959" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarShareOptionsMember" xlink:label="pmn_CanadianDollarShareOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmn_CanadianDollarShareOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UsDollarShareOptionsMember" xlink:label="pmn_UsDollarShareOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmn_UsDollarShareOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" xlink:label="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - SHARE-BASED COMPENSATION - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100430687858567" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_639100430687858567" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitPlanMember" xlink:label="pmn_DeferredShareUnitPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmn_DeferredShareUnitPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_639100430687862966" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_639100430687862966" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430687867339" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430687867339" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UsDollarShareOptionsMember" xlink:label="pmn_UsDollarShareOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmn_UsDollarShareOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_639100430687872053" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_639100430687872053" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_VolumeWeightedAveragePriceThresholdTradingDays" xlink:label="pmn_VolumeWeightedAveragePriceThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmn_VolumeWeightedAveragePriceThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" xlink:label="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails" xlink:type="extended" xlink:title="99940806 - Disclosure - SHARE-BASED COMPENSATION - Statements of operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639100430687890468" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_639100430687890468" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - INCOME TAXES - Credit carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_639100430687896372" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_639100430687896372" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NonCapitalLossCarryforwardMember" xlink:label="pmn_NonCapitalLossCarryforwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="pmn_NonCapitalLossCarryforwardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_InvestmentCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Segment Reporting - Significant expense categories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_639100430687906929" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_639100430687906929" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Pmn310DevelopmentProgramCosts" xlink:label="pmn_Pmn310DevelopmentProgramCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="pmn_Pmn310DevelopmentProgramCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_OtherNonEmployeeResearchAndDevelopmentCosts" xlink:label="pmn_OtherNonEmployeeResearchAndDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="pmn_OtherNonEmployeeResearchAndDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_SegmentReportingOtherSegmentItemAmount" xlink:label="pmn_SegmentReportingOtherSegmentItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="pmn_SegmentReportingOtherSegmentItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639100430687913162" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_639100430687913162" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CollaborativeResearchAgreementMember" xlink:label="pmn_CollaborativeResearchAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pmn_CollaborativeResearchAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RelatedPartyTransactionFundingCommitment" xlink:label="pmn_RelatedPartyTransactionFundingCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmn_RelatedPartyTransactionFundingCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CashPaymentsRelatedParty" xlink:label="pmn_CashPaymentsRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmn_CashPaymentsRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalFees" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639100430688039340" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_639100430688039340" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639100430688039340" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_639100430688039340" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TerminationWithoutCauseMember" xlink:label="pmn_TerminationWithoutCauseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pmn_TerminationWithoutCauseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ChangeInControlOfCompanyMember" xlink:label="pmn_ChangeInControlOfCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pmn_ChangeInControlOfCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100430688045046" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_639100430688045046" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionPlan2015Member" xlink:label="pmn_StockOptionPlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmn_StockOptionPlan2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688050290" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688050290" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ArrangementOptionInitialAwardMember" xlink:label="pmn_ArrangementOptionInitialAwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmn_ArrangementOptionInitialAwardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" xlink:label="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_639100430688053186" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_639100430688053186" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementAnnualBaseSalary" xlink:label="pmn_EmploymentAgreementAnnualBaseSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmn_EmploymentAgreementAnnualBaseSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" xlink:label="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementSeveranceAmountCalculationTerm" xlink:label="pmn_EmploymentAgreementSeveranceAmountCalculationTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmn_EmploymentAgreementSeveranceAmountCalculationTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100430688070702" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100430688070702" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UbcAgreementMember" xlink:label="pmn_UbcAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pmn_UbcAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" xlink:label="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RelatedPartyTransactionTermOfAgreement" xlink:label="pmn_RelatedPartyTransactionTermOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pmn_RelatedPartyTransactionTermOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AnnualLicensePayment" xlink:label="pmn_AnnualLicensePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pmn_AnnualLicensePayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688082062" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688082062" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails" xlink:type="extended" xlink:title="99941303 - Disclosure - NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639100430688087724" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639100430688087724" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitsMember" xlink:label="pmn_DeferredShareUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pmn_DeferredShareUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639100430688093439" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_639100430688093439" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688099112" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688099112" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementMember" xlink:label="pmn_January2026PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pmn_January2026PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceOneMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pmn_January2026PrivatePlacementMember" xlink:to="pmn_January2026PrivatePlacementIssuePriceOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceTwoMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pmn_January2026PrivatePlacementMember" xlink:to="pmn_January2026PrivatePlacementIssuePriceTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceThreeMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pmn_January2026PrivatePlacementMember" xlink:to="pmn_January2026PrivatePlacementIssuePriceThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688104858" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688104858" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsMember" xlink:label="pmn_CommonShareWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_CommonShareWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceOneMember" xlink:label="pmn_CommonShareWarrantsIssuePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pmn_CommonShareWarrantsMember" xlink:to="pmn_CommonShareWarrantsIssuePriceOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceTwoMember" xlink:label="pmn_CommonShareWarrantsIssuePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pmn_CommonShareWarrantsMember" xlink:to="pmn_CommonShareWarrantsIssuePriceTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceThreeMember" xlink:label="pmn_CommonShareWarrantsIssuePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pmn_CommonShareWarrantsMember" xlink:to="pmn_CommonShareWarrantsIssuePriceThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pmn_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_639100430688111003" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_639100430688111003" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DirectorsAndManagementMember" xlink:label="pmn_DirectorsAndManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pmn_DirectorsAndManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightIssued" xlink:label="pmn_ClassOfWarrantOrRightIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pmn_ClassOfWarrantOrRightIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightPricePerWarrant" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pmn_ClassOfWarrantOrRightPricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" xlink:label="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>pmn-20251231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 1:44:30 PM-->
<!--Modified on: 3/25/2026 1:44:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Shareholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' (deficit) equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares, no par value, unlimited shares authorized, 2,152,397 and 1,307,520 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and shareholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized, Unlimited [Fixed List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, unlimited shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_GainLossFromChangeInFairValueOfFinancialInstruments" xlink:label="pmn_GainLossFromChangeInFairValueOfFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_GainLossFromChangeInFairValueOfFinancialInstruments" xlink:to="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gain (loss) from change in fair value of financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) from Change in Fair Value of Financial Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of loss on issuance of common share and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on Sale of Common Shares and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on issuance of common shares, warrants, and pre-funded warrants in July 26, 2024 PIPE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (Income) Loss:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income per share attributable to common shareholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net (loss) income per share attributable to common shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average outstanding Common Shares, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average outstanding Common Shares, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted weighted-average common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Shareholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other Comprehensive Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Series2PreferredSharesMember" xlink:label="pmn_Series2PreferredSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_Series2PreferredSharesMember" xlink:to="pmn_Series2PreferredSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_Series2PreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to series 2 preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_Series2PreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series 2 Preferred Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_Series2PreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series 2 preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PipeFinancingMember" xlink:label="pmn_July2024PipeFinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July2024PipeFinancingMember" xlink:to="pmn_July2024PipeFinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July2024PipeFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to July2024 Pipe Financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July2024PipeFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2024 Pipe Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July2024PipeFinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2024 Pipe Financing</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2024Member" xlink:label="pmn_AtMarketOffering2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AtMarketOffering2024Member" xlink:to="pmn_AtMarketOffering2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AtMarketOffering2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to at the market offering for the year 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AtMarketOffering2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_AtMarketOffering2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 ATM offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_AtMarketOffering2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2025Member" xlink:label="pmn_AtMarketOffering2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AtMarketOffering2025Member" xlink:to="pmn_AtMarketOffering2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AtMarketOffering2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to at the market offering for the year 2025.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AtMarketOffering2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_AtMarketOffering2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 ATM offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_AtMarketOffering2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 22, 2025, exercise of discounted warrants and PIPE offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025, Exercise of Discounted Warrants and Pipe Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Exercise of Discounted Warrants And Pipe Offering</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:to="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 28, 2025 exercise of discounted warrants and PIPE offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Exercise Of Discounted Warrants And Pipe Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Exercise of Discounted Warrants And Pipe Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series 2 Convertible Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series 2 Convertible Preferred Shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common shares, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common shares, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="pmn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of pre-funded warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" xlink:label="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" xlink:to="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase to additional paid-in capital (APIC) for re-measurement of equity classified stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Apic Share Based Payment Arrangement ReMeasurement Of Liability Classified Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Re-measurement of liability-classified CAD stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net (loss) income to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain (Loss) on Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Negative cash flows from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity of short-term investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance allocated to common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Common Shares pursuant to 2025 and 2024 ATM offering, respectively, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_NetProceedsFromIssuanceOfWarrants" xlink:to="pmn_NetProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of pre-funded warrants from July 22, 2025 Registered Direct Offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance allocated to common shares warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of warrants from October 2022 PIPE</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of net proceeds from issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds From Issuance Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from Private Placements, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds allocated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash financing activities</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" xlink:label="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" xlink:to="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The non cash part of reclassification of July 2024 PIPE warrants from liability to equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Pipe Warrants From Liability To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of July 2024 PIPE warrants from liability to equity</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" xlink:label="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" xlink:to="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in share based share-based compensation liability on CAD denominated share options reducing additional paid-in-capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in Additional Paid in Capital For Share Based Compensation Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in share-based compensation liability on CAD denominated share options increasing additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountForFairValueModificationOfWarrants" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredDiscountForFairValueModificationOfWarrants" xlink:to="pmn_DeferredDiscountForFairValueModificationOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The deferred discount for fair value modification of warrants in noncash financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Discount For Fair Value Modification Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred discount for fair value modification of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental fair value</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountIssuanceCostRecognized" xlink:label="pmn_DeferredDiscountIssuanceCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredDiscountIssuanceCostRecognized" xlink:to="pmn_DeferredDiscountIssuanceCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredDiscountIssuanceCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The deferred discount issuance cost recognized in noncash financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredDiscountIssuanceCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Discount Issuance Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DeferredDiscountIssuanceCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred discount issuance cost recognized on completion of PIPE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:to="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on prepaid expense and other assets current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Other Assets Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedLiabilitiesTextBlock" xlink:label="pmn_AccruedLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AccruedLiabilitiesTextBlock" xlink:to="pmn_AccruedLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_AccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WARRANTS</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantsAndRightsDisclosureTextBlock" xlink:label="pmn_WarrantsAndRightsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantsAndRightsDisclosureTextBlock" xlink:to="pmn_WarrantsAndRightsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantsAndRightsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantsAndRightsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants And Rights Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantsAndRightsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WARRANTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign and Functional Currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShortTermInvestmentsPolicyPolicyTextBlock" xlink:label="pmn_ShortTermInvestmentsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShortTermInvestmentsPolicyPolicyTextBlock" xlink:to="pmn_ShortTermInvestmentsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShortTermInvestmentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for short term investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShortTermInvestmentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments , Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_ShortTermInvestmentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:label="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:to="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy related to prepaid and accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid And Accrued Research And Development Expenses , Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and Accrued Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PatentCostsPolicyTextBlock" xlink:label="pmn_PatentCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PatentCostsPolicyTextBlock" xlink:to="pmn_PatentCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy related to patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Income (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="pmn_EmergingGrowthCompanyStatusPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="pmn_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to emerging growth company status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of major categories of assets and liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of common shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of fair value of the liability</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ScheduleOfWarrantExercisePriceTableTextBlock" xlink:label="pmn_ScheduleOfWarrantExercisePriceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ScheduleOfWarrantExercisePriceTableTextBlock" xlink:to="pmn_ScheduleOfWarrantExercisePriceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ScheduleOfWarrantExercisePriceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular Disclosure of warrant exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ScheduleOfWarrantExercisePriceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrant Exercise Price [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_ScheduleOfWarrantExercisePriceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrant exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the activity of share options</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock" xlink:label="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock" xlink:to="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of deferred compensation share based arrangement liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Deferred Compensation Share-Based Arrangements Liability [Table text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of share-based compensation liability activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of fair value of share options granted estimated using Black Scholes with the assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of total share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant components of the deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant expense categories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of computation of basic and diluted net loss per share attributable to common shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DESCRIPTION OF BUSINESS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from the sale of Common Shares, Common Share warrants, and pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse share split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PreFundedWarrantsMember" xlink:to="pmn_PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre- funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WARRANTS</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PercentageOfOriginalAmountInvested" xlink:label="pmn_PercentageOfOriginalAmountInvested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PercentageOfOriginalAmountInvested" xlink:to="pmn_PercentageOfOriginalAmountInvested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PercentageOfOriginalAmountInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of original amount invested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PercentageOfOriginalAmountInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Original Amount Invested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PercentageOfOriginalAmountInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original amount invested percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Liability, Classified, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount" xlink:label="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount" xlink:to="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of assets measured on a recurring basis in and out of Level 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets (Liabilities), Level 1, Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets (liabilities) in and out of level 1</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount" xlink:label="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount" xlink:to="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of liabilities measured on a recurring basis in and out of Level 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets (Liabilities), Level 2, Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets (liabilities) in and out of level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets in and out of level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of liabilities in and out of level 3</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidUpfrontResearchPaymentsCurrent" xlink:label="pmn_PrepaidUpfrontResearchPaymentsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PrepaidUpfrontResearchPaymentsCurrent" xlink:to="pmn_PrepaidUpfrontResearchPaymentsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PrepaidUpfrontResearchPaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for upfront research payments that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PrepaidUpfrontResearchPaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Upfront Research Payments, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PrepaidUpfrontResearchPaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront research payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidLicenseFeeCurrent" xlink:label="pmn_PrepaidLicenseFeeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PrepaidLicenseFeeCurrent" xlink:to="pmn_PrepaidLicenseFeeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PrepaidLicenseFeeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for license fee that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PrepaidLicenseFeeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid License fee, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PrepaidLicenseFeeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fees</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredFinancingCostAssets" xlink:label="pmn_DeferredFinancingCostAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredFinancingCostAssets" xlink:to="pmn_DeferredFinancingCostAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredFinancingCostAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred cost assets classified as financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredFinancingCostAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred financing cost assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DeferredFinancingCostAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedLegalFeesCurrent" xlink:label="pmn_AccruedLegalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AccruedLegalFeesCurrent" xlink:to="pmn_AccruedLegalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AccruedLegalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AccruedLegalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Legal Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pmn_AccruedLegalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedResearchAndDevelopmentCurrent" xlink:label="pmn_AccruedResearchAndDevelopmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AccruedResearchAndDevelopmentCurrent" xlink:to="pmn_AccruedResearchAndDevelopmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for Research and development . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development , Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pmn_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMON SHARES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PrivatePlacementMember" xlink:label="pmn_July2024PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July2024PrivatePlacementMember" xlink:to="pmn_July2024PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July2024PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 2024 private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July2024PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2024 Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July2024PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2024 Private Placement</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaCommonShareWarrantMember" xlink:label="pmn_TrancheaCommonShareWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_TrancheaCommonShareWarrantMember" xlink:to="pmn_TrancheaCommonShareWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_TrancheaCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche A common share warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_TrancheaCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TrancheA Common Share Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_TrancheaCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Tranche A</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheBCommonShareWarrantMember" xlink:label="pmn_TrancheBCommonShareWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_TrancheBCommonShareWarrantMember" xlink:to="pmn_TrancheBCommonShareWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_TrancheBCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche B common share warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_TrancheBCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B Common Share Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_TrancheBCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Tranche B</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheCCommonShareWarrantMember" xlink:label="pmn_TrancheCCommonShareWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_TrancheCCommonShareWarrantMember" xlink:to="pmn_TrancheCCommonShareWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_TrancheCCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche C common share warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_TrancheCCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche C Common Share Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_TrancheCCommonShareWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Tranche C</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options issued and outstanding under stock option plan</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitsOutstanding" xlink:label="pmn_DeferredShareUnitsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredShareUnitsOutstanding" xlink:to="pmn_DeferredShareUnitsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredShareUnitsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of deferred share units outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredShareUnitsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Share Units Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DeferredShareUnitsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred share units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares available for grant under stock option plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, capital shares reserved for future issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Common Shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfVotesPerCommonShare" xlink:label="pmn_NumberOfVotesPerCommonShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_NumberOfVotesPerCommonShare" xlink:to="pmn_NumberOfVotesPerCommonShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_NumberOfVotesPerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of votes per common share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_NumberOfVotesPerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_NumberOfVotesPerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk Free Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOfferingMember" xlink:label="pmn_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AtMarketOfferingMember" xlink:to="pmn_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to At the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Market offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-Market Offering (ATM)</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareUnitsMember" xlink:label="pmn_CommonShareUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CommonShareUnitsMember" xlink:to="pmn_CommonShareUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CommonShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information representing to common share units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CommonShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CommonShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Units</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedUnitsMember" xlink:label="pmn_PreFundedUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PreFundedUnitsMember" xlink:to="pmn_PreFundedUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PreFundedUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Pre-funded units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PreFundedUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PreFundedUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Units</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarDenominatedWarrantsMember" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CanadianDollarDenominatedWarrantsMember" xlink:to="pmn_CanadianDollarDenominatedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to canadian dollar denominated warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canadian Dollar Denominated Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canadian dollar denominated warrants</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaAndBWarrantsMember" xlink:label="pmn_TrancheaAndBWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_TrancheaAndBWarrantsMember" xlink:to="pmn_TrancheaAndBWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_TrancheaAndBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Tranche A and B warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_TrancheaAndBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TrancheA And B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_TrancheaAndBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A and B Warrants</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UnitsIssuedDuringPeriodSharesNewIssuance" xlink:label="pmn_UnitsIssuedDuringPeriodSharesNewIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_UnitsIssuedDuringPeriodSharesNewIssuance" xlink:to="pmn_UnitsIssuedDuringPeriodSharesNewIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_UnitsIssuedDuringPeriodSharesNewIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of units issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_UnitsIssuedDuringPeriodSharesNewIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Units Issued During Period, Shares, New Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_UnitsIssuedDuringPeriodSharesNewIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units issued</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PricePerUnit" xlink:label="pmn_PricePerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PricePerUnit" xlink:to="pmn_PricePerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PricePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the price per unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PricePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PricePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs of units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfCommonSharePerUnit" xlink:label="pmn_NumberOfCommonSharePerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_NumberOfCommonSharePerUnit" xlink:to="pmn_NumberOfCommonSharePerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_NumberOfCommonSharePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of common share per unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_NumberOfCommonSharePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Common Share Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_NumberOfCommonSharePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common share per unit</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfWarrantsPerUnit" xlink:label="pmn_NumberOfWarrantsPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_NumberOfWarrantsPerUnit" xlink:to="pmn_NumberOfWarrantsPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_NumberOfWarrantsPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of warrants per unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_NumberOfWarrantsPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_NumberOfWarrantsPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants per unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common share per warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercisable term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiry term (in years)</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" xlink:label="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" xlink:to="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold days after the completion of tranche milestone events within which the warrants should be exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Days After Completion Of Tranche Milestone Events, Considered for Expiry Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold days after completion of tranche milestone events</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysToGetShareholdersApproval" xlink:label="pmn_ThresholdDaysToGetShareholdersApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ThresholdDaysToGetShareholdersApproval" xlink:to="pmn_ThresholdDaysToGetShareholdersApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ThresholdDaysToGetShareholdersApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of days from the closing date to get shareholders approval.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ThresholdDaysToGetShareholdersApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Days To Get Shareholders Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ThresholdDaysToGetShareholdersApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold days to get shareholders approval</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares by each warrant entitles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants to purchase common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightPricePerWarrant" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ClassOfWarrantOrRightPricePerWarrant" xlink:to="pmn_ClassOfWarrantOrRightPricePerWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Price Per Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common share purchase warrants price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, measurement input</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AggregateGrossProceeds" xlink:label="pmn_AggregateGrossProceeds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AggregateGrossProceeds" xlink:to="pmn_AggregateGrossProceeds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AggregateGrossProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount of cash that the entity expects to raise from the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AggregateGrossProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Gross Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_AggregateGrossProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_OfferingCostsAndAgentFee" xlink:label="pmn_OfferingCostsAndAgentFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_OfferingCostsAndAgentFee" xlink:to="pmn_OfferingCostsAndAgentFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_OfferingCostsAndAgentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 2024 private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_OfferingCostsAndAgentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs And Agent Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_OfferingCostsAndAgentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs and agent fee</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightIssued" xlink:label="pmn_ClassOfWarrantOrRightIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ClassOfWarrantOrRightIssued" xlink:to="pmn_ClassOfWarrantOrRightIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability and accelerated warrant liability at issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of the derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of the warrant liability and accelerated warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" xlink:to="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reclassification to permanent equity of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassified to Permanent Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of previously liability-classified US$ warrants reclassified to additional paid-in-capital as of July 1, 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassified fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds allocated to Common Shares</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UnitedStatesDollarDenominatedWarrantsMember" xlink:label="pmn_UnitedStatesDollarDenominatedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_UnitedStatesDollarDenominatedWarrantsMember" xlink:to="pmn_UnitedStatesDollarDenominatedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_UnitedStatesDollarDenominatedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to united states dollar denominated warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_UnitedStatesDollarDenominatedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States Dollar Denominated Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_UnitedStatesDollarDenominatedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States dollar denominated warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" xlink:label="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" xlink:to="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, capital shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 22, 2025 discounted warrant exercise offer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Warrant Exercise Offer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Exercise</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 22, 2025 discounted warrant exercise offer relating to Tranche A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Warrant Exercise Offer, Tranche A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Exercise, Tranche A</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 22, 2025 discounted warrant exercise offer relating to Tranche B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Warrant Exercise Offer, Tranche B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Exercise, Tranche B</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 22, 2025 discounted warrant exercise offer relating to Tranche C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Warrant Exercise Offer, Tranche C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Discounted Exercise, Tranche C</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025PipeOfferingMember" xlink:label="pmn_July222025PipeOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July222025PipeOfferingMember" xlink:to="pmn_July222025PipeOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July222025PipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 22, 2025 PIPE offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July222025PipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Pipe Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July222025PipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 PIPE Offering</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 28, 2025 discounted warrant exercise offer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Warrant Exercise Offer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Exercise</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 28, 2025 discounted warrant exercise offer relating to Tranche A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Warrant Exercise Offer, Tranche A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Exercise, Tranche A</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 28, 2025 discounted warrant exercise offer relating to Tranche B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Warrant Exercise Offer, Tranche B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Exercise, Tranche B</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 28, 2025 discounted warrant exercise offer relating to Tranche C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Warrant Exercise Offer, Tranche C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Discounted Exercise, Tranche C</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025PipeOfferingMember" xlink:label="pmn_July282025PipeOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July282025PipeOfferingMember" xlink:to="pmn_July282025PipeOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July282025PipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 28, 2025 PIPE offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July282025PipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 Pipe Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July282025PipeOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28, 2025 PIPE Offering</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantJuly222025Member" xlink:label="pmn_WarrantJuly222025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantJuly222025Member" xlink:to="pmn_WarrantJuly222025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantJuly222025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 22, 2025 Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantJuly222025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant July 22, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantJuly222025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 22, 2025 Warrant</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantJuly282025Member" xlink:label="pmn_WarrantJuly282025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantJuly282025Member" xlink:to="pmn_WarrantJuly282025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantJuly282025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants issued in July 28, 2025 PIPE Offering .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantJuly282025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant July 28 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantJuly282025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 28 2025 Warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="us-gaap_MeasurementInputMaturityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputMaturityMember" xlink:to="us-gaap_MeasurementInputMaturityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputMaturityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Maturity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputMaturityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreModificationMember" xlink:label="pmn_PreModificationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PreModificationMember" xlink:to="pmn_PreModificationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PreModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to scenario before modification.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PreModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Modification [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PreModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Modification</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PostModificationMember" xlink:label="pmn_PostModificationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_PostModificationMember" xlink:to="pmn_PostModificationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_PostModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to scenario after modification.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_PostModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post Modification [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_PostModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post Modification</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of gross proceeds from issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" xlink:to="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of discounted warrant exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Discounted Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for discounted exercise warrants</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" xlink:label="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" xlink:to="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of class of warrant or rights exercised during the period at discounted exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Exercised, Discounted Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_BeneficialOwnershipLimitation" xlink:label="pmn_BeneficialOwnershipLimitation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_BeneficialOwnershipLimitation" xlink:to="pmn_BeneficialOwnershipLimitation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_BeneficialOwnershipLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of beneficial ownership limitation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_BeneficialOwnershipLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beneficial Ownership Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_BeneficialOwnershipLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beneficial ownership</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd50.50Member" xlink:label="pmn_WarrantExercisePriceUsd50.50Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd50.50Member" xlink:to="pmn_WarrantExercisePriceUsd50.50Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd50.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $50.50.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd50.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $50.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd50.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 50.50</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd315.00Member" xlink:label="pmn_WarrantExercisePriceUsd315.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd315.00Member" xlink:to="pmn_WarrantExercisePriceUsd315.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd315.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $315.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd315.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $315.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd315.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 315.00</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd240.00Member" xlink:label="pmn_WarrantExercisePriceUsd240.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd240.00Member" xlink:to="pmn_WarrantExercisePriceUsd240.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd240.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $240.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd240.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $240.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd240.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 240.00</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd187.50Member" xlink:label="pmn_WarrantExercisePriceUsd187.50Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd187.50Member" xlink:to="pmn_WarrantExercisePriceUsd187.50Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd187.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $187.50.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd187.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $187.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd187.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 187.50</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd152.50Member" xlink:label="pmn_WarrantExercisePriceUsd152.50Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd152.50Member" xlink:to="pmn_WarrantExercisePriceUsd152.50Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd152.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $152.50.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd152.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $152.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd152.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 152.50</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd43.75Member" xlink:label="pmn_WarrantExercisePriceUsd43.75Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd43.75Member" xlink:to="pmn_WarrantExercisePriceUsd43.75Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd43.75Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $43.75.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd43.75Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $43.75 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd43.75Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 43.75</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd62.50Member" xlink:label="pmn_WarrantExercisePriceUsd62.50Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd62.50Member" xlink:to="pmn_WarrantExercisePriceUsd62.50Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd62.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $62.50.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd62.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $62.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd62.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 62.50</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd31.25Member" xlink:label="pmn_WarrantExercisePriceUsd31.25Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd31.25Member" xlink:to="pmn_WarrantExercisePriceUsd31.25Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd31.25Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $31.25.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd31.25Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $31.25 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd31.25Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 31.25</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd0.25Member" xlink:label="pmn_WarrantExercisePriceUsd0.25Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_WarrantExercisePriceUsd0.25Member" xlink:to="pmn_WarrantExercisePriceUsd0.25Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_WarrantExercisePriceUsd0.25Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price USD $0.25.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_WarrantExercisePriceUsd0.25Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price USD $0.25 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_WarrantExercisePriceUsd0.25Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price 0.25</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_August2026Member" xlink:label="pmn_August2026Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_August2026Member" xlink:to="pmn_August2026Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_August2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the August 2026 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_August2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">August 2026</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_April2028Member" xlink:label="pmn_April2028Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_April2028Member" xlink:to="pmn_April2028Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_April2028Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the April 2028 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_April2028Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">April 2028</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_February2029Member" xlink:label="pmn_February2029Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_February2029Member" xlink:to="pmn_February2029Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_February2029Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the February 2029 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_February2029Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">February 2029 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_February2029Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">February 2029</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026Member" xlink:label="pmn_January2026Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_January2026Member" xlink:to="pmn_January2026Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_January2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the January 2026 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_January2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_January2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2027Member" xlink:label="pmn_January2027Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_January2027Member" xlink:to="pmn_January2027Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_January2027Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the January 2027 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_January2027Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2027 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_January2027Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2027</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2029Member" xlink:label="pmn_July2029Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July2029Member" xlink:to="pmn_July2029Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July2029Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the July 2029 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July2029Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2029 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July2029Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2029</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2030Member" xlink:label="pmn_July2030Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_July2030Member" xlink:to="pmn_July2030Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_July2030Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the July 2030 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_July2030Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2030 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_July2030Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2030</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RegisteredDirectOfferingMember" xlink:label="pmn_RegisteredDirectOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_RegisteredDirectOfferingMember" xlink:to="pmn_RegisteredDirectOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Registered Direct Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Direct Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Direct Offering</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromPreFundedWarrantExercises" xlink:label="pmn_ProceedsFromPreFundedWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ProceedsFromPreFundedWarrantExercises" xlink:to="pmn_ProceedsFromPreFundedWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ProceedsFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow associated with the amount received from holders exercising their pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ProceedsFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Pre-Funded Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ProceedsFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExpired" xlink:label="pmn_ClassOfWarrantOrRightExpired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ClassOfWarrantOrRightExpired" xlink:to="pmn_ClassOfWarrantOrRightExpired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants expired</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExercised" xlink:label="pmn_ClassOfWarrantOrRightExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ClassOfWarrantOrRightExercised" xlink:to="pmn_ClassOfWarrantOrRightExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:label="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:to="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of warrants net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionPlan2015Member" xlink:label="pmn_StockOptionPlan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_StockOptionPlan2015Member" xlink:to="pmn_StockOptionPlan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_StockOptionPlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2015 Stock Option Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_StockOptionPlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plan 2015</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionAndIncentivePlan2025Member" xlink:label="pmn_StockOptionAndIncentivePlan2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_StockOptionAndIncentivePlan2025Member" xlink:to="pmn_StockOptionAndIncentivePlan2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_StockOptionAndIncentivePlan2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Stock Option and Incentive Plan ("2025 Option Plan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_StockOptionAndIncentivePlan2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option And Incentive Plan 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_StockOptionAndIncentivePlan2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plan 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarShareOptionsMember" xlink:label="pmn_CanadianDollarShareOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CanadianDollarShareOptionsMember" xlink:to="pmn_CanadianDollarShareOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CanadianDollarShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Canadian dollar share options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CanadianDollarShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canadian Dollar Share Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CanadianDollarShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canadian Dollar Share Options</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UsDollarShareOptionsMember" xlink:label="pmn_UsDollarShareOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_UsDollarShareOptionsMember" xlink:to="pmn_UsDollarShareOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_UsDollarShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to US dollar share options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_UsDollarShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Dollar Share Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_UsDollarShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Dollar Share Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Share Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable at the end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (years) and Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value of share options granted</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of fair value of options in a share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, By Share Based Payment Award Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options in a share based payment arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Share-Based Arrangements, Liability, Classified, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at the beginning</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" xlink:label="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" xlink:to="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase in additional paid in capital due to decrease in fair value of share based compensation liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Fair Value Of Share Based Compensation Liability, Increase In Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" xlink:label="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" xlink:to="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of options in a share based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement, Weighted Average Fair Value of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitPlanMember" xlink:label="pmn_DeferredShareUnitPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredShareUnitPlanMember" xlink:to="pmn_DeferredShareUnitPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredShareUnitPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to deferred share unit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredShareUnitPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DSU plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States of America, Dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Employee [Member]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_VolumeWeightedAveragePriceThresholdTradingDays" xlink:label="pmn_VolumeWeightedAveragePriceThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_VolumeWeightedAveragePriceThresholdTradingDays" xlink:to="pmn_VolumeWeightedAveragePriceThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_VolumeWeightedAveragePriceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days that common stock price must meet or exceed specified share price to trigger vesting of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_VolumeWeightedAveragePriceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volume Weighted Average Price, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_VolumeWeightedAveragePriceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of threshold days</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" xlink:label="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" xlink:to="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold share price of the common stock to met or exceed for vesting of the options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Volume Weighted Average Price Of Common Shares, Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold volume weighted average price</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value of options to be recognized under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares redeemable per unit in shared-based payments award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Redeemable Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares per unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation related to options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation related to options outstanding expected to be recognized over weighted-average remaining service period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-capital losses carried forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenditures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInvestments" xlink:to="us-gaap_DeferredTaxAssetsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment tax credits</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" xlink:label="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" xlink:to="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from tax value of technology rights and property and equipment in excess of accounting basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Value Of Technology Rights And Property And Equipment In Excess Of Accounting Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax value of technology rights and property and equipment in excess of accounting basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible reserves</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" xlink:label="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" xlink:to="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restricted interest and financing expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Restricted Interest And Financing Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted interest and financing expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred income tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred income tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NonCapitalLossCarryforwardMember" xlink:label="pmn_NonCapitalLossCarryforwardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_NonCapitalLossCarryforwardMember" xlink:to="pmn_NonCapitalLossCarryforwardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_NonCapitalLossCarryforwardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deductions derived from non-capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_NonCapitalLossCarryforwardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Capital Loss Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_NonCapitalLossCarryforwardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-capital income tax loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCreditMember" xlink:to="us-gaap_InvestmentCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canadian federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue costs recorded, net of equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" xlink:to="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Return to Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return to provision adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Tax Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Jurisdiction of Domicile [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canadian federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provincial taxes (Ontario)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue costs recorded, net of equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" xlink:to="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Return to Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return to provision adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Tax Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reporting segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Items [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Items [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Segments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Pmn310DevelopmentProgramCosts" xlink:label="pmn_Pmn310DevelopmentProgramCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_Pmn310DevelopmentProgramCosts" xlink:to="pmn_Pmn310DevelopmentProgramCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_Pmn310DevelopmentProgramCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense incurred for drug PMN310 development program costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_Pmn310DevelopmentProgramCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PMN310 Development Program Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_Pmn310DevelopmentProgramCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PMN310 development program costs</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_OtherNonEmployeeResearchAndDevelopmentCosts" xlink:label="pmn_OtherNonEmployeeResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_OtherNonEmployeeResearchAndDevelopmentCosts" xlink:to="pmn_OtherNonEmployeeResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_OtherNonEmployeeResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense incurred for other non employee research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_OtherNonEmployeeResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Non Employee Research And Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_OtherNonEmployeeResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-employee research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other general and administrative costs</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_SegmentReportingOtherSegmentItemAmount" xlink:label="pmn_SegmentReportingOtherSegmentItemAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_SegmentReportingOtherSegmentItemAmount" xlink:to="pmn_SegmentReportingOtherSegmentItemAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_SegmentReportingOtherSegmentItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_SegmentReportingOtherSegmentItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pmn_SegmentReportingOtherSegmentItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Composition, Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CollaborativeResearchAgreementMember" xlink:label="pmn_CollaborativeResearchAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CollaborativeResearchAgreementMember" xlink:to="pmn_CollaborativeResearchAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CollaborativeResearchAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the collaborative research agreement entered with related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CollaborativeResearchAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative research agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CollaborativeResearchAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative research agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RelatedPartyTransactionFundingCommitment" xlink:label="pmn_RelatedPartyTransactionFundingCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_RelatedPartyTransactionFundingCommitment" xlink:to="pmn_RelatedPartyTransactionFundingCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_RelatedPartyTransactionFundingCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of funding commitment in related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_RelatedPartyTransactionFundingCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Funding Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_RelatedPartyTransactionFundingCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funding commitment</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CashPaymentsRelatedParty" xlink:label="pmn_CashPaymentsRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CashPaymentsRelatedParty" xlink:to="pmn_CashPaymentsRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CashPaymentsRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash payments to related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CashPaymentsRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Payments, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CashPaymentsRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments made for consulting services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CEO</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TerminationWithoutCauseMember" xlink:label="pmn_TerminationWithoutCauseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_TerminationWithoutCauseMember" xlink:to="pmn_TerminationWithoutCauseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_TerminationWithoutCauseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to scenario, termination without cause</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_TerminationWithoutCauseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination without Cause [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_TerminationWithoutCauseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination without cause</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ChangeInControlOfCompanyMember" xlink:label="pmn_ChangeInControlOfCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ChangeInControlOfCompanyMember" xlink:to="pmn_ChangeInControlOfCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ChangeInControlOfCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to scenario, change in control of the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ChangeInControlOfCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Control of the Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ChangeInControlOfCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">change in control of the Company</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ArrangementOptionInitialAwardMember" xlink:label="pmn_ArrangementOptionInitialAwardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ArrangementOptionInitialAwardMember" xlink:to="pmn_ArrangementOptionInitialAwardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ArrangementOptionInitialAwardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time relating to initial awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ArrangementOptionInitialAwardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangement, Option, Initial Award [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ArrangementOptionInitialAwardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Award</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" xlink:label="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" xlink:to="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time relating to performance awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Performance Awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche one</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche two</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementAnnualBaseSalary" xlink:label="pmn_EmploymentAgreementAnnualBaseSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_EmploymentAgreementAnnualBaseSalary" xlink:to="pmn_EmploymentAgreementAnnualBaseSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_EmploymentAgreementAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of annual base salary under employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_EmploymentAgreementAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Annual Base Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_EmploymentAgreementAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual base salary</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" xlink:label="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" xlink:to="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of target bonus on annual base salary under employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Percentage of Target Bonus on Annual Base Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of target bonus on annual base salary</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementSeveranceAmountCalculationTerm" xlink:label="pmn_EmploymentAgreementSeveranceAmountCalculationTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_EmploymentAgreementSeveranceAmountCalculationTerm" xlink:to="pmn_EmploymentAgreementSeveranceAmountCalculationTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_EmploymentAgreementSeveranceAmountCalculationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of salary, a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits for calculation of severance amount under employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_EmploymentAgreementSeveranceAmountCalculationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Severance Amount Calculation, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_EmploymentAgreementSeveranceAmountCalculationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance amount calculation, term</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold trading days volume-weighted average share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Threshold Trading Days Volume-Weighted Average Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading days volume weighted average price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award vesting rights, percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award vesting period</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the multiplier for volume-weighted average share price for calculation of exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Multiplier for Volume Weighted Average Price for Calculation of Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Times of exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UbcAgreementMember" xlink:label="pmn_UbcAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_UbcAgreementMember" xlink:to="pmn_UbcAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_UbcAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to UBC Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_UbcAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UBC Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_UbcAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UBC Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" xlink:label="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" xlink:to="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the accruals for royalty payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Accruals for Royalty Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals for royalty payments</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RelatedPartyTransactionTermOfAgreement" xlink:label="pmn_RelatedPartyTransactionTermOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_RelatedPartyTransactionTermOfAgreement" xlink:to="pmn_RelatedPartyTransactionTermOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_RelatedPartyTransactionTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of agreement in related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_RelatedPartyTransactionTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_RelatedPartyTransactionTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AnnualLicensePayment" xlink:label="pmn_AnnualLicensePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_AnnualLicensePayment" xlink:to="pmn_AnnualLicensePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_AnnualLicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of license payments made during the year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_AnnualLicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual License Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_AnnualLicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of annual license</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of potentially dilutive securities - Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of potentially dilutive securities - Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitsMember" xlink:label="pmn_DeferredShareUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DeferredShareUnitsMember" xlink:to="pmn_DeferredShareUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DeferredShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to deferred share units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DeferredShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred share units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DeferredShareUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Share Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementMember" xlink:label="pmn_January2026PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_January2026PrivatePlacementMember" xlink:to="pmn_January2026PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_January2026PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to January 2026 private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_January2026PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_January2026PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 PIPE</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceOneMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_January2026PrivatePlacementIssuePriceOneMember" xlink:to="pmn_January2026PrivatePlacementIssuePriceOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_January2026PrivatePlacementIssuePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to January 2026 private placement at issue price one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_January2026PrivatePlacementIssuePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Private Placement, Issue Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_January2026PrivatePlacementIssuePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 PIPE at issue price one</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceTwoMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_January2026PrivatePlacementIssuePriceTwoMember" xlink:to="pmn_January2026PrivatePlacementIssuePriceTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_January2026PrivatePlacementIssuePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to January 2026 private placement at issue price two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_January2026PrivatePlacementIssuePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Private Placement, Issue Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_January2026PrivatePlacementIssuePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 PIPE at issue price two</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceThreeMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_January2026PrivatePlacementIssuePriceThreeMember" xlink:to="pmn_January2026PrivatePlacementIssuePriceThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_January2026PrivatePlacementIssuePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to January 2026 private placement at issue price three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_January2026PrivatePlacementIssuePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 Private Placement, Issue Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_January2026PrivatePlacementIssuePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2026 PIPE at issue price three</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsMember" xlink:label="pmn_CommonShareWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CommonShareWarrantsMember" xlink:to="pmn_CommonShareWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CommonShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common share purchase warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CommonShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CommonShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceOneMember" xlink:label="pmn_CommonShareWarrantsIssuePriceOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CommonShareWarrantsIssuePriceOneMember" xlink:to="pmn_CommonShareWarrantsIssuePriceOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CommonShareWarrantsIssuePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common share purchase warrants issued at issue price one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CommonShareWarrantsIssuePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants, Issue Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CommonShareWarrantsIssuePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants at issue price one</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceTwoMember" xlink:label="pmn_CommonShareWarrantsIssuePriceTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CommonShareWarrantsIssuePriceTwoMember" xlink:to="pmn_CommonShareWarrantsIssuePriceTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CommonShareWarrantsIssuePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common share purchase warrants issued at issue price two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CommonShareWarrantsIssuePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants, Issue Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CommonShareWarrantsIssuePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants at issue price two</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceThreeMember" xlink:label="pmn_CommonShareWarrantsIssuePriceThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_CommonShareWarrantsIssuePriceThreeMember" xlink:to="pmn_CommonShareWarrantsIssuePriceThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_CommonShareWarrantsIssuePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common share purchase warrants issued at issue price three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_CommonShareWarrantsIssuePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants, Issue Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_CommonShareWarrantsIssuePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Share Warrants at issue price three</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Domain]</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DirectorsAndManagementMember" xlink:label="pmn_DirectorsAndManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_DirectorsAndManagementMember" xlink:to="pmn_DirectorsAndManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_DirectorsAndManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to directors and management member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_DirectorsAndManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors And Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_DirectorsAndManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors and management</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" xlink:label="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" xlink:to="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold days after the completion of milestone events within which the warrants should be exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Days After Completion Of Milestone Events, Considered for Expiry Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expiry period</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Rule10b51ArrModifiedFlag" xlink:label="pmn_Rule10b51ArrModifiedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_Rule10b51ArrModifiedFlag" xlink:to="pmn_Rule10b51ArrModifiedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_Rule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arr Modified Flag.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_Rule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arr Modified Flag</label>
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NonRule10b51ArrModifiedFlag" xlink:label="pmn_NonRule10b51ArrModifiedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmn_NonRule10b51ArrModifiedFlag" xlink:to="pmn_NonRule10b51ArrModifiedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pmn_NonRule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Rule 10b5-1 Arr Modified Flag.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pmn_NonRule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Rule 10b5-1 Arr Modified Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>pmn-20251231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 1:44:30 PM-->
<!--Modified on: 3/25/2026 1:44:30 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedStatementsOfShareholdersDeficitEquity" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureAccruedLiabilities" roleURI="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquity" roleURI="http://www.promisneurosciences.com/role/DisclosureEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureWarrants" roleURI="http://www.promisneurosciences.com/role/DisclosureWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxes" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSegmentReporting" roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReporting" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureNetLossPerShare" roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSubsequentEvents" roleURI="http://www.promisneurosciences.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureAccruedLiabilitiesTables" roleURI="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityTables" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureWarrantsTables" roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSegmentReportingTables" roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReportingTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureDescriptionOfBusinessDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityFutureIssuancesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityRightsOfCommonSharesGrossProceedsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityRightsOfCommonSharesGrossProceedsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityEquityTransactionsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityWarrantsLiabilityDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityAtMarketOfferingAtmDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityRegisteredDirectOfferingDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureWarrantsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureWarrantsAdditionalInformationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationShareOptionsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureShareBasedCompensationStatementsOfOperationsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxesCreditCarryforwardsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSegmentReportingDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReportingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSegmentReportingSignificantExpenseCategoriesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pmn-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639100430688130206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639100430688130206" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_639100430688130206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_639100430688130206" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639100430688136067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639100430688136067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_639100430688136067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_639100430688136067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639100430688136067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639100430688136067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639100430688136067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639100430688136067" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639100430688136067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639100430688136067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639100430688136067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639100430688136067" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639100430688136067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639100430688136067" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639100430688141741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639100430688141741" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639100430688141741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639100430688141741" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639100430688142687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639100430688142687" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639100430688142687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639100430688142687" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639100430688142687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639100430688142687" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639100430688142687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639100430688142687" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639100430688142687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639100430688142687" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639100430688142687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639100430688142687" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_639100430688147919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_639100430688147919" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_639100430688147919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_639100430688147919" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_639100430688147919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_639100430688147919" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_639100430688147919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_639100430688147919" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_639100430688147919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_639100430688147919" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_639100430688147919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_639100430688147919" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639100430688153303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639100430688153303" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_639100430688153303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_639100430688153303" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_639100430688153303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_639100430688153303" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_639100430688153303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_639100430688153303" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_639100430688153303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_639100430688153303" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_639100430688153303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_639100430688153303" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_639100430688158541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_639100430688158541" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_639100430688158541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_639100430688158541" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_639100430688160939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_639100430688160939" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_639100430688160939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_639100430688160939" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_639100430688160939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_639100430688160939" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639100430688160939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639100430688160939" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_639100430688160939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_639100430688160939" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_639100430688166245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_639100430688166245" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_639100430688166731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_639100430688166731" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639100430688166731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639100430688166731" order="39" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639100430688166731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_639100430688166731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639100430688166731" xlink:to="us-gaap_AssetsCurrentAbstract_639100430688172040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639100430688172040" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100430688172040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639100430688172040" xlink:to="us-gaap_ShortTermInvestments_639100430688172040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639100430688172040" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100430688172040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639100430688172040" xlink:to="us-gaap_AssetsCurrent_639100430688172040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639100430688166731" xlink:to="us-gaap_Assets_639100430688172040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639100430688172040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100430688172040" xlink:to="us-gaap_AccountsPayableCurrent_639100430688172040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100430688172040" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639100430688172040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100430688172040" xlink:to="us-gaap_LiabilitiesCurrent_639100430688172040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_639100430688172040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430688172040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_Liabilities_639100430688172040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_CommitmentsAndContingencies_639100430688172040" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_StockholdersEquityAbstract_639100430688172040" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_CommonStockValue_639100430688172040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_AdditionalPaidInCapital_639100430688172040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639100430688172040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639100430688172040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_StockholdersEquity_639100430688172040" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639100430688172040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100430688172040" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639100430688172040" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue_639100430688190033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue_639100430688190033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_639100430688190033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_639100430688190033" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639100430688190033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_639100430688190033" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639100430688190033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_639100430688190033" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_639100430688190033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_639100430688190033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639100430688190033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688190033" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639100430688190033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639100430688190033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688190033" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639100430688190033" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639100430688195830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688190033" xlink:to="us-gaap_OperatingExpenses_639100430688195830" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639100430688196360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688190033" xlink:to="us-gaap_OperatingIncomeLoss_639100430688196360" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_639100430688197406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_639100430688197406" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_GainLossFromChangeInFairValueOfFinancialInstruments" xlink:label="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639100430688197406" xlink:to="pmn_GainLossFromChangeInFairValueOfFinancialInstruments_639100430688197928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639100430688197406" xlink:to="us-gaap_InterestExpenseOther_639100430688197928" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639100430688197406" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639100430688197928" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639100430688197406" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430688197928" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639100430688197406" xlink:to="us-gaap_NonoperatingIncomeExpense_639100430688197928" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_639100430688197928" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_639100430688197928" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639100430688197928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_639100430688197928" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100430688203762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100430688203762" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100430688204226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100430688204226" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639100430688204226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639100430688204226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639100430688204226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100430688204226" xlink:to="us-gaap_StatementEquityComponentsAxis_639100430688204226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_639100430688204226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100430688204226" xlink:to="us-gaap_PreferredStockMember_639100430688204226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639100430688204226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100430688204226" xlink:to="us-gaap_CommonStockMember_639100430688204226" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639100430688209518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100430688204226" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639100430688209518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639100430688210060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100430688204226" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639100430688210060" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639100430688210499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100430688204226" xlink:to="us-gaap_RetainedEarningsMember_639100430688210499" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639100430688210499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100430688204226" xlink:to="us-gaap_EquityComponentDomain_639100430688210499" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639100430688210499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100430688204226" xlink:to="us-gaap_StatementClassOfStockAxis_639100430688210499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Series2PreferredSharesMember" xlink:label="pmn_Series2PreferredSharesMember_639100430688210499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639100430688210499" xlink:to="pmn_Series2PreferredSharesMember_639100430688210499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639100430688210499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639100430688210499" xlink:to="us-gaap_ClassOfStockDomain_639100430688210499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100430688204226" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PipeFinancingMember" xlink:label="pmn_July2024PipeFinancingMember_639100430688210499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" xlink:to="pmn_July2024PipeFinancingMember_639100430688210499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2024Member" xlink:label="pmn_AtMarketOffering2024Member_639100430688215806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" xlink:to="pmn_AtMarketOffering2024Member_639100430688215806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2025Member" xlink:label="pmn_AtMarketOffering2025Member_639100430688216922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" xlink:to="pmn_AtMarketOffering2025Member_639100430688216922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688217446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688217446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688218488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" xlink:to="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688218488" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688219002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688210499" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688219002" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639100430688219002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100430688204226" xlink:to="us-gaap_StatementLineItems_639100430688219002" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688219002" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639100430688219002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_StockholdersEquity_639100430688219002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_639100430688219002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_SharesIssued_639100430688219002" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639100430688219002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639100430688219002" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639100430688224225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639100430688224225" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639100430688224750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639100430688224225" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639100430688224750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639100430688224750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639100430688224750" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688224750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_639100430688224750" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688224750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodValueWarrantsExercised_639100430688224750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="pmn_StockIssuedDuringPeriodValueWarrantsExercised_639100430688224750" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_639100430688224750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_StockIssuedDuringPeriodValueWarrantsExercised_639100430688224750" xlink:to="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_639100430688224750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_639100430688224750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_639100430688224750" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions" xlink:label="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions_639100430688230482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions_639100430688230482" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100430688230482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_NetIncomeLoss_639100430688230482" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639100430688230482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_StockholdersEquity_639100430688230482" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_639100430688230482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100430688219002" xlink:to="us-gaap_SharesIssued_639100430688230482" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_639100430688236236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100430688236236" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688236236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688236236" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688236236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688236236" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688236236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688236236" xlink:to="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688236236" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PipeFinancingMember" xlink:label="pmn_July2024PipeFinancingMember_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688236236" xlink:to="pmn_July2024PipeFinancingMember_639100430688236236" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100430688236236" xlink:to="us-gaap_StatementLineItems_639100430688236236" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639100430688236236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639100430688236236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639100430688241457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639100430688236236" xlink:to="us-gaap_ProfitLoss_639100430688241457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100430688241973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639100430688236236" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100430688241973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639100430688241973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100430688241973" xlink:to="us-gaap_ShareBasedCompensation_639100430688241973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430688241973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100430688241973" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430688241973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_639100430688241973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100430688241973" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_639100430688241973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100430688241973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639100430688236236" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100430688241973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100430688241973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100430688241973" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100430688241973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639100430688241973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100430688241973" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639100430688241973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100430688247709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100430688241973" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100430688247709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430688247709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100430688241973" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430688247709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639100430688247709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639100430688247709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_639100430688247709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639100430688247709" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_639100430688247709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_639100430688247709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639100430688247709" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_639100430688247709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100430688247709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639100430688247709" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100430688247709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430688253436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430688253436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfWarrants_639100430688253436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" xlink:to="pmn_NetProceedsFromIssuanceOfWarrants_639100430688253436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_639100430688253436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_639100430688253436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430688253436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430688253436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639100430688253436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" xlink:to="us-gaap_ProceedsFromWarrantExercises_639100430688253436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430688253436" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639100430688252927" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100430688253436" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639100430688259192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639100430688259192" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639100430688259192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639100430688259192" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6391004306882591921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6391004306882591921" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639100430688259192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639100430688259192" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity" xlink:label="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity_639100430688259192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639100430688259192" xlink:to="pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity_639100430688259192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability" xlink:label="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability_639100430688259192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639100430688259192" xlink:to="pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability_639100430688259192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountForFairValueModificationOfWarrants" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants_639100430688283921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639100430688259192" xlink:to="pmn_DeferredDiscountForFairValueModificationOfWarrants_639100430688283921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountIssuanceCostRecognized" xlink:label="pmn_DeferredDiscountIssuanceCostRecognized_639100430688284410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639100430688259192" xlink:to="pmn_DeferredDiscountIssuanceCostRecognized_639100430688284410" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_639100430688284410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100430688236236" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_639100430688284410" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_639100430688284410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_639100430688284410" xlink:to="us-gaap_InterestPaidNet_639100430688284410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_639100430688290858" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_639100430688290858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995210301 - Disclosure - FAIR VALUE MEASUREMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_639100430688293390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_639100430688293390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="995210401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock_639100430688293390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock_639100430688293390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilities" xlink:type="extended" xlink:title="995210501 - Disclosure - ACCRUED LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedLiabilitiesTextBlock" xlink:label="pmn_AccruedLiabilitiesTextBlock_639100430688293390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="pmn_AccruedLiabilitiesTextBlock_639100430688293390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquity" xlink:type="extended" xlink:title="995210601 - Disclosure - EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639100430688299144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639100430688299144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="995210701 - Disclosure - WARRANTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantsAndRightsDisclosureTextBlock" xlink:label="pmn_WarrantsAndRightsDisclosureTextBlock_639100430688299144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="pmn_WarrantsAndRightsDisclosureTextBlock_639100430688299144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="995210801 - Disclosure - SHARE-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639100430688299144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639100430688299144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995210901 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_639100430688304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_639100430688304954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSegmentReporting" xlink:type="extended" xlink:title="995211001 - Disclosure - Segment Reporting" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_639100430688304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_639100430688304954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="995211101 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639100430688310617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639100430688310617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211201 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639100430688310617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639100430688310617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211301 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_639100430688310617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_639100430688310617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211401 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_639100430688315838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_639100430688315838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639100430688318147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639100430688318147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_639100430688318147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_639100430688318147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639100430688318147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_639100430688318147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_639100430688318147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_639100430688318147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_639100430688318147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_639100430688318147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639100430688318147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639100430688318147" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShortTermInvestmentsPolicyPolicyTextBlock" xlink:label="pmn_ShortTermInvestmentsPolicyPolicyTextBlock_639100430688323494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="pmn_ShortTermInvestmentsPolicyPolicyTextBlock_639100430688323494" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_639100430688324166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_639100430688324166" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_639100430688325225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_639100430688325225" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_639100430688325697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_639100430688325697" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639100430688325697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639100430688325697" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_639100430688325697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_639100430688325697" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_639100430688325697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_639100430688325697" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_639100430688325697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_639100430688325697" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_639100430688325697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_639100430688325697" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:label="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_639100430688325697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_639100430688325697" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PatentCostsPolicyTextBlock" xlink:label="pmn_PatentCostsPolicyTextBlock_639100430688331588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="pmn_PatentCostsPolicyTextBlock_639100430688331588" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_639100430688332170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_639100430688332170" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_639100430688332741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_639100430688332741" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="pmn_EmergingGrowthCompanyStatusPolicyTextBlock_639100430688332741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="pmn_EmergingGrowthCompanyStatusPolicyTextBlock_639100430688332741" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_639100430688332741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_639100430688332741" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="99930403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_639100430688339172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_639100430688339172" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesTables" xlink:type="extended" xlink:title="99930503 - Disclosure - ACCRUED LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639100430688341358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639100430688341358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityTables" xlink:type="extended" xlink:title="99930603 - Disclosure - EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688341358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688341358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_639100430688341358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688341358" xlink:to="us-gaap_FairValueByLiabilityClassAxis_639100430688341358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688341358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_639100430688341358" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688341358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639100430688341358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688341358" xlink:to="us-gaap_WarrantMember_639100430688341358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_639100430688341358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688341358" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_639100430688341358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_639100430688341358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_639100430688341358" xlink:to="pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_639100430688341358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_639100430688347310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_639100430688341358" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_639100430688347310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="99930703 - Disclosure - WARRANTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ScheduleOfWarrantExercisePriceTableTextBlock" xlink:label="pmn_ScheduleOfWarrantExercisePriceTableTextBlock_639100430688348069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="pmn_ScheduleOfWarrantExercisePriceTableTextBlock_639100430688348069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="99930803 - Disclosure - SHARE-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639100430688348069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639100430688348069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock" xlink:label="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock_639100430688348069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock_639100430688348069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639100430688353734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639100430688353734" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639100430688353734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639100430688353734" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639100430688353734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639100430688353734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSegmentReportingTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Segment Reporting (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_639100430688359369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_639100430688359369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931303 - Disclosure - NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639100430688359369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639100430688359369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639100430688359369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639100430688359369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - DESCRIPTION OF BUSINESS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_639100430688359369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsequentEventTable_639100430688359369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100430688359369" xlink:to="us-gaap_SubsequentEventTypeAxis_639100430688364927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639100430688364927" xlink:to="us-gaap_SubsequentEventTypeDomain_639100430688364927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639100430688364927" xlink:to="us-gaap_SubsequentEventMember_639100430688364927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100430688359369" xlink:to="us-gaap_SubsequentEventLineItems_639100430688364927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688364927" xlink:to="us-gaap_OperatingIncomeLoss_639100430688364927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688364927" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639100430688364927" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688364927" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100430688364927" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100430688364927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688364927" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100430688364927" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_639100430688370580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_639100430688370580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_639100430688370580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_639100430688370580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_639100430688370580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_639100430688370580" xlink:to="us-gaap_NumberOfOperatingSegments_639100430688370580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639100430688375786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639100430688375786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639100430688375786" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639100430688376237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639100430688376237" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100430688376237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100430688376237" xlink:to="us-gaap_OfficeEquipmentMember_639100430688376237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100430688376237" xlink:to="us-gaap_ComputerEquipmentMember_639100430688376237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639100430688375786" xlink:to="srt_RangeAxis_639100430688376237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639100430688376237" xlink:to="srt_RangeMember_639100430688376237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100430688376237" xlink:to="srt_MinimumMember_639100430688376237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639100430688376237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100430688376237" xlink:to="srt_MaximumMember_639100430688376237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639100430688381796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639100430688375786" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639100430688381796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_639100430688381796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639100430688381796" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_639100430688381796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639100430688381796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639100430688381796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688381796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688381796" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688381796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688381796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688381796" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688381796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember_639100430688381796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688381796" xlink:to="pmn_PreFundedWarrantsMember_639100430688381796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688381796" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PercentageOfOriginalAmountInvested" xlink:label="pmn_PercentageOfOriginalAmountInvested_639100430688388170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" xlink:to="pmn_PercentageOfOriginalAmountInvested_639100430688388170" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_639100430688388170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_639100430688388170" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688388170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688388170" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_639100430688388170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" xlink:to="us-gaap_DeferredOfferingCosts_639100430688388170" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639100430688388170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" xlink:to="us-gaap_UnrecognizedTaxBenefits_639100430688388170" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_639100430688388170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688387179" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_639100430688388170" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100430688394297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100430688394297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_639100430688395229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100430688394297" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_639100430688395229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_639100430688395229" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_639100430688396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_639100430688396112" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_639100430688396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100430688394297" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639100430688396112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639100430688396112" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100430688396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100430688396112" xlink:to="us-gaap_FairValueInputsLevel1Member_639100430688396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100430688396112" xlink:to="us-gaap_FairValueInputsLevel3Member_639100430688396112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100430688394297" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100430688396112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_639100430688396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100430688396112" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_639100430688396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_639100430688401432" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639100430688396112" xlink:to="us-gaap_InvestmentsFairValueDisclosure_639100430688401432" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_639100430688402074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639100430688396112" xlink:to="us-gaap_AssetsFairValueDisclosure_639100430688402074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100430688402074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100430688396112" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100430688402074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_639100430688402074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100430688402074" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_639100430688402074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430688402074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100430688402074" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430688402074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_639100430688402074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100430688402074" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_639100430688402074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - FAIR VALUE MEASUREMENTS - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount" xlink:label="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount_639100430688407935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount_639100430688407935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount" xlink:label="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount_639100430688407935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount_639100430688407935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_639100430688407935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_639100430688407935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_639100430688407935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_639100430688407935" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidUpfrontResearchPaymentsCurrent" xlink:label="pmn_PrepaidUpfrontResearchPaymentsCurrent_639100430688407935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pmn_PrepaidUpfrontResearchPaymentsCurrent_639100430688407935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_639100430688413135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivable_639100430688413135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_639100430688413923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance_639100430688413923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PrepaidLicenseFeeCurrent" xlink:label="pmn_PrepaidLicenseFeeCurrent_639100430688414866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pmn_PrepaidLicenseFeeCurrent_639100430688414866" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredFinancingCostAssets" xlink:label="pmn_DeferredFinancingCostAssets_639100430688415744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pmn_DeferredFinancingCostAssets_639100430688415744" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_639100430688416598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_639100430688416598" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100430688417374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100430688417374" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - ACCRUED LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedLegalFeesCurrent" xlink:label="pmn_AccruedLegalFeesCurrent_639100430688417634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="pmn_AccruedLegalFeesCurrent_639100430688417634" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639100430688417634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639100430688417634" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AccruedResearchAndDevelopmentCurrent" xlink:label="pmn_AccruedResearchAndDevelopmentCurrent_639100430688417634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="pmn_AccruedResearchAndDevelopmentCurrent_639100430688417634" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_639100430688417634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent_639100430688417634" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639100430688417634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639100430688417634" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639100430688417634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639100430688417634" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639100430688425119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesIssued_639100430688425119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639100430688425307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_639100430688425307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue_639100430688425307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockNoParValue_639100430688425307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - EQUITY - Future issuances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639100430688425307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_639100430688425307" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688425307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688425307" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688425307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688425307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688425307" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688425307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PrivatePlacementMember" xlink:label="pmn_July2024PrivatePlacementMember_639100430688425307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688425307" xlink:to="pmn_July2024PrivatePlacementMember_639100430688425307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688430707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688425307" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688430707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688430707" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688431090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaCommonShareWarrantMember" xlink:label="pmn_TrancheaCommonShareWarrantMember_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688431090" xlink:to="pmn_TrancheaCommonShareWarrantMember_639100430688431090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheBCommonShareWarrantMember" xlink:label="pmn_TrancheBCommonShareWarrantMember_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688431090" xlink:to="pmn_TrancheBCommonShareWarrantMember_639100430688431090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheCCommonShareWarrantMember" xlink:label="pmn_TrancheCCommonShareWarrantMember_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688431090" xlink:to="pmn_TrancheCCommonShareWarrantMember_639100430688431090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688425307" xlink:to="us-gaap_ClassOfStockLineItems_639100430688431090" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688431090" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639100430688431090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688431090" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430688431090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitsOutstanding" xlink:label="pmn_DeferredShareUnitsOutstanding_639100430688431090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688431090" xlink:to="pmn_DeferredShareUnitsOutstanding_639100430688431090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100430688436947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688431090" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100430688436947" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639100430688438070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688431090" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639100430688438070" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityRightsOfCommonSharesGrossProceedsDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - EQUITY - Rights of the common shares gross proceeds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfVotesPerCommonShare" xlink:label="pmn_NumberOfVotesPerCommonShare_639100430688438070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="pmn_NumberOfVotesPerCommonShare_639100430688438070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - EQUITY - Equity transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639100430688438070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_639100430688438070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_639100430688438070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688438070" xlink:to="us-gaap_FairValueByLiabilityClassAxis_639100430688438070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_639100430688438070" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688443852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688443852" xlink:to="us-gaap_WarrantMember_639100430688443852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688438070" xlink:to="us-gaap_MeasurementInputTypeAxis_639100430688443852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_639100430688443852" xlink:to="us-gaap_MeasurementInputTypeDomain_639100430688443852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688443852" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_639100430688443852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688443852" xlink:to="us-gaap_MeasurementInputExercisePriceMember_639100430688443852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688443852" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_639100430688443852" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_639100430688443852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688443852" xlink:to="us-gaap_MeasurementInputExpectedTermMember_639100430688443852" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_639100430688449250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688443852" xlink:to="us-gaap_MeasurementInputSharePriceMember_639100430688449250" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639100430688449676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688438070" xlink:to="srt_RangeAxis_639100430688449676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100430688449676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639100430688449676" xlink:to="srt_RangeMember_639100430688449676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639100430688449676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100430688449676" xlink:to="srt_MinimumMember_639100430688449676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639100430688449676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100430688449676" xlink:to="srt_MaximumMember_639100430688449676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688449676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688438070" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688449676" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688449676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688449676" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688449676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2024PrivatePlacementMember" xlink:label="pmn_July2024PrivatePlacementMember_639100430688449676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688449676" xlink:to="pmn_July2024PrivatePlacementMember_639100430688449676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOfferingMember" xlink:label="pmn_AtMarketOfferingMember_639100430688455794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688449676" xlink:to="pmn_AtMarketOfferingMember_639100430688455794" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688456185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688449676" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688456185" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639100430688456185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688438070" xlink:to="us-gaap_StatementClassOfStockAxis_639100430688456185" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639100430688456185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639100430688456185" xlink:to="us-gaap_ClassOfStockDomain_639100430688456185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareUnitsMember" xlink:label="pmn_CommonShareUnitsMember_639100430688456185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639100430688456185" xlink:to="pmn_CommonShareUnitsMember_639100430688456185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedUnitsMember" xlink:label="pmn_PreFundedUnitsMember_639100430688456185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639100430688456185" xlink:to="pmn_PreFundedUnitsMember_639100430688456185" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688456185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688438070" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688456185" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688456185" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember_639100430688462644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" xlink:to="pmn_PreFundedWarrantsMember_639100430688462644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarDenominatedWarrantsMember" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember_639100430688463228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" xlink:to="pmn_CanadianDollarDenominatedWarrantsMember_639100430688463228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaAndBWarrantsMember" xlink:label="pmn_TrancheaAndBWarrantsMember_639100430688463228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" xlink:to="pmn_TrancheaAndBWarrantsMember_639100430688463228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaCommonShareWarrantMember" xlink:label="pmn_TrancheaCommonShareWarrantMember_639100430688463228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" xlink:to="pmn_TrancheaCommonShareWarrantMember_639100430688463228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheBCommonShareWarrantMember" xlink:label="pmn_TrancheBCommonShareWarrantMember_639100430688463228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" xlink:to="pmn_TrancheBCommonShareWarrantMember_639100430688463228" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheCCommonShareWarrantMember" xlink:label="pmn_TrancheCCommonShareWarrantMember_639100430688463228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688461581" xlink:to="pmn_TrancheCCommonShareWarrantMember_639100430688463228" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639100430688463228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688438070" xlink:to="us-gaap_ClassOfStockLineItems_639100430688463228" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UnitsIssuedDuringPeriodSharesNewIssuance" xlink:label="pmn_UnitsIssuedDuringPeriodSharesNewIssuance_639100430688468851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_UnitsIssuedDuringPeriodSharesNewIssuance_639100430688468851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PricePerUnit" xlink:label="pmn_PricePerUnit_639100430688468851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_PricePerUnit_639100430688468851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639100430688468851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639100430688468851" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfCommonSharePerUnit" xlink:label="pmn_NumberOfCommonSharePerUnit_639100430688468851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_NumberOfCommonSharePerUnit_639100430688468851" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NumberOfWarrantsPerUnit" xlink:label="pmn_NumberOfWarrantsPerUnit_639100430688468851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_NumberOfWarrantsPerUnit_639100430688468851" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639100430688468851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639100430688468851" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688475074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688475074" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639100430688475074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639100430688475074" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm" xlink:label="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm_639100430688475074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm_639100430688475074" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysToGetShareholdersApproval" xlink:label="pmn_ThresholdDaysToGetShareholdersApproval_639100430688475074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_ThresholdDaysToGetShareholdersApproval_639100430688475074" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688475074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688475074" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688480640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688480640" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_639100430688481246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_SaleOfStockPricePerShare_639100430688481246" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430688481246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430688481246" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_639100430688481246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_639100430688481246" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightPricePerWarrant" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant_639100430688481246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_ClassOfWarrantOrRightPricePerWarrant_639100430688481246" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430688486435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430688486435" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639100430688487665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639100430688487665" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AggregateGrossProceeds" xlink:label="pmn_AggregateGrossProceeds_639100430688487665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_AggregateGrossProceeds_639100430688487665" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_OfferingCostsAndAgentFee" xlink:label="pmn_OfferingCostsAndAgentFee_639100430688487665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_OfferingCostsAndAgentFee_639100430688487665" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightIssued" xlink:label="pmn_ClassOfWarrantOrRightIssued_639100430688487665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_ClassOfWarrantOrRightIssued_639100430688487665" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_639100430688493184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_639100430688493184" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100430688493184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100430688493184" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639100430688493184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100430688493184" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639100430688493184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_639100430688493184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_639100430688493184" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430688498451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_639100430688498451" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639100430688500449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639100430688500449" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_LossOnSaleOfCommonSharesAndWarrants" xlink:label="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430688500449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="pmn_LossOnSaleOfCommonSharesAndWarrants_639100430688500449" order="27" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639100430688500449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688463228" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639100430688500449" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails" xlink:type="extended" xlink:title="99940605 - Disclosure - EQUITY - Warrants liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688506635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_6" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688506635" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_639100430688506635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688506635" xlink:to="us-gaap_FairValueByLiabilityClassAxis_639100430688506635" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688506635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_639100430688506635" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688506635" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639100430688506635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_639100430688506635" xlink:to="us-gaap_WarrantMember_639100430688506635" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688506635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688506635" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688506635" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688506635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688506635" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688506635" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UnitedStatesDollarDenominatedWarrantsMember" xlink:label="pmn_UnitedStatesDollarDenominatedWarrantsMember_639100430688511805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688506635" xlink:to="pmn_UnitedStatesDollarDenominatedWarrantsMember_639100430688511805" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarDenominatedWarrantsMember" xlink:label="pmn_CanadianDollarDenominatedWarrantsMember_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688506635" xlink:to="pmn_CanadianDollarDenominatedWarrantsMember_639100430688512235" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TrancheaAndBWarrantsMember" xlink:label="pmn_TrancheaAndBWarrantsMember_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688506635" xlink:to="pmn_TrancheaAndBWarrantsMember_639100430688512235" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_639100430688506635" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_639100430688512235" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_639100430688512235" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639100430688512235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_639100430688512235" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity" xlink:label="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" xlink:to="pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity_639100430688512235" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100430688512235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100430688512235" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639100430688517884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639100430688517884" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639100430688517884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639100430688512235" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639100430688517884" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails" xlink:type="extended" xlink:title="99940606 - Disclosure - EQUITY - At-the-Market Offering ATM (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639100430688517884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_8" xlink:to="us-gaap_ScheduleOfStockByClassTable_639100430688517884" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688517884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688517884" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688517884" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688517884" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688517884" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688517884" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2024Member" xlink:label="pmn_AtMarketOffering2024Member_639100430688523064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688517884" xlink:to="pmn_AtMarketOffering2024Member_639100430688523064" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AtMarketOffering2025Member" xlink:label="pmn_AtMarketOffering2025Member_639100430688523962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688517884" xlink:to="pmn_AtMarketOffering2025Member_639100430688523962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639100430688523962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688517884" xlink:to="us-gaap_ClassOfStockLineItems_639100430688523962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_639100430688523962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688523962" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_639100430688523962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount" xlink:label="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount_639100430688523962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688523962" xlink:to="pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount_639100430688523962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688523962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688523962" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688523962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430688523962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688523962" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100430688523962" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails" xlink:type="extended" xlink:title="99940607 - Disclosure - EQUITY - Registered Direct Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639100430688529178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_9" xlink:to="us-gaap_ScheduleOfStockByClassTable_639100430688529178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688530343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688529178" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688530343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688531128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688530343" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688531128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember_639100430688531592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688531128" xlink:to="pmn_PreFundedWarrantsMember_639100430688531592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639100430688531592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688529178" xlink:to="us-gaap_ClassOfStockLineItems_639100430688531592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688531592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688531592" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688531592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_639100430688549282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688531592" xlink:to="us-gaap_SaleOfStockPricePerShare_639100430688549282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688555113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688531592" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688555113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_639100430688555113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688531592" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_639100430688555113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639100430688555113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688531592" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639100430688555113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails" xlink:type="extended" xlink:title="99940608 - Disclosure - EQUITY - Exercise of Discounted Warrants and PIPE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_10" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639100430688555113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_10" xlink:to="us-gaap_ScheduleOfStockByClassTable_639100430688555113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688555113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688555113" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688555113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688555113" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688560748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688560748" xlink:to="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferMember_639100430688560748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferMember_639100430688560748" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_639100430688560748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferMember_639100430688560748" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_639100430688560748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July222025DiscountedWarrantExerciseOfferMember_639100430688560748" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_639100430688560748" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025PipeOfferingMember" xlink:label="pmn_July222025PipeOfferingMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" xlink:to="pmn_July222025PipeOfferingMember_639100430688560748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember" xlink:label="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688560748" xlink:to="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferMember_639100430688560748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferMember_639100430688560748" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_639100430688560748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_639100430688560748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferMember_639100430688560748" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_639100430688560748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_639100430688566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July282025DiscountedWarrantExerciseOfferMember_639100430688560748" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_639100430688566094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025PipeOfferingMember" xlink:label="pmn_July282025PipeOfferingMember_639100430688566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_639100430688560748" xlink:to="pmn_July282025PipeOfferingMember_639100430688566094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639100430688566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688555113" xlink:to="srt_RangeAxis_639100430688566094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100430688566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639100430688566094" xlink:to="srt_RangeMember_639100430688566094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639100430688566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100430688566094" xlink:to="srt_MinimumMember_639100430688566094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639100430688566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100430688566094" xlink:to="srt_MaximumMember_639100430688566094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688555113" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688566094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688571264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688566094" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688571264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantJuly222025Member" xlink:label="pmn_WarrantJuly222025Member_639100430688571755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688571264" xlink:to="pmn_WarrantJuly222025Member_639100430688571755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantJuly282025Member" xlink:label="pmn_WarrantJuly282025Member_639100430688571755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688571264" xlink:to="pmn_WarrantJuly282025Member_639100430688571755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_639100430688571755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688555113" xlink:to="us-gaap_MeasurementInputTypeAxis_639100430688571755" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639100430688571755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_639100430688571755" xlink:to="us-gaap_MeasurementInputTypeDomain_639100430688571755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_639100430688571755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688571755" xlink:to="us-gaap_MeasurementInputSharePriceMember_639100430688571755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_639100430688571755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688571755" xlink:to="us-gaap_MeasurementInputExercisePriceMember_639100430688571755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="us-gaap_MeasurementInputMaturityMember_639100430688577474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688571755" xlink:to="us-gaap_MeasurementInputMaturityMember_639100430688577474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_639100430688577474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688571755" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_639100430688577474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_639100430688577474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639100430688571755" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_639100430688577474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639100430688577474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688555113" xlink:to="srt_StatementScenarioAxis_639100430688577474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639100430688577474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639100430688577474" xlink:to="srt_ScenarioUnspecifiedDomain_639100430688577474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreModificationMember" xlink:label="pmn_PreModificationMember_639100430688577474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639100430688577474" xlink:to="pmn_PreModificationMember_639100430688577474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PostModificationMember" xlink:label="pmn_PostModificationMember_639100430688583133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639100430688577474" xlink:to="pmn_PostModificationMember_639100430688583133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639100430688583133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639100430688555113" xlink:to="us-gaap_ClassOfStockLineItems_639100430688583133" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants_639100430688583133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="pmn_ProceedsFromIssuanceOfCommonStockAndWarrants_639100430688583133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639100430688583133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639100430688583133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_639100430688583133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_639100430688583133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice" xlink:label="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice_639100430688583133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice_639100430688583133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688588799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688588799" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredDiscountForFairValueModificationOfWarrants" xlink:label="pmn_DeferredDiscountForFairValueModificationOfWarrants_639100430688589321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="pmn_DeferredDiscountForFairValueModificationOfWarrants_639100430688589321" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688589321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688589321" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_639100430688589321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="us-gaap_SaleOfStockPricePerShare_639100430688589321" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639100430688589321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639100430688589321" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_BeneficialOwnershipLimitation" xlink:label="pmn_BeneficialOwnershipLimitation_639100430688594600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="pmn_BeneficialOwnershipLimitation_639100430688594600" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430688595641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants_639100430688595641" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639100430688595641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639100430688583133" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639100430688595641" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - WARRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639100430688595641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639100430688595641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688595641" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688601223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688601223" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd50.50Member" xlink:label="pmn_WarrantExercisePriceUsd50.50Member_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd50.50Member_639100430688601223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd315.00Member" xlink:label="pmn_WarrantExercisePriceUsd315.00Member_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd315.00Member_639100430688601223" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd240.00Member" xlink:label="pmn_WarrantExercisePriceUsd240.00Member_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd240.00Member_639100430688601223" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd187.50Member" xlink:label="pmn_WarrantExercisePriceUsd187.50Member_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd187.50Member_639100430688601223" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd152.50Member" xlink:label="pmn_WarrantExercisePriceUsd152.50Member_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd152.50Member_639100430688601223" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd43.75Member" xlink:label="pmn_WarrantExercisePriceUsd43.75Member_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd43.75Member_639100430688601223" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd62.50Member" xlink:label="pmn_WarrantExercisePriceUsd62.50Member_639100430688601223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd62.50Member_639100430688601223" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd31.25Member" xlink:label="pmn_WarrantExercisePriceUsd31.25Member_639100430688606400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd31.25Member_639100430688606400" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_WarrantExercisePriceUsd0.25Member" xlink:label="pmn_WarrantExercisePriceUsd0.25Member_639100430688606862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688601223" xlink:to="pmn_WarrantExercisePriceUsd0.25Member_639100430688606862" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_639100430688606862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688595641" xlink:to="us-gaap_AwardDateAxis_639100430688606862" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_639100430688606862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_639100430688606862" xlink:to="us-gaap_AwardDateDomain_639100430688606862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_August2026Member" xlink:label="pmn_August2026Member_639100430688606862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_639100430688606862" xlink:to="pmn_August2026Member_639100430688606862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_April2028Member" xlink:label="pmn_April2028Member_639100430688606862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_639100430688606862" xlink:to="pmn_April2028Member_639100430688606862" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_February2029Member" xlink:label="pmn_February2029Member_639100430688606862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_639100430688606862" xlink:to="pmn_February2029Member_639100430688606862" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026Member" xlink:label="pmn_January2026Member_639100430688606862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_639100430688606862" xlink:to="pmn_January2026Member_639100430688606862" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2027Member" xlink:label="pmn_January2027Member_639100430688612008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_639100430688606862" xlink:to="pmn_January2027Member_639100430688612008" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2029Member" xlink:label="pmn_July2029Member_639100430688612596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_639100430688606862" xlink:to="pmn_July2029Member_639100430688612596" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July2030Member" xlink:label="pmn_July2030Member_639100430688612596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_639100430688606862" xlink:to="pmn_July2030Member_639100430688612596" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639100430688612596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688595641" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639100430688612596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688612596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688612596" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688612596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639100430688612596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688612596" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639100430688612596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - WARRANTS - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639100430688618706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688618706" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688618706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688618706" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688618706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688618706" xlink:to="pmn_PreFundedWarrantsMember_639100430688618706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688618706" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688618706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688618706" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688618706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RegisteredDirectOfferingMember" xlink:label="pmn_RegisteredDirectOfferingMember_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688618706" xlink:to="pmn_RegisteredDirectOfferingMember_639100430688618706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July222025DiscountedWarrantExerciseOfferMember_639100430688618706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688618706" xlink:to="pmn_July222025DiscountedWarrantExerciseOfferMember_639100430688618706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025DiscountedWarrantExerciseOfferMember" xlink:label="pmn_July282025DiscountedWarrantExerciseOfferMember_639100430688624385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688618706" xlink:to="pmn_July282025DiscountedWarrantExerciseOfferMember_639100430688624385" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July222025PipeOfferingMember" xlink:label="pmn_July222025PipeOfferingMember_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688618706" xlink:to="pmn_July222025PipeOfferingMember_639100430688624800" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_July282025PipeOfferingMember" xlink:label="pmn_July282025PipeOfferingMember_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688618706" xlink:to="pmn_July282025PipeOfferingMember_639100430688624800" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688618706" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" xlink:to="pmn_StockIssuedDuringPeriodSharesWarrantsExercised_639100430688624800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromPreFundedWarrantExercises" xlink:label="pmn_ProceedsFromPreFundedWarrantExercises_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" xlink:to="pmn_ProceedsFromPreFundedWarrantExercises_639100430688624800" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise" xlink:label="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" xlink:to="pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise_639100430688624800" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightIssued" xlink:label="pmn_ClassOfWarrantOrRightIssued_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" xlink:to="pmn_ClassOfWarrantOrRightIssued_639100430688624800" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExpired" xlink:label="pmn_ClassOfWarrantOrRightExpired_639100430688624800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" xlink:to="pmn_ClassOfWarrantOrRightExpired_639100430688624800" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightExercised" xlink:label="pmn_ClassOfWarrantOrRightExercised_639100430688629967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" xlink:to="pmn_ClassOfWarrantOrRightExercised_639100430688629967" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:label="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_639100430688630931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688624800" xlink:to="pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_639100430688630931" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688630931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688630931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639100430688630931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688630931" xlink:to="us-gaap_PlanNameAxis_639100430688630931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100430688630931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639100430688630931" xlink:to="us-gaap_PlanNameDomain_639100430688630931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionPlan2015Member" xlink:label="pmn_StockOptionPlan2015Member_639100430688630931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100430688630931" xlink:to="pmn_StockOptionPlan2015Member_639100430688630931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionAndIncentivePlan2025Member" xlink:label="pmn_StockOptionAndIncentivePlan2025Member_639100430688630931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100430688630931" xlink:to="pmn_StockOptionAndIncentivePlan2025Member_639100430688630931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688636551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688630931" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688636551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100430688636551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688636551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100430688636551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639100430688636551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688636551" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639100430688636551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - SHARE-BASED COMPENSATION - Share options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688636551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688636551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639100430688636551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688636551" xlink:to="us-gaap_AwardTypeAxis_639100430688636551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688641727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639100430688636551" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688641727" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarShareOptionsMember" xlink:label="pmn_CanadianDollarShareOptionsMember_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688641727" xlink:to="pmn_CanadianDollarShareOptionsMember_639100430688642242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UsDollarShareOptionsMember" xlink:label="pmn_UsDollarShareOptionsMember_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688641727" xlink:to="pmn_UsDollarShareOptionsMember_639100430688642242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688636551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688642242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430688642242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639100430688642242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639100430688642242" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_639100430688642242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_639100430688642242" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430688647444" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100430688647444" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_639100430688648730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_639100430688648730" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639100430688648933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639100430688648933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639100430688648933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639100430688648933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639100430688648933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639100430688648933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_639100430688648933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_639100430688648933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6391004306886489331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6391004306886489331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_639100430688654101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639100430688648933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_639100430688654101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100430688654641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688642242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100430688654641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639100430688654641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100430688654641" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639100430688654641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6391004306886546411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100430688654641" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6391004306886546411" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_639100430688654641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100430688654641" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_639100430688654641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_639100430688654641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688642242" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_639100430688654641" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions_639100430688654641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688642242" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions_639100430688654641" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - SHARE-BASED COMPENSATION - Share-based compensation liability activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_639100430688660237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_639100430688660237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital" xlink:label="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital_639100430688660237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8" xlink:to="pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital_639100430688660237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_6391004306886602371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_6391004306886602371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688665859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688665859" xlink:to="us-gaap_AwardTypeAxis_639100430688665859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639100430688665859" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688665859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CanadianDollarShareOptionsMember" xlink:label="pmn_CanadianDollarShareOptionsMember_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688665859" xlink:to="pmn_CanadianDollarShareOptionsMember_639100430688665859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UsDollarShareOptionsMember" xlink:label="pmn_UsDollarShareOptionsMember_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688665859" xlink:to="pmn_UsDollarShareOptionsMember_639100430688665859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688665859" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688665859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions" xlink:label="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688665859" xlink:to="pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions_639100430688665859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639100430688665859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688665859" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639100430688665859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639100430688671586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688665859" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639100430688671586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639100430688671586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688665859" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639100430688671586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - SHARE-BASED COMPENSATION - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688671586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688671586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639100430688671586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688671586" xlink:to="us-gaap_PlanNameAxis_639100430688671586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100430688671586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639100430688671586" xlink:to="us-gaap_PlanNameDomain_639100430688671586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitPlanMember" xlink:label="pmn_DeferredShareUnitPlanMember_639100430688676837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100430688671586" xlink:to="pmn_DeferredShareUnitPlanMember_639100430688676837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_639100430688677439" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688671586" xlink:to="srt_CurrencyAxis_639100430688677439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_639100430688677974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_639100430688677439" xlink:to="currency_AllCurrenciesDomain_639100430688677974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD_639100430688677974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_639100430688677974" xlink:to="currency_USD_639100430688677974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639100430688677974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688671586" xlink:to="us-gaap_AwardTypeAxis_639100430688677974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688677974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639100430688677974" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688677974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UsDollarShareOptionsMember" xlink:label="pmn_UsDollarShareOptionsMember_639100430688677974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688677974" xlink:to="pmn_UsDollarShareOptionsMember_639100430688677974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_639100430688677974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688671586" xlink:to="us-gaap_GranteeStatusAxis_639100430688677974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_639100430688677974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_639100430688677974" xlink:to="us-gaap_GranteeStatusDomain_639100430688677974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_639100430688683182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_639100430688677974" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_639100430688683182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100430688671586" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639100430688684246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639100430688684246" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639100430688684246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639100430688684246" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_VolumeWeightedAveragePriceThresholdTradingDays" xlink:label="pmn_VolumeWeightedAveragePriceThresholdTradingDays_639100430688684246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="pmn_VolumeWeightedAveragePriceThresholdTradingDays_639100430688684246" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger" xlink:label="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger_639100430688684246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger_639100430688684246" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions_639100430688684246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions_639100430688684246" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639100430688684246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639100430688684246" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639100430688689482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639100430688689482" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit_639100430688690021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit_639100430688690021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639100430688690021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639100430688690021" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639100430688690021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639100430688690021" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639100430688690021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100430688683761" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639100430688690021" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails" xlink:type="extended" xlink:title="99940806 - Disclosure - SHARE-BASED COMPENSATION - Statements of operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639100430688695764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639100430688695764" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639100430688695764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639100430688695764" xlink:to="us-gaap_IncomeStatementLocationAxis_639100430688695764" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639100430688695764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639100430688695764" xlink:to="us-gaap_IncomeStatementLocationDomain_639100430688695764" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_639100430688695764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639100430688695764" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_639100430688695764" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_639100430688695764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639100430688695764" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_639100430688695764" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639100430688695764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639100430688695764" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639100430688695764" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639100430688695764" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639100430688695764" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639100430688695764" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - INCOME TAXES - Deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100430688701518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639100430688701518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInvestments_639100430688701518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis" xlink:label="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis_639100430688701518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100430688701518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_639100430688701518" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses" xlink:label="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses_639100430688701518" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639100430688701518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross_639100430688701518" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639100430688707300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639100430688707300" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639100430688707300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_639100430688707300" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - INCOME TAXES - Credit carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_639100430688707300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable_639100430688707300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_639100430688707300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_639100430688707300" xlink:to="us-gaap_TaxCreditCarryforwardAxis_639100430688707300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_639100430688707300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_639100430688707300" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_639100430688707300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NonCapitalLossCarryforwardMember" xlink:label="pmn_NonCapitalLossCarryforwardMember_639100430688712517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_639100430688707300" xlink:to="pmn_NonCapitalLossCarryforwardMember_639100430688712517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember_639100430688712517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_639100430688707300" xlink:to="us-gaap_InvestmentCreditMember_639100430688712517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_639100430688712517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_639100430688707300" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_639100430688712517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_639100430688714332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_639100430688712517" xlink:to="us-gaap_TaxCreditCarryforwardAmount_639100430688714332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - INCOME TAXES - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100430688714332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100430688714332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639100430688714332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_639100430688714332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639100430688714332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639100430688714332" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430688714332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430688714332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_639100430688719562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount_639100430688719562" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_639100430688719562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_639100430688719562" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639100430688719562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639100430688719562" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_639100430688719562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100430688714332" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_639100430688719562" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100430688723259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100430688723259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639100430688723259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639100430688723259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639100430688723259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639100430688723259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639100430688723259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639100430688723259" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430688723259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100430688723259" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent" xlink:label="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_639100430688723259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent_639100430688723259" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639100430688723259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_639100430688723259" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639100430688728484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100430688722149" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639100430688728484" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSegmentReportingDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Segment Reporting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_639100430688730747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NumberOfReportableSegments_639100430688730747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Segment Reporting - Significant expense categories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_639100430688730747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_3" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_639100430688730747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_639100430688730747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_639100430688730747" xlink:to="srt_ConsolidationItemsAxis_639100430688730747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_639100430688730747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis_639100430688730747" xlink:to="srt_ConsolidationItemsDomain_639100430688730747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain_639100430688730747" xlink:to="us-gaap_OperatingSegmentsMember_639100430688736470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_639100430688730747" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_639100430688736470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_639100430688736470" xlink:to="us-gaap_OperatingExpensesAbstract_639100430688736470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Pmn310DevelopmentProgramCosts" xlink:label="pmn_Pmn310DevelopmentProgramCosts_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="pmn_Pmn310DevelopmentProgramCosts_639100430688736470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_OtherNonEmployeeResearchAndDevelopmentCosts" xlink:label="pmn_OtherNonEmployeeResearchAndDevelopmentCosts_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="pmn_OtherNonEmployeeResearchAndDevelopmentCosts_639100430688736470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="us-gaap_LaborAndRelatedExpense_639100430688736470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_639100430688736470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639100430688736470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="us-gaap_OperatingIncomeLoss_639100430688736470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_SegmentReportingOtherSegmentItemAmount" xlink:label="pmn_SegmentReportingOtherSegmentItemAmount_639100430688741680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="pmn_SegmentReportingOtherSegmentItemAmount_639100430688741680" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100430688742254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="us-gaap_NetIncomeLoss_639100430688742254" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_639100430688742801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100430688736470" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_639100430688742801" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688742801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688742801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100430688742801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688742801" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100430688742801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639100430688742801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100430688742801" xlink:to="us-gaap_RelatedPartyDomain_639100430688742801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CollaborativeResearchAgreementMember" xlink:label="pmn_CollaborativeResearchAgreementMember_639100430688742801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639100430688742801" xlink:to="pmn_CollaborativeResearchAgreementMember_639100430688742801" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639100430688748030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639100430688742801" xlink:to="us-gaap_RelatedPartyMember_639100430688748030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639100430688748621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688742801" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639100430688748621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RelatedPartyTransactionFundingCommitment" xlink:label="pmn_RelatedPartyTransactionFundingCommitment_639100430688748621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688748621" xlink:to="pmn_RelatedPartyTransactionFundingCommitment_639100430688748621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CashPaymentsRelatedParty" xlink:label="pmn_CashPaymentsRelatedParty_639100430688748621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688748621" xlink:to="pmn_CashPaymentsRelatedParty_639100430688748621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_639100430688748621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688748621" xlink:to="us-gaap_ProfessionalFees_639100430688748621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100430688753847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100430688753847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100430688753847" xlink:to="us-gaap_RelatedPartyDomain_639100430688754377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639100430688754377" xlink:to="srt_ChiefExecutiveOfficerMember_639100430688754377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" xlink:to="srt_StatementScenarioAxis_639100430688754377" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639100430688754377" xlink:to="srt_ScenarioUnspecifiedDomain_639100430688754377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_TerminationWithoutCauseMember" xlink:label="pmn_TerminationWithoutCauseMember_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639100430688754377" xlink:to="pmn_TerminationWithoutCauseMember_639100430688754377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ChangeInControlOfCompanyMember" xlink:label="pmn_ChangeInControlOfCompanyMember_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639100430688754377" xlink:to="pmn_ChangeInControlOfCompanyMember_639100430688754377" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" xlink:to="us-gaap_PlanNameAxis_639100430688754377" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100430688754377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639100430688754377" xlink:to="us-gaap_PlanNameDomain_639100430688754377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_StockOptionPlan2015Member" xlink:label="pmn_StockOptionPlan2015Member_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100430688754377" xlink:to="pmn_StockOptionPlan2015Member_639100430688760088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" xlink:to="us-gaap_AwardTypeAxis_639100430688760088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639100430688760088" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688760088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ArrangementOptionInitialAwardMember" xlink:label="pmn_ArrangementOptionInitialAwardMember_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688760088" xlink:to="pmn_ArrangementOptionInitialAwardMember_639100430688760088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember" xlink:label="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100430688760088" xlink:to="pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_639100430688760088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" xlink:to="us-gaap_VestingAxis_639100430688760088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_639100430688760088" xlink:to="us-gaap_VestingDomain_639100430688760088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_639100430688760088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639100430688760088" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_639100430688760088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_639100430688765846" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639100430688760088" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_639100430688765846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100430688748621" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementAnnualBaseSalary" xlink:label="pmn_EmploymentAgreementAnnualBaseSalary_639100430688766876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="pmn_EmploymentAgreementAnnualBaseSalary_639100430688766876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary" xlink:label="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary_639100430688766876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary_639100430688766876" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_EmploymentAgreementSeveranceAmountCalculationTerm" xlink:label="pmn_EmploymentAgreementSeveranceAmountCalculationTerm_639100430688766876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="pmn_EmploymentAgreementSeveranceAmountCalculationTerm_639100430688766876" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639100430688766876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639100430688766876" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639100430688766876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639100430688766876" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice_639100430688766876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice_639100430688766876" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_639100430688772595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_639100430688772595" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639100430688772595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639100430688772595" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice" xlink:label="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice_639100430688772595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100430688766876" xlink:to="pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice_639100430688772595" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100430688777798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100430688777798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639100430688778338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100430688777798" xlink:to="us-gaap_TypeOfArrangementAxis_639100430688778338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100430688778833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639100430688778338" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100430688778833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_UbcAgreementMember" xlink:label="pmn_UbcAgreementMember_639100430688778833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100430688778833" xlink:to="pmn_UbcAgreementMember_639100430688778833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100430688778833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100430688777798" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100430688778833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CollaborativeArrangementAccrualsForRoyaltyPayments" xlink:label="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments_639100430688778833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100430688778833" xlink:to="pmn_CollaborativeArrangementAccrualsForRoyaltyPayments_639100430688778833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_RelatedPartyTransactionTermOfAgreement" xlink:label="pmn_RelatedPartyTransactionTermOfAgreement_639100430688778833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100430688778833" xlink:to="pmn_RelatedPartyTransactionTermOfAgreement_639100430688778833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_AnnualLicensePayment" xlink:label="pmn_AnnualLicensePayment_639100430688778833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100430688778833" xlink:to="pmn_AnnualLicensePayment_639100430688778833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639100430688784574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639100430688784574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688785073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688784574" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688785073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688785073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688785073" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688785073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember_639100430688785073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688785073" xlink:to="pmn_PreFundedWarrantsMember_639100430688785073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639100430688785073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100430688784574" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639100430688785073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688785073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100430688785073" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688785073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - NET LOSS PER SHARE - Computation of basic and diluted net income (loss) per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639100430688809539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639100430688809539" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_639100430688809539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100430688809539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639100430688809539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_639100430688809539" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100430688809539" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639100430688809539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" xlink:to="us-gaap_EarningsPerShareBasic_639100430688809539" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639100430688814758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639100430688809539" xlink:to="us-gaap_EarningsPerShareDiluted_639100430688814758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails" xlink:type="extended" xlink:title="99941303 - Disclosure - NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100430688816314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100430688816314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639100430688816314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100430688816314" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639100430688816314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639100430688816314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639100430688816314" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639100430688816314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639100430688816314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639100430688816314" xlink:to="us-gaap_EmployeeStockOptionMember_639100430688816314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639100430688816314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639100430688816314" xlink:to="us-gaap_WarrantMember_639100430688816314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DeferredShareUnitsMember" xlink:label="pmn_DeferredShareUnitsMember_639100430688816314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639100430688816314" xlink:to="pmn_DeferredShareUnitsMember_639100430688816314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639100430688821539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100430688816314" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639100430688821539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639100430688822044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639100430688821539" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639100430688822044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_639100430688822562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_639100430688822562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639100430688822562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100430688822562" xlink:to="us-gaap_SubsequentEventTypeAxis_639100430688822562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639100430688822562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639100430688822562" xlink:to="us-gaap_SubsequentEventTypeDomain_639100430688822562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639100430688822562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639100430688822562" xlink:to="us-gaap_SubsequentEventMember_639100430688822562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100430688822562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100430688822562" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100430688822562" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688828073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100430688822562" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688828073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementMember" xlink:label="pmn_January2026PrivatePlacementMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100430688828073" xlink:to="pmn_January2026PrivatePlacementMember_639100430688829227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceOneMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceOneMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_January2026PrivatePlacementMember_639100430688829227" xlink:to="pmn_January2026PrivatePlacementIssuePriceOneMember_639100430688829227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceTwoMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceTwoMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_January2026PrivatePlacementMember_639100430688829227" xlink:to="pmn_January2026PrivatePlacementIssuePriceTwoMember_639100430688829227" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_January2026PrivatePlacementIssuePriceThreeMember" xlink:label="pmn_January2026PrivatePlacementIssuePriceThreeMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_January2026PrivatePlacementMember_639100430688829227" xlink:to="pmn_January2026PrivatePlacementIssuePriceThreeMember_639100430688829227" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100430688822562" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100430688829227" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100430688829227" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100430688829227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsMember" xlink:label="pmn_CommonShareWarrantsMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688829227" xlink:to="pmn_CommonShareWarrantsMember_639100430688829227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceOneMember" xlink:label="pmn_CommonShareWarrantsIssuePriceOneMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_CommonShareWarrantsMember_639100430688829227" xlink:to="pmn_CommonShareWarrantsIssuePriceOneMember_639100430688829227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceTwoMember" xlink:label="pmn_CommonShareWarrantsIssuePriceTwoMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_CommonShareWarrantsMember_639100430688829227" xlink:to="pmn_CommonShareWarrantsIssuePriceTwoMember_639100430688829227" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_CommonShareWarrantsIssuePriceThreeMember" xlink:label="pmn_CommonShareWarrantsIssuePriceThreeMember_639100430688829227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmn_CommonShareWarrantsMember_639100430688829227" xlink:to="pmn_CommonShareWarrantsIssuePriceThreeMember_639100430688829227" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_PreFundedWarrantsMember" xlink:label="pmn_PreFundedWarrantsMember_639100430688834929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100430688829227" xlink:to="pmn_PreFundedWarrantsMember_639100430688834929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_639100430688834929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100430688822562" xlink:to="srt_TitleOfIndividualAxis_639100430688834929" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_639100430688834929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_639100430688834929" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_639100430688834929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_DirectorsAndManagementMember" xlink:label="pmn_DirectorsAndManagementMember_639100430688834929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_639100430688834929" xlink:to="pmn_DirectorsAndManagementMember_639100430688834929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_639100430688834929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100430688822562" xlink:to="us-gaap_SubsequentEventLineItems_639100430688834929" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100430688834929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100430688834929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688834929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100430688834929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688840660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100430688840660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightIssued" xlink:label="pmn_ClassOfWarrantOrRightIssued_639100430688841178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="pmn_ClassOfWarrantOrRightIssued_639100430688841178" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_639100430688841178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="us-gaap_SaleOfStockPricePerShare_639100430688841178" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ClassOfWarrantOrRightPricePerWarrant" xlink:label="pmn_ClassOfWarrantOrRightPricePerWarrant_639100430688841178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="pmn_ClassOfWarrantOrRightPricePerWarrant_639100430688841178" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688841178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100430688841178" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm" xlink:label="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm_639100430688841178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100430688834929" xlink:to="pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm_639100430688841178" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_Rule10b51ArrModifiedFlag" xlink:label="pmn_Rule10b51ArrModifiedFlag_639100430688848082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="pmn_Rule10b51ArrModifiedFlag_639100430688848082" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pmn-20251231.xsd#pmn_NonRule10b51ArrModifiedFlag" xlink:label="pmn_NonRule10b51ArrModifiedFlag_639100430688848082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="pmn_NonRule10b51ArrModifiedFlag_639100430688848082" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 25, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-41429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROMIS NEUROSCIENCES&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0647155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite&#160;200, 1920 Yonge Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Toronto<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">ON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">M4S 3E2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">847-6898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PMN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,967,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 5pt 0pt;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2026 annual meeting of shareholders, or the 2026 Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2026 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tewksbury, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001374339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 6,116,556<span></span>
</td>
<td class="nump">$ 13,291,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">33,753<span></span>
</td>
<td class="nump">33,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,032,112<span></span>
</td>
<td class="nump">5,587,238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,182,421<span></span>
</td>
<td class="nump">18,911,456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,182,421<span></span>
</td>
<td class="nump">18,911,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,543,415<span></span>
</td>
<td class="nump">1,737,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">7,868,416<span></span>
</td>
<td class="nump">480,962<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,411,831<span></span>
</td>
<td class="nump">2,218,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Share-based compensation liability</a></td>
<td class="nump">29,182<span></span>
</td>
<td class="nump">199,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,441,013<span></span>
</td>
<td class="nump">2,423,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Shares, no par value, unlimited shares authorized, 2,152,397 and 1,307,520 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">129,518,812<span></span>
</td>
<td class="nump">107,546,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(371,184)<span></span>
</td>
<td class="num">(371,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(130,406,220)<span></span>
</td>
<td class="num">(90,687,073)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' (deficit) equity</a></td>
<td class="num">(1,258,592)<span></span>
</td>
<td class="nump">16,488,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' (deficit) equity</a></td>
<td class="nump">$ 9,182,421<span></span>
</td>
<td class="nump">$ 18,911,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common shares, unlimited shares authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">2,152,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">2,152,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 33,379,321<span></span>
</td>
<td class="nump">$ 10,637,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,787,987<span></span>
</td>
<td class="nump">6,189,502<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">40,167,308<span></span>
</td>
<td class="nump">16,827,478<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(40,167,308)<span></span>
</td>
<td class="num">(16,827,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_GainLossFromChangeInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="nump">5,592<span></span>
</td>
<td class="nump">22,581,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">442,569<span></span>
</td>
<td class="nump">626,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_LossOnSaleOfCommonSharesAndWarrants', window );">Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,524,535)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">448,161<span></span>
</td>
<td class="nump">19,606,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (39,719,147)<span></span>
</td>
<td class="nump">$ 2,778,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic</a></td>
<td class="num">$ (22.61)<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted</a></td>
<td class="num">$ (22.61)<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average outstanding Common Shares, basic</a></td>
<td class="nump">1,756,844<span></span>
</td>
<td class="nump">1,036,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average outstanding Common Shares, diluted</a></td>
<td class="nump">1,756,844<span></span>
</td>
<td class="nump">1,058,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_GainLossFromChangeInFairValueOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_GainLossFromChangeInFairValueOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_LossOnSaleOfCommonSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss on issuance of common share and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_LossOnSaleOfCommonSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' (Deficit) Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Shares </div>
<div>Series 2 preferred shares</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>Series 2 preferred shares</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>July 2024 Pipe Financing</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>2024 ATM offering</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>2025 ATM offering</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>July 22, 2025 Exercise of Discounted Warrants And Pipe Offering</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>July 28, 2025 Exercise of Discounted Warrants And Pipe Offering</div>
</th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>2024 ATM offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>2025 ATM offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>July 22, 2025 Exercise of Discounted Warrants And Pipe Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>July 28, 2025 Exercise of Discounted Warrants And Pipe Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>2024 ATM offering</div></th>
<th class="th"><div>2025 ATM offering</div></th>
<th class="th"><div>July 22, 2025 Exercise of Discounted Warrants And Pipe Offering</div></th>
<th class="th"><div>July 28, 2025 Exercise of Discounted Warrants And Pipe Offering</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,590,426<span></span>
</td>
<td class="num">$ (371,184)<span></span>
</td>
<td class="num">$ (93,465,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,753,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2023</a></td>
<td class="nump">46,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series 2 Convertible Preferred Shares (in shares)</a></td>
<td class="num">(46,667)<span></span>
</td>
<td class="nump">46,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,307<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,689,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,689,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions', window );">Re-measurement of liability-classified CAD stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778,873<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,546,433<span></span>
</td>
<td class="num">(371,184)<span></span>
</td>
<td class="num">(90,687,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,488,176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,307,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,391,027<span></span>
</td>
<td class="nump">$ 11,144,467<span></span>
</td>
<td class="nump">3,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,391,027<span></span>
</td>
<td class="nump">$ 11,144,467<span></span>
</td>
<td class="nump">$ 3,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,449<span></span>
</td>
<td class="nump">416,436<span></span>
</td>
<td class="nump">51,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions', window );">Re-measurement of liability-classified CAD stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,719,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,719,147)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,518,812<span></span>
</td>
<td class="num">$ (371,184)<span></span>
</td>
<td class="num">$ (130,406,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,258,592)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for re-measurement of equity classified stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (39,719,147)<span></span>
</td>
<td class="nump">$ 2,778,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">857,628<span></span>
</td>
<td class="nump">825,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_LossOnSaleOfCommonSharesAndWarrants', window );">Loss on issuance of common shares, warrants, and pre-funded warrants in July 26, 2024 PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,524,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of financial instruments</a></td>
<td class="num">(5,592)<span></span>
</td>
<td class="num">(22,581,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,555,126<span></span>
</td>
<td class="num">(4,598,597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">805,952<span></span>
</td>
<td class="num">(6,105,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">7,387,454<span></span>
</td>
<td class="num">(1,025,564)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(28,118,579)<span></span>
</td>
<td class="num">(27,182,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(33,753)<span></span>
</td>
<td class="num">(33,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturity of short-term investment</a></td>
<td class="nump">33,051<span></span>
</td>
<td class="nump">32,358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(702)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Common Shares pursuant to 2025 and 2024 ATM offering, respectively, net of issuance costs</a></td>
<td class="nump">708,468<span></span>
</td>
<td class="nump">190,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of pre-funded warrants</a></td>
<td class="nump">3,050<span></span>
</td>
<td class="nump">28,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,944,670<span></span>
</td>
<td class="nump">27,875,809<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash</a></td>
<td class="num">(7,174,611)<span></span>
</td>
<td class="nump">693,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">13,291,167<span></span>
</td>
<td class="nump">12,598,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">6,116,556<span></span>
</td>
<td class="nump">13,291,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity', window );">Reclassification of July 2024 PIPE warrants from liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,689,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability', window );">Decrease in share-based compensation liability on CAD denominated share options increasing additional paid-in-capital</a></td>
<td class="num">(170,081)<span></span>
</td>
<td class="nump">222,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember', window );">July 22, 2025 Exercise of Discounted Warrants And Pipe Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of pre-funded warrants from July 22, 2025 Registered Direct Offering, net of issuance costs</a></td>
<td class="nump">697,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from Private Placements, net of issuance costs</a></td>
<td class="nump">8,391,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountForFairValueModificationOfWarrants', window );">Deferred discount for fair value modification of warrants</a></td>
<td class="nump">930,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountIssuanceCostRecognized', window );">Deferred discount issuance cost recognized on completion of PIPE</a></td>
<td class="num">(930,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember', window );">July 28, 2025 Exercise of Discounted Warrants And Pipe Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from Private Placements, net of issuance costs</a></td>
<td class="nump">11,144,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountForFairValueModificationOfWarrants', window );">Deferred discount for fair value modification of warrants</a></td>
<td class="nump">1,794,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountIssuanceCostRecognized', window );">Deferred discount issuance cost recognized on completion of PIPE</a></td>
<td class="num">$ (1,794,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PipeFinancingMember', window );">July 2024 Pipe Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from Private Placements, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,657,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in share based share-based compensation liability on CAD denominated share options reducing additional paid-in-capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DeferredDiscountForFairValueModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred discount for fair value modification of warrants in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DeferredDiscountForFairValueModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DeferredDiscountIssuanceCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred discount issuance cost recognized in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DeferredDiscountIssuanceCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_LossOnSaleOfCommonSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss on issuance of common share and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_LossOnSaleOfCommonSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NetProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NetProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non cash part of reclassification of July 2024 PIPE warrants from liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;<b style="font-weight:bold;">GAAP</b>&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;<b style="font-weight:bold;">ASC</b>&#8221;) and as amended by Accounting Standards Updates (&#8220;<b style="font-weight:bold;">ASU</b>&#8221;) of the Financial Accounting Standards Board (&#8220;<b style="font-weight:bold;">FASB</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On November 17, 2025, the board of directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of&#160;<span style="-sec-ix-hidden:Hidden_EKVA16217E2dxeEyM3doRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>:1, effective November&#160;28, 2025 (the &#8220;<b style="font-weight:bold;">Reverse Share Split</b>&#8221;). All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Share Split, unless otherwise stated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of financial instruments. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (&#8220;<b style="font-weight:bold;">CODM</b>&#8221;), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company has one operating segment and its Chief Executive Officer serves as the CODM. Substantially all of the Company&#8217;s assets are located in Canada. Refer to additional Segment Information in Note 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Foreign and Functional Currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company determines its functional currency as the currency of the primary economic environment in which the Company operates. To determine the primary economic environment, the Company considers salient economic factors, including cash flow indicators, expense indicators and financing indicators. Functional currency is a matter of fact, not a policy election and the Company will only reevaluate its functional currency if there is a significant change in facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Prior to July 1, 2023, the Company&#8217;s functional currency was the Canadian dollar (&#8220;<b style="font-weight:bold;">C$</b>&#8221;). Translation gains and losses from the application of the United States dollar (&#8220;<b style="font-weight:bold;">US$</b>&#8221;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative foreign currency translation adjustment, which is reported as a component of stockholders&#8217; (deficit) equity as accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Following the Company&#8217;s voluntary delisting from the Toronto Stock Exchange in July 2023, the Company determined there was a significant change in its facts and circumstances, and completed a reassessment of its functional currency. The Company determined that, as of July 1, 2023, the Company&#8217;s functional currency had changed from the C$ to the US$. The Company reassessment included analysis of various factors, including: the Company&#8217;s cash flows and expenses denominated primarily in US$, the primary market for the Company&#8217;s Common Shares trading in US$ and a majority ownership by U.S. shareholders from financings denominated in US$. The change in functional currency was accounted for prospectively from July 1, 2023 and consolidated financial statements prior to and including the period ended June 30, 2023 were not restated for the change in functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">For periods commencing July 1, 2023, monetary assets and liabilities denominated in foreign currencies are translated into US$ using exchange rates in effect at the end of the reporting period. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after July 1, 2023 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations within operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2025 and 2024, the Company did not have any material cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Short-term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Short-term investments consist of guaranteed certificates of deposit with a maturity greater than 90&#160;days and up to one&#160;year at the time of purchase. Accordingly, all short-term investments are classified as current assets in the accompanying consolidated balance sheets. The short-term investment is being held as collateral for the Company&#8217;s credit cards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees 100% of the original amount invested. As of December&#160;31, 2025, the Company has not experienced any losses on its cash or short-term investments as a result of credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures, </i>(<b style="font-weight:bold;">&#8220;ASC 820&#8221;</b>) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, as established by ASC 820, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; Observable inputs, such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; Inputs (other than Level 1 quoted prices) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s warrant liabilities were classified as Level 3 financial instruments for the&#160;year ended December&#160;31, 2024. The Company&#8217;s share-based compensation liability was classified as a Level 3 financial instrument for the&#160;years ended December&#160;31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The carrying amounts of prepaid and other current assets, short-term investments, accounts payable, and accrued expenses are generally considered to be representative of their fair value based on the short-term nature of these financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company historically evaluates its long-lived assets, which consist of property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not have any material long-lived assets as of December&#160;31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Property and equipment, net are historically stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Laboratory and equipment are depreciated over <span style="-sec-ix-hidden:Hidden_NcV6rL8tMk-QI6TxetjyIg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to five&#160;years. Computer equipment is depreciated over <span style="-sec-ix-hidden:Hidden_xwYBGyVeBki9Pw78B3ou9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to three&#160;years. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accompanying consolidated balance sheets and any resulting gain or loss is included in loss from operations in the accompanying consolidated statements of operations. Expenditures for repairs and maintenance are expensed as incurred. The Company did not have any material property and equipment as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Definite-lived intangible assets are historically stated at cost less accumulated amortization and any accumulated impairment losses. An intangible asset&#8217;s carrying amount is assessed for impairment whenever there is an indication that the asset may be impaired. The Company&#8217;s definite-lived intangible assets consist of acquired rights and patents. Intangible assets are amortized on a straight-line basis over the lesser of the life of the intangible asset or its estimated useful life, which is 15&#160;years. The Company did not have any material intangible assets as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Collaboration Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company may enter into collaboration arrangements with pharmaceutical and biotechnology partners. The Company analyzes its collaboration arrangements to assess whether they are within the scope of FASB ASC 808, <i style="font-style:italic;">Collaborative Arrangements, </i>(<b style="font-weight:bold;">&#8220;ASC 808&#8221;</b>), to determine whether such arrangements involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. ASC 808 does not provide guidance on the recognition of consideration exchanged or accounting for the obligations that may arise between parties. The Company concluded that ASC Topic 730, <i style="font-style:italic;">Research and Development, </i>should be applied by analogy to payments between parties during the development activities of its collaboration arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">General and administrative expenses consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development and protection of intellectual property, professional service fees, and other general overhead and facility costs, including rent, depreciation and amortization, which relate to the Company&#8217;s general and administrative functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of the Company&#8217;s platform technology, as well as discovery program expenses. The Company expenses research and development costs as incurred. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, related benefits and share-based compensation expense, for employees engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CROs</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of acquiring, developing, and manufacturing clinical study materials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Costs associated with preclinical and clinical activities and regulatory operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Prepaid and Accrued Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Substantial portions of the Company&#8217;s pre-clinical development, manufacturing and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors. These vendors generally bill&#160;monthly for services performed, or bill based upon milestone achievement. For preclinical and clinical studies, the Company accrues expenses based upon estimated work completed and the remaining contract milestones. At times, the Company is obligated to make upfront payments upon execution of research and development agreements. Upfront payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses until such goods are delivered or the related services are performed. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. The actual timing of performance or the level of effort may vary from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company issues warrants, including pre-funded warrants, on its common shares in connection with financings as well as for compensation of intermediaries and advisors. The Company accounts for warrants as either equity instruments or as liabilities depending on the specific terms of the warrant agreements in accordance with FASB ASC Topic 815, <i style="font-style:italic;">Derivatives and Hedging </i>and Topic 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i>. When classified as equity, warrants are recorded within additional paid-in-capital at the time of issuance and are not subsequently remeasured. Warrants identified as meeting the definition of a liability are recognized as a liability and treated in accordance with the derivative liability accounting policy described above. The Company periodically reassesses the appropriateness of the classification of its financial instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Share-based compensation expense related to share awards granted to employees, directors and non-employees, excluding awards with market conditions in which the award does not vest unless the market condition is met, is recognized based on the grant-date estimated fair values of the awards using the Black- Scholes option pricing model (&#8220;<b style="font-weight:bold;">Black-Scholes</b>&#8221;). The value is recognized as expense ratably over the requisite service period, which is generally the vesting term of the award. The Company adjusts the expense for actual forfeitures as they occur. Share-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Black Scholes requires a number of assumptions, of which the most significant are expected volatility, expected option term (the time from the grant date until the options are exercised or expire) and risk-free rate. Expected volatility is determined using the historical volatility for the Company. The risk-free interest rate is based on the yield of U.S. government treasury bonds with a remaining term equal to the expected life of the option for C$ options and based on the yield of U.S. government treasury bonds for US$ options. Expected dividend yield is zero because the Company has never paid cash dividends on common shares and the Company does not expect to pay cash dividends in the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">For awards with market conditions in which the award does not vest unless the market condition is met, the Company will incorporate the market condition into the award&#8217;s grant date fair value calculation and derive the expected service period using a Monte Carlo simulation. The estimated expense is recognized on a straight-line </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">basis over the derived service period. If the market condition is satisfied during the derived service period, the remaining unrecognized expense is recognized during the period the market condition is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'TimesNewRomanPSMT';">Awards of options that provide for an exercise price that is not denominated in: (a) the currency of a market in which a substantial portion of the Company's equity securities trades in, (b) the currency in which the employee's pay is denominated, or (c) the Company's functional currency, are required to be classified as liabilities. The change in the Company&#8217;s functional currency, effective July 1, 2023, resulted in the reclassification of outstanding stock options that were previously denominated in C$ from equity-classified to liability-classified options (see Note 8), which are accounted for as a share option modification in accordance with FASB&#8217;s ASC 718 &#8211; </span><i style="font-family:'TimesNewRomanPSMT';font-style:italic;">Compensation </i><i style="font-family:'TimesNewRomanPSMT';font-style:italic;">&#8211;</i><i style="font-family:'TimesNewRomanPSMT';font-style:italic;"> Stock Compensation</i><span style="font-family:'TimesNewRomanPSMT';"> (&#8220;</span><b style="font-family:'TimesNewRomanPSMT';font-weight:bold;">ASC 718</b><span style="font-family:'TimesNewRomanPSMT';">&#8221;). Under ASC 718, when an award is reclassified from equity to liability, if at the reclassification date the original vesting conditions are expected to be satisfied, then the minimum amount of compensation cost to be recognized is based on the grant date fair value of the original award. Fair value changes below this minimum amount are recorded in additional paid-in capital. For each reporting period after the modification date, the stock option liability is adjusted so that it equals the portion of the requisite service provided multiplied by the modified award&#8217;s fair value at the end of the reporting period. Increases in the fair value of the liability in excess of the minimum grant date compensation cost described above are recognized as share-based compensation in operating expenses in the consolidated statement of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Share Issuance Costs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Common share issuance costs are incremental costs directly associated with an offering of securities. These costs typically include fees paid to bankers or underwriters, attorneys, accountants, as well as printers and other third parties. Prior to the effective date of an offering of equity securities, specific incremental costs directly attributable to a proposed or actual offering of securities may be deferred and charged against the gross proceeds of the offering. &#160;The Company capitalizes these deferred financing costs as prepaid expenses and other current assets in the accompanying consolidated balance sheets until the completion of the offering, unless the offering is abandoned, at which time the deferred financing costs will be recognized in the consolidated statements of operations. &#160;The Company had approximately $32,000 and $0 in deferred financing costs as of December 31, 2025 and December 31, 2024, respectively, which was recorded in prepaid expenses and other current assets on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company is a taxable entity under the Income Tax Act (Canada). Deferred income tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the respective income tax bases of assets and liabilities, measured using substantively enacted income tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are recognized to the extent it is more likely than not that taxable income will be available against which the deferred tax asset can be utilized. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company follows the provisions of ASC 740-10, <i style="font-style:italic;">Uncertainty in Income Taxes</i> (&#8220;<b style="font-weight:bold;">ASC 740-10</b>&#8221;). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Basic and Diluted Net (Loss) Income Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Basic net (loss) income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net (loss) income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">dilutive shares result from the assumed potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. The proceeds of such exercises or conversions are assumed to have been used to repurchase outstanding stock using the treasury stock method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Both basic and diluted net (loss) income per share calculations include financial instruments that allow for the purchase of common shares issuable for little to no consideration, including pre-funded warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company is an Emerging Growth Company, as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (&#8220;<b style="font-weight:bold;">JOBS&#160;Act</b>&#8221;). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740):</i> <i style="font-style:italic;">Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 became effective for the annual period starting on January 1, 2025. The Company&#8217;s income tax disclosures are disclosed in Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires public entities, among other items, to disclose in a tabular format, on an annual and interim basis, purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion for each income statement line item that contains those expenses. ASU 2024-03 becomes effective for the annual period starting on January 1, 2027 and interim periods starting on January 1, 2028. The Company is in the process of analyzing the impact that the adoption of ASU 2024-03 will have on its disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span>FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following are the major categories of assets measured at fair value on a recurring basis as of December&#160;31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Aptos Narrow';font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b><b style="font-weight:bold;">Level&#160;3</b><b style="font-family:'Aptos Narrow';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 199,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 199,263</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,592</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 204,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 204,855</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">No transfers between levels have occurred in either reporting period presented. Refer to Note 6 for disclosures related to the warrant liability and Note 8 for disclosures related to share-based compensation liability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span>PREPAID EXPENSES AND OTHER CURRENT ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Prepaid expenses and other current assets consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Upfront research payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,625,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,087,692</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 36,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78,034</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 238,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 335,976</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 62,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,255</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 47,281</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,032,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,587,238</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on prepaid expense and other assets current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_AccruedLiabilitiesTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span>ACCRUED LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Accrued liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Legal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44,610</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 159,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,182</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,460,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223,559</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 79,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,328</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 79,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 79,283</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,868,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 480,962</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_AccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_AccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">EQUITY </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has authorized an unlimited number of both Common and Preferred shares. As of December&#160;31, 2025 and 2024, the Company had 2,152,397 and 1,307,520 issued and outstanding Common Shares, respectively. All share classes have no par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Common Shares reserved for future issuance consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,639,005</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 180,827</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred Share Units granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Shares available for grant under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 80,686</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Common Shares reserved for future issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,900,561</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preferences, privileges, and rights of the Common Shares are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Voting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Subject to any special voting rights or restrictions, holders of common shares entitled to vote shall have one vote per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s board of directors may from time to time declare and authorize payment of dividends, if any, as they may deem advisable and need not give notice of such declaration to any shareholder. Subject to the rights of common shareholders, if any, holding shares with specific rights as to dividends, all dividends on common shares shall be declared and paid according to the number of such shares held and paid in Canadian dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Liquidation Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In the event of the liquidation, dissolution or winding-up of the Company or any other distribution of the Company&#8217;s assets for the purpose of winding up the Company&#8217;s affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled <i style="font-style:italic;">pari passu</i> to receive any remaining property of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 2024 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On July 26, 2024, the Company entered into a Unit Purchase Agreement (the &#8220;<b style="font-weight:bold;">Unit Purchase Agreement</b>&#8221;) to raise $30,332,984 in aggregate gross proceeds for the Company (the &#8220;<b style="font-weight:bold;">July 2024 PIPE</b>&#8221;) before deducting $2,675,487 in placement agent fees and other expenses. All gross proceeds were received by the Company as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Pursuant to the terms of the Unit Purchase Agreement, the Company agreed to sell to PIPE Investors in the Offering, an aggregate of (x) 390,307 common share units (the &#8220;<b style="font-weight:bold;">Common Share Units</b>&#8221;), each consisting of (i) one Common Share, (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share (each, a &#8220;<b style="font-weight:bold;">Warrant</b>&#8221;, collectively, the &#8220;<b style="font-weight:bold;">Warrants</b>&#8221;) and, for certain investors, (y) 174,841 pre-funded units (the &#8220;<b style="font-weight:bold;">Pre-Funded Units</b>&#8221; and together with the Common Share Units, the &#8220;<b style="font-weight:bold;">Units</b>&#8221;), each consisting of (i) one Pre-Funded Warrant to purchase one Common Share (each, a &#8220;<b style="font-weight:bold;">Pre-Funded Warrant</b>&#8221;, collectively, the &#8220;<b style="font-weight:bold;">Pre-Funded Warrants</b>&#8221;, and the Common Shares issuable upon exercise of the Warrants and the Pre-Funded Warrants, the &#8220;<b style="font-weight:bold;">2024 Warrant Shares</b>&#8221;), (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The purchase price for each Common Share Unit was $53.75 per Common Share Unit, and the purchase price for each Pre-Funded Unit was $53.50 per Pre-Funded Unit. The Pre-Funded Warrants have an exercise price of $0.25 per 2024 Warrant Share, are immediately exercisable and will expire when exercised in full. The Tranche A Common Share purchase warrants have an exercise price of $50.50, for aggregate gross proceeds of up to $28.5 million, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) 18 months or (ii) within 60 days of the Tranche A Milestone Event (as defined below). The Tranche B Common Share purchase warrants have an exercise price of $50.50, for aggregate gross proceeds of up to $28.5 million, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) 30 months or (ii) within 60 days of the Tranche B Milestone Event (as defined below). The Tranche C Common Share purchase warrants have an exercise price of $62.50, for aggregate gross proceeds of up to $35.3 million, are immediately exercisable and will expire on July 31, 2029. For purposes of the foregoing, &#8220;<b style="font-weight:bold;">Tranche A Milestone Event</b>&#8221; means the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with multiple ascending doses of PMN310, and &#8220;<b style="font-weight:bold;">Tranche B Milestone Event</b>&#8221; means the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with multiple ascending doses of PMN310. Pursuant to Nasdaq Listing Rule 5635(d), the exercise of the Tranche A and Tranche B Common Share purchase warrants is subject to shareholder approval (&#8220;<b style="font-weight:bold;">Shareholder Approval</b>&#8221;). The Company agreed to convene a shareholders&#8217; meeting, or otherwise obtain written Shareholder Approval, on or before 90 days following the Closing Date, to obtain such approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Tranche A and Tranche B Warrants (&#8220;<b style="font-weight:bold;">AB Warrants</b>&#8221;) were classified as liabilities (&#8220;<b style="font-weight:bold;">AB Warrant Liability</b>&#8221;) and recorded at fair value utilizing level 3 inputs at issuance due to the requirement for Shareholder Approval. Under the applicable accounting guidance, the requirement for Shareholder Approval precludes a financial instrument from equity classification, as it cannot be considered indexed to the Company's own stock. &#160;The preclusion is because of the potential of the settlement amount differing than a fixed for fixed option on the Company's shares. The fair value of the AB Warrant Liability at issuance was determined to be $31,182,033, calculated using a Black Scholes calculation on July 26, 2024 with the following weighted average assumptions: share price of $50.50, the most currently available Nasdaq Official Closing Price for the Company&#8217;s Common Shares when the Company entered into the purchase agreements, exercise price of $50.50, volatility of 102.5%, risk-free rate of 4.34%, and a term of 2.1 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company incurred offering costs totaling $2,675,487 that consisted of placement agent fees and direct incremental legal, advisory, accounting and filing fees relating to the July 2024 PIPE, resulting in net cash proceeds of $27,657,497. The value of the AB Warrants exceeded the net proceeds received. As a result, the entire proceeds and offering costs were allocated to the AB Warrant liability, and also resulted in a loss on issuance of common shares, warrants, and pre-funded warrants of $3,524,535, which was recorded in other income (expense) in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">On October 23, 2024, Shareholder Approval for the AB Warrants was obtained during the Company&#8217;s Special Meeting of Shareholders. Following Shareholder Approval, the Company determined that the AB Warrants met the criteria for equity classification. The Company re-measured the fair value of the AB Warrant Liability at October 23, 2024 to $8,689,149, calculated using a Black Scholes calculation with the following weighted average assumptions: volatility of 100.9%, share price of $23.75, exercise price of $50.50, risk-free rate of 4.10%, and a term of 1.9 years. The change in fair value of the AB Warrant Liability of $22,492,884 was recorded in other income (expense) in the consolidated statements of operations and the remaining fair value of $8,689,149 was reclassified from liability to additional paid-in-capital in the consolidated balance sheets. As of December 31, 2025, 942,510 warrants issued with the <span style="-sec-ix-hidden:Hidden_YqiLGZ_RnUeciaPL5_1Scw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">July 2024</span></span> PIPE are <span style="-sec-ix-hidden:Hidden_zqmpoD10K0mYm-cj5Mnc8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> (314,170 each from Tranche A, Tranche B, and Tranche C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">A summary of warrant liability activity, which is based on level 3 inputs, for the years ended December 31, 2025 and 2024 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,592</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TkWIfmwCtk2L1o77RyTsVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of C$ warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,592)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 94,185</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 2024 PIPE AB Warrant Liability at issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,182,033</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_K9LLXyDMFk2irW-0jw4rvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of 2024 PIPE AB Warrant Liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,492,884)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reclassification of 2024 PIPE AB Warrant Liability to equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,689,149)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NKYPClXPwkOL6W5cM2Ychw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of C$ warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,593)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,592</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 2025 Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;">On July 22, 2025, the Company entered into a securities purchase agreement relating to the issuance and sale of a pre-funded warrant to purchase </span><span style="color:#191c1f;">39,389</span><span style="color:#191c1f;"> Common Shares (the &#8220;</span><b style="color:#191c1f;font-weight:bold;">RD Pre-funded Warrant</b><span style="color:#191c1f;">&#8221;) to such investor (the &#8220;</span><b style="color:#191c1f;font-weight:bold;">RD Offering</b><span style="color:#191c1f;">&#8221;). The RD Pre-funded Warrant was sold at an offering price of </span><span style="color:#191c1f;">$20.31</span><span style="color:#191c1f;"> per share, which represents, if it were applicable, the per share offering price for the Common Shares of the Company, less a </span><span style="color:#191c1f;">$0.0025</span><span style="color:#191c1f;"> per share exercise price for such Pre-funded Warrant. &#160;The gross proceeds from the RD Offering were </span><span style="color:#191c1f;">$800,000</span><span style="color:#191c1f;"> before deducting offering expenses of </span><span style="color:#191c1f;">$102,342</span><span style="color:#191c1f;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 22, 2025</span><span style="color:#191c1f;text-decoration-color:#191c1f;text-decoration-line:underline;text-decoration-style:solid;"> Exercise of Discounted Warrants and PIPE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">On July 22, 2025, the Company accepted a discounted warrant exercise offer from a healthcare-focused institutional investor for certain July 2024 PIPE warrants (&#8220;<b style="font-weight:bold;">July 22, 2025 Discounted Exercise</b>&#8221;). Related to the July 22, 2025 Discounted Exercise, the Company also entered into a securities purchase agreement (the &#8220;<b style="font-weight:bold;">July 22, 2025 PIPE</b>&#8221;) with the same existing healthcare-focused institutional investor. The Company raised $9,199,765 in aggregate gross proceeds from the July 22, 2025 Discounted Exercise and July 22, 2025 PIPE before deducting $808,738 in transaction costs paid by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In the July 22, 2025 Discounted Exercise, the Company <span style="-sec-ix-hidden:Hidden_sIX-I_ihFUyckByqXSCcEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> 336,449 Common Shares in exchange for the exercise of 336,449 of the <span style="-sec-ix-hidden:Hidden_rAT-TO71IkG83cETElUNVQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">July 2024</span></span> PIPE warrants (112,150 each from Tranche A, Tranche B, and Tranche C) for $20.31 per warrant. The Company determined that discounting the exercise price represented a modification of the July 2024 PIPE warrants. In accordance with <i style="font-style:italic;">ASC815 &#8211;</i> <i style="font-style:italic;">Derivatives and Hedging </i>(&#8220;<b style="font-weight:bold;">ASC 815</b>&#8221;), the Company accounted for the incremental fair value of the modification as the difference between the pre-modification fair value and the post-modification fair value of the July 2024 PIPE warrants, as calculated using Black-Scholes. The modification date incremental fair value of $930,841 was initially recorded as a deferred financing cost, as the discount was directly attributable to a proposed offering, and was subsequently recognized as an equity issuance cost upon the closing of the July 22, 2025 Discounted Exercise and July 22, 2025 PIPE. The range of valuation inputs used in the pre-modification fair value Black Scholes calculation of the July 2024 PIPE warrants included a share price of $14.70, exercise prices of $50.50-$62.50, time to maturity of 0.53-4.02 years, risk free rate of 3.9%-4.3%, and annualized volatility of 106.5%. The post-modification fair value Black Scholes calculation used the same <span style="-sec-ix-hidden:Hidden_vE8nknvrREuwISKkbV-t1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair</span></span> value inputs <span style="-sec-ix-hidden:Hidden_sDMpaTJpt02AivVLsCelvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as</span></span> <span style="-sec-ix-hidden:Hidden_UiLMq0ECGUuuIc3ZT61PGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span></span> <span style="-sec-ix-hidden:Hidden_bE979HFoxkSnleUqfJBh_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pre</span></span>-<span style="-sec-ix-hidden:Hidden_qaJfvU25ukC0j9SFajVEUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modification</span></span> <span style="-sec-ix-hidden:Hidden_z2jv6MWYFkOFbHtRCJPIPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value</span></span> calculation apart from the modified exercise price of $20.31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Pursuant to the terms of the July 22, 2025 PIPE, the Company agreed to sell a warrant to purchase 504,673 Common Shares (the &#8220;<b style="font-weight:bold;">July 22, 2025 Warrant</b>&#8221;). The July 22, 2025 Warrant was sold to the investor at an offering price of $4.69 per share and has an exercise price of $31.25 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The July 22, 2025 Warrant is immediately exercisable and will expire five years after the date of issuance. The holder of the July 22, 2025 Warrant may not exercise it if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of Common Shares outstanding immediately after giving effect to such exercise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company determined the July 22, 2025 Warrant met the permanent equity criteria classification. The July 22, 2025 Warrant is classified as a component of permanent equity because it is a freestanding financial instrument, is immediately exercisable, does not embody an obligation for the Company to repurchase its shares, and permits the holders to receive a fixed number of common shares upon exercise. In addition, the July 22, 2025 Warrant does not provide any guarantee of value or return. The Company used a Black-Scholes calculation to determine the fair value of the July 22, 2025 Warrant at issuance and allocated a share of the net proceeds based on the relative fair value of the July 22, 2025 Warrant. Net proceeds allocated to the July 22, 2025 Warrant were $4,284,557, with the remaining net proceeds of $4,106,470 allocated to the Common Shares issued in the July 22, 2025 Discounted Exercise. The aggregate net proceeds of $8,391,027 are recorded in additional paid-in-capital. The valuation inputs used in the Black Scholes calculation of the July 22, 2025 Warrant at issuance included a share price of $14.70, exercise price of $31.25, time to maturity of 5 years, risk free rate of 3.9%, and annualized volatility of 106.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 28, 2025</span><span style="color:#191c1f;text-decoration-color:#191c1f;text-decoration-line:underline;text-decoration-style:solid;"> Exercise of Discounted Warrants and PIPE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">On July 28, 2025, the Company accepted discounted warrant exercise offers for certain July 2024 PIPE warrants (&#8220;<b style="font-weight:bold;">July 28, 2025 Discounted Exercise</b>&#8221;). Related to the July 28, 2025 Discounted Exercise, the Company also entered into a securities purchase agreement (the &#8220;<b style="font-weight:bold;">July 28, 2025 PIPE</b>&#8221;) with the same existing investors. The Company raised $11,623,047 in aggregate gross proceeds from the July 28, 2025 Discounted Exercise and July 28, 2025 PIPE before deducting $478,580 in transaction costs paid by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In the July 28, 2025 Discounted Exercise, the Company <span style="-sec-ix-hidden:Hidden_2uiJ2Xl62UWXxUyC2yNBhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> 416,436 Common Shares in exchange for the exercise of 416,436 of the <span style="-sec-ix-hidden:Hidden_u1jGCHE0JUyEOMipzgeTYA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">July 2024</span></span> PIPE warrants (138,812 each from Tranche A, Tranche B, and Tranche C) for $20.88 per warrant. The Company determined that discounting the exercise price represented a modification of the July 2024 PIPE warrants. In accordance with ASC 815, the Company accounted for the incremental fair value of the modification as the difference between the pre-modification fair value and the post-modification fair value of the July 2024 PIPE warrants, as calculated using Black-Scholes. The modification date incremental fair value of $1,794,146 was initially recorded as a deferred financing cost, as the discount was directly attributable to a proposed offering, and was subsequently recognized as an equity issuance cost upon the closing of the July 28, 2025 Discounted Exercise and July 28, 2025 PIPE.<b style="font-weight:bold;"> </b>The range of valuation inputs used in the pre-modification fair value Black Scholes calculation of the July 2024 PIPE warrants included a share price of $20.88, exercise prices of $50.50-$62.50, time to maturity of 0.52-4.01 years, risk free rate of 3.9%-4.3%, and annualized volatility of 107.4%. The post-modification fair value Black Scholes calculation used the same <span style="-sec-ix-hidden:Hidden_88CXrfs02k61Q4fWLfzeFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair</span></span> <span style="-sec-ix-hidden:Hidden_XdTVGA3HiEy71yJOaEE4tg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">value</span></span> <span style="-sec-ix-hidden:Hidden_Dh34ZOTg80WsRg6qGMRmNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inputs</span></span> as the pre-<span style="-sec-ix-hidden:Hidden_p37SpWW4dk6Jm7sLGseshg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modification</span></span> <span style="-sec-ix-hidden:Hidden_fQaxwlZiKkGwEDVd1NMCVQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value</span></span> <span style="-sec-ix-hidden:Hidden_DM6veFeJkkWgBQ6DbhWYUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">calculation</span></span> apart from the modified exercise price of $20.88.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Pursuant to the terms of the July 28, 2025 PIPE, the Company agreed to sell warrants to purchase 624,654 Common Shares (the &#8220;<b style="font-weight:bold;">July 28, 2025 Warrants</b>&#8221;). The July 28, 2025 Warrants were sold to the investor at an offering price of $0.1875 per share and has an exercise price of $31.25 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The July 28, 2025 Warrant are immediately exercisable and will expire five years after the date of issuance. Certain holders of the July 28, 2025 Warrants may not exercise it if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of Common Shares outstanding immediately after giving effect to such exercise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company determined the July 28, 2025 Warrants met the permanent equity criteria classification. The July 28, 2025 Warrants are classified as a component of permanent equity because they are a freestanding financial instrument, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, the July 28, 2025 Warrants do not provide any guarantee of value or return. To determine the fair value of the July 28, 2025 Warrants at issuance, the Company used a Black-Scholes model and allocated a share of the net proceeds based on the relative fair value of the July 28, 2025 Warrants. Net proceeds allocated to the July 28, 2025 Warrants were $5,885,032, with the remaining net proceeds of $5,259,435 allocated to the Common Shares issued in the July 28, 2025 Discounted Exercise. The aggregate net proceeds of $11,144,467 are recorded in additional paid-in-capital. The valuation inputs used in the Black Scholes calculation of the July 28, 2025 Warrant at issuance included a share price of $20.88, exercise price of $31.25, time to maturity of 5 years, risk free rate of 4.0%, and annualized volatility of 107.4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">November 2025 Reverse Share Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">On November 28, 2025, the Company filed articles of amendment to effect a <span style="-sec-ix-hidden:Hidden_bzJ1h69P5Uu2r6edpFDPOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five reverse share split of its Common Shares (the &#8220;<b style="font-weight:bold;">Reverse Share Split</b>&#8221;). As a result of the Reverse Share Split, every <span style="-sec-ix-hidden:Hidden_uNKYSpxl1EOc5rSnKnyhFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span> Common Shares issued or outstanding were automatically reclassified into one validly issued, fully paid and non-assessable new Common Share, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportional adjustments were made to the number of Common Shares awarded and available for issuance under the Company&#8217;s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company&#8217;s outstanding stock options and other equity securities under the Company&#8217;s equity incentive plans. All outstanding warrants were also adjusted in accordance with their terms, which resulted, among other changes to the warrant terms, in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise prices of such warrants. The Common Shares outstanding following the Reverse Share Split remain fully paid and non-assessable. The Reverse Share Split did not affect the number of authorized Common Shares or the par value of the Common Shares. All share and per-share amounts have been retroactively adjusted to reflect the Reverse Share Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">At-the-Market Offerings (ATM)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In September 2023, the Company filed a shelf registration statement with the SEC. In conjunction with the shelf registration, the Company entered into an ATM agreement in January 2024 (the &#8220;<b style="font-weight:bold;">2024 ATM Agreement</b>&#8221;) to offer up to $25.0 million of the Company&#8217;s Common Shares. During the year ended December 31, 2024, the Company sold 3,034 Common Shares for net proceeds of $190,274 after deducting sales commissions. The 2024 ATM Agreement was terminated in July 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In August 2025, the Company filed a shelf registration statement with the SEC. In conjunction with the shelf registration, the Company entered into an <span style="color:#191c1f;">ATM Agreement with H.C. Wainwright &amp; Co., LLC (the &#8220;</span><b style="color:#191c1f;font-weight:bold;">2025 ATM Agreement</b><span style="color:#191c1f;">&#8221;) on August 26, 2025 to offer up to </span><span style="color:#191c1f;">$18.0</span><span style="color:#191c1f;"> million of its Common Shares. During the year ended December 31, 2025, the Company sold </span><span style="color:#191c1f;">40,795</span><span style="color:#191c1f;"> Common Shares for net proceeds of </span><span style="color:#191c1f;">$708,468</span><span style="color:#191c1f;"> after deducting sales commissions pursuant to the 2025 ATM Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_WarrantsAndRightsDisclosureTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span>WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, outstanding Common Share warrants and exercise prices related to unit offerings are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:50%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price $</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiry&#160;date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$50.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 314,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">January 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$315.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">August 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$240.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">August 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$50.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 314,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">January 2027</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$187.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">April 2028</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$152.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">April 2028</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$43.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 449,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">February 2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$62.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 314,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">July 2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$31.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,129,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">July 2030</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 74,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">None</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,639,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">During the year ended December 31, 2025, 51,197 pre-funded warrants, including 39,389 issued in the July 2025 RD Offering, were exercised for gross proceeds of $3,050. Refer to Note 6 for discussion on the discounted exercise of 336,449 July 2024 PIPE warrants on July 22, 2025, discounted exercise of 416,436 July 2024 PIPE warrants on July 28, 2025, issuance of 504,673 new warrants in the July 22, 2025 PIPE, and issuance of 624,654 new warrants in the July 28, 2025 PIPE. During the year ended December 31, 2025, 11,184 warrants expired without being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">During the year ended December 31, 2024, 16,319 warrants expired without being exercised, and 112,150 pre-funded warrants were exercised for an equivalent number of common shares for net proceeds of $28,038.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_WarrantsAndRightsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_WarrantsAndRightsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span>SHARE-BASED COMPENSATION </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">2025 Stock Option Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">At its June 2025 Annual Meeting of Shareholders, the Company&#8217;s 2025 Stock Option and Incentive Plan (<b style="font-weight:bold;">&#8220;2025 Option Plan&#8221;) </b>was approved by the shareholders. The 2025 Option Plan replaces the 2015 Stock Option Plan (<b style="font-weight:bold;">&#8220;2015 Option Plan&#8221;</b>), originally referred to as the 2007 Option Plan. No new awards can be issued under the 2015 Option Plan. &#160;The Company reserved 117,868 Common Shares for issuance under the 2025 Option Plan at the time of adoption. As of December 31, 2025 and 2024, the Company had 80,686 and 118,535 options available for grant under the 2025 Option Plan and 2015 Option Plan, respectively. The Common Shares underlying any awards under the 2025 Option Plan and 2015 Option Plan that are forfeited, canceled, or otherwise terminated (other than by exercise) are added back to the shares available for issuance under the 2025 Option Plan. Share options are granted in either USD or CAD. Upon the change in the Company&#8217;s functional currency, effective July 1, 2023, CAD share options previously classified as equity were reclassified as liabilities. All grants following the Company&#8217;s change in functional currency are in USD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Canadian Dollar Share Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following table summarizes the activity of the C$ share options under the 2015 Option Plan for the&#160;years ended December&#160;31, 2025 and 2024. All amounts are denominated in Canadian dollars, except&#160;year and share amounts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 189.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 229.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 32,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 184.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,346)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 209.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,704)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 54.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 170.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 170.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The aggregate intrinsic value of options outstanding, exercisable, and vested and exercisable is calculated as the difference between the exercise price of the underlying options, and the fair value of the Company&#8217;s Common Shares. There were no C$ share options granted during the years ended December 31, 2025 or 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Upon the change in the Company&#8217;s functional currency effective July 1, 2023 C$ share options previously classified as equity were reclassified as liabilities. The C$ options were re-measured as of December 31, 2024 and had a fair value of $199,263. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">A summary of share-based compensation liability activity, measured using level 3 fair value inputs, for the year ended December 31, 2025 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 199,263</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (170,081)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">A summary of share-based compensation liability activity for the year ended December 31, 2024 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 422,002</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (222,739)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 199,263</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following table summarizes the weighted average of significant assumptions used to calculate the fair value of C$ share options using the Black Scholes option pricing model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value of C$ Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 106.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 99.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Expected volatility is based on historical volatility of the Company&#8217;s Common Shares over the expected life of the option, as the Company&#8217;s options are not readily tradable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S. Dollar Share Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company began making share option grants denominated in US$ following the Company&#8217;s change in functional currency in July 2023. The following table summarizes the US$ share options outstanding under the 2015 Option Plan for the years ended December 31, 2025 and 2024. All amounts are denominated in US$, except&#160;year and share amounts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 107,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 110,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 165,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The grant date fair value of 55,400 and 107,478 US$ share options granted during the years ended December 31, 2025 and 2024, respectively, was estimated using Black Scholes with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:88.88%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value of US$ Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 107.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 101.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In October 2024, the Company granted its Chief Executive Officer 19,614 options with an exercise price of $28.75, which will begin vesting if and when the Company&#8217;s 10-day VWAP of its Common Shares trading on the Nasdaq Capital Market meets or exceeds $86.25. The Company determined the share price requirement to begin vesting represented a market condition and performed a Monte-Carlo simulation to determine the fair value of the award, discounted for the likelihood of achieving the market condition. The resulting fair value of the option award was $383,000, with $168,946 and $39,344 recognized during the years ended December 31, 2025 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">and 2024 in the accompanying consolidated statement of operations, with the remaining $174,710 expected to be recognized over approximately 1.4 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">DSU Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has a Deferred Share Unit plan (&#8220;<b style="font-weight:bold;">DSU Plan</b>&#8221;) for senior officers. Under the DSU Plan, rights to the Company&#8217;s Common Shares may be awarded on a deferred payment basis up to a maximum of 667 common share units. Each common share unit will fully vest upon cessation of employment with the Company and then can be redeemed for one common share of the Company by the unitholder. The Company has 42 units outstanding as of December&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">S<b style="font-weight:bold;">hare-based Payment Expense</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following table summarizes total share-based compensation for both the C$ and US$ share options included in the Company&#8217;s accompanying consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 49,405</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 819,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 776,403</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 857,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 825,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, there was $1,265,556 of unrecognized share-based compensation related to US$ options outstanding, which is expected to be recognized over a weighted-average remaining service period of 2.7&#160;years. There was no material liability yet to be recognized for C$ share-based compensation as of December 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span>INCOME TAXES </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025 and 2024, the net deferred tax assets have not been recognized in the accompanying consolidated financial statements. A valuation allowance is recognized to reduce the deferred tax asset as it is more likely than not that a tax benefit will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following are the significant components of the Company&#8217;s deferred taxes as of December&#160;31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,810,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,850,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,022,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,175,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,944,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,043,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax value of technology rights and property and equipment in excess of accounting basis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 160,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 193,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issue costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,066,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,275,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted interest and financing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 337,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 41,005,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,883,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41,005,721)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,883,000)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, the Company has available research and development expenditure credits for income tax purposes of approximately $11,407,000, which may be carried forward without expiration to reduce future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, the Company has non-capital income tax loss carry-forwards of approximately $131,360,190 available to reduce future income for income tax purposes. The income tax loss carry-forwards have expiry dates between the&#160;years 2026 and 2046.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As of December&#160;31, 2025, the Company has approximately $2,553,000 of non-refundable investment tax credits available to offset future income taxes. The non-refundable investment tax credits have expiry dates between 2025 and 2035. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">A reconciliation of the combined federal and provincial statutory income tax rate applied to the net (loss) income for the&#160;year to the income tax recovery as of December&#160;31 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount ($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent (%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Canadian federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,960,583)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provincial taxes (Ontario)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 127,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issue costs recorded, net of equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (372,011)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,027,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Return to provision adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 161,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ek1qQB57M0uiwz7O77M-zA;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Effective Tax Rate</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company does not expect a significant change in the amount of unrecognized tax benefits over the next 12&#160;months. However, any adjustments arising from certain ongoing examinations by tax authorities could alter the timing or amount of taxable income or deductions and these adjustments could differ from the amount accrued. The Company&#8217;s federal and provincial income tax returns files for all&#160;years remain subject to examination by the taxation authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span>Segment Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: life science. The life science segment consists of the development of clinical and preclinical product candidates. The Company&#8217;s chief operating decision maker (&#8220;<b style="font-weight:bold;">CODM</b>&#8221;) is the chief executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the life science segment based on net (loss) income, which is reported on the income statement as consolidated net loss (income). The measure of segment assets is reported on the balance sheet as total consolidated assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As such, the CODM uses cash forecast models in deciding how to invest into the life science segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss (income) is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management&#8217;s compensation, along with cash forecast models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025, and 2024: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:45pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:89.6%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">PMN310 development program costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,226,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,275,268</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other non-employee research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 885,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 772,501</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Employee costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,051,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,336,580</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other general and administrative costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,004,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,443,129</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Operating Loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,167,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,827,478</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (448,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,606,351)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss (Income):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,719,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,778,873)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reconciliation of Profit or Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated Net Loss (Income):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,719,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,778,873)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup>Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span>RELATED PARTY TRANSACTIONS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">UBC Collaborative Research Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">In April&#160;2016, the Company entered into a collaborative research agreement (&#8220;<b style="font-weight:bold;">CRA</b>&#8221;) with the University of British Columbia (&#8220;<b style="font-weight:bold;">UBC</b>&#8221;) and the Vancouver Coastal Health Authority in the amount of C$787,500, with the Company&#8217;s Chief Scientific Officer, as principal investigator at the UBC. In January 2022, the UBC CRA was amended to extend the project for an additional three years, and in December 2024, for an additional 1 year. Aggregate funding under the agreement was increased to a total of C$5,830,000 through February 2026. During the&#160;years ended December&#160;31, 2025 and 2024, the Company made cash payments of $428,860 and $587,000, respectively, and incurred costs of $573,187 and $584,226, respectively, which are included in research and development expenses in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Neil Warma Employment Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In October 2024, in connection with Mr. Neil Warma&#8217;s appointment to the role of CEO, he entered into an employment agreement with the Company (the &#8220;<b style="font-weight:bold;">CEO Employment Agreement</b>&#8221;) providing for an annual base salary of $500,000 and annual discretionary bonus with a target of 50% of his base salary. Mr. Warma was also provided (i) severance in the amount of 12-months&#8217; salary, a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a termination without cause and (ii) severance in the amount of the sum of 18-months&#8217; salary and a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a change in control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In connection with his appointment, Mr. Warma was also granted (i) an option to purchase 45,765 of the Company&#8217;s common shares (the &#8220;<b style="font-weight:bold;">Initial Award</b>&#8221;) and (ii) an option to purchase 19,614 of the Company&#8217;s common shares (the &#8220;<b style="font-weight:bold;">Performance Award</b>&#8221;). Per the Company&#8217;s 2015 Stock Option Plan, the exercise price of each of the Initial Award and the Performance Award is $28.75 <span style="-sec-ix-hidden:Hidden_VGlBM7hgKUyWd-Dp-bhCdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per</span></span> share, the 5-day volume-weighted average price (&#8220;<b style="font-weight:bold;">VWAP</b>&#8221;) as of October 8, 2024. The Initial Award is 25% vested upon grant with the remaining shares vesting ratably over thirty-six months. &#160;The Performance Award shall vest 25% on the date that the 10-day VWAP of the Company&#8217;s common shares on the Nasdaq Capital Market exceeds three times the exercise price, with the remainder vesting ratably over the following thirty-six months. &#160;Refer to Note 8, Share-Based Compensation, for further discussion on the Performance Award.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></span>COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Research, Development and License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company enters into research, development and license agreements with various parties in the ordinary course of business where the Company receives research services and rights to proprietary technologies. The agreements require compensation to be paid by the Company, typically, by a combination of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fees comprising amounts due initially on entering into the agreements and additional amounts due either on specified timelines or defined services to be provided;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">milestone payments that are dependent on products developed under the agreements proceeding toward specified plans of clinical trials and commercial development; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">royalty payments calculated as a&#160;percentage of net sales, commencing on commercial sale of any product candidates developed from the technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Milestone and royalty related amounts that may come due under various agreements are dependent on, among other factors, preclinical safety and efficacy, clinical trials, regulatory approvals and, ultimately, the successful development and commercial launch of a new drug, the outcomes and timings of which are uncertain. Amounts due per the various agreements for milestone payments will accrue once the occurrence of a milestone is likely. Amounts due as royalty payments will accrue as commercial revenues from the product are earned. Through December&#160;31, 2025, no events have occurred that require accrual of any milestone or royalty related amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">UBC and the Vancouver Coastal Health Authority Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In April&#160;2016, the Company entered into a three-year, CRA with the UBC and the Vancouver Coastal Health Authority. The agreement was amended various times through November&#160;2021. Refer to Note&#160;11 Related Party Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">UBC Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In February&#160;2009, the Company entered into an agreement with UBC to further the development and commercialization of certain technology developed, in part, by the Company&#8217;s Chief Scientific Officer. The agreement was amended and restated in October&#160;2015. Under the amended and restated agreement, the Company is committed to make royalty payments based on revenue earned from the licensed technology. An annual license fee is payable over the term of the agreement. The agreement remains effective unless terminated under the provisions of the agreement. The Company made annual license payments of C$25,000 during each of the years ended December 31, 2025 and 2024. Through December&#160;31, 2025 no accruals for royalty payments have been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Indemnification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 36pt;">against liabilities that may arise by reason of their status or service as directors or officers. The Company currently has directors&#8217; and officers&#8217; insurance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">NET LOSS PER SHARE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common shareholders by the weighted average shares outstanding during the period, without consideration for common share equivalents. Diluted net earnings per share applicable to common shareholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common share equivalents outstanding for the period, determined using the treasury-stock method and the if-converted method. For purposes of the calculation of dilutive net (loss) income per share applicable to common shareholders, stock options, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share applicable to common shareholders when their effect would be anti-dilutive or would not add additional Common Shares to the denominator of the calculation due to being out-of-the-money.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">As of December 31, 2025 and 2024, respectively, 74,673 and 86,481 Pre-Funded Warrants to purchase common shares for little to no consideration, issued in connection with the August 2023 Private Placement and July 2024 Private Placement (see Note 6), were included in the basic and diluted net (loss) income per share calculation. The following table sets forth the computation of basic and diluted net loss (income) per share attributable to common shareholders:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,719,147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,778,873</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,756,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,036,799</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Effect of potentially dilutive securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">          Warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,882</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">          Stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 789</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Diluted weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,756,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,058,469</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income per share attributable to common shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.68</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share attributable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.63</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been antidilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options issued and outstanding under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 180,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 142,978</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,564,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,199,175</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,745,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,342,195</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></span>SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;">On January 29, 2026, the Company completed a private placement &#160;for aggregate gross proceeds of &#160;</span><span style="color:#191c1f;">$75.5</span><span style="color:#191c1f;"> million to sell an aggregate of (i) </span><span style="color:#191c1f;">6,815,296</span><span style="color:#191c1f;"> Common Shares, (ii) Common Share purchase warrants (&#8220;</span><b style="color:#191c1f;font-weight:bold;">Common Share </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><b style="color:#191c1f;font-weight:bold;">Warrants</b><span style="color:#191c1f;">&#8221;) to purchase </span><span style="color:#191c1f;">6,915,296</span><span style="color:#191c1f;"> Common Shares, (iii) Pre-Funded Warrants (&#8220;</span><b style="color:#191c1f;font-weight:bold;">Pre-Funded Warrants</b><span style="color:#191c1f;">&#8221;) to purchase </span><span style="color:#191c1f;">100,000</span><span style="color:#191c1f;"> Common Shares (collectively the &#8220;</span><b style="color:#191c1f;font-weight:bold;">January 2026 PIPE</b><span style="color:#191c1f;">&#8221;). </span><span style="color:#191c1f;">6,090,075</span><span style="color:#191c1f;"> Common Shares and </span><span style="color:#191c1f;">6,090,075</span><span style="color:#191c1f;"> Common Share Warrants were sold at a price of </span><span style="color:#191c1f;">$10.77</span><span style="color:#191c1f;"> for one Common Share and </span><span style="-sec-ix-hidden:Hidden_g2-t6Gg1-USHvtLxsXmEHw;"><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="color:#191c1f;"> Common Share Warrant. </span><span style="color:#191c1f;">100,000</span><span style="color:#191c1f;"> Pre-Funded Warrants and </span><span style="color:#191c1f;">100,000</span><span style="color:#191c1f;"> Common Share Warrants were sold at a price of </span><span style="color:#191c1f;">$10.77</span><span style="color:#191c1f;"> for one Pre-Funded Warrant and </span><span style="-sec-ix-hidden:Hidden_z_3eEpwo3UirEsenSR7Cow;"><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="color:#191c1f;"> Common Share Warrant, less an exercise price of </span><span style="color:#191c1f;">$0.0001</span><span style="color:#191c1f;"> per Pre-Funded Warrant. </span><span style="color:#191c1f;">725,221</span><span style="color:#191c1f;"> Common Shares and </span><span style="color:#191c1f;">725,221</span><span style="color:#191c1f;"> Common Share Warrants were sold to certain of our directors and management at a price of </span><span style="color:#191c1f;">$12.13</span><span style="color:#191c1f;"> for one Common Share and </span><span style="-sec-ix-hidden:Hidden_bKWVPXSjm0mG5YAXBCSUsw;"><span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="color:#191c1f;"> Common Share Warrant. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="color:#191c1f;">The Common Share Warrants have an exercise price of </span><span style="color:#191c1f;">$14.40</span><span style="color:#191c1f;">, are exercisable immediately and will expire upon the earlier of (i) within </span><span style="color:#191c1f;">60 days</span><span style="color:#191c1f;"> of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants have an exercise price of </span><span style="color:#191c1f;">$0.0001</span><span style="color:#191c1f;"> per Pre-Funded Warrant, are immediately exercisable and will expire when exercised in full. For purposes of the foregoing, the &#8220;Milestone Event&#8221; means the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with multiple ascending doses of PMN310. Fees and other expenses are currently not estimable by the Company, as they are still being determined.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (39,719,147)<span></span>
</td>
<td class="nump">$ 2,778,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_Rule10b51ArrModifiedFlag', window );">Rule 10b5-1 Arr Modified Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NonRule10b51ArrModifiedFlag', window );">Non Rule 10b5-1 Arr Modified Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NonRule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10b5-1 Arr Modified Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NonRule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_Rule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b5-1 Arr Modified Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_Rule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk Management and Strategy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognize the importance of assessing, identifying, and managing risks to the security, confidentiality, integrity, and availability of our business systems and confidential information, including personal information and intellectual property. We have developed a cybersecurity risk management program in accordance with our risk profile and business. Leveraging the support of a third-party information technology provider, our cybersecurity risk management program includes cybersecurity awareness training for employees and periodic systems monitoring and vulnerability scanning.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not identified cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However, like other companies in our industry, we and our third-party vendors may from time to time experience threats that could affect our information or systems. For more information, please see the section entitled &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We recognize the importance of assessing, identifying, and managing risks to the security, confidentiality, integrity, and availability of our business systems and confidential information, including personal information and intellectual property. We have developed a cybersecurity risk management program in accordance with our risk profile and business. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee. Our Vice President, Finance, with input of other members of Company management and the Company&#8217;s information technology provider, periodically makes presentations to the Audit Committee on the Company&#8217;s enterprise risk management program, which may address cybersecurity risks and related cyber strategy, as applicable. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Audit Committee<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Vice President, Finance, with input of other members of Company management and the Company&#8217;s information technology provider, periodically makes presentations to the Audit Committee on the Company&#8217;s enterprise risk management program, which may address cybersecurity risks and related cyber strategy, as applicable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Governance Related to Cybersecurity Risks </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Vice President, Finance and Chief Executive Officer, with the assistance of the Company&#8217;s third-party information technology provider, are responsible for the strategic leadership and direction of the Company&#8217;s cybersecurity program.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Vice President, Finance and Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our Vice President, Finance, with input of other members of Company management and the Company&#8217;s information technology provider, periodically makes presentations to the Audit Committee on the Company&#8217;s enterprise risk management program, which may address cybersecurity risks and related cyber strategy, as applicable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;<b style="font-weight:bold;">GAAP</b>&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;<b style="font-weight:bold;">ASC</b>&#8221;) and as amended by Accounting Standards Updates (&#8220;<b style="font-weight:bold;">ASU</b>&#8221;) of the Financial Accounting Standards Board (&#8220;<b style="font-weight:bold;">FASB</b>&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of financial instruments. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (&#8220;<b style="font-weight:bold;">CODM</b>&#8221;), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company has one operating segment and its Chief Executive Officer serves as the CODM. Substantially all of the Company&#8217;s assets are located in Canada. Refer to additional Segment Information in Note 10.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign and Functional Currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Foreign and Functional Currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company determines its functional currency as the currency of the primary economic environment in which the Company operates. To determine the primary economic environment, the Company considers salient economic factors, including cash flow indicators, expense indicators and financing indicators. Functional currency is a matter of fact, not a policy election and the Company will only reevaluate its functional currency if there is a significant change in facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Prior to July 1, 2023, the Company&#8217;s functional currency was the Canadian dollar (&#8220;<b style="font-weight:bold;">C$</b>&#8221;). Translation gains and losses from the application of the United States dollar (&#8220;<b style="font-weight:bold;">US$</b>&#8221;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative foreign currency translation adjustment, which is reported as a component of stockholders&#8217; (deficit) equity as accumulated other comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Following the Company&#8217;s voluntary delisting from the Toronto Stock Exchange in July 2023, the Company determined there was a significant change in its facts and circumstances, and completed a reassessment of its functional currency. The Company determined that, as of July 1, 2023, the Company&#8217;s functional currency had changed from the C$ to the US$. The Company reassessment included analysis of various factors, including: the Company&#8217;s cash flows and expenses denominated primarily in US$, the primary market for the Company&#8217;s Common Shares trading in US$ and a majority ownership by U.S. shareholders from financings denominated in US$. The change in functional currency was accounted for prospectively from July 1, 2023 and consolidated financial statements prior to and including the period ended June 30, 2023 were not restated for the change in functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">For periods commencing July 1, 2023, monetary assets and liabilities denominated in foreign currencies are translated into US$ using exchange rates in effect at the end of the reporting period. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after July 1, 2023 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations within operating expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2025 and 2024, the Company did not have any material cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShortTermInvestmentsPolicyPolicyTextBlock', window );">Short-term Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Short-term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Short-term investments consist of guaranteed certificates of deposit with a maturity greater than 90&#160;days and up to one&#160;year at the time of purchase. Accordingly, all short-term investments are classified as current assets in the accompanying consolidated balance sheets. The short-term investment is being held as collateral for the Company&#8217;s credit cards.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees 100% of the original amount invested. As of December&#160;31, 2025, the Company has not experienced any losses on its cash or short-term investments as a result of credit risk.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">FASB ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures, </i>(<b style="font-weight:bold;">&#8220;ASC 820&#8221;</b>) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, as established by ASC 820, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; Observable inputs, such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; Inputs (other than Level 1 quoted prices) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s warrant liabilities were classified as Level 3 financial instruments for the&#160;year ended December&#160;31, 2024. The Company&#8217;s share-based compensation liability was classified as a Level 3 financial instrument for the&#160;years ended December&#160;31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The carrying amounts of prepaid and other current assets, short-term investments, accounts payable, and accrued expenses are generally considered to be representative of their fair value based on the short-term nature of these financial instruments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company historically evaluates its long-lived assets, which consist of property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not have any material long-lived assets as of December&#160;31, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Property and equipment, net are historically stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Laboratory and equipment are depreciated over <span style="-sec-ix-hidden:Hidden_NcV6rL8tMk-QI6TxetjyIg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to five&#160;years. Computer equipment is depreciated over <span style="-sec-ix-hidden:Hidden_xwYBGyVeBki9Pw78B3ou9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to three&#160;years. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accompanying consolidated balance sheets and any resulting gain or loss is included in loss from operations in the accompanying consolidated statements of operations. Expenditures for repairs and maintenance are expensed as incurred. The Company did not have any material property and equipment as of December 31, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Definite-lived intangible assets are historically stated at cost less accumulated amortization and any accumulated impairment losses. An intangible asset&#8217;s carrying amount is assessed for impairment whenever there is an indication that the asset may be impaired. The Company&#8217;s definite-lived intangible assets consist of acquired rights and patents. Intangible assets are amortized on a straight-line basis over the lesser of the life of the intangible asset or its estimated useful life, which is 15&#160;years. The Company did not have any material intangible assets as of December 31, 2025.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Collaboration Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company may enter into collaboration arrangements with pharmaceutical and biotechnology partners. The Company analyzes its collaboration arrangements to assess whether they are within the scope of FASB ASC 808, <i style="font-style:italic;">Collaborative Arrangements, </i>(<b style="font-weight:bold;">&#8220;ASC 808&#8221;</b>), to determine whether such arrangements involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. ASC 808 does not provide guidance on the recognition of consideration exchanged or accounting for the obligations that may arise between parties. The Company concluded that ASC Topic 730, <i style="font-style:italic;">Research and Development, </i>should be applied by analogy to payments between parties during the development activities of its collaboration arrangements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">General and administrative expenses consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development and protection of intellectual property, professional service fees, and other general overhead and facility costs, including rent, depreciation and amortization, which relate to the Company&#8217;s general and administrative functions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of the Company&#8217;s platform technology, as well as discovery program expenses. The Company expenses research and development costs as incurred. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, related benefits and share-based compensation expense, for employees engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CROs</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of acquiring, developing, and manufacturing clinical study materials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Costs associated with preclinical and clinical activities and regulatory operations.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock', window );">Prepaid and Accrued Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Prepaid and Accrued Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Substantial portions of the Company&#8217;s pre-clinical development, manufacturing and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors. These vendors generally bill&#160;monthly for services performed, or bill based upon milestone achievement. For preclinical and clinical studies, the Company accrues expenses based upon estimated work completed and the remaining contract milestones. At times, the Company is obligated to make upfront payments upon execution of research and development agreements. Upfront payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses until such goods are delivered or the related services are performed. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. The actual timing of performance or the level of effort may vary from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company is a taxable entity under the Income Tax Act (Canada). Deferred income tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the respective income tax bases of assets and liabilities, measured using substantively enacted income tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are recognized to the extent it is more likely than not that taxable income will be available against which the deferred tax asset can be utilized. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company follows the provisions of ASC 740-10, <i style="font-style:italic;">Uncertainty in Income Taxes</i> (&#8220;<b style="font-weight:bold;">ASC 740-10</b>&#8221;). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Basic and Diluted Net (Loss) Income Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Basic net (loss) income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net (loss) income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">dilutive shares result from the assumed potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. The proceeds of such exercises or conversions are assumed to have been used to repurchase outstanding stock using the treasury stock method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Both basic and diluted net (loss) income per share calculations include financial instruments that allow for the purchase of common shares issuable for little to no consideration, including pre-funded warrants.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company is an Emerging Growth Company, as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (&#8220;<b style="font-weight:bold;">JOBS&#160;Act</b>&#8221;). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to prepaid and accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShortTermInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShortTermInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of major categories of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,753</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Aptos Narrow';font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b><b style="font-weight:bold;">Level&#160;3</b><b style="font-family:'Aptos Narrow';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,051</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 199,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 199,263</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,592</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 204,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 204,855</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Upfront research payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,625,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,087,692</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 36,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78,034</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 238,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 335,976</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 62,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,255</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 47,281</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,032,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,587,238</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Legal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44,610</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 159,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,182</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,460,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223,559</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 79,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,328</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 79,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 79,283</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,868,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 480,962</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Summary of common shares reserved for future issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,639,005</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 180,827</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred Share Units granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Shares available for grant under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 80,686</p></td></tr><tr style=""><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Common Shares reserved for future issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,900,561</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of fair value of the liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,592</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TkWIfmwCtk2L1o77RyTsVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of C$ warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,592)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 94,185</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 2024 PIPE AB Warrant Liability at issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,182,033</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_K9LLXyDMFk2irW-0jw4rvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of 2024 PIPE AB Warrant Liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,492,884)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reclassification of 2024 PIPE AB Warrant Liability to equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,689,149)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NKYPClXPwkOL6W5cM2Ychw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of C$ warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88,593)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,592</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ScheduleOfWarrantExercisePriceTableTextBlock', window );">Schedule of warrant exercise price</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:50%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price $</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiry&#160;date</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$50.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 314,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">January 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$315.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">August 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$240.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">August 2026</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$50.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 314,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">January 2027</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$187.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">April 2028</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$152.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">April 2028</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$43.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 449,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">February 2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$62.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 314,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">July 2029</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$31.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,129,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">July 2030</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">US$0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 74,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">None</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,639,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ScheduleOfWarrantExercisePriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular Disclosure of warrant exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ScheduleOfWarrantExercisePriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the activity of share options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 189.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 229.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 32,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 184.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,346)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 209.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,704)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 54.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 170.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 170.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 107,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 110,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 165,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock', window );">Summary of share-based compensation liability activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 199,263</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (170,081)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,182</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 422,002</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (222,739)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 199,263</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of fair value of share options granted estimated using Black Scholes with the assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value of C$ Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 106.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 99.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:88.88%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value of US$ Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 107.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 101.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of total share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 49,405</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 819,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 776,403</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 857,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 825,808</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of deferred compensation share based arrangement liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the deferred taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,810,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,850,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,022,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,175,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,944,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,043,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax value of technology rights and property and equipment in excess of accounting basis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 160,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 193,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issue costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,066,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,275,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted interest and financing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 337,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 41,005,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,883,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41,005,721)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,883,000)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of significant expense categories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:45pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:89.6%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">PMN310 development program costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,226,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,275,268</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other non-employee research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 885,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 772,501</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Employee costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,051,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,336,580</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other general and administrative costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,004,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,443,129</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Operating Loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,167,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,827,478</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (448,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,606,351)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss (Income):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,719,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,778,873)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reconciliation of Profit or Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated Net Loss (Income):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,719,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,778,873)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup>Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of computation of basic and diluted net loss per share attributable to common shareholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,719,147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,778,873</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,756,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,036,799</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Effect of potentially dilutive securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">          Warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,882</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">          Stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 789</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Diluted weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,756,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,058,469</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income per share attributable to common shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.68</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share attributable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.63</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options issued and outstanding under stock option plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 180,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 142,978</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,564,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,199,175</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,745,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,342,195</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40,167,308)<span></span>
</td>
<td class="num">$ (16,827,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,406,220)<span></span>
</td>
<td class="num">(90,687,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Negative cash flows from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,118,579<span></span>
</td>
<td class="nump">$ 27,182,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from the sale of Common Shares, Common Share warrants, and pre-funded warrants</a></td>
<td class="nump">$ 75,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 28, 2025</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse share split ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Depreciation term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Depreciation term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Depreciation term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Depreciation term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PercentageOfOriginalAmountInvested', window );">Original amount invested percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred financing costs</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest expense or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_PercentageOfOriginalAmountInvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of original amount invested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_PercentageOfOriginalAmountInvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 33,753<span></span>
</td>
<td class="nump">33,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">33,753<span></span>
</td>
<td class="nump">33,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Share-based compensation liability</a></td>
<td class="nump">29,182<span></span>
</td>
<td class="nump">199,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">29,182<span></span>
</td>
<td class="nump">204,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">33,753<span></span>
</td>
<td class="nump">33,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">33,753<span></span>
</td>
<td class="nump">33,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Share-based compensation liability</a></td>
<td class="nump">29,182<span></span>
</td>
<td class="nump">199,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">$ 29,182<span></span>
</td>
<td class="nump">$ 204,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount', window );">Transfer of assets (liabilities) in and out of level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount', window );">Transfer of assets (liabilities) in and out of level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfer of assets in and out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Transfer of liabilities in and out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis in and out of Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis in and out of Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PrepaidUpfrontResearchPaymentsCurrent', window );">Upfront research payments</a></td>
<td class="nump">$ 2,625,049<span></span>
</td>
<td class="nump">$ 5,087,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest and other receivables</a></td>
<td class="nump">36,522<span></span>
</td>
<td class="nump">78,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">238,000<span></span>
</td>
<td class="nump">335,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PrepaidLicenseFeeCurrent', window );">License fees</a></td>
<td class="nump">62,059<span></span>
</td>
<td class="nump">38,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredFinancingCostAssets', window );">Deferred financing costs</a></td>
<td class="nump">32,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Miscellaneous</a></td>
<td class="nump">38,150<span></span>
</td>
<td class="nump">47,281<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,032,112<span></span>
</td>
<td class="nump">$ 5,587,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DeferredFinancingCostAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost assets classified as financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DeferredFinancingCostAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_PrepaidLicenseFeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for license fee that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_PrepaidLicenseFeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_PrepaidUpfrontResearchPaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for upfront research payments that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_PrepaidUpfrontResearchPaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_AccruedLegalFeesCurrent', window );">Legal</a></td>
<td class="nump">$ 88,411<span></span>
</td>
<td class="nump">$ 44,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accounting</a></td>
<td class="nump">159,900<span></span>
</td>
<td class="nump">95,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">7,460,614<span></span>
</td>
<td class="nump">223,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Severance</a></td>
<td class="nump">79,748<span></span>
</td>
<td class="nump">38,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">79,743<span></span>
</td>
<td class="nump">79,283<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 7,868,416<span></span>
</td>
<td class="nump">$ 480,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for Research and development . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">2,152,397<span></span>
</td>
<td class="nump">1,307,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">2,152,397<span></span>
</td>
<td class="nump">1,307,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY - Future issuances (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">2,639,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options issued and outstanding under stock option plan</a></td>
<td class="nump">180,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredShareUnitsOutstanding', window );">Deferred share units</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Shares available for grant under stock option plan</a></td>
<td class="nump">80,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Common Shares reserved for future issuance</a></td>
<td class="nump">2,900,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaCommonShareWarrantMember', window );">One Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">314,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheBCommonShareWarrantMember', window );">One Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">314,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheCCommonShareWarrantMember', window );">One Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">314,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">942,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DeferredShareUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of deferred share units outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DeferredShareUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheBCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheBCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheCCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheCCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY - Rights of the common shares gross proceeds (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Vote</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfVotesPerCommonShare', window );">Number of vote per share</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NumberOfVotesPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes per common share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NumberOfVotesPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY - Equity transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 22, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 23, 2024 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>D </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs of units | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,675,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance allocated to common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,468<span></span>
</td>
<td class="nump">$ 190,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds allocated to Common Shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,657,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_LossOnSaleOfCommonSharesAndWarrants', window );">Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,524,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,524,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember', window );">Pre- funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares by each warrant entitles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,673<span></span>
</td>
<td class="nump">86,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaAndBWarrantsMember', window );">Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Warrant liability and accelerated warrant liability at issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,689,149<span></span>
</td>
<td class="nump">$ 31,182,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm', window );">Threshold days after completion of tranche milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ThresholdDaysToGetShareholdersApproval', window );">Threshold days to get shareholders approval | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_AggregateGrossProceeds', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,332,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_OfferingCostsAndAgentFee', window );">Offering costs and agent fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,675,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Pre- funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfWarrantsPerUnit', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common share per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | One Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm', window );">Threshold days after completion of tranche milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | One Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | One Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from issuance allocated to common shares warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Common Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_UnitsIssuedDuringPeriodSharesNewIssuance', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PricePerUnit', window );">Price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfCommonSharePerUnit', window );">Number of common share per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Common Share Units | One Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfWarrantsPerUnit', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common share per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Common Share Units | One Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfWarrantsPerUnit', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common share per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Common Share Units | One Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfWarrantsPerUnit', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common share per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Pre Funded Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_UnitsIssuedDuringPeriodSharesNewIssuance', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_PricePerUnit', window );">Price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Pre Funded Units | One Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfWarrantsPerUnit', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common share per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Pre Funded Units | One Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfWarrantsPerUnit', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common share per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember', window );">July 2024 Private Placement | Pre Funded Units | One Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NumberOfWarrantsPerUnit', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common share per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOfferingMember', window );">At-the-Market Offering (ATM) | Pre- funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs of units | $</a></td>
<td class="nump">$ 102,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares by each warrant entitles</a></td>
<td class="nump">39,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price | $ / shares</a></td>
<td class="nump">$ 20.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from issuance allocated to common shares warrants | $</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember', window );">July 22, 2025 Exercise of Discounted Warrants And Pipe Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs of units | $</a></td>
<td class="nump">808,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds allocated | $</a></td>
<td class="nump">$ 8,391,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,391,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | July 2024 Private Placement | One Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from issuance allocated to common shares warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | July 2024 Private Placement | One Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from issuance allocated to common shares warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk free interest rate | Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Exercise Price | Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.9<span></span>
</td>
<td class="nump">102.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life | Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Share price | Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.75<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Warrant liability and accelerated warrant liability at issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,182,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants. | Canadian Dollar Denominated Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of the derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,592)<span></span>
</td>
<td class="num">$ (88,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants. | Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>COMMON SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of the derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,492,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,492,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity', window );">Reclassified fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,689,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,689,149)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cash that the entity expects to raise from the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification to permanent equity of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_LossOnSaleOfCommonSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss on issuance of common share and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_LossOnSaleOfCommonSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NumberOfCommonSharePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common share per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NumberOfCommonSharePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NumberOfWarrantsPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NumberOfWarrantsPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_OfferingCostsAndAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to July 2024 private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_OfferingCostsAndAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_PricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_PricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold days after the completion of tranche milestone events within which the warrants should be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ThresholdDaysToGetShareholdersApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of days from the closing date to get shareholders approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ThresholdDaysToGetShareholdersApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_UnitsIssuedDuringPeriodSharesNewIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_UnitsIssuedDuringPeriodSharesNewIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaAndBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaAndBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheBCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheBCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheCCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheCCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pmn_CommonShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pmn_CommonShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pmn_PreFundedUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pmn_PreFundedUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_CanadianDollarDenominatedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_CanadianDollarDenominatedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY - Warrants liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 23, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaAndBWarrantsMember', window );">Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Warrant liability and accelerated warrant liability at issuance</a></td>
<td class="nump">$ 8,689,149<span></span>
</td>
<td class="nump">$ 31,182,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Warrant liability and accelerated warrant liability at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,182,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants | United States dollar denominated warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
<td class="nump">94,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants | Canadian dollar denominated warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of the warrant liability and accelerated warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,592)<span></span>
</td>
<td class="num">$ (88,593)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants | Tranche A and B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity', window );">Fair value of previously liability-classified US$ warrants reclassified to additional paid-in-capital as of July 1, 2023</a></td>
<td class="nump">8,689,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,689,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of the warrant liability and accelerated warrant liability</a></td>
<td class="nump">$ 22,492,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,492,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification to permanent equity of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaAndBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_TrancheaAndBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_UnitedStatesDollarDenominatedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_UnitedStatesDollarDenominatedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_CanadianDollarDenominatedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_CanadianDollarDenominatedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY - At-the-Market Offering ATM (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 28, 2025</div></th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse share split ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance allocated to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,468<span></span>
</td>
<td class="nump">$ 190,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOffering2024Member', window );">2024 ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance allocated to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOffering2025Member', window );">2025 ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance allocated to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOffering2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOffering2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOffering2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_AtMarketOffering2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY - Registered Direct Offering (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs</a></td>
<td class="nump">$ 2,675,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares by each warrant entitles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,673<span></span>
</td>
<td class="nump">86,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY - Exercise of Discounted Warrants and PIPE (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 22, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,675,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember', window );">July 22, 2025 Exercise of Discounted Warrants And Pipe Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,199,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountForFairValueModificationOfWarrants', window );">Incremental fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 930,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds allocated | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,391,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,391,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise', window );">Shares issued for discounted exercise warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountForFairValueModificationOfWarrants', window );">Incremental fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 930,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds allocated | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,106,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise | July 22, 2025 Warrant | Share Price | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise | July 22, 2025 Warrant | Exercise Price | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise | July 22, 2025 Warrant | Volatility | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise | Minimum | July 22, 2025 Warrant | Maturity | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise | Minimum | July 22, 2025 Warrant | Risk free interest rate | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise | Maximum | July 22, 2025 Warrant | Maturity | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise | Maximum | July 22, 2025 Warrant | Risk free interest rate | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheMember', window );">July 22, 2025 Discounted Exercise, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember', window );">July 22, 2025 Discounted Exercise, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember', window );">July 22, 2025 Discounted Exercise, Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares by each warrant entitles | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expiry term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds allocated | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,284,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | July 22, 2025 Warrant | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | July 22, 2025 Warrant | Share Price | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | July 22, 2025 Warrant | Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | July 22, 2025 Warrant | Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | July 22, 2025 Warrant | Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | July 22, 2025 Warrant | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | July 22, 2025 Warrant | Volatility | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_BeneficialOwnershipLimitation', window );">Beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Minimum | July 22, 2025 Warrant | Exercise Price | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Minimum | July 22, 2025 Warrant | Maturity | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Minimum | July 22, 2025 Warrant | Risk free interest rate | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_BeneficialOwnershipLimitation', window );">Beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Maximum | July 22, 2025 Warrant | Exercise Price | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Maximum | July 22, 2025 Warrant | Maturity | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering | Maximum | July 22, 2025 Warrant | Risk free interest rate | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember', window );">July 28, 2025 Exercise of Discounted Warrants And Pipe Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Aggregate gross proceeds | $</a></td>
<td class="nump">$ 11,623,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs | $</a></td>
<td class="nump">478,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountForFairValueModificationOfWarrants', window );">Incremental fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,794,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds allocated | $</a></td>
<td class="nump">$ 11,144,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,144,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise', window );">Shares issued for discounted exercise warrants | shares</a></td>
<td class="nump">416,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="nump">416,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 20.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredDiscountForFairValueModificationOfWarrants', window );">Incremental fair value | $</a></td>
<td class="nump">$ 1,794,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds allocated | $</a></td>
<td class="nump">$ 5,259,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | July 28 2025 Warrant | Share Price | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">20.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | July 28 2025 Warrant | Share Price | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">20.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | July 28 2025 Warrant | Exercise Price | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">20.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | July 28 2025 Warrant | Volatility | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">1.074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | July 28 2025 Warrant | Volatility | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">1.074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Minimum | July 28 2025 Warrant | Exercise Price | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Minimum | July 28 2025 Warrant | Maturity | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="nump">0.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Minimum | July 28 2025 Warrant | Maturity | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="nump">0.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Minimum | July 28 2025 Warrant | Risk free interest rate | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Minimum | July 28 2025 Warrant | Risk free interest rate | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Maximum | July 28 2025 Warrant | Exercise Price | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Maximum | July 28 2025 Warrant | Maturity | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="nump">4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Maximum | July 28 2025 Warrant | Maturity | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="nump">4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Maximum | July 28 2025 Warrant | Risk free interest rate | Pre-Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise | Maximum | July 28 2025 Warrant | Risk free interest rate | Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheMember', window );">July 28, 2025 Discounted Exercise, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="nump">138,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember', window );">July 28, 2025 Discounted Exercise, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="nump">138,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember', window );">July 28, 2025 Discounted Exercise, Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="nump">138,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice', window );">Warrants exercised | shares</a></td>
<td class="nump">31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares by each warrant entitles | shares</a></td>
<td class="nump">624,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="nump">$ 0.1875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expiry term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds allocated | $</a></td>
<td class="nump">$ 5,885,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering | July 28 2025 Warrant | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">20.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering | July 28 2025 Warrant | Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering | July 28 2025 Warrant | Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | Y</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering | July 28 2025 Warrant | Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering | July 28 2025 Warrant | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">1.074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_BeneficialOwnershipLimitation', window );">Beneficial ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_BeneficialOwnershipLimitation', window );">Beneficial ownership</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_BeneficialOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of beneficial ownership limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_BeneficialOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of class of warrant or rights exercised during the period at discounted exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DeferredDiscountForFairValueModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferred discount for fair value modification of warrants in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DeferredDiscountForFairValueModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gross proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of discounted warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantJuly222025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantJuly222025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pmn_PostModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pmn_PostModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pmn_PreModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pmn_PreModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantJuly282025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantJuly282025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>WARRANTS (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">2,639,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd50.50Member', window );">Exercise price 50.50 | January 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">314,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd50.50Member', window );">Exercise price 50.50 | January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">314,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd315.00Member', window );">Exercise price 315.00 | August 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">20,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd240.00Member', window );">Exercise price 240.00 | August 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">5,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd187.50Member', window );">Exercise price 187.50 | April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 187.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">13,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd152.50Member', window );">Exercise price 152.50 | April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 152.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">2,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd43.75Member', window );">Exercise price 43.75 | February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 43.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">449,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd62.50Member', window );">Exercise price 62.50 | July 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">314,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd31.25Member', window );">Exercise price 31.25 | July 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">1,129,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd0.25Member', window );">Exercise price 0.25</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">74,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd50.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd50.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pmn_January2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pmn_January2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pmn_January2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pmn_January2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd315.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd315.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pmn_August2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pmn_August2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd240.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd240.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd187.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd187.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pmn_April2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pmn_April2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd152.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd152.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd43.75Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd43.75Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pmn_February2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pmn_February2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd62.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd62.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pmn_July2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pmn_July2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd31.25Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd31.25Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pmn_July2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pmn_July2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd0.25Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_WarrantExercisePriceUsd0.25Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 28, 2025</div></th>
<th class="th"><div>Jul. 22, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ProceedsFromPreFundedWarrantExercises', window );">Proceeds from exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExpired', window );">Number of warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,184<span></span>
</td>
<td class="nump">16,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember', window );">July 22, 2025 Discounted Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise', window );">Shares issued for discounted exercise warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember', window );">July 28, 2025 Discounted Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise', window );">Shares issued for discounted exercise warrants</a></td>
<td class="nump">416,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember', window );">July 22, 2025 PIPE Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember', window );">July 28, 2025 PIPE Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="nump">624,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember', window );">Pre- funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of warrants net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ProceedsFromPreFundedWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ProceedsFromPreFundedWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of discounted warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025DiscountedWarrantExerciseOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025DiscountedWarrantExerciseOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July222025PipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_July282025PipeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Shares available for grant under stock option plan</a></td>
<td class="nump">80,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">2,900,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmn_StockOptionPlan2015Member', window );">Stock Option Plan 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Shares available for grant under stock option plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmn_StockOptionAndIncentivePlan2025Member', window );">Stock Option Plan 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Shares available for grant under stock option plan</a></td>
<td class="nump">80,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">117,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmn_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmn_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmn_StockOptionAndIncentivePlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmn_StockOptionAndIncentivePlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share options (Details)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Share Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pmn_CanadianDollarShareOptionsMember', window );">Canadian Dollar Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Share Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,740<span></span>
</td>
<td class="nump">35,930<span></span>
</td>
<td class="nump">35,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">54.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 170.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years) and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the beginning (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions', window );">Fair value of options in a share based payment arrangement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember', window );">US Dollar Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Share Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,238<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.25<span></span>
</td>
<td class="nump">$ 46.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at the end (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years) and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the beginning (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Grant date fair value of share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of options in a share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmn_CanadianDollarShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmn_CanadianDollarShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share-based compensation liability activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Fair value at the beginning</a></td>
<td class="nump">$ 199,263<span></span>
</td>
<td class="nump">$ 422,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital', window );">Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability</a></td>
<td class="num">(170,081)<span></span>
</td>
<td class="num">(222,739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Fair value at the end</a></td>
<td class="nump">$ 29,182<span></span>
</td>
<td class="nump">$ 199,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in additional paid in capital due to decrease in fair value of share based compensation liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pmn_CanadianDollarShareOptionsMember', window );">Canadian Dollar Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions', window );">Weighted average fair value of Options</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">106.40%<span></span>
</td>
<td class="nump">106.40%<span></span>
</td>
<td class="nump">99.70%<span></span>
</td>
<td class="nump">99.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.86%<span></span>
</td>
<td class="nump">3.86%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember', window );">US Dollar Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions', window );">Weighted average fair value of Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.40%<span></span>
</td>
<td class="nump">107.40%<span></span>
</td>
<td class="nump">101.70%<span></span>
</td>
<td class="nump">101.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.79%<span></span>
</td>
<td class="nump">3.79%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value of options in a share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmn_CanadianDollarShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmn_CanadianDollarShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Additional information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,628<span></span>
</td>
<td class="nump">$ 825,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember', window );">US Dollar Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,400<span></span>
</td>
<td class="nump">107,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="nump">$ 27.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember', window );">US Dollar Share Options | Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">19,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_VolumeWeightedAveragePriceThresholdTradingDays', window );">Number of threshold days | D</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger', window );">Threshold volume weighted average price | $ / shares</a></td>
<td class="nump">$ 86.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions', window );">Fair value of option awards | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,946<span></span>
</td>
<td class="nump">$ 39,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation related to options outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation related to options outstanding expected to be recognized over weighted-average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation related to options outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,265,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation related to options outstanding expected to be recognized over weighted-average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmn_DeferredShareUnitPlanMember', window );">DSU plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit', window );">Number of shares per unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of units outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of options to be recognized under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares redeemable per unit in shared-based payments award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold share price of the common stock to met or exceed for vesting of the options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_VolumeWeightedAveragePriceThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price must meet or exceed specified share price to trigger vesting of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_VolumeWeightedAveragePriceThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmn_UsDollarShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmn_DeferredShareUnitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmn_DeferredShareUnitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Statements of operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 857,628<span></span>
</td>
<td class="nump">$ 825,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">37,674<span></span>
</td>
<td class="nump">49,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 819,954<span></span>
</td>
<td class="nump">$ 776,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital losses carried forward</a></td>
<td class="nump">$ 34,810,450<span></span>
</td>
<td class="nump">$ 24,850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenditures</a></td>
<td class="nump">3,022,831<span></span>
</td>
<td class="nump">3,175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment tax credits</a></td>
<td class="nump">1,944,821<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis', window );">Tax value of technology rights and property and equipment in excess of accounting basis</a></td>
<td class="nump">160,999<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share issue costs</a></td>
<td class="nump">1,066,620<span></span>
</td>
<td class="nump">1,275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Non-deductible reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses', window );">Restricted interest and financing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">41,005,721<span></span>
</td>
<td class="nump">31,883,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(41,005,721)<span></span>
</td>
<td class="num">(31,883,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restricted interest and financing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from tax value of technology rights and property and equipment in excess of accounting basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Credit carryforwards (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 11,407,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=pmn_NonCapitalLossCarryforwardMember', window );">Non-capital income tax loss carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">131,360,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember', window );">Investment Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 2,553,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=pmn_NonCapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=pmn_NonCapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Canadian federal statutory income tax rate</a></td>
<td class="num">$ (5,960,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">127,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share issue costs recorded, net of equity</a></td>
<td class="num">(372,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">6,027,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount', window );">Return to provision adjustments</a></td>
<td class="nump">15,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 161,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration', window );">Tax Jurisdiction of Domicile [Extensible Enumeration]</a></td>
<td class="text">country:CA<span></span>
</td>
<td class="text">country:CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Canadian federal statutory income tax rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Provincial taxes (Ontario)</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share issue costs recorded, net of equity</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent', window );">Return to provision adjustments</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates tax jurisdiction of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Significant expense categories (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Operating Loss:</a></td>
<td class="num">$ (40,167,308)<span></span>
</td>
<td class="num">$ (16,827,478)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Income) Loss:</a></td>
<td class="nump">$ 39,719,147<span></span>
</td>
<td class="num">$ (2,778,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemCompositionDescription', window );">Segment Reporting, Other Segment Item, Composition, Description</a></td>
<td class="text">Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense<span></span>
</td>
<td class="text">Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_Pmn310DevelopmentProgramCosts', window );">PMN310 development program costs</a></td>
<td class="nump">$ 39,719,147<span></span>
</td>
<td class="num">$ (2,778,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_OtherNonEmployeeResearchAndDevelopmentCosts', window );">Other non-employee research and development costs</a></td>
<td class="num">(448,161)<span></span>
</td>
<td class="num">(19,606,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee costs</a></td>
<td class="nump">40,167,308<span></span>
</td>
<td class="nump">16,827,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative costs</a></td>
<td class="nump">4,004,065<span></span>
</td>
<td class="nump">4,443,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Operating Loss:</a></td>
<td class="nump">5,051,277<span></span>
</td>
<td class="nump">3,336,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_SegmentReportingOtherSegmentItemAmount', window );">Other segment items</a></td>
<td class="nump">885,907<span></span>
</td>
<td class="nump">772,501<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Income) Loss:</a></td>
<td class="nump">$ 30,226,059<span></span>
</td>
<td class="nump">$ 8,275,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_OtherNonEmployeeResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense incurred for other non employee research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_OtherNonEmployeeResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_Pmn310DevelopmentProgramCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense incurred for drug PMN310 development program costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_Pmn310DevelopmentProgramCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_SegmentReportingOtherSegmentItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_SegmentReportingOtherSegmentItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of composition of other segment item not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_CashPaymentsRelatedParty', window );">Cash payments</a></td>
<td class="nump">$ 428,860<span></span>
</td>
<td class="nump">$ 587,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmn_CollaborativeResearchAgreementMember', window );">Collaborative research agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_RelatedPartyTransactionFundingCommitment', window );">Funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,830,000<span></span>
</td>
<td class="nump">$ 787,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Payments made for consulting services</a></td>
<td class="nump">$ 573,187<span></span>
</td>
<td class="nump">$ 584,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_CashPaymentsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_CashPaymentsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_RelatedPartyTransactionFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of funding commitment in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_RelatedPartyTransactionFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmn_CollaborativeResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmn_CollaborativeResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details) - CEO<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_EmploymentAgreementAnnualBaseSalary', window );">Annual base salary | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary', window );">Percentage of target bonus on annual base salary</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Stock Option Plan 2015</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice', window );">Threshold trading days volume weighted average price</a></td>
<td class="text">5 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Stock Option Plan 2015 | Initial Award</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">45,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Stock Option Plan 2015 | Initial Award | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Stock Option Plan 2015 | Initial Award | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Stock Option Plan 2015 | Performance Award</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">19,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice', window );">Threshold trading days volume weighted average price</a></td>
<td class="text">10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice', window );">Times of exercise price | item</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Stock Option Plan 2015 | Performance Award | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Stock Option Plan 2015 | Performance Award | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Termination without cause</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_EmploymentAgreementSeveranceAmountCalculationTerm', window );">Severance amount calculation, term</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">change in control of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_EmploymentAgreementSeveranceAmountCalculationTerm', window );">Severance amount calculation, term</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_EmploymentAgreementAnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of annual base salary under employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_EmploymentAgreementAnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of target bonus on annual base salary under employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_EmploymentAgreementSeveranceAmountCalculationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the term of salary, a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits for calculation of severance amount under employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_EmploymentAgreementSeveranceAmountCalculationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the multiplier for volume-weighted average share price for calculation of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold trading days volume-weighted average share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmn_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmn_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmn_ArrangementOptionInitialAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmn_ArrangementOptionInitialAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pmn_TerminationWithoutCauseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pmn_TerminationWithoutCauseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pmn_ChangeInControlOfCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pmn_ChangeInControlOfCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_CollaborativeArrangementAccrualsForRoyaltyPayments', window );">Accruals for royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_RelatedPartyTransactionTermOfAgreement', window );">Term of agreement</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pmn_UbcAgreementMember', window );">UBC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_CollaborativeArrangementAccrualsForRoyaltyPayments', window );">Accruals for royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_AnnualLicensePayment', window );">Payments of annual license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_AnnualLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of license payments made during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_AnnualLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_CollaborativeArrangementAccrualsForRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the accruals for royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_CollaborativeArrangementAccrualsForRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_RelatedPartyTransactionTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the term of agreement in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_RelatedPartyTransactionTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pmn_UbcAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pmn_UbcAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common shares</a></td>
<td class="nump">74,673<span></span>
</td>
<td class="nump">86,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Computation of basic and diluted net income (loss) per share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income</a></td>
<td class="num">$ (39,719,147)<span></span>
</td>
<td class="nump">$ 2,778,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic</a></td>
<td class="nump">1,756,844<span></span>
</td>
<td class="nump">1,036,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Effect of potentially dilutive securities - Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of potentially dilutive securities - Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding</a></td>
<td class="nump">1,756,844<span></span>
</td>
<td class="nump">1,058,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share attributable to common shareholders, basic</a></td>
<td class="num">$ (22.61)<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share attributable to common shareholders</a></td>
<td class="num">$ (22.61)<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive</a></td>
<td class="nump">2,745,201<span></span>
</td>
<td class="nump">2,342,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive</a></td>
<td class="nump">180,827<span></span>
</td>
<td class="nump">142,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive</a></td>
<td class="nump">2,564,332<span></span>
</td>
<td class="nump">2,199,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmn_DeferredShareUnitsMember', window );">Deferred Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmn_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmn_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ / shares in Units, $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 29, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 29, 2026 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 26, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember', window );">Pre- funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,673<span></span>
</td>
<td class="nump">86,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,815,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm', window );">Warrants expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE | Common Share Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common shares</a></td>
<td class="nump">6,915,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE | Pre- funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase common shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,090,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price one | Common Share Warrants at issue price one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightIssued', window );">Number of warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,090,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightPricePerWarrant', window );">Price per warrant | $ / shares</a></td>
<td class="nump">10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="nump">10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price two | Directors and management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightPricePerWarrant', window );">Price per warrant | $ / shares</a></td>
<td class="nump">10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price two | Common Share Warrants at issue price two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightIssued', window );">Number of warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightPricePerWarrant', window );">Price per warrant | $ / shares</a></td>
<td class="nump">10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price two | Pre- funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightIssued', window );">Number of warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price three | Directors and management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="nump">12.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | January 2026 PIPE at issue price three | Common Share Warrants at issue price three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightIssued', window );">Number of warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmn_ClassOfWarrantOrRightPricePerWarrant', window );">Price per warrant | $ / shares</a></td>
<td class="nump">$ 12.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ClassOfWarrantOrRightPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ClassOfWarrantOrRightPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold days after the completion of milestone events within which the warrants should be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementIssuePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementIssuePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsIssuePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsIssuePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementIssuePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementIssuePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pmn_DirectorsAndManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pmn_DirectorsAndManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsIssuePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsIssuePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementIssuePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pmn_January2026PrivatePlacementIssuePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsIssuePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pmn_CommonShareWarrantsIssuePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>247</ContextCount>
  <ElementCount>317</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>102</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureAccruedLiabilities</Role>
      <ShortName>ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureWarrants</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityTables</Role>
      <ShortName>EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureWarrantsTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureWarrants</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureSegmentReporting</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940203 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - FAIR VALUE MEASUREMENTS - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails</Role>
      <ShortName>ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityDetails</Role>
      <ShortName>EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - EQUITY - Future issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails</Role>
      <ShortName>EQUITY - Future issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940603 - Disclosure - EQUITY - Rights of the common shares gross proceeds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityRightsOfCommonSharesGrossProceedsDetails</Role>
      <ShortName>EQUITY - Rights of the common shares gross proceeds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940604 - Disclosure - EQUITY - Equity transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails</Role>
      <ShortName>EQUITY - Equity transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940605 - Disclosure - EQUITY - Warrants liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails</Role>
      <ShortName>EQUITY - Warrants liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940606 - Disclosure - EQUITY - At-the-Market Offering ATM (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails</Role>
      <ShortName>EQUITY - At-the-Market Offering ATM (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940607 - Disclosure - EQUITY - Registered Direct Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails</Role>
      <ShortName>EQUITY - Registered Direct Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940608 - Disclosure - EQUITY - Exercise of Discounted Warrants and PIPE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails</Role>
      <ShortName>EQUITY - Exercise of Discounted Warrants and PIPE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureWarrantsDetails</Role>
      <ShortName>WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureWarrantsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - WARRANTS - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>WARRANTS - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - SHARE-BASED COMPENSATION - Share options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - SHARE-BASED COMPENSATION - Share-based compensation liability activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share-based compensation liability activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99940805 - Disclosure - SHARE-BASED COMPENSATION - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99940806 - Disclosure - SHARE-BASED COMPENSATION - Statements of operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Statements of operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - INCOME TAXES - Deferred taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>INCOME TAXES - Deferred taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - INCOME TAXES - Credit carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails</Role>
      <ShortName>INCOME TAXES - Credit carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - INCOME TAXES - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureSegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureSegmentReportingTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Segment Reporting - Significant expense categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails</Role>
      <ShortName>Segment Reporting - Significant expense categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99941302 - Disclosure - NET LOSS PER SHARE - Computation of basic and diluted net income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Computation of basic and diluted net income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>99941303 - Disclosure - NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pmn-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.promisneurosciences.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pmn-20251231.xsd</File>
    <File>pmn-20251231_cal.xml</File>
    <File>pmn-20251231_def.xml</File>
    <File>pmn-20251231_lab.xml</File>
    <File>pmn-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="pmn-20251231x10k.htm">pmn-20251231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pmn-20251231x10k001.jpg</File>
    <File>pmn-20251231x10k003.jpg</File>
    <File>pmn-20251231x10k004.jpg</File>
    <File>pmn-20251231x10k005.jpg</File>
    <File>pmn-20251231x10k006.jpg</File>
    <File>pmn-20251231x10k007.jpg</File>
    <File>pmn-20251231x10k008.jpg</File>
    <File>pmn-20251231x10k009.jpg</File>
    <File>pmn-20251231x10k010.jpg</File>
    <File>pmn-20251231x10k011.jpg</File>
    <File>pmn-20251231x10k012.jpg</File>
    <File>pmn-20251231x10k013.jpg</File>
    <File>pmn-20251231x10k014.jpg</File>
    <File>pmn-20251231x10k015.jpg</File>
    <File>pmn-20251231x10k016.jpg</File>
    <File>pmn-20251231x10k017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="521">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="17">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pmn-20251231x10k.htm": {
   "nsprefix": "pmn",
   "nsuri": "http://www.promisneurosciences.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "pmn-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pmn-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pmn-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pmn-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pmn-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "pmn-20251231x10k.htm"
     ]
    }
   },
   "keyStandard": 238,
   "keyCustom": 79,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 70,
   "hidden": {
    "total": 44,
    "http://fasb.org/us-gaap/2024": 34,
    "http://www.promisneurosciences.com/20251231": 7,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 247,
   "entityCount": 1,
   "segmentCount": 102,
   "elementCount": 651,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 521,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/ecd/2024": 17,
    "http://xbrl.sec.gov/cyd/2024": 12
   },
   "report": {
    "R1": {
     "role": "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity",
     "longName": "995200300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity",
     "shortName": "Consolidated Statements of Shareholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMw169EA8Uy88PupRPJN3g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMw169EA8Uy88PupRPJN3g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurements",
     "longName": "995210301 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995210401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilities",
     "longName": "995210501 - Disclosure - ACCRUED LIABILITIES",
     "shortName": "ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquity",
     "longName": "995210601 - Disclosure - EQUITY",
     "shortName": "EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.promisneurosciences.com/role/DisclosureWarrants",
     "longName": "995210701 - Disclosure - WARRANTS",
     "shortName": "WARRANTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:WarrantsAndRightsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:WarrantsAndRightsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensation",
     "longName": "995210801 - Disclosure - SHARE-BASED COMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.promisneurosciences.com/role/DisclosureIncomeTaxes",
     "longName": "995210901 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.promisneurosciences.com/role/DisclosureSegmentReporting",
     "longName": "995211001 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactions",
     "longName": "995211101 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211201 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.promisneurosciences.com/role/DisclosureNetLossPerShare",
     "longName": "995211301 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.promisneurosciences.com/role/DisclosureSubsequentEvents",
     "longName": "995211401 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99930303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "99930403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesTables",
     "longName": "99930503 - Disclosure - ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pmn:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pmn:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityTables",
     "longName": "99930603 - Disclosure - EQUITY (Tables)",
     "shortName": "EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.promisneurosciences.com/role/DisclosureWarrantsTables",
     "longName": "99930703 - Disclosure - WARRANTS (Tables)",
     "shortName": "WARRANTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:ScheduleOfWarrantExercisePriceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pmn:WarrantsAndRightsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:ScheduleOfWarrantExercisePriceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pmn:WarrantsAndRightsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables",
     "longName": "99930803 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesTables",
     "longName": "99930903 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.promisneurosciences.com/role/DisclosureSegmentReportingTables",
     "longName": "99931003 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931303 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
     "longName": "99940101 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "99940202 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_DFTrDh2oYk6khT-4RADKcQ",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_DFTrDh2oYk6khT-4RADKcQ",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "99940203 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:PercentageOfOriginalAmountInvested",
      "unitRef": "Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:PercentageOfOriginalAmountInvested",
      "unitRef": "Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails",
     "longName": "99940301 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g",
      "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "99940302 - Disclosure - FAIR VALUE MEASUREMENTS - Additional information (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount",
       "pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount",
       "pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount",
       "pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount",
       "pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "99940401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:PrepaidUpfrontResearchPaymentsCurrent",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:PrepaidUpfrontResearchPaymentsCurrent",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails",
     "longName": "99940501 - Disclosure - ACCRUED LIABILITIES (Details)",
     "shortName": "ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:AccruedLegalFeesCurrent",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "pmn:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:AccruedLegalFeesCurrent",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "pmn:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityDetails",
     "longName": "99940601 - Disclosure - EQUITY (Details)",
     "shortName": "EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
     "longName": "99940602 - Disclosure - EQUITY - Future issuances (Details)",
     "shortName": "EQUITY - Future issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:DeferredShareUnitsOutstanding",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityRightsOfCommonSharesGrossProceedsDetails",
     "longName": "99940603 - Disclosure - EQUITY - Rights of the common shares gross proceeds (Details)",
     "shortName": "EQUITY - Rights of the common shares gross proceeds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:NumberOfVotesPerCommonShare",
      "unitRef": "Unit_Standard_Vote_I7wc_r8nuUinrT38wY9WLA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:NumberOfVotesPerCommonShare",
      "unitRef": "Unit_Standard_Vote_I7wc_r8nuUinrT38wY9WLA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
     "longName": "99940604 - Disclosure - EQUITY - Equity transactions (Details)",
     "shortName": "EQUITY - Equity transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails",
     "longName": "99940605 - Disclosure - EQUITY - Warrants liability (Details)",
     "shortName": "EQUITY - Warrants liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_qo_eeZpMdkKWqiKn5hBbMQ",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_eoUbqM8EvkG5L47UIBVk4A",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
     "longName": "99940606 - Disclosure - EQUITY - At-the-Market Offering ATM (Details)",
     "shortName": "EQUITY - At-the-Market Offering ATM (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_Kfapro2AwUiDsFbp7-NsnQ",
      "name": "pmn:CommonStockCapitalSharesReservedForFutureIssuanceAmount",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
     "longName": "99940607 - Disclosure - EQUITY - Registered Direct Offering (Details)",
     "shortName": "EQUITY - Registered Direct Offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_7_26_2024_YRF1DtgvqEykJgtUIbZvgA",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
     "longName": "99940608 - Disclosure - EQUITY - Exercise of Discounted Warrants and PIPE (Details)",
     "shortName": "EQUITY - Exercise of Discounted Warrants and PIPE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g",
      "name": "pmn:ProceedsFromIssuanceOfCommonStockAndWarrants",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails",
     "longName": "99940701 - Disclosure - WARRANTS (Details)",
     "shortName": "WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_7_26_2024_YRF1DtgvqEykJgtUIbZvgA",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_BLU4_tV9gUySljXY2fjsag",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pmn:ScheduleOfWarrantExercisePriceTableTextBlock",
       "pmn:WarrantsAndRightsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
     "longName": "99940702 - Disclosure - WARRANTS - Additional information (Details)",
     "shortName": "WARRANTS - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:StockIssuedDuringPeriodSharesWarrantsExercised",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "pmn:WarrantsAndRightsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:ProceedsFromPreFundedWarrantExercises",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "pmn:WarrantsAndRightsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails",
     "longName": "99940801 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_lzS6k88pCESIdR5eDOhhpw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails",
     "longName": "99940802 - Disclosure - SHARE-BASED COMPENSATION - Share options (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Share options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails",
     "longName": "99940803 - Disclosure - SHARE-BASED COMPENSATION - Share-based compensation liability activity (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Share-based compensation liability activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g",
      "name": "us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pmn:ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ",
      "name": "us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails",
     "longName": "99940804 - Disclosure - SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Fair value of share options outstanding and exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ",
      "name": "pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions",
      "unitRef": "Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ",
      "name": "pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions",
      "unitRef": "Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
     "longName": "99940805 - Disclosure - SHARE-BASED COMPENSATION - Additional information (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails",
     "longName": "99940806 - Disclosure - SHARE-BASED COMPENSATION - Statements of operations (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Statements of operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lI1_7YZGDkiVsD04bzBKuA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails",
     "longName": "99940901 - Disclosure - INCOME TAXES - Deferred taxes (Details)",
     "shortName": "INCOME TAXES - Deferred taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails",
     "longName": "99940902 - Disclosure - INCOME TAXES - Credit carryforwards (Details)",
     "shortName": "INCOME TAXES - Credit carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "longName": "99940903 - Disclosure - INCOME TAXES - Reconciliation (Details)",
     "shortName": "INCOME TAXES - Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.promisneurosciences.com/role/DisclosureSegmentReportingDetails",
     "longName": "99941001 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails",
     "longName": "99941002 - Disclosure - Segment Reporting - Significant expense categories (Details)",
     "shortName": "Segment Reporting - Significant expense categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:SegmentReportingOtherItemCompositionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingOtherItemCompositionDescription",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails",
     "longName": "99941101 - Disclosure - RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS - UBC Collaborative Research Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:CashPaymentsRelatedParty",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "pmn:CashPaymentsRelatedParty",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
     "longName": "99941102 - Disclosure - RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS - Neil Warma Employment Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ",
      "name": "pmn:EmploymentAgreementAnnualBaseSalary",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ",
      "name": "pmn:EmploymentAgreementAnnualBaseSalary",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99941201 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:CollaborativeArrangementAccrualsForRoyaltyPayments",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q",
      "name": "pmn:CollaborativeArrangementAccrualsForRoyaltyPayments",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails",
     "longName": "99941301 - Disclosure - NET LOSS PER SHARE (Details)",
     "shortName": "NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_igRnDfASGkG63gecqvoxGA",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails",
     "longName": "99941302 - Disclosure - NET LOSS PER SHARE - Computation of basic and diluted net income (loss) per share (Details)",
     "shortName": "NET LOSS PER SHARE - Computation of basic and diluted net income (loss) per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails",
     "longName": "99941303 - Disclosure - NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)",
     "shortName": "NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941401 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_7_26_2024_YRF1DtgvqEykJgtUIbZvgA",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "Unit_Standard_CAD_0bIGG6MBEkexQleS433poA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20251231x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r579"
     ]
    },
    "pmn_AccruedLegalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AccruedLegalFeesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Legal Fees, Current",
        "negatedLabel": "Legal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_AccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AccruedLiabilitiesTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on accrued liabilities.",
        "label": "Accrued Liabilities [Text Block]",
        "terseLabel": "ACCRUED LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accounting",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "pmn_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for Research and development . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development , Current",
        "negatedLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r58",
      "r112",
      "r419",
      "r437",
      "r438"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other Comprehensive Income (Loss)",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r7",
      "r13",
      "r350",
      "r353",
      "r393",
      "r433",
      "r434",
      "r715",
      "r716",
      "r717",
      "r723",
      "r724",
      "r725",
      "r727"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r579",
      "r806"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r723",
      "r724",
      "r725",
      "r727",
      "r781",
      "r809"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r264"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r25",
      "r77"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AggregateGrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of cash that the entity expects to raise from the offering.",
        "label": "Aggregate Gross Proceeds",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r624",
      "r634",
      "r667"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r627",
      "r637",
      "r670"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r662",
      "r671",
      "r675",
      "r683"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation",
        "verboseLabel": "share-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r299"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "pmn_AnnualLicensePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AnnualLicensePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of license payments made during the year.",
        "label": "Annual License Payment",
        "terseLabel": "Payments of annual license"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive common shares equivalents excluded from computation of diluted net loss per share for periods presented because including them would have been antidilutive",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "NET LOSS PER SHARE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "pmn_ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for re-measurement of equity classified stock options.",
        "label": "Apic Share Based Payment Arrangement ReMeasurement Of Liability Classified Stock Options",
        "terseLabel": "Re-measurement of liability-classified CAD stock options"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_April2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "April2028Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the April 2028 member.",
        "label": "April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ArrangementOptionInitialAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ArrangementOptionInitialAwardMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time relating to initial awards.",
        "label": "Arrangement, Option, Initial Award [Member]",
        "terseLabel": "Initial Award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r91",
      "r108",
      "r129",
      "r169",
      "r177",
      "r192",
      "r196",
      "r205",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r343",
      "r347",
      "r381",
      "r415",
      "r486",
      "r552",
      "r553",
      "r579",
      "r591",
      "r745",
      "r746",
      "r795"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r113",
      "r129",
      "r205",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r343",
      "r347",
      "r381",
      "r579",
      "r745",
      "r746",
      "r795"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total assets measured at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r573"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_AtMarketOffering2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AtMarketOffering2024Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to at the market offering for the year 2024.",
        "label": "At The Market Offering 2024 [Member]",
        "terseLabel": "2024 ATM offering",
        "verboseLabel": "2024 ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_AtMarketOffering2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AtMarketOffering2025Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to at the market offering for the year 2025.",
        "label": "At The Market Offering 2025 [Member]",
        "terseLabel": "2025 ATM offering",
        "verboseLabel": "2025 ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "Market offering",
        "verboseLabel": "At-the-Market Offering (ATM)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r620"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r620"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r620"
     ]
    },
    "pmn_August2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "August2026Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the August 2026 member.",
        "label": "August 2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "pmn_BeneficialOwnershipLimitation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "BeneficialOwnershipLimitation",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of beneficial ownership limitation.",
        "label": "Beneficial Ownership Limitation",
        "terseLabel": "Beneficial ownership"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_CanadianDollarDenominatedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CanadianDollarDenominatedWarrantsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to canadian dollar denominated warrants.",
        "label": "Canadian Dollar Denominated Warrants",
        "terseLabel": "Canadian dollar denominated warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_CanadianDollarShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CanadianDollarShareOptionsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Canadian dollar share options.",
        "label": "Canadian Dollar Share Options [Member]",
        "terseLabel": "Canadian Dollar Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r107",
      "r541"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r64",
      "r127"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r64"
     ]
    },
    "pmn_CashPaymentsRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CashPaymentsRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments to related party.",
        "label": "Cash Payments, Related Party",
        "terseLabel": "Cash payments"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ChangeInControlOfCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ChangeInControlOfCompanyMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to scenario, change in control of the Company.",
        "label": "Change in Control of the Company [Member]",
        "terseLabel": "change in control of the Company"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "CEO"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r109",
      "r110",
      "r111",
      "r129",
      "r153",
      "r158",
      "r161",
      "r163",
      "r171",
      "r172",
      "r205",
      "r221",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r235",
      "r236",
      "r239",
      "r242",
      "r249",
      "r381",
      "r442",
      "r443",
      "r444",
      "r445",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r474",
      "r495",
      "r517",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r706",
      "r720",
      "r728"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "COMMON SHARES",
        "verboseLabel": "EQUITY",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r171",
      "r235",
      "r236",
      "r237",
      "r239",
      "r242",
      "r247",
      "r249",
      "r442",
      "r443",
      "r444",
      "r445",
      "r562",
      "r706",
      "r720"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails",
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails",
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price",
        "verboseLabel": "Exercise Price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "pmn_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercised.",
        "label": "Class of Warrant or Right, Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ClassOfWarrantOrRightExercisedDiscountedExercisePrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ClassOfWarrantOrRightExercisedDiscountedExercisePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of class of warrant or rights exercised during the period at discounted exercise price.",
        "label": "Class Of Warrant Or Right Exercised, Discounted Exercise Price",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ClassOfWarrantOrRightExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ClassOfWarrantOrRightExpired",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights expired.",
        "label": "Class of Warrant or Right, Expired",
        "terseLabel": "Number of warrants expired"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights issued.",
        "label": "Class of Warrant or Right, Issued",
        "terseLabel": "Number of warrants issued",
        "verboseLabel": "Number of warrants sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "NET LOSS PER SHARE",
        "verboseLabel": "WARRANTS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of common share per warrant",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares by each warrant entitles",
        "verboseLabel": "Number of warrants to purchase common shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants",
        "verboseLabel": "Number of Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ClassOfWarrantOrRightPricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ClassOfWarrantOrRightPricePerWarrant",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Price Per Warrant",
        "terseLabel": "Common share purchase warrants price",
        "verboseLabel": "Price per warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "verboseLabel": "Collaboration Arrangements",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "pmn_CollaborativeArrangementAccrualsForRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CollaborativeArrangementAccrualsForRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the accruals for royalty payments.",
        "label": "Collaborative Arrangement, Accruals for Royalty Payments",
        "terseLabel": "Accruals for royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "pmn_CollaborativeResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CollaborativeResearchAgreementMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaborative research agreement entered with related party.",
        "label": "Collaborative research agreement",
        "terseLabel": "Collaborative research agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "verboseLabel": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r84",
      "r417",
      "r473"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r215",
      "r216",
      "r537",
      "r740",
      "r744"
     ]
    },
    "pmn_CommonShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CommonShareUnitsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information representing to common share units.",
        "label": "Common Share Units [Member]",
        "terseLabel": "Common Share Units"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_CommonShareWarrantsIssuePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CommonShareWarrantsIssuePriceOneMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common share purchase warrants issued at issue price one.",
        "label": "Common Share Warrants, Issue Price One [Member]",
        "terseLabel": "Common Share Warrants at issue price one"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_CommonShareWarrantsIssuePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CommonShareWarrantsIssuePriceThreeMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common share purchase warrants issued at issue price three.",
        "label": "Common Share Warrants, Issue Price Three [Member]",
        "terseLabel": "Common Share Warrants at issue price three"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_CommonShareWarrantsIssuePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CommonShareWarrantsIssuePriceTwoMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common share purchase warrants issued at issue price two.",
        "label": "Common Share Warrants, Issue Price Two [Member]",
        "terseLabel": "Common Share Warrants at issue price two"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_CommonShareWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CommonShareWarrantsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common share purchase warrants.",
        "label": "Common Share Warrants [Member]",
        "terseLabel": "Common Share Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "totalLabel": "Total Common Shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "pmn_CommonStockCapitalSharesReservedForFutureIssuanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Amount",
        "terseLabel": "Common stock, capital shares reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Shares",
        "terseLabel": "Common Shares",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r723",
      "r724",
      "r727",
      "r781",
      "r805",
      "r809"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common shares, par value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Common shares, unlimited shares authorized",
        "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r474",
      "r492",
      "r809",
      "r810"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Shares, no par value, unlimited shares authorized, 2,152,397 and 1,307,520 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r418",
      "r579"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment",
        "terseLabel": "Computer equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r96"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r89",
      "r133",
      "r169",
      "r178",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r552",
      "r553",
      "r745",
      "r746"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r89",
      "r133",
      "r169",
      "r178",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r552",
      "r553",
      "r745",
      "r746"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r543"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r694"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r694"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r607",
      "r696"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r607",
      "r696"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r698"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r607",
      "r696"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r600",
      "r689"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r690"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r690"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r688"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r688"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r688"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r602",
      "r691"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r693"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r693"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r694"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r608",
      "r697"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r606",
      "r695"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r692"
     ]
    },
    "pmn_DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in share based share-based compensation liability on CAD denominated share options reducing additional paid-in-capital.",
        "label": "Decrease in Additional Paid in Capital For Share Based Compensation Liability",
        "terseLabel": "Decrease in share-based compensation liability on CAD denominated share options increasing additional paid-in-capital"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in additional paid in capital due to decrease in fair value of share based compensation liability.",
        "label": "Decrease In Fair Value Of Share Based Compensation Liability, Increase In Additional Paid In Capital",
        "negatedLabel": "Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Share-based compensation liability",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareBasedCompensationLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Classified, Noncurrent",
        "periodEndLabel": "Fair value at the end",
        "periodStartLabel": "Fair value at the beginning",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Share-based compensation liability",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "pmn_DeferredDiscountForFairValueModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredDiscountForFairValueModificationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferred discount for fair value modification of warrants in noncash financing activities.",
        "label": "Deferred Discount For Fair Value Modification Of Warrants",
        "terseLabel": "Deferred discount for fair value modification of warrants",
        "verboseLabel": "Incremental fair value"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_DeferredDiscountIssuanceCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredDiscountIssuanceCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferred discount issuance cost recognized in noncash financing activities.",
        "label": "Deferred Discount Issuance Cost Recognized",
        "terseLabel": "Deferred discount issuance cost recognized on completion of PIPE"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_DeferredFinancingCostAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredFinancingCostAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost assets classified as financing.",
        "label": "Deferred financing cost assets",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred financing costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "pmn_DeferredShareUnitPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredShareUnitPlanMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to deferred share unit plan.",
        "label": "DSU plan"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_DeferredShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredShareUnitsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to deferred share units.",
        "label": "Deferred share units",
        "terseLabel": "Deferred Share Units"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_DeferredShareUnitsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredShareUnitsOutstanding",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of deferred share units outstanding.",
        "label": "Deferred Share Units Outstanding",
        "terseLabel": "Deferred share units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Investment tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Non-capital losses carried forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "pmn_DeferredTaxAssetsRestrictedInterestAndFinancingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredTaxAssetsRestrictedInterestAndFinancingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restricted interest and financing expenses.",
        "label": "Deferred Tax Assets, Restricted Interest And Financing Expenses",
        "terseLabel": "Restricted interest and financing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share issue costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Non-deductible reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "pmn_DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from tax value of technology rights and property and equipment in excess of accounting basis.",
        "label": "Deferred Tax Assets, Tax Value Of Technology Rights And Property And Equipment In Excess Of Accounting Basis",
        "terseLabel": "Tax value of technology rights and property and equipment in excess of accounting basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "pmn_DirectorsAndManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "DirectorsAndManagementMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to directors and management member.",
        "label": "Directors And Management [Member]",
        "terseLabel": "Directors and management"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r267",
      "r295",
      "r296",
      "r298",
      "r567"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r620"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r620",
      "r663"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) income per share, basic",
        "verboseLabel": "Net (loss) income per share attributable to common shareholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r150",
      "r153",
      "r161",
      "r162",
      "r163",
      "r168",
      "r337",
      "r340",
      "r357",
      "r358",
      "r413",
      "r427",
      "r544"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per share, diluted",
        "verboseLabel": "Diluted net (loss) income per share attributable to common shareholders",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r153",
      "r161",
      "r162",
      "r163",
      "r168",
      "r337",
      "r340",
      "r357",
      "r358",
      "r413",
      "r427",
      "r544"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Net Income (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r165"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r164",
      "r166",
      "r167"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Tax Rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r570"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Canadian federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r308",
      "r328",
      "r570"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r570",
      "r722",
      "r776"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r722",
      "r776"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r722",
      "r776",
      "r777"
     ]
    },
    "pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Return to Adjustments, Amount",
        "terseLabel": "Return to provision adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Return to Adjustments, Percent",
        "terseLabel": "Return to provision adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Share issue costs recorded, net of equity",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r776",
      "r777"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Share issue costs recorded, net of equity",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r776",
      "r777"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "Provincial taxes (Ontario)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r570",
      "r722",
      "r776"
     ]
    },
    "pmn_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "SHARE-BASED COMPENSATION",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation related to options outstanding expected to be recognized over weighted-average remaining service period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation related to options outstanding",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "pmn_EmploymentAgreementAnnualBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "EmploymentAgreementAnnualBaseSalary",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of annual base salary under employment agreement.",
        "label": "Employment Agreement, Annual Base Salary",
        "terseLabel": "Annual base salary"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of target bonus on annual base salary under employment agreement.",
        "label": "Employment Agreement, Percentage of Target Bonus on Annual Base Salary",
        "terseLabel": "Percentage of target bonus on annual base salary"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_EmploymentAgreementSeveranceAmountCalculationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "EmploymentAgreementSeveranceAmountCalculationTerm",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of salary, a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits for calculation of severance amount under employment agreement.",
        "label": "Employment Agreement, Severance Amount Calculation, Term",
        "terseLabel": "Severance amount calculation, term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r103",
      "r117",
      "r118",
      "r119",
      "r134",
      "r135",
      "r136",
      "r138",
      "r143",
      "r145",
      "r147",
      "r170",
      "r206",
      "r207",
      "r211",
      "r251",
      "r326",
      "r327",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r393",
      "r426",
      "r433",
      "r434",
      "r435",
      "r452",
      "r517"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r624",
      "r634",
      "r667"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r610",
      "r621",
      "r631",
      "r664"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r374",
      "r573"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r374",
      "r573"
     ]
    },
    "pmn_FairValueAssetsLiabilitiesLevel1TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "FairValueAssetsLiabilitiesLevel1TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis in and out of Level 1.",
        "label": "Fair Value, Assets (Liabilities), Level 1, Transfers, Amount",
        "terseLabel": "Transfer of assets (liabilities) in and out of level 1"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_FairValueAssetsLiabilitiesLevel2TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "FairValueAssetsLiabilitiesLevel2TransfersAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis in and out of Level 1.",
        "label": "Fair Value, Assets (Liabilities), Level 2, Transfers, Amount",
        "terseLabel": "Transfer of assets (liabilities) in and out of level 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r373",
      "r374",
      "r376",
      "r405",
      "r406",
      "r407",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r573",
      "r575"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityTables",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r375"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r364",
      "r573",
      "r785",
      "r790"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r371",
      "r372",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r412",
      "r573",
      "r576"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "verboseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r253",
      "r258",
      "r361",
      "r374",
      "r405",
      "r563",
      "r564",
      "r565",
      "r573"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3",
        "verboseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r361",
      "r362",
      "r363",
      "r364",
      "r374",
      "r407",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r573",
      "r575"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityTables",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r375"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "verboseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityTables",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityTables",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r375"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Summary of fair value of the liability",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r370",
      "r375"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r364",
      "r573",
      "r785",
      "r790"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "terseLabel": "Transfer of assets in and out of level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r789"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of the derivative liability",
        "verboseLabel": "Change in fair value of the warrant liability and accelerated warrant liability",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r375"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "verboseLabel": "Warrant liability and accelerated warrant liability at issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r375"
     ]
    },
    "pmn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reclassification to permanent equity of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassified to Permanent Equity",
        "terseLabel": "Fair value of previously liability-classified US$ warrants reclassified to additional paid-in-capital as of July 1, 2023",
        "verboseLabel": "Reclassified fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Transfer of liabilities in and out of level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r789"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r375"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r373",
      "r374",
      "r376",
      "r405",
      "r406",
      "r407",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r573",
      "r575"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r790"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r375"
     ]
    },
    "pmn_February2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "February2029Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the February 2029 member.",
        "label": "February 2029 [Member]",
        "terseLabel": "February 2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign and Functional Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r671"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r671"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "pmn_GainLossFromChangeInFairValueOfFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "GainLossFromChangeInFairValueOfFinancialInstruments",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in fair value of financial instruments.",
        "label": "Gain (Loss) from Change in Fair Value of Financial Instruments",
        "terseLabel": "Change in fair value of financial instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r497"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r620"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r71"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r366",
      "r370",
      "r375",
      "r430",
      "r432",
      "r502",
      "r540",
      "r574",
      "r804"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r366",
      "r370",
      "r375",
      "r430",
      "r432",
      "r502",
      "r540",
      "r574",
      "r804"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r303",
      "r308",
      "r313",
      "r314",
      "r315",
      "r318",
      "r323",
      "r329",
      "r331",
      "r332",
      "r333",
      "r447",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Effective Tax Rate",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r101",
      "r146",
      "r147",
      "r169",
      "r179",
      "r196",
      "r307",
      "r308",
      "r330",
      "r428",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r305",
      "r306",
      "r318",
      "r319",
      "r322",
      "r325",
      "r441"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r570",
      "r776"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Canadian federal statutory income tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r776"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r776",
      "r777"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Effect of potentially dilutive securities - Warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r163"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of potentially dilutive securities - Stock options",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r157",
      "r163",
      "r266"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r662",
      "r671",
      "r675",
      "r683"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r687"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r687"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r687"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Other",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r125",
      "r126"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest and other receivables",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r811"
     ]
    },
    "us-gaap_InvestmentCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCreditMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Tax Credit Carryforward",
        "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r788"
     ]
    },
    "pmn_January2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "January2026Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the January 2026 member.",
        "label": "January 2026 [Member]",
        "terseLabel": "January 2026"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_January2026PrivatePlacementIssuePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "January2026PrivatePlacementIssuePriceOneMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to January 2026 private placement at issue price one.",
        "label": "January 2026 Private Placement, Issue Price One [Member]",
        "terseLabel": "January 2026 PIPE at issue price one"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_January2026PrivatePlacementIssuePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "January2026PrivatePlacementIssuePriceThreeMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to January 2026 private placement at issue price three.",
        "label": "January 2026 Private Placement, Issue Price Three [Member]",
        "terseLabel": "January 2026 PIPE at issue price three"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_January2026PrivatePlacementIssuePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "January2026PrivatePlacementIssuePriceTwoMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to January 2026 private placement at issue price two.",
        "label": "January 2026 Private Placement, Issue Price Two [Member]",
        "terseLabel": "January 2026 PIPE at issue price two"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_January2026PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "January2026PrivatePlacementMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to January 2026 private placement.",
        "label": "January 2026 Private Placement [Member]",
        "terseLabel": "January 2026 PIPE"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_January2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "January2027Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the January 2027 member.",
        "label": "January 2027 [Member]",
        "terseLabel": "January 2027"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July2024PipeFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July2024PipeFinancingMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to July2024 Pipe Financing.",
        "label": "July 2024 Pipe Financing [Member]",
        "terseLabel": "July 2024 Pipe Financing"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July2024PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July2024PrivatePlacementMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 2024 private placement.",
        "label": "July 2024 Private Placement [Member]",
        "terseLabel": "July 2024 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July2029Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the July 2029 member.",
        "label": "July 2029 [Member]",
        "terseLabel": "July 2029"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July2030Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the July 2030 member.",
        "label": "July 2030 [Member]",
        "terseLabel": "July 2030"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July222025DiscountedWarrantExerciseOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July222025DiscountedWarrantExerciseOfferMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 22, 2025 discounted warrant exercise offer.",
        "label": "July 22, 2025 Discounted Warrant Exercise Offer [Member]",
        "terseLabel": "July 22, 2025 Discounted Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July222025DiscountedWarrantExerciseOfferTrancheBMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 22, 2025 discounted warrant exercise offer relating to Tranche B.",
        "label": "July 22, 2025 Discounted Warrant Exercise Offer, Tranche B [Member]",
        "terseLabel": "July 22, 2025 Discounted Exercise, Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July222025DiscountedWarrantExerciseOfferTrancheCMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 22, 2025 discounted warrant exercise offer relating to Tranche C.",
        "label": "July 22, 2025 Discounted Warrant Exercise Offer, Tranche C [Member]",
        "terseLabel": "July 22, 2025 Discounted Exercise, Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July222025DiscountedWarrantExerciseOfferTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July222025DiscountedWarrantExerciseOfferTrancheMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 22, 2025 discounted warrant exercise offer relating to Tranche A.",
        "label": "July 22, 2025 Discounted Warrant Exercise Offer, Tranche A [Member]",
        "terseLabel": "July 22, 2025 Discounted Exercise, Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 22, 2025, exercise of discounted warrants and PIPE offering.",
        "label": "July 22, 2025, Exercise of Discounted Warrants and Pipe Offering [Member]",
        "terseLabel": "July 22, 2025 Exercise of Discounted Warrants And Pipe Offering"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July222025PipeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July222025PipeOfferingMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 22, 2025 PIPE offering.",
        "label": "July 22, 2025 Pipe Offering [Member]",
        "terseLabel": "July 22, 2025 PIPE Offering"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July282025DiscountedWarrantExerciseOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July282025DiscountedWarrantExerciseOfferMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 28, 2025 discounted warrant exercise offer.",
        "label": "July 28, 2025 Discounted Warrant Exercise Offer [Member]",
        "terseLabel": "July 28, 2025 Discounted Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July282025DiscountedWarrantExerciseOfferTrancheBMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 28, 2025 discounted warrant exercise offer relating to Tranche B.",
        "label": "July 28, 2025 Discounted Warrant Exercise Offer, Tranche B [Member]",
        "terseLabel": "July 28, 2025 Discounted Exercise, Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July282025DiscountedWarrantExerciseOfferTrancheCMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 28, 2025 discounted warrant exercise offer relating to Tranche C.",
        "label": "July 28, 2025 Discounted Warrant Exercise Offer, Tranche C [Member]",
        "terseLabel": "July 28, 2025 Discounted Exercise, Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July282025DiscountedWarrantExerciseOfferTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July282025DiscountedWarrantExerciseOfferTrancheMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 28, 2025 discounted warrant exercise offer relating to Tranche A.",
        "label": "July 28, 2025 Discounted Warrant Exercise Offer, Tranche A [Member]",
        "terseLabel": "July 28, 2025 Discounted Exercise, Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 28, 2025 exercise of discounted warrants and PIPE offering.",
        "label": "July 28, 2025 Exercise Of Discounted Warrants And Pipe Offering [Member]",
        "terseLabel": "July 28, 2025 Exercise of Discounted Warrants And Pipe Offering"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_July282025PipeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "July282025PipeOfferingMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 28, 2025 PIPE offering.",
        "label": "July 28, 2025 Pipe Offering [Member]",
        "terseLabel": "July 28, 2025 PIPE Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Employee costs",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r129",
      "r205",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r344",
      "r347",
      "r348",
      "r381",
      "r472",
      "r545",
      "r591",
      "r745",
      "r795",
      "r796"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' (deficit) equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r85",
      "r421",
      "r579",
      "r721",
      "r737",
      "r791"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders' (Deficit) Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r106",
      "r129",
      "r205",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r344",
      "r347",
      "r348",
      "r381",
      "r579",
      "r745",
      "r795",
      "r796"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "verboseLabel": "Total liabilities measured at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "pmn_LossOnSaleOfCommonSharesAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "LossOnSaleOfCommonSharesAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss on issuance of common share and warrants.",
        "label": "Loss on Sale of Common Shares and Warrants",
        "negatedLabel": "Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE",
        "terseLabel": "Loss on issuance of common shares, warrants, and pre-funded warrants in July 26, 2024 PIPE"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r260",
      "r300",
      "r364",
      "r410",
      "r429",
      "r431",
      "r439",
      "r464",
      "r465",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r538",
      "r539",
      "r558",
      "r562",
      "r566",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r747",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Exercise Price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_MeasurementInputMaturityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputMaturityMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Maturity [Member]",
        "terseLabel": "Maturity",
        "documentation": "Measurement input using due date of last payment of principal and interest for financial instrument. Excludes expected term."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "terseLabel": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Free Interest rate",
        "terseLabel": "Risk free interest rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Share price",
        "verboseLabel": "Share Price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r575"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r575"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r260",
      "r300",
      "r364",
      "r410",
      "r429",
      "r431",
      "r439",
      "r464",
      "r465",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r538",
      "r539",
      "r558",
      "r562",
      "r566",
      "r575",
      "r576",
      "r577",
      "r580",
      "r747",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Negative cash flows from operations",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net (Income) Loss:",
        "totalLabel": "Net (loss) income",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r66",
      "r88",
      "r104",
      "r114",
      "r115",
      "r119",
      "r129",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r159",
      "r205",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r337",
      "r340",
      "r358",
      "r381",
      "r425",
      "r494",
      "r515",
      "r516",
      "r589",
      "r745"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net (loss) income",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r139",
      "r140",
      "r141",
      "r142",
      "r150",
      "r151",
      "r160",
      "r163",
      "r340"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_NetProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "NetProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net proceeds from issuance of common stock and warrants.",
        "label": "Net Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from Private Placements, net of issuance costs",
        "verboseLabel": "Net proceeds allocated"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_NetProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "NetProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) net of issuance costs.",
        "label": "Net Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of pre-funded warrants from July 22, 2025 Registered Direct Offering, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_NonCapitalLossCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "NonCapitalLossCarryforwardMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from non-capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Non-Capital Loss Carryforward [Member]",
        "terseLabel": "Non-capital income tax loss carry-forwards"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r662",
      "r671"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "pmn_NonRule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "NonRule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Rule 10b5-1 Arr Modified Flag.",
        "label": "Non Rule 10b5-1 Arr Modified Flag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_NumberOfCommonSharePerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "NumberOfCommonSharePerUnit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of common share per unit.",
        "label": "Number Of Common Share Per Unit",
        "terseLabel": "Number of common share per unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r731"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reporting segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r557",
      "r731"
     ]
    },
    "pmn_NumberOfVotesPerCommonShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "NumberOfVotesPerCommonShare",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityRightsOfCommonSharesGrossProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes per common share.",
        "label": "Number of Votes per Common Share",
        "terseLabel": "Number of vote per share"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_NumberOfWarrantsPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "NumberOfWarrantsPerUnit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants per unit.",
        "label": "Number Of Warrants Per Unit",
        "verboseLabel": "Number of warrants per unit"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_OfferingCostsAndAgentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "OfferingCostsAndAgentFee",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 2024 private placement.",
        "label": "Offering Costs And Agent Fee",
        "terseLabel": "Offering costs and agent fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "verboseLabel": "Laboratory and equipment",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating loss",
        "totalLabel": "Loss from operations",
        "verboseLabel": "Net Operating Loss:",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r546",
      "r730",
      "r732",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segment",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r552",
      "r553"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r67",
      "r68",
      "r82"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other general and administrative costs",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r808"
     ]
    },
    "pmn_OtherNonEmployeeResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "OtherNonEmployeeResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense incurred for other non employee research and development costs.",
        "label": "Other Non Employee Research And Development Costs",
        "terseLabel": "Other non-employee research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Miscellaneous",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r738"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r626",
      "r636",
      "r669"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r629",
      "r639",
      "r672"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r629",
      "r639",
      "r672"
     ]
    },
    "pmn_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to patent costs.",
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs of units",
        "verboseLabel": "Transaction costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchase of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "pmn_PercentageOfOriginalAmountInvested": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PercentageOfOriginalAmountInvested",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of original amount invested.",
        "label": "Percentage of Original Amount Invested",
        "terseLabel": "Original amount invested percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "pmn_Pmn310DevelopmentProgramCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "Pmn310DevelopmentProgramCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense incurred for drug PMN310 development program costs.",
        "label": "PMN310 Development Program Costs",
        "terseLabel": "PMN310 development program costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "pmn_PostModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PostModificationMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to scenario after modification.",
        "label": "Post Modification [Member]",
        "terseLabel": "Post Modification"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_PreFundedUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PreFundedUnitsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Pre-funded units.",
        "label": "Pre Funded Units [Member]",
        "terseLabel": "Pre Funded Units"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to pre-funded warrants.",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre- funded warrants",
        "verboseLabel": "Pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_PreModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PreModificationMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to scenario before modification.",
        "label": "Pre-Modification [Member]",
        "terseLabel": "Pre-Modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Shares [Member]",
        "terseLabel": "Preferred Shares",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r805",
      "r809"
     ]
    },
    "pmn_PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to prepaid and accrued research and development expenses.",
        "label": "Prepaid And Accrued Research And Development Expenses , Policy [Policy Text Block]",
        "verboseLabel": "Prepaid and Accrued Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_PrepaidExpenseAndOtherAssetsCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on prepaid expense and other assets current.",
        "label": "Prepaid Expense And Other Assets Current [Text Block]",
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r559",
      "r738"
     ]
    },
    "pmn_PrepaidLicenseFeeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PrepaidLicenseFeeCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for license fee that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid License fee, Current",
        "terseLabel": "License fees"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_PrepaidUpfrontResearchPaymentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PrepaidUpfrontResearchPaymentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for upfront research payments that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Upfront Research Payments, Current",
        "terseLabel": "Upfront research payments"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_PricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "PricePerUnit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the price per unit.",
        "label": "Price Per Unit",
        "terseLabel": "Price per unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds from issuance allocated to common shares",
        "verboseLabel": "Proceeds from issuance of Common Shares pursuant to 2025 and 2024 ATM offering, respectively, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "pmn_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross proceeds from issuance of common stock and warrants.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Gross proceeds from issuance allocated to common shares warrants",
        "verboseLabel": "Proceeds from issuance of warrants from October 2022 PIPE",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "pmn_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) net of issuance costs.",
        "label": "Proceeds from Issuance of Warrants Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of warrants net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds from the sale of Common Shares, Common Share warrants, and pre-funded warrants",
        "verboseLabel": "Aggregate gross proceeds",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r442"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "terseLabel": "Maturity of short-term investment",
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r63"
     ]
    },
    "pmn_ProceedsFromPreFundedWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ProceedsFromPreFundedWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their pre-funded warrants.",
        "label": "Proceeds From Pre-Funded Warrant Exercises",
        "terseLabel": "Proceeds from exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of pre-funded warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Payments made for consulting services",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r589",
      "r807",
      "r808"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net (loss) income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r115",
      "r123",
      "r129",
      "r137",
      "r143",
      "r146",
      "r147",
      "r205",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r337",
      "r340",
      "r342",
      "r345",
      "r346",
      "r358",
      "r381",
      "r414",
      "r424",
      "r451",
      "r494",
      "r515",
      "r516",
      "r571",
      "r572",
      "r590",
      "r717",
      "r745"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r392"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r97",
      "r100",
      "r423"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r392"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Depreciation term",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r252",
      "r260",
      "r290",
      "r291",
      "r292",
      "r300",
      "r364",
      "r408",
      "r409",
      "r410",
      "r429",
      "r431",
      "r439",
      "r464",
      "r465",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r538",
      "r539",
      "r558",
      "r562",
      "r566",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r583",
      "r741",
      "r747",
      "r785",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r252",
      "r260",
      "r290",
      "r291",
      "r292",
      "r300",
      "r364",
      "r408",
      "r409",
      "r410",
      "r429",
      "r431",
      "r439",
      "r464",
      "r465",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r538",
      "r539",
      "r558",
      "r562",
      "r566",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r583",
      "r741",
      "r747",
      "r785",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "pmn_ReclassificationOfPipeWarrantsFromLiabilityToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ReclassificationOfPipeWarrantsFromLiabilityToEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The non cash part of reclassification of July 2024 PIPE warrants from liability to equity.",
        "label": "Reclassification Of Pipe Warrants From Liability To Equity",
        "terseLabel": "Reclassification of July 2024 PIPE warrants from liability to equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of significant expense categories",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r610",
      "r621",
      "r631",
      "r664"
     ]
    },
    "pmn_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Registered Direct Offering.",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r259",
      "r397",
      "r398",
      "r416",
      "r422",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r493",
      "r524"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r397",
      "r398",
      "r399",
      "r400",
      "r416",
      "r422",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r493",
      "r524"
     ]
    },
    "pmn_RelatedPartyTransactionFundingCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "RelatedPartyTransactionFundingCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of funding commitment in related party transaction.",
        "label": "Related Party Transaction, Funding Commitment",
        "terseLabel": "Funding commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r498",
      "r499",
      "r502"
     ]
    },
    "pmn_RelatedPartyTransactionTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "RelatedPartyTransactionTermOfAgreement",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of agreement in related party transaction.",
        "label": "Related Party Transaction, Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r259",
      "r397",
      "r398",
      "r416",
      "r422",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r491",
      "r493",
      "r524",
      "r794"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r398",
      "r401",
      "r448",
      "r449",
      "r450",
      "r500",
      "r501",
      "r502",
      "r521",
      "r523"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r540",
      "r552",
      "r803"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r622",
      "r632",
      "r665"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r612",
      "r623",
      "r633",
      "r666"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r630",
      "r640",
      "r673"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Severance",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r742",
      "r743"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r77",
      "r420",
      "r436",
      "r438",
      "r446",
      "r475",
      "r579"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r134",
      "r135",
      "r136",
      "r138",
      "r143",
      "r145",
      "r147",
      "r206",
      "r207",
      "r211",
      "r326",
      "r327",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r349",
      "r351",
      "r352",
      "r354",
      "r356",
      "r390",
      "r391",
      "r433",
      "r435",
      "r452",
      "r809"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "pmn_Rule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "Rule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rule 10b5-1 Arr Modified Flag.",
        "label": "Rule 10b5-1 Arr Modified Flag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds allocated to Common Shares",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price",
        "verboseLabel": "Price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r261",
      "r707",
      "r726"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "pmn_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of common shares reserved for future issuance.",
        "label": "Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]",
        "terseLabel": "Summary of common shares reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of deferred compensation share based arrangement liability.",
        "label": "Schedule Of Deferred Compensation Share-Based Arrangements Liability [Table text Block]",
        "terseLabel": "Summary of share-based compensation liability activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of the deferred taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of computation of basic and diluted net loss per share attributable to common shareholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of total share-based compensation",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of major categories of assets and liabilities measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r392"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsUbcCollaborativeResearchAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r498",
      "r499",
      "r502"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of the activity of share options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of fair value of share options granted estimated using Black Scholes with the assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityRegisteredDirectOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r73",
      "r75",
      "r76",
      "r77",
      "r109",
      "r110",
      "r111",
      "r171",
      "r235",
      "r236",
      "r237",
      "r239",
      "r242",
      "r247",
      "r249",
      "r442",
      "r443",
      "r444",
      "r445",
      "r562",
      "r706",
      "r720"
     ]
    },
    "pmn_ScheduleOfWarrantExercisePriceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ScheduleOfWarrantExercisePriceTableTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular Disclosure of warrant exercise price.",
        "label": "Schedule of Warrant Exercise Price [Table Text Block]",
        "verboseLabel": "Schedule of warrant exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r169",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r182",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r203",
      "r547",
      "r550",
      "r551",
      "r552",
      "r554",
      "r556",
      "r557"
     ]
    },
    "us-gaap_SegmentReportingOtherItemCompositionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemCompositionDescription",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Composition, Description",
        "documentation": "Description of composition of other segment item not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r181",
      "r182",
      "r196",
      "r552"
     ]
    },
    "pmn_SegmentReportingOtherSegmentItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "SegmentReportingOtherSegmentItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "negatedLabel": "Other segment items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r199",
      "r202",
      "r548",
      "r549",
      "r555"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSegmentReportingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "pmn_Series2PreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "Series2PreferredSharesMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to series 2 preferred shares.",
        "label": "Series 2 Preferred Shares [Member]",
        "terseLabel": "Series 2 preferred shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of units outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of options to be recognized under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value of Options",
        "terseLabel": "Fair value of option awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "SHARE-BASED COMPENSATION",
        "verboseLabel": "SHARE-BASED COMPENSATION",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common Shares available for grant under stock option plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares redeemable per unit in shared-based payments award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Redeemable Per Unit",
        "terseLabel": "Number of shares per unit"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value of options in a share based payment arrangement.",
        "label": "Share Based Compensation Arrangement, By Share Based Payment Award Options",
        "terseLabel": "Fair value of options in a share based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years) and Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options granted.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Fair Value",
        "terseLabel": "Grant date fair value of share options granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the multiplier for volume-weighted average share price for calculation of exercise price.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Multiplier for Volume Weighted Average Price for Calculation of Exercise Price",
        "terseLabel": "Times of exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning",
        "terseLabel": "Options issued and outstanding under stock option plan",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Share Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold trading days volume-weighted average share price.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Threshold Trading Days Volume-Weighted Average Price",
        "terseLabel": "Threshold trading days volume weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable at the end",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable at the end (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "pmn_ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value of options in a share based compensation.",
        "label": "Share-Based Compensation Arrangement, Weighted Average Fair Value of Options",
        "terseLabel": "Weighted average fair value of Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche one",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShareBasedPaymentArrangementOptionPerformanceAwardsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time relating to performance awards.",
        "label": "Share-Based Payment Arrangement, Option, Performance Awards [Member]",
        "terseLabel": "Performance Award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at the beginning (in years)",
        "verboseLabel": "Outstanding at the end (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at the end (in years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares",
        "terseLabel": "Warrant liability",
        "documentation": "The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r713"
     ]
    },
    "pmn_ShortTermInvestmentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ShortTermInvestmentsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for short term investments.",
        "label": "Short-term Investments , Policy [Policy Text Block]",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r109",
      "r110",
      "r111",
      "r129",
      "r153",
      "r158",
      "r161",
      "r163",
      "r171",
      "r172",
      "r205",
      "r221",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r235",
      "r236",
      "r239",
      "r242",
      "r249",
      "r381",
      "r442",
      "r443",
      "r444",
      "r445",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r474",
      "r495",
      "r517",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r706",
      "r720",
      "r728"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r55",
      "r56",
      "r103",
      "r117",
      "r118",
      "r119",
      "r134",
      "r135",
      "r136",
      "r138",
      "r143",
      "r145",
      "r147",
      "r170",
      "r206",
      "r207",
      "r211",
      "r251",
      "r326",
      "r327",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r393",
      "r426",
      "r433",
      "r434",
      "r435",
      "r452",
      "r517"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r170",
      "r391",
      "r411",
      "r440",
      "r463",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r496",
      "r497",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r584"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Shareholders' (Deficit) Equity"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r261",
      "r707",
      "r708",
      "r726"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r170",
      "r204",
      "r391",
      "r411",
      "r440",
      "r463",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r496",
      "r497",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r584"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r625",
      "r635",
      "r668"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series 2 Convertible Preferred Shares (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r52",
      "r55",
      "r77",
      "r233"
     ]
    },
    "pmn_StockIssuedDuringPeriodSharesDiscountedWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesDiscountedWarrantExercise",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of discounted warrant exercise.",
        "label": "Stock Issued During Period, Shares, Discounted Warrant Exercise",
        "verboseLabel": "Shares issued for discounted exercise warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued",
        "verboseLabel": "Issuance of common shares, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r77",
      "r442",
      "r517",
      "r532"
     ]
    },
    "pmn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series 2 Convertible Preferred Shares",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r55",
      "r56",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common shares, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r77",
      "r452",
      "r517",
      "r532",
      "r590"
     ]
    },
    "pmn_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_StockOptionAndIncentivePlan2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "StockOptionAndIncentivePlan2025Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Stock Option and Incentive Plan (\"2025 Option Plan\").",
        "label": "Stock Option And Incentive Plan 2025 [Member]",
        "terseLabel": "Stock Option Plan 2025"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2015 Stock Option Plan.",
        "label": "Stock Option Plan 2015"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total shareholders' (deficit) equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r69",
      "r476",
      "r492",
      "r518",
      "r519",
      "r579",
      "r591",
      "r721",
      "r737",
      "r791",
      "r809"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders' (deficit) equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r128",
      "r234",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r251",
      "r355",
      "r520",
      "r522",
      "r536"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse share split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r403"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r403"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r403"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r403"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r403"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r404"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityAtMarketOfferingAtmDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails",
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails",
      "http://www.promisneurosciences.com/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Credit carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxJurisdictionOfDomicileExtensibleEnumeration",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Jurisdiction of Domicile [Extensible Enumeration]",
        "documentation": "Indicates tax jurisdiction of domicile."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r570"
     ]
    },
    "pmn_TerminationWithoutCauseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "TerminationWithoutCauseMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to scenario, termination without cause",
        "label": "Termination without Cause [Member]",
        "terseLabel": "Termination without cause"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold days after the completion of milestone events within which the warrants should be exercised.",
        "label": "Threshold Days After Completion Of Milestone Events, Considered for Expiry Term",
        "terseLabel": "Warrants expiry period"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold days after the completion of tranche milestone events within which the warrants should be exercised.",
        "label": "Threshold Days After Completion Of Tranche Milestone Events, Considered for Expiry Term",
        "terseLabel": "Threshold days after completion of tranche milestone events"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ThresholdDaysToGetShareholdersApproval": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ThresholdDaysToGetShareholdersApproval",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of days from the closing date to get shareholders approval.",
        "label": "Threshold Days To Get Shareholders Approval",
        "terseLabel": "Threshold days to get shareholders approval"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold share price of the common stock to met or exceed for vesting of the options.",
        "label": "Threshold Volume Weighted Average Price Of Common Shares, Stock Price Trigger",
        "terseLabel": "Threshold volume weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r793"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "pmn_TrancheBCommonShareWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "TrancheBCommonShareWarrantMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche B common share warrant.",
        "label": "Tranche B Common Share Warrant [Member]",
        "terseLabel": "One Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_TrancheCCommonShareWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "TrancheCCommonShareWarrantMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche C common share warrant.",
        "label": "Tranche C Common Share Warrant [Member]",
        "terseLabel": "One Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_TrancheaAndBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "TrancheaAndBWarrantsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Tranche A and B warrants.",
        "label": "TrancheA And B Warrants [Member]",
        "terseLabel": "Tranche A and B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_TrancheaCommonShareWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "TrancheaCommonShareWarrantMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche A common share warrant.",
        "label": "TrancheA Common Share Warrant [Member]",
        "terseLabel": "One Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "USD"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_UbcAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "UbcAgreementMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to UBC Agreement.",
        "label": "UBC Agreement",
        "terseLabel": "UBC Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "pmn_UnitedStatesDollarDenominatedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "UnitedStatesDollarDenominatedWarrantsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to united states dollar denominated warrants.",
        "label": "United States Dollar Denominated Warrants",
        "terseLabel": "United States dollar denominated warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_UnitsIssuedDuringPeriodSharesNewIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "UnitsIssuedDuringPeriodSharesNewIssuance",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of units issued during the period.",
        "label": "Units Issued During Period, Shares, New Issuance",
        "terseLabel": "Number of units issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Change in fair value of financial instruments",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r511",
      "r512",
      "r513",
      "r514",
      "r529"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r317",
      "r569"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "verboseLabel": "Interest expense or penalties",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r569"
     ]
    },
    "pmn_UsDollarShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "UsDollarShareOptionsMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to US dollar share options.",
        "label": "US Dollar Share Options [Member]",
        "terseLabel": "US Dollar Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r93",
      "r94",
      "r98",
      "r99"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureRelatedPartyTransactionsNeilWarmaEmploymentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "pmn_VolumeWeightedAveragePriceThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "VolumeWeightedAveragePriceThresholdTradingDays",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price must meet or exceed specified share price to trigger vesting of options.",
        "label": "Volume Weighted Average Price, Threshold Trading Days",
        "terseLabel": "Number of threshold days"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "pmn_WarrantExercisePriceUsd0.25Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd0.25Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $0.25.",
        "label": "Warrant Exercise Price USD $0.25 [Member]",
        "terseLabel": "Exercise price 0.25"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd152.50Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd152.50Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $152.50.",
        "label": "Warrant Exercise Price USD $152.50 [Member]",
        "terseLabel": "Exercise price 152.50"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd187.50Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd187.50Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $187.50.",
        "label": "Warrant Exercise Price USD $187.50 [Member]",
        "terseLabel": "Exercise price 187.50"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd240.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd240.00Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $240.00.",
        "label": "Warrant Exercise Price USD $240.00 [Member]",
        "terseLabel": "Exercise price 240.00"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd31.25Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd31.25Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $31.25.",
        "label": "Warrant Exercise Price USD $31.25 [Member]",
        "terseLabel": "Exercise price 31.25"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd315.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd315.00Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $315.00.",
        "label": "Warrant Exercise Price USD $315.00 [Member]",
        "terseLabel": "Exercise price 315.00"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd43.75Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd43.75Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $43.75.",
        "label": "Warrant Exercise Price USD $43.75 [Member]",
        "terseLabel": "Exercise price 43.75"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd50.50Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd50.50Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $50.50.",
        "label": "Warrant Exercise Price USD $50.50 [Member]",
        "terseLabel": "Exercise price 50.50"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantExercisePriceUsd62.50Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantExercisePriceUsd62.50Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price USD $62.50.",
        "label": "Warrant Exercise Price USD $62.50 [Member]",
        "terseLabel": "Exercise price 62.50"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantJuly222025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantJuly222025Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 22, 2025 Warrant.",
        "label": "Warrant July 22, 2025 [Member]",
        "terseLabel": "July 22, 2025 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "pmn_WarrantJuly282025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantJuly282025Member",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants issued in July 28, 2025 PIPE Offering .",
        "label": "Warrant July 28 2025 [Member]",
        "terseLabel": "July 28 2025 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityTables",
      "http://www.promisneurosciences.com/role/DisclosureEquityWarrantsLiabilityDetails",
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareOutstandingPotentiallyDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants.",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588"
     ]
    },
    "pmn_WarrantsAndRightsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.promisneurosciences.com/20251231",
     "localname": "WarrantsAndRightsDisclosureTextBlock",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on warrants.",
        "label": "Warrants And Rights Disclosure [Text Block]",
        "terseLabel": "WARRANTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureEquityEquityTransactionsDetails",
      "http://www.promisneurosciences.com/role/DisclosureEquityExerciseOfDiscountedWarrantsAndPipeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants exercisable term",
        "verboseLabel": "Expiry term (in years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average outstanding Common Shares, diluted",
        "verboseLabel": "Diluted weighted-average common shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r163"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.promisneurosciences.com/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.promisneurosciences.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average outstanding Common Shares, basic",
        "verboseLabel": "Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r163"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001104659-26-034554-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-034554-xbrl.zip
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M6ODA7X /=1; ]VE2^QK)YS5L>FH;?T9X0:IQ:S\V7<)=4?@X^]Y1"Q/?"O(
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MY;B%DN2\KZ$H<?WY*%.PCS57L.*O)406+>>44,7B=3.'\<DN>0EFV/2<N;&
M_%(FQ1'W833X=MC8U*PM6>"W&79)\DY UV/FPAKH_^L%WRQ*QLJ.9/,7[ZW@
M1/[1W;7G4\O)-W8;BC3'6TY:0WM9T&KA%OHG5<STVKEDN4L5??'5JB1ZK-S%
MBKYAI!KN!R5K*'XZF[KH>,,%' ?(:&WAZ%6EOS11,T:K*OW%B9HU.M5+U%!<
M/X/,8I#;^X1-O,Z<9HNI:BA6<<;_:<\/7.[!@=A5.AQ8[D+R5]R7]*_522])
M%<F_KSK\U 8Y'6U#MOCG_P-02P,$%     @ 0(1Y7)*HWUY4#0  5K8  !0
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MOZ33Y70#B.TMA4&-DBX/YI%*5W<&?CL*9(_PTA#?0JH9F%H$/!&P4:$^?M\
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M7VQY%JV_JNJ&6[C; (9)W6^XXW9M&SM?_+;K\EVAAOH"C*\U]\O&"51QAJ*
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M V.Q:51Z>2O'Y?'9!9Q7M)J3*!6U5B%/EGC!1EM2N;8=1ED MAT%5<V=5NF
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M\58%6-4"PX8!1S)/GKM R/1O,<341+0U8Q#*678R<;U6954U'[$$'NA"2R<
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MOPLQ@N"WW(48B<)OSD\N+\ZU7\XW&V*48&PJ#B9G*WOVS;/^U[.^*"2&6PF
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M) (_@5VG]?%1)_\;3E58JVO,K6%YOQEV2,UEV%1/A[S/INY &N46;'5J0&]
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M@H@^:9SP990GQ^V(8*V;F8/P F(95CLOH(-PY="]_'1>0 >K.H6UYV(PZ+R
M]AG2N95H]OP!ZU8214@@- N,(/0Y2SRE7/O+/.MRJLEEG@(<CL"XTRVU)(R%
MEJEU3,Z#6"LK\3X_,5^<],\&8%:JLO*@8@*RG4E']V[PCU=KV]T@1%VHRC0
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MU66R;18!FPY?Q,A?J);XY P^)1C]W?:0-_'5WQ> _$VEI[CZN0%,M<H,JBS
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MAV\]@$N$B/WM6\Q[*PZD^OO_!U!+ P04    " ! A'E<*>?,8VF&  #%H @
M%    '!M;BTR,#(U,3(S,5]L86(N>&UL[+UM<^,XDB[Z_42<_X#;]T1,=83<
MW54]/=,]L;LG9%ON\1Z7Y;5=/;NGXL8$+4(R=RA20U*N\O[ZBQ>^@!1 @B1
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M')TO1Y:_ 0O/TE,]] [4VL:8B2?TT4CGC*8:8 9^T4L,.^X!(:Z[C@['+&6
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MD\$4'0MMCQE-[#C@)(A]]LY,A-$K&8S6Y,N>,8KHJX,AH@]R$SYH#=_734A
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M=#ASI?ZZS"XG^RE*#WC#:O=?QGL2G<@$;VD+V/RZ)"Q-4-40J!EVLCO>%/F
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M&AV5PZ-J_,E7WI-)6_ZNAC-&:R#Y*?5_^N&[GW[H2AYM[P07?_1E;J24MO2
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M&=K<#X_UV0$#K=KFXR1XH9>9Z)%"='K9B;\V[T513,\YT#$+0E['+6*O%--
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MUZ"+_H'0=SWD,]/1M\"&$[QW5D;VNCWNR>%-<QY.4@O2 8PXTFSR 8RW4"G
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MEGWP54O>,%/6EHU)N;?+1?#6*W;[S(0=@>,0K=+/ /]B,U9*.AX44.<M.6C
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MV="*=@L3$]JR)JIF0ZM\%G7.H2W%DX#;49L")J\TZ5P'NF<E\M.:W7MI2!?
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M-B=VD*)G\'2#8A"=$86!@LW/=\@K3#/3KYJR*]1%NSE0BKY$*&Y*-#3S63L
MPC$N6D0655=Q4,O$S<FF*.0H%H(C'L/BA633?:9^\"I5:!U>N=;FV]SK!>I]
MN]GJ8:=I;-DXTGZS.1Q*H3KJJ9D-F72'9(:!.?ZNV=LU_ !A1HZ5D4VW94[)
MV< Y/8D3HOKTV/!CVT;;$N^>\^Y\+1/<?7HBN<K%W%+-[&5\2C8B9I,EQ?)?
ME5QD6V8B$/UI=F;JKJX9'BSL@D-12S965*;A^ *65U)2GA]OY9-$MP#VSK(/
M*+Z_AS ]F%:AMCZ)58+\E#_/_@H<+^(E?O,4*2$=A4K<.F7!YO207,C&*<!&
MW/'$RLBF^"SE8-4IYPZCK)VP-T_"T0"'R=Q,-T7G:$%2,E"M +S@BMYF5,"8
M]7>K(&,N+21$V!MV^S5D#!FN\CN%2MY=]/OP_VJ[I\@EBQ*2*W'(YG7K,CLV
MS9-FH!&RT@S-3O.VIZ@E&QURJ2Q^XLB+6OZ'%BG(@C1AVAX.H+5F[X%[9YDG
M9V[FHP=U<Q^#-\7$(=6C#EI"K< [L+VSN!?*::(9FY/A:1(Y%]"QB-S&QZ!.
M#AG4*\ABIKT)9V[RK4+.5UC0=6;(/*1;VZ\V/LI6"5^J&4>KEE2] C_FMYRF
MBNTWH._?H#+':(+8@^D/N,CH#EC8.C8_<(4]^*C,+UF"\B<,+CHWK&';SIME
MH.,Y>M9\KYV=7RWC=  )8:41O?H.U(SGD@BP7IF)/6F]9@OT-?7&++!Z+9'H
MG.M)@C3%\_Y67$>#=F_44YGDU<NJ7EF-<T\04;GY"V"+]UX\Y1-U9F^9(N*5
M%%G>O<;3R7#UHZ$#^\&R\4L4_&/DW#W?D;;:LG2K9J276JS!0!G5(.C&-8B0
M,S:W?O[T/2R=)]-P^S90\&3^]#1;/TV?UZO&^/D>_OR\GCU_G3Y/9M.5_,$S
M2-*YP,1$TF"L*RJ<1BP88?1<"SO];)D;S)^C%VUTL39X?2@Q(@>#D1BWAES<
M2(_&4:IH5/:70<Z#\UT$,L'_+;5L0B+#3D<63[A2=7Y+-GKIJ,R76SEJZ:(C
M>LPPMI*4(A2C4([1J_J6)CR@R_8$X.5UDQU\^+:0;&KEH9KX_IH2L_(^=!RF
MVBSO*9Z?D(UXPM:LTH7*R=$BGF2,<_STZ#R^V=@GS7#@@75IG37#/8=Q0E,F
M-/9&9.-=Z>J/SX:<!"9ZMF0)OXP\2N!.(5P#4EA$5_&#,Z> D$1[&Z>_F?2<
MU![U#<K0%9 ][9%D2K$/S@1JD=0H;.\S\!+.+X#M&6.9K8:=6ZOA\W3=>)RO
M5HW%=-E8_7V\G,IO*IQJMJF;^XL<,N+KXHM7O#<V-,>9[W[SSA+NW/9N-TD&
M/7R%.-&'W=Y ;)[*+(W$MIILJ%2VD:1")=C5L.43DNDU!X+G>C8=4I( B[1V
M'" ^,R744(('6#52TH  539[U\(&*$,(V 8(\#$*,"654"A!(?$]&0M(3JHL
M8! H9VAGFJ^(E93@0^&)G@Q7]$&M'%X\G]!0F.]68'."9P<=.!/-,,#V[AP.
MEJ @$W'H6U6"661B4+*KH$Q*F9@D.3$BYYZ3&SC?W&F.OH&'\WO=.+E@&\L5
M7^"(>9/T)>6(^:41Z4G#VC5>45\:FKEM;/W>-$S@-G2O/XT_P::</S>.P&XX
MJ%.U.:'*<C*-J7[\#D6+9OBUA?PN+-,+G(A\SN&$ZG.&?-[.V5IL, Z;HUYG
M)&2"8CG+\H0JVII=-8OXL$<6UI3!B,)\*Y-G(C?>"=?2RX*/AJLS/[F.JWEI
M&S,F*M9F9.$:RPS%!:/R.W):*9 F)J8V9*$*5QKD9U>M9R,X(]O>599F!/.P
M!W_LNK;^"O>X_@P-CR"!KSS<<H<'$0S5"K3X08C'6T)2Q0&IAI&DJ)^%B$EL
M^).?1015K_ C&-D']H@;%;"MR[A6/@@!>4B%4X@0D6MS<JM,VN"EEOT@=*''
MSBE*ADRD" 8%)2V"TG'AM+J#GMCG+A41@X2>4V2)%&H(,99'A+:P7/@='>XG
MSYX ]'<07=9S6,D[5%;R2!<:QVL??",Y[$1CX_7"-XL[GW9QSMV]NN./H>1#
MH5_OE:8_-L8)JO@!\BMVM9($0/=LD\='$@.SWVF)\0QCL5%5( &5/8@*"N7N
MG-X *3E4>5^4A9\5<N^6\%7+MW[LS\Q.E55--AY630E:4F9(3&5F^1%A 8@D
M!B2^5<:65X-+&9I,V?HSX57^^CJP#Q,I$"M34[5G8Q283C[5"_<^^*HW$[Z8
M.L$-%U>T9KIDAEJ"85F&;0+U^OF8X;7+J_FX\-LMT>9$%;>_9&$J[ZM04#I^
M+/MR:.RWG1![N]F5<:[D1"?N["7(L*PM5#76T]7IU0'_.<$6I^_H I/9*-J]
M?9VZ>KE;3?_Y,GU>-Z:_>I'MI#=Q)L60X8.&+UZQJ3/>#Z+!,J5HDL^]?EOL
MNI:AA9CYD1:/RH?=)$AR=GA,:<FUC-=<MM))"&NF=W)6=UQYV75/4B"5^@DP
M:T0 <O[*M+(**)Z@NDS5$T J;])"4.%>5;//*PV=\3Q+7L:TGUI>=@XP3OST
M& 6:NHIK_XH/&8[FNTBH'?(:D%DQ(:NAZ,>D;$I-(44^Q+*%(_B'9IZ@#.#O
M^PM;?]=<L#"T#3D:9V:=!/)1NST0J^M\NHH;1_.A%KT@L"I]YC@G/[8^+M<Y
M>P.RT"&_%JF90(M>75K@$IJS-_ A:4%&+]H278 6L(&"\T6DB8])C0S\RE^X
ME1/;3(;]1?ZS!1M&3A2H650S"1C ID9*&A"@RG:,B+BV9\8UPY950JD$I<3G
M?#:84FX(4R#0G0_H*LJB;W9M96I:Z7, $0]I_T]7\4.H7<%]/AD/<7]/6_5C
MJ%[R?7P%84F'G>ZH+=9-K=CBS0)2]&!.WYD[MAO9E<.?KCMR^,,?:^1%,]_-
MS*W^KF]/FI%R#L.6DTW7.<Y?;-@X/6OG=^YBU>YONOOF)<) D4W>]./:FIJN
M[IY3SU\Y6I"%$6QJS:!##LBRG<ON=1ML8%$4S>9),[4]^6:'5%QJ%>=057S"
M9T8N>N?.V\OC,<.='5=<%EKP=_ B0^04U$*<_A>VM0%@ZR#W8[1YU4QX6+7]
MJ]+I?TYP\&"8D%U1<DZ0%7O+BYR *XH*7=V$@>[/O6/.]OYDHQ 7 '8F" ST
M#+Y[?\).'U25:T:< J#K%5U._O#VPVZSWV^J3+8RI,')5,%K"DLW6Z7A]@==
MFJ4*7SHA@59K(#@;>3X^Y$%92M@VD4O5U>'+,\F%+ZFRO1=CQ6O"B%PP2PG:
M5L70#Z$%OZ6= Q+5:J+Z0G!+"<XFVRYD^@/8&]T)+NMVR66QQ;+WR&JK)J3B
M+X. :0,I=KNI4PVZU'%0HH1[[>R,=_!+Z,FN ?P7NT^Z 1S7,H'_='!BF8X.
M$8'M@V5/?QQU^XS2#:=,13R:K0FK2A5'0+"AK!E]O6\Y8//SWGK_!6RV_N=F
M/L"UK7EA.%.";6<\D>YUN[WD ^F@T4;0:B/1;.DOI*,H_4E[L[W.U?"'/VY@
MXVR3684YI&8_&:#5?.VU8,-/UE;?Z9!MAI8,+$TJFN#CL#D4\Q"*3K*7K.DL
M:$)+EXC[L52U/5LF@^8(I=54'BN@4']%-_M1_94\&2XL0]_HP$&V6?K)<) U
M&8;->GGE/+OO%A9DF1<#],PX-^< Y^3\BE89SUYS7NK.M^MUU-C<KEQ;<\'^
M?$5!B[[7:R;1QS[50-]J7#_FB2#\7"/V/199_/47?[@%O_N?_Q]02P,$%
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M 3T?J<LG3!/92:(X;_4638B#-=6!7P5@\PG*,OP\E($5\1D.CI:IR13+AT4
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M.-U</NGI8N!V.MPE6E]2.X3JI^+$3,*)FUQ[R')$M)#PTD^@7-5#?^"KX[Q
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M]-]<:-K^+@QL0W4=\-?&I[O^\M+I%8\S$;]:/%K_^] /#JE]?6K[CO4.^)=
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MK+3#EDNYY( '46;(,=-X 0Q)<IRLIQKO3G+6J[6+\. +/-W+);C09MHSUA8
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M]\#B#=W[E6IS-9?6*5?A-<_\2^L9K1#ECS/MVK(.[/W8NFSH'E?K5@L*-6N
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M^'QP,>F2^_N[,@GBY:O=PZ.-M&^D?9VT/\O2'$_&XI*3"K<_MU4F"=A-D=W
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MO%:==9C8IL-W!Z)@A>=H44(.(#0P#E..[OGI+,:">M'&8&T$_QYX 8GG>N#
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MF@S5'"S 4P&'^M.4%<ZI3S@'F1M$!_^N4Y2A=82M;+T[:GADNWWK]#OG9NU
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M.78Z2@(D= C0P(K=/Q#]/2M)P0,>AAO.)HL*'2YY91$MHH+ 4Y3(=("1)L4
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M,Q.76;/ <[@*],U("$7Z/(E>H\>(_-'?WP4F"L @AHYQG)0]F<SGL^KQHT>
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M072/9?D0JX!M9[LF3,)Q+OAS>QTMA3"<N$<G6C;$6@9AVFMN0!@.M??!SA8
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MMIPB?[--!JZTF4LK]IJNQ!_0,]O?>&8;S^Q!@3F?B<L P\258YCX2SR=/;$
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MS=\B9[F5ADNIT9YI@V/M#DNF,BE"[(\A\IK^,L'I='6]YF$0()<6=PB6YP;
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MH,K7!7%J4O^->MU7B)@SI=J"];NJM^#=@4 %?R13RXVFS>QC;5'^$90KNJF
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M[81IRFGS\S?AZ93U48D?H@)0VJ!$JAU@^W-/?++7!FS+=PGJ'S5DPA\TJI-
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M;#$>P91TR[NMH[AY"KQA'IDAFE4?6]4S:ME#J#+4DR7W-K]+WIRF+KT:&?9
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MYGON_+OKM?1;#'.1N5$W6\+3" B8JGW?$>4WS5U+%VWO;K88.%T*Q*IV4D*
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M*&4SF8XRXM"'KLH_-+M-^NE2LW,]N2QD2<H?'1S!9(4%0E@_Z:+I&RIA;K6
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M@.C^?H)WW2'Y ^>5RK1L+H$\ #>%4#7)56%WQD;";_\1G8K:L8K$NI%1R3E
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MVQ9>>HXHW>]3O%M4Q> =^]=2W.S7-1@)I#S<=/YOFOZE7*T+UG2A;VMQ\.4
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MQU8LY6<EF9-- [$,'UA"S"HC:Q"E#"5[UC^_^J[PU3D(3ZVPB3!X63JK$8Q
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M;51MYCC^W#5<_7CF4^ETG4YJGQG+'(W5Y2]+)P =M9&EEW=YXOZG!JXOVP$
MU5TG(5\1$Z["'4N>W.)B]:<0R1B%LI-1<*?)*YZA7+L"+PAF8V#!PM&T</T?
M/,&H_R3=A_* ,Z3>H\R.X(V/JVSD?'[!+W#XH:'I(*+3TY0Z2#.#WZ<?%/,>
M<ZBW,AJ<VU7BF"GKB?Z&V2VV^B.L,K#;AOO\W4<?7+S ?LO>O'_3OJ&01[RJ
M0J!_UC3Z][][?O'BO?@W/"E51Q@FXBM7',!^ 4M*-,D?/J<1CH^GY\&9)^7-
MM^/J X:I<&%,*NIMF@SK]O*>(5J(AHN9+<+LB3PYIBXQS5=@%3B\DJ8=H1_,
M4 I7PU%G0HC245]VPO33ED30ESL*>0J/B:'=6YS@T:237_;)"E)Z(8W$<\B(
MC$V1;D';0[38755'Q[I@2/7LH8I] 3E4.520DQ4'@/*5K)GF]<7JJY(Y'6R!
MLB=[2_?1]X0*NI;[F#_0XTDNC'YRDL^9DQT6"MBP%9\YXZV'"/<4#L<^_W[-
MG+F0>!Q:0?]*0L_=66X%,C 2]P<S8V[#NH\64E 9%Q8/L4<O/OB\[)_!-9^Q
M%=+/GG\.OV:*'CKR]O#Z&K4C5_"=GOYQXDPF!YG,F3XMHC]/D_CODZ6ILS1U
MGC3QWUUIZJ*?$AJQ&_U;YOJ1<@!'G$HTQUAB"\Z4FXC^8DUY^*XBK_^0(..W
M(>HKWN:9DP^OF8=<'U@J',R08A%RLB9V-.>S7R,68V:X]"ZZV K2P&'JE>,)
M^9*"K4E4)2^9YDT"XDLIDOG=\P\_N/A( S4&W&P&+KFB$(5\TDH"="=TU!(A
M,A9\&"Q38PN#([S-0)$(#N7K*,7SCPL[Q?3.^'=Z>SP> QOLXGF\FQ_#).-P
MYZ5$J!-F$T'PSD:"DZA/&*\,6\IXH"SA(;(&YE@:?YQ)D.0>!>[,5%_(3,>8
M?(1@$:G[2?B!F"L/CGVJQJ6G<J3IM4V(IV_;G$H4"K&+6#'/X8C-DHA*6=@/
M\YG 0V]>>%<-;L.#3#E1J<^J:%%7D" D,^&9H\",3;!DF #_PO='DH3-L4C'
M"W$:IZ\&AU>N0KE-;%2'?Y2.!'U%N7<\:XY^<VTD,?34699*=5@\\%1N3WGX
MZVB?^"Y\8H3S%3ACF[,GP?A3_LQ7:D9*(>,:"H/<YHL='3-0RT2CEC1FN(+.
M4@7A9@B([I,*!N8YES;4ELDB!%:=3!).ZBM;TO_!(:9VH%X$IXN0[6 BO?>,
M./3H8_HDK>@1N#2F980#E.!=B.?98XPJJ*6V;V3E+8'S919]BS7.[4U-3)&H
M=>CU,F3KX9(]^J9$B9Q]<R/0?S@1'"S3VP[^&G\UZA&O&D8N=*AY<04A"?Q.
MZ5$D'<F4"$SPJ1#C<O>'+WE&-X,](JJ#0@@-0>DS^2=D//&9\>?XO_#HC>FN
MT)8Y"*.B',*1L,C3V1"H<BBEAN/ DF*F9%]"1H,OG)(C_T:T:?+ LU4<FE V
MS?@7>4BFO7<A'ST%U2E"E+)R?^=7@1RGZUE-=TZ11H+C5I) 6W&G[N$)4)6;
MH@!7S=<71)6/?.LIU,3A1I.^$7 KY<4BD;4MN!*GS'!&*Q<!WV]J1-T@U*GF
M?T96G%AE-)RQ07T9GU%ZMLY>\4_X>$.M6)=R UZ7"V%*7>6A[*U4$RF>2(;&
M:Y'>P !+- (2_B_]@NDBXT5GEE.'#K*_CV\OA>MT8'547&JC\T_^D'';LAWW
M)]XE-99*:>S+3I2)6Y'"L:]'S1WCC+:(+XZ6""QC$+&=E)2*\46>6>JQ-@;1
M&%[E#BFL 'XGM_W*;ONQ] =?W[U0E_B':F<G[X1VO'0:><+"J)9SGC\]L=6T
M#)_'NS\HRN/.!<ZD5GK[6HWCVU@^_B,][:),O C#SE?%N +MTD2MI6N6>%M9
M>]'$7BSO7I:W'BJ$3ONHM%>HD*./;]K+LA:;HS%MGYLMQK<8W[V,3]KGL94/
M<9 D$HW/?H@G5U !ULJD"HR0-U@#+6J1UMC>PT!OL<[%.N]EG5$C(^FT4WUJ
MOZ]*TD(5!&W5;AD1Q?E0%S;I<9U"$[QJ+D;6-R3$T:S(&2_VNMCKO>S5#?88
M7BM-O!;36DSK7J:U9?SE@'XJH;"(B),NA1Y%J-5B=(O1_9+H$'LQ,4*<ZV5Q
M=[+<R!&;55*5P2.>>3ACED\-+O7I I=:X%+WA$LM+GAQP?/F=\G3"IX2F!CB
M(-UYAND.@5VH^JT#I(J'O2(.6N,+I1%^\"S;9_(+7U"2'A6QF<#BP0\:1#CY
M2Q 6&M'B3GDP(7ZL:IE72\*3DM@K<91R2:N6/7#/,@"8$EKT\>K459#+"^$C
M0^[B3U?K<%5>H[R-R_\-Y+1MCKDFTV*4BU'>RRB/)#\<5N4-N#@B>AR3"WJP
MF%0&CO#)GJ%0Q,[ZB(SO@\7VGH[M#5P51417 ,-@^04XL'\" ZR9VWK.L/(!
M.[D>2Q8>9MB690RFLU<.YI#*_C(HJ<0=QGP/.OJLI"3$;4AA$7Y&,(2",56^
M!8/T50>P#X/T*7UKX0"W1E!=> X(#V[D]);9/AX-#<P/CC>)VHE#S45PC.-F
M9"O/TNB-8"S*Z'U Y)B(A"0S\0^)!HQ88 +B)L.^,P2!RMI2AP$^$ 1@1B,
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M[0E:+ZH#R/B> 5/U^'F26F"?+DBJ!4EU3R35 T3"L<;WLJ.4L9C=L.1)L1:
M*3W-T#HA0I-8PK].V:ZY\(,13#>T9/M&%>Q&S.+,[83G"#\JF:E2 U--I8ND
M]$F23_-[3&WVMOAY"R))6&(*IG_GPD=L=6\O+"2U$9:)4GK\6E-;K[TRGJ2(
M-<]Z+E%D-5E+E%$C;A!E6'BB!RU.X0,K*P'J:D(^/$2V:S?[Y)2A,5Z0L)#+
M-B=I*;M D<+*$EE0*5Z,M4S+N=&F: 0KU,1BO0M">2)CAL>RPKJ^7M#414D
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M2]$%:HY=G8- 8I).6&LO-,1!)?%WPOV[E*O$9TG'"@UVU77TW F!O&>.CX_
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MYUE0$I3XT^K+$/9W[;[<#,#>2LZ+11R^>IX5-2-VA]_DLBNW(OG!W22NB_6
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MZ26!U01O;HHA;B2.?%=MP>2M-=?FT&295:TSWJ )2LO*:90='QGRQ\KB:#Y
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M;48/-)@H'$T7J<*M%\^OJNNP3W&W\[,B7'EU1I?X!Y&R 9*CF.RO!4C\G!0
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MBGB.#YI,['?BD(K'JP$Q\Z ,TC!2N70^QMOD&D!;S* ^0I;75VV[+DQ3HM.
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MR2+87I$>$9I+'76XHSLK'778D<ILP?Q[ \$>H]WM#&AE-M!92C60*:N'6!J
MB]C\0.)*&1[NL+D^@^'1V[G>>FD+TP8SD&1*SN:-9H/[$[3_3-D,;3)5*EI$
MA!C961 +7-7-\U_.W<4?_-]^]_+\G+7CB#J4W^+;[WY^\?Q;?0G<6609FQ9*
M[Z6]@7Y(EITO:R9<C!B)R=.!]'-;=?FX^"=\Q;]G3,MG>=_WSY"3<MW'YRMK
M8^+%+%!SL!GC0!M)=DD8TD?A/O+ZQDH'^$AY&UU[C'97)[TQ"3%4VL!G-"/N
M5W+>"YXW$;&?I[J47J>9(9;H-=&"\[@\;C<BT"=$Z2*13\[VFF;+><HCO8%#
MG;H5:;KE">"-6^>/+BLWGH<6N+"4?EUI&E5Z>RB+I&8H$;/PL@('.)#F(28)
M.:MK.'==9L5"N/^,5I\ZBZ[K]<C$X*P#6#MNGDP%F]'-/ @EC\TC9=P6^J9)
M5ZB0A L.\%^,&^78<M#A#->YPW9I[BLHC'Q7>%2!OJZWDH$F&"U3? F[<U==
M$< 3'?R9?4BH![[)24*>DWQBVS5U2:<ZFXV7<@EL^O"%Y\]?AE7'IL*D>FD'
M'[BUM>4*OEE(T.68$4 U$2[T_O;:"Q[59O1ZJLB4=O<S'0H_%8@"C&!@7:';
M@]N%YXT+21,2/(2*\GJWF0]&3BW5H0$A&O??(4FV04=<CCIA]OU#MP>_:B\F
MD%EQ5*  %B#$$)+1[6EDA=%N>AV.>6AVE"U-$.4IS4/!;=\0WF62:S@3/'YD
M-ME"XYLR%NYP4B%,:M9@LVT\)BQ,P2*H0]F_5@4@]G%TGGCUQ!98[?LP*E\F
MTU#/YDRF5.4UW6'F%C:VPXX0EC3\\:AF XC.#-DXS'@NY#S@;;(>'.#]>Z-J
M#8N9GAG<(V>+[^O7E7M^1V[(V@CZ7+V3?5$^^MBL/CO]$+!D@!ZU=APVUVW8
M:<;49WT<R5Y2EHXC1H#FTZBR(BVS<+DTI'UP3: __AT8=L.Y6B1%L(PWV,\G
M]R^LV/&(I&#,UI;2;$"'RQLTF<'6"<WBD9.EI08,K&.R&*8'0F;;?BV)POMR
M:!MC._MA+_ S^M?7--!@S/GAVQ^^/G]81-&1.,Q&.V@]^7@"*2Z*]S/S+(7H
M\KA%DBIH);:L5:@_&RYN#&;O*>YI84WSX<.VHF:BNM^FLL+'-[@.(%.ELZQK
M3KS )\,W/S\'*_*H.D<1/(_>$*'#)BV@NN.B >GD2K^49&*%>UBU]2(5#16U
MFDLG]B*=3;EC*2QVYE8F1I$6W67;"?7&O*6/(S.W9J(ZM;RRK1;FIH-Y\5Q5
MW&<@[\X64E^.?30:*5EF7[%W_P_OW?]$E$3&3:$FP+^@V_-.3H4]8=FVDM2B
M)Q']8WH_?IJ[<UU,-D1 <-)2YW48R"XS"!YG0'CJ\%)"Z%W_2WM+K9.&=GQ^
M.K,3K:<Q1P+TDP;3D7%:0T136^;S<H:S'D)1(!AB730F%>"R:[S?] [Z<'%%
MXM-N66(YA;4Q687TP0()3=*QX9\0C-?(_H59:>*W<8;Q"*1TJ"%(KC>1/2N^
M*J,-B3$F-XPT#R$ "'&--KK]C69V5=G*_UO9C'0>?%$( 0_6;%B[+YE@A-[B
MG+VM,%!,NV8#\%+G"0:6WB@RZS]2M1G\;;D'OYP][G-^7#B<XC*^E%?>"?-I
M[R:>&'KI,N\TL@7;[^E@>7OQ/!P@):\9$(F!+R$^RHQ?RVRN9/JQE&V,=)UP
MZIQS/\K,2S2@86;:??9K/',8[G7;^=_&Q8=^.UZ=A]ZE7.*LB@IBJ_V24D;B
M7J FT9(4Q#E+$M&M9I/Y[/W,\#WNQG  7;&ZU#ZA9/ZS.:*. S>E0(ETRQ@X
MIO6C+D'XR,U,9L.47AV/&&_3+'5/OK2..@\BY53J@4/Y1"*%0$-5=QUV@.,<
M#E^[W+1+RMFGB+<_DICEFV,Y+F/PL!S)6^57* X78J<9 Y&=OR*=-GN=![,;
M\"&-X(NQ@^9$IYQ0D?$2(]V[Y;5X\<OBKRCOB.EX&=\W"G(L'M#'OG[YTT,?
MT_!;-LI1/1DNU]M=-RR/*-YZ=4VN?+CF#Q44'U@A2+C*J  E"0\\(-XFA#\O
MPKX)H<)J<1[.L/!$+\A[U(S4+V=_/WNC%XD?#J]#]NB2>2*M057>%/^65_;W
MR*]-ONS3QT^^F'UV$4#Z>YBE==AI#^@*#Q.Y&FT86J"9?0$:9:;EQ/;*G;0H
MK.'20OJDL1<X[6:U"W"<Q+YOB .X9X[H])9@1T5GLM7*5%)M)8P$J2?@+Y6D
MC&(RR3D)I/YCMM.OXA"T4_:!!_[%N7;ATS@58A; AH"07\C(TI15[T1J[F7A
M[LFI<'<JW-T?%APY1=0J\"GB,R[L^5G*%-N^O @6.&Q2[& B\,JL"5RC< :*
M4=*31&_B_+ Y<OFKUK@2LZ>(%L0;'9"XS]F/R7VI9ZCF7![#(C1SX+ZOM*^2
M3!"P14)7[#-5?#X<&C8C)[2$ATF.Q@<.-X 4 Z9B:I7Y:96+W;Q.3FUP?DI3
MC,ZMS0(]Y33:[BJ0NQP\Y6-V G096CUTSXN,5EOS4LB_WA+94"62>>#<F?F0
MT"%2TJKOQ7GG@!64<,((QR$#SFY'#Y&H?P#9HO3SG 56YS5+(V;#(8WDGDXW
MZJ5X(J+="!=[MRE3HMZ8-&(5A8S+/WH?+YB^!+Y&/@XD7KPU8E*Y>]MP"I;9
M2E**] ^*B+D#8V,3ZB)1T=_M;$6JAY&XRC,!FK@:ZO>FWL;BP9_8JM@7_O10
MZ]?"[[,F&[1FJA61<U>-["0\3I]AN7>[R''0D*S]!FLI7#B$5[SRP$W$GIA)
MQD?C^6#"-6_.L:L96^?%*R+#)JKQYP*"HUCS^:8$?^"#/P5']]7SY_2>B8/[
M73*X<'=_UA$^5T/\Y_-U</K68_!I_\3?^OKG\S\]?,A9IE@N.UO\"@898G]V
MA4^Y]0)BP/)M#&::9;*:L5(F^IVV*CMB^Z1>8WV\J9U@XGHB_W^TW#^"/%KP
M=>M4S40ETY3$O!2H:]59;D83]CI2R:= J2Y7ZT<R:%!OI$D+84XEF62;1RW0
M).M$@X(#2SLAN1$N5$;W^9HP)_\%CM(//EJ7T#_8B89YQIFIZG7E>F;HR*$P
MW.2G(.<C%)V),S]9YG>7_?R9EY-;_U?8H>UNT/PY=M)J'_GG==N^^(4EI26F
MX[/Q&ZNB/OB3_9LV":W]=;34#%9A$P$GGW/6K02ZX39_&X,A?O($Z;Q/Q&C'
MJUN9H312N_*Z:D;F+M*!M@T^L6QX\A@/\H,$VW_QB!(PG'>RA[7;1B'80>5B
M+B LR$\0C<W9XMOVIHHI>KV ;8GK,$-K.CDQWIO@4:SW+&9NG-CKF(TH&]5S
MT"T41X+3\D0L#E8J8D"$0 'N@)P*\<YA+HF,KJ(CF++;.F.OKNI*U&Y>A>=?
M?%MV2Y!<*4OUW1%/;VBL+Z^B=:W5WY239.%/'2\W\>(7&VG)5!PP]S3\8'[@
M&O%DL9.3="E9?GN,LG>^L1TUSM7P#\)'<!A>X82G!']Q[,P+1UP8$,X/B%FE
MXU:3(O0 0N4\-FK9Z*SXKEE\'687*2'CH)\_XV1_E_$]X78/E:PN6YURW/-;
MSUJ"*'Q!W$(;_PB?/"%RXX%P*HT1"MGE$FK\EBJ]X7F80EVSY&Y$%0<C-2S*
M7"OM)YGR\, B$24%.QG[7@YQ]?J8@JNWIXBB4HZY$,4&NO^#7P3<P(6#AY*N
M>OH9)\*^_N7\_"&9JB=?!FO55/B3J\'+W!<NQ49+0>>L/U@>\GD=?"]QQ<B;
MLEU@6CQOL"Q5<88>)"TCA;FXJ+NM2B =>BYKD-*'TK4IZ_$BV/C%!7.<20FB
MBM(D,7DZH^>;[14W7'0$JX&%,%A4\%7-<0-ZI/%*Y(^,,@-,:*J:!"BOW>79
MZR0/5)?KO0<L'2QG111EB*'JWV&LL.%'J4AN2.F<ZC:;DLOKC=X CS(+:973
MJTXDO_F<#>]R!),<GE62K82]*;RL1"%,N;]'+'$_*/HR1(UKY44\X R@XC >
MPQ^Z2#,IY<PUBICW/B_TMJU*<G1[<Z)XXXK9#5LI0WW2YDJR_(Q 40-NKBZ&
M+KE]FHP7"EDD?4H6Z[NN$8/IEO9K:3;D\F=1^DB,CQ*\07(Q#POH-Y3'H5OK
MP&SV?'L]OLW*<5^,'I4ABEFWL'I1.I-C[8JADF-#:+RM+)!->(-^5>XJ5\SY
M \M?D4\W5NP4[6DK4".W@^D@B]TN*!,"8K.D-&8@N5BK6):,M_(9N+R"D$4=
M1],E?NJQZ!!U!:^V<X"8C'*8'S11C[12&2^(B\6X8\[^;?E[O0TA</A5.(4_
M^<NGSYX^7CP@&-TGSYY\?O:9<Z+,MCU<A$G;2"?!I_^IRGM#.T!8I-NL;^C<
ME"(HB4T!]*.;C93+.7R[J'NJCI+C(E$(.>OD8%R%54IN.PK9\R]A,;5V2HA:
MK\"3:*X94<&5ZHTB/MBJ<.6I)]4WDI8PE+'0+'IU)X*&<S7:]5 <ODE!9=^8
MW\MN]SS+ES&LY6V;$N9L'H%0:.6QOJ0DU/S6)]V8L?/=AEEW77-97HK@+2C<
M/21/DL&<1)XMFTO=MS LJF&S)2T,\FO ^"!D6"0".R(/)(P7FH]64H[:_<YK
MW43[HP7[1.OS;'&@)>?=1OU>EN:>GDISI]+<_2G-Y0(!AYJ'>\4)S33%F5[[
M_^;&N(A.S3J)]"R2=@,51!>F(E71C8J&OAM*D<RI$%%$TQ@\!T H*FI20P(Y
M+76?(HC("H^"ZEK%U'X86I'ZG6*RDC.%2R@.C?N<#V2M<L%78L\AK>3I,9(W
MB%QP/T9V4,R>"V&HI/BX3DY4P.#B@9MH=&L!AN7E-\"9J#+WLA+I+N"?R5ND
MIG:&6TN66U6]7;P313#S%>LT[+PRV_]/:VL",&M$5Z'28G"8LJLFG&F7M2F(
M4;(2:66\(P5+P8V]1,O_@_/O'A;J(B$/!GK83'<M4HCQL#K6 1X0B"KV"(\E
M.G6*I)B6LIE5QG,1!+1S)F5OT8+ A26L1KY()3"3+4D=$5W-?,QY]\@\U!VK
MPZF4QLHP$:7TO#.Z:C<.&NR"K2"I/]\C!?/S \O@ \]@BIE]O\DKTME#[/@Q
M*)MS_AC*JF,M)0P:TTNXYL?V&Y>:D@WG0VG=C#?-1%_4$BS65W'^79B=SNH4
M/I$<J3C([ET'.R\J-X O_SAV:D+"-=YD_C,!W1E+*I&#;A;_4LF**/1\P5%4
M++[[N4C6!3X2LX(%YU:*:(?I!TX3U=Q!ZW=H(2->\<E$RRH$21-K$D)@US%5
MR)LK$IB[(\<.S[>LRS!#89AH2,95W>A!1\<RNUC\OF0;2&!KQ8YI..9)%=$M
MY8NN'-?!*J]*ZD *2_T22F3E,(2 I/? X&V[KDBIJP[+7LCK>-#T-P^+1!U,
MQC0XNJ\ARDC/+&NR,J6PJKFNNQ9NI6#$>4#HN=GH4_Z<\V(TL9DH55PO_I )
M/H@$H?0'6EV'>Q;'QK41IRU*APT#^O3:;2V(ZL1,S$RT:L-"E9(=:,7,LX1]
MMWY$ ?>!KT<6=?%_JNA.%(F8M)/SJONP_AB&*QD2B*]?H&&+AH\ZR)W0)CK_
MN>_6^ABL9\ /KLH60XK\MCUT8#C>8R?E)_ 1PS U![?NL#]L7ZD7=.NF.KZG
MPF+59A%J7QKI961G'=YEV%O%VVTV62!H$/3K(]]Y=W4 N@(>&DW&75=:-<"I
MQ[FY#H\>8B'S4LN>%?1FZS0I#DD2JAL?DB;&93EVP6[P",=US948/@<UG8<B
M0HT[E&EO/!^A4\2]2!12&CO8#);="@<#%0K$^^-U38P)Y:4T^EZ-V[+Q8L:6
M$.6PWF3Z8DFAKWR'W^$QC!>("<<JO-.J]_W%R \?&B,=EUD-8*O J)C@I,_%
M@1N<-_F==W+0(QP>-OSWX0%\S?EX2;VY#+#Y5+I'&)1%:*A>-0-ZBC;'&*%6
M?)V*K4UM%PI7^<O9XKQ7B7JJS#<E&6]^:GX:*1ST"?(JZQB/<7RTSX*4H.S\
M(\QVN%R_[X=*:G&7TKRR&SM8ZO!GF!K9]V%0P@9'DO[(U=TUV?N@18;JP8M?
M>(YAU<.TUKL-4$.5>8A:;QFQ>KR9$)8W]*?SK+LEO@:K"5Z;RU?8BO2"BISP
M7;4$!(P?=05B_!69!PKU]]7 6*)@L3>N-L=U*$$2M4[?3T:I:9M';J]2O*$E
M#C]=R'$IX\$?65KS/$=<++>RM;/X9.6D))R6L(/+?2T5I5W9#U+]Z9.ZZC6]
MN;#B)44#Z?H/6[7]5V5D@53L6O&4MTUJ'3*CZHU=VTQ/%2/U@<Q,7PV4V#O:
MZB[[+*G!":*)>P>!\-$O;CF15E/%3?JQ4T !]RJ&)\E)E]0TEQ';(["\SPHJ
MSZQ&U/Z0?*=K"T3GA0*UR\4_]$!X2?J?'B1(>^N #3M3-,^K8+3*3LDLA*(A
M+G8L=">M2_[02/.-NK]P;PE<'E/DYP0)M'HY:C-6Z8@A8C,XT!CEL+H2#*!9
M^:4E<1FMYYB^9-AYLV55?># >)ER#.MQ%GO74H& TC/ 7T3]U1E^+UB%"-R3
M]*4:.A=(T(HKM-\]?(<2^]J>"OE%PTVYAPE#YV-N.!+Y\:3\/].'B[9&6($8
M='<YUFO;+=A+50IUT?F611L#H-I3B]!I!<ZLG[5A_YNVY8S UT3M?)[LD6*1
M0,'S1YF[U99D?"GY45'/K54P8WM=M<Z]$-S]7E;N/CE5[DZ5N_M3N1-M8P&^
M),0WJB;4J]"UF$'-I3B/+VOVUA;CZ"9Q8'PC4NH ?U,70!7,)8-&G-54!*M%
MI%G\$BS#;(A"5Y>*GZ3 UJPAW!J[$"=CG>P]!Q;P5#2X(-^;W=5IK,35F 2V
MXSW2PHD-6RF.@;ZN5<*[#ITO9$ZX7IH]98[!/98[F'=:O.G*7<TUF]%E<I/F
MD)G3UP]"K,"@3$9_LD N3'AE+20B:,X@0V%\Q\'(! X]TR!L=K&G)O@P'*W[
M()R6\XI:]B*&QXD.4Q/.U.,D/<-6$M#6P+>IE%T0);^PAL-BV((MNMDCH2+\
M@C)K8T,1!&B%- W$90@Y;^6@7+D<9)(_(V ]A<.76&LU$Y//9_Z0H$I0;7M-
M4DJV*"HZ6%)2&CYC[E*8N6[/42ZE9T  ZEGIEZ5P.0>$(FA[0Q"AJWKG>E+G
MWT-YYVPOA6O53%"I6:18!!"J#\G9 K9&(]"&2+83GYR3N@B\&3]+M0E7NU $
M:0QN+9>9I(3)88;%,C>2[!MM!3(9FAIR<142N>NPH\*_S;SY"<J)&X[PU!I+
MY#+$E.6*.9>X38J>'?@]+*:4:*G=7=&SLDN^#7:M76?QB?/5BA1/5F\DJK9>
M9->TB][#J^ G\#ZM^R.,(<7![+B5G2:K( 1OS3Y.!&=,-)_,F$$L.5^OB1EM
M=-9)NC.<8"-V>5)*21^/&A,%3R<$O:EUF*'^30OS,Z7%#VFAWXO@^D7$,\C)
M_LW7Z$!]\<-Y5%/W,)*)G$9"Y]6ZWK!?FMH1[#8 @F;N PY EM_RW/HVNUN8
M6OH1^64/!=1PD8_U68@)4MC_TG9WRMEH&&8G\-T)WC<2V*/A$0^%(UW/,7EO
M9D$:B?HR>_DPJJ  5 ;6F-X4H(NQ8 )Q&^QU9H%R$I=20>+H217H.+>EQEA5
M17PI]4<MI<$BW5T;FRXBZ=6AE9NM161U?[!?ITMSL6ZEZT?\@])=T"MGIEA]
MU2&V#NXNAZ@F+8H7$:^:+WZZ6%,EWY:M8J@T9SL\2C:[4+7IJQOR9[-\2,96
MI60&[//0K76:]0A;5N IVTE&\XT'H? VT*N-YC>R(;<VY$/?BKM>>Q?N?)W%
M0 @,J>6VA8.D"P$;$-KKR.#X/B"UFN2\:D);^DCUI'.?GD01'(:%-VG7G/+:
MTN@DJR[K;:-,[HQ$"=N,916[\<$F6M7;$.ST''<LT1ZRJ!D7DW^6*)!Y.P5?
MVC\!GLMCP=EM(B(U1?"QMXMRQQ75,=GZ>^^="ECDT3H:*5T3=S;]KZKJM2>0
MG%NOTZHY&<=1&A":6-7C,%(;OF37<%3D%D (YVSK]D/PQK3^GFSGM&2_K#1"
MG>(-SY1K;&+W:8JQF*F_XW#?D*M/AH^5>XX$.!AEW.; 4RCA7#JIM%I0Y8_4
MF[]:[Q'7!^+1YSV+V967+_T,8)12%?#1VEL2P-^42I3A::1Z&CEN#ABDV0MK
M^H.L?(XT/736'KH6#JQHW'V(:PP3EG=A*,C%W,,>N0.50#"!5'!!AP_P!.J!
M($H'H468"24-/.A3S7M4EIR0Z72Y(;T\M5?C*NN/Q@_^-I:(?''"U_)H%M$.
M9[V&=&KR\HT25'I@-W/PL1G8[1_)(&DY?%Y;I(\A-BT]2GAW<(TY9>-V0Y,=
M^,0C=,D<M!73)=$*\94WI -=(2'V 12QSH++8W!]+T_\J)P/>,+^BH)UGSG"
MHJ?\4-VD5%]D&1]1D25L)AQRUF\:EG3DW+_LVINP<<,$Q3L^"CYXO?9O @ON
MK0Z?<LJ?&ONIM.Z>GJ_.YO,;P;B-2Y,/P?VI[$Z"P6I$+P!1+Y$L(DCCJJL9
M#DD*FU3.C*>'3H5UI\[A&?GI*[',_+KT+E5#36_2G6'E)O?V.G)%]EIRUP+L
MN#W7L&/<,'GD8 >:ZJ(V,9.X6L)]P_:2'C5;5K0:" G%OM+2 "(Q87J&U#M7
M_:9H4B EGI_'A$[9]R636KJ#=Q:T0T-X+\M-GY[*3:=RTWTJ-_D4'1CW%=K*
MPAABLA7R^ -*QV222@9\7'!V'<D[]NK">^&-Q $4 CXZH"U/ZXG?YZR<WFV)
MKU(:6(FRKO8]H2L:+49Y>D,<=@)8J-:TU?227-A'2Z]/=J;8A F>E!JL/?2+
M+\VT$)[1.)@]PL41YD[@(O]='VZC^-/_?"7G =MKP-^>/O,L)I&D./V(<YA^
M8K?H!W&+@D=3_X]@3.ZRC:%LR-,G:B;52W?K(1Z.R\CZD-!YL*<BP R<C J8
MX,/$NR_QQ#+FJT( "Y02(!1X=QE^_2_7:B5 ['+?"@+/@Y1B_4J<%O9$R2N7
M #+]AG1."GE ZH^P"Y U-_R71YG]+U+=OH<JQW^$KC$MZ'6U%9_[0**_2 L%
M,Y'G,UM5'XVZ]FFI?61++<LG]%3XR/*$RVI35X"R+: FI$O2TD$:%9W6VVF]
MO>5Z,]%P9"]'CB++U146'#EFFG(+:RR$I_+-TT([+;0W.4.-9G$H?Z\B=4'9
M973<95A18>%]1,OI\6DU?72K23J;V781$*S<4>"F'2*+P\MG/O\!DV&YE[L)
MR[0O#+K',?&&C/!,MC%/N6L)839D*Q0YXNMB,;M;;JG^U'NZ5'=3EP? 378E
MTN/^89!J31"&A[IFM8"2^=1(?+KZ%MAI7)&X7FFNE"/IQ7?&<I))=8J$3\)=
MR&SDTDGF@%XETU[2F58R?YW/&"3-]VF#7B_H2VU10SRYV!%6,6RL$3N/J7%J
M8!)7KM(M+S--DU..)ER=M1Z3!'*XX=#1\2MMLIBM:3;=5&EI,)W.+Q>B--N?
MBX][G+ M)VU4CB]I_6S:L8<QXD;6#/?!G$";U]0:M[K"8)\MOB=4W(8 %0US
M1&>Q.*5H)%NERQ'HE=BYK1D!;=5.7I_7&7@Z/A#/2PH8(2D'I@)QN06'_.!2
MMJW)JW 5LDC]5,:1>[>6]5JFO@W; 3L8F%[NP*O"[B%6W'1!)5!>X0]7QCC;
M_U*^4 -0=S,5!M>7/$WL"6^Q;EQD5@!XW PU]<3/;5U6,1T'VZ%:YL/M;,5[
MDS!/,/5Q\?.\5^'TQZ3*&=&@DEK+],!4P^YYVW5CN,9+E81%"VMXWR=??O[Y
MXL$WSU^>L_Z#Z)HO2$3QT;*KEY6 $?"+%5]&:9SN#"+REH, "6D</NM@K F"
MN]!7(RL_#FJ9DK>WS[3=[-L7B>6F?&$LQ-%*RLQ7V#@"H&1\IC O9@#@NQI1
M,)-^)2\L:^/IXR>/.2M+(ZB=R9N]DV%1Y#8H=QC!7A \'O^E<1.*#@"T:4!@
MCRZYGKT?KH31F&#!822J6OB>NS![&\5LRT\%MS52YT56SF;UH%K ;PKRK)N+
M<%'&J<N?2\&O).A[R:XAWXM_1<X)>W4<]:90S31A3G1!-31H"4'6:MFVK[6N
M28T.X@,Q#<Q0"6:(<BUH9[C85)(Q3Y1N)?&M^'EU'F#0KVLIR%K\;*S_@];^
MF3@$L)2-=L](BX$(CR;[B#ACJ_*ZCIK?4O88E,)8D7;]% 3@&;!E?'38D]*]
M_1)5INE<)I7U#=@P&#DQ 4"F9R%U-*P=;T-DE/=U W@?[<I$DN6TDBN)$BPI
MM=Q$B!>+H501'!%?(5;2:94(US.-8V.BL\HE%UY&<5IVE_ \E]RII/1WXH@P
M1D ^;B+#Z&C:;!+($UWV5G1\Q#2'K]'>8Y>6>KUB .VXQPWH#QN_^'\S6K1'
M*775*5<*266.-"7:\-YA:(+/2/2%0EXE\E]R^KLQPA:0MIDU=XO@(Q?EB@*U
M6FAP,_C!(:IS-5WJW/(& TI7+QSW/W4]H!SI^).-- 1HCOQR.6X8:A"'8?R$
MU-7B9(9KS;D'#[19X($)IL+_3%%HL:0KM;1BTADT8-W)5,*.^.4I<+3H/ID_
M5!P@[9SQK\[N)9;CLQ.6XX3EN%,LQWN'"6XG!S<*_"P2]^MA4S!D>4-$.?A!
MNX*,1IR1\ZZO+[:D;2EE()93@V<@-G;4D.DT,^/I3SCKC+W=535=6QY[76\;
MCVA7A,/Z<0"-(YR<J_4D8'2>S&8_C?3O+,3YE;/8CCK4D]\Q-,^&W4W%<I\?
MH!]D[L\6/R3W8#= M5?30Q%M!W($23=.GV.U'>N-]W6II4@)?. 9>F8?Z0DU
M-WJ1J;G>>@'_ ()]1(XB!SK.>C>^TXD_2E+=JK'J#KY$V%I8X9SG3[]2"N:$
MP]#%L> [0:HH^FX% /G N6C>C3-B&@9W4 TWR+L#>*XX6R3=KT"\Q @9:EG@
M33[PVM(QC998[D 0BKRXZHK%ZWKUF@Y% G"1^-R: .>-SPG1T+(:D*0@$@'T
M.0QHE$GHS-$*$2"4,4PAW;) FL'$#^D846S:LK^$,<1B9PFQL"C"J+1;LET-
M>04B6!0]1G[ZV6$^6[R0;>9WH) 8,F\:=R8!#*6F49ISDV6"&#2FURDG*KWH
MQUI0?/X[6M'H97/B'#PV,&Q"%1O]Q[#$!HY7*$(AEX3H(;FS/BJZ2P\T)1'-
MKB23'YNVJU4Y\LUO*I;3D/2C^)BQAZ6VQ$W2#<>]Q9(^5TD0FL>Q>=W ^P\#
MV"C4BV%[1-S0]B)=SY7D03#QHVA]Q2 0&S1AP3<K:G%WAS4Y4H*#XF@PB.,R
MI>\NS,S9/,\&^E5*C2/T#KP?&8!..]^%0QS[E5G^&3T/2= ]V_:0=Y,#GU;/
M<3ZPP(V]NBV:CRK/&6%^.^+;4G&9E.F];3@CA36F\XV^.-NS0L8@Z3>*H8,_
M=XTF<W>^^N$AI@A*.$=J[KODR(S-6ZQV&\>%LN64 R!.@<N6VV,OV$M VB%I
M06#W#4:RZLX6KVB,Y-RU\;VI'.VAY9;T9%=R0N,K+V+U(&IHPUH@:]<ZS1F:
M*@GS]7?V'KX_C;8Y97>DI9<A<%:&%,ODGDR'@O,AF@%#7D,85L-U@K7@;%<X
MI2=MO4ZL5\-T+PBN-Z L3B/MNG@.U6?3Q:?;.+9F32\GE+Y"Q2O6$&:+CS>V
M_K$YWQ(:+W_XQR=/'IO&A+(*ITD%3EEP"OKX<M[+">O5BZ@"B[Z8DI]>"F9I
MX_\L:W=T?LS>W'T#UJ2OU T(K?>!:84H*J@\L[%GF$O8=E=UMQJW3'[2A]6X
M;QNG7M%NBM1<F\*!RDL(TZC8[)E,"9\=<V-&^T-95:( HHHWR:-,Z]3("X4=
MI$ ^(X?H26TD;QJ-&2AA2E1]8!":!(-Q= #3UCT_AOK4:=-;7@^9/%)L!> S
M,3V*L5'0K$172I %9<:1!RB!-@B+'PN,NK8HW#YAY(V_XE"4DM+:)97?><>T
MD)SQY2\C!5VU-EY.UH]72T(FE"XQTZJ/:\SS9#-S9-H(V4\Z(?TJ2B@.PP>_
MJ9;=2-W(1H-I(0Y#VXEX\^EG_TEMJV$ Z2M<II=C]GGPP]:L//E#]7N]:LU6
M5!QD1"GG?H3TA_06E])=CV7>A 40WNY*>%P63Q[_IX=I'+KW5=A 9XMO:U(F
M5UYP_JP -(3J-[:"8Z6R'VK3@>"'';5&F:58>YLO54P*><SZZ/BL*'%*&7I:
M]_H ;:--EZ 0>#FY7R(50J<PGLW.X;1.CK\1P]<6]4)R7[F@$?FI5LCWRHZ(
M-JL*ZZ;=$ME:C"Z7U7!#7*/;\K=VDC+FSXM*'17GN<O[Z.X0F4*[EQFT*//=
M#PY7)9^/%M":N^GX<IOKF)D6/N3I/;T3C#E(A_;?:*4_M._\9I[R3PB"?HJ]
M2^3G?.4;H;^3T/]C\>U_K5@.U+LHIAS W'O!T_),R.34@N<N7?"(<.&Y@5"0
M5X[%HUR+*R6D%:]/O6*]G^8U%9(\1T8@#!UCSQ1JW%Q/-PB/I*A39%5*E'ND
MH!-#V? !K*:[57F:H6:?NIG4^,?0&Y$0%1%+$74X6T11-'3X?AUV2$6YOQX<
M(]0KQ]FL)>5S.R9LB3/+!E[^4&UW5Z [:@^PSYG;@]7BKY.3M1W@LU \<%]5
MKZ5NKJ29*0-6ZE?A?&'KF&&E7+L9:"S+#2'(#GQ&H7J10-W]S41>[V=Y["^G
M\MBI/'9_6IU?.C'&:/=5VP*YC7(5O 3R)#0QQ[Z$@QD16F.E^UHB<(:Z<&J3
MQ3!5"R-K016_G5/$42\#EFE7#I)\,,UJ<FV,:2X*2"+IY1/]3"<UH[Z!?MCQ
M@C05.\V#3RS^W;'Q^9A44AN<F*M?5W;D5)9<E9,VIJ82IB)&3E7EH+Z" )Y[
M_O[YUQJ6P.<+$Q4>C&!.8-R7,5-UEDJPZOU^NPOFEN4TO@[>!^8;)SE@JP3]
MV8#BCPDK)9&V#H%<28([IA-$L-:!L+>8@:O@A0:_C!!3X =%U@?U-1D%TUQ)
MAL #13QELMSNT;8- >Y>TKYAL' 6*?*>*8?._^__^?+3OT 0NMSN-VUPIG:;
M,H1GX=Y?U6U8VR;&4H9%&A;/MEPN'IROQZMJLWVXN"D=/U3* /BWL:DXZ12"
MR"<.%G6^6E4;@6.9-Q4FY^J&@)KC,..#T&U0RC%JD7#]\# 4I9*^BS9C?%^%
M1ZSPB-]7_ZRVR_HAG]LOZKZL,=C\5FCE!_TOZK]*^6:$F/0=>8]P_4\4)-;H
MU?]>]V.S*>7JW]?,0"R7]'Q5_'0_2K2HYSQ7+8C+M/(**W%-\Q+ER?ES.C./
MC)  4QA)9,XW_[JJVJ;@H?BN69T5]+NZ"<^R./^J",'Q>!E&X67JF3QOSV3P
MAG7XQO/VLF%WZF>W:)*+\F"&[Q7^BR\VM0P$C=5SO&N(Q_X:S +X>%Z=G8=/
M_;W<_+4*ZS9]B/3Z_ZB"==INP_I9G/\U_!B>OQN"1T@_G*]"N-OD7_???MF1
M%6Y*FFF$ =0AXC_P4[L*J_#;$(U ]^&O7A6/GJTAURS$BP.4=NF%&$=(F8MZ
M78<UQZCH7X/5.31(&5Z1MW&6=3NPJ?D(L:,IK@E?= V.":'?)Q9'+9-%'\N*
M11S4G)$'3CGTU&V- W"^7/Z_NDJ6T//%=SP9K\YI02&#GRZR)EC0W\/D7X3/
MR(@3N'R'OS4DXT.3D7R'_WU./1>ES&;R]_!YLLN3F4X^])SH@\+B?C4WS>$!
MPNFSWU;);[\FH>KZ\-K^6WO5]$:S46YWS_17?ID$V]/W5>,7R:/Y1?)S^;I:
MET?WW)TI63M"857;:5.):O.*#(9=;N34T4.X)F$ ,N:71)0E()%"N,$2&,TE
M6,-]]B15^043X%#C!(P.$U>9#WDP1<+2*,2>A;I4V!9YK?PHQ6#>Q)0WNV=Q
M9,-LAB$ KH(M%G!,N?KG6/=U A"9;]=R,:  ,;1?(1;QH76-(SZ.%F_J\)(4
MDLE!"AK4$$5O23RQ(]YADC+2Z8TS>;9X)1^AM"]EKH/W3^"M>#J98<*[RS$U
MEY9A (X'$JN:TA'G% MG ^;1Q*&MUO$1% 4R\<L34SGVO%)6W5@;K(,!J_03
M"($NZBK)!@GIGHK8,!EZ4VW29YDNG/#^4CMQC7.749?J8HX9U"FX0]Y -74R
M 4[#*8/M$T63IJ*..OI%N'"A%1#IF?IQ])F*1;NC!/C8H)*H$'7M?:1)WK#2
M);E-D^5@V8\\%*@.IDXLJ55D*2W9]1?5#:^N#9U0.&UH^:R-(YZ++X)O;L+Z
MKK&QR0<%D5+?NVH^=MDMF1Q:L/(>QL-/ER_F8H.9Z]BHP<>\KJ1!G)/!3B(#
M884/*6(0X<HV</)G[I*J:T338P:'^&*QC$FG;8"<'SW,XBCQNRV'=*.@F<BX
MY OP;[MNQFDZ4T*F>A:5SO9'A!34[KE;I$SR8]?'<ASN/H]/RI=BLOTL(6C4
MIE)#EKRK-/1K[1^Y*=R0/Y][8#,O12_L-V+B),UE@[L*,0SF85+-=Q<.OI(4
M(%BMHUWV[:8:*N._== F)^V&II:(4)M=\>EB-W"!M^]W&+U/!XVG[H@AR2V(
M9<OGS, 11J3H5F,=0TV25"+BBECT;=MHM'[H2FYR-/?O+*U,UE3O+C_?#58Y
MEP&?JUEPD2+G,0[[8;^0U ,M^K"I1,=YYLOV\.#VU7VA!Z8-\88$.]-Z"<M"
M]H*HS*?J;;9%LI_F+Q<W V;8E1%P[I$.@&V>CP9WED[+3']," 9J\-8D\GBO
MJ[WW/<S9**80K&7E^WK@1F:8F@_+T_S6G;6R]DW2M688LI9$8VIFVDA4Z"CA
MJ&L'3HE*'2EZ:=G@F3>5U?-L%%$((ALB5XJ ]G%'&@X0\^SUY)S,4.:YTF>>
MO_B1L@]AEG]%0.H=.'<->9A^\$G?[';N98:J%,9E%;PQ:D%AZ;8.NMC5;T(Z
M<T3O[M#(A"^]7=O5NXKRBH51+G*9FAW.A"1^0X)9ZXE2A6119VN"!_K7!(HF
M-;,9=^5>%K8^/Q6V3H6M^U/8>NZ*XN211QL;XUU)3"SK-O-=K'2/?&,P2FM6
MQ 6S%M'XD-*A91>\Q;JY:@&KH&,"9NIUO=FXW ZK/!@%E[@3ZBO!G"?BDU>9
M((<+UN$)HY-5P)9JN7(\ R.%Q0 FSES$/AFB0,5WQ'>:.>>59#@^2IN@?XE2
MA1N6N;T[=Q5;855&:>^FXE>,%Q/A#Y==B3Z=5V.![ILK(8:+"F 1U2OM*H&^
M' &<1$(@^VR8N7%SR2&QR0E:D'A($:[P5V)>R&WL :$3\$;98&+5<QQVX_ Q
MN7-3$+9U=R!MCC36D#1AW"C:=C5V"23:=0,8>G29<LTQ_]7!@]2E7V\Y.>^F
MT0!0&X@J$8"*\A?2<C@=QAS!B$;]-#][Q'U @$PV0.^(]*=FCG%7WM%3K3I%
M"&> 5K^!. -V0!<%FZJB!(=44NKFMU$T(JFD/C++1KA0I D9&UHRV/EKKJAG
M&E.3='6,\$5,QQ$*'&P,D&7'B 2W]TF'MV+916;$\'=R?U'YUJ13Z:;L&E;R
M;9"ZMKG5E#4_34%@8A&M)XD0]-ZE;1TBR$B4;\CT$D;KN6]I$%(TD1R%YNJ:
M!84'U4?BQ@5#.JRBJ(]0B$>?%ZX^*Y920QRH1ZS+XL 0ON'N)7F/M]JX<_DX
MJ#F6J9-^@9/T1A)@W%^1=5Y)321+4%O2'^I19;=&U"P;*SQ3S8I%B T()1<L
M+7'/%?.+R')O__6_C7)<'/.GGSRY>/KX_5[I;N@N/^ +O*%GO*X4(I^QL+W)
M:74BZ3VMNG=:=7+J3KJ23POJM*#>:4%1J7C=E3<LBI=5=3D%6.^([N*TPDXK
M[)U6&&O!H), ;BG3F#!(CQS+RY,!.RVO]_##:BH$2= 10P,#Y@ZD,JN),(L7
M3LOMM-S>:;GYV'C;-IP5#,<G"$O;F7/3D8F?5MUIU;W;JG.0I)2))T)WB$=H
M [8C\^B$EH>DBB;)->-W8J"IT;>?ENAIB;[3$M7JO6@6G;1C3DOI?71E$M*A
MM)R1)=EN U3<,_T93NM3E2W"U!1'ZKG+WXN!B4%#[:[R;$_OQLM4' ?!O.E$
M^5J3 8ZEUT\5WI'&K]8H2$?H,O-['1L#O"#.O7$"0S];G&^&*Z#R40.QT5TY
MD6\6[<'[)J*LTSKH!,5;@IAP6/PVKB^W,A!]-0R,:1?:!F:-XDL+M:  K0OF
M_&DWE1+U!=>RB.  ?44M.@.80*0FK@Z"(HU!K[)A<2Q?4^(XD[&_+ID2,5QX
M,_;&4K*NT$>RW"CS]7P]_M#:0<K<"(V8FJ=UCZ6(!_Q%R+9H(E25!FXW0R5T
MF-$<<-D"SK#F\7>CC2&BP:F4A$I6/H8H<AL:_M;-Q&3,)WAE>LQ"BF3ISBW\
M;KT8F[7C#J,F'GX?3Q21:4;=S"(P9AC=[(WH!0CDV[=-W/:\A-RSF-Q4W/EC
M+!<R0Z30,9+.3=4X;=4$U9Y"LP^6_PJ&FPP55XL=1&7F%8;8: Z\3,E(I/D&
M@F>1_FX.Z"O/# [-.1-!FDUFPM"M:B,'T(K#K-Q+B-X7)XC>":)W?ZG9!8$6
M[,6&.B)B2Z7KI#.X%RPEF0+#C,-K[(06I_Z@P/FWQ0JA>W 8JNT.9R,(L45<
M1"B^#"XBV.,!ZH+H3-YHDX)_[V!SN6FP*I7$5IMW,UX=1JXE'!O!_8F()#.=
M3#3'!'$VZ"6\@(KIR(SRV $0#\Z*<%-!3P-:1C@^&##/W=I17G .,NU0'N="
M]RE>)25W"P>#499":+9AW/B /?1LBRVM/K N XL(^.&UH _7K;M$^DK9.:9M
M#@ZR$DGDDL[!!0Q6KP5<8\T.WZ9VB,N*?MY=T??H"(J>R*IE7!)]:],&RT?'
MDK[6WL#^P@42/G@;6QBQJ%@/[ZX#_G-NE("S1+QP:'K#U5GV9\N]@"J!1(EW
MAB]A6;;1,U-1(2(K& [A2^.G#][Y-G3IKWD@%=<'VM,O%N8QP-'D-KDPK\R.
M]29K>UDE7"8-8;7(4V::;7K/L5%=(^S#OF]7[)UBUR9=?>$*VX^&$>^&6M6O
MZAV]&@4(S\,B#@/^ZJKLQ)[0;XDU=11F1C 'OF1Z'V&X^%@PK3,OT/D@,LP
MPLQF\8^R7Y?_Y!B3C4K).HK[=K26VH/<RB6NY%"<Z4W;)A*;B[3& NFRL\7'
M,E+OXH+\&/EFOE!6U)LJ4K[<='4X\AK:X:0T"APWCS-0CKST960K";M KIOJ
MGLA7OI<1_FD,@__99Y\]?E ^?/#TH6[%POB-/GD,^U.M1C3064?9&J3]'34K
M">2<CAJC(ZHX.EJ%51%"1Z7M4SVM9:V"J0KX2J>8R'AT:I?5IKUA+&+=U-MQ
MN_B/)V>/']/YNNBOG.*VV<&$_[6K+EGBP U$B4#^ZS"RZ#%X\I3'.^:Y[N\J
M"F&FS/"ZVJ!_;#*ZRN2JS94XY"9TI)CT?XY,>A+96PK0)]':TD8-HA,(.S9$
M/THG6\>6:EU%V0,H=<"F#C.W!I][A *6X:S8]T.,865-&=\/R_"X[";=A:G$
M-:R.AX[ 7OGPI+0!"[]YBNNKFGRP:'3@:='-'X7;/A+>^DARJQ)IFN4B.OMU
M==E5>-)27UVZS[,WO]'OLVOA"Z'O-0/<O[L)6X4RT/:G1%D\YA@6_QQ;3=7,
M[L!GTRF:X;Y<NUG3B<>V[F<M][,P."H)+.(Y9+!Z,>MSMIZV-Z$0GCY^MJL:
MLOI#NWJ-WSQYY@B_7KUXSC*HA2;-8#JZ]C6D/^79IM>G8T>"H? !H*'I*K0&
M<EUIF*^2,X)Q Q'*'<DW=#KA?I%5?++RG\7VIDK$9R:KW<T'+W=M@W5-4H>'
M!(__S.^F6 &HPQF<!AO!JG<&2S^V=Y)4VC.ALM:L-H/S*]6E!.F!S;%-;$D[
MQ/&S>#X@4?=C,2"B;<$[707S"*:?Z#C&@4=70-F\%KG4L)_)AP6R'SPU;HKD
M5 27P[#@5$75B(P+=SCHWG?-!%-%9]?H+Q+GVO=KPXB5HCX)>+,=/PZM [P8
M.2H?U4GSG5%[ZTS+ZC,$4+IMZAXTM"/G-XJ%Z;/2B&8\R$V(58-7$ZR<&L@0
MZ8W=W7% _CS[9-INEGLB"&FHCP4]/4CM@*V97D$'J[]"4$[!9,N1)7X(D?;B
M2CC@D%HZ/(2B%R>C6+)&:CQ4L% 1/UYI60=[C6+NAI5HEON%[!<J=83C8Y8#
M"^SXEKD&J0F[WR%H@DWOJ5&&?>L8?5'7I586T#E)-JH.X?@:H64\(DRD/7+%
MWS8(/G3&B]"UW9M(X8*L;[DK5]KVO^S;;DF'MO:[0U2F4[U;?@JY[\<C+A2\
M,_)5A[TG'X/][U6&!LRN_96G<Q6I-P[+]>]C<U%>APB:9F_VLR&^'J/2;91E
MZ(0\@.P8_XV]:#9I,P9,60*HZ%?]8;M6R,-G_,F9<$$B29/>-J+0A.--AD8J
M6(?F00=8Q\]PCTZ?E]-]&ST?B+P\$>?>P]$CQXX ; /J<NQ:(DQF%\!N;4=_
M>.A#CW6V>''H@9'4A9(WK1^N0D&O<'J#.1]+$E.TX]6)GWX1&==<@>?0>9A<
M?C8EB#U]X%7MIC&EI(5!KB"W+$@"WBJZL V$<4D@A<_SM@LQ(Z=/401;1Q,E
MJT'<A^0\YU65K'OPFCDRW"/;^*:YA/"#NQ0:/,GYXNRQW[M(:S;:%ZW70[WP
MC>ZW(C>OGTSQO2RP?7DJL)T*;/>' T-L/9H40YC-"  [OOFL@8:3L.%!PBEK
M=,QM3<<LWAQ3DJTB-Y/_*CGR^"4Q6EU^8*--Y(.?UN_E^#PW(E&%-?G,^$S<
MCQ@.@L*_2VA6_:XY2)7S*Z+:GS+A-W3>;GB U(E$,4ZHC>BDCI$A<JCJ-- ]
MTE)/MVLA<Q8&L^[O5$+N*X3RK1Y=]GKDW.;9S$],4XN&ST:HF!E #J)#*$P!
M 36O85*@E"1T"&"R"\90)HF$P4@L&V,5:QA&Q:%!?' 0:E*FBKZ9WH.IK@V;
M4UY>4H(6Q(44"/Q>;UFM^"^/9V^:N19)W97YK9CIA+P:S@$-[65%AVXAK?&N
MX)!R!YOSB!AB2_7EKI?<LKTOKRF#[>2ZIUQ<-A7"+: ]E&"(LT &8PLJ7Q;"
M;C=4HS6-8$3(&W ZNN0@^5P<V""3TO?5X$549U=MV&Q-7WYX==6WTSZ,6I]Q
M;L FT R<,3$=/.B!57"AZN!?=H(U:ZAFU.64&UHQW";<9LFVWX60]XI3DW'3
M])0!DA1E.KZQS$"= 5M4\,2G;^EQ++>)N<437Q&+47)QEIBC! "130  4# ;
MCA+PM5U\4_9&*5/HDI,X49!=%39?(B5Q(A"B=Z\V3*ARY XW$-V4@Z@CAU-3
M9TJ(N:ZN$6H;>6H<=EI=O)[<,'XT)PA3T#9:ZM+"=T_#3/P9_-:2X@R';F,I
M<,:%TKZ*F<VLHM@M7@;_INH(HFB9>AS!_O H"?K6K1]1-G8/O -B$.*[2X]F
M78*,SE-6JG6]&14X$).I=\JX.#N@)@U_<$R96#XR=$VKVD<^S3_FX\WXV:_:
MLJ/-Q>1>\B "7\<0)T]T:#KI ?+K\SG56OU!X)"LI:6 $M&.M3X>K3RY"H4+
MR6@.8MUBNH  0:)4=PO!D:9W!(K)%D,$2N_$*$JGV^TRRREE>\GU&?6F4'QH
MV]>+<-Z, M.Z-2[_:WTMH"FB]+$TN23ZC)T6W%T7==11[$2.&192$Z*K,CB]
M%V1"KQ)A3('WJF(L@[G+'>W_1\S^QIKK0F:+RH _SV[:[C5+3^ [OM:;4)=Y
M0IU;ED<\-^/H&D2(-RE#I<WU]+/%RS?5;:-27X=25&LLI9,RXUWM\UQ[]56U
M&]A3?,IU[T\PCL%A@^IJ0CD/^B1&W#=T &\7KQY]LGCP#15,_]&>+3[YY)-'
M3S__]"^???'0U!JH%F=RK"2J$T*1DF8FZA*F3_$E/\7B ?[_53A5+XB(*#[%
M*WV*AP6S\6^D>MA*CL]]-K=&U-NG&[.7W]#!O^IJKA8!7[&CQ;2NEH-;$X52
M3<$N_)E*S(VT ' ::KN,9<QPA(;?:[4[G+TD8BM$K!ON'.03M^;XC#%W,[FX
M["'B8I4$D/L3K3IGCM1+(5,:H22?87 _Q10C_P*G@_V+\P&6YP<V%3^JEW.N
MA3J>TJ]^_NZOQ>+[[Y_[U**^J=ZTB/8+V43Q9,>=NC+JY[OC^#^>?G;V>!%V
MP,:UNJ1;=3)F]-)2_"P'E.?9T&GYTP;!U89O75:2 +5>"^OW,$ LIC=W]KE2
M+.3]$E*07H2 3MEW#":1+$LOT( 0W3.)&\ R.UI\=KWSIB%ZK9^0.:#2R(99
M+L/P_<?GG^E \>R.P6-]FH@GWSZ9=*I*7?8NB9[#NALOP\<63SYQ,*=W-S]?
M?/G9YY^_N_GYE!\"UN>S#VU]WM\B'-_E<R,9=_F;[_%OSYZ?+7XMZ^8&GM""
M58F>MV^Q[XNWV/A/OOBC-O[Q&;U7&U\7-=]=\ P1?!E?XVSQJMSP4GOWPV6Y
MIU=BIW-'50?$/]XS ^("&B+S4Q@?S25PE'&1]H"&KN:KT@7KZRHB-B(XG#_O
MX5+:=35[[[=9 SH(Q+99O%E-*RL-)7FD/\[1DQB.6P+Z!-YF.FY6]B7^]2R&
ML'CTD*MK0C=%C$ATN\\V:3(^#MVP4J/KDDA%O.9D?&<KNKFT"G8=QV@2[6B(
MG2]R=L^U(!PW1>%I<Z>Z!V&]YW=Q=Z"WC_'=?2RM??GX5%H[E=;N3VE-X9FN
M3QQ1_3I+GJ59X4G29]COI $K!'*O55PCV+LL8<34:L0R3^<-VX!"<$U\7G 4
M64F;. V=-RC0&.O0Q,W156;-OB_[@>P8LO<Y('/RU HP?ATN-K#;1REQTA$9
M),6<)");S10#?/P;I\QFBB?7;33QN:I>G8$T#CP:YV<D:R;7T^'"]QD90CS-
MECY=2D62A*IGDJ3PC_3 ",.\K<?_C[TW;6X;2]*%O]]?@:BIGK B(!;WQ>[I
M"'FK=D^Y[+%=7=/WC1L*D  EE$F C46RZM>_N9T- +78M$C9N#>FRY)(X"QY
M,O/D\CP*((!\40.%36$>:D0,N;,A223=0L-2$7,A\4(O]'#"UR?@M1SKD#&Y
MT[GJZ\,E8;KO2B V43#6SX(D"&.8X"_!I8B'"DJ#.#"!BYWOL0JK[2PH59WL
M[>;WUDQ:A'/;I%&2WCQ]=L)$9$B85W)!4(VJ)I!<&GD:UN8WSQ^#L#&NIRZ_
M<5Q[>P$),0(EV'U(12*E.8?0&5AP#<==0Y&59KU<9B4G9IRY)*:K%3M5*YD$
M\:ZHNX;2B<*U8^#Z*MI0<FYZU;\[0.X'B!-T/SAHREB,Q[H0/2^_6"-,.J/;
M#@*O3<KOHOU5@E%==5CP'_[6AT&6F_M?J)\&?W'LJ5T! +8/+378=505I$]4
M<7N>6O<JMH<*^B6 8QJRGI-PPPG.5V[KKQ*5O;?2.J;K2;X.QN^1U0.B-G!^
M#RM#-NZ'OP4RYK_^-+__39& SU&+L=>JN!M5',,YV:ZM>XSSRBFC8^U=Q('N
MMC7'V1>G@EHCS"%?8P!6R*L%1FFUNO8=5/JRXE0EO4_Y*^:IK7"WPKU5N#7:
M@:)552WA=FZ<'%$$STBL-D]=GB;&A\LM G$].0J-A6=ROUM'D>K"OT:>6Y#*
M5ERO$U?DGK*N5N9FY48Q$$HEMV,9>$%4$0LG95%/5G"^H!*/I@HB>E:J.\'<
MNM8^UYA2A8_UAB4_CYM])8#!-U76[Z_A!3%"?&1P1EXE<)&CJZLW[A_WND/J
MF.QK!1[?0^C!B@1^C([?8(#A:1SR5?H5QG'DY[_^%-__]N_95_V@0BZP @1V
ML5^OE2"CR]594)@>-1W<>6^$\"1$L N*$2#ANG<("*Q?%/_ZX.16:D% #O1@
M#M=4IBJ4)QW#I1PO^TWU""+AYMCW)PDDY9&N)UY(&1U%5NM)/<JZ"B&G5(#I
M,MM]HIT%5&&F"[M#*[M)P1UN\D5N24(9PEZR./59K (*//F<R49^=]\3("6E
M^1H37E:3";[=UGY:6N&%U<3XQHGPJ2@>Q[X$^5/=':GH,=>OE[W'J*X,3[H)
M\IH\5+T15/4L(C49R ]7"+[H,(E0!+HD(L(H*-NW]!*Q%4SW/A9'4$6N^FR^
M1GY'U?_(H ?53_M-')L*$:0"C,'"$215!]2MCV@>H8),V#8F*L.K;Y(8Y4,^
ML+??FYS DA*3VOK'FZ?OO1,A!7:J(#!_P$Z_*KO(37\%]O>L-^+LXYDQB^GL
MBRYU=3>("T&<+F:G,!8K@K=NHJ4(OKLH<XM-?V=OB$$*+<D,!:!^L[HRA7P!
MR%-!0(3(=!M(M:XER<K))SKPM55=3STM6/CM](K;@!AR,MHX2RO!7TF",:1B
M2:M3RA"$Z<:Z +AHCZ#Z"7(,'_Z&:+DPY\BAFHSX>1D/(PF9RX:."0AW!AI?
M0+VX[BHO0<'+RU/[1&E0'SX'4MQ).*:F9\*B8Q<H#/T$G:,U)TI7ZK;<-^V1
M^MR8?<V]3.%<*")R(_JFCYG0>),\4'$E*K\5V&4#A(-MQ5>6A$J;5U.=>7Y#
M,/.A5?WUVJJ_MNKO,ZO^OI_ ?:NL=^3_8$@&'(\D3>9Q(@[%19RCEZ(2G5N4
M-V/;U0$65/7U&?Z:<#"#Q7F)'13!%2MS0:R_P/H*+.BF+U)_T_XCIG<-'%0
M^&,;:)1*VL'A"F\1M%+H" H_*\-2=^Y3S.TX 75C4 C!PD2YW2N""O)&ICMQ
M _FLQ&1N@]^F$-9L(#H;,.$B1;6TBC3*?3T0PE,S(0\K&(*^]$HUS"2I@F=
M-H7FT(PA30+?/1#BA>:/RL,I_!)DJYC[X:F/"$N#PD"A4\"ZYJ 7N#WA"C[K
M/8J/^"<-VRN?6]+M(2%*7H(%4P]869#HU W7ZVYI:O'AZ>KQ.M^F>KN+%!NI
M)=T+T\ESQ3=(IZU $@P8^X^]3G\P\N:J^RC%(3<^E?JFL9V,E "+ *&X(J_
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MA9#B9YQZI=IG-A\P9+[8B.TZCS>4XKG$@H 50GF#C0.ASH5KRF+>$V2JQ8*
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M,5%!61V0@5L7-D42F44(A@#6;T%_D"YB26[*B)"B>[U9I5<1&_F$HG02/]O
MAQ6X8Y.$VH>6NQHP:886XAC< PHTR&M<%K*,RGTP+)EHM",L7A"?PK[XP6?Q
M3_ &]BF6>E"^&;AR6M30L3)3%CS=?MY38<Q"@+P\4"R.<(LC!KX\Y[ /TA_R
MB\&@1B"WQ_A?A25FGVA:7X6W2U=RHTG1[TDBQ9>IX:0KQK?F73E*AQ3.62;+
M<(,">F)G_1Y0QG+09BS;C.5G9BQ;.[9[.Z;-E-18R)T&@[$;4OM.QH&:%Z@'
MO^8"ZFB!9<Y$E6/R:;-B<Z+\-S92Z#3IZT2#[T2NCFJ4OD89>JVG<R\2PE=2
M*T%4.)B(L+0E7DO!YF:ZJ+]Z\25K2-;8CL6J-&5)S39B_U3<O7[A%-)675M8
M_P2C2+5R\=7DPM1\6]M(?9P4'#&^$5*BPJ@Q][T*YFEFBK X3^Z9%@%FXC6A
M$=#^7":!$4SM#2J.5;J7GJ?(0V>/ 7W"3(D9T=%Q4,AZ.;,<&W0%(]*^%B4C
MS"JBQ,+I\]V1F4E %8(/@I$Q]D>=:P'FHC$_Q1U?]A@;W<1K8V].M$U1:)CT
M6-TW!=&@LD4I]D!W&H[J(K>3ZY9ONT:M3C659U&R4#AGEM/=V6FG\6W2Z;:L
M]H<$UN^0B>TODKN+T9_81/ 2R_.M'5'A/7* Y,*O2,T<:5<YZ3*1>O=$!7/O
M%L;7,=K&J'VM>E3B_!;G6IE($Q"FX,B)E]EQ*H"G0:VJ*AJJDN'NP%2-N,Y(
M2D^14[!LK11_S&KODPNX.416EC$+,/;)D1MU>%2?!\9R(F'=IC"TG &32XFV
MQ#_W5O2TOS/PQ>BJ$>K*1/=/K,$\%;@;IFA*U9SAFH=6@1!75\EI,6:A0CVT
M"BYUE([H B-A*\=#N>:L/&.T,4ZGZBBT\\\27KC%R]UJ0YOXD3)K<%C(PC%-
MI2H-,51!5,E74IW7G2:]/UI<U!Q7QX3BJKI7417YU;9?1E05XG.U]%=472D5
M<\1$P@5SA .&50!1MOWO%=(1/O/X*NEDQ)!21'PQ-D)'JFI!I$:/*\SQ?W@_
MN.11DX?2I9/+RBB\2@5L>G.P1XARI]0"D)TIPB2=1;7C9J&BDN7P+?4Z42%<
M4:PB9@%3(&B(+I+3ZOQ1AF>,C("N$%R6YI3&(X\X] S>K*;WCB]B*H>@0\5,
MEFYQJWF+J>O$<>CUN^(^Q" D?BARZ*EN/I#V:&XG07#R@&+M\PA[2)OW";G,
M>+>V_%G;,FLW.]Z+@*Q;0RDE)>IX!*K7GE96%R?!7G-[E$%VX$(9<6'@5^07
ME=J\8.N52EWF2C2+*ZZ(E#(5QFINFD,# &0SG+ JOPDT<P[_K$X/#YQ;VB[@
M^!'$ _?IR(@:=DES<AAL97G>/KO[-%^8L_(E)6Y<G5LO\K$N<ZS=. =L2GEH
MF4E!BRHD^3)_=]CB]8>U"I5M!1>);P/7C:AZ92US.7KD]&_3[201%[(;J!VX
M*!5/N2+N#8,U*OO@DKMC1)OH,=H2K[V92XTM4R:J?1H^GY8;59]ER9TR>#QV
M[JO&$@^],Y;)*25W/,=I<:>86*$;1D:F$L.NBW.[B7 9@U<4HPD/2TYK*#LG
M1<<KQ^*Y&#$@ @BN@8H*;+_LA +A=O"S&PVD.S[J;I>B0XY%*9R!F/0Y.G[+
M$M1EG;$QB9:Q4^7N$ P?D/]D (QT-3:5L$5X#5C@JBH3(@4^.I G9664:T%+
MD)-&W+*4#K#& G;FS\BH-VS-.TR@>5*\=&<7P.EKI 7."GHOR#Q*_S5SPX"E
MX-)7F[=C;C 1J!.-DT%LIZJ1FZE;Y;;5L.JHI*PF1]R%4LP#PHY(T;R^8:T)
M#O\.+R9)B"PYX'X ]A\$>[[$SI(Y!5O(Q)+N0E_"\L-=NT9?7$H9L,5#PH#^
MBJ%=P?OKR5D-)/49LCQC94Y:S@OAMR7'G><@(Z']2,%?)Q?'HK[43C]/"-UE
M/7YBAS<3O';XY%)L>7G#>_ UUNHNG46U%UL-]4X+K9=NRVAEV9;7B84E!KSD
M:B25?AX+OF/[23D8]8?(PZ"401,1,DSPR:-E6*,3'^=<3GY=!X3;I]\0U+@O
MI::(1DQW4HA]\Z"DR8&1C?<9\)6O*1360ZVWIIE+O3W5?";DEZRN1 \BE!(,
M<WZEVV^XI\&T5NOENHBT4J)>7%7_%3#Z$4DA+C/WFTESP2N%6OY.T-C>BXI3
M3@A][4-&@"%75@."_S IZ8=MZKI-73^<9ELN"7+.L39?M;/,3HX^R2>8!+C2
M![FI=PCA; B"BLVE/-![)"%8^1/:)+H,9E&1I0H,S+3U'VU3T^PF5"A^*BSU
M3H\4Z[SWTLK4FPR5"5VD8<0:#;0E;C-B)($I!MV7))SB1KB3Y]&"6@F]08]Z
MK.!_=31'.\$Z +-,L^V%R[9/1YI9=Q.%*AR4H2,=VH J'*Q/M@3I80?!'*S2
MRT:8MC(A<83ENI20N^,W&&NA]X7*L62IJ\9%697]88)8$!U&Q+9-B>*\N,J<
M+%Y=29@(PP\82<"; 5]%57.$/#,VY^"S$B:^V97F%HAT2RX%]K!0V+GHK#%\
M+@:H&,D)Q0*S. 3:%U"3[=KG2CGJ X-?R6WN@A%!82C8#:YG(Q?#**&XE\\#
M<7O$P>6@\K;J1VV^-^R/8F11/EP419<8H/V^;9E^*Y6K"_2SVJ5:VNGY:;%5
M%ZA(<>W](@36)&'J+1T?X:7EEV0A!^<P]KFFC$T&_Z:( H?5:LFF98-$<&^8
M0"[:8"7XJRQ*EX>1\;E5"],'I8O N%%Y(?=Q?,C*]<8)$@MJ+BX2;J_[)P.:
M:0? K//)0&\^KJ"3QY032]WLNAZ:XE'7NN;WV7_3L,ROD&ZS-_&-)E>KIZUB
MTP)R^'S+"M%CU#JH0R-=$91GM"XU!B2([3B!@I6LG>6V4S$%6X>$9(1BLFSP
MI.K $& 3#*5I P %M%['9Q8]H:G_M5$D&*>@X[V/DP6']6#RF0:-Y3&=N&.*
M<7G[(]]:DRL](E+#E%VP@8[0!'L9F%+L,I);1E"W%&@*&"*OWD3]CQ*$;>C+
MJRE.E$3>T_C,>QH%)4A$N8*?P#(BFQEV4PM)-H6453Z1=_B:A502+ZK$\9/L
MZ3:@.-WRF%YS2KD-G5+?XFW4>]#YSTX#+^9 P!Q8XD[[S<6 DH?WZQ7F863:
MM]$%,Y%[1WA<J5+^A?4R2YJBY"+.TD2>D2Q71OQXI $:%+>KO()#7YR;.<:4
M:O)-J86U6[7>MFMA$]0G.]YO"J#]8P(.%]GCB@2K1)IO@3-2P*O^L06F?R+X
M,90:H[F.,GKE1L%SLB-;PJG*KW)P:Z29Y5*>JPU80^&04E>FDDB*ZY#/H(BY
M%T"E+1 "EA)C+IHS331>^O1!&*_YJXJ8JQZA-<KF/*KCJ6DA7Q],&.G54J6,
M,8F+)R9C'YT[+'-2Q!A>@\-N(PLIG+I';U^^>G8D.NSO%C.L"WZM'(ZM/KD*
M+"_VF,]_2I%)==N0NDN[+(X'[!."0^$&#;&D=ZV+<@0@07]+Y<%U6%7=BQE$
M7\LC/]C^REF:ABADVE2J *JJ#Z+^>H27V8IZRH(:2?XB\'#'-$0KF(&ANA56
MX',%9)3?H'/)DO&N/F14?TBGPAGM>F0><SJ7[C[3SDVH4LPI,,.@@NI+K/*U
MI!L.@*@*(/?/\(8H>_*#"H\LT[2 647'_1_^UN/0!GQB;R[6W]-+!!'EXA!L
MA2/O$J_ #(_L@J.R_"AU*N=6]L*1"@NGB8[8)0.X:CW(?\>?'!('D6O68PCL
MA=(:D\0S(*R@H;B(AJQXG4B\L4?P2#2W"+GN ,W*O<\2)/O0U04R=;+C=5GS
M3@B^N<8HK7MO-70LJIHXI#2Y]79\>/VM8#FCF!;[44](-#37QF1$3/18K\2$
M'++6B+DH>E-^@RP<_>K71X;(7N\!U3[Q'CS2^XG"H""O^/."(PUS,MJC$%)-
M!#V1:MWZ?(YP< A2%<_+0N71Y5NT.US5%S%DB+!WJ$,N%7^J7=69(A<6-/&"
MR--5FE;$F</O3#B"835EWN4)6I=16*ZBRY0:% QHO'6M2JRP***&VP#:*0E&
M&J91VA7.<]'H-*JP9:7/,:*A/ RXA"\^8LKSDEI/N=H( Q]*IJFDDM#KE*[E
M0J<"'+5"F=,;A$WVK<)14)F^LC=W,:C*HU,<'K:MOL\T#UY%%/:SKCG":HB2
M&A%]PP9@C5#A_Z/D2BP4815\6LAMLU=O\?EK[*!19"J]3+CXJK*NA$AWGL+G
M'QN6'PK>Z%LG_QF+[[@$@.,C^L^<0D\*.VWYQ.+T<8KV?),EIC(F+0\L*<XG
M%R)#5'MU%B3DGU&8QTKV5W/-7%W/8<U"*#7D(&_!'I \DRG29HHMD\OHCU0Z
M1G-U;CYY.;CS<&!6P>*C2<($7ARB,!E;2Z9VUUD0"@7MRH/HL2?@_?KA^6/O
M[8HB=G"*B*25CKGB>CT/A,&,P9I@,^A@!W ?O,ICK@QZ^2^Y8,>="/8B2L@*
MTF-(ZK&\DFIQ\W.&7J;2-[C5!!@\A/^1@W"]YS9RXOG-3IMK9.6+8^>+'77&
M&'R3 KFDP& 1B+?D.'Z@V,"C-EW9IBL?3KKR><P( CRM5;F>Q\$3F\$MH(NF
MZ'3M7BZ-4V2YY5MLH^)D1V;>E81"T.]DM),G3!EWH6U6D>&M!/Q@XP!;%3YD
M#U6-S2?L$*%23+@)9UC:O,%B",964<&5:A!O*3VUI:!%I@EG*Q!BE0.%4K?!
M>2D!Z[T2E! BBL>[B1UM#J.%6T#$3[>]<//;<[*W5'.LN9BHA)"#7@U>G#4J
M5;;+N5Q<![?<XYU).!U,P.=-K=W)]#==,NQ:B91;*EY*B$R4( +S5V*66*)O
M!L1P<37'1Q2@3E7!.[E;E#]7^$WX&2G>PG!Y3O<X^C!<;LN,D'ARN!CMEA_G
M;L<O0F"<2,5.;9(VJF*6P0O[3^[+;4(J@"KKHQ&YA3VM 1M,,G<(#H8W"Y^N
M- (FJ=9-P1X*N"HW;:+G$.IF"[F%6Z#BYE.5=0<U0#XJ@D &1: +F'FL"A<9
M.1"#PFF[XZ$L,]B@K%PH&AE[Q,HW5;$RO#]>E"N\?8N"D,)OBB[HQ;J(X1CB
M -9H33%V4!4'#$M'60;'/L>(;)#ASW!2P7\O$U6Y3FN!QS>CEOCMLDD_'\.F
MP6M91RC-Q*5<46%'WR[BP*,OGZ\51@RRBZXD20#_MT1W*0M*2:^;T+6WCO.2
MMUYU*E'S#3<$XT4V2Y,SS+8H\),Y063'E&6V45_@ (;4_P3?A:\>I\MC54@K
M$_/5/\#1/ ](. AE=(%YY$ NM">O? ^[<-/U)86-U%>U,J"9<0HN73->%7D[
M(=R9K.&:M6L6HI3N61&6TT<1W6@?F07=@/-[3M$)?OU1QSLIL$2!%U>:.G'T
M6)N)U?ZL\?]D.D2!NF7^,*Y-MWOOU;)(,Y;)J]N4@7(\60[7J#X96-4]GYG>
M"W4:A$U$YR01MIA",,SG0<45F4Y;:%:4@O@Z''H_JC6X9I\XFI(A(P^UWM2.
MKZ=[#UP( 9_'ORBYT0!&3MFAQC-@]M$6^/F5.9KG\'DZ?BK\;U*?LM?\('4Z
M\;=H3DW(S<+W8W:DI,3R(DZB83_XE9(9E(M"MZ$L"1H-A()2GCQN07=2QY;I
MPG2'+?;#J^(5_5:F2J;>AT3LF K-$&D3SR%@-JLJP ,6:MBA_Z)>VF&*9,P6
M5/$![9HH@C8*:LC6G'-B3ZR")T+G2RM,HKKS52^_;P-(5E'2M@!.R,1L^@-%
MVJT8%M@0.(C-=;14:;^YX)Y";!CDN"%.!<<,$BSEXTCY6DCQ&/&3F87*KA7L
MRT!>8U%ARB*9)B+5FXK+E#I<.8C HNQP6K5=\BL+3-MFBJ5B&:6[*0(@2EOZ
M!N$;W*5K:14.>2MLZ#(SHL$]E8M5$*^ER5+7]UAZT>KWX4YQLT&<1CIRRZMR
M=03=A8"=* L9D(KU+[ESPI'$K2"6!K6;) ;/T-Z:6\[C5:2QOC&HH="\*U[0
ME5ELUS4E*BPM5\V>D"5QY*(4U[MAE'01RR-VF<9G^KS<,H-FK\S71D5KT;J+
M9OBRK+S_[FREC/X:"TE$@9+&.6,LNTAB6/K0;0QROJU >,EL(D>'\3=:G"?I
M*CV3I,PF8^5L%Y1HST-Y&7!Y_\@P(UOW,C>;R85L BTN[HPFY10'0+?@*.]<
M5N;9NS?P%NUU6?@?] /JHT ZRGY*LXKC(.6)#/L;IE;%Q)O2 /CENE&%<(@Q
M%V*#IIC&'3&0U,QW20U"5*(1ICY'=8GW>T[,M91I"[C\"+-,6QZH+V1Z*)S.
M6_*-K6"2;]I5W1UIM1'YHG%D'UBM52X*Q!$NI=.T=WJGK 93"S0CL,I8UHB=
M@0O"OD4C>XST*JOIJJ54+?B:ST!3Q:A&'X/'8S=&5=!%;.5RD\XX@/)@PH*F
MBH*F\B'8V(R<)&[WM<ZXGI1F126V3.%5)/]"-W4KOY8@<DPRC4JO4($I7]?F
M6.]0O%R@B^A)5H5IXTAT]QE]FJK<5E>& $NK8$.MYP).2&Y/M2A;RD2*V+U0
M<6XIM]35499>4L:S8C2)H%UYA8H="ND\;"%RA.9@XC[/+;P<84]]^?R$94<1
M)[*1L2H<-1"2P;32-",*]XD,4",*N*HHCU66*G9@:,ZQL#DP5$F($8MH.+!X
MY_'&&A 'VY)HY6M3@1LAWHNXK(HG@MNYJ?I=-H]O60Z$#3<D*@QUJ:9VD,'5
MBZ1C4*T# XUSX@=?P>%H<X>&U5$ L(F%RK&=)9=%F ) 5OVX53G64,YVWZUY
MNAY]J<2&/7-JK1,$"M"]D;LK8IGLG'I -"81/TKC/=G%3EKRYF5X%A72LL 2
MM\+M1+?W>A'2TL)#8SXQ*F (KM0Y!F'&JFP=LP!#6:+J=)GADK!2K-CQ3L2B
MR.0+6FTY3@$W#)&[JDL2!*=D09QY*M6?VT2?E:*%!YEG&[=YMC;/]G#R;):>
M4<I%=-O-EE#K=3="9"ER&^0_S<4=Q_?<AN;#KV3Q2'&EZ*DNC+]A54'%"5X#
M*$X#.B?FK$"92!DX[MW^TBF-'H=]FU5KJI%9\A5W[W'UH4&G6TJW%1,,H/L=
MHY^&4(Z<H6-]; "1T!R1R3'/:-A,#2]SFXIWMY%"%XMC+5\>44FXI>!M*5BG
M1/"ZD%U"#^(-F#Z\WG";Y0@G\2L\DGHO>WV[.8,2BM;0,<":GY>%AW=C]6)E
MAZQZ9-N.Z=DJ3&)[*T3J);]TSF"$RS);<>@X$\DC7W'KZ3#Y"C:GZ<9\L\+N
M2C$#++&/G%X:G!--B2*S=L"U3A]7A<]WW!+QZ2SO1 .\N)%/.&0& =]VON[6
M ;FWXW6'M4RIDG6+DVX\75Y#79BVA217PM&4LZ*4@4XF(U9UR6%2Z^]P\][H
M6GC>EKSY);82_ YW_XNN=[\ER^ BY5RKT[(4+TPWKJX$O4[3W;&/=Y_@B\TH
MK3J$O86Q2KBOK561F*W;ZN59X 'REQKO8<=[BVWL$F-SVD8R'0*NI&8D R@G
M!"^G== EL>)F2YOVTN";R2@OP66.$LN;H4>%Z0J3^FSCJ+U ^J6JXTHSAFSC
M(F'I)ZX@+P5L<B))A8CNT:-#K0.3=E** =F^/!<I"@E=,N<B)#4!OE8;)I%&
M\J1+) 1#.M.@P%1.NCFG"#_OOULBX#VR3=V:TJM$")PL5UA?-8^*2^QC>8>5
MQP&M]F\?D9\S.C*Q>>NIA6>E3ZD$P?AD;DI+:GJ9QLS:61UR35<-B43K6HQI
MWX;./+V>S2V+O/51*.$[W5#1D.%Q.RF:>,RP7U!<*%^'\VOXP7;?J8 '8\N^
M0A#&3!;=O;G\ W$F^<F$' HW:8W]; $2;N5]- M! 4+37@("LX@WU"/,+2IT
M$"37:0(P9KO2S#I,*^K9JD @21-"36M>,ZS[T8*:5-NZX-VY$_Y=G$LL6+I*
M,Y(*-Y1J(J2B5S6((@=;F)Q=L\WRKEBVQ!(6R40Q[JRZ.]YYU!WOL[_ZUWGV
MD_P//^*5%?Y5BW#;Z5LI6YPGP>GSGX[\;>M2H<FZ;GW<&"2?LS":<QP,@^N%
M1NINZ'5QP<$52_6[B.GFWW-N])QXJ3=4T(B>$KXC-.E+.V%)?Y..YPCO,/1<
MP=W%_A*I.V,_DLE]]9+B^'@5)>)O/\3W"+DWYBH1S+*7FY5"IU7+:'NT!#$J
MJ="+%-^@<ED-7,0:2H8J$$0JESH1;M(=1A,XN.W8]$,BQ,:4>Z9)+Q\&XL4M
M,<ZY">.TUQLMI\O>Y#2:1H/387\:G4Z#*#A=#L-^V)TO>O/Y1/HS^!NO0$QZ
M3W]+D $1D=+>(]4#MLN@33N=]*:C[D[[.>[2K0Q#XUMV[RGVH*LA>C1&3PUR
M7[OT:YI$]M)/@J WFR['I\M>=WPZ#*+I:1 ,QZ>#63!8@%A.>H-1?>F?/;,3
M2*>CP630'>YSQ;W>LX[G#(HF&7]"/I5?RS6\8\%00Y^*=QAM?%ZR+W[:@_^/
ML8S3#^EIKW\ZD)_*[J]O1B=_GX<?UW]>_.N7/_-G\<GD\@<O"=88/[P*'SMO
M Y/U\760!$Q@_E;EW%ZFV0G^%T_R*RK166(EWDD2TH?AGQ_8D_L XWJ*-#$_
MT")_F)_^=O'IPXO!GT]''__[V8?A__Z6KT^'O?_Y06N_\*2XYG.G^+'>#Z##
M0!?#@(NLC/83R/QKO-T4DJG_Z)F%(\7V'BOOHS/8P7AO3<][EQPL]3TCN-RZ
M:(S.SG[].?[ECS]?!">S?_U<QB_&'Y:7U<W^/:("N#-LQE/UXD0>PWVK@9)+
ML)Y&,I659>$TGC[!Q<B(?:?B3/!><;3&S;H(XI45_7#2B:JVA4*!=NF:4ZMF
MU>-2LLS]NRJUC%984%URV!D^B+#P7V'K^+W_]4/\J7B\C#]%X3$M\6=OZ<M5
M<,:[^6N09:?'%^^NRN._GT;=8++Z-'[YMBS_=WU&.T@^@DD2!Y5R#RK 79OC
M(^6;=&-;+-(L-*4-%%S"C\-GEO&*;Q36Y<!9-80^<']Q:*OZ 4N:WF(QU(OD
M#'Y77=/BGY_>QW]$LW^_".)9[RSXY7A3P$O_]@N%H\\44YXP"W,1LU5A55N/
M+<5AJHS;;^@@V;XY!"655SZ.:/,1G9 "K_D4<TBS2MP:ZW[2$#9 G2)#,\N.
MI[0S\-'+\0H*?Y+.R,J./K0,[J3-X+89W,_,X(+HB^,DP&;7.5GB/'TKCD==
MSRZ#57Z3HN7<PNKJ1.+2;[)WFN'F%\*U^)!6/_4.@:J11Z^H:./%B_\;;CZ\
MZ__V8GSR^^NGX_]Y];^O,LO"46\Y>R'QUII&*8?ER"=EK.F[:ST($T,75ILL
MLFEY#!I'[2OPA:IZM%T0UW\1]]1OCNU3*JN1@4T#Z5@=:8Q1%4<-S716&7=#
M431%$&HH.'9;G;-2DE0QX2_;GJ69J:=^J3I;'6]LPU@#>10I3Y#KJ16]C4 !
MD#?_DHNF-"A&PL6P)XP6]"YB>YO@F^#:UCW^;V.=["-ZSR[XNW05O5E:_D7-
MZ_[?TWEX^L^S_TU^"Q8ORW_^3[$Z7X;_<_A7K)\I1D6.X#M3 >HL@/>._/QO
M[,+U95Z[6)'\3?9,,W&^XZ B4C94%%QZ_';6_VV>A]U___>G:3<?_C'Z^>TE
MIP#W=I>\80IU$?_E_?/>\?JWMX,7_X[?GIQ?))/^Z[_71/R?V+_X5F')^ IH
MG+35L_,X6GHO/L& "#ON#7-2U'W/JK+5A=P(VI3K6ZJ@*R&HB;2!Y(XVO-$M
M9QN@YZP11D2+PWY4ZGFY@\=J_*^^OM(FSDY]LX=]KQO_- VR\,WRN>($>8.9
M972SZOO\ZVCSL;]:GSU[\?N_3V:CDXMH\L_C6@!A'VH :WEI(AJK@=N?<V:
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M(M)-&UBS)F* [,\:5\MAF!5NO[,8>6E)*.[VEM@09>#[:"$4,4!5T+D#Y3S
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MXZ_T1G]1G^2:&U8U^N8N"])IF@/C9I39&3_J!L.([?9*Z\EG9.QK:1L#)8V
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MP7367DF5_^M@<8Z?6@G3 N[..4@$284)^8LK^89<@/^.KM!0X7LT,+CB$B?
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M!^U@:)$>7"IIV*:2VE327KNJ[E1]145#7PO%\(MJ:_Y%[;HO;M.NNR]-[Z(
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M]Y:^W^MV_6%OYQSOK:RVLKIKI'9_-.SZT]U3K;>RVLKJKN-!HYD_[NV0\?P
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M#\>[@)?."] 0>.B"S0;VA+Z616<E6,4TN\+?9BEHIQR]-'@TG"CX2 SGF&A
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MU#:$^F!"J">VKGYGZ^KGEJY^(;IZ7]KP?3E'347T%F3;A3C)XA_3VL0PL7
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MKPBQ,2%T!TC>:NCXFMUL"[E5MK_!*J3Z\VS<$L=)IRYG9FR^8A7=3+'2;"U
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M2U1<I0K25!Q1,Q29%2W#VRS[@/MV?3K?DU%RE4K7J994T?-BAV8TA,DY:T;
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M0:_"7=LCY_8J?,44J=6W*;E0ZBUT93G>IK%!F4JV/.E$!@X%.HZ2L/H>="A
M!OY)A\+7? GM9"8SL5U>T8J.Z:JYE%!7 0,#:%8J3B)D'$^^Q\/7[$ZX(%CK
M'M=]#17[HA2HO?3&O&^,P>S]BWL?+DT@E]Z7>^.<JS'EO6?6%"?VU]2T[;]A
M-L ?5WC#/0J637<X52[#VR>LRGWQA=UXD16/[SY7E(%F[(2FHAF;SU.98J^'
M")4!R0BH7]<-3\4I3_U'B7!&\>GJJ]P^(X<*NT%&AC;]*;@Z!.7IK!<C82SW
M]$S=,?.M%%(>V0W S  >$*<H.DY3.#3CH1E_&R'^*!D;M[YP:'7?U[JOG-"O
MVDB.S15OYB O(!X;BK8F0:LYLM'NVVA5]0F;-ZLM-5GQ=6.?-&U!6Y3=F8W@
M#-]%4[6BNUT)G;5Z:L,7^Y**S(J6X6V<75<L/[$F#=CG/0,X89!%=C4W'3W3
M-LN$.5OR)K_R)@<,8 Q[/!*ZAK9O=&/7M\&.7[5<3\.;7S=?3\.;KUG2L:J%
MDF)B)+)!MT,Z)546]6X#L"0P8Q_)&ZY)_JXJ(&M3UU%D:+9>N=EZ2O?;M0%[
MKU.+R :<]YX>@<_U3=J;[P3!<F1.F2GSZK+A"2WT)_2(2U/TO=KE-\O)]Z&
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MRQ\;WMJ2*,P[[5*OA2@=>DE4.$W9ZMY8](B\TC;6IK!-.[KK8FR-TEHY=MX
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M6(_1C(*0F\*DGJF6!Q7'[T05V@0[OY'U905ML$K-)*IZ+=\H\?NF5:^T$;O
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MS" 8<[%0[GC6Q$KMKISA-R,2&[82Z<VZT? VTV^JB))Q B<A7A3>,A O"M$
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MOS30;_N#5W@'O9SIY*"=BE2KM45R8@00+%.S?Z 6 /*+SU#@,:>R,4%+C)M
MQ%X8H[K!\W*),@F2/7':?.M1N3WS:WC."5;+;#7"_AX%8_)O:E;98#@]:<Y@
MV@EYL3U4&&-UT#+1&YLQ3AN.8R_P/[C6J']H>X]?Q!]-_0P/XIT.(D;L<.%!
M?/A!Y"Z2V? @SN @0M9T)@?Q5"62\"!"UO0I#^)/4^&?%%_?L3'=^X6M/,6/
M/\CYX '#'_NDWU1R^R"XV"\JX(?&NHPGKB!EC6!G\!)!-:*!-[TC-CW%RT*H
M?2(:/'.HO4\IM:\&M6]-H:%H\ 78TBN*!J*FP(__[T?JQY_"*/'1I?VR+XY
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MA[F!V(N9IP></K](C29PID[@;6OR-N:Z66+L8DFJ&SNHT"EI0XND*H1#@9)
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M3Z'VV%]<ZY!\(DX!84MUDX16EL8<8")+Y**90I0_T$*%-$1.=,D.3(/!@/4
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M@"F?ZVRS#WIBREN"J$WW5JYQ5\,["X+ILE!,C_/=^_J\<(LVB73-V&Y:,&<
M3'SM,JVW>ZG. $OW-6E\GT\.'_)X9 !,#>'>J.V5V[M2>JU.Y-N./KV-P<@
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MY4^AN+]0_*&6XGGX[9FM>#LXV#LJ=MFANO%49W-T&:FB7')NV;Q,4Y/Z9)B
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MY58LQ2%31B2(=-Z!+3$4/ V+TO$H=9,3L0\0-29YWG2\;BS@THF6O5?%-T'
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M*LNY^^L?33_=5H,S(PLXTDNX/^Y%'WM84;PB<B8,2:='-CP&[=0MP*)>A5#
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MV?UPB?VT<?9-<6WLLW9RP]E9W<Q!O@X1^.1<Z8]I1W/0.8D.A96%VQH)"Z-
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M[7\Y1&)VG /F 30W9 /_]-&>*3BTKUNFV]J$_Y%"&I #"O_ZQ^!,";P;N(Y
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MY$" $AP-@AH/LHAT"Q;Q<ZN/Q!*T@=$ERBFK,C7OQG -0]71Y+.YC;T) YZ
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MO"3RF5Z^O4334Z4Z85AUJ5D@FDB$E&F@][2[1]?O!U=T"_Z< 6N,0H('Q/.
M #<L=C\(FO89R=D6E"X2@&0JK#'^+Q^2Q[NZ7AI+$"71BB@2YR'^2N*[QP8*
MP?_NZOB\&(3]@9T6X UV!.+O^5?"1QP;/+Z&)%#$A:A$8A%),QS8=&_O[D(6
M''$+*2G.'6"T/!T)/9@PZ7J)L-[= O!Y0$.@6WV[Q_- OWKZ:@(!"L'(T8O'
MA,J85QP!@AT!':R!;T/06$FS;-/QOPD5K.CCTVTVE ]0$,&N2G:$AQK>AOB
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MMME7GV&OP%J?NL,8W^(N/ 27\7@\NTS(A"&KH\%@56TU6BG^$X7S>D"!+"#
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MRQ;!WP,N]]P!KT5, I9)7!J2N35% 2S:O;AVCU%AY/Q;<$QX1ZXE:N^)3]K
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M8#JV<,Q*.*Q8)FEF-,%Y"4(88VC\A;@W "U-IWOFV$)QF<(:Q+A;'J_%[*,
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MI63<W8\=3YJ=X'$!18=-3FWPEI3B>9+!X<!<.JMGYY4$)XN9S+S>EM8$+8,
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M)LY$K!?.$OY$FO\3(E,3ZH7_;=>8HXV"7W-,MQ_]^M/V1!]8&PQ4,UZ?Y&U
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M")4K4JT%"RO)!MY>R372I3[)Y9&%[9"DQB0S=18^$PV\OH]UM,V0G+25>:-
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MP1;L!DK0?/D:]3T%--B5(8G0'%WJ,*UWHHHA5XAA[F*P]SCWRU_8?R]K?W/
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M_D;J*E@3@'KO#YZO%)'@Q?[(X5U4.(5$!#P'_D#$([2J1H0Y $;;Y]G@PJ-
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M[F> BA<]WW=96B] >@Q 8MUB?4PQ+2XW+#?HPJI#9U(- "")7W\(,IY,/"Z
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MBL60.'[;S6(_*52O'+$[4:OA]_R>JTI8R$UWQTUO&Y_WRTVA"KMQ%19"S*U
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MU+,45? 8&/R8_OO<.\>A@WR.@I:OEM/ B .GVX]O9&,8_K).Y?\\*\>YC\?
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M.!?6$$>\^ D$$0W,?;2;N^'+:&0H6+(5<0SX2!@U @#CS#_1VN\4G<_ATJI
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M5)WR\8SK!YPZZ[E7M^^[^573':G6$G1^.%+FFV6_O+$8F4ZZ 7D0I]+(427
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MEHRFJ+-4S;I)5^0S;NQ=:[U7>..%RWJ@^I+Y\J24:KD*N]XP729OJ!,\L^V
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MJC5_ID\UOSE=Z\%?BD;F*QK\Q+\.U\36;$9+N.G!-@[PD0*\B[J/!]QD_C>
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M41JM[G4O?DJZQ\/KJ2/I[?&H?7N>9UU;4ZDLZ&Z?U;DUPJ((B[ZVAVSW6'2
MZN,6L4BN'-<[HZ1S49J)T\>AD4J>Z/$^8!$JEKE8FD_'DM*+</0GN\LN:!<
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MAT&*Y?1#FL1/.H-AK=M(75N5\VI-V-@F_"@(MP: "P. .I@%>KR*\LR^PJ
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MI6OG]OS6$/*YR2:0^F'=-DAB3)8+0=!,CI[X2O[AEA=;K?.K3I6<B)< FLY
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MM1L37!,M8(_+ V!,S2T=;$7'?RYU]IIX:.)YB#VIHEEJG W"UW>PH)R-CU5
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M4;-H/O7\?*!N$6R/0%3O>S\%3^M?&L5>OGDR/$DG^T1Y>#2G)Q\JPA4Z#E
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MP/S@]),E=SF_,#:]:Q8'$EGFXEXT)?6[=WH1T)MV 4^^V/0]X'<./!]C,'K
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M2<0T$=.\CVD.N'W0&YGJ4WNQ10SVZ0R6?6T!/J\9UX<TR#^'@[;8JRVBEN]
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M5WIP <[F<BK-(*0J6U;GZJRA3.3C@LK+_/V=.RZ1@FOV?_R3D1)A NKU[>2
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M^>=7]Z@+Y-73F/HY-FT6]?#<4'V/E.>8 )M',6T\:UL-E5H.XRK 0O8 ;OP
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M 1KLWFPU+,>#"I8%2V/$J%B6$KR$"SRO0;I(<L? 3@P/H[<X)HWBFL@:C2Z
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M%?0X>+O?LN0#*%L,<Y[3[M) EPBU%2C,%?.*&S,E@BO#IF A+/+I+H@(;$/
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M9_VQU)EC\M3(=5DR$@V'#L/SY&/I-9\W*KWH!3:3D'.?.B JORB[^]Q]^<@
MELXU56XR8,"?R8,9JMPRGVFL9F+%!T6?C0Q *L;'Z[MOG95$WC)Y7[V_8R+)
M)FH'7@5)");D?:.PSG?UJA[D,I^)"A]7)B8.F03T//TE_\BL9Y->9??OQ^U*
M)P8?1A*%7GHA'D-^96ZH<[,P>0^7>]::AD.F7I1\:'[$7K1J@;$TJ%J4HEK4
M&TMS1_LC%Q::^ZET;<-\".A2X:'Y!*D\5D99*CQTZ2<%CKY2VX&&3J4."4;0
M7/ZNB['G#^TG^(HAE;IS=8FNPT%1507C;@3@(,;=( =+X6"]<3==ZO\"_BW!
MKTLG8;Y&<&P46J3?W8BR:$20"%#:IMQH3H('$O9']#%!X);*;,4(6$O(SC;Q
MARY]=GCMC:IUT_GE QHCBA#0I0"ZWHBBBR" 0>3XVJ*@\E+$BKG(Z%@QE>?T
MTB_$!UQ?TQ%@E/T= L<_>B W+GPU[.(CMP\? IR'2X"_\WQHN_>,ZFTM 4P(
M]^."NXPGM4CW4N@^J/>L=E8K>1'O^1QK"=H!C(S()[@FR+6<*^.J<%2K0HL]
MNF:\0\T?UX8RUH9Z@]>NGF@_8B=@247"!=X#=S^27P#/+\2A[I!D2\ E[><L
M-WILNE&+DK>6B#;AN)M-O=.!:3N!*;(46;H'2U55-UOZ'Y.QVV#S76GJRA.C
MZ4"O-YINBQU:4U1SON#KC4-<!)3 @+(04 BH\I2]>@/FMFV;+YF2YK.#N1'Q
M:9P"E!&*)_SL$)<,;/BC2UT;_OXV'-I]V)X7U?EJ":9#I-:.5 ,#^)"E);#4
M$". ;_\D?(ONY(63*1BU1/,)AU T5VZB+1YA(6W+H*T8P88[Y-@J#Z]X&G2B
M&JJ&S$1FEL!,,0(;*^-E+=&-R,OZ>:DC+Y&7)?!2C,I'!73,PA'A1BUA5LC,
M^IEI(#.1F24P4XR*2A]\[X'Z&3$3W]+H/@K"C)%%O8,,#,0Z44::R$AD9 F,
M%*Q<TWJ]LBQB8G33B1*SB<0\36(&)2-3C))0%>&REFI0B,OZ<=GZ'8-Y3H&;
M*2D3AW%3U70U=A@W*@J_>?7^*AV%0[\I'?!# #N+]2%9K,]"^.867W;VUFL@
M\U2Z<,(@M*DC2U?#(>WS8*(O!-8?*8X*,A&! B.PC>1[R>0K?X]M689A<(51
M,YNF-E 3C;'>R)LN4\] 3>M+2;*I8!;%>+8FW52FKNU/OJOHGKI4^F$[CDW&
MP9E$,_0M?HL5?TM1W71%P:Q.Y/L,V+<4;A9*H)/.M-5VXW.BERZV0X_;<40*
M*3IV;@"WJ:#.BN0N)6C2K->3/@XSBN IR%R"U/VI_(OXMA<%DNU"=X2>'^S%
M7(G/JF7<KMG])]B5N@TU(2Y<21T#$M4730%'@U/TDT>:ED/3>CWEYVAURSX0
MU,W4%7[TR-138*J&P?.(UC+16J]#_?9<23SE79KO;E7E[ QA,WO!B@H FK8_
M9%<XWS\_9$\E7S_K8!WQ=6+X*GJFKBJ6;JBQB11FHA6;2!L5Z85)MD^8UDQ]
MNP6EC2/DQB%]FA!KCEM+UE%)V\<P*F6:8H?"518&3UQ>"S(UQ)Y)>R?AE]15
MJ3A7VSVEF<GS6S_T.,-:VVR=IP0N \&%X#H$7!5I7?DTQ5\]6>($*,:R% 1F
MHDW5R+$5>AERK!#'3.08<FP7CNF*9:A:DW%,UPQ=-=,SZLHTL,Q_<?71QB)$
M-NSKU#0=>[J9<\,LQ=!ZCIPE('FTPQ'_=!=VKKX=VO!T_/CZ"5KDWE.IXXW'
M=A"P#2+\+_:G3/4_';'#L--$["!V#L).9?I3BIV-9P![P$=#^-0,GQ;"!^&S
M$3ZFV=9;,%\4U6HI2FHTUU5-,6*C>65*3YPT-IO=N4/'9-O%6 !S'MH1;\=&
MGC.@?L K.L(W02-4V"G-Y: -%LH-2$9,!U$UJ*R=[6>@V!^\)OC[+87.V3T:
M\'OHC7DU^F>I]+X679J1%']7LMKOJM+*U6?G/_^6;WV/]!_N?2]R!ZS<NN>?
MOU;XOW>YQTK*K&N\:^YIH^=3\M @0_CF<^(\DFF0/&;+D@$2<?7V<R5M%:]$
MSTO\_";E?F?]L=29BZ7B\Z7:DX_-5VM/+ZZJ*3]W7SXR +1S3959[?@Q_)D\
MF*'*+?.9QFHF5GQ0]-G( -YB\+R^^]99R?*MD_Z.B22;P1UX%20A6)+WC<(Z
MW]6K>I#+?"8J?%R9F#AD$M#S])?\([.>37J5W;\?MRN=&'P8211ZZ85X#/F5
MN:'.S<+D/5SN66L:#IEZ4?*A^1$[6D7#VM79%H_S4379H)HPE619.S'@HF88
MJ79BP'1I5ZR=K#RRYZL[/[3_0>!]B^;C>!$W1%4V,C.Q$K<3MTPP DU%0"[M
MXT^%I!*35)5;<3ZY SIVXXAW-N.%M^ @CU;Q2$4>(8^*&74 1@HHW!F,E);6
MK%AM.M*3K+\B9RII3>30C$,:<JA.#BU'MSYWLHMG 0^>9>V/GQQ]Y)/%CXCN
MTR>$GZ-1@U9ORTP%$&2:*9!,14\3^-0;;3?OL=A</*V*S[*-%#T=9J[N,5:Q
MP(];&E">)F=M>![[#"A>(#8!2%J<9Q?8$XS8G:)QSR;\[3>^]\N.?17_08D#
MI)KEP(C"D>>S#[\!+/7HB#A#;JT?V<X F)<A\.]D/'DG_?#&N6O)S3K0,I^N
M_/8/@-'^Z$PBTB3J.79?&GG!Q Z)\S9MV!H_RU*TQG]&Q(=! =0N@%M5&O_<
M1.XUU/Y"IE*2%,1\BRJCW!31<QR9+1ZS5P/;4)KMF1VM\HQKZX+X"J8^D_;-
M>K9W")_16G85OW#="+"^S+?/O"8OX]H4%A$I=I+/UAU=31:>109>=6+0L78F
M;S)Q>\Q8)Z)W.;)./-;MJY_66].F2R<DV3L7I-U' KHE$,.A[I"P'??54N2R
MI!HKD;>!=7I=:AVR#E@GHDL[LNZ(6-=NSEQ-3:6I:B+LQ5=P+,881U,W]/H/
MTK=)S$( &[P$<L8X=N- <T4]QW"IE*1N1'AQ>(GH$H_P.B)X67H[!Z^6IHF@
MJ.UTW%&.?O5,IQVH8>4@U49((:0.@E13;^8A5:T36C60JN%(MHV0FD'*0D@A
MI(K%.IN*92JZ-B.45;%GVJ;SV,5T,5M<_]-\?6+N &=IN70%X97!JX5N_@BO
M AI6RB]5L5JJE>-7FF.T7@UK3W[]Y0$R7"I])I.];%B;-*_"YO<-$)ME%\5=
M8HYA&!J #$-3%IJRA(84Q@T@I-"4A:8LH2&%T04(J>*[P::BM'4M\]YJ*JIF
MB6#-2B&5P\**.FEBVJV2NA>IU:J)G&*<0H]ZY-1S< J5*>14F9PR?T=0G32H
MTOW:+&ZG9=9O&<\B+5M)I.7,!3VVV30QU'+!B?_D:=:4132S([GJ5K%6%< !
M]:IM67$!'+5EM.,,[LVJ"D>L0=\UORP-?6\,\QQ@\PCL\T=>%-".YTU8"N7K
MZYNTWF#..)0I4CNH0CZ%GF&2("6OV:[49V(TG+*+I-_W(C<DRSDWM@4V-@N5
M\HH?P\+Z-PG%+*084NRPT&NK9FO6)S>P!\ QZ#C.F8D':@QH80-OPC@2!R5K
MK4+1T]8JR&#P=!5HTE19%7&W^&+95'TFL87-H*96EW_PV@YX9>5NU -ZV(27
MB8"_Y\U#N3DHG>8DU'$2GI:"L#@G]>KF9,=S@Z3@^0?R "OFG>V MOZ]>\;V
M(6>P<QC0"5M4X3T^GZ.4%71)[!;)3H)I $/;'Y_Z\JGC\GEBRZ=>X?+9X3OX
M-(-X;(VD0]";:3_BEM%O0W@5IO!-Y <1K*1,B[Z-'/KWUVI3>:?JI*&:;^A;
M"?3EW&5S$%_.3=[XE5.=PAI.X1.;PI4EPETSA6?UJ7$*ES"%<0*?LO:LUSV;
MEQ=D7HE^S4R'C]W MWH#4*<3ZU9^\JMMZ;O<E3LRL_NS[TE)8"K2J:O;5@L-
MZ2<UTP_*@J\8YBS(64]@8;6JT]_7Y^;K..215<Z4;K@9?<]3.38-E@WFL6F<
M6[TO)K[M)*E,L8#&>U51Y4]?NZ@DU*GE?W(=VZ72_WZXO88Y$(2$"?6EUX^X
M0P\78O4=MPS;Z:N#]-6!!U_K>J%$)A-VYF/'+C^?V%"3.)WE)6  %EN'2CW:
M)U$ MPF#^-M"<A](K+HQ.R$:#))3H>P>LV:EWW>RDZ3;^0=.$E$FR1UY\EQO
M/ 7LA]3E;A[=_HB.239K3K8D=1M+4F-)ZI7"NJ4D=:Z'>"_'K<8JU96L+IV+
M:UQ=!%Y=.L3I1TYLV[BVW8<>BU0K:ZTY6JF]O/H3I59@J;VD0]NU46CGA/;Z
MX@,*K<!">TUZU$%YS>3UYO8*Y55@>;WQ*7,:0MT@+[8&BFR=(MOQ?K%S<]B]
MQR=DJZV!;X9L9QDRJSH)YJQ][(R.[=P(7!DPDV)B7D_.VQ3U][<'%WQ-+2RY
M[6KAYY=GPYN:8Y3Y3;\JJQ8=K]CVSF\@=S&5I'=D#[9T.V9R4.0F?%4BV::L
M9#82UW-I-E 2V[]*BJ3,+"/QS[*VW#OLI[.'EYO:P@8Z?<JVK*6F@(VB/K)#
MRB,CF WCT2>I]#=ETZR21_\7!2RT*[.1+9G(YB;^FH@.-MLUH]!LMW39,"H-
M&=_ZQ%^("R3@IP7,<L1 P'QF^MYX FL8"3U_*O$TFW"1^#X+DN,UJ&?/O; 4
MI;+1E-MBR\;>7?5?QS[6-Y[/@)2$$MB!E!P_LU/4 ?/.B#-4$.:Z; </P5MI
M1'ZQ@R$*PS^V^6(PR;E<? KI6&HJZIO>VS>J\C9)AI&:0KJ-SXM2DF*]G$>?
M0?C\]9#_6UC%V9>+!4Q8:0Z<%(8JEDSMI\O!I#"KS9FQ]0'^Y"?_S'. G6X^
MK\3.GV&T5[>47[)Y(,%Y@[]IO6XZK]:HVNX*:G5:L[F'UGQL!VH6'JCA@5J1
M S7>1'OP/Z]^]EI6OZV9ZD^EW31^&@K1?I+A0/VIZ;U>JT6M@::V7\7?&G^B
M^^GCUXN[[[=7W9]JVU);R8O/GVV(=[*J99T\:TB)1-EB/<A[?#(W%)_^?V3[
M7"4-DJ2!>=]/IK6JYIO!V_A"$D*YJGKJ19^'=JF6;IPE=T[C+$$+"J0!2\W
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M)%9/T&-]8)39TY79(UCU^4%IAP0CN!\*K7A"&UOTNW%MJI,]R4<!%59 41-
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M"X?^\NS!ZKJAK[+&]KS!%/XS"L?.^_\ 4$L#!!0    ( $"$>5P#"E%*<[L
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M^=H=U$92SYYQ7$5Y68+9W9=AU#U"BGH;&6/>'7C_U=Y-<?PIR*+%G]F^^$L
MC3S173X#S?)T@85/>#MLW$]U<5WJH7(Z]&]%&^O_A:+D)W^?(S.$^J] K=[_
M P>R^C3+XBWVQ;<8<M5JD)A+\(3%O[#Q2P:QKNS\"M,]Z$^Y&_DG=CV\_QKM
M_X'R=Z&DV!G7UOFEF]D:6<0-#PLFWDOCO\@AR_K-368O !,97JJMH]Q7N%X
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ME1(B( IN[#&A[/;D R.]3_>KY8SS2;"':[,(#S)1OY#A.3F2+W5C6+#??FX
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M!(1D@B*FSD$.+.#DYT;DYX4T'H5"QKL^:9J=!],;8;KQ$YY8W"ZZB 2(%)*
MS782@-5O(2^!CEUC2_G#!L&_:;"P8K![2OF9XA+KPCY(#8%B;Y@C/K0%[R_
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M8"9Z1![-]Q6!E[+)N'6>@#AQ;LXC)?4D !;U4W]/XW3PLN!%< 99Q#V'XPW
M5LJ=9BC$MGC-]*]K(I3E,:-D?1MTBP1\&T7B/NOB=!4EP(M/^^$8>7'BY4BR
MJ5(I>!'BWKO^"\IN! CWR!DK2%[2KP^.U0^:90\(PG=6@8DTS63!J;>^-!94
MEH'OV)17^GTUVQLWMN8)2T]&#T=$?'C=[L([N\B,S'A!\ 9*RGRXFYJ"7GJI
M$33XI@N[), CZ([W^R$/2&?==NJO7K\',WGQ@A=M^N 8<P9R2W331P"G N\<
M287/M(#^YO3?\*Y>$\+O@O;;TI[">_1(@%?B0F33)@W#P0<I,)Y#C>SE/5 (
M#QUH^]HR!"=!;JY"TJ*]WQ-^PSOT:U3;$"%FM*!MF64P3O+GT'02$) [\_-7
M(H%^9&4M2^ZR'D6O\PPCG/>3['\WDOI]DD?!N*(9\BC)>+(EQH:&[+,V>[,N
MM>YE=?8P*0X!EU/9B1^IWR<#E*Z"$5HNH-(@)^?J7\)\X\3C$W(T*2RE A,Q
M?\#Y'5[V\B>Q!P%G)'VVP9?6O2__P;>U_Z;,43[^L[S:LM8?LW#];=9!I_NL
M;;^2$Q%R;/[7Y-)4IW#4^7T^FRW>)V!WO'+@I]_N\_9S-_[%CTSAZ%]YXV:A
M_GLK#4;Q'INNZ6GWY"S\XP;QP.!?QS^M%/R%4[T^E4?_'A%_A7J77;8G]#%M
M3Y#*N4C<S?P#_'(ZKI@$@.#T\/6GY<22>SF8UJ6#B$CL92\DO_G?_3K +S]!
M, O&((A:\0'P=0X8"4AM!FVM+1W2_?%E >FN3D.7_HG;L[)/U?BJG0PH^1$-
ME3T 7@<STD2XMD@"&N73C3/R:UI.FEW1&.%^PUNSM%>#'9I^7<?T:*7J5DG5
M_AL+4[&6L\0C2<(LF![,B06-?8;JSA2V!&#J<M&Y/2>7B4)%JE"8.V^%9T7\
MZ6\1RO9NG\/%;.U-;^8$S^=SN@P4]IBO*DG.P5[MAE,VR7<EEY]&^?CV"V;P
MYEI.9+H^,U>*U+W5@X5M,,^ *%$K\?+=Y7O:WK>&8*+/MO@MW-X?X[IPAZRL
M, 9[H85N('169 TT[2#>0Z/\LRV*OM@&$2<MX;.JMR-8EX$KM(*)KRO'*#+6
MM*&K=;Y*'.LX*EGV-/R:<J*T('QT,5 L?4Z4R>;13C4(I8O^D8*N3O+A=N,6
M1,UR/13CF5(_IJ7%Z'MJ?HDFRE#1X>BZ&S.ZY\V=H,(UB/D0E? +Z/!)?MYK
MR].7DV4+&0GI>3.EA"@\S^-7LMIMJ7%7/YFVGFQK-5Y4OK::ID4H*+W$$"8U
M3;V)Z3RY-WEG5/<<HN;(]\P+SZ71_O"+'1!(PY2Z?M-@5EKI#AZVM#!QV*&&
M2T%#&''2>*.L-9=BG#MKTN8^] 9M_>3',YHIK-TXF;U(G.O<I+.4-U?3BPE;
MIOE&EJ@:'S?NWB\4N?/04_UD@4:(5(1893YLRS89=7O;YNQI&UYN4$;/L:"N
M%*'RC;CA F?U@LX4!A?A1?J(W%R>TTRJGTWNL.L&V8TU5&S?>$U1[JNI_([P
M^KX=9&M7:"W&1NF:[O!FUD[/IQK3HUM>"ABA-P5.2K F6HL<$\#R33W?B?IE
M+0/>LMW",!^&7D7)3%S(IO%K:X^P4-9:_)-D0<NCRO,./>=&ND/G$,?=A/82
M<'E3$G5%I>65 Y]NWL/*N&?17$ZC29PD)"F?4YL#CWTP[7->N\375VIR-+9^
M(?96B<OZ6/ [GO<MFOVI^FDLZ9L#6*D(WO3YV7QO'T-O;UW/*EP,>ER78X7(
M E4'F2%])^IMF.(%STO6O+U"0Q/M7I!<9TP(4CR;GV)7)SX$$QS"JXQ$6^>X
M.CKVF9B@#=A[>4B *N3>L#1OBIA![UK*/8/'60)V1%5U%D--E=\_-J*8.RS<
MN)IBPQE7!!6,S.N"I4^4EDXNU'YQ2WW\0DMNQ81F;B20!*#E^VJN!+J+2=NY
M_8 6Q&I&?U\VE>MVI]PM%,(4-BC=;R5>P,7:*=?F6!NKMQ3S=MF<?BS:SW3'
ML3%J/&2)*(YCVU;%3@X-^UF\@*/9^YU6\CC,+2<79'4J-^O;>(8V\I0Y[^W9
MK,&VRF=[8N)DN.\@RNPFD?;!U>/S5;M*T7 4I/',!"Y5X-66'AK_(?X&%V3?
M3_F.^_S(=02'%,<&7LC!WJ(BJ"FZY%J$KU<8NP-#S]G"F!F,1DZZFV[S4VW:
MK*JZ7E'[=&5MIGXMB6KQ.S=[=&W7YC#TQ3/B(43J@91 ]YK+(W#4M?D+3Y[W
ML/%?]SP=4HF^*!ZP?S &3XA5[#F[OL3-705UESX0]DB>AI)WCO%:4T[ZQ3K]
MZ/FQUFRILV7N008,B=$]<]-!S@S,9>&PXVG7A.P,ZK2?0J<L5OVVAVOLX9SC
M7M=QN:?ERS[DV%3Q?'!LU"DN'YA^-O"Q\ ,? '#D,5 LHT8":V"9*V5O;;&X
M0%$?C:KPOKJ6YZ,QU6!7H9%\W:%+#R>E-B8&CK09.RN-'19+-U8R"M?L"UJK
M5I E9L'9;HC;O8@;(WF%SAROKW@7='3<>_EJ3.A3M]:Z\-!:FQ>'!3A$61I7
M;CK(&_.]KU]408<IY12EV KWRVD^#M8U@T6C,-[^5V4_;P-.U;?GS5TR<!W*
MR"@Q]G$]H&;1>]3J3K<Q+^^=/F+$L%!_BH/?B[E4I4WVW A%)K%WFD':<Z2D
M!"LB^4A('!1UY5*+S_.L<Z>WS=ZT<]_Z0JU+Q;.[O5OG:SY<IU2U,NXU^N1(
M\L15)(&Q?JQ5\="@6<@SX<X]PZ(5,P[<^ SL[!2M*5^32[FK*&,"[X4Y*Q6)
MAVH4%10]')EN+^<0?HH//YO8H(R"1>T+Q;0>\%U>66+\^%KDT]49#)W7!D]Q
MII<*!M:0Q-QPZ-Q9=Z&O*[]YMWVTAK?_(IJP5?TU[ =0(-=M]PDGBH$T56WZ
MUO'8&G<7/A>5TJF*37Y7Y=%X*4G&W4[D_:3OG9N;QA7JPL5GASXF:D$.-?NK
M?E1GX<PU:H9*[;[G28W+)MJ%)HS;:O@^B[9CU\.EH76$]+\,%$J/:WN.[X1O
MH%T7AKKY^.=H*S"28<FQVTL;%U*\C+#EC4GW1HPP4_'N*>,VB0%#0P6Q/OH=
ME[_Y=-_Z(M!P;7]4_FOKRD,$BQ#4JKY*[-VATG#HW 6V*">GY8V:^>&:\K!T
MP1>5>AS7=?DXTG.RH)J7\V6>><.'0T+&7<=FIZJY'K<?GG/*L:/,_O4_4LC(
M6[MFQM-?L*MT:U%!@?9FY\#$K1=%GSA$O#^_]I'IS?S:)\XW..,)M1E6DC?@
M#XVS$$OQ;L]1/#1*\.G'VBE?'I "45J[V+DJU[HICRS]>$"=KM89:QJD@G8A
M:]K<YB=#NY @=A]VS&;H\_02_P:BI ENJ?B5UB=MKC=BIL?>GKQPKNK(PLZZ
M,>'14I(1AS$*#DG9M0HC"KJ9HU=*(6=L,2O]IO97FMJ[?[!SO3&@FGGV;(Z2
MMZS$V[*U2=ZT("/3M-G[B?/9.*XW9R5N9J50&77!6? 6: 2K6Z,J5B,IS[;N
MG%O)4:@VA"GSH[VH@.!-E/;#)T[\H-BSU^3FC5*(W431"-@Q'/S&H!3.2<=6
MVR3T^SIT W5BOHQ=+%16;5^QOG1O;UJKH:]B[MZVP[)3%:*%!%!9'^ZVA+H6
MJO/\/^R]=UC32[<H'$5%$02ITE50D"+2+9"(2!,A] Y1D1KIT@-1D2)50& +
M0J0W :7W*%5 B-1 D-Y[(BV0]H5=W?MMYYQ[SGWN_>[[Q^]Y9C*KS,R:6;/6
M9,U,KHMP"-0SQ%BRIHTU0>_0K/>&0<P:(Q;K&*0%% R#L#RE'9D?0W,24J7;
M_(P1/C0?TP0&&D6(Z@-%%4.]6[W3LEZE27?#=1]G''>_'2T/\(,U2%I>+$P_
M1\J:2GV\+3>!#2_=R^"/AV-X9JZVN>'[Y\*_IOE6P$$K^?V+<%[8T6DM,UYY
M;9QLUF[9M7#AX>N^T:?H\FT.12M-<FV(3J=*&/?#M+ WE+%R"3F6%CYSGN<^
M&+7V%G$ZOXZ,.J<#.+DQWCC("7@XNS_0(W*#XXZS?P1U#;#]])>H2MH3?_+%
M&NT&X3/D!7*M_*;L5AO5 ;P@U4_^=! ?RK6',*0 8@B(_<6)+^BZQ("26-P>
M!3"\1PYYU"#RIL+=*D';;+<7]RY;WBSW@D5*D7Y<N:I8KL1!)JG((#[;/E)0
M+ZG!*"F]4&JWH&]+-D/2YI(C%<\L5]P^TE3;+%]"V6BN(&Y+9CC#("F]P-V[
M,&Y+5D][.U[^A9%9KH1?C;A^X@<[@SMQ6P5Z@R-^AI>@%Q_?SA>Z4_!%)T1/
MF>:EFF.%T!UJOB-5$J0$MT9B>&#*7XV;,',?@>?Z9PYS"BI\:[G.[\6[LI1,
M;"7%!YY9:;R!S[P/SP'+I=ID?:[BD._%/25]###/[4-J%\[C7"-%_'._S0W:
M&85[+*&K=578VOR>OPR@&I>>R 0U/:7=%-(0V9#WW!:=<,9/SWZ+R<M*RH#7
MZ0[$;8%W[?EO71?.>/I[.(8&HS$%\'C 4U 10NK7B')64V'5_SV2XV!9;B7^
M:6M*^'^+*<TPGV"3UW4DR<C5HL-Y=,HWPUBRJB#N*G Z;D7C0V-U575-655U
MVEB5LM@'41FU00U.VB6CQ7?.GJ:<5'\KQN%6&U1BM0OTX6[K7.5WEJ[8&+VN
M2.8 +2VY!!NW7-(S\QN^C[R.D[_@+D78+\K-G-DI--#U8E>YT< -1I9JWDCA
MAD:H[ZQ6);+9HUW&FF*?1H\G&.MCHX.++$B9NKV/5PB11S>=BZQCL=?IWPNQ
M%:EPV'.!'QN6]8MM$20=H Y'*_*.'#\7I0M05/TJ:;"%.F&?+#Z0=#TPYKZU
MF]!X(F9$P'K[K&U%7L:J6*3_!JT]5^I47?W7K=&ZG!6%G=@Z!/XT9Y')9/09
M(^$9@Q>J7\,!.HJ2X(R(9QJ/C-[W/]K*,Q,5-1&;MKVL=[SIDO7 Y*G<H7>]
M*N>"?Y9HAXVZM83 $:7!GR;IBD@?K"D D"L%,/$@-87%P=DB(Y\">&1" :"^
M@7:',PD/VLF!4U37J97]P7R,^QP;^(]?^$?909N[C*0=X;)3]KN7=0TH@$HQ
M^,(Z/V%5]P>R$5<.$"\>\X@.<,S=:8TADIHI@(!PT.^PMCR]Z_^8[?UNOKE.
M$<1_/V+6QQZW;@/R\ <* %$-W_B@]@>D6'.R8M<K0]!:!/\>(91,8(7_SB'C
MR[7,;S4J^O_GX-DHTS,=WY*%$.0&ED$N5\[5G_8]_P!X[W7/1(X#XG<1_8&O
M\I.'6HU[>.X/(HKYG;%IJ(Q_DG !_/\&O#<A?U+SN$(*X+G5A>JZM-L5SPOK
MKI#VMX16K+KS\I'X4!<WIQ>36E<S-3@_,\RSA(\2%!#?7#KK7+?G;A$;P*+<
M0;F1T+1]+Z ;/(COTOW6+- N"=Y6V('5;'7JZ^,G'@?C2K(;44*[W-\S5[_#
MW9 BJ^2OA;.^B.&?O <I (C _ G@47Q-#+LK?/(6/,H8_J3QBG.B#GSR#CPJ
M +SC"ZJ>2."WBR=$[>F3>POG2+#/Y.9F8"F! ICD%^H@@'RZ:TVIBO, W!@^
M,M-6U-<V00$<CB="5V+*.DAMQ+Q?*EQ(T*Y*VMZ\,'O5;@CB1P$(S"R!["2X
MJS2YX40Z,"Y/D)0">SPF)H[$BH/:&C__@O0+!>HL<33Z3FY\2 $4XHU_P9Y>
M(+VN]QF3(;@03\80'>L1I50M/IJ#</IU?S&@[,>J&\(=T:O(DM>@Y?73VTGC
MR,]X3PK !A$FWJ]=0;6J/E, ;>GP$;5I@<+3.9A):IE6#!&Z_@OW@MO/E'@0
MYV9/C6^E02&EY,9[U1XGQG^NQ&0^Z.%$6'>_5OG!=B.52"%R-09W=H'+)I=\
MK)TLNXL:F27/!!H$I('7Y><T"7IE:R18IP4HV-)FM^0["#2Q<PO_:DRF"TP\
M16U#&;D=P6*>DV3W\PYD5.!STL]H:C_3, 1A#.NI+8">;[[\2^>GH@C<,/#]
MMH1?X8WC=Z[@L\9D"D%$Q@@B=,ON%VD#?Q9]/KFW@,!>>O?Z,@50$KM73P%\
M +<J]VM0>^TC'MF6$;%S%I\K@\M*MHG4+0/T<>-[>M.T#RVP[6O]V(T&]0'&
MP[T/MSC@*[.N"%HRVQ+B.(S-+GWI\\F"T)KJ]FZ9W$*NM67PCW*OYGF3.JH8
M]NF6B*39^>LB?RI+Z"H[#MR$UTYT9A8R?3IKV\E?Z^]O /^9EQYO:MAB/O#'
M@>O-]IJ73>C'+E5I^A(='O]C0S.F;-7T-'M!8[_BP-ZKWX*%KN_K5:]^%OXO
MDOME'^\7$#WE(T\J=4C]F'@N[3F_/S<GM=56347CQP[3=2T3R,CZ<2SG59O&
M]NH%_"!9 PNQ'OYI%#'@X)ZU#^$3^[V:.*<[X[#K1^Y1 $TJ+NT+OP:-ZI(O
M@)-F(UW^]UZ02OWR D==YGT#85:V;E4^/8&O9MR87MU^J'1I]N(4HO.I);.N
M3LIGUFKI-KJ 20L8$G+'-UE6^&2>Q*Y[X&[?DUI^%<GLVS9&GD8NM2<^@>YP
M&:@9V!G:$@K 0DLWVWNU3F6'AQP-%;2+U7[[QQF+_[7O%(L%!1#WVH$"N$==
M:C(9'AD!_Z1ML0R:;69;WE5TM=W[>;%/#D_A9PGH])#FVJ413'M$3%O[L?ZX
M!E3V8DFB(*X][.:,Q0 (>X$ZNPNZ9I"GHY/7,T!K2]1L';(LE_@9-^ZK$1 2
M8*T""Y6((=YEY")G_5)<T($[V3)#MCT(:#\\071$EMD1/R<A]"#WR;3# \:M
M?3!5G,[2M*(^M9@J2ZY"H18$^ZDTP4$X5@J,*R!_06R>YV?Z&7STL7&S'NPN
MSG5IVHFJ:VFHBI"K2*B% N"(3A.F#DZLW %"9S[Q<VB+@3&Q#OYTUY,-*X-@
M)3ZX[I-KPK]#$L(/F@:*^GQ]C+,J!:WM@W&YI'C]O5B)%\(E>U2_DF;K5%8,
MR0*A1%S9K 5'6,GQ*I@7P2=A2**A4?ST;C0KDP*D*":;2,TS"E/9:+X0IJ[Q
M57C^C 'C>2+BC(*[=,P9:!!YFID"P!D:@2,#;U MU?!V2PK@TW,JDE"" <2!
MO3H\@@)(<L&"[N25?!D!2OML/<:E-5  09QP?$&^4!N"/SI-%HW$6DM0 &RZ
MI->@>=4(4!:YF<C8CQ']/@^.0C#=G&G#4 !D^IR#>+,L) _P7'3:51R  JA^
M-4$TU.S*:>R3,9T3VN'<SU0)U-/ H::%>7Q66@3(TQYPG$$7!$,[K1(\RR$Z
M$^"GSU(8-C]PX?$CGJE7E<=W9!DED@GJO78R$\-VR]ML5(_C4*,458Y<"J==
M"FYVL6<RG8:8+?R4U2ZTZ!=D%6OU*&/ZF]5"PXFV+(/IK?LJK :)&K3C+KOF
M>P:>@OR^R#&7.=T^_IL9X9?"?IM'(AI^0H0*WE]BRY_^_R:F_."#:1;X!*ZT
M @7PL2[WIU+US8;@%7.:BK?Z%MMY,YVO?I-&%5GB&C.+?%AF:$.VH[27-8IE
MQ.6UR0,V#Y2/Z?,4;72 +-"#C1Q8N:1)0K?MBK:&D:79XKBE;YSS,64T7U!:
M0NQT3% C-RXZO=#*T14LALG.\C+FMA&AMY]"TWSHC(:.FBQZF&F.5=3O7X2]
M*0TO0,A<V!@GF\FAM3RA'C-=3FIZ S(Q8?L-W[Z_J\U)2UJN0W66N!]OGXKI
MJ;/D:*LMJGI!YL&#6R3.+_OQ9:SW/YSVMPT5'MF@ (9* FOP-%/<A:*%JE4U
M)I?%SO5;ZKF#/$X?!>SNJ<D6%L(N8N<KIL59+&HJ//*6Z)@QAC";FQ]/@<*+
M39:E>MN179H"(K[:(JG)R8T(D&\'.9$0D[S1*(/QB9\)#)T^.68C+F,N6B,^
M7=IE>W6 ?_SJMG5?5AF^AC$*J&AO-M93GEA[+QFJ";VB?>_N?<L0R42AK9+L
M"I?@1JXASR)I \3=8.?'NQ),+]AT7ZPTW-Q#<CD78@N;S1JK<AW[EGI;O1_P
M*,^*9!";C[RGB5]:,@UP#$[(V('FI%  QM?Y+"/KG#,"OR=9>FTN#>,8:)JP
MB*A:&V2PK+B:077_^FP-NN)%SD4Y/8_9>["L[3.\HDN8[ZA3@=UD9FQQS;&B
MW(Z"=D_6Z06&P#G>3SV6?O+ BF7/]O!"KF*%XAU+L+Y$\T Z)^%VO//^C9(5
MI'<>U9UO\<N23W(S,0-[NDY?/:<:I^8<_O8AXK-Q6^ 1?%5^28L_!<#DR(_!
M+@$E-;M,&M&GS4WH:';T65@BWQ\)E-U1S<TQ6[GNV1V\*NIFY\&M(B/1^S62
M*3"CU!,"P'N;8TDYH0%9YA9+<L'T[)%(01O@_+?'K0Z<PN.+;5D7+B;[\XOB
M16>04>60HXX<1KM<=VO5@LL)FJ_72MB2EW>[?>5%*GVN6EU="1_&AK9*<. O
M%&]#ZXJ +G3C^-I-;;G=.],^!OGWS\5?/61RJ(I7VJHH*[ ;2-]/A.9#-Y?D
MT+=T'XD5O5;7U&5R!O2<81Y94!2M2)E"AEQV.OJN]D(6=7X]<E+N?-A)2J_M
MB-$WN]:<(1EU/=6J/0@F2<JI5\KS*? ',0UKYCML^L"@[WFEM1Z^I "RE-F'
M#6JDU A8;QZ>2[()N ><Q( 917W+RJJ4%B[/RB@:X//]>(?:Z+ 6=;+?N<ZR
M*S8*6R.1Z*_ T_@;DQ.''0OS[<T8*A&![Q4+OIU[L'*2S?J,X)O+UMK7&3*2
MVD"T1-Z9-551DK]2Y8"$@!)3:H2HE+O7!SWY4V!:F9KIU#[1D>ZV/KNH8?+7
MY(3G7, 8ZSH]!*2T;QX[UKW_ /KJU0./*SSL2CS1;LL5L0<;U$SO8!)9^%!C
M+3Y_+=MVW40,!L-A_'3M%9NMX/<S?&J.._F-S)]\<1*W<1=:*F>TOXJ-CZKW
MIU>=W/%Z*>PE/O$<<&I$MAI!3Q1+E&-75BXGB#_3Y'UW0>J#6"8S (3AM9\/
MO:>3MT_U7 91?+B8-<8B>[3;R-+78;";6\:P969'W$N4V_F<A4^$)\QN%BXM
MX,C&2WCH##1531^AC?84%U"JOQUSUY;I\[R_:Y28[YZ)\S7.I26K[1S84>RQ
M&#LXU&$JXFHZ\HFY1?ZW-O6GWYCB-#XJ1#XNE ,=A3'FFBF6\W&5FEB=$'\C
ME2C!$ZR9+QCG;NBW3\?ZMI8F6&T >Z,D.E TF=M>=DV282VDPO9>31Q_F6^$
MH'N5Y+NHJ.RKJ"/R%=[((^1+^/Z6\7/8P:1P9.EL:$L@*]^%2O;34MP/^,;N
MWM6X47K98&%0RQOC\@E,LR1WTL9IJNMVE>G0 M39>E[XG$F<QM4C3U&<1=W2
MG_SXHCQSOHTXO#0'YU"7JQ$O][/SW!9ML&P*P$Y2C0* T6GK.G:<DIE/'95;
MS AO6:(3SGBBP+)3:.H,F9I+=D!?;S$VVTBZG IUFZUHVKOLM4Z"=DL ^:'L
M+#[>VKBC%>.A4U$N;7(=#NF:^3)K1\X/N4@_#CISZB-OPS',/MH NY-29.F
MEA]RLT#E=N]$: AR7NEX)B_1>((-,0,.)?/A7]QWL9E6%.$U&AJ_[\;JP<YG
M\83I#),2[9&8MLHH3<%HA[YY9[5$H@"3SXT94%0]?^:RWKB/WJA6_T9FN'^\
MU/"XIN BMI#9K<8ZJG)':#Q^AC949H,3YHT]%E&D$)75&%%HH2!ZXW;1>0U;
MMNCCL[0N/7759'J\6;-*55]YJIPB7Y_X';3!?>C+/LTC^>>='[BKZM#$]PLT
M6.%*FI!T,)7J#X@6/S&NK!V1%2?!=YV]M*/UA[-<O8H#GR5)S5?O\0M);-=L
MAC:3O#; >%2FCQ>#[<%_W7[:#04C)F#%3_&/SX^/$$MGB=/RWCH:5]LN >66
MDA$O@-+X&AD2I^R4W5LE&;']CE+V:.] W$U:MYG1[(!#><236/:BS*5:2W2(
M6%JSEIV_NH&4KQA^7$GOE/8Q#5E5^$C[5$77[3Z\7N_X56*VM>#KD3=K0MX"
M*\9K OZO:_6K)+;W.,C'5J*FP<\#V0:LOD/W+I9J[;)$WGC?&0=G\MVP'#3L
MVZK3X@!7O7]?%=W7,W;$38EYS4#WZR&CPF/KZYXJIH)-X<)9.C_LA?Z\']KT
MPZ&#DM?;D%\/HT81NP,D_^&N]?H< CH+"X3O .'I*1)W<L4MDK+U$QNV8-!+
M6D/Y'<875PQFBTY'7.H:*M PFELQ%%PR$SC!FKUAF+WH^*5AN;R!P3[2](X9
M%2\QO\M,@%T_L4#SZV"-8U8#@YQPPH5%QS>IR[,-# ;Q#0^[IPVI,,87"MQW
MWYD.,F<UB+RJ\+)*N&/6D7I:1*.O0*.OJ*.O,(O9\N[+IBBQTBL&*IQBX)NB
M%Q^W;,>,:+8V7L2B6\<N,YZZN9NQUR+O]62*3^Q[>[^+!7J9UX=V-94 4L&F
M-'45.K[,QUW.>IHMZ''$+O8,N6)C>].G(#9??VPQ8 BB^M@>$^!9=8_J/D5N
M=9PE=)-7X"+167_$I[#^:+W]>)CP*_ YU;([?# '?_[B^$K(2WG+ZGY(0DX\
MU[?H<.&<LS\$+-)$_&D[6A=G1P8>O' TW.I"LL_6GXI!;?+R3QOL!:JWDPK@
MLTIU5$E1W8VWR5O@YQ3 ][OUHE0?J M.8A?M^4N496W)"9^'/B63%$#PHY[<
MO"5EPO6Q>I+<?5;D<CNGB ]1&-*T1PX63+L$V8,;^(FSS8.P&?WDT!).^&0G
MB"RK1A2F#H3TE38(7BJ& H@R,K)$:<8E;9)I<W6MK"D .G'0HA\NB4R?20',
M&,";(L#[?/4V5%.?ZC?@!]DMF_\-^V_8?\/^&_;_5=AC:7_:DBK'L">WQ.=B
MXOSB#U-5LJ]$.)F55[Y=+A&';V^5:/Q8DZBY=1GH?H4QJ2^5RJ$3LL]#-*0
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MV0*-Z*W<*I7#0N6JX:> D0L=SK;>XWW;A!H4KV-[& 5@<WOHLL))N%.^$K3
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MK[FP7S9\@93S*&O(TQ*DC8T)J_#J=V8HWS0U%WWKME';X'$'>3TG!>IU+W$
MQ=4QVW-E*;8W-*\DO'QQB\3=1I:]OMHHU\_G9#C[Q-ZH]*=L\ ;S]62"=#/'
MRV4^WG[GLP2UN)VELC5'(SW)R&I%[J&<.^V7I9Y?$OXNL=Q&M;-T?)_^=A^
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MIYP,A?=EIK[*YWYBK'<;J@B/,'NSZ0[6BDZ&8R!-#EG#8TK0=U96EHY.F13
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M+A\"GO46ZEO/=1<RK8FX+-IQ;TQS6.[@F3;T/??+2;3^;'ZYV 4%K"(RW;K
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M9R <X3%0@$D+237453=/'=1ON?M@+\Z26^-<"=/ U<E$SA-;#OCDL' O ?U
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MD6A5?C\1.E+ZV1!GHE^%T\.2ZT:J5)3:N&JJQAJ!&Z\GDC5>"Y7+.5;<#S/
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M]L%E#9'R,K>5(?UK$>[6-J-Y-$9<%A6)M27FS9WMQ3 Y6Y,' B6$FK@L-?(
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M3J"RQ+ME!>XHJ)SX)4#H1<X[4HJ#!2?N^8$5DGB?=@?ZBAK60=I]],F7XMK
M=[Q*.:*D_?!U]A7K?3&DVSEY')/:_4+9H^T:$%X?<[V]/02%3SIMO>U<9ZI/
M=";;793ZW?L(4!L"6'XV4& D=WZ1G'&Q%$:L=!L2%&^DI-SE?9+E:VDT#=DO
M2 N0F0ZUL*Y':=;XW_8S >_H-N^)6;:8R.L7? AB3FDRN"V_M&4'%;^P3K3+
M^0&H;[6EBZA,!K;DK*0*J]9Q0TI\,$/]Q*6?%>5>U55)!R/I3.Z+92G]07TP
MY0+O$Y,!8TRQ(I9Y'^JMM$,O+JF:LI[0,.4_FKG_!HKYG2T!GAO-A4FY6X^
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MV/G9UICQ5I2W?*/2D7Q;2&<( ]O?LF2M*W]@%VARMHI,*;,6)X1,.1F]JC;
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M^)"R@^5\(Y(<R1U"<2?31DNQ=O7%NKP]_L#5*HG"P2P?OWZ3-0H8M2I_G5[
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MA8XNFJ,_6G-?1^>]\.,V\7.5"'NB[2$U&L"6- CZ"N$7USQ:6-9)RIYL(V%
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MVTTN^*UJH)SGXXDC[XA6PHE:[>( /Q&+1L-Q31I)O7)-SELI$1OB8@(_]!F
M$VV7V_-Q-\ '_(@?3"M<PS:J&TX7-1A?URGE?A@?._\;%23T73FSD(9(=Q9I
MQA21)RZ1]'Z'#5GVX.,4Y(YLIP6,[HM<\MV1]QWPA+H\ F+V-"9\#4_.8Q3E
M?ED>_MY^!"P=R3/QKL@?S_3R^T:S+8)6F%U!OQ@ZBQV3UGV@Q,A,7@78K=?'
MI(]SLDVW+LI.-K[)]E(-;P==^<5':?:31WQJ3@CZW=4K-@X#V[+H"""=I*?]
MJZVC AC_&N1[W;\8T#B[XV+5X3H8#Y[66P<YV/H?@(3K9=*^IV2Z?U:FV>&N
MH;FNGP8DE3VEW[BWK3_8:JM$2^T<MS!$^BDRRW&__+;9=Q*"8A85N&/SHJR&
M];N62I+5T];[7\<^5<BO;<]K]KQ?L1"<$,+CGO6<3H;AL0D71^79_GVH(S3G
M#*^NL<R"6S7$K*U.H:>5ZKD+]HB^#3'=2?"2IW_UR?="R3W[W]"8L*8 ;OS$
M,X'G:#^61T?W<0"DQR%)B(?4Y_V/@&C:MVU>WQS^L7-]Z/!?)U]A]D[R40EN
M^\#%8?;)9K<]S&.?EJK/3$I_OJEJ^N1/DXG$Z;M.L@PC14"T]_M\PF%?',3I
M%!Z^4]=]V;$/3K+:+)A+I,!]]8VB&B$/SYQD V;L#\\X4GDF?@-F.S _3@9$
ML4V39*6W[L"7R,[ZVQ[>7M(.PX87Z=3/XD A]"DEWEG ;PUW6;T!W3OXC@^.
M!%T8P-)G<Y,PQ'RASLXO"+ZR]KJW3#D/3@O;PI-G,]V!]%Q:JFW2)T6WUGA@
MFC\1LK>X]6QS[ [L1E%MM]\=6\T^-^G7\BB';W@X5((9X$7 .4R/-ER89IIE
MB0(C^)45MHL"MHJN6LY7[C]+Z(M8]5O2I/(;T.P#Z)'3UB<9.:J\M%+C7G3@
MKV+CY]7^-P4NTZ:>DCY<](N_7D>&Y]J N97EI7](%8GO=^,D(.?#@D,? 9@P
MQ,)D\2!3G&][9D*J0A"BV\"6CC[6VJ]E:BW7NO=/MUC)-,4$Q JE M>@4_S%
MCOS:5HD"#>:%Y-\G\J0ORU9F>ZXTY#!-:S/^<F&+)67*(/DLH%7!P'3WK.B%
M%7)ZL+7HZ-C<HI_( Q-JV[)2N#C0"* )8U %%!&C;;4!H]K/DJ6]-@\N\WE$
M-[:&\G%BC]]'3&LW"RI^L^Y85["L<:"OUHX_3>:6BXDN(=1D#.V3+,877D0%
M!-S7N508/@*LCF!?!JM@C@,B ^GLOS&GJIQ ;^NI=";>6/)KR3LR2LT)6Q#[
MF_1+'D ? 7&'5VB,515-S$]\FXLY37T-\L.W.C>T([UNM1 @"@[=+,;P!\'U
M$VN$!0Q-4#>/ -4BDV"JETX\BGO4.^N$_,9-[O>M/_![OV(I7(.4=6@>])%G
MT<(GP(&KQ<"-6/C<B8AXS7K?MH9ZC>*>_H4>>U>12":F :;RYA#&;BHYAV*Z
M%H[<9ETR+#I:I$-51(U.#]&I+5)]Y??#9"W'VGKW-/%#8O+IW#A^>(9 K&>/
M#;[Q64+S"=V@+ @QG.A#M_'LC]]2Q-Y1\'3>.;^I4J@#.'Q>ZJ7R(KTDO^[0
M[,_!BIYI[+4-E.^@&V$5[;A'9>.1;ZIYN4?7E2\TX8VN#1>O@<2(OE69!S5L
M>H )8'% Z6<-;ZGW^MKKZGV+YR-CX:E8/X#+JII*4UCN?AKYHW(RS(^W!T@_
MUQR_0708]0A0Z\X;.U!2<?.BN_9B+0(J+60S)Z1&@?)N#:XL4=HU$#4D0?_V
MB0@?1(HMM@.:;. /SZV3KL?3-R17M?9-50(GY*>RLL6^X4NTEWMVR4=XX HS
M#32(T \2WTXR8UP];/]#((!9/MT@SB:1<O:!\-L[CEZ*X]!&X"#7=K #97(E
M*F*H3WUE)2BVV<S*Y."L- Z-(W9[)&F$Q3Y'LF!,.UM*"1]PJ?G,?WL %E7_
MV=Z8*,Y8HTS1I<9; _3Z4S5^0P0EQV="\C1E>!-AFH+,3]Z]T_%!<[SNN/.I
MI7XO<X>TIK0 %NOZ]G.+Z0]J>GH9C3;#O' HJ'ZZ^@YS_I).#M/_XQ9O48N[
M?[J5BDQEIE[F9SH]ZC/ 3A9^SW;6[H..N$4"H]P\1$\L[D[AJWUZUX^;P(,\
MWS3HN!O;Q"QEPIY!LJ.$$4/FZ*ZE'CU:"C"I"1@)FW5<TG:TH.#V.2'Z(FCV
M\HITE:=CF%F/([TZIIN5*4]N<[5-RA#X_+[4FX /^Z#FJ^DXF)'3Y171W_Q1
M[C_5\?QI]N4"K-5O& &IZ+N*!2<2%*/^Q?VPGZ?=079;'=_O!)R< EU=A^J[
MU#X;?:7)3>%PBI7]8"E/.%:^#UC<_]0ENF)^H.W/-^A+9N%/W=S)X<IK$U0C
M*RPG-717Y"<4X-3L>4R%/T "_%,;9\Y1 MR=6J?\&<K&;. ^V$C=2W.L"0!Z
M]8S6)O<S4K?8\_X-=MR;7=)LUKWR9[?JUVDE+CO^,[./@=DHT1=I:L?=EJW5
M/?=71A2V]!I1,]K9J*]>%54P3?#-%G^<7KN67]VV<&>MU:N' KO*;AM(YT0Y
M:^X 2]R=G$D_SKJZ(J)723MM0;)^TKN&NLCC@/^5$%[O%!O.@XMU%X P//PE
MFUQ5?-&ZM7T,-'^X 34#ED&T1KA-ALB>(;_J+&Y"(A<C/]K*]!N[NOK:Z-<H
MAR"O$.XS$0TFC>*1M$.;/)24$J;'*#BACWF;Q<IM[1%0#:XEW_L)@G_MX%;_
MYF!.V9HUUT<)M?\'_?7;1!3Z[>T1<ZQE<!'$LMR3J%[N]-?80-H."= !Q;))
MD!P=2'[3:*;.6%RFLG?$PTV=8$;ITH*4C*C^)$H86=ZKS(S%7/?9O^RJ.KNO
M2Z!IMGE\I&F-82\*9A)#F.CRK3RUW@$]:IF,=V^5?P>:)=#H7D>%>@1LQY]A
MH(34$/_NP'ZZ%@0!;CY<N((M!E Q(0T,]S>>,9@DZ=0OVE0UV]$ISX,-+!9D
MP2B"/C%?WR.?[P[MTU>0*SO(R&X:B_U$FI1P>3HKX0X<=]>='.,@E.[A5Q?O
M[ /+8:!%^G?>9">2UH[9OS9!3ASOO9L278U$[[(>/*<(ZIA_>+2>X$S=J2.[
M=1J1PS&7_L*W.E!CKD-*J)B4;2ZU_))FVQB53[HCH.-\@&^RN4'<+?&!V4S%
MO#OJX50XR*FMB6XY3M"\G'(/V[,WRD;-:,^&33M>)1UZ6B2WO10#[D!-5AT&
MVNY.&(@FN]FYN0.B?-6#_.%QEM96V)>)=,S[Q0-A-D=RM-(FM:MJ4H[9HO6C
MKBXVT.;<!#;JD NT<1=N!6=B#,@XE((]=JM03!<5ZE.&@IITY^&>LDJ:%19^
M7M6PUZ.6#E]+?6EK^")&U#12CK='7=I#-G_+#;B,^O@V8DZS+>E5PSSWYW#F
M%P*"XWL<-(*@CV$#68S:F !=:</FK.>L(B9ASR3B]ZA!W2C&5X! JKC:1P <
M?89/V )W?3P(?N) RGNGRF+_]BO()L<$:W^45.U'4U \Y;L/XK]Q&E$_V?_[
M < *Q1.6%B 'M]E0/1D7E1UFX=8\5*O+\5X+.LY3+ONJ[L"P\&63^,ES44'P
M8XOJ"@[-;;4$82M.2G6W)BH+K[9[,U<6/0(FFN80PKX&]E 6$Q)H2@>@S>^%
MR;JA?*[HS-S-U^Z0*RZ>R1BO?ZI,AY_?Y6PT]^KCJT@,>EM0-O$0[VVK+WCS
M&)N,BDCYVVC('HBMMJ=035Q0% C14&J-#?!SXN'XT<F^0, .'@&$PJ1V_LY_
MI>R_-B]N^=LJ$6;]PXI0"^NIHFN=MZ.Q-TEPL8ZUWG)1&C &_S-^!/S&SL:T
M)_._;$[R.]\(7#&92K4"YFRF1FK=TT4R,_K(E"_.CA+U7;M18X4?EB3)Y=1H
M B=]RAQGW_"4!U6)^.JYZY6F8VG?*X'X+:4R:6IDU =U# _\KHS-!JM)S NA
M+YP<*R=*,S,")CK&=CS13#,/H!1_'FA0U2TO7)GSS(1Z%[^*^Q#0B5NU=,W3
M#W*](I]5QM# 3*/Q4Z31UCHY)(W!,A-\"%;C^7O_>D6];=ZU?"!0I*LHC>9+
MHG4B6]K2&/]WF\*['\-.@@7??U?._Z7C^HE_NC>LU_@3L1&]D*V?_=I;K7/$
M%$N16<HZ3=XH+"42UHD0Y;C(1/)^M_UF:LY;%G#5$6&TE^2;N)JY6:\[3T_O
MO<W 59ENU(7DK; E_Y?G4U3HXK/+C>2J:5KVW"DG0\?O>L8\1%Y8O4GY@9GQ
M8Z7_U3H0Q]Z<?ZXI$:2QD&?0>HO5W)V56OU,D_9M:I,RB9 /=1^P&Q":4<M5
MA\1)_"L7(T?,TUQHI[<D,OEA_%UW;+,8$E-,<'T95VN4/&V2W0 _XI4>4<?X
M[EN*['AD=PS38.#SF.;OFW/.ES(?3F&CD"'LK5]E(YLO8]CX%2&YH %. Q9
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MGSM#QJK2_'[@.$PCG_6 +5!^GQW\'L"-68=H]XE;0-$^"<.0\\4#=/7=RMK
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M^7:#R&&,=.OX9QZ9[GX?Z7J.HVXG%XW]A:?=QC48#(KY256+,("<R ^6R\C
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M;TZ<,.*T]8\6W^OZ/I.DW#P6^G:8C);6UM L: LQ9G<@;I'))^=R2!@ X
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MFW-R 5RCD,1LR5)SAL<CIC3\4Z':ZQKD L+Z"'49;2"22"_?[/)-*RY/SD!
MY&"0Y3)Z9)Q0!Q<R2P3.&X 9@20.G3('Y]N.:C C5?FD!;M@''_ C]?2NC\5
MZ5J"JMUJJSPWT<GV*X%PX)#1JH7!SR"O4\\KG/S5A[0XWAIMRG'S8P..G!SR
M .?8T 6;>>T:2&)X!(SM^\0,=I_NKD#=G/4@U+X<O;>VU5$G3RT?=%YL4FUH
MRRE-V&X(!(8CC..HJC.T(M8(XF+,-V\,".X/ Z8_'WQ2W*IO25W661Q_JUP
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MS7MVE?MX^.=+TSPG"?"GP^U'4?"VF6FEZ/KFI^%K>ZU&SAM5"VY2>3+!D(W
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MDEYR$==-D-+W7A6EWO&EU>J/<^LI_%FF/K\8[95"RPJ]4L;&%/A*&*CK"W:
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M\/XS9CH'EP.6D(0-A?"?,%_T3<%+ZR+#7[9@EY4P[*7INST"':)['?;ANJC
M'0?RAM$[")Y7;;?[J.9D,4->;5T@91&<737B>&7R4H8?X=&0;>"J(6]@?B.G
MG3"'B&V6<83L(6DOZZ4<>$Y4VA "+\=(^(?&L*;BG7%5]0'F)E_IP;5>&_>(
M^?Q2T/I4$">_N(#*[[S7QDW2009]?1KSD$^.\.^<$AR9)P]U"BXG/"3-D;]O
M0V62:1"!F6D4:5X**H@W6X?^=]_RER*JVL9(X)VKQB:X85MQ E7,C&GD%2$
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MVE2:"07KR&$Z$^6%IF!@C=J?KM]19N%"0G\]]LSE'OJ$PXKZJ@-.U.'.G G
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MJ6GI&9F?OV05%9>4EI575%8U-D%AS2W?OK?V]/;U#PP.#?^8G)J>F9W[/;^
M0*YO;&YM[^SNH4].S\XO_F#^7O[#"PN C?4_RO\C+_)[7@]P<+!Q\/_AA?7
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MU)E&!W7TQ;5L5YQZP3;7I>TIM"G<,H)C[$-% 4!85Q%H7Q1"Q/V_0UU8W1W
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M/0)V"QWQ56CC'M X67A7):'^?M<LOY^)6!<SBO(W;)YXF(VDG/ZZ>B5^))$
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MV;VMX6KW[HX5S]DO=<1>,* 'S,:#P=M]CJ294)55E*1N$R'OH$XUSI6_=:[
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MD8%]"#KHE+?HWS5=_KL1_GON?P!02P,$%     @ 0(1Y7$/U]F,^R0  ,N0
M !<   !P;6XM,C R-3$R,S%X,3!K,# V+FIP9]2Z9U046]<N6F0DYR110) H
M" @2&D622)0@&02) B(Y-AG)24 1;()D29)CDW-0H@3)$B1U@T!#-]VGW>_>
M[][O-[[OC'ON.#_N+7J-P:I5-==\:LXUYS-7%>8;9A6@>J2BK@+@X ( #O8/
MP"P"2@ >+N[O'_; Q_X(B D(\/$)2(B("(G)2,C(2$E(2<DI:*C(*:@I2$FI
M&*BH:>GHZ>G)*!F9&.B8:.CHZ7X+P<'#WH-/<(V X!H=.2DYW?_Q@>D$J(EQ
M0G"'\7!N +C4.'C4.)A>@ .K)P'.'P?PYX&#B]61D(CX&@DI]H)Z*@ 7!P\/
M%Q_OM];8T2#L.(!/34##)7:?D%;7FNB&.YUX:$H>,?>#FBYZO:\PGCO/7H5=
M(V%@9&)FX;W)QW]+0$)2ZJZTS#VEA\HJJFKJCY[H&Q@:/34VL;%];F?OX.CD
MX>GE[>/KYQ\>$1D5_3HF-C7M37I&YMMW6?D%'PN+BDM*RS[7UM4W-#8UMW3W
M]/;U#PP.#4].3<_,SGV;7UA;W]C\L;6]L_L3?GSRZ_3L''%Q^1L7#H"'\]?Q
MW^*BQN+"Q<?'PR?ZC0L'U^?W!=3X!%QBA#3W=8FLW6EOB(<2TSU(R:OINL9]
M1P]&_^S55Q(&'HDU7OAO:'\@^W\&+.S_%;)_ _L;UP) AH>#-1X>-0 "KI[D
MQVXHB(Z4*\-Z^D#?3&8@T5X#4T5QVC/UUV:9A%V-'_5QMW*7A?SP$U@Y_!"!
M]WE"HAX.BE60]$T4)C*36N:?KAO! !0.E]^_Q]9?M4^;C-?8>^&KXWL(B<65
MW$_A.NX69&Q^_IQ&I3!X,$CE87N N[WL@<ZZH@W)*DQQQ#Y\CM.+:0QPT#4(
MGA=%74Q<#&" /MVS(?#V.'@<A!8($=;5U\K?$Q\XDSD7S\#S#,(!, !C4ZG"
MWU?K$)0)5"WR8@"(# :0Q@"(LO]_#2::/U!+\S#6C@_M49U.)H('?"'X^7\L
M?.Q_.X@!@E3_+VNM78\UNX('!EC1Q0!P3QS7V+"%C8/;JOP$#V.9!+V83P?H
MY0$Z7>7_H:DYX#A4O?.JB@=3>;*!=6#HAI$\YWM%30TF B-%#[^ [=3+"_.7
M507,U-MGKU4<IPG9:MQCB\^M\*_J!K%;("!=M\WVHL=FK&?JS5G4#X3->'N,
M+9=,_/I4UCC>"I\?\ $U0#8)\,M$H.HL GPR#D;",,":ZEF\Y1($C0(A?N-Y
M[_0R#_BTFA:*C-Y<A6C;:*&_QB'3L("B,0 )4*]L\,\^J.X9>A,#G*]A@&ZL
M3QJ _]%/.F""-H.N$&!8+JF^@>6_>P5(%=%#;0P0S('BQYVA-_I']__V5$7D
M6C0_I":: +5CCKQQV0 6H/7_D_I#"(;-RL5=NW.*7Z5S7A'3X<C3Z2H2_+,9
MMM:&ZS1D+/]D.A3^H9>J+$"H^F2:RI?SDJ56&7@.[I;\6%@)<95HY7(KOC=D
M3]RHF3&:&^G0?SL"5U$P'M=I5JP4 RQR7&55S. PL_0HG+_H!)02"LC\6+UD
MMGE^,0W( %!E.AT"8] F']'5J[2+0I.RS^!!+<K+#;Z31_7_H0OY&//8S:/Q
M:DD,P+K#3I?*?YIC-_+8ST^YI>GI"-DID#( =8KFI?<3YY7NLM :4,K6S?JQ
M@7B_=NOM#5^(JIUKJ-LZSQ7ASQK*I$ 9CUN); &:&8KN-2(;SRB_L,BL7\8M
M*#5_L=4A_G1_0YAL]!EZKD;\])O($Y\?V5/Y\*@X:3=1HYJ@8O*&'Q24>5VK
MD]M)+[?#?[[8*G?B@.^#5[2OB VHURMX"QWZBQUL=5/#O ;9/]J]"UAGD])X
M17#:X',+ YA!E]E_!:B=,]9%>]A:G15*)LL]^?@NL.I T/(.\_RVB/M>_$QY
MD,7X/N3&3V;W.=O0FM.NHF+&6@(]2CM3.:-^:!T9!Y6<+E)YST0TS+7-@/PJ
M,3K/TL3"<9E3RM\P/>?!WL$3\X7W$::A/&+T"UQO<G(#LR6#$J=N)&O@?,B>
M.B>[M$NKJ[ QX+6#5DR,E(-CP;0V5]F5<B2!ENL^LZZ!@AB E%G.8B%BZUA>
M\D5<>W7SRA8ATK^,\OW5X\B7 /,!FCI0';X%*0\4K9MI,ZAPRO*)Z^!R\C!=
M,OMY1YU3PU%2UF_?+$,F1,A;C\?VX/N656#NW(ZW,I<5X2LQDX8JL"3"$Q4I
M*+TX![?<"OR!U$+YP!N[OULX@ZZIYH;:KY&;]AF15\Q/O+1#TF4,<VJ+.)RY
M,9*?L"VJ$3GN!&X/@-F".1&5BZ8(&Z%7R[XMY[T-W@QS[#CNA2M@N^O$DM<S
M$RI=PSZ6Q5N+^PU2OB4F>5E\0"W 'M^&C'UR(S0[R<-X9\,. Y2O''^AR]B[
M_,J1W8%_51D(MEXOY6F?K=LY19K?5?QR2DGHW.UXZ'8J?2K;*KBS_] C(G&U
M[.+3<)JMD&VI;E,0$<QM7042A+1 /8.U@:DF8J2>[J8M.MYE:?.(,Y[5Z&N)
M)?7DLCD.:50ER6N*'S3^5AO$>_:-D?D=X6%(]=;'DRF<1K(@9<LZ;?-[:!X/
ME3&^1=C-_+R3+QB !NWI!\?F!O"]#[8*#N?<4Z#-ZXY8M\F\(*G7_]6( 6*\
MBMTWJT AY>G*D?]UH?[5N)@+\T.D=6$:G64MP]@E+EP$.8@B]W]L[$C\9K2)
MYX?4\./RNH3/;!OD8VZ._H0Y:RZ"CR8]XY@\#Z3&(G1,%CG5-G0J0@"4^NF0
MO*:KP?49[ZS!<A?<%]6+.3TV5O:-TC+;1;+8E,B?'R+P'0-\JL< E5"DH$%9
MA0_Z\QRZ!0/L5Q@Z /FQ_/]JR:QS[_8P0%UF#XC2Z<11W!>J/5T_>/U%BT(T
M5'^:6R'!V>GS(Q!]+J5&'Y?T@85H.7HJ(X,J9A_-X;NA4R=<;6:V"W,D&=MA
MU/LPGQA 9D@::()H7%^<;8%M=X\I:4YQ:^8ZWXN,K9M(&9]YNPI0$#^C\)AP
M]9N+YQ"8.3/-3A>C*KHP:A<9GE.(7D]3F#DY\3W9F%9R1SRWE\;C42TS)1H(
MRAW'XU TOB__U"LW4!,Q'8U6%RGG/X<\>AQLDC>Q^^0 <EP39(T!N)%)N2UG
M!5@EKU'V5<5]O76")G$^%]TE.(N/N\A1@TPE^8-1(J#8V+N:,-G>V:$/WC]9
M'G[# !UNYZSPK[X3<F139WL7EDL<QAJ^T*;S>)(*#I;XE=-AT-;INM)&9F^(
M^^]HW;MBV?"-<NJ 8[8,W*.(6!!LOHMB@8/>UQA,.;@T"??KBW\H3N=A[YV^
ML@,-H[>T9]=0GS% I^4%AR)<E7Z5[RP=+E_#\0)Q?WU/7Y[MA7T3_B4.F58G
MLAHO?/PE"60AW! #Y)MO4**HG4"H&-59ZWD,L"J*BCX=#BK$ "$CJ*3@JO1@
M^>"I97Z$/;P83:W)L-=]_,G;7[ZO*EKTX(>+J7E ZX7+5NRD<I-.!8L*QTUF
M8$C(P(_-"3V];24*.QE0KDF] 4NL5OWB^OD)I 1OI=W&)- ?]B,S7A2EMT(>
M"':I7#'NLI;O01@9+<$>',LYZ715NSA^E+'0.M0".FMNZVE-8  <\*9HI9Z[
MTR04\1RM>KT0/:\@.@^GU)CV3*#R?>N4]M2789FX\.DI9TO$++X9X9L,!PO)
M#+U(D/<%0.6<@O! ^B,P@"4LL:#,N44T.C?5.8=A2BUK<G;-*M416LMR*>.C
MU7M;4TU.D;I7.V=1*\ 790K+7S3Y*IF!T-UX>O1+=DQ5MZ8-TN-?C90X[\LZ
M?ESGVY/Y3"FP/+O$C,QZW@D# )X8X%K/6HG"==\B>08VPSF3Q,5]_SCZMH98
M?JLW,J]6A%[VMWK4-Z3>YTG3ATNL'TE<>@9=R0;S:C ^LB0_WT<?)!6A!5%6
MGQ$Z@2"Z!8::=6$E\];4X?X>936RSVH9QTM2CR=[0_Q>-@^YYE*<;C:N-#)&
MV2-<UB$TBPX+1:$BD+41;2K'A'7;L.L!B"/F]3JN@G?#MW*D0.^J2V28+;,*
MX!P'@K#&/I:BR*!*1_]8RQT?&O-OI.LO-L-4P]28X[5O,!#*?-1M5KOX+ ,D
M2LVM4^YO%VGGCBZ8/B4G6>Z>[3:NMZ.^3Y^=JN%4J3D^2WPL2WF'-X9YZ<%Z
M<(W69:.;ZI4WQ^PNKQ>X^0BLU8.ZA?2SM+R9)-?"JB!15S_IM8NZSQ?&<"M,
MNVAI,:^IT;$RG;Q622R9?/R@X_;'[/"?EA3!=Q"U?2L<DAPD+3LF51&JT7ES
M-$>/&G/XIM@=P5\K#FU3AH>/NUFL&*1C0^[C6[_O#S1>/YH/'U#@FY53+2TL
M^'G9,L1V-5,</SFXQ).B3%<R1'^)6\76)O"3D)6?C$++6X$]T.PJNX/.N26J
M8@U,]6V7=F5,>&SL'2*.=+[NLTW 5:*F6G=%I YQ/#T)T,E4_C36W_(X& R[
MYIOE>N9V&&RA.L_FU)YY.5)UB0UAGRM\(ZL."F%9QYHIOA,]GS42^B7@A-F;
M_K^:^OPAH7+F18AM14T/M:;8$ZVVE"SFU7>\JB3>J>Q2S[D%5.XK1"<KEAA$
M?,\?L[;(41UA+)W25::O^?)/&DX_BGH(/\R$371E06+JHS*1"EWT.58Z%JIV
M^@F,//Q"A[&DXB7?,Y[K//6<CK +45"MQZ:O)Q6^@D_@A.\9(W/:)*W7R>W-
MHB;5W?*:PK6G;1L39Q>>>RX<WZ=.&W]NG1'_NJ&#:+JBQ+3H,^R=&,_+L!ZB
M^.Q$]\27SHG3'0""\:FI5\M7\XVPK;/M$8W%U[,V/EYGK25;I)RT2CP([RC-
MKZG  M#GHX1^X#L.?@7^)0!8'@B"+W8O.;#<]-$*VC\X&B4P0X?SCA?%L:##
M<2=)0&L .71@"*ZKP #;Q3O@[IB_:5XN"70!&XI.IGZ!L(5  A3UZXH285#&
MCYL[[3* JKLBOS7M@KVK"GM7ZMD9N=1DP$CI1D-]F%2&8]'+&!;^D3MBG0"@
MSA=RQT*PPG?N*:+0GNR,L24I0H[(G2N6M/RAPRF4ZEAET8#;JZ(54'O/[EPJ
M$D5@\&Y+3]<HA>:-5?-'[PX1Q-C:$:F36X&BFYSJNI>^&T*UCM3#RS^T8^-Q
M;D2#R@%OCRKS]E8E"W*=K]>-UFS$N5BI /$TC&Y^,6_VE+]+YH8=)7G%QQ!O
MT9?-NTWNYJKA:!9R455SD0GMZ&YVMA,6FT+'A(:M+94?1<W-3YH_VHQ0:=3:
MUB6E"GZI&[LYI5*;.#N\(&CJT$_#GRQ0<H;;?%&FC_ TQP9D,&3)P\.@[&K"
M6R'@:F7[G/UN,8JV&8X75-"/!L&]FP:DJQMG;:?6#$#=&,!*X_F;@#?LT7)I
MDXY0W& Z1YYZ:$C@G>V4Z*;WZK'&*U<7;!HUJZ]Z/PA.J9I8U']R+*G<@A7E
M5D!+.R$1$')*U"":"0-T"7&@7,N64%2()SXW+]#LB$?VG69#N8MB &MH&H>6
M^D!SE=H$G1=]$7:YG6!+-@Q #$]"&+%38$E&\"(&2/@2C(NZX0HE1[$&=W T
M8( -K]WLRZ\3%2(&W\QJ]OWL47<FNMKSP&LFOG<==D!K_[J$8&7_!.;.R1O,
MC)!@&Q:7 [V0%KJ# 82N!&=K#+PH$6>@HV)TQ*U7JC4*XVQ)$F[S*ZOP_HEH
M"[J0^.392PDQ]J 9''FHJ),->AQ,]*,?&Y9]_09W6[64DL:<9\74DYPLQMF2
MV]^ TMDU, #9/,R-XU@[\.X4.C0& _1.NR E43?M>0,%75S;\QLR?&UT=TH2
MZ8( M@G_TWW=6/ELT)O@8;8D+@P0Y83 UEH/%L"KS^>P]4>1.E(BD#^%)(E2
MPH_I.T.>=[Q\CU!(^"&QY+YT 5/!?$]U^QL.I7[HVKM@1O 7V2?8QXO&IM>!
MW178*%8/DG0D17E=\B,(E9.M?8,JQ**?X!9SZ9G$W/Q#)(G&?E43'(*P<XL*
M:<RD:'=KLHYLC/5R"*?PCVP&3N6=Q)"B@>*&@^R\1%6HA,L)R^*%\H6=PGU'
ML #CS X&N(%,HG.;!Z^]9]WH;3[% !%08PRP6?8>S5R[MAIC0V3Q+9> J-<_
MAI,B^UT,2$]=?JCJ>7Z2M<:%3I!%TK%HTPCL]*/4/8H<-Z!7S%3E-2F-=R3P
MRD\.9[8NH]PQ_)Y7U=4K[4V![RX-4;NF#[%A2^R_I:)<TH4?N25P3O17&M@@
MK]LL*Q#@;O6/EFT>NPTFYDLM88.NO,W3+...R]\IX&2\/L"CNB8F_L^J7*>6
MT994$PF!MXJ=6'+KINHE9B3)!=:9MJZ6TN;-S4P>?W7MH;-O]-%1>5!-E*QI
M#+?OIB1'3.FT=4Q7%"-=9MH+FYL:FU.9;S#,D7NXPM.Y;3Z.FMW>"Z%0I2]=
MJ[KFV$'X56*,42U6[47>NR7FYXX?4]5)AWA2U39K6UM;:VMXW\7PI#K@N2%5
M)M#!>1@ &HYR0'^MQ0"0$O#1*@;X7?3:??\I%:7A]NNM;R;:G_*PL=WX/ZX0
M@<Z:8( YRZOTLC' \#^&0'4OL!'M)P<2 >K_-.F52]*C4_\,:(I)4L0/@6Q;
MZ'X*?-$!URKVRT?=GMIO4_)P%FMH@XL4OK3^LL_#3!:F3%"YI4=\NRM=K] V
M@Z%39N&PU ^^8C!=5TZNLO$08?IQC+>AZM."QN98Y9+*:-K\?1$E91=:+N,B
MLSL-.U\S;>/]VT7\3G.DIM1@+MGL;+"^3[?<"'X9CK ZDX24921;\>OD ILO
M /*RC2))@3)_5R3KJ:#*A_<= SB?4!*P'[]B%?@0Y7J(XD^:,: U=OR>0G;U
MA2PS\A]MBK^<&[(3[_ ].I #%5KT%/84.GS9Y:"4DZ<YB-:>LHD8C4,/EQP_
MNR0 E\C+@BD11EJP44JV-SQRT9ZUP_WJ=FY'LC5" TN_F/!"36]\/O,2<-8S
M\;;<AF[:[)<9S'[ZU"IZLG)8,[3S@19V&/G2==WA4'3XP'EQ)%QNT]_ME1I[
M#]Y""V]'+5[<6Z+J9'""2;^C8I\;B7M8G4%BR9-(20=!>FS]\?>C3_XI98^V
MR/W#NDXS]'EY1L@'6'/_ZX0CN,X%])>-OBK2@^N$0=N'?W3+5<&.5WEBR,?2
MQVF0VV"_JSVMLF)41!&V -+% '=S\?XAYB^O ?UA^'IEP #]Y1^>0%A@CP%
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M= K*.\LP@'42\@2\LHVM%A5Z.,ZWL EL BV95VH#Z(8:H/]]1B(H"G0TA@'
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M72D.EJAB0WP$K]U&S,,VNN\'+@:H;\+I?SV$63?T/,  1\)S\\1G-]MC;3
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MY*KY2JN_\"?9+9M]JMGJ J;6/O/4S0.;#JHE\(0GMCBTO/)7HI] G6LCSS'
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MU.GCZRK.N?H(*!P/C\6HVX6^^C:N,\LB%RBRL#P$6XJ+.GDLM'*SZ&<*&6
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M#?PL:3U,UIF>%^TP;&EWL<A_40*=H?WV8[B9;]M:3+OT5TP7C+ \-I \()6
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M5Z..(>2PII.[+/ODUODY>*&,4B580E. =P2EHM1!0"GD8%"]T6OR1::21N#
M5()TEK#E%!1T5;XT4D"B>M_&]'VO4/5&K1S'Q^F;5>\$HA8,>U)6.(_I]VC@
M<ES[2EIKYQ9[U^X@PM032G]@@0*I1T:+,T[) C_36RP]I;>+.K'&R9$+\ZO<
M?A.?4XJQU"0Y^B@*<TKSNZC_<@MP=\<.9TB_B$G^#]%"5SC1^X9=JK_^>8;_
M.QE:PV=U0=MW,:?@0S-44*;NKX+E;DRC\@Z$Q$#&4UM'?#E^5R;5WS4AZP0W
M3GL(MP3.-Z=:G1 #9K_T5/*SIZB*5BP@:8P%&@/ /2HGJ[#HC%__?+[T<\A;
MOVOGQ"_:^1N!_[\(_3+W/$MZ >$\/&[J&CG\*VMV>:F_<DICS%C:O.U&5)+=
M ] <#9[+/[P\)A ^F4=:89[>_0,DKK\M&L "889[]E &R+:(*1;XJG^OT1_G
MGKP,PA%ET&.1O3O9Z:'GM]'+?]K3D"&^E?[!+_36EZ.K,\L82BS0S84P.W_[
M!G;P4$M;#]H"/N&0NH(%BGD3,<&/MWBN@EJBTAK94".'K_0)6^=/0/4B6. 5
MC^WYU8K!L81CJN\S\A)4$G<?-2\EW./N:EJFD&?UPR-P:M=0V&]N=Y93=7&5
M7%IT;;725]'0'/ZL+(<%="=M6*O'#;2>E]BM'5^Z8X\+!)J6\2,O%Q)/PN-3
M2_AB;L87*#H:>^9"3'J%CAYRAC[$NT*A,/W>3Z$7O^,R[8"%@>BDD[7\3L)4
MP7SR)(DK=_==P<$;E0LC?';H_;@X'1BBS/95_:AIZ6CY^3TFDM'L@LS2WA5%
ML0[M*H7.=%_@)3  ]+N]1Z!Z*)_#Q?,LCMTQ=">I#8]1EGN.[]^<00PC, _=
MJN!+**W'GJL-] ),1Q7O\G4?E;@K<C\A6VKEB4K\1.$NW#DID^>V]&S"B_]5
MFA[[I9$>LU2N"U4?E,RX%3E9S8"7%*(#%QW'MUZ=Y[\Z6W.%-.UOG7'RSQ3@
M1%F8\7Y%:/Z$^R>L+.9+P@(9NUMYA>K*6" V;Y'_[,(&]%0*4UN[EH: :9VD
M"&.$UV'LM$->DE@@YJP5<D15B5N/\_3.%6WM>5/:')O96H6>L(@9&^6'DTD3
M.%QFI9!_HAG/-DC(LM[!-[!6X66.,(VH2<4"3RJN5OS(*YB1E<I8%3R/U5\F
M><7 :G(XT[3LM."O=UC4W.LMKUX]NB.\Q#L><-X0^)EET/+12,G#8=#=X]#"
MRV*7GSK.54LOZNMY?X%8S-'6O%>YG_0MY NAG2L!_ .+M)A8X1?TJW'U9R)#
M+RPFJM3F9+U=V06ZI"9ONW.;7'HH$*MXF8;*T8#=W&A=[?G&  ;B7'6R[3%:
M$%BD.O;)>N7G_HM04'/[':N[]$A"M)(!^ST<Q@9OD,/Z3MI\(*?%;&??Q0:E
M([UZ*F%PGCI,^]C!(!^H;%-$T9G'6MS_)OJB6!-(;$!:@DS>2^? ;KB GM^*
M9\>ZS@KU26-%,7,[PWKW> -UD495OY.QQ])P3Z-># N\U,=A?/EO6EIZ7W'H
MA$.W%7IT<0P+''@'.#L/*BU"B]8CDV%7),&:-*JR3M<ZA\ 75H9?H6R=IE"@
MEYCYH"MKQU;7I5<2KYGBOXR)EG0C8.%O:Z2H:YSTTLAQ&]6L+JTK;0QEU)D;
MW6$Q^UB?<4OP)@7W!:"[ [AF5+\GJ7G$>U^)H#[E-KL]VU3(BT?]4?5:HNPN
M[*]K2446^=*LC!TMLG6;%R_?O,-<FQ\'3ERQV1M_W%6MVM"H'K-C0%,<;S&>
MXJ$V89"HI%R4=1"E;V0Q\/[6F Y_)V1?$*T![T9S+#+-WEP9T2[XQ)_$**Y'
M05P\0,[J/UA@,G[NJE>/O%GDFC/?O3H[4^/.<,O  P 6   @\R5.,VB7,KTX
M"%/OS^D=.+F'\Q:%NH)LM5+?SN-@RQ,8<LBWE"^0#1J-S?$5<*DK.GF^>?>,
MNCSJ_$9H@PZ,WK/LZ&*QJNSU#06C<5*3+J%>Z&V>>ZVM):J1:%_W#CN![J:N
M ?D/Z$?GZ4[S 8T<C:,5YW3GMZV%ZAKTYJ94;"4"IZ:^%][\-'T[U4'FG?F[
M_+0GT\^6O$QKR2^A<;#[W5YKVT35?>'5M_GFKC<ZGXT6L8=J1DS-\;SC1M;Q
M<$4Z+;,PW,%<BR8[^GG<)KD([<\/WL*AOO6;!>/*6ACIQ%\W2:DUU_&^+#;:
M(UXW>")E%LDJEICO/[IK<'L*%+ARUINUCE2N7$3E=/&[.A)QH?EI*_*,5^(D
M$W<DEW3GB;RXZLN&S6)QB"%A%42VOF.CD&3#%R*7 #Y:?*<L.@BJ$2O,@$-:
MS_B#4NG*1ZUYC2K,X:%LUQCW%A6&C4-I!J7TS'-#)>DY8Q57LE>XN)^=G$*:
M13=KGB>6!/6?0#Z*>$G"SU3(+(:G=*X_OZ*?%+D6\RUVH,_]M9$B^R'[!(R&
M\FVGSI.79UJ/C-+S$X*>&'U^;UR\J?.8J%W5R$/3+-A+,=--1:YVO*)?;5!N
MI."Y9#LFS2Y:FGCY2GWDP^QN?/;(]'JK19$=66OC1=VBBVC1X2Q4R)*GZYTY
MV:P\X<#HA25Z5V+B//_HZP3W'E )<;M&>BJ>?ZI718+4*R9];FWQN'K3# _2
MX M*%E]A*,CEN7Q;>H5(-GDA[:7-# 6]B+@XAXLQ=\((]_;!(,J2W/_#()JW
MZ,+2)(9*B1\CKA)TE(22=@;'D;?;$BC=N[O2N2A^[XTW0=)A'ACQ&0.JF76$
MZS(K1FF.C<VQ?-CB,FY:\'"X=%=5SV=@_DKAPEX6@CRHD":Z[_5HNHLC9II"
MB?PU)UNH5LYW;RR N.@!Z_FY_4J ^W\(2J*B$F)  5;VP(46D:JXT(((484)
MU7H'1GCC H!.[O#Y,I$6Q9(Z>.*[MP!I;[IN3M,2(]$GXW"G#NF%$>CW.#CY
M.=4N(60A$$<@./U0G']KF3[OEXY(H#_I0]8S46 L0#@!0SOD&6*&0<01^=D^
M-U%"XM?Q= W+&9?F'EMB^K  $4T.B 3-<N]3%"IZ"N'MLU9AM0$E\J*$\Y"D
MI:'$'XS@\]PE819DD*$B<ZR0\QCGL\FN&,"PJX'*P2VE@E(WW22B5(MT<-!#
M#@>26Q^B;TM*<: DSH6W##%BRG7GJ1CZ^;F/O45!4M35=9PWW9V47CMX=S\9
M$P&7!;6$=4MT8QA1<F; +;.A L6F=:FUQUJ)KT2DPD[/P@B/ E"ZHQ@Z+?_.
M20-<;+/TGGR*&FXCBDI<V,<AJI_TGR^>)S=2MS/)25UU4QW^($"U/K$[FG4[
MZ.TWEQTE_NU)1((K/V<KB+ N-7^*-(<3"US+=#^BW73!-"Z>%W5&!5:-!O,V
M7D>I+;IT4[863-^]1F:''S>:/ RF\Z(<Q5#SDV.!A1%R#%\-"@N\CGHW' 1"
MY*,Y^##D*>G3W9W'<LNB^-?PFK:YZ(],40]C\HWAAGY^7#W9B,.OE\C<SN>+
MA!5[<[G$#N4?2MU&L1\@(WTA/[@(L0#]8Q\>%"<FB!0?"URR@R"=>S9!I57-
M#4_XIWQH4<(]!UQINEPLWY\37COXHO)=?:'>/%>*"L4) ")N'F/0M@][%IZ3
MPQ?7O"G'H&&-%Y\VWD4@3C>+<72HO4P1%YX65T5ZW6,WO4VQ>00/)KCP8'Z:
M#>KA_P3%A%B2(SV'(G!Q[X1XM6V9>>7PLOTG^"7'MR?$-=:(J*8)N^"7"+.@
MS\&.*YV9#_)."/+&&CQ"L ")?Q/D0-S-$3?:(0C2J0,%79A572HK1=H$N+I*
M!,=(7\HBJ0]_ >2F=;-_ H!N=J,"2$L^XC5D674(@M#&S9CZ^6!+T44+7N;9
M1/\#$J5L/KI5QH61!?E(Z];CT&9I4LS0VMR'@;YK(R-XH3I_>\DE8YB"!>A@
MRTM2=W!KKDTO#BO46OL$7T7OHG!ZP<F(#,*TNAB>FHY:K0OR'[>O#Y+@UDY'
M"!MQZ*VBD<&!A[6P(*F+AB#+Q*.HG)OO$Q($#<KWVDR>93^_YBN-?^6IG(>3
M6*%:E03/XM;@9:7L;K-K5$Q;7&\XJ/,HV.+P0A?"[S0UB[%TU&SE1L8]U\\<
MF@KSRZ%7->#\JH,9G%(^.%7316V.=Y20*&:NJ<3HP-]3+13NSKY]VRW&R7;M
MY1!* *X142]=:&C.V::8>>)2\HU$W8$]9AGO RNA^#/JT6JI^+X-+$!;87UO
MK96ZW?:U86LWNTO=<)?=R6!2$*/$)V-:4E@[,T1E2%=QU.:C8LB/N2/M@Q/V
M4 O]P,NO27L.%O"&J./ZW?8R(M]S*/<<[V96>-?E>:]EY\)I,H29=)&C@WV'
M*E?<!"0XD7D=5U6YS%[QQ;G>IA)$A^#[2C<QT[-3B)VHT*ZFBJ,\+> 13(\G
MG")<P!065_T5J69XRW1+[[,\SZ..,K)[2L[0+,**@B]>KF#BE5XLJ855C'Y\
M<J;<9\O63TWA>/-%X"O_ ;'N+K'\J*MH^3$)6ZNL*16+5U]?O"#<NUW>)?'A
M>4GOO9E419;JK4Y.[H K)CQR:E/=DJX5&%.-@H 4,5F;::LU6Q0GERR-UE J
M@ZHL36JK[J>_X?TXE#P68,]JQD&A4AS0)-(W-99!J1Z(M$&N&A3M2_JU3$B*
MP^=;ZT"\++R.NE9YY<X$"FPQ1AIB UH$" CW-MH:426'%(DX4.KGZQA].L*[
MRUDZ<:-*FD;5_2+4\2)P 1G9N+1EH N*>(,%X'IN'M^>9.@-"<NE3A&Q&<6V
M+"LHLN(=CUT@(F0F?>1S%^6K@_HZ2S<ABGZTJO0Y>[Z._54]#!H>2>8XY%0$
M366BYJH9&<[BYYV#!BU[4A0%A=-P\WQ-A'MBP$E#7N;EB)FIW<#=ZQ57+Z5D
MFP_/OA_95HU<-6/C:KAD'_YI[6V[5OWH?#L+ >)IK+,^GUC 08GUF1[>YU##
M6W(Z0D9-L0Q5C -*#@YN$&JWQOWV9QN4L^T$QD]*(UNHB8MYKYKX?>?D[>YF
M8&DI<ZK# ML-<G/[756U>WK@&&<6U!?&L_QZ$Y9W=MZ7"Z=>/"[)(%C9E</@
MUH^^I9R0=[D]BN:3ZY&MG1#R@T%@2W!C4J<Q3:B%"EEUI!@L[O< )/&91I3!
M^;:8A+W^E]J=]JCP1L9-$N^L6;WF*YHBBL;.!(W:%I\$WX0$:WQGQ<<W7R#[
MP&*]I (R=/MFL>%H9?K*ZA5EX-1("]LU^QPQ48*X069D)Z#NPZQGD6 @,EQ8
M$08MM9B8)+&_W:@+GA'W;?%[JH"?Y6/Q.$![6*WPQXB';G<!+Q8@\)EZ;UDA
MJRWN$[5/O<@20_=VJ<!3Q=>(Q/.[FO#!LTY\! /MP$15Z&$'DC^D0EDC<+Y2
MKUL4-'NE[2WJ B%<6WAC2"WB%M>/A"RZZ^WC<9&38LHBF,=%P;!MDM\V<M^/
M0I9S46&8IEHS3!2LL# 41'((^;"%MAKV4>#1;;FO8Y7*/7RP 1Z?-9 E@=0.
MX!UL*YN,[U"K>]-K%X^Q,7TIKXY<(%?+9X!PUWX:()5Q9)C:/&/)RG=3;N3Q
M>HV436K4O\\#$F(-I>;Y +\AK+!(0"?*V-3I999IIQ,9]2K#LM_"#"+9D75Q
M[7T.).L+Q<M[^."/UZ>'3/4OO/WTB<P#3(7:5QZ5XK"ZOQIBD655J=7'1^DL
MKF7++5/QS?=Q\<OOC(0$+&CC<*1(\*Z$;I&!Y>E;&5?7ZZY[DY9K $#X$L"O
M68I5$5Z!6RSR,C1<[ZFSG>P[0%*GGR1/Z W^D.SKD9!9!#-8#'I:0,QR4#9B
M4TJZV5GM[?6J"RGA=C(_MB:SNXI2>:I1]HN2XBW)AJ%%G#73N7H6_:^,;2A#
M'*_C3=L1D'XVB[T[+=PZ\>&^8(::W7I^T5POAF&06E,XI_UP\@ +^.&B%X^L
M9(?DOVSH3G+E0+HU$6OG;YW!YZ!7^OJ.(ZBLK5.VKT6MY"KC :Z@BT)N%8,A
MIZ3EFU<YDK)>RDGOC7\R<654U9-TFB?U4@'YUSMG6.Z;2%N#=Q48V]X0E^#7
M$+>-M'$]#A\3L8A1S%3CTV5)003N*TP>%EVS2KTYFG]X*WRH:\>5N/J=XET>
MP01"&WRS*F))GL\H"T29$B(HU)G$EL)BHC:I80RJ/)I1'V+"HO9H7ZCY!647
M9?B1&/,)\F,4712YRF+_75DW?J$(?72)/;L-4X_6[0!I5O^N@06?^#R13C#E
MC)4/\_A-73$;(5$=)B<G[U*;A^$C7M]ORPE*X[/:3]035TLH/[4UV6'DR$K7
M/)B4\XQI?P7/E'67A6T=GM [LU^%-;6[ _/I5E'6-MXW8D1HL4!C31%_X:XJ
M\BF4OL53F6QB:6"LR%E,F&3Y<L]UXCHVO6B\+K&%3ZZKU8\/$?;O:4X2(I_.
M3^:L+JX055<?G1NNXV3@VOO:KM/)N^0?=GQ[(":[)\(P__DC3@O0J2RM1X4/
MW['9-LG+],\UU9$C1&;)LH$,0W7=;!>?/Q-4Y/R,'VL5,2HEZB4VR;_SQFD^
MF(5^C-\FQ:BJLF+">B7!S#C@N8;#B]0F_&09W$H=8HB7CJK*UNM<-*0TG'%S
M+MA]Z?^XPH^!A=K9F/?]/(Q8_[VL1%^N/!D\Y&4VO6X+[$H&(C5IT2I"715"
MM7FZ,K4I<ESE,MQ1Q.Z"E*90>&_]+,>6\8<2W4NY!RSOR"PCRTWT!1<Z0G>*
M$?WEQC!1R4M/Q9>N/2/X]SI1T#_7Q+JK/EIP*<4Y[(4T)5BA,^THC_/I+]5*
M?BU'HOP<"[25[F*J81@_BV-7(BO\7C:"")HR@75@>37.@J?D7FR=A!:.A!0K
M9G3*-+:=:0/G15W&LL)O"51F^>CP.([NMEO;.BEL\U,<TVXO_4+[MU(G2,CW
MIW)(S@"T[E*WPYY;9]OQ:?B3WL S]MNWK>6'6LW#Q;V6CXOL554O?:E)5+]O
MK<A5F GYI6#7+^6-OMQW_@I>FOBE3%#6ZPOUB8OR'2\.\G@->,DVYZ:8>=_I
M% 7_@+MO'VR0<.=3=D E9Z?+N#GJM<639"CZ0C@>ZV4^?BR5)8/D7Y3W]Z%>
MC\IQBUR=Z"80[(L.;E7FEJN)B9='9+.6?;IQ@40PTJH7#?[JMG84QJDZL</O
M0^<E'&]OFZ:+!3*V3OO,Q#QSA@)+WH63<U/=%!/_(KU7#B7VN6BPU<B&"Y.7
M.A$S*N+*S -)Z9:E[,<"@LS#LX:U4;R%M"$F5<$DGD:*X4))"8V!^ 1CA:]_
M=$?==8UY"U<!W*R:IBY6AL!G\96'#CQM;I04ERL8J:C1/F"4'%1S%RN(VIY^
M NG,_Z46T8MU*\XV#,^P%W6ZWI;4]?%M)]X;DY<\SQ^O\.XL$OB*B$=GL/L*
MNK,3-U!F%I1XGMT?Q7A?_ZTVS<"?I+U/=YZ/(<IA1>LC1-FRI6Z4#V+"O^(B
M'5TT)19(ART8HF\5@%$K]++:1Y+R9_<',=ZO?J=2]H=<]W915E%O<:']"R\B
M+!# G(6+13(P5^<7?+% <O._B$@;CT'*\K' VJ\BS)O?F/#K<.!-(WSUL];6
MZ(8!+C8DM4?(,.)HP!;T/'!07M;B9[C( YWJ7$AISR_I1+HV#?1E/F"Y4;XI
M#]H;^?#B$/)'0;>,/PV09Q ,S_(A@PQK(\ 8&A<(VB'=<"IQH75/B@]%X2NG
M@.1-]('N322T2++]QVGMNX,M5?P%>.A050NORDVP0+NB60S*O1Q^IHIF9 6A
M=%,O-C-#X!RE/\,W/7*Y?WL8_*>9UJ_[C!E>^K#@I8O@DO)O2S!$NT2A+/G]
M'RQAZ.;?.N( ,A%O(A9@_DJ8C@7,M+' 8/[O%:<@OQFQ 2X^(95%F ,0N(T;
M/7,4FKW2$.WP*Q4;'+^J?N67DFG4.=,#EHCS%#,L(%7\:PTYR)](NL^CA;!
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MR*^2(7Z3[(/)Z@?N7+5W">BEOS2K^P?XL%_!+]U<E?R'V!G-#BN-;YN8Q1*
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M7[FDZ?XE2I=S\ 8)IQ(?R']BGR9,F.1,MCB*@U0ET"Y98U.:>8QDG]5KLXX
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M@RM'!$#>PC0<N)JAKYIAJ&^IMB]KUEB<.@O&&[HO[YS$SX'QZ=HV53^/F"$
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MP<7Y8Q(HZ-=G8& 186$1<5"147'^?[>73@ F J#L#1,T%"7@#284-";42R^
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M\I"QR@<O"EQR@?6#KI 7C-L9Q!K7;+"C5C)^^AW">G1XKY.%M'/>&D'X^MA
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M/!""I2:-=>93/^Y,K>6;'DAB=WU#W,$-.&J10T8.U^FA18%2_<(*8>?&'[Q
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M8T.MX!ABDYX67'XWPE!(PFM$UOL"J*YXI'9996]Z]:*<XQ? ><RMG_R\\PO
M[/1!:-'NH?0NQ^O1\Y1E_^O'N3W-W.<)-[2J]?>$H)]@_:];W?;+VA:<6MG]
MU0/LDOCE1C&3OH. $E(Y$%S%@^KC)WV_5<84S2"%\X;(RR;'DB7'J1.9G(,;
M*P)XXU53_43Q2^Z!,C?KH@?:-'5A2'\871@!^]G;VP0!YSNLSA)70)'EYVZ;
MS04AUZ6'ND2(]C5=%:2]@&0OJ%6[$.24/OJM D_%O>SK,J4<\21@>L5:N(Q,
MV"Y0@)[<2Z+,0^BVPV@K"O-(D"A1>I8='>, HTN@+[ T.BB60(2> =\X1E,>
MX1"!'P/87L%QZW0>^;M[E1N"%U[WY$SBWJO5BZ%I4UW)J39W/1$5_Y:-L53*
M4*.&YQ  37RORA* HR@,^]\=4V?TVM+<I/^,"=F(>PS.<M>3Z'JE=N89Q3*=
M([%;:<EB#H]4KMWO*;/4!B.04C5Q!%^W2EYAT&Z'2^M>[P+;SIQ?6MA,_+."
M;$SH74F/?C7YM!?,2.9:5^XX!(H]Y8EU7BURTZ:&<IRZM.E.W);&H+%?TX6;
MF&40/DOK>9H4I?8\W[?$\B8J5]?"39:W=T[M>AYOS>"[< ?_&<HG"=)=,'4T
M.;=@$)[94Y[@:QD0^%LTI6_.SL(YP'^B6?)-@,_8>(?UU'>6%A"-&\JVCX?9
M,P&V=F4RV"5,%L*.ETY8,\EAQ>"-><C[B=2JU0 :".[WN/UI1L^ 8D0>'J/%
MV5'#7)0'@M\BS2A:T=#HVBP!JM0^#\B4S-=C:#/@OE,>M6L"?=;]Z33$S9AF
M[5;N]R#YR _!76RHG]NKL\NOKR13GCH]-K*DZ3?3I O!C8L9I!,HL>SLP&NE
MAU!>G$Z+S- F7\SAEQO7M58UUJ0,16,3%\?UAT_6<SO!*I1Y5)B?%_23U>*%
M.2'KVDC;H)K;@LA!H,,1,U<4)1W7POTADIVV5G]3_NIB7$7?UKB!>@_L6Z[B
M6[P^":TY1UWF^<]6-.P'5S+>V(=N=7U#:DIP(WFJH12!%"*&B  ,MA]L2X79
MH7 XBF* ?W0O7 _U%\#W!*\I4L+;G"U4*KG;B&LK/H4Y&R:FK.>>:>V1$#HG
ML1%M+-M,E%B%,ONU\TMOL,MSJ,WS9_:.9_$*E-M7RJ.IV41_"N<->OXQI",/
M-M?_(ECT6C3G/$]W7"I[7_CFO0 N.,C^]F"B5>EHO^W"(\/\M1#=30]T._BZ
M<I%9" ]6*8*O8#=Q]]>*Y(#X>+[0QOX+H/;L"6?M,=/<^S%"XE& [#KM!9"=
M\@+X@?K^!1!3LLOCV.9C*+>="H"5!9-.%(P1OP!JIAJ"T$V=:-[U1]RYS EX
M&5Y7GGHRO0#0)9X*O/?S7P [T*]LN6WQ]^GUV8:RCPFPWWARSKGW*@8+B-D9
ML9::ZMN43N]T)'O'F8C;972/%_\'0NU8U>:QZ%GX9WPL]U3\#]9EUM8B"@2V
MF)? 2P'G1#)DU8M$Z?LWS1^T5,Y(;_1W18MPCA<OU_YMG<)_T[/'(%AOAM$$
MGW16ZQU,K/_[!H%#H,G/5OXM^5+&G?J2Q_Z"M^511?^)6@,F%G_ZOAMXJ.U8
M,';Z";VT4Z'\I#$*WKU&6ZUZ ; *U GN3?4\(T4]R.\]2YO]EUG+"_J%SI7&
MP:+2YS>^Y65>5*[*AUKLB2XV3T'Y&:R*A7H?B>"6H&]L^QOQR9C=8A7Z+L1V
M>'3VX''!'B*OB\IL9#R%37L?+'VN2$ZED9=GU<K17KX1NG43.N%[ 8AQO0#>
M$>J_ *C^!XW>::!,;X8+VBO@)EDPM5 =VOQ'#SD#'0U^OQW_IL2.V B[+-'&
M;&Q^G&>9\7IKS^0+P'SMGK[C3GCJ!7!'&/5O\ZF/B&/P)8L0IN^F#6V;S?QM
M9^0\D[YJY@4P*?<"&(9+? $,SOXFYF11L.3__K&"%$%-R'V>6%4@VW^:^& 8
MD6OF_M_OG_'^NPSMMD'"H=Q3,D7:(\"VUE2LG#6.Q&LG<R(#&E9;!:T )=:%
MU7RL,NK4V8KIHBNR_\19:L_]N2D"R,/2KUPD^/P3@OX3%()I>30[3V4M/(KL
MH?ZGT 3<1^"RV[B>L$Q++C7&G=:$I4;N+]X80"XU!ITT^5F?"@9TK,3F9/7?
M%B^ K$N;_T2J]OK@@:+<V!D*>#HK?58>78(\=S*36Z)G),T'2<NW7@SNX\&K
M#@O[4[I+&<<"',[2M &B=M_8>BJ[!G>;]/_=3H&/;"^ :.]([V.]UU4ENG2$
M#U2^>"K_TQV\_V^;DOO61CQ%(_UKV4G$KS!L;E4"<JA8X5/0@2J8)LR6I=QS
M/JOT*7O7[M#HQ.C7UBR9S+\9[']PFM&0;\3;E"^ -<K4+V%TV_+M/]JR\>IT
MHW(E'G'_HAFV?]&,T#\TLWK^2>0-A^ AG[+TI[G?^3,/F256@&TWQ1-L6%7!
MH"G]OUAO_$_K1?QI/=E_6N]B(0 2'43:6#)G/V"HID@H>?0=)A@?^Q1-A'36
M6FUA<GCI+S R[H2GA?Z"@NV?*'Y][3"/WV8(_27570CP(H'EE+$O%=%!N<9Q
M8/)+^^8I\%?=ROZ+;L=?=9OQJEM6\$&-[G 1CNP?O*W[/)B,'&!6&Y,=X1-]
M0A;-@9:K7#<8K]$'OL\0_S][,>/_KE8?RY/\\@9'1B8M9)*>H<AM:,IP1Z/0
M4LJ B4UV4W@?C"^A 6H'? 3%-Z%Q:DV7_Z2[I'_27?FM]@L EOXIYU%BTW)$
M3F*3"\RT-<D1UJ?PZF)VC(16OR8YU9;)$B0GJR:V8# D*Z+>8[%;#8=FVD6T
M61;>TKP*D9[S C"<#Q:Z''?5%OL-3.G7&=ZK_]^8Q.P/Z8</N3DF0!)B*5HS
M6@A,7K-T/XZIH.E\T^$=!J0G:687T90^RRL8[?^[(13_S8G/;TO7_7$Y)[#<
M3H.Q!%/M9&A^R/<%E)(;U<I$[>A_O36T(#XM;LAAN1Z\?@'\RWQF?YL/_D_#
M060\.6<QNQK\4^W[6>Z54HB^((5)HG\+'E#0.BCHYLB39XM7J=B^9$E@I@</
MU/V!MN,OKA/WIP>^QH=_A'W4YMJZT.X;SUKJ6F\JA$X*7WSRZ^?6>:IK]6U_
M:K<8?9JHSMF1H^$ O13!_1/_'YMY>"\ P+V_=Y=BQU]U&/?OGKT^AVT.ULW%
M9FIE7:8\I03Y9ZU5,'2&.YZ,<\1C18B?RB1AX;C8+V%Q?())/<\$P%=NMB[H
MR<]5\QY.7#OK#"W?\_V#Z_Z<,^F_&?BO:%H1CS/O[% \KNY@&0DE$^1BEH!5
MW$A40Q7ED:($2JKM5:1Z3Y%XG&FE[NNO.=7KUGVM/V*3_K&=B[PW]M=J7[=!
M<M+ DX_C']J FVEE<;<!OIM:QN\_D S'53P5<U[EBNM.U&I+FJB-,[*\YH:)
M7A4C2]K[1FJP[CG5N05N]T;^F #$J9PLC(T_88Z<>[QW(VGOUAM6?7L(=II_
MC/HH=*YB W81NOB#-/*]_SWQHN7DI,:^YO/LR?Q0+G#WIM)#QLP*293=3A1#
M/]&P'^[,"PZX_QN-N,@GAV&L.+[YO3:I)V_[Y"+5R@O@;_RH=_/ [K5&1O),
M?M!\W/P"B&Q?HZF=9)1XH.P6R"S!OB$GV.>=WUURJG@E,B/].^C;C.>6KA=
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M3P=Z0>=23D11P;Q,[3$@QQ5Y]X!0HLZLUK8UH"U(B%[ <MR( *Y9"/8H.2B
M7\R@5.--HIH#=57[<D3GMMG"5.]TZOGO" &P<_L\;:L)KU*XR]=+_9!V='T
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M2-)9HGZJC?>2W>$\$_Q7)9Q6AS0PI\59U=V^NPPT^OMQBY= ?S'FJ)5<B?V
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MH"AA"ZFR;CI*MD2)Y)U612:%XMA1P U)W3JKG^O+;<%:T47,1&Z YRDO^*_
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MNKREQRX ]./*JA--7 ED7PFN:E-,==&E$FIUTQ5Z?S<G#VZ^/7[[N?B6H::
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M/-,1T8J0UA=<:)\<ZC,(L^W*AP@)9&JU\9*+UCPLH=_O$Z4G"5,#M$;+D%I
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M=<WY9@N/,-KHW<F#,G_ASZB8AP,NB(=3^L4FZDH/GJ/Z$4)7E"6'MV#$3"
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MVW8$#91E5!>$I=T$W,_=CM/>.GF"Z$;^4'^> =J^S;K?K^?C4OMS-T)8FO*
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M.#V@ZL,R*WH60TKSPBZQ;=GH*1/<A#LJ#:I]V)?.2@FF?2O?),1=9>,8BIB
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MIN_^BNQ-<BY#1[UQ<YWBQ$B//A"E*I65'I&DDQ*[[^A= TJ">T9:21EW"L/
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MA=O,)?.$T*'-I[[Z-IY_Y*K\=QY_[@NX,2M!URL3:)T>QCG,956<]>+.=.[
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M6:75?N^L-)O<+-$C6U&=4>Y5A:<J&S;\9JO)6Q'I&X__R"V_,6*HO_ =KK>
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ME?:Y4I4F3'.,9W3\AC.3,&MBX\EOQFK5)UN;)XLVA_I3XB/ @VNS,S%94NQ
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MQ\06>*_8[SB28V?[7V 1<%D5E7KAF.19?I_:=OUH,*9D64_SO^WBN#O/KW>
MCRQ034E1[H]J%%B(-Z7>V,\D35#0>MKJT0#=SP"XDLP^<0UYT(8D'AKV)7A9
MFK.<L[?=<*2>^P\YKZL =4RJ&A-%NA;E$L58?OR;O*%!-493Q-ZH?OVNX?^"
MB,BV"/&]+E::>N %BH,HDPO+T!T4'$:?[W(KG)S]F=6,$5OJ23-4X ^[7/<
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M!U>%V+.FQG% "$K0+R+K$I[VE?I#I:I?F $_+XY="I4N4=;:U5R O &?J[-
M:ZA[^61$<[9[J7 [U#M^5R1M!>1[+/9/W3)WS!HF<<)NJ5?&IZ9L1V0F8F0F
MKC>Y]B S4H#C4Q%'6XM:)SG[*C&@B$!NQU<_8.>U&NK$5VB2AU58G1-!-(&#
MPXWK'CC;)N\=F48HA*'[;HQ1P\;N/GV0"BD"RZW,1-!2=\USP3DTC9^3QLWB
ME=3,O);M)[@W&_,'5B 5G)]M-!990RTZ;4R89&]-/R!-M[4LKK]1 VD,0E1+
M$& G9AYST'W\DX4BOTGZA131"/M07R6[*_VN7"I^I?R*N7!TD1<K\T=;W'B3
M6[@JA_>#H5FS58FBR>;TSV6]=CMG5?-9*X  -DU?GV8R,.6&AK3[/F"EQ^]J
MC95,OR#])&C'^LN?8%SLIL5H1M(YUF3__9>7S%4OXTPB%^HO!4!:>=I"WV0V
MWI CY7@F#FBO_I@) 867L-:?U 1RS,S.3\*TUB'XU#QS^<DB?X;TV;6%@,L1
M8&'$T:X,I4Q&$!4-' '3\6Y>E>\$*;<BN02T^&)277OTUT_PQIFQ@6\=IK)B
M("?97N9VFMB8%CAK<\=2RK)57;T]Y$$![>.#;360FA$$K)]!&B[3\H;EH$,*
M4V5.HN%B LB=6>=R&[Z3O =JD [(&1&KI2_87SLDX"0_2#7B:P-<'E6^'RIL
MK8?V+F6/:G9QVSQ-Z9-5#6 A_4@,ZR97AD1#'C:F.04C$=!+TU88]YT@U59S
M-;!(#:1N!%&&MYBMS?$Z7L)U-$F'"W#[,LUZ9*^&%T]II>_TBL1W=JOFLE9X
M@5C!4,A;$/MV*!(]_TY)>:KVKLNX+NK#!"29P9ASG%I15Z!'30"E*>>1YF'P
MK^<-]_\!1Q3-6S3C?"@PH^,_8$;R\YX<HLYQR<]=Y"072;^G$73 ;/@;.M%Q
M%]?_YT)_(_CO%R(@U'M*.#*P[05O)0,RCE\C1M#_^56QH%G?3#%69R]V8 9X
MQ)+0C3]/TGQ%!@BGG5''$'=K(T+S#P@UO+.$PI.?N)C^[?0E=IUT*IX,B'H5
MP2?D>\B IFD7Q[^;[OP:(49S3$>A.T[PKF2B/!DHN15S(IG6$#\.7^)P)VWZ
M3U+(]Q"%5MW 4S"<C0_HV%PE0+28#'1>63R9 D@O*(:\Y$@)%($\D/D#$G^7
M")58G12CEE8"K\ G.BAJ9J34(?X&9K-1KT$[VG448O48*GTB>G>C0JAR2(N!
M5OQW]?P_WP'C=^-7'&F.RD[RF=RFX)@C46%\AYDBQ61.%O04C("=X4>*\Y'S
M!PI0T+&EG&_ 7P <;B1 (U(GDG7N96 O%RE(W-^+#%PJIF!EFQWX"OVG!= 1
MNV?)\4'DGZC_V_SPSH(\^'@=\I@JG?77U)\V_8-_AQZ4S($L %(NFI!S\IOT
MK!J.0.[HU%$@U.-7\R=G]V<T#@T)O<1>2L'YP4NQL Y2XR'J^.(*S5'\G^CX
M1?V4EL"AMPF,TY3:&"U4FJ& _Q@! 4J51Z-(T13!Z;)(/"X&5SC/BV_H:!0X
M.U:GG7\C.S73K#_76E:WOO5^^Y"B\99W7N.VA<5?&'D\F32*W'$%L8,WC$=1
M>Q'.P-$H:J$$1=7"9P.=V$R]B,+GNQ%5" O:1!)T'B_F1KJ"8CD12V>=,<2_
M.FR,.2*.H[#WYXG&SGA+TJE:K'9;P^6A\EL2]<_GUGQ>3%J&#24_ZA)Z:Y4Z
M<Z:TJZ39>9-$Z0]=+GA*V]FR4!AUE@S%=TV>:7CN/+G^8%3_QB>=A@37H+-[
M<DMP;K!C@!#:H" ;!M$?VO9WPX',HC.'ZD!?$PB/5ECFE9QXF5Q<>0N'WJN:
MM&,*&5[A&-H&\ R--L(XE59I#_K(;*NU!QJ@N=@GX9E75#JM3&-)G1 6KMMX
M'Q<<C76<RD,,**8(/>XU"TF4M%?#6=XQ%*<5ZXY(I6=:^CQ4S<V$%<6$M8/W
M^B,A9Z_6W<KNIH+0$U5^Q'4S-I&8MJM3O%=3TRQ.T,&,)?IX)X*J_TV\_&G8
MC28+U=<OIR/G+:?I:^/=>]RJ_3LG#VTM(6<;KN!OH0T07H878$GWL+,Q3A42
M"9%P]1#:7S%"0:P61[N6)_62^Q\\\4^PTVW@LV8<DWG6EU9J+!%D8)4+K-BX
M]^[-Q)A'P:F[NT[2U_DR.+S[\SLT>L76QQK$1@+E @=($K$C-G@&]&8DL?NY
MU%6OVA4_8E:FXQ/;X?2.G6+OW3OXA)("^1^XX?;A>V3 WS%V<M4=9'7I=BM\
MWGAQI._:H]G/VZMY_9+&8ONJ1T2%[/)W&9)- 5TE_;=B@DTL"D/U(6T-M\;L
MVV_.PHIQ8)U9NH=ND[5-+WL:[,:WIDEI=;JY>L@^9XR_QEM+T3_! F%3 6S'
MU^(D L:8]Q1SEE4*=J-(O8&,YC<U.>N=X:O3K3X4@R2>/P.F\=Q4LD/>Q9DB
MRB-#^/1<,+7C)\+>H"P%' O;%G*68B!4:PW+P!K]Q7 EJP6OWPWT90,D84=>
MR!W\ZN*[R_<VK9V>[RMHIXMA\\"1IMHY_L].OM2)V9J,U-'@6'H5/7(G9E:2
MAG"'QE^=OH >H"PV*?0F>R/'[:$9)D\O;Z^JM3\(R=)PO96K?>[48)WVI:!S
MOW=&]7\^]GC[\>F=%=7U4SN$F"#(.=+9_#E_$#[,)V\5ZXF%Q.2\6A<_"]I_
M,?>XGX'OJEYNXP6:E)8AN-L%V6MYN!OHF C_4^HN4XF?"XJ=(J@6#\?(0!TW
MWRYCAP=$W5\5_VUA/E))?:2.%^-RHS71-C3>\(?Y*8&/]GQY!X*F)0:%5PJ:
MLNL0'[NOXZW[;BUL;W)D^^N-N]6)%CD>SM'@X[-O7Y5C981JWEMG4]C=_'VO
MPXM^2WFBJX,W>,EAG(G6;SR<-()B"FN5#MN%O;GC.42ZB-<4'O._42P^*5(Q
M<M>LM7>.^\.%)8V$*TN+@K8-^(>+'_"?L#W-@5((4!FSAU[5R)D+Z#/?"CA
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M<\L![7#]5V&-GC=%=FR_V1:3K6_YVX@[BDA&,18,5027NC#/EF*YYTC+JLS
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M]E9PR4Q6/ *H7^B1=(5@MH0B5D^>0W*N;[7P#:!'/QG'Q=!Y<*M5.U'NES<
MX V &N2&6^V_(.D&DVD[]K14R1CF53W0$-12WY9*?'!G=)OU:;BNM3E\%<V&
MN7R-$5B-/Q5Z$&*_TYB>8Y:,OJ\!.[3^R6;EZJ?,E^)X"!X!Z.->8I[JAMT
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MI!FHS:(##WJ\?'!R3%'L]'[-*JPPAO#<Z97'IA'@P%**<89/8[]70P7@F<>
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MUN'X,+-Q+?V'V,,Z&I(5A]1D09?&,(R;>ILNEK"GI62G;@[ZAMMPR.=;O=F
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M3@Q[5M[E<G%2YA;)16P^&7 #\YM8-6_MEK]D/_%*?S#+V:-DZ:/<KQE['OA
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MNR*>K5&/]-]*.MHE2*/B\YO-GZU=5>RP&J(5BQJB'7U)\)"%!NG'.P<YJZT
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M'@4.I#4IS%;N);FA[I5ZBGS,XE[JET%$F$(@6Q#.*!2D$7T?>4%"(M/>&K;
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M+<$G\P+PR]$[@J,DR'-$; ?>7O2WG^'P+?G]<RT@.8XPT;VRQ4%/)7*"T%/
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MQ'L#G"<,;!\T+WTSHFW*QP2YF/A_4$L#!!0    ( $"$>5R:DZI7-#D   Y
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M7-M?;(:R!HB@+C2"J^5+*=;1):[6XL0++@?<KS>R"*U26M<Y5-+P\K:GS[X
M()=5>_PYJ#OC. <;L\+K51*?67RHK.^S ^_C(0++32I-374IND-NN34<;Z7-
M3G^Z>^G*FZ>3QS0\K,6*2:($2$LO>.%WJT0CM*0FK]3U=\IT.5[20NEXF?"W
M+5?7MR\<%&G>,=A_*]ZZ'9(X1$Y5N4;"@2'0UGGJ8:E'26MQRF5R?\!J28X/
M)AW"]^PR]&8IP.FC'[V[][QZU;(@_<2!I/^ SN.+#S]\O3T;>E: )!--/L%_
MJ*/AU(G7[3I+1WVD&TJ60]3_AA'790[#]^';QN[D?-AO7;0.4OO5K((+^'6N
M4"\[*K0^P?M3TJA&FK_A+=-?WEHO*4!X*+D/NV-V$4VPL*7Z2OPO&LE%%\D#
MUR-CW.8!30$%"-0G87A7N=%O,Z]2X[:% C@A#B1X8:#41^HYX4+_NX9[NYJ+
M @Q-"U. + $T2(_^JO41OO]VQX2D(;,72@&RXY]1=^(/Z_7_HD%<,M4_2&V=
MV:$SH0  9I]QY (%4-"*_)\9357>0OJ1 YTIP"P'=8<.VA$+COTP @$[SDN.
MTNTE,TNAP78_S)KQH1W)#BPZO(D4:YF^0*PZ: HJ%.Q_YK"G'!^I?'?2(%/^
M:HGL4D&PNB_\2_5.,HDSF6RB@\,>CF/(J8^+YY&UH14:Y[5CRG48;RC$J%4-
MF3E/>*YYVJP.O[Y;(%9_&,6@Z7M+_]K3G?+97/_+5::Z-QFX3"__;X656GFU
M$YD[A)F)C"3N3ISU:US/>4DH^U(QFC'B\4"'JN46;F=,6,R9=^%-1%09(OXE
MF^2.5P-\L;P=+3P%%I!/?"; KV:V6N;'N..6E 1=_:\=B"0=9'?92(59/;W,
M\M[PBK9&41:D[^,_!=P&;&X:\=MDJWPA:>;H.GHCBIQ4]A=5&D'G:$YH&?)#
M/_JM&_3-@7@VMC1^-I3+]/H_ZKRF!*I'GU* KB64*@7P,Z4 @V[#J F$(;I9
M#3V_HW4*_;F0 BS7K#2)QF#G4SLIP&@16?^&(-B_"_,(IVY=?NRK7\N(11:3
M<IXH\??_VT+WSV*W? "KV22)C4DEG\ 2[B)?*U83\,U%Z!;5D4N->[6']-/.
M=5T=FRK><B35\KZD940&EGL'QK.<2;A#M7TTA0)$O!O>$025)!2%M"[9QU3]
MY&FQ3U!^D/75\G)O@B$P-QX(N])YS5)[(.G/)"1:1P$PS]%3L&_8%"OTKAP%
M:) \L/ROE,^:(;]?^N3"U(0OVE<%V"YE1Y%K](.IN"C[CZ1V8$1FHN*1V#O"
MW-&Z/@4PKKVS[>9_C@+0_Z( B7V@!WDOAP+D3[P'8ZE(GN .I0#6!?M"JNYS
M^D-''4(2W0,IZK>2\]!I<EJ-EN+9A?]5(?[?RV7M93W<ZN7C1Y+;H_C:P%T(
M,P5HAI.95^$!XL-*GTS8=8KNC3LGE_6XYTGYHCY6F<]^I+%X]0?8]^V6]^4O
M'[ENA^,AP8U"N%Y0,K-E"M$ZWK(B?'J4X:@S0JI][9:@Q.#U!-6XCAQ/BPA)
MFZT;:['B=#LHS[Q<(8D_>0WM)0SX._EHD%2\GT=%U%O0PVQL7O%?=04:[!0
MV>FKLQV/7[#27]"*$B]?M4.>T>6Z]8]H*,_%SJ9AMWRA;+#I(?3.A!=">70
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M]3(T)^3_QN _83O8+K=*FHW<7?R.KIHAQ5K"CYYG'K&,QHM-<J]B_UU#2N^
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ML:&QI;6MO:/S2U?WP.#0\ AY=(PRR9SZ,3WS<W9NGK.RNK;.W>!M_OI;KFV
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M]_))9.RF.EQ6YTLO$K'P  Z#ZCM8.MAT9#O&&]'L?7"#_OB!=0?':]F7FL6
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MS<QR/.513YI:"7HJAXX336K&,8^:DAI2&2JBTN \T:BIF:=!.>I12C-S0',
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MDG.5ZL$W,L#\J:M(<-;$[# W$UV2J',M[UQEXS0"D22HR@MDBGZ#XD.NFU=
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M:)\<AT^E[L)(]ZYY<25U$353<Q->OPZX3]6-:_XF/4\;+!O$ T,&&NX$ ?'
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MQ]WKK<*H*C^W/+X"%A@X'KH\;FPBO^T_;E1%JK&0OY^N;*@A+?+X_E1+>49
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M/.><_^O\7Z]GN%^O8>ZYYOI<U^?]_KS?UW4-XSMC MA[0<] #V#: 0!,\ _
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M\+&ZL:FYI;7M<WM';U__P.#0]^&12?S4],^9V;GY!=+JVOHO\@9E<VL[+B:
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MU<V?F<^OW5%/RLHRL"/OJ;GQZ:7%Z5A!B,.**D/Q,"CO78\3&YE_X/CZADB
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M5^D,@#!$Y7.MO#=BMZ@M5EN1+*!Q\ /1=BHG?S/CRKNR!N:OJ<Q5SQG N 9
MN .ZBVS6'K''<RE^<O%TAO;7D?BGK<,+I9Y]*Q=$W=RK%^MJM=$9E]9\>U_F
MX^*(48B+IH^*0>_6.H4GY=4G;N5B,Z0>/;4MG-YM.B65O#_9T7[M:):&N0;S
M3 (#8&6G/WW\LEQ,II<U?W[68"_8* 466QVX->HQK#3]8G?;AM^\M;4BC:^,
M;$H<3W+)G1<[5=&[WGF^68U\U4ZXWSZ<3Y2?Q_WTI5- "Q#D@4H?1\+\'QEH
M_TU;G-*MVR='VY-^)P[/97BA@FH7YR_7*NO6?EW/UV::-;IUUZ$K-U\PV3$
M!L"M3W^.G7O# 'XR7V$ TZZ;&\T(/N1$EK8,:4]AD:OVP?HDLP$/IWY%R7 4
MW^E2$Y58N2*).%>%V?NW90"G$-D801,>LUWV>9VR*VYS_M\7+//+^^\F\TD%
MC9@8>0]"^OUB1^G96E9YP9\A-DK:&\NY%7PA>*$7,U.1I>;FZ!;CG>7)IWVO
M\_# ^#GGE</?SENIQ7L&RP:/"-IQEH=/Z1%_A6>_J9E+P>1_"1+'3UT6F5@M
M3)=TL><)M3Y+^B"]0VV$,BU!KP4=#A'7+A*EVJ*]Z88-6^Z9=8\KX_+]W,SJ
M'MH_-+>_NL]&C9XMN'M8 YC5ZA_!$C:H0GYAEI4#%28\SNDI!6X>Y!.*131$
MD!SIS(O-\P1GJ\M:!'8A@FW>*U]K',&AX-H9!_:(6HW<V*LSJQUC$@,^:N<1
M7P>65:9$3IZ[Z$0_\.$N)I3RG1I\1^<2/ DA]=$I5:EVN].7>PG7XT>_EZ\9
MN#Z\8HM0EKEIY2GQ-C;-/C8U)<'@TMT\>@5H7Y#]/@JC)7]L,'>?:Z@)LVW5
MZ#37!ZW-4OHBFP9KJ=<76W"TC2R7H++N[G7:L>]UJ(V4-E>=^/"$4;P*. <>
MBMW3+QN;\_#A:=&-.*0SM]@<6NR7QRYG:_>LO!R7A&$#U0_$7[3>G6_"7:2R
MC'2E! ;QQWD3^**J+\:_/B \I8(=$9P:S(&ER.176*3L)*?XX(3M9*K*XIJ*
M'>6Q9=/5+A(ZF$?Q N9,N>GL@)J]W.E"5CC$9U#[HB_HK>7OK%"QLU>VO2V\
M0G1#YN4C*Y&ECW>9CP&S(G&%.MPT/@^R?F6,_E.$L M)/X>K^H;TXPI 3C_%
MH1FP#E[9N)G7&?<LH3?DU.5))('3:ZK[B9TRQ>OMG)MCP&2!,YIJ?20N]2VR
MHXP0PWKC^S+V8/H-YB)\7I@ON9125A2XA\*)1PA1[HAJ3UF7?.B;J#(R$TS!
MT<6WQL=B7AF(')#K.KU'@[F*?ZH2231%#PM>)+'E% U3NDW*AU2E8A5]3FC)
MOY7ZTONR<9>C0,8+F0DV:=$"=3R*L$E%T%!$<P;PJ-9F:K!_G7/F\;+\Y0N#
M[FGI1\R</R?*\/2_3\@)?'_RP<TK[>H"KWZI91_U+-AE'HM/KU[&Y&_F=-3"
M0\3*16DJHND2;\6^&Z:(KH\Y- O?2O:65PGX_(;GVK@N<ZDFZL15SD,'D^WC
ME;F")*9P(^QMZ8BV.HO&DP(93N_F1F[?-S.ZHZ4)'H]\$PK/G:VN)%7U0UR'
MF42"ND%B_IF#0U^T$90<!L"R2L1&>F=Z&)-8UQ^D) >P93M)]E)>>3_UNVEU
MP^M 1D)EM:S]0_8#878S6*(9>OC4G97EB#AYUL%L85W_$\3!G/J??'MC)()2
M%8!;P($ISU]%%^64^"8&Q0._4D=&$#K-^VMSA*)C+Z;NGC,S-6AI;_]H.S96
M22ZM2JB8P(XL-EO'$V.SZB;<-(-TK&O[RF<_%@\,$VB+-6XVKX\6[OEY6*@(
MY2#&56*[=.#$"N@$YQLD6#$4*X]KZGYI,#EV<5@_(^=N53QO@_35U6_7GT^S
MWUKOB!<M]IP0CB/T4 ^.+XX+]1?6BQ<EIG-]JXUN,R:V3!^[UE'YQ7U7!IWE
M(\^YI;?\S_8H[S1GMC& \S(TN$V8[9WGN_DLZ9YUPH69&</A%7DMB2"^WA_G
MLV\F9[HS.5T';DE+ KN*^F:X&$ ,MKPJ3IN#=IXD54%[@(@*U+Q1J6PUGQ[\
M&!1=C,%6%ELIB*?/BIE9E@G87*XM9KUQZ9H9$4N(PH_2K5?Q4XWI*EO\Y#<S
M+<NJK:6)K8VGA'%F\9WUH_9)-U^&?"VHZT@U/SVKW@R7=I/O4RTQ#ZIGH]:#
M'#W,]B^'9T^*S#<O[A.,0@5E_^!)2SOSM==@_^&<5#*5_B1O4*'"14OWE4'^
MF'2J9^ X=_WQKGK3"#?LL/JQU;2<!J1W\ISG:9$'W(2F(K_T3L,D8XJGZX:Z
M8(R#E^C7.OEJ70E<[C-M.^K!Y?>KK=/5^H_&]?!\VKK=-#YSAT?^*&X%QX_N
MLH0+A4'*GSQ8Q&]54?6'=]O9-1ZCUG;]>FBQV\4%4:6_9#2YZ$=8KT,U5=_F
MJ;WW^FHP9VV4^91WHAK3[4^L=B>^BW5%ZQ\TPVQ74]E46X>FAB]HLJ?]1$U7
MANV,B02DQ0 &5J0J@WXD>J8#9.PC;+G12K/B$S$E2E"!G[4\!ZPZB_6E1]U]
M!&JK:L!XX[>M.\,E_/GN&EX/7>0Y9%)IT38(PS9N>-]%TIY<S#"ET[A\R$?E
MJ2;!C)O3=9>7=\D3O=(.>?43II]V&VM>Q=).(<@W&,"K# ;PC.LR TAXR[R0
M+_OS=QMFT9NUCV2<.H7FF!N7[%&H'WVU*'!I04!=VT9_]LS171)!1<P*Y@^;
M #U_X!M;!9_I:5;X0NP[0^6GK'C/+*\T5G6-2WX<R/F04'E-PDC\0W_Z^:7X
M3A^!_?H':CH\/-837\NL2])?:($.4XI1U4/A6O9O_/9=)0F-.>(S;)3R[<Y;
M$PXS@ L5F0):.AQUY=?/4ZPX U^SBK)E4V_Z'1Z$R.-#QD,^Y]]76'EWQM08
M.C_:=<"T<6V<+?'*F#L"+9QRK8SW@H2,O"TKAJ T48)7Y'<9:>FD6)@029X*
M6/RN0H+*8F9286W]E4*%TP9CXMHWWE@-W9DX\Y*;B1Y5JXD'.8('D15JR5.*
M@F"C+]X0I.C6#^&YESZ7KU3<*<Y,HHN)FZKEB-_U'_ZP:A14@$) [9#<-YH7
MU2EX8 L7_BL3V2PL/T03!YWZO6M>?ZS*N).IK-:^-_FV<ND+,8Z$?HOO?("I
M[O^QB^DGJB*.EM[6:D+=IXJF'TJ/&]:$C!PF</2H='4HODF?X,  #I>0DJ#F
M+TX,X/RM'+(Q TBRI,#S?>-6+ -X?>P;>W[/WQJ;SB&;4/19J>-6?B)&/7F)
MFZI"(*RJ'Q@=S0^1/"\D</YKB_P^9I'B'QTVZ<,9$^Q-HV,ZS:F^$'_I0%MD
M)0-P&5YH6;D],WHP-<8E+3M.^:'$;=T?$YJ.X6ZS(KA19$N/W9C-*/;1+0%(
M,L.(][7@[E294/GT>[<<1X,)$@^QNUFD8C]<O6Q;'=R#YE&@.9$T]8BS8>MQ
MH@M98AZ45#_K#HI+:LGCFO/(WF6G^[$72U12E2""<D*RR(;LWCTHL@DQ*V+"
M8U23C.G14L]Q@1 ][N#D/JIV9NY(;D6M9OE\9J5>R-&?:<\G[EEFO:G_A(G&
MWO#@\4.W@!5Q!*-\2F<CDACJES@%\7A44$"JL;S^4LUM:5CVG8]D"?K\EK9'
MG: 5AG+]QJ3+=^E_[>+?C((KWNNJZ"E3BD)I:^+;F&LG?%B<3OH6!J0=-M=:
M4<Y)O9P8\W8I8UC(/#V77?T;7?,5-@VS5*.XN1X&T14IIO141P:@'0_B<AD
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M+A#.+QMB]Q,5[ Y72%*CE&2>&S^@*/EEY"+K0/E<2<+NH^2>.*5/5E;A72R
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M+-#4[E]V=@1<2\V!&_4#F&30*6Y3NWMD%OJ)H*NVH\S_"XW_A<;_>VC\C*K
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M8=>N>ET0A U16X26?F8BL.P3]L=Z_],10(8&<9I_3A(?L8K8;L\UF]Y!4;7
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M#A./1NAH_2\3QL%._&'"P* AN_3<G'OO;IP:ET]O#]AEUA/=;.=^-G.3'@"
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MFI/ "R,"=C8O-;OQ$,V$KA>?Q2@)!F+N^.&6@O".O?+88%VR0AP'"A*A<CE
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M?FH>.JCH!0$(:ZH:1P(72V:<.08!K183I HU-N%%$@1<ZT)R]&RM1#"Y-R%
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M^Q>3,^*39QAAZ1#V"XINP8;I/GL;T8ZHS!"$@&VI\SP0X(AI1*[MTUN9X03
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MT//JQ5??@D'38%:\!B70;L=BH?2!M/[')A)*][<([3S$U9FJY&CR ?4$17T
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M;MR'2=91".BWHO&#<0GO;M5$CZJQ$S"E"$XR3@SWX\-L7\'*4 &G.363<3(
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MX<>Z:*='#[C&2JI$NES=)JK%L=\I]":F 578&Z/:N1Q.SXBGHVN$1&>#<C_
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M2$7=(EV=BTZEQ.@\09-7U8C+^'X=V=/3:J^I0YGGG\_%O[?YH)75//Y&U@(
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MV>]ALXN7=YY;:6]" Z>HK4*@R&VC<[=/>3]4>I<_&PO,$R'G.?C8QU@;Q]:
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M*AW)E9ZYK:?[;[]3XV7W_1M02P,$%     @ 0(1Y7-)YHK?%I   <ZH  !<
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M8_CLBGTNPJW()(ED@,BVR9UJR!G_7<=2("65_9C)F3>X-X^@JBSKE-LQ.W7
M7*W;.=.%>?P]C>E@U=IDU;J=$M5*6PARBP_UF%4SZ^ 73"%5CC56U^C!;Z:)
M2%A;-5^[@($3.:)0Y>JRU]G;H6867GG>VD,<_!WOTX>0[,H5Q"9H[+*7%$1;
M]%0.AGSI'-6@2'?JT,)$[U#%65$)%]3^6UCP4T,7X<R6TN#=CSL\.EO0A?0J
MO%ED[^U4.6E(/Q;A#"JXZRTT,&&;!NM$G&[Y8G>>+T"<@7]RX4MBS/R7GVG
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M>&WC28 2.:R:@D/1V#7*I7V:#M)?5A[[>\O1+62)HSBXQ N@SWCX!1"G]@+
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M[[BWZK_OXJ'AC19E'-U1<,9BL>*\DL:;Q!7%R9V%  6.O=H%K_7=*=N5IA?
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MO_A-3#8_YS!_9;M=;(PMK3K\0IZ&I 8-%IUH^8V"9(%>!M:C,<7D$B=)VI
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M7&7A"F]*ONDDZ@JZ/B.7,%&QEXY\K6QKQ8<B4PLEO%?LF:V9VQR?&-1V]DO
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MS^LQYD$CL\^NK%3QE]B!,T-:6*!-YGG!Q>^K7D#7NIL'0HFR%K,?!NYHR4P
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M 6]4# _9>6W0QJCV#(G"H/B61?%7E<OYC@&-'?EL\X;QK]B*ZH7^/<+^3TM
M4JMRW<F2<JF90QW+QZQ30K66X7N$M/U$$:EQ%B"O_IG2LY/9E7X_RJ&1$:L$
M84(0V7<@XZ!(O2F#>N,^; W@.X23*'WWIF4K"U>P'8:V_4^;6P;#K<)D\+LH
M/+/$':.YI.>(1ICX-QLWI3H9Q@65'+P(,##>)L*]9FU__K!]N[VKJRE]9ZA5
MO[?[/8//,USWEJC38OIX?'Q+HS%\?AZS!LRU:UP8CHY%[53\_^P!$[<IKQ->
MD1;H*[H/0;0.X)^B]@O,YMQ\4EJ#JSEDZ:%,6'MGS*U_$A5<R2]G,/("-?P/
M_S_YP_]=Z2]9=[7-G^\LU-HT]/I;@,\=(B?35.1@9^3VF\_Z.-H<R4=/+'$1
M6C=*+2BRW6"!P0ZZN)*<XT-5Z,B0NE2!-$,G,,>^Q_=*QH=]]#)9X3Z1B-%)
MZ)HYH'6()Q$!$4#V#LC@J9:/!/$D^<0)?LJH'>1R)MQ432P4+A#XI#]LE(TA
M]0QP^"CQ.-GA=D92"ZS8.7MOCE+66KAX$R.K;AFR)1X "IR_Z'-*;<WLE#:T
M6>MX]JL 5U*HRE_D!^7+B%I0+R+=N0.<YYM^\G+M],Q7&TPH&+2%(TOQ)UE3
MB^+'$>BP8,UJ=V/EAU5,QXN;C HMZVJKDQ8GP^4IUSUA A7F1>IA@^\)+E!2
M=_YV]-<! #J%_U^XA+=Z035(2REBBE?LFA0,//CIC$L&8Z!:X)OXSG]AJ?"!
M=_1<?"4&0O205M/S K7U'LD=LP-DZ6B?MZM'ZLXXSL2ZPARRW?*[9C;4&B2+
M4Y\ C.BC,%Q ,-;_LN$DXZI<717$/>^K(YDZ_5Q$M[=_CY2R?EVNSOQV8GJ0
M"^_F!RL;+G)Y=TO3]( W3B=P=/;#DZ8'GT%E*:14B#NX:O:3,\ O"X,?RH,H
M;<QZF10/6FN'X"'A79TWD2B_G90$PQRZJ&N3ZS,1I0"[[B6>WR#A[I90+OD!
ME^4C#_24]A+^EWC/<SWR]E[I@$M@W_<^V<W[7?W# :E7%R/25-^1%EG1W!"Y
MTC54Y@UI6_-<:7>2&VN<5_L\X=JJTO(8X&/$D<G-$X"T"]=O%PBAPDB\EQ))
MV&%2A:-^JU ^\'9.@P?^1&!?!6_F7==]N><HA"ATH KA=Q9&<FU+/()F5<\J
MCU.8H3]E,G"^Y[;J\,!(#1.S&8SO!U_ZF>BH&%D$T3WS?PB1G' '2^K01:</
MX5<SFO?$P[ B80&*BV\?YZ[&'  BHU10X27"8 &3VQZ&^::U7YRUOR4DS,:0
M^V93[G%,V1^*G=/3,^EQ_$3KOH0ZS;RX5U_Q.3.TPC#S+S/[4T.OP:HS+RG?
M$@C^!.H\TUZ'48V^7U KC72M:B--(5K[=/62=6 KRHJPI!,1=1%;_5ML3:M#
M_M HD\$#_&I3F5Y>LS3D,JSRE**6R0:/E_<%(-C6P&Z)<Z>'5,OON27Y/=QU
MGBUUI(W[H7UZ8Q#G>NQYCRPJMQ!BC;A-#&$!-3A+TT<,7)J9YU+52._:-[[K
M>]&E(W \29^A^?)Z89<YPC4M@G#-KQ<;$ESGI#WD5>+?[<W& [YPN>:X((X3
M$M654H-90-<3E@E5Z[EI5//## W6,5\!I&N+>B20+%%(1MGF-K#:R@BMQ4&%
M(^C;"'"GF1#DU0UG;AJX*;QARZ$9^][<NBD79C19X;WU#.+1A$J"KZWEUA&Q
MQ-'D.?4Z="0CSQC66,#G[SL&W<<\PK].@[F33PG>C@#HK.8L,>ZD_1UW?!,0
MAX.&E)TS1: 47ZKW74B3 CV(B\4%I\P:68RKW#/=<SZH5N;G/W\O(D)QA9X
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M:?'SK!0-7AFGN!E+?F(PGN\,W2Q+'864PA]NH/X0KF?SM&:%A5G.],0C_P+
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MO30QZP.U[?]M<31^+3KH7K'@DLO0-KTQZ_9[$2-WX=AQ_-*T+WQ%+8YF&N7
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MDEUH-$O-NGVK(&8A?;D[>DIA-O=!;CROLYD_CJ9X)LL*"G@)VVJ+E1ME;_C
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MK84F\P#C(<()-<+%Y-8KCA0BD_,SMN$[^PWK6:/WQL'N4%02ULRR/YBU/Z3
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MS<5+5RY=NL)$2TW+]%]?Q$X /249+YD[.=EUP 5Z,G)Z,F(O@)<TSTMD?[D
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M9@ASL2?K?T1VL!S544\7A0,A[2SZ5/IC/^%4T"4YOI+OFW_$>?D-VV@WQ@3
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MPFW*5FF)WI>A-I^V EY(Y?B7N;,^M_QNW3NY8&?[12"&;<HI9^XMU<<+>FH
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MD(D7L%Y=%[#@P!Z$^4OI'TH6COHU"?.[<CPU>M7:)YI+R@IKR_7KAS.Y3-A
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M:'<-6/./SZ'27]OTHT-.USDMAEU[=5Z46$T][Q4]GVD/QCY!ZW>%7<!7A=T
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M!\I>+2K/_;F7Q?7D<]N.=$:=F59?5HK)9>;DP%A'6#?R3(,'=G*>H,][\NB
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MRV_-O^VB_Q>/MCO@M%SDLU1TN)HO)8/;.%+8_O>G'QT?>/[_N^4'ED(0Z*8
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M*M!N"K(AX^,0%F%EGK;XK:TY7*5>^&D/HP';)7<+ZS1YQJL_MN?7@\SH59>
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M&B#*,_U3T6]ND_.*?\&Q'-'4 I_W9GDV=]!ACZ3=F2W,FEA)*$"][;SPK=M
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M-:LMK3B?:S4%@RS%$Q677R?PW,%._;Y]'_<Y$I<PX *6"01#;G&*T)UI]6?
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MWP4,[I6JX#72QEG.^$Y]-P/H.LEJ5#N@'U!BJA(D;1@D@D1&3VK'#GJ*I_V
M);$$.0EOL5+AO@SJS2"LQ^KH22U'E2L>TH$]A%^3,H\>[@EW)\)]O)=64 T_
MX\XTYO*I.$L24X/P>S\!VI6TUX&N6Y:[WU,GPR1_,G#R2>1*HMN--K@TK1,O
M!S6=-0/BA<HKCD2P<"+3'_"CP+-56E (OHDKYEU9H>)-^CN.'(<,HYF5^ =2
MN;I)U()<%6'X*'<],U_%ND6J9#4?\+2B9]=X0+KJ@,%/<-6"\@R,D-<%\%+%
MVL.UT54%+ ,#!ML4V[R,NG BH81_# F=I8#?5%62UK(Z4J.LGKEW<?YE78F?
MRC)MK[DG_:(LU"E1OP-W]G5^_HY]._I:@ *!Z@X'6H.K?QT"\^@6 ECCM>B"
M Z3X@2UH%'H'56L%,P4;;X9V(1.$J89'HX>/Z$'A%N$EF(;IM5P.;GNM]=:Y
MS"<4=['?:V_/]GO^EH<YE.#H>/SP>!/X.@^0ZT0F7V:FK(MTZ!W^O'[1AK>_
M</1ZC$!D3+_KZ,)]%$5QN$_B((YND,9"SN!,($A<3F%N)S*#G;".R)X^'1T_
M#& D?W:T$O;1!Y/TP21],,G_K]7O@TGZ8))O$DRR0KJQ-; K]?;A)5_/XOA(
MU@V["<E[0WX"4U[I5+6, @(;P$I"\!;W5*2@6#AK'\PD,@/8/86V%9@,8)!?
MK;H:P5)!>S_VM'9- OJ#[9\UMHHWSHP;>-PXFRL>@CG0A_QVY!1&YZITYN4$
MK P8./DXL1U0Y69S?B/#.<($<0!1WSL[S%XYH"<RBMK (=IR!QH&B"W*')1(
MFCI.PL<H*[3V%JJPBMPC"V4R7+ZD)A##&6AEC-W'2[$PNB37,*T+.C9B&Q"[
MQZDO504+J?-);1"1WWE^:RST.T4=6;H@,J2GRSOPG7#[*,__8+Z4)_OX4F(3
MO.T0;+%83";!!V)O831T"B#!L:F^!Q?B-VL=.ITQR9T'YCT$Y[(&OCY 6F9/
M S12(&/X$<=^$!S_*VTEB^S#-=-!AX/XV,RG\&*0@7NRFX'_JG( +$K<8]15
M^84QU02&G2T;1#8$FTAAU4(:V7&/(Y"+O>;"PE=V*A-R=+9]J6U_/SM&H3OO
MBH7^*9(&NTDRJ:%#.9.ZL.V5Q.'1B0(3 2%B/<(+PX#C!J-[=N7ZC]S?*@2
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M@!'BNI5:Q:G4W'+YU1F0:N7WB,0CA]5:O5IS:@WBN-[1D><>D_>79/^FUSK
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M(.28ZY$7\1"XA0;_^NFDYAR>3K-QSS""F%'IH?!.YVUD$?B7,PS-/NLR &T
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M9WK;DPF@7N^'5A#DAB+]8GY0^>\IB! HYP9EPAQ^K)N*J"X1E?E_0&1$$YE
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MPOM,DHM1PK3><GM<=HXR&<N65MG>422 =2@EDF_R_0OQMS7EF^<%O^6'@R\
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M[7;6\38RN[@3FHNC5=P[?P%02P,$%     @ 0(1Y7%/V+QXH!   :A$  !<
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MUU64F(\'GBKS%+.K(1\KT51,CM]V#_JS3<NWA:XVXK\&H^>^1>._4$L#!!0
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MC*=UFO+9&ARAZ"C:_(C+IB$J*8:CS,0L\=0$RPJ,S'5K FHBM\.S&I.$+T#
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MOZ]RZT1E!_ ;*@>KT@%E<8?'[_'1H\LQ2<,!?,T'<*.F3]]I:\L@NAI!I44
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M2P$"% ,4    " ! A'E<DJC?7E0-  !6M@  %               @ %3&
M<&UN+3(P,C4Q,C,Q7V-A;"YX;6Q02P$"% ,4    " ! A'E<NAM2\7)"  #5
MC 0 %               @ '9)0  <&UN+3(P,C4Q,C,Q7V1E9BYX;6Q02P$"
M% ,4    " ! A'E<*>?,8VF&  #%H @ %               @ %]:   <&UN
M+3(P,C4Q,C,Q7VQA8BYX;6Q02P$"% ,4    " ! A'E<3#&&'WY>  !2U 8
M%               @ $8[P  <&UN+3(P,C4Q,C,Q7W!R92YX;6Q02P$"% ,4
M    " ! A'E<?JY4B'A_! "TEB8 %               @ '(30$ <&UN+3(P
M,C4Q,C,Q>#$P:RYH=&U02P$"% ,4    " ! A'E< PI12G.[  #U#@$ %P
M            @ %RS04 <&UN+3(P,C4Q,C,Q>#$P:S P,2YJ<&=02P$"% ,4
M    " ! A'E<3419=<EV  !S=P  %P              @ $:B08 <&UN+3(P
M,C4Q,C,Q>#$P:S P,RYJ<&=02P$"% ,4    " ! A'E<$=A^R"!,   P50
M%P              @ $8  < <&UN+3(P,C4Q,C,Q>#$P:S P-"YJ<&=02P$"
M% ,4    " ! A'E<4+CM.3!7  !#70  %P              @ %M3 < <&UN
M+3(P,C4Q,C,Q>#$P:S P-2YJ<&=02P$"% ,4    " ! A'E<0_7V8S[)   R
MY   %P              @ '2HP< <&UN+3(P,C4Q,C,Q>#$P:S P-BYJ<&=0
M2P$"% ,4    " ! A'E</A2A^L-A   P:@  %P              @ %%;0@
M<&UN+3(P,C4Q,C,Q>#$P:S P-RYJ<&=02P$"% ,4    " ! A'E<\8A;A-"V
M   7Q   %P              @ $]SP@ <&UN+3(P,C4Q,C,Q>#$P:S P."YJ
M<&=02P$"% ,4    " ! A'E<4UF*!M!;  #480  %P              @ %"
MA@D <&UN+3(P,C4Q,C,Q>#$P:S P.2YJ<&=02P$"% ,4    " ! A'E<FI.J
M5S0Y   .0   %P              @ %'X@D <&UN+3(P,C4Q,C,Q>#$P:S Q
M,"YJ<&=02P$"% ,4    " ! A'E<KQ'?B?UI  "B<   %P
M@ &P&PH <&UN+3(P,C4Q,C,Q>#$P:S Q,2YJ<&=02P$"% ,4    " ! A'E<
M_60B+EL^   _3P  %P              @ 'BA0H <&UN+3(P,C4Q,C,Q>#$P
M:S Q,BYJ<&=02P$"% ,4    " ! A'E<567H ILP  !<0@  %P
M    @ %RQ H <&UN+3(P,C4Q,C,Q>#$P:S Q,RYJ<&=02P$"% ,4    " !
MA'E<ME/,$)\E  !!+P  %P              @ %"]0H <&UN+3(P,C4Q,C,Q
M>#$P:S Q-"YJ<&=02P$"% ,4    " ! A'E<E9A1^>L=  "D)@  %P
M        @ $6&PL <&UN+3(P,C4Q,C,Q>#$P:S Q-2YJ<&=02P$"% ,4
M" ! A'E<TGFBM\6D  !SJ@  %P              @ $V.0L <&UN+3(P,C4Q
M,C,Q>#$P:S Q-BYJ<&=02P$"% ,4    " ! A'E<AP*&$L-B  "!;0  %P
M            @ $PW@L <&UN+3(P,C4Q,C,Q>#$P:S Q-RYJ<&=02P$"% ,4
M    " ! A'E<@"[C3/<>  #)SP  &               @ $H00P <&UN+3(P
M,C4Q,C,Q>&5X,3!D-#<N:'1M4$L! A0#%     @ 0(1Y7(2B;$;R#   X6X
M !@              ( !56 , '!M;BTR,#(U,3(S,7AE>#$P9#<U+FAT;5!+
M 0(4 Q0    ( $"$>5P#VUQ16@,  /<.   7              "  7UM# !P
M;6XM,C R-3$R,S%X97@R,60Q+FAT;5!+ 0(4 Q0    ( $"$>5Q3]B\>* 0
M &H1   7              "  0QQ# !P;6XM,C R-3$R,S%X97@R,V0Q+FAT
M;5!+ 0(4 Q0    ( $"$>5QGC]XX9PD  ,5#   7              "  6EU
M# !P;6XM,C R-3$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( $"$>5RMU5WD
M/0D  !-#   7              "  05_# !P;6XM,C R-3$R,S%X97@S,60R
M+FAT;5!+ 0(4 Q0    ( $"$>5SPQGRK/08  #8I   5              "
M 7>(# !P;6XM,C R-3$R,S%X97@S,BYH=&U02P$"% ,4    " ! A'E<<XV9
MNE4\  !2N0$ %@              @ 'GC@P <&UN+3(P,C4Q,C,Q>&5X-&0T
:+FAT;5!+!08     '@ > /\'  !PRPP    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>pmn-20251231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pmn="http://www.promisneurosciences.com/20251231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pmn-20251231.xsd" xlink:type="simple"/>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_jgbAwglzZ0mcOj7IwSXxRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_cyhzjHJjgkSJTrqFS2S_jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_VQxtOloCU0Kve5DNgHGdOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_gC5uKZAs906va_wVMOoBxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_B8nAGHl8yECKdcx4365Ong">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_Gcz0PPFqSkCFQ8-TE6lbgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_rc0mwg3aNEm7zVK6UJmkYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_uFsROG-NVU2k94DCS0QXRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_w1492Mmr_kecq-xQFv__cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_PI4broZKXEewo9ML5txgmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_e9DEwqxr8EKiOrKOtaJIGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_FP_FrTOu2Uu1Wd6byIXwSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_CajStywymUK5c3CbpY5bmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_DYaPxO1FXk29eQlC70YMrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_aHA4MFp8MUyKpl5PvcxEWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_sQgJPaD0DE-aVvUQ9j8Tng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_PVYYZPfc3UauSC4uMd_VJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_nNyk22XD9EK1oyNQIa_tUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Okge8-wzBU2jlOsUJvycVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Ywf0QSn_MU67VjykM1HpRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly282025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_GvLUVdGT7kKjraQdVt5bsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DuvCQ_GM9UKztjhwWQu6pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_dJb2jjHN40ybk15--NzTxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_p9xR5oScN0uow2EdFjwW2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_5TAIotjO30iMxfHyMzA2CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y-QIx4_sEUmBnP424eXzYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DRD7WoeXBU-JH-rKWT9PFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_-BYZBHNW00qP6PIyK-XiTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_eO14_co7TEenwcFziElAIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_qwWinEz9-E2cc-au3SCIuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Gqt906yAIEyMV9y-5GtbIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_wj2kZqXnhEOGN-1dq0Xllg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PreModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_C_yFUr1E9EemPsRRHjvb2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_yidCUH_4PUG39J6n_b7EEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_neufGN5uEk2IUYIIK5t4qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:PostModificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_y4m6ZNV0Q0Kp3hRUT7r-aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_xEmsDgSeNU-j_EYzMwwGPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_YtOhhYng_UGNJq2bFO6jYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_aepTXAELwE2v1b_eEMAxzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_AD1d2zJY0Ue1O3lheBiTPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantJuly222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_sgCMr1pSoUC2ePK4kj1p-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-23</instant>
        </period>
    </context>
    <context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qIdSELbVFkaYdmFaMjb2AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-23</instant>
        </period>
    </context>
    <context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hE5JvZ3pGkuLwiBtavfN2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-23</instant>
        </period>
    </context>
    <context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RbMHvC0yfUeVN1ARzZnBIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-23</instant>
        </period>
    </context>
    <context id="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_C7t5pUTfOU2-H7yBZeKMnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-23</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OBE-rahe30mjEaB9k6wKdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0ulmsA0VAkKV0dAMZCrDbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SMlc3z5xwU2h8j7yM4L-sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_irrRYii8eE21ooTnYfcNCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_oIAjV4RAJk26fwCLgDL5rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember_QgKzyfBAJkiVQVpxeqeEuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_pmn_NonCapitalLossCarryforwardMember_i2OXSaXBF0CPpT0LBRI-Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pmn:NonCapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_Nk1_WvPkJUiSujdxjoOzOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_x5pcthNFT0ihjd4LzbTnhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_hIXk7T7AhEypKsAQMXXglg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pmn:DirectorsAndManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_6VuupOYBAkOYhCWeJHRGrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_B_WytrX9uEGjxCiY6yXfMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_bj8OdyKOgkSN2xamZTJ45w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_jzjohLSy8kiD2BCrS5ZH6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zYsxCnpXe0KHopuDgqbqvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:Series2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T2FBENRGJ0aV_HOn6Nz-tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:Series2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2025-11-28</startDate>
            <endDate>2025-11-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__TYAGjaVLEGvdKi8ag1ZZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r75dt_d2N0-jq-dK5XbpKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1hHfoCkg_ky9CLByNbJgvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L4zZj1oYT0W-2XHWII1COQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5FgCE8zX30-mupqCfqO9Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEDCy0IDbk6AIgd9hmwmxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EQwMMLg4YEGiDu7FMobu8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMw169EA8Uy88PupRPJN3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bZ9SGI8L40et_WctpSEuqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Oh5tArIfbUWmdvd8QxM1uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__rxEw1kCCEqZzbbgn51WGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_a3Lixc5gK0udx4DuG-SYdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:Series2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w7-zVhUC1kKywOJd7lAuXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_LlWSStT2D0-0Npx7XslrPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_oUDs-NDYv0qB68laQ04sGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_535wZCcGeEeaUhW6qrPQIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_ZnKVIeo_bUW1r1sdCiTiBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_DAPNYxdYn0qZikf9-Z1Hkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Pm7NX9q6C0GTLtp_fVq02Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ArrangementOptionInitialAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_lzS6k88pCESIdR5eDOhhpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_HkhKPStIm06ybEXHIFwi_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YXkmIVrXsUao5mEA8VBliw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ShareBasedPaymentArrangementOptionPerformanceAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hegnycuWWk64ZdX1vlM55g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ArrangementOptionInitialAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CgSeHaCH60uJVtf2HXDdBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ShareBasedPaymentArrangementOptionPerformanceAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1Gx3t3xx065WtYKYn1A9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ArrangementOptionInitialAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_Y-LkZ-hLQ0uB5SljT10LcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pmn:DirectorsAndManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-29</instant>
        </period>
    </context>
    <context id="As_Of_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_C9tRwMO6rE-LT1JzUAMX2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-29</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_krcSoJs8uEGhJeQTOJRxjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GjkWBqs9q06nWLBBRIYSgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_DFTrDh2oYk6khT-4RADKcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__MZVg_HiDUGOdFb43rdmsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iyRZGqr_Ek6zR0Ofkljmjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v5tCRtG69EORGsNwZgNgJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qb681Op0wU2HNAyg8TBGWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_anrOgR3un0mVCIt8ZEvpkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_AXkBdGaKv0Sxf5BYb0bqKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_47_m4S0qR0iRJtAX5RQLIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_c27Fx9k4pkmbZZyNSQSBcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nE9oOriQukSZ_Xm8_Ompeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GFBuNQasRUSBVwbZTVEbuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_JgwQ5vRSwU6dCCuhwG_xZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:UnitedStatesDollarDenominatedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_xaU9LQGLVkuHu1Sq5gLwdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_eoUbqM8EvkG5L47UIBVk4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:UnitedStatesDollarDenominatedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_qo_eeZpMdkKWqiKn5hBbMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-23</startDate>
            <endDate>2024-10-23</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_Ec-PTVWrHU6jtSro-6pQ3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_T8HONw3a-0-21izjx6PztQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_PmbPPIZSikyMOvx6yPh_Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CanadianDollarDenominatedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_aET_q1kz20eyyiAplvmU3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CanadianDollarDenominatedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_YoanmoqTME6ncgb6u864pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CurrencyAxis_currency_USD_AW-HI8NCBUijoCTjKG1Vyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_CurrencyAxis_currency_USD_2N501AziF0iBtEVWWSNtGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6VYWxtDOn0yRARELn8NX6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2025_Z_D8BnWwH0KI4VRbsA5wGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionAndIncentivePlan2025Member_8TYcGUAhwU2A4TqH-py3Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionAndIncentivePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_okOBjDtFkk6dhuoxmA-XUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_mnaOojJ8ckOxdhKed7q5Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_JIhTf2m0-0KabLXPYhKDMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_n8K5Hi-d6EKuzXBWSyVZug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_igRnDfASGkG63gecqvoxGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_YLC21hJnUUecfOnIoqyf6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-29</instant>
        </period>
    </context>
    <context id="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_NrDzHyxGB0mKB6zttI9Mtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-29</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2030Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd3125Member_BEwiO-eDbUWWmJRIGGfGtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:July2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd31.25Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd6250Member_ZBhfqWXuAEO3TU5tCv6HmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:July2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd62.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2027Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_OxC1c99JokOfGf-9JXcpPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:January2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd50.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_BLU4_tV9gUySljXY2fjsag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:January2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd50.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_February2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd4375Member_96PtobwXOEKcI7qN4vYumA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:February2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd43.75Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd31500Member_xOPbGlUKKEeb6s_MpQYu2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:August2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd315.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd24000Member_3gS1r2Q7ikiBMcspRxwhdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:August2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd240.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd18750Member_DceMNtnvik6aFW0Sn6WY3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:April2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd187.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd15250Member_M2aoRgqepE2Z5hmL4ieMNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pmn:April2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd152.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd025Member_QbxyhQijfEureNNbf38Kiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:WarrantExercisePriceUsd0.25Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_TP3g5_42vkuIAbWzNvhidg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_IxRv2RxvLk-C6APbD0vZoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_7IREftZcLkyg0wHsVKlqFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_SKI98Sng40qCm1MAstf_uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OTZaBhXrTk-ATiBJ5MN0xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_YRF1DtgvqEykJgtUIbZvgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2BUfm8XxKEiVAOa9cCeI-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qm2HZYqej0K6tZkucd3Jzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I1pUDf-UVkWE1fMJu2oIPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DtZmtuC1ykum9CataBZk8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_-Oj0jlKSiEGQv00Y8TYf4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmn:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I_iDsTdFrk6-anUo_VHT0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a-CEo9VCBE-UkGXp15OLEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_fsghA6bgmEe7eA6MOqoAlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmn:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_8kidyz1Xz0e1GRFRPcmD0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lI1_7YZGDkiVsD04bzBKuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rhZmPGlkfEOEJZUvfYbOgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_bAqN9UYOfk6qG8Vt8Q_g7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-qWN91AyB0iMTTieOzW1eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4me8oDqyvUC5VCBKaBFb0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_cuRNgn1GhEKPKyrtju0bxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_FcVZtKmJ30yeYVCm5Ilgeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_ywYEmzxlq0GiCBn4u9aJUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_8DzdAeeke06K0IAuzwW1iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_vATcI-2w8ku4HaP9mKA02A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_1g3BSYKGr0uWzgGWV2G3HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KTeicbzkpEaKVTYwByBWeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_RegisteredDirectOfferingMember_CC8gh5SgoE2iWhbtumf2UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4P_Kz5oy5k-CBSt-JdWqyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_I6q6e-G_hkObQ4WrMKNO1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:ShareBasedPaymentArrangementOptionPerformanceAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:CanadianDollarShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmn:DeferredShareUnitPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4m9O5GYGnEyywiNYhqVX6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmn:UsDollarShareOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2016_To_4_30_2016_pOn31i6lLEW5JuoImgoy_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_yUl-HCLG1kqLzAcQbh7uGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmn:CollaborativeResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_DdNjmpvgs0aZ4rzq8r7w_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmn:CollaborativeResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_w1RADThn2Uar_4m_e19qyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_WoxRD2BhjUizfdZS0HDjoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_v_5AQ8INOEWby_KGMYOsxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OX19e1OjNUi2f5RsX_WMag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheCCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_bpZRccBbfUmU6W3r5YkXHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_6T695C591UiyeQbCleHuxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheBCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_sO-pqyxjMUuCAIj5bfCXDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:PreFundedUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_3sNvUqnERk29CoEwJ1LNig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaCommonShareWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_Cj0bmR9KNU-gOSr3An81OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="As_Of_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_8p18K6uLmk6qW32n10mbgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmn:CommonShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_JaWdR8WEoEu-vtz5zRuEhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_RQMPznxiJUaeXSv1Kr1dkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-23</startDate>
            <endDate>2024-10-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:TrancheaAndBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_TerminationWithoutCauseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Wm0yqUihf0aj0uy8QZAwtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:TerminationWithoutCauseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_ChangeInControlOfCompanyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ce9A_GawfUqwocEsnGglEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pmn:ChangeInControlOfCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2025_To_8_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_TnDWza_UfEC6NE6VKGF_Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_Kfapro2AwUiDsFbp7-NsnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:AtMarketOffering2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_4lfKtp945kqn9mXeMmjskQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pmn:UbcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_atViPoIYo0CLfKm49OwGMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pmn:DirectorsAndManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_br3i9uDnNUeb1G3P44Ok7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_MI2T6mOoo0yiJyx9T1pfEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsIssuePriceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_p9u06d6usECaMSjjXOcQkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsIssuePriceThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceOneMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_Q86c3TOUPUerZkUpsynvOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:CommonShareWarrantsIssuePriceOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:January2026PrivatePlacementIssuePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_0I2NUUyQSkuP1T4GHvUZvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_qwFZGwi9q0GjlBqTpS8zEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_w0AL93LAOE2_XbQOQb0LCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_RGzUOpKNXUufjxjn7adS1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_T1JrdAuH_EGgMvUA5bYqhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_g16vuarcVkaajTr5ylg-0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_IjbEDJQXzEyRlHeHW-e5vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025DiscountedWarrantExerciseOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_yEzxtOjj-EyFV6MUX2x0TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pmn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_SWJwnPT2MUWAT21zy7PWMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_wj_YaF2jk02-OwZm2Ww4xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July282025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_iEMqWL4XT0SxMr2o3-qqIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y36YA1aV8EG9tI8Bg4zyLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July222025PipeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_Oi4UAzx7LkqdsUQQKfYJbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pmn:UbcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pmn:July2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_7w8rUzbi_Uy4GsvvvVtdxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2026_SY15PzBp9E2bG8QJJwE36w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <instant>2026-03-25</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g">
        <measure>pmn:segment</measure>
    </unit>
    <unit id="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">
        <measure>pmn:Y</measure>
    </unit>
    <unit id="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Vote_I7wc_r8nuUinrT38wY9WLA">
        <measure>pmn:Vote</measure>
    </unit>
    <unit id="Unit_Standard_item_ETwbko2pdkCFGeE5avOMiw">
        <measure>pmn:item</measure>
    </unit>
    <unit id="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_JjSvLYrH-EWdNko9j1YiTg">
        <measure>pmn:D</measure>
    </unit>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Hidden_olqw5_anRE-ovFTa05ir5g">http://xbrl.sec.gov/country/2024#CA</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      id="Hidden_l39J4Y1B40mg3R9l36E2rg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      id="Hidden_sKnba67HJUyKJfz0lH5rZQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_rucG13QTg0OVmCb4N2yaXA_2_1">0001374339</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_mZh2zab32UePXY86VKReoA_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_vIqMGYCKlEiYu7t2P6GoUg_6_1">false</dei:AmendmentFlag>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Hidden_GhxEAIH_YkG5x-Ih-SQnQg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Hidden_3xvePPGvP0eierxX7svGGg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Hidden_-mp4ech9zk6NryxWw8E4mQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Hidden_BbSWnuivdEu78V4TAp4ZYg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="Duration_1_1_2024_To_12_31_2025_Z_D8BnWwH0KI4VRbsA5wGw"
      id="Hidden_SdkTB3HWa020CccPjwzO6Q">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      id="Hidden_6oppxBhmXEeEh4xZRJJ3vQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      id="Hidden_b4hNM_E66Ua0TaTRWn1_tA"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A"
      decimals="2"
      id="Hidden_EKVA16217E2dxeEyM3doRA"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_krcSoJs8uEGhJeQTOJRxjQ"
      id="Hidden_NcV6rL8tMk-QI6TxetjyIg">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GjkWBqs9q06nWLBBRIYSgA"
      id="Hidden_xwYBGyVeBki9Pw78B3ou9w">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_okOBjDtFkk6dhuoxmA-XUw"
      decimals="INF"
      id="Hidden_YqiLGZ_RnUeciaPL5_1Scw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">314170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_mnaOojJ8ckOxdhKed7q5Fg"
      decimals="INF"
      id="Hidden_zqmpoD10K0mYm-cj5Mnc8w"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">314170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_PmbPPIZSikyMOvx6yPh_Ag"
      id="Hidden_TkWIfmwCtk2L1o77RyTsVw">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw"
      id="Hidden_K9LLXyDMFk2irW-0jw4rvw">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_aET_q1kz20eyyiAplvmU3A"
      id="Hidden_NKYPClXPwkOL6W5cM2Ychw">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheCMember_g16vuarcVkaajTr5ylg-0Q"
      decimals="INF"
      id="Hidden_sIX-I_ihFUyckByqXSCcEg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">112150</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheBMember_IjbEDJQXzEyRlHeHW-e5vA"
      decimals="INF"
      id="Hidden_rAT-TO71IkG83cETElUNVQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">112150</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_C_yFUr1E9EemPsRRHjvb2g"
      decimals="2"
      id="Hidden_vE8nknvrREuwISKkbV-t1g"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">14.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_5TAIotjO30iMxfHyMzA2CA"
      decimals="2"
      id="Hidden_sDMpaTJpt02AivVLsCelvw"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">0.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_qwWinEz9-E2cc-au3SCIuw"
      decimals="2"
      id="Hidden_UiLMq0ECGUuuIc3ZT61PGA"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">4.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_p9xR5oScN0uow2EdFjwW2w"
      decimals="3"
      id="Hidden_bE979HFoxkSnleUqfJBh_Q"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_eO14_co7TEenwcFziElAIw"
      decimals="3"
      id="Hidden_qaJfvU25ukC0j9SFajVEUw"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.043</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_yidCUH_4PUG39J6n_b7EEQ"
      decimals="3"
      id="Hidden_z2jv6MWYFkOFbHtRCJPIPQ"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.065</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheCMember_w0AL93LAOE2_XbQOQb0LCQ"
      decimals="INF"
      id="Hidden_2uiJ2Xl62UWXxUyC2yNBhA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">138812</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheBMember_RGzUOpKNXUufjxjn7adS1A"
      decimals="INF"
      id="Hidden_u1jGCHE0JUyEOMipzgeTYA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">138812</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_CajStywymUK5c3CbpY5bmQ"
      decimals="2"
      id="Hidden_88CXrfs02k61Q4fWLfzeFg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_B8nAGHl8yECKdcx4365Ong"
      decimals="2"
      id="Hidden_XdTVGA3HiEy71yJOaEE4tg"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">0.52</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_PI4broZKXEewo9ML5txgmg"
      decimals="2"
      id="Hidden_Dh34ZOTg80WsRg6qGMRmNA"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">4.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_gC5uKZAs906va_wVMOoBxQ"
      decimals="3"
      id="Hidden_p37SpWW4dk6Jm7sLGseshg"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_w1492Mmr_kecq-xQFv__cg"
      decimals="3"
      id="Hidden_fQaxwlZiKkGwEDVd1NMCVQ"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.043</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_DYaPxO1FXk29eQlC70YMrA"
      decimals="3"
      id="Hidden_DM6veFeJkkWgBQ6DbhWYUw"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.074</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A"
      decimals="2"
      id="Hidden_bzJ1h69P5Uu2r6edpFDPOQ"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_11_28_2025_To_11_28_2025_RyAuux14gUKkNHiO0lEC5A"
      decimals="2"
      id="Hidden_uNKYSpxl1EOc5rSnKnyhFA"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      id="Hidden_ek1qQB57M0uiwz7O77M-zA">http://xbrl.sec.gov/country/2024#CA</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A"
      decimals="2"
      id="Hidden_VGlBM7hgKUyWd-Dp-bhCdA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">28.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pmn:ClassOfWarrantOrRightPricePerWarrant
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceOneMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_Q86c3TOUPUerZkUpsynvOQ"
      decimals="2"
      id="Hidden_g2-t6Gg1-USHvtLxsXmEHw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">10.77</pmn:ClassOfWarrantOrRightPricePerWarrant>
    <pmn:ClassOfWarrantOrRightPricePerWarrant
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_MI2T6mOoo0yiJyx9T1pfEg"
      decimals="2"
      id="Hidden_z_3eEpwo3UirEsenSR7Cow"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">10.77</pmn:ClassOfWarrantOrRightPricePerWarrant>
    <pmn:ClassOfWarrantOrRightPricePerWarrant
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_p9u06d6usECaMSjjXOcQkA"
      decimals="2"
      id="Hidden_bKWVPXSjm0mG5YAXBCSUsw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">12.13</pmn:ClassOfWarrantOrRightPricePerWarrant>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_ewbUS11rzUK9eONFHbpzdw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_GG_0b8XqBUC2UEZI_AlRHw">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_gCpdL26VEUK6qgDEwu9Opg">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_brryoR3qXkiGiPUuPv7cAQ">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_4M9FcTpPXU6OrJ9yDFDL2w">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_V54GSep9f0aPyCttsenKOw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_Qpr8PjRbQ0CI327H45VqaA">001-41429</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_EF4I3nnfuk6sVJMJ8vpVJQ">PROMIS NEUROSCIENCES&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_vIfiU3gC-k-4y2YjM-uxjw_1_0">A6</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_bdA1_jVYgUeh8eKE2cYTeg_1_1">98-0647155</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_vhTNbiL2vkyW1XCdawtuqw">Suite&#160;200, 1920 Yonge Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_CEgHcUchpUiC_8ii4fmMVA">Toronto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_FJZmim7T3UamUzmJBNVlGA">ON</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_VB-r5-5D10mVfgTeNOSFeA_3_1">M4S 3E2</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_pDSSUpSog0KrEhLhvAYOAA">416</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_7zZlGe9h0UCf0C9PbwamYA">847-6898</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_reXv-EeFokKtAtp3ljMxSQ_3_0">Common Shares, No Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_F8b_e-EfUEq5Hef44h8P9Q_3_1">PMN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_E-L-JfFen0SsKUoHAVmWLw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_-cMKrf3fvkiATKrqhQ-i_w">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_Z0xonDd25kSWBvIVlSh0Pw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_0JSALouM502mSnlQ24sn0g">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr__evg077LaEWWjVUJnqUSLw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_LwZcE8eSEke6jMiOU_GmbA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_KonyUNWMHk6vQeXBjtzGwA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_StkcTvkFHkqa9CK-MH_QJg">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_bTvkGAYYI0uLHRQ7SPNHcg">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_34kqMcRUfEizFfW6v_YWPA">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_6W1wY_vVnU6GFvpBuEH7Rw">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_KSmc7wciXEa2JmXg24s9FA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2025_7w8rUzbi_Uy4GsvvvVtdxQ"
      decimals="-5"
      id="Narr_M4q0rgeWDEyHP1XC-pC_Dw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">29700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_25_2026_SY15PzBp9E2bG8QJJwE36w"
      decimals="INF"
      id="Narr_SEe38r8beU-DCa21Bn2G8g"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">8967693</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_M7UQKzvVBEWS8JIR6Otxuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 5pt 0pt;"&gt;Portions of the registrant&#x2019;s definitive proxy statement relating to its 2026 annual meeting of shareholders, or the 2026 Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2026 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_UvxTE3zB5kKCT4XUsm_41Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk Management and Strategy&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We recognize the importance of assessing, identifying, and managing risks to the security, confidentiality, integrity, and availability of our business systems and confidential information, including personal information and intellectual property. We have developed a cybersecurity risk management program in accordance with our risk profile and business. Leveraging the support of a third-party information technology provider, our cybersecurity risk management program includes cybersecurity awareness training for employees and periodic systems monitoring and vulnerability scanning.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We have not identified cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However, like other companies in our industry, we and our third-party vendors may from time to time experience threats that could affect our information or systems. For more information, please see the section entitled &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_5ggNGiLjzEaA9YGuiE6Tfw">We recognize the importance of assessing, identifying, and managing risks to the security, confidentiality, integrity, and availability of our business systems and confidential information, including personal information and intellectual property. We have developed a cybersecurity risk management program in accordance with our risk profile and business. </cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_-vRyu-H_e0a7lx6FPuuXmg">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_tVxSije9qEai91gaL-pt7w">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_cEZdpTR2UE6AWMB6QIXIrg">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_X_bd_VgXnUacFuVQtlhfdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Governance Related to Cybersecurity Risks &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our Vice President, Finance and Chief Executive Officer, with the assistance of the Company&#x2019;s third-party information technology provider, are responsible for the strategic leadership and direction of the Company&#x2019;s cybersecurity program.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_o-P92Ubsd0qKx80s4j5GPw">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_LSD1-mUP3EqiPAhvn72MHQ">Vice President, Finance and Chief Executive Officer</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_N5pk2lmgCEWqA95Ave7V-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Board exercises oversight of risks from cybersecurity threats primarily through its Audit Committee. Our Vice President, Finance, with input of other members of Company management and the Company&#x2019;s information technology provider, periodically makes presentations to the Audit Committee on the Company&#x2019;s enterprise risk management program, which may address cybersecurity risks and related cyber strategy, as applicable. &lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_iR5m5FsAmku60g9iZwyfBQ">Audit Committee</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_rwcbg8e5gEOQ7r6efMrTmA">Our Vice President, Finance, with input of other members of Company management and the Company&#x2019;s information technology provider, periodically makes presentations to the Audit Committee on the Company&#x2019;s enterprise risk management program, which may address cybersecurity risks and related cyber strategy, as applicable.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_1wC55z_faUCkT7Ph8l-zGA">Our Vice President, Finance, with input of other members of Company management and the Company&#x2019;s information technology provider, periodically makes presentations to the Audit Committee on the Company&#x2019;s enterprise risk management program, which may address cybersecurity risks and related cyber strategy, as applicable.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_Qd2HoPq5kEimLDkRGOsldw">23</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_xAIV4WQswkSuYcUfBODYPA">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tc_2f0yLWobTUiw5akyrJ5lvw_2_0">Tewksbury, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_7ERVIdDYXk27TXvB09VGRA_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">6116556</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_Sah5tPdCmEGLrIuCILRSqw_5_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">13291167</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_XWazV78_ikOTahHu0JYMIg_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33753</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_i62IDcz_cUiplPHX0Y1uVA_6_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33051</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_2S59zcyaQEGdo8L6DKI6ow_7_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3032112</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_f2lc9FUwxkCOjYNf-l_qVQ_7_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5587238</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_QTfuyt_9P0yPTkVXOaVooA_8_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">9182421</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_s_PtR5gwo0mYuVwKh7UQuQ_8_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">18911456</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_-nHntwpsNUu300EP0J-vbw_9_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">9182421</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_99e-YEyALkeOH7nZBC6mUQ_9_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">18911456</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_1OhUnY7jdUKpTbGbx7klxw_12_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2543415</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_UgvHxTfP0UCQ921rJ0GEhw_12_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">1737463</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_hTLxFa-zlUWh8Yj4aXwsKA_13_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">7868416</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_oOaN0_ZQokmNy5uhcbLEIQ_13_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">480962</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_QcZfUE4fS0yubP_UqnnUWQ_14_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">10411831</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_JquoDogL30Cmvdc3rwoGJw_14_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2218425</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_LIqbT4W3UESIwx6WFbgFYw_15_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">29182</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_gkqcabY3iEGk_8VfSjzyNA_15_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">199263</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_cBrEbxVWwkyBtB2VUVzaYA_16_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5592</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_dYyfzY3mjk6awi42shmOrw_17_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">10441013</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_k1oFm9aJoEuoYekciKCtiQ_17_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2423280</us-gaap:Liabilities>
    <us-gaap:CommonStockNoParValue
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="INF"
      id="Narr_CksMGDZvj0OksiQ4ycY_Gg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Narr_yJK8f9BxvUq6AU08aSZBpQ"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Narr_18Zx0HJVbUOEOeM_r2e5XA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2152397</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Narr_lHLrl63an0uwPfq1JYBkTA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2152397</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="INF"
      id="Narr_AxZZl6nn102iRNUhiUJ29A"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1307520</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="INF"
      id="Narr_REcqZVmzLUKOLqlDcWDFsw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1307520</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_DbnIPB14lEe_KPHcfU8RQA_22_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">129518812</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_EK-jlW81gEaQObw-rrOogQ_22_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">107546433</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_tLUzD3CR2k-2YR7863bR1g_23_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-371184</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_W0KWaIYy1k6fhwSlTknj1Q_23_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-371184</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_dM7BP7ScLkGaV8Ai0AFtxA_24_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-130406220</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_x9R7eJykdUWIo7DovMm9AA_24_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-90687073</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_AtKZVGsftk-FpeJIqSJj8w_25_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-1258592</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_VgI6AKNAG0eqXQ-Svn5YrA_25_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">16488176</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_BnjG2V9J1kCMvJ5XbzLHSA_26_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">9182421</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_4AgT5tsaD0yrW40eZ1uZdw_26_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">18911456</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_wKX8w5Cd10iXbKOCTcsPRg_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33379321</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_4Nh05Ec3_k-mhhUcosn-GQ_6_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">10637976</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_Q-T0H1Ana0urRZaNxHlzVg_7_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">6787987</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_IQtjfD7I-EeMbixd8ttw_A_7_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">6189502</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_NkFW4y-AEEyZh4R51PWNkg_8_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">40167308</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_H_Wr_Z1BG0qGjCZNUIjpkw_8_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">16827478</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_NKqafxcFpEKaY2H9Msi3Ng_9_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-40167308</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_2FIIjV-zGkufeQRSGmMvfw_9_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-16827478</us-gaap:OperatingIncomeLoss>
    <pmn:GainLossFromChangeInFairValueOfFinancialInstruments
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_BgRy3-gbZ0OYA6luuok2dQ_12_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5592</pmn:GainLossFromChangeInFairValueOfFinancialInstruments>
    <pmn:GainLossFromChangeInFairValueOfFinancialInstruments
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_cIfZx0D25E-V2Nrn1rtK9A_12_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">22581477</pmn:GainLossFromChangeInFairValueOfFinancialInstruments>
    <us-gaap:InterestExpenseOther
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_-gMM02HAZ0O5xM_tflsAZQ_13_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">76775</us-gaap:InterestExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_vY7rarEFlECh-MTwiO3Mfg_14_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">442569</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_P444iAYIvEKZXGkkYH9d5Q_14_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">626184</us-gaap:OtherNonoperatingIncomeExpense>
    <pmn:LossOnSaleOfCommonSharesAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_-bTjUbaqdkW9Ti12mDOEJQ_15_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3524535</pmn:LossOnSaleOfCommonSharesAndWarrants>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_NPz9dHJXqkevhzB2ZK75SQ_16_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">448161</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_P4T5CCjsuUeiItougF9_Pg_16_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">19606351</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_8As-ig1CsUG7CIXX0_LZ6A_18_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-39719147</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_BVxqf_hdXkCPtoGS90KfsQ_18_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2778873</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="2"
      id="Tc_-n6IEwpotkCToK4omvUoUw_20_3"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">-22.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="2"
      id="Tc_trMHJeo260y1zb89cLqPWQ_20_6"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">2.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="2"
      id="Tc_3pkyBextj02F6FemepMvQQ_21_3"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">-22.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="2"
      id="Tc_gOZTIrMYWEa-SYhLA7HqXg_21_6"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">2.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_dC0fYgQcZ0qsLVZe50Ohdg_23_3"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1756844</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_4TeDjd4TdE29LdSMri9FrA_23_6"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1036799</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_RJ90_QWqU06_oe8UHrBdNg_24_3"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1756844</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_RK7gyVOkcEa_BvypE9MNHw_24_6"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1058469</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_a3Lixc5gK0udx4DuG-SYdw"
      decimals="INF"
      id="Tc_jZ2krpr580-JcqOLJWk1kw_5_3"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">46667</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w7-zVhUC1kKywOJd7lAuXQ"
      decimals="INF"
      id="Tc_UrBgRHXU50evNnjXcayWrw_5_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">755362</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMw169EA8Uy88PupRPJN3g"
      decimals="0"
      id="Tc_VQntC5AdsUqATsmycwVMFQ_5_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">97590426</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bZ9SGI8L40et_WctpSEuqg"
      decimals="0"
      id="Tc_sGy-2EGl60uIVSgUI0WpzA_5_17"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-371184</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EQwMMLg4YEGiDu7FMobu8Q"
      decimals="0"
      id="Tc_dKWf1-SESUWsZXhVrzG5yA_5_20"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-93465946</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ"
      decimals="0"
      id="Tc_8SNyrcTlAkOgR3eFOTKOtA_5_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3753296</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw"
      decimals="0"
      id="Tc_gwu655bnAkKM8BGo-gswoA_6_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">825808</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc__LQlRB4NzEiBEgUyd99_Hg_6_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">825808</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zYsxCnpXe0KHopuDgqbqvw"
      decimals="INF"
      id="Tc_keWLALwzJ0auZNSAlObIgA_7_3"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">-46667</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_pmn_Series2PreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T2FBENRGJ0aV_HOn6Nz-tQ"
      decimals="INF"
      id="Tc_LRtRVM-w2kCyrTvewOrkVg_7_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">46667</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_jzjohLSy8kiD2BCrS5ZH6w"
      decimals="INF"
      id="Tc__uacrnc1tUS0zKBB6kHW3A_8_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">3034</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_x5pcthNFT0ihjd4LzbTnhw"
      decimals="0"
      id="Tc_53dhx027F0yi7lXGY0yJtA_8_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">190274</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg"
      decimals="0"
      id="Tc_APUegcHFdk-_60hGUyzvGA_8_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">190274</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_bj8OdyKOgkSN2xamZTJ45w"
      decimals="INF"
      id="Tc_zKNnQ1G-fUC-2NvpyV0pvA_9_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">390307</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw"
      decimals="0"
      id="Tc_l20P0yuK7EitX_A64oUA5w_10_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8689148</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_ixgf7acZtkOCqbmsIiqgew_10_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8689148</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw"
      decimals="0"
      id="Tc_T3s1PZBvjEaU1RDl3Mc9TQ_11_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">222739</pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions>
    <pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_ZQ7iFMny00Waepxd-MG8Mw_11_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">222739</pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions>
    <pmn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4P_Kz5oy5k-CBSt-JdWqyg"
      decimals="INF"
      id="Tc_K-NoE2o2Q0qUfAcIAngsKg_12_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">112150</pmn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5gZO1BJ-70G5tuhDVH6aJw"
      decimals="0"
      id="Tc_DsT4wG0uBEKSwe4JmOup9w_12_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">28038</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_F1gtESWVq0iBG5SZmQUWsA_12_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">28038</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GFBuNQasRUSBVwbZTVEbuA"
      decimals="0"
      id="Tc_xV8ZjmbFJECUbx5wDMo8jQ_13_20"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2778873</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_xd0_Z9l1tU2lfqnjEqesUQ_13_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2778873</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__rxEw1kCCEqZzbbgn51WGA"
      decimals="INF"
      id="Tc_vaWW3u9FGk-CGjeFzj7MdA_14_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1307520</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5FgCE8zX30-mupqCfqO9Hg"
      decimals="0"
      id="Tc_zFrooetCs02d18O1XOSqHQ_14_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">107546433</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VEDCy0IDbk6AIgd9hmwmxA"
      decimals="0"
      id="Tc_vcAiO2tkyUapruIMc2jt0Q_14_17"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-371184</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L4zZj1oYT0W-2XHWII1COQ"
      decimals="0"
      id="Tc_Of3FV2Df3kys5gDR9ilqsg_14_20"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-90687073</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_Ssta3XbgOk2xw6OU11qxlw_14_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">16488176</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ"
      decimals="0"
      id="Tc_-TuSlafAuk2WDUYsZoGD1A_15_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">857628</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_ALJ-EsdugEShi4KeFMDXjA_15_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">857628</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_B_WytrX9uEGjxCiY6yXfMw"
      decimals="INF"
      id="Tc_2HTYr7loQUSiAuW3R32NDA_16_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">40795</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_Nk1_WvPkJUiSujdxjoOzOQ"
      decimals="0"
      id="Tc_GxtZQnDHFUmz3M1arsdNQA_16_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">708468</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g"
      decimals="0"
      id="Tc_AqnySAykYkO61LUixXLCyw_16_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">708468</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ"
      decimals="0"
      id="Tc_jqrojhglskGaEskFutBHoQ_17_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">697658</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_VL4qG-7hxkqM0y7YpOhjWQ_17_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">697658</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <pmn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KTeicbzkpEaKVTYwByBWeQ"
      decimals="INF"
      id="Tc_y_JojzdgAky0VA7BjX4e7g_18_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">51197</pmn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ"
      decimals="0"
      id="Tc_s2O7CqfX2k6HBO1-izXJhQ_18_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3050</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_inqInsDLmk-gy7dKCJeQRg_18_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3050</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <pmn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_1g3BSYKGr0uWzgGWV2G3HQ"
      decimals="INF"
      id="Tc_A3F1hWgi8E6FGM6iF9Xy4Q_19_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">336449</pmn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_8DzdAeeke06K0IAuzwW1iA"
      decimals="0"
      id="Tc_DKnfLxhOnUi0nkMBon3iXw_19_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8391027</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg"
      decimals="0"
      id="Tc_BTV6VUnnSUmguppxmUji_w_19_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8391027</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <pmn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_vATcI-2w8ku4HaP9mKA02A"
      decimals="INF"
      id="Tc_hmR2JTWdCUyf62bS-ByxQQ_20_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">416436</pmn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_ywYEmzxlq0GiCBn4u9aJUg"
      decimals="0"
      id="Tc_YMEXOQlhM0ym5LTxwkJGCg_20_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">11144467</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <pmn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA"
      decimals="0"
      id="Tc_slO6g3r9wE2_fCdfYFgFrA_20_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">11144467</pmn:StockIssuedDuringPeriodValueWarrantsExercised>
    <pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQpjgLGPIU-b2YtPuIlJrQ"
      decimals="0"
      id="Tc_woaaV_Oq6kujub5yyFHf5g_21_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">170081</pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions>
    <pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_zMrOAk92LU2MYigeqpSLtQ_21_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">170081</pmn:ApicShareBasedPaymentArrangementRemeasurementOfLiabilityClassifiedStockOptions>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nE9oOriQukSZ_Xm8_Ompeg"
      decimals="0"
      id="Tc_SusXUqVTkkaknKPbyW1e2Q_22_20"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-39719147</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_bR6Whf_DwUm1lAOnF0lvzA_22_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-39719147</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Oh5tArIfbUWmdvd8QxM1uA"
      decimals="INF"
      id="Tc_G8h9tPWzQkGru3PzLDf40g_23_8"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2152397</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_r75dt_d2N0-jq-dK5XbpKA"
      decimals="0"
      id="Tc_gzSwYdZ9A067vRQoWkZ4Rw_23_14"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">129518812</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1hHfoCkg_ky9CLByNbJgvQ"
      decimals="0"
      id="Tc_4XTqpKNVr0-EifutfOHCFA_23_17"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-371184</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__TYAGjaVLEGvdKi8ag1ZZg"
      decimals="0"
      id="Tc_Qb8cfYZBY0KNss_7bBG6dg_23_20"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-130406220</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_uPg4Z6U5MEGirdnhJ456cQ_23_23"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-1258592</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_LjQJ0rTZeEieGtKgZ7c-Tg_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-39719147</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_7eLiG_aX5EOuLLi8PjQJrA_5_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2778873</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_9Ay8YtQYpUSAE92x2qxCLQ_7_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">857628</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_BLIvVwO92kuaqPDerUJaGg_7_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">825808</us-gaap:ShareBasedCompensation>
    <pmn:LossOnSaleOfCommonSharesAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_3q14u4lThkCKlPz-zpf3ZQ_8_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3524535</pmn:LossOnSaleOfCommonSharesAndWarrants>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_p0FUpeNRlUqTDrImV3IOtQ_9_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5592</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_yaAHABFLSUub9mOWubnFNA_9_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">22581477</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_SHefCp0Ly0yqJtdBbfNBbg_11_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-2555126</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_034ze3MNq0CE-IWn3DwTLw_11_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">4598597</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_LBvG8EnKckefO47R-I9Trg_12_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">805952</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_Fh4UxFFTF0CetOXis4L6eQ_12_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-6105673</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_nnNlSayGm0OJVX_lKLg_wg_13_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">7387454</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_giBRbHP80k-Z73uyOVgknA_13_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-1025564</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_hpnht7Qhx0qZ9te4_pBV-g_14_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-28118579</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_RQMobzzv6UydQFTN7SHoxA_14_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-27182095</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_qD9UuQUb2UaKSCayo_twQg_17_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33753</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_wPu8xo396kiDNd0z3yM8iw_17_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33051</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_ruWp8oLPAky5BVdDCCgWVA_18_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33051</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_GD47rcWOyECo1St_j8hhrw_18_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">32358</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_Nuc29AN3cUy3s2d4_kqNDQ_19_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-702</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_2hKldCsOY0iHfvUnetdKoQ_19_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-693</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_ELQCpRScyUmIRQ60-S-JLw_22_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">708468</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_Ritc5jnKuUu9KYH7SgB6pw_22_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">190274</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pmn:NetProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg"
      decimals="0"
      id="Tc_kqzR5HKjakm0ijGDp3Dh9g_23_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">697658</pmn:NetProceedsFromIssuanceOfWarrants>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg"
      decimals="0"
      id="Tc_BzsILihyo0S2jPkm1Xb_VA_24_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8391027</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA"
      decimals="0"
      id="Tc_oi_GSpxqFkiPPJ4aBlfF8w_25_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">11144467</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PipeFinancingMember_JaWdR8WEoEu-vtz5zRuEhA"
      decimals="0"
      id="Tc_ylku8hFBUkWEmflCAaVrLQ_26_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">27657497</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_eHiFHTKNZ0Gnq0Fmm0gvdw_27_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3050</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_kgN16U0d60uiKx_KGxAk9Q_27_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">28038</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_tuUWJuQ8PkKFlkvQK0IXzg_28_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">20944670</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_Rx7vx96H6k2Gmc8mCvbXRQ_28_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">27875809</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_kxnxCH67EEG3BQthjLJBRA_29_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-7174611</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_VKwzxryZ90qx-ptAqSkDUQ_29_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">693021</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_rd9Ck1AvAE-EQLuGSCU9Nw_31_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">13291167</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ"
      decimals="0"
      id="Tc_HS9HUhdhG0eL5L2LV56_Kg_31_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">12598146</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_U9zNm-Njq0GsyZh3NNNhWA_32_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">6116556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_oGoXne08yEqlMh_ziJ4T-w_32_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">13291167</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <pmn:ReclassificationOfPipeWarrantsFromLiabilityToEquity
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_SHJQQv0o2kesi07LUWz2mQ_35_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8689148</pmn:ReclassificationOfPipeWarrantsFromLiabilityToEquity>
    <pmn:DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_yhCRRVjkd02Hp2nS_cc4pQ_36_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-170081</pmn:DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability>
    <pmn:DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_4rYS8sypGUqyF63xVLbnXw_36_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">222739</pmn:DecreaseInAdditionalPaidInCapitalForShareBasedCompensationLiability>
    <pmn:DeferredDiscountForFairValueModificationOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg"
      decimals="0"
      id="Tc_TaVQpOs2M0O35thowt0M9g_37_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">930841</pmn:DeferredDiscountForFairValueModificationOfWarrants>
    <pmn:DeferredDiscountIssuanceCostRecognized
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_O10vBhSX3kqpjsL8HFYwNg"
      decimals="0"
      id="Tc_ESCrH0NZ0UKgVNtauG1Pyg_38_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-930841</pmn:DeferredDiscountIssuanceCostRecognized>
    <pmn:DeferredDiscountForFairValueModificationOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA"
      decimals="0"
      id="Tc_xKHW1yff0UWH08V9P1VWVA_39_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">1794146</pmn:DeferredDiscountForFairValueModificationOfWarrants>
    <pmn:DeferredDiscountIssuanceCostRecognized
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_zbSHjr_XDE-eKDTAbZusPA"
      decimals="0"
      id="Tc_ZNlwVJMwf0mcsCIoW13H1Q_40_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-1794146</pmn:DeferredDiscountIssuanceCostRecognized>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_SDIrC4uQHkmR0l5iOzZXVQ_43_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">76775</us-gaap:InterestPaidNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="-5"
      id="Narr_VYV7oKNr6k2vFlKGUGsCpg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-40200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="-5"
      id="Narr_8UptSvUH7EauS2AGoRIlfw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-130400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="-5"
      id="Narr_3aGPD-tO8E20WfROR4E2ow"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-28100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qb681Op0wU2HNAyg8TBGWA"
      decimals="-5"
      id="Narr_-C9JrjuIt0eObyH9bJqqIw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">75500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_Zkqq4guoxEai-3tecnFYYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/span&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;&lt;b style="font-weight:bold;"&gt;GAAP&lt;/b&gt;&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;&lt;b style="font-weight:bold;"&gt;ASC&lt;/b&gt;&#x201d;) and as amended by Accounting Standards Updates (&#x201c;&lt;b style="font-weight:bold;"&gt;ASU&lt;/b&gt;&#x201d;) of the Financial Accounting Standards Board (&#x201c;&lt;b style="font-weight:bold;"&gt;FASB&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;On November 17, 2025, the board of directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of&#160;&lt;span style="-sec-ix-hidden:Hidden_EKVA16217E2dxeEyM3doRA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;25&lt;/span&gt;&lt;/span&gt;:1, effective November&#160;28, 2025 (the &#x201c;&lt;b style="font-weight:bold;"&gt;Reverse Share Split&lt;/b&gt;&#x201d;). All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Share Split, unless otherwise stated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of financial instruments. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (&#x201c;&lt;b style="font-weight:bold;"&gt;CODM&lt;/b&gt;&#x201d;), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company has one operating segment and its Chief Executive Officer serves as the CODM. Substantially all of the Company&#x2019;s assets are located in Canada. Refer to additional Segment Information in Note 10.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Foreign and Functional Currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company determines its functional currency as the currency of the primary economic environment in which the Company operates. To determine the primary economic environment, the Company considers salient economic factors, including cash flow indicators, expense indicators and financing indicators. Functional currency is a matter of fact, not a policy election and the Company will only reevaluate its functional currency if there is a significant change in facts and circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Prior to July 1, 2023, the Company&#x2019;s functional currency was the Canadian dollar (&#x201c;&lt;b style="font-weight:bold;"&gt;C$&lt;/b&gt;&#x201d;). Translation gains and losses from the application of the United States dollar (&#x201c;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&#x201d;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative foreign currency translation adjustment, which is reported as a component of stockholders&#x2019; (deficit) equity as accumulated other comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Following the Company&#x2019;s voluntary delisting from the Toronto Stock Exchange in July 2023, the Company determined there was a significant change in its facts and circumstances, and completed a reassessment of its functional currency. The Company determined that, as of July 1, 2023, the Company&#x2019;s functional currency had changed from the C$ to the US$. The Company reassessment included analysis of various factors, including: the Company&#x2019;s cash flows and expenses denominated primarily in US$, the primary market for the Company&#x2019;s Common Shares trading in US$ and a majority ownership by U.S. shareholders from financings denominated in US$. The change in functional currency was accounted for prospectively from July 1, 2023 and consolidated financial statements prior to and including the period ended June 30, 2023 were not restated for the change in functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;For periods commencing July 1, 2023, monetary assets and liabilities denominated in foreign currencies are translated into US$ using exchange rates in effect at the end of the reporting period. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after July 1, 2023 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations within operating expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2025 and 2024, the Company did not have any material cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Short-term Investments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Short-term investments consist of guaranteed certificates of deposit with a maturity greater than 90&#160;days and up to one&#160;year at the time of purchase. Accordingly, all short-term investments are classified as current assets in the accompanying consolidated balance sheets. The short-term investment is being held as collateral for the Company&#x2019;s credit cards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees 100% of the original amount invested. As of December&#160;31, 2025, the Company has not experienced any losses on its cash or short-term investments as a result of credit risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;FASB ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures, &lt;/i&gt;(&lt;b style="font-weight:bold;"&gt;&#x201c;ASC 820&#x201d;&lt;/b&gt;) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, as established by ASC 820, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2013; Observable inputs, such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2013; Inputs (other than Level 1 quoted prices) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company&#x2019;s warrant liabilities were classified as Level 3 financial instruments for the&#160;year ended December&#160;31, 2024. The Company&#x2019;s share-based compensation liability was classified as a Level 3 financial instrument for the&#160;years ended December&#160;31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The carrying amounts of prepaid and other current assets, short-term investments, accounts payable, and accrued expenses are generally considered to be representative of their fair value based on the short-term nature of these financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Impairment of Long-lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company historically evaluates its long-lived assets, which consist of property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not have any material long-lived assets as of December&#160;31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Property and equipment, net are historically stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Laboratory and equipment are depreciated over &lt;span style="-sec-ix-hidden:Hidden_NcV6rL8tMk-QI6TxetjyIg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to five&#160;years. Computer equipment is depreciated over &lt;span style="-sec-ix-hidden:Hidden_xwYBGyVeBki9Pw78B3ou9w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to three&#160;years. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accompanying consolidated balance sheets and any resulting gain or loss is included in loss from operations in the accompanying consolidated statements of operations. Expenditures for repairs and maintenance are expensed as incurred. The Company did not have any material property and equipment as of December 31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Definite-lived intangible assets are historically stated at cost less accumulated amortization and any accumulated impairment losses. An intangible asset&#x2019;s carrying amount is assessed for impairment whenever there is an indication that the asset may be impaired. The Company&#x2019;s definite-lived intangible assets consist of acquired rights and patents. Intangible assets are amortized on a straight-line basis over the lesser of the life of the intangible asset or its estimated useful life, which is 15&#160;years. The Company did not have any material intangible assets as of December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Collaboration Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company may enter into collaboration arrangements with pharmaceutical and biotechnology partners. The Company analyzes its collaboration arrangements to assess whether they are within the scope of FASB ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements, &lt;/i&gt;(&lt;b style="font-weight:bold;"&gt;&#x201c;ASC 808&#x201d;&lt;/b&gt;), to determine whether such arrangements involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. ASC 808 does not provide guidance on the recognition of consideration exchanged or accounting for the obligations that may arise between parties. The Company concluded that ASC Topic 730, &lt;i style="font-style:italic;"&gt;Research and Development, &lt;/i&gt;should be applied by analogy to payments between parties during the development activities of its collaboration arrangements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;General and Administrative Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;General and administrative expenses consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development and protection of intellectual property, professional service fees, and other general overhead and facility costs, including rent, depreciation and amortization, which relate to the Company&#x2019;s general and administrative functions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Research and development expenses consist primarily of costs incurred in connection with the development and research of the Company&#x2019;s platform technology, as well as discovery program expenses. The Company expenses research and development costs as incurred. These expenses include:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;employee-related expenses, including salaries, related benefits and share-based compensation expense, for employees engaged in research and development functions;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;external research and development expenses incurred under arrangements with third parties, such as contract research organizations (&#x201c;&lt;/span&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;CROs&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x201d;), and consultants;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the cost of acquiring, developing, and manufacturing clinical study materials; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Costs associated with preclinical and clinical activities and regulatory operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Prepaid and Accrued Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Substantial portions of the Company&#x2019;s pre-clinical development, manufacturing and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors. These vendors generally bill&#160;monthly for services performed, or bill based upon milestone achievement. For preclinical and clinical studies, the Company accrues expenses based upon estimated work completed and the remaining contract milestones. At times, the Company is obligated to make upfront payments upon execution of research and development agreements. Upfront payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses until such goods are delivered or the related services are performed. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. The actual timing of performance or the level of effort may vary from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company issues warrants, including pre-funded warrants, on its common shares in connection with financings as well as for compensation of intermediaries and advisors. The Company accounts for warrants as either equity instruments or as liabilities depending on the specific terms of the warrant agreements in accordance with FASB ASC Topic 815, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging &lt;/i&gt;and Topic 480, &lt;i style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/i&gt;. When classified as equity, warrants are recorded within additional paid-in-capital at the time of issuance and are not subsequently remeasured. Warrants identified as meeting the definition of a liability are recognized as a liability and treated in accordance with the derivative liability accounting policy described above. The Company periodically reassesses the appropriateness of the classification of its financial instruments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Share-based compensation expense related to share awards granted to employees, directors and non-employees, excluding awards with market conditions in which the award does not vest unless the market condition is met, is recognized based on the grant-date estimated fair values of the awards using the Black- Scholes option pricing model (&#x201c;&lt;b style="font-weight:bold;"&gt;Black-Scholes&lt;/b&gt;&#x201d;). The value is recognized as expense ratably over the requisite service period, which is generally the vesting term of the award. The Company adjusts the expense for actual forfeitures as they occur. Share-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Black Scholes requires a number of assumptions, of which the most significant are expected volatility, expected option term (the time from the grant date until the options are exercised or expire) and risk-free rate. Expected volatility is determined using the historical volatility for the Company. The risk-free interest rate is based on the yield of U.S. government treasury bonds with a remaining term equal to the expected life of the option for C$ options and based on the yield of U.S. government treasury bonds for US$ options. Expected dividend yield is zero because the Company has never paid cash dividends on common shares and the Company does not expect to pay cash dividends in the foreseeable future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;For awards with market conditions in which the award does not vest unless the market condition is met, the Company will incorporate the market condition into the award&#x2019;s grant date fair value calculation and derive the expected service period using a Monte Carlo simulation. The estimated expense is recognized on a straight-line &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;basis over the derived service period. If the market condition is satisfied during the derived service period, the remaining unrecognized expense is recognized during the period the market condition is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;Awards of options that provide for an exercise price that is not denominated in: (a) the currency of a market in which a substantial portion of the Company's equity securities trades in, (b) the currency in which the employee's pay is denominated, or (c) the Company's functional currency, are required to be classified as liabilities. The change in the Company&#x2019;s functional currency, effective July 1, 2023, resulted in the reclassification of outstanding stock options that were previously denominated in C$ from equity-classified to liability-classified options (see Note 8), which are accounted for as a share option modification in accordance with FASB&#x2019;s ASC 718 &#x2013; &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';font-style:italic;"&gt;Compensation &lt;/i&gt;&lt;i style="font-family:'TimesNewRomanPSMT';font-style:italic;"&gt;&#x2013;&lt;/i&gt;&lt;i style="font-family:'TimesNewRomanPSMT';font-style:italic;"&gt; Stock Compensation&lt;/i&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt; (&#x201c;&lt;/span&gt;&lt;b style="font-family:'TimesNewRomanPSMT';font-weight:bold;"&gt;ASC 718&lt;/b&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;&#x201d;). Under ASC 718, when an award is reclassified from equity to liability, if at the reclassification date the original vesting conditions are expected to be satisfied, then the minimum amount of compensation cost to be recognized is based on the grant date fair value of the original award. Fair value changes below this minimum amount are recorded in additional paid-in capital. For each reporting period after the modification date, the stock option liability is adjusted so that it equals the portion of the requisite service provided multiplied by the modified award&#x2019;s fair value at the end of the reporting period. Increases in the fair value of the liability in excess of the minimum grant date compensation cost described above are recognized as share-based compensation in operating expenses in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Share Issuance Costs &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Common share issuance costs are incremental costs directly associated with an offering of securities. These costs typically include fees paid to bankers or underwriters, attorneys, accountants, as well as printers and other third parties. Prior to the effective date of an offering of equity securities, specific incremental costs directly attributable to a proposed or actual offering of securities may be deferred and charged against the gross proceeds of the offering. &#160;The Company capitalizes these deferred financing costs as prepaid expenses and other current assets in the accompanying consolidated balance sheets until the completion of the offering, unless the offering is abandoned, at which time the deferred financing costs will be recognized in the consolidated statements of operations. &#160;The Company had approximately $32,000 and $0 in deferred financing costs as of December 31, 2025 and December 31, 2024, respectively, which was recorded in prepaid expenses and other current assets on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company is a taxable entity under the Income Tax Act (Canada). Deferred income tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the respective income tax bases of assets and liabilities, measured using substantively enacted income tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are recognized to the extent it is more likely than not that taxable income will be available against which the deferred tax asset can be utilized. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company follows the provisions of ASC 740-10, &lt;i style="font-style:italic;"&gt;Uncertainty in Income Taxes&lt;/i&gt; (&#x201c;&lt;b style="font-weight:bold;"&gt;ASC 740-10&lt;/b&gt;&#x201d;). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Basic and Diluted Net (Loss) Income Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;Basic net (loss) income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net (loss) income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;dilutive shares result from the assumed potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. The proceeds of such exercises or conversions are assumed to have been used to repurchase outstanding stock using the treasury stock method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Both basic and diluted net (loss) income per share calculations include financial instruments that allow for the purchase of common shares issuable for little to no consideration, including pre-funded warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company is an Emerging Growth Company, as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (&#x201c;&lt;b style="font-weight:bold;"&gt;JOBS&#160;Act&lt;/b&gt;&#x201d;). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;In 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740):&lt;/i&gt; &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt; (&#x201c;ASU 2023-09&#x201d;), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 became effective for the annual period starting on January 1, 2025. The Company&#x2019;s income tax disclosures are disclosed in Note 9.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;In 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;), which requires public entities, among other items, to disclose in a tabular format, on an annual and interim basis, purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion for each income statement line item that contains those expenses. ASU 2024-03 becomes effective for the annual period starting on January 1, 2027 and interim periods starting on January 1, 2028. The Company is in the process of analyzing the impact that the adoption of ASU 2024-03 will have on its disclosures.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_ayCCt6AhDkicdpA0qT83vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;&lt;b style="font-weight:bold;"&gt;GAAP&lt;/b&gt;&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;&lt;b style="font-weight:bold;"&gt;ASC&lt;/b&gt;&#x201d;) and as amended by Accounting Standards Updates (&#x201c;&lt;b style="font-weight:bold;"&gt;ASU&lt;/b&gt;&#x201d;) of the Financial Accounting Standards Board (&#x201c;&lt;b style="font-weight:bold;"&gt;FASB&lt;/b&gt;&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_Gk7CXTze9kGmrII1Q2gKvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_sGXXyHF6xE6TCGbLAJb0Rw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of financial instruments. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_0WbdHHUb00madA1jH5vOCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (&#x201c;&lt;b style="font-weight:bold;"&gt;CODM&lt;/b&gt;&#x201d;), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company has one operating segment and its Chief Executive Officer serves as the CODM. Substantially all of the Company&#x2019;s assets are located in Canada. Refer to additional Segment Information in Note 10.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="INF"
      id="Narr_oypYvD2ghEaW7a5qy0yn3g"
      unitRef="Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_yj6hakUydUSDoVicDsmKTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Foreign and Functional Currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company determines its functional currency as the currency of the primary economic environment in which the Company operates. To determine the primary economic environment, the Company considers salient economic factors, including cash flow indicators, expense indicators and financing indicators. Functional currency is a matter of fact, not a policy election and the Company will only reevaluate its functional currency if there is a significant change in facts and circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Prior to July 1, 2023, the Company&#x2019;s functional currency was the Canadian dollar (&#x201c;&lt;b style="font-weight:bold;"&gt;C$&lt;/b&gt;&#x201d;). Translation gains and losses from the application of the United States dollar (&#x201c;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&#x201d;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative foreign currency translation adjustment, which is reported as a component of stockholders&#x2019; (deficit) equity as accumulated other comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Following the Company&#x2019;s voluntary delisting from the Toronto Stock Exchange in July 2023, the Company determined there was a significant change in its facts and circumstances, and completed a reassessment of its functional currency. The Company determined that, as of July 1, 2023, the Company&#x2019;s functional currency had changed from the C$ to the US$. The Company reassessment included analysis of various factors, including: the Company&#x2019;s cash flows and expenses denominated primarily in US$, the primary market for the Company&#x2019;s Common Shares trading in US$ and a majority ownership by U.S. shareholders from financings denominated in US$. The change in functional currency was accounted for prospectively from July 1, 2023 and consolidated financial statements prior to and including the period ended June 30, 2023 were not restated for the change in functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;For periods commencing July 1, 2023, monetary assets and liabilities denominated in foreign currencies are translated into US$ using exchange rates in effect at the end of the reporting period. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after July 1, 2023 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations within operating expenses.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_4ksIyqdDXkSWLVoqY4SC1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2025 and 2024, the Company did not have any material cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <pmn:ShortTermInvestmentsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_FS83Mjirl0y8xqJAdjjaNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Short-term Investments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Short-term investments consist of guaranteed certificates of deposit with a maturity greater than 90&#160;days and up to one&#160;year at the time of purchase. Accordingly, all short-term investments are classified as current assets in the accompanying consolidated balance sheets. The short-term investment is being held as collateral for the Company&#x2019;s credit cards.&lt;/p&gt;</pmn:ShortTermInvestmentsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_4Y1tuQ2idEm-Zg9Qe0GtFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees 100% of the original amount invested. As of December&#160;31, 2025, the Company has not experienced any losses on its cash or short-term investments as a result of credit risk.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <pmn:PercentageOfOriginalAmountInvested
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="2"
      id="Narr_aRSELsFjJ0KZnyO9mUIVcA"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1</pmn:PercentageOfOriginalAmountInvested>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_CvbauMNShECUh4yWS7gnHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;FASB ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures, &lt;/i&gt;(&lt;b style="font-weight:bold;"&gt;&#x201c;ASC 820&#x201d;&lt;/b&gt;) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, as established by ASC 820, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2013; Observable inputs, such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2013; Inputs (other than Level 1 quoted prices) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company&#x2019;s warrant liabilities were classified as Level 3 financial instruments for the&#160;year ended December&#160;31, 2024. The Company&#x2019;s share-based compensation liability was classified as a Level 3 financial instrument for the&#160;years ended December&#160;31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The carrying amounts of prepaid and other current assets, short-term investments, accounts payable, and accrued expenses are generally considered to be representative of their fair value based on the short-term nature of these financial instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_p-0IbYd0HU2rsFb1cRo4Jg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Impairment of Long-lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company historically evaluates its long-lived assets, which consist of property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not have any material long-lived assets as of December&#160;31, 2025 and 2024.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb__Y-c6YH340yHoxTf3AFhVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Property and equipment, net are historically stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Laboratory and equipment are depreciated over &lt;span style="-sec-ix-hidden:Hidden_NcV6rL8tMk-QI6TxetjyIg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to five&#160;years. Computer equipment is depreciated over &lt;span style="-sec-ix-hidden:Hidden_xwYBGyVeBki9Pw78B3ou9w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to three&#160;years. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accompanying consolidated balance sheets and any resulting gain or loss is included in loss from operations in the accompanying consolidated statements of operations. Expenditures for repairs and maintenance are expensed as incurred. The Company did not have any material property and equipment as of December 31, 2025 and 2024.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_DFTrDh2oYk6khT-4RADKcQ"
      id="Narr_UltyNtgivUiN3AQ6ctFkRg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__MZVg_HiDUGOdFb43rdmsQ"
      id="Narr_3VAFIMMmJ0KWzfE1nAdE9A">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_hvcf7Xynf0WSQJU7p9MGNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Definite-lived intangible assets are historically stated at cost less accumulated amortization and any accumulated impairment losses. An intangible asset&#x2019;s carrying amount is assessed for impairment whenever there is an indication that the asset may be impaired. The Company&#x2019;s definite-lived intangible assets consist of acquired rights and patents. Intangible assets are amortized on a straight-line basis over the lesser of the life of the intangible asset or its estimated useful life, which is 15&#160;years. The Company did not have any material intangible assets as of December 31, 2025.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      id="Narr_kA2C8Gjlo0CykAN4cbaCig">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_VTc_80r2sUiSzn-xy5tKpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Collaboration Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company may enter into collaboration arrangements with pharmaceutical and biotechnology partners. The Company analyzes its collaboration arrangements to assess whether they are within the scope of FASB ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements, &lt;/i&gt;(&lt;b style="font-weight:bold;"&gt;&#x201c;ASC 808&#x201d;&lt;/b&gt;), to determine whether such arrangements involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. ASC 808 does not provide guidance on the recognition of consideration exchanged or accounting for the obligations that may arise between parties. The Company concluded that ASC Topic 730, &lt;i style="font-style:italic;"&gt;Research and Development, &lt;/i&gt;should be applied by analogy to payments between parties during the development activities of its collaboration arrangements.&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_LXwoGEFaNkWXJmI9fNwpKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;General and Administrative Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;General and administrative expenses consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, costs incurred in development and protection of intellectual property, professional service fees, and other general overhead and facility costs, including rent, depreciation and amortization, which relate to the Company&#x2019;s general and administrative functions.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_NxLbbdd7FkW3YqxkEhrWTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Research and development expenses consist primarily of costs incurred in connection with the development and research of the Company&#x2019;s platform technology, as well as discovery program expenses. The Company expenses research and development costs as incurred. These expenses include:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;employee-related expenses, including salaries, related benefits and share-based compensation expense, for employees engaged in research and development functions;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;external research and development expenses incurred under arrangements with third parties, such as contract research organizations (&#x201c;&lt;/span&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;CROs&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x201d;), and consultants;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the cost of acquiring, developing, and manufacturing clinical study materials; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Costs associated with preclinical and clinical activities and regulatory operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pmn:PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_y3GH4SerG0SnZ1b4zzpdgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Prepaid and Accrued Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Substantial portions of the Company&#x2019;s pre-clinical development, manufacturing and clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors. These vendors generally bill&#160;monthly for services performed, or bill based upon milestone achievement. For preclinical and clinical studies, the Company accrues expenses based upon estimated work completed and the remaining contract milestones. At times, the Company is obligated to make upfront payments upon execution of research and development agreements. Upfront payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses until such goods are delivered or the related services are performed. The Company estimates the period over which such services will be performed based on the terms of the agreements as well as the level of effort to be expended in each period. The actual timing of performance or the level of effort may vary from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.&lt;/p&gt;</pmn:PrepaidAndAccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock>
    <pmn:PatentCostsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_HW8vG-Xljkuck6qK3nJMWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations.&lt;/p&gt;</pmn:PatentCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Narr_MgTC0qfUMk6NTDxe3VGh5g"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">32000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Narr_MJ79MF_qgUCdb9epWNVS1Q"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_ECsTgg-Fm0mEHyIoeXeM2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company is a taxable entity under the Income Tax Act (Canada). Deferred income tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the respective income tax bases of assets and liabilities, measured using substantively enacted income tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are recognized to the extent it is more likely than not that taxable income will be available against which the deferred tax asset can be utilized. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company follows the provisions of ASC 740-10, &lt;i style="font-style:italic;"&gt;Uncertainty in Income Taxes&lt;/i&gt; (&#x201c;&lt;b style="font-weight:bold;"&gt;ASC 740-10&lt;/b&gt;&#x201d;). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Narr_iftQj32S7ECE8gh6m9AHPQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Narr_E_qockheUkWMIiCkBgKwtQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_o4IAhor000qbm850TUmfcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Basic and Diluted Net (Loss) Income Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;Basic net (loss) income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net (loss) income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;dilutive shares result from the assumed potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. The proceeds of such exercises or conversions are assumed to have been used to repurchase outstanding stock using the treasury stock method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Both basic and diluted net (loss) income per share calculations include financial instruments that allow for the purchase of common shares issuable for little to no consideration, including pre-funded warrants.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <pmn:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_nqUSKCzv7kezRNua2wHzyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Emerging Growth Company Status&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company is an Emerging Growth Company, as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (&#x201c;&lt;b style="font-weight:bold;"&gt;JOBS&#160;Act&lt;/b&gt;&#x201d;). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;</pmn:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_OyzvrtepFUyz8_cMfMJ1iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/span&gt;FAIR VALUE MEASUREMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The following are the major categories of assets measured at fair value on a recurring basis as of December&#160;31, 2025 and 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Aptos Narrow';font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;b style="font-family:'Aptos Narrow';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 204,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 204,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;No transfers between levels have occurred in either reporting period presented. Refer to Note 6 for disclosures related to the warrant liability and Note 8 for disclosures related to share-based compensation liability.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_e6am47peVke6xlI4BN627g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Aptos Narrow';font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;b style="font-family:'Aptos Narrow';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 204,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 204,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2BUfm8XxKEiVAOa9cCeI-A"
      decimals="0"
      id="Tc_emqaHLqKZ0iO4D6qVFVP3Q_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33753</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ"
      decimals="0"
      id="Tc_xzQkw8xs_EuPbErJ_qu7lA_4_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33753</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2BUfm8XxKEiVAOa9cCeI-A"
      decimals="0"
      id="Tc_-YOnvviF-UGadM-3ICypeA_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33753</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ"
      decimals="0"
      id="Tc_Ok-Y6u0lAEOtmtOBEsahiA_5_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33753</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6VYWxtDOn0yRARELn8NX6Q"
      decimals="0"
      id="Tc_D9pkfAGnQUOh0kFfq17AWw_7_9"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">29182</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ"
      decimals="0"
      id="Tc_0cAFYc1AaUaOS7T_OSkAVw_7_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">29182</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6VYWxtDOn0yRARELn8NX6Q"
      decimals="0"
      id="Tc_YngQpf6BwEq2yiZRg1fnYw_8_9"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">29182</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ZPUIQlF0y0KQnn3rLOWMVQ"
      decimals="0"
      id="Tc_9Jfu0fIH40e4jk5FIlHwog_8_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">29182</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qm2HZYqej0K6tZkucd3Jzw"
      decimals="0"
      id="Tc_gm9gOZtUxkKZIXittAh-MQ_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33051</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg"
      decimals="0"
      id="Tc_DVSgnyzI-kKCorjNQfovjQ_4_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33051</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qm2HZYqej0K6tZkucd3Jzw"
      decimals="0"
      id="Tc_JwVxyatDbUupZEI1cLHnYA_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33051</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg"
      decimals="0"
      id="Tc_Teb6XgUwFEGiWg7hDB01Mg_5_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">33051</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng"
      decimals="0"
      id="Tc_YXsn_eVgT0aQKJhPA83oGQ_7_9"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">199263</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg"
      decimals="0"
      id="Tc_AgIb_iUJBk6iWsyTEJ2dBQ_7_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">199263</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng"
      decimals="0"
      id="Tc_EJS0vbsJkUGo-vHYJKmxOg_8_9"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5592</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg"
      decimals="0"
      id="Tc_cKjjD-rkIkWD7x4xYo6sDQ_8_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5592</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p9E9lmgij0CSmFihYD-Tng"
      decimals="0"
      id="Tc_fhoUG8L-N0aAqstck86gPg_9_9"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">204855</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wWpKtEQ6p0eVsmU-bxu8Zg"
      decimals="0"
      id="Tc_zaXUK9Vt-U26nQoQaaYqdg_9_12"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">204855</us-gaap:LiabilitiesFairValueDisclosure>
    <pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Narr_yRgUIlbHBkuILETN6Tx8rw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount>
    <pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Narr_0NBrG3k840SJgNpmCNCUmA"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</pmn:FairValueAssetsLiabilitiesLevel2TransfersAmount>
    <pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Narr_0EBQT-lUz0i_kDRhXXX7mg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount>
    <pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Narr_kip-2bfXI0WvE-_TDU8tSg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</pmn:FairValueAssetsLiabilitiesLevel1TransfersAmount>
    <pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_WtqWzt7_mkeB2oJWBNsl9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.&lt;/b&gt;&lt;/span&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Upfront research payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,625,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,087,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued interest and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 36,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 78,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 238,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 335,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 62,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 38,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 32,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 38,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 47,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,032,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,587,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pmn:PrepaidExpenseAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_2BAazFr3tkKkydKhG3eAzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Upfront research payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,625,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,087,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued interest and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 36,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 78,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 238,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 335,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 62,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 38,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 32,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 38,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 47,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,032,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,587,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <pmn:PrepaidUpfrontResearchPaymentsCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_DwmxF8eEf0yYxbmCRiU5mA_3_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2625049</pmn:PrepaidUpfrontResearchPaymentsCurrent>
    <pmn:PrepaidUpfrontResearchPaymentsCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_jQAQpCwayU6a-hEe44CHug_3_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5087692</pmn:PrepaidUpfrontResearchPaymentsCurrent>
    <us-gaap:InterestReceivable
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_Yo3sEGskikOvDNX3iUGGhw_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">36522</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_Jbt8WcLtJkel3SD8yjPsEw_4_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">78034</us-gaap:InterestReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_yMyKoxBJtUapyObMdDqFPw_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">238000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_W-5QDg81eU-wS4a5EadgeA_5_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">335976</us-gaap:PrepaidInsurance>
    <pmn:PrepaidLicenseFeeCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_B7N1HraYs02GO3uJoGBkAg_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">62059</pmn:PrepaidLicenseFeeCurrent>
    <pmn:PrepaidLicenseFeeCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_2PD_sORBu0uMDMgSeh15JA_6_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">38255</pmn:PrepaidLicenseFeeCurrent>
    <pmn:DeferredFinancingCostAssets
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_Cvh3S2qgPkqYRWA9BjZNUg_7_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">32332</pmn:DeferredFinancingCostAssets>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_oNWA0bc6IUipMCmjDVN3rw_8_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">38150</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_m09qTOnlzUKLBfYmnLXltw_8_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">47281</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_vTwnXRumyEK9hn5az0u4Vw_9_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3032112</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_QBJ1htP2MECjiU7azVaXKw_9_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5587238</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <pmn:AccruedLiabilitiesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_1e5ACMxLDEuWLcRrX1mF8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.&lt;/b&gt;&lt;/span&gt;ACCRUED LIABILITIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Accrued liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Legal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44,610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 159,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,460,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Severance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 79,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 38,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 79,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 79,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,868,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 480,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pmn:AccruedLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb__68yCvVA-E650rXTLTd8vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:36pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Legal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44,610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 159,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,460,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Severance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 79,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 38,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 79,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 79,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,868,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 480,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pmn:AccruedLegalFeesCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_5YFECuUJ2Eqkf4i2VwSL9g_3_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-88411</pmn:AccruedLegalFeesCurrent>
    <pmn:AccruedLegalFeesCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_Uj99HdFki06JaQQ4GS4agg_3_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-44610</pmn:AccruedLegalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_wTydNU5GSEmFrnHqEj-hFQ_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">159900</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_UMOHNvbnDk-_aF3cCoQ9sA_4_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">95182</us-gaap:AccruedProfessionalFeesCurrent>
    <pmn:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_PPVsaaxJRE6JMhoD-UsJVw_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-7460614</pmn:AccruedResearchAndDevelopmentCurrent>
    <pmn:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_C9pbtwsXoUqpzS7uw2jQFA_5_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-223559</pmn:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_pc7eyBcoikSkfdn2T3bb7Q_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">79748</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_wCEtsf4wVE6KkNssbszlPg_6_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">38328</us-gaap:RestructuringReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_doJNxA02OUOpEGBTySTPdA_7_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">79743</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_UM59a4ePVUe-1QoM50XViA_7_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">79283</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_LDHkBETXDkOJ_nzlwZc9vA_8_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">7868416</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_n2sFF0e_6kOwPZ_oXzuDnA_8_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">480962</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_FqsUdyaRykOXCQ9is13ZaQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EQUITY &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company has authorized an unlimited number of both Common and Preferred shares. As of December&#160;31, 2025 and 2024, the Company had 2,152,397 and 1,307,520 issued and outstanding Common Shares, respectively. All share classes have no par value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Common Shares reserved for future issuance consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,639,005&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options issued and outstanding under stock option plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 180,827&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred Share Units granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Shares available for grant under stock option plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 80,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total Common Shares reserved for future issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,900,561&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Common Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The preferences, privileges, and rights of the Common Shares are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"&gt;Voting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Subject to any special voting rights or restrictions, holders of common shares entitled to vote shall have one vote per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"&gt;Dividends&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company&#x2019;s board of directors may from time to time declare and authorize payment of dividends, if any, as they may deem advisable and need not give notice of such declaration to any shareholder. Subject to the rights of common shareholders, if any, holding shares with specific rights as to dividends, all dividends on common shares shall be declared and paid according to the number of such shares held and paid in Canadian dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"&gt;Liquidation Rights&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;In the event of the liquidation, dissolution or winding-up of the Company or any other distribution of the Company&#x2019;s assets for the purpose of winding up the Company&#x2019;s affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled &lt;i style="font-style:italic;"&gt;pari passu&lt;/i&gt; to receive any remaining property of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equity Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;July 2024 Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;On July 26, 2024, the Company entered into a Unit Purchase Agreement (the &#x201c;&lt;b style="font-weight:bold;"&gt;Unit Purchase Agreement&lt;/b&gt;&#x201d;) to raise $30,332,984 in aggregate gross proceeds for the Company (the &#x201c;&lt;b style="font-weight:bold;"&gt;July 2024 PIPE&lt;/b&gt;&#x201d;) before deducting $2,675,487 in placement agent fees and other expenses. All gross proceeds were received by the Company as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Pursuant to the terms of the Unit Purchase Agreement, the Company agreed to sell to PIPE Investors in the Offering, an aggregate of (x) 390,307 common share units (the &#x201c;&lt;b style="font-weight:bold;"&gt;Common Share Units&lt;/b&gt;&#x201d;), each consisting of (i) one Common Share, (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share (each, a &#x201c;&lt;b style="font-weight:bold;"&gt;Warrant&lt;/b&gt;&#x201d;, collectively, the &#x201c;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&#x201d;) and, for certain investors, (y) 174,841 pre-funded units (the &#x201c;&lt;b style="font-weight:bold;"&gt;Pre-Funded Units&lt;/b&gt;&#x201d; and together with the Common Share Units, the &#x201c;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&#x201d;), each consisting of (i) one Pre-Funded Warrant to purchase one Common Share (each, a &#x201c;&lt;b style="font-weight:bold;"&gt;Pre-Funded Warrant&lt;/b&gt;&#x201d;, collectively, the &#x201c;&lt;b style="font-weight:bold;"&gt;Pre-Funded Warrants&lt;/b&gt;&#x201d;, and the Common Shares issuable upon exercise of the Warrants and the Pre-Funded Warrants, the &#x201c;&lt;b style="font-weight:bold;"&gt;2024 Warrant Shares&lt;/b&gt;&#x201d;), (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The purchase price for each Common Share Unit was $53.75 per Common Share Unit, and the purchase price for each Pre-Funded Unit was $53.50 per Pre-Funded Unit. The Pre-Funded Warrants have an exercise price of $0.25 per 2024 Warrant Share, are immediately exercisable and will expire when exercised in full. The Tranche A Common Share purchase warrants have an exercise price of $50.50, for aggregate gross proceeds of up to $28.5 million, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) 18 months or (ii) within 60 days of the Tranche A Milestone Event (as defined below). The Tranche B Common Share purchase warrants have an exercise price of $50.50, for aggregate gross proceeds of up to $28.5 million, are exercisable immediately upon Shareholder Approval (as defined below) and will expire upon the earlier of (i) 30 months or (ii) within 60 days of the Tranche B Milestone Event (as defined below). The Tranche C Common Share purchase warrants have an exercise price of $62.50, for aggregate gross proceeds of up to $35.3 million, are immediately exercisable and will expire on July 31, 2029. For purposes of the foregoing, &#x201c;&lt;b style="font-weight:bold;"&gt;Tranche A Milestone Event&lt;/b&gt;&#x201d; means the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with multiple ascending doses of PMN310, and &#x201c;&lt;b style="font-weight:bold;"&gt;Tranche B Milestone Event&lt;/b&gt;&#x201d; means the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with multiple ascending doses of PMN310. Pursuant to Nasdaq Listing Rule 5635(d), the exercise of the Tranche A and Tranche B Common Share purchase warrants is subject to shareholder approval (&#x201c;&lt;b style="font-weight:bold;"&gt;Shareholder Approval&lt;/b&gt;&#x201d;). The Company agreed to convene a shareholders&#x2019; meeting, or otherwise obtain written Shareholder Approval, on or before 90 days following the Closing Date, to obtain such approval.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Tranche A and Tranche B Warrants (&#x201c;&lt;b style="font-weight:bold;"&gt;AB Warrants&lt;/b&gt;&#x201d;) were classified as liabilities (&#x201c;&lt;b style="font-weight:bold;"&gt;AB Warrant Liability&lt;/b&gt;&#x201d;) and recorded at fair value utilizing level 3 inputs at issuance due to the requirement for Shareholder Approval. Under the applicable accounting guidance, the requirement for Shareholder Approval precludes a financial instrument from equity classification, as it cannot be considered indexed to the Company's own stock. &#160;The preclusion is because of the potential of the settlement amount differing than a fixed for fixed option on the Company's shares. The fair value of the AB Warrant Liability at issuance was determined to be $31,182,033, calculated using a Black Scholes calculation on July 26, 2024 with the following weighted average assumptions: share price of $50.50, the most currently available Nasdaq Official Closing Price for the Company&#x2019;s Common Shares when the Company entered into the purchase agreements, exercise price of $50.50, volatility of 102.5%, risk-free rate of 4.34%, and a term of 2.1 years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company incurred offering costs totaling $2,675,487 that consisted of placement agent fees and direct incremental legal, advisory, accounting and filing fees relating to the July 2024 PIPE, resulting in net cash proceeds of $27,657,497. The value of the AB Warrants exceeded the net proceeds received. As a result, the entire proceeds and offering costs were allocated to the AB Warrant liability, and also resulted in a loss on issuance of common shares, warrants, and pre-funded warrants of $3,524,535, which was recorded in other income (expense) in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;On October 23, 2024, Shareholder Approval for the AB Warrants was obtained during the Company&#x2019;s Special Meeting of Shareholders. Following Shareholder Approval, the Company determined that the AB Warrants met the criteria for equity classification. The Company re-measured the fair value of the AB Warrant Liability at October 23, 2024 to $8,689,149, calculated using a Black Scholes calculation with the following weighted average assumptions: volatility of 100.9%, share price of $23.75, exercise price of $50.50, risk-free rate of 4.10%, and a term of 1.9 years. The change in fair value of the AB Warrant Liability of $22,492,884 was recorded in other income (expense) in the consolidated statements of operations and the remaining fair value of $8,689,149 was reclassified from liability to additional paid-in-capital in the consolidated balance sheets. As of December 31, 2025, 942,510 warrants issued with the &lt;span style="-sec-ix-hidden:Hidden_YqiLGZ_RnUeciaPL5_1Scw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;July 2024&lt;/span&gt;&lt;/span&gt; PIPE are &lt;span style="-sec-ix-hidden:Hidden_zqmpoD10K0mYm-cj5Mnc8w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; (314,170 each from Tranche A, Tranche B, and Tranche C).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;A summary of warrant liability activity, which is based on level 3 inputs, for the years ended December 31, 2025 and 2024 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_TkWIfmwCtk2L1o77RyTsVw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of C$ warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 94,185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;July 2024 PIPE AB Warrant Liability at issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,182,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_K9LLXyDMFk2irW-0jw4rvw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of 2024 PIPE AB Warrant Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,492,884)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reclassification of 2024 PIPE AB Warrant Liability to equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,689,149)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NKYPClXPwkOL6W5cM2Ychw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of C$ warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,593)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;July 2025 Registered Direct Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#191c1f;"&gt;On July 22, 2025, the Company entered into a securities purchase agreement relating to the issuance and sale of a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;39,389&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Shares (the &#x201c;&lt;/span&gt;&lt;b style="color:#191c1f;font-weight:bold;"&gt;RD Pre-funded Warrant&lt;/b&gt;&lt;span style="color:#191c1f;"&gt;&#x201d;) to such investor (the &#x201c;&lt;/span&gt;&lt;b style="color:#191c1f;font-weight:bold;"&gt;RD Offering&lt;/b&gt;&lt;span style="color:#191c1f;"&gt;&#x201d;). The RD Pre-funded Warrant was sold at an offering price of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$20.31&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; per share, which represents, if it were applicable, the per share offering price for the Common Shares of the Company, less a &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$0.0025&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; per share exercise price for such Pre-funded Warrant. &#160;The gross proceeds from the RD Offering were &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$800,000&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; before deducting offering expenses of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$102,342&lt;/span&gt;&lt;span style="color:#191c1f;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#191c1f;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;July 22, 2025&lt;/span&gt;&lt;span style="color:#191c1f;text-decoration-color:#191c1f;text-decoration-line:underline;text-decoration-style:solid;"&gt; Exercise of Discounted Warrants and PIPE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;On July 22, 2025, the Company accepted a discounted warrant exercise offer from a healthcare-focused institutional investor for certain July 2024 PIPE warrants (&#x201c;&lt;b style="font-weight:bold;"&gt;July 22, 2025 Discounted Exercise&lt;/b&gt;&#x201d;). Related to the July 22, 2025 Discounted Exercise, the Company also entered into a securities purchase agreement (the &#x201c;&lt;b style="font-weight:bold;"&gt;July 22, 2025 PIPE&lt;/b&gt;&#x201d;) with the same existing healthcare-focused institutional investor. The Company raised $9,199,765 in aggregate gross proceeds from the July 22, 2025 Discounted Exercise and July 22, 2025 PIPE before deducting $808,738 in transaction costs paid by the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;In the July 22, 2025 Discounted Exercise, the Company &lt;span style="-sec-ix-hidden:Hidden_sIX-I_ihFUyckByqXSCcEg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; 336,449 Common Shares in exchange for the exercise of 336,449 of the &lt;span style="-sec-ix-hidden:Hidden_rAT-TO71IkG83cETElUNVQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;July 2024&lt;/span&gt;&lt;/span&gt; PIPE warrants (112,150 each from Tranche A, Tranche B, and Tranche C) for $20.31 per warrant. The Company determined that discounting the exercise price represented a modification of the July 2024 PIPE warrants. In accordance with &lt;i style="font-style:italic;"&gt;ASC815 &#x2013;&lt;/i&gt; &lt;i style="font-style:italic;"&gt;Derivatives and Hedging &lt;/i&gt;(&#x201c;&lt;b style="font-weight:bold;"&gt;ASC 815&lt;/b&gt;&#x201d;), the Company accounted for the incremental fair value of the modification as the difference between the pre-modification fair value and the post-modification fair value of the July 2024 PIPE warrants, as calculated using Black-Scholes. The modification date incremental fair value of $930,841 was initially recorded as a deferred financing cost, as the discount was directly attributable to a proposed offering, and was subsequently recognized as an equity issuance cost upon the closing of the July 22, 2025 Discounted Exercise and July 22, 2025 PIPE. The range of valuation inputs used in the pre-modification fair value Black Scholes calculation of the July 2024 PIPE warrants included a share price of $14.70, exercise prices of $50.50-$62.50, time to maturity of 0.53-4.02 years, risk free rate of 3.9%-4.3%, and annualized volatility of 106.5%. The post-modification fair value Black Scholes calculation used the same &lt;span style="-sec-ix-hidden:Hidden_vE8nknvrREuwISKkbV-t1g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fair&lt;/span&gt;&lt;/span&gt; value inputs &lt;span style="-sec-ix-hidden:Hidden_sDMpaTJpt02AivVLsCelvw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;as&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_UiLMq0ECGUuuIc3ZT61PGA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_bE979HFoxkSnleUqfJBh_Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;pre&lt;/span&gt;&lt;/span&gt;-&lt;span style="-sec-ix-hidden:Hidden_qaJfvU25ukC0j9SFajVEUw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;modification&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_z2jv6MWYFkOFbHtRCJPIPQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fair value&lt;/span&gt;&lt;/span&gt; calculation apart from the modified exercise price of $20.31.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;Pursuant to the terms of the July 22, 2025 PIPE, the Company agreed to sell a warrant to purchase 504,673 Common Shares (the &#x201c;&lt;b style="font-weight:bold;"&gt;July 22, 2025 Warrant&lt;/b&gt;&#x201d;). The July 22, 2025 Warrant was sold to the investor at an offering price of $4.69 per share and has an exercise price of $31.25 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The July 22, 2025 Warrant is immediately exercisable and will expire five years after the date of issuance. The holder of the July 22, 2025 Warrant may not exercise it if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of Common Shares outstanding immediately after giving effect to such exercise. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The Company determined the July 22, 2025 Warrant met the permanent equity criteria classification. The July 22, 2025 Warrant is classified as a component of permanent equity because it is a freestanding financial instrument, is immediately exercisable, does not embody an obligation for the Company to repurchase its shares, and permits the holders to receive a fixed number of common shares upon exercise. In addition, the July 22, 2025 Warrant does not provide any guarantee of value or return. The Company used a Black-Scholes calculation to determine the fair value of the July 22, 2025 Warrant at issuance and allocated a share of the net proceeds based on the relative fair value of the July 22, 2025 Warrant. Net proceeds allocated to the July 22, 2025 Warrant were $4,284,557, with the remaining net proceeds of $4,106,470 allocated to the Common Shares issued in the July 22, 2025 Discounted Exercise. The aggregate net proceeds of $8,391,027 are recorded in additional paid-in-capital. The valuation inputs used in the Black Scholes calculation of the July 22, 2025 Warrant at issuance included a share price of $14.70, exercise price of $31.25, time to maturity of 5 years, risk free rate of 3.9%, and annualized volatility of 106.5%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;July 28, 2025&lt;/span&gt;&lt;span style="color:#191c1f;text-decoration-color:#191c1f;text-decoration-line:underline;text-decoration-style:solid;"&gt; Exercise of Discounted Warrants and PIPE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;On July 28, 2025, the Company accepted discounted warrant exercise offers for certain July 2024 PIPE warrants (&#x201c;&lt;b style="font-weight:bold;"&gt;July 28, 2025 Discounted Exercise&lt;/b&gt;&#x201d;). Related to the July 28, 2025 Discounted Exercise, the Company also entered into a securities purchase agreement (the &#x201c;&lt;b style="font-weight:bold;"&gt;July 28, 2025 PIPE&lt;/b&gt;&#x201d;) with the same existing investors. The Company raised $11,623,047 in aggregate gross proceeds from the July 28, 2025 Discounted Exercise and July 28, 2025 PIPE before deducting $478,580 in transaction costs paid by the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;In the July 28, 2025 Discounted Exercise, the Company &lt;span style="-sec-ix-hidden:Hidden_2uiJ2Xl62UWXxUyC2yNBhA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; 416,436 Common Shares in exchange for the exercise of 416,436 of the &lt;span style="-sec-ix-hidden:Hidden_u1jGCHE0JUyEOMipzgeTYA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;July 2024&lt;/span&gt;&lt;/span&gt; PIPE warrants (138,812 each from Tranche A, Tranche B, and Tranche C) for $20.88 per warrant. The Company determined that discounting the exercise price represented a modification of the July 2024 PIPE warrants. In accordance with ASC 815, the Company accounted for the incremental fair value of the modification as the difference between the pre-modification fair value and the post-modification fair value of the July 2024 PIPE warrants, as calculated using Black-Scholes. The modification date incremental fair value of $1,794,146 was initially recorded as a deferred financing cost, as the discount was directly attributable to a proposed offering, and was subsequently recognized as an equity issuance cost upon the closing of the July 28, 2025 Discounted Exercise and July 28, 2025 PIPE.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;The range of valuation inputs used in the pre-modification fair value Black Scholes calculation of the July 2024 PIPE warrants included a share price of $20.88, exercise prices of $50.50-$62.50, time to maturity of 0.52-4.01 years, risk free rate of 3.9%-4.3%, and annualized volatility of 107.4%. The post-modification fair value Black Scholes calculation used the same &lt;span style="-sec-ix-hidden:Hidden_88CXrfs02k61Q4fWLfzeFg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fair&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_XdTVGA3HiEy71yJOaEE4tg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;value&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_Dh34ZOTg80WsRg6qGMRmNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;inputs&lt;/span&gt;&lt;/span&gt; as the pre-&lt;span style="-sec-ix-hidden:Hidden_p37SpWW4dk6Jm7sLGseshg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;modification&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_fQaxwlZiKkGwEDVd1NMCVQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fair value&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_DM6veFeJkkWgBQ6DbhWYUw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;calculation&lt;/span&gt;&lt;/span&gt; apart from the modified exercise price of $20.88.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;Pursuant to the terms of the July 28, 2025 PIPE, the Company agreed to sell warrants to purchase 624,654 Common Shares (the &#x201c;&lt;b style="font-weight:bold;"&gt;July 28, 2025 Warrants&lt;/b&gt;&#x201d;). The July 28, 2025 Warrants were sold to the investor at an offering price of $0.1875 per share and has an exercise price of $31.25 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The July 28, 2025 Warrant are immediately exercisable and will expire five years after the date of issuance. Certain holders of the July 28, 2025 Warrants may not exercise it if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of Common Shares outstanding immediately after giving effect to such exercise. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The Company determined the July 28, 2025 Warrants met the permanent equity criteria classification. The July 28, 2025 Warrants are classified as a component of permanent equity because they are a freestanding financial instrument, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, the July 28, 2025 Warrants do not provide any guarantee of value or return. To determine the fair value of the July 28, 2025 Warrants at issuance, the Company used a Black-Scholes model and allocated a share of the net proceeds based on the relative fair value of the July 28, 2025 Warrants. Net proceeds allocated to the July 28, 2025 Warrants were $5,885,032, with the remaining net proceeds of $5,259,435 allocated to the Common Shares issued in the July 28, 2025 Discounted Exercise. The aggregate net proceeds of $11,144,467 are recorded in additional paid-in-capital. The valuation inputs used in the Black Scholes calculation of the July 28, 2025 Warrant at issuance included a share price of $20.88, exercise price of $31.25, time to maturity of 5 years, risk free rate of 4.0%, and annualized volatility of 107.4&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;November 2025 Reverse Share Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;On November 28, 2025, the Company filed articles of amendment to effect a &lt;span style="-sec-ix-hidden:Hidden_bzJ1h69P5Uu2r6edpFDPOQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty-five reverse share split of its Common Shares (the &#x201c;&lt;b style="font-weight:bold;"&gt;Reverse Share Split&lt;/b&gt;&#x201d;). As a result of the Reverse Share Split, every &lt;span style="-sec-ix-hidden:Hidden_uNKYSpxl1EOc5rSnKnyhFA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;25&lt;/span&gt;&lt;/span&gt; Common Shares issued or outstanding were automatically reclassified into one validly issued, fully paid and non-assessable new Common Share, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportional adjustments were made to the number of Common Shares awarded and available for issuance under the Company&#x2019;s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company&#x2019;s outstanding stock options and other equity securities under the Company&#x2019;s equity incentive plans. All outstanding warrants were also adjusted in accordance with their terms, which resulted, among other changes to the warrant terms, in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise prices of such warrants. The Common Shares outstanding following the Reverse Share Split remain fully paid and non-assessable. The Reverse Share Split did not affect the number of authorized Common Shares or the par value of the Common Shares. All share and per-share amounts have been retroactively adjusted to reflect the Reverse Share Split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;At-the-Market Offerings (ATM)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;In September 2023, the Company filed a shelf registration statement with the SEC. In conjunction with the shelf registration, the Company entered into an ATM agreement in January 2024 (the &#x201c;&lt;b style="font-weight:bold;"&gt;2024 ATM Agreement&lt;/b&gt;&#x201d;) to offer up to $25.0 million of the Company&#x2019;s Common Shares. During the year ended December 31, 2024, the Company sold 3,034 Common Shares for net proceeds of $190,274 after deducting sales commissions. The 2024 ATM Agreement was terminated in July 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;In August 2025, the Company filed a shelf registration statement with the SEC. In conjunction with the shelf registration, the Company entered into an &lt;span style="color:#191c1f;"&gt;ATM Agreement with H.C. Wainwright &amp;amp; Co., LLC (the &#x201c;&lt;/span&gt;&lt;b style="color:#191c1f;font-weight:bold;"&gt;2025 ATM Agreement&lt;/b&gt;&lt;span style="color:#191c1f;"&gt;&#x201d;) on August 26, 2025 to offer up to &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$18.0&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; million of its Common Shares. During the year ended December 31, 2025, the Company sold &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;40,795&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Shares for net proceeds of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$708,468&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; after deducting sales commissions pursuant to the 2025 ATM Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Narr_4EMfl319XEiTIKNxei-UNA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2152397</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Narr_fiL9aTGuS0uHQFzmrO1WWQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2152397</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="INF"
      id="Narr_3o2iQxOWbUK-qJXfhKzQUQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1307520</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="INF"
      id="Narr_Vp_CCNsj5Eqk3jYacsEx-Q"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1307520</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockNoParValue
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Narr_TiETkOKDCEe1vgjd8BMxqw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0</us-gaap:CommonStockNoParValue>
    <pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_uy2WEp5WZk-f07rhk088mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,639,005&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options issued and outstanding under stock option plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 180,827&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred Share Units granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common Shares available for grant under stock option plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 80,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total Common Shares reserved for future issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,900,561&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pmn:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Tc_DO_fwCZQ6Uu2JP2XTJqahw_3_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2639005</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Tc_f9QUE4-tFkGUM69b1vTyBg_4_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">180827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <pmn:DeferredShareUnitsOutstanding
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Tc_T9gqqUOjjEKRaz7y50KsEQ_5_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">42</pmn:DeferredShareUnitsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Tc_AqlYf8unu0q50_dys2tn5w_6_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">80686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Tc_wE8wT6Jh4EGCkv2V-rwq-A_7_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2900561</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pmn:NumberOfVotesPerCommonShare
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="INF"
      id="Narr_22ccacN7ZkGkXau8JwZnpw"
      unitRef="Unit_Standard_Vote_I7wc_r8nuUinrT38wY9WLA">1</pmn:NumberOfVotesPerCommonShare>
    <pmn:AggregateGrossProceeds
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA"
      decimals="0"
      id="Narr_TtE73sctiUGEx196lIEmwg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">30332984</pmn:AggregateGrossProceeds>
    <pmn:OfferingCostsAndAgentFee
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA"
      decimals="0"
      id="Narr_yBbxudVbwEeHywIEQ--H0A"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2675487</pmn:OfferingCostsAndAgentFee>
    <pmn:UnitsIssuedDuringPeriodSharesNewIssuance
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_WoxRD2BhjUizfdZS0HDjoA"
      decimals="INF"
      id="Narr_KX055QAIEU6Fv-xoB9MxmQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">390307</pmn:UnitsIssuedDuringPeriodSharesNewIssuance>
    <pmn:NumberOfCommonSharePerUnit
      contextRef="As_Of_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_8p18K6uLmk6qW32n10mbgw"
      decimals="INF"
      id="Narr_-QNOh-cVEUiAz23w9o1emw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfCommonSharePerUnit>
    <pmn:NumberOfWarrantsPerUnit
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_3sNvUqnERk29CoEwJ1LNig"
      decimals="INF"
      id="Narr_l2TzWT_2MkKygEc_0rhPnw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_3sNvUqnERk29CoEwJ1LNig"
      decimals="INF"
      id="Narr_SJGJa1tNhE28P1al23fJ_g"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pmn:NumberOfWarrantsPerUnit
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_6T695C591UiyeQbCleHuxg"
      decimals="INF"
      id="Narr_lxP21pU4TUS-yNErs0j2pA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_6T695C591UiyeQbCleHuxg"
      decimals="INF"
      id="Narr_XK-Qo83vcEqGYyOw3DxNug"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pmn:NumberOfWarrantsPerUnit
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OX19e1OjNUi2f5RsX_WMag"
      decimals="INF"
      id="Narr_WF2o5HbHGUiQKA1yrxl9tg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OX19e1OjNUi2f5RsX_WMag"
      decimals="INF"
      id="Narr_Ye9l14bArkqcxzEh0bjuJw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pmn:UnitsIssuedDuringPeriodSharesNewIssuance
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_w1RADThn2Uar_4m_e19qyQ"
      decimals="INF"
      id="Narr_j9dt9_yCWkeuFx8Vf6cn-g"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">174841</pmn:UnitsIssuedDuringPeriodSharesNewIssuance>
    <pmn:NumberOfWarrantsPerUnit
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_Cj0bmR9KNU-gOSr3An81OQ"
      decimals="INF"
      id="Narr_zwU5aYOm3UeaDSdCSWMaWA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_Cj0bmR9KNU-gOSr3An81OQ"
      decimals="INF"
      id="Narr_3iOiaYUOK0i-OcRZP94wZA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pmn:NumberOfWarrantsPerUnit
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_sO-pqyxjMUuCAIj5bfCXDw"
      decimals="INF"
      id="Narr_-YsPeUl2Wkiy556MY9Kxag"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_sO-pqyxjMUuCAIj5bfCXDw"
      decimals="INF"
      id="Narr_-PrkjlTDxU6cEbM65YMXxg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pmn:NumberOfWarrantsPerUnit
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_bpZRccBbfUmU6W3r5YkXHA"
      decimals="INF"
      id="Narr_WjcPYmmT8UeMPL_FWO0vmA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_bpZRccBbfUmU6W3r5YkXHA"
      decimals="INF"
      id="Narr_0hXPoZGFn0GIKRJeFH8ecg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pmn:NumberOfWarrantsPerUnit
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_v_5AQ8INOEWby_KGMYOsxQ"
      decimals="INF"
      id="Narr_QURm-2QwdUGDUAfW87qvpg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:NumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_v_5AQ8INOEWby_KGMYOsxQ"
      decimals="INF"
      id="Narr_Ot77decOm062HUEJXc2NhA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pmn:PricePerUnit
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_CommonShareUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_WoxRD2BhjUizfdZS0HDjoA"
      decimals="2"
      id="Narr_NAGJjxth20Kib5IyBmGK7g"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">53.75</pmn:PricePerUnit>
    <pmn:PricePerUnit
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_StatementClassOfStockAxis_pmn_PreFundedUnitsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_w1RADThn2Uar_4m_e19qyQ"
      decimals="2"
      id="Narr_0_eEXHT1s0OEFrGtgqXmmw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">53.5</pmn:PricePerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_26_2024_YRF1DtgvqEykJgtUIbZvgA"
      decimals="2"
      id="Narr_IjdjAeweG0exjhCOOkb_Hw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OTZaBhXrTk-ATiBJ5MN0xg"
      decimals="2"
      id="Narr_P2wL__-tOE28hJuAm6_R8w"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_AXkBdGaKv0Sxf5BYb0bqKw"
      decimals="-5"
      id="Narr_NlHNp7lBv0aNMDtxn7Eg9g"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">28500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_OTZaBhXrTk-ATiBJ5MN0xg"
      id="Narr_kiBzp2TOu0-_20u-FSBMfQ">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pmn:ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_FcVZtKmJ30yeYVCm5Ilgeg"
      id="Narr_k6dt44k9E0KnHjh61P91ww">P60D</pmn:ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_SKI98Sng40qCm1MAstf_uw"
      decimals="2"
      id="Narr_a3ZbNaMEckOhcJiyEu6t8Q"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_7_26_2024_To_7_26_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_anrOgR3un0mVCIt8ZEvpkg"
      decimals="-5"
      id="Narr_VJxFl-6qtUiZY2Vs5gTrRg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">28500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheBCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_SKI98Sng40qCm1MAstf_uw"
      id="Narr_LFSTvmk0VkSONpng8RSu0Q">P30M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pmn:ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA"
      id="Narr_PLnGOguXiUONVRcwdCvtdw">P60D</pmn:ThresholdDaysAfterCompletionOfTrancheMilestoneEventsConsideredForExpiryTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_7IREftZcLkyg0wHsVKlqFQ"
      decimals="2"
      id="Narr_6nvOw9QZ40ukiKz-t6HLIQ"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">62.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheCCommonShareWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_47_m4S0qR0iRJtAX5RQLIg"
      decimals="-5"
      id="Narr_pHdQP3b7f0ePXQ1vCVfjuw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">35300000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <pmn:ThresholdDaysToGetShareholdersApproval
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_KA2XVF21qEq7pqiSmtDRPA"
      decimals="INF"
      id="Narr_fx4HDXHTx0ChlNgEUmxnsg"
      unitRef="Unit_Standard_D_JjSvLYrH-EWdNko9j1YiTg">90</pmn:ThresholdDaysToGetShareholdersApproval>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_7_26_2024_To_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_Ec-PTVWrHU6jtSro-6pQ3g"
      decimals="0"
      id="Narr_zjgZYVwiWEejgVTkME4xLQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">31182033</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OBE-rahe30mjEaB9k6wKdQ"
      decimals="2"
      id="Narr_mKvByLX4LUyCTDZgDTZt5Q"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_oIAjV4RAJk26fwCLgDL5rw"
      decimals="2"
      id="Narr_lOeJu9G3IUiLJz0V1RwmZQ"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SMlc3z5xwU2h8j7yM4L-sQ"
      decimals="1"
      id="Narr_jPj238l4CU2Ci0fTExQjUQ"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">102.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0ulmsA0VAkKV0dAMZCrDbA"
      decimals="2"
      id="Narr_ZP0wcUS4f0G-iV5D51BrOA"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">4.34</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_26_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_irrRYii8eE21ooTnYfcNCA"
      decimals="1"
      id="Narr_c4vnot842U-tcafdBTa3bA"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">2.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg"
      decimals="0"
      id="Narr_oZFjvhH-JUix4Fgqj1x1hQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2675487</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg"
      decimals="0"
      id="Narr_sA2WpImO-UG5hOv2SfAxlg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">27657497</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <pmn:LossOnSaleOfCommonSharesAndWarrants
      contextRef="Duration_7_26_2024_To_7_26_2024_zuxvntHenUaiscoTgH2IGg"
      decimals="0"
      id="Narr__kQPJ6FYGEGwnL18ME2OTg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-3524535</pmn:LossOnSaleOfCommonSharesAndWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_qo_eeZpMdkKWqiKn5hBbMQ"
      decimals="0"
      id="Narr_2Gy2SZQcIU2Y-CFtLbdW7g"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8689149</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hE5JvZ3pGkuLwiBtavfN2w"
      decimals="1"
      id="Narr_x5xtLG3LSEmd-RJU50NLkw"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">100.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_sgCMr1pSoUC2ePK4kj1p-A"
      decimals="2"
      id="Narr_yjlGB6hzkkqHv1ImqLNIrA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">23.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_C7t5pUTfOU2-H7yBZeKMnA"
      decimals="2"
      id="Narr_nZxGU0-hV0G4xe-8eK486g"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qIdSELbVFkaYdmFaMjb2AA"
      decimals="2"
      id="Narr_-IqeEK-evkWbBl3EEFC6gg"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">4.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RbMHvC0yfUeVN1ARzZnBIQ"
      decimals="1"
      id="Narr_GJDbnFy6VEKX8rTovDMAWg"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">1.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_RQMPznxiJUaeXSv1Kr1dkg"
      decimals="0"
      id="Narr_Fraq6R2ISEmoawtm_R1WGQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">22492884</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <pmn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity
      contextRef="Duration_10_23_2024_To_10_23_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_RQMPznxiJUaeXSv1Kr1dkg"
      decimals="0"
      id="Narr_ItI50JdJwEKWRxbsQKCnVg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8689149</pmn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July2024PrivatePlacementMember_n8K5Hi-d6EKuzXBWSyVZug"
      decimals="INF"
      id="Narr_kIRXiXdXxU2BD67ktUW2WQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">942510</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaCommonShareWarrantMember_JIhTf2m0-0KabLXPYhKDMQ"
      decimals="INF"
      id="Narr_zYPlRvRpq0-bIaZjD109Fg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">314170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_YoanmoqTME6ncgb6u864pQ"
      id="Tb_H2NEwcf350aPFyKmsq_uqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_TkWIfmwCtk2L1o77RyTsVw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of C$ warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 94,185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;July 2024 PIPE AB Warrant Liability at issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,182,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_K9LLXyDMFk2irW-0jw4rvw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of 2024 PIPE AB Warrant Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,492,884)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reclassification of 2024 PIPE AB Warrant Liability to equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,689,149)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NKYPClXPwkOL6W5cM2Ychw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of C$ warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88,593)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:77.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_xaU9LQGLVkuHu1Sq5gLwdw"
      decimals="0"
      id="Tc_P0sV5IiJgE63t8wDPYj-xg_3_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5592</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_PmbPPIZSikyMOvx6yPh_Ag"
      decimals="0"
      id="Tc_1VRYM3t8N06ETI8wD8QjkQ_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-5592</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_eoUbqM8EvkG5L47UIBVk4A"
      decimals="0"
      id="Tc_GSzWSiYCz0STeeqLtIBQaA_3_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">94185</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_T8HONw3a-0-21izjx6PztQ"
      decimals="0"
      id="Tc_1Y3yHK8JoEe61FChxaHhHA_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">31182033</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw"
      decimals="0"
      id="Tc_iNpkjm-HZkCwVepJ2_piAQ_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-22492884</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <pmn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_TrancheaAndBWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_R-bDvQWa7kW94mxAml5wLw"
      decimals="0"
      id="Tc_wUCZv97Gykumvul765uxaA_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-8689149</pmn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifiedToPermanentEquity>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_CanadianDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_aET_q1kz20eyyiAplvmU3A"
      decimals="0"
      id="Tc__31mpY62jEaNVom0iCq3cg_7_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-88593</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_UnitedStatesDollarDenominatedWarrantsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_JgwQ5vRSwU6dCCuhwG_xZA"
      decimals="0"
      id="Tc_PMlvC65jm0eqYLkjCwD95Q_8_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5592</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w"
      decimals="INF"
      id="Narr_xDeT03pBJ0eMB1_ES1k0mg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">39389</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w"
      decimals="2"
      id="Narr_alrUEPuhgkiIhHg83YFJIw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.31</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_bWsGTueIHkee3FuO6Nuj8w"
      decimals="4"
      id="Narr_-oIAjuFbI0KbGr2MPGxL5g"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_c27Fx9k4pkmbZZyNSQSBcw"
      decimals="0"
      id="Narr_bLgFh8VaOk6O0nb05al6nQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOfferingMember_c27Fx9k4pkmbZZyNSQSBcw"
      decimals="0"
      id="Narr_XVna9MbfD0yu9Ym_74UmYA"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">102342</us-gaap:PaymentsOfStockIssuanceCosts>
    <pmn:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g"
      decimals="0"
      id="Narr_mVb_zUnbWk-uGMwLDJ2W4Q"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">9199765</pmn:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g"
      decimals="0"
      id="Narr_WF7AxAk1uUa0Qd1Ics3PTw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">808738</us-gaap:PaymentsOfStockIssuanceCosts>
    <pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg"
      decimals="INF"
      id="Narr_Ijaq2raQPUm51ifFqt-VnQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">336449</pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg"
      decimals="INF"
      id="Narr_yMCXNrtBTEitQAGSur5QIg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">336449</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferTrancheMember_T1JrdAuH_EGgMvUA5bYqhA"
      decimals="INF"
      id="Narr_A8UchikPuU6NAuUwb0y0CQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">112150</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_IxRv2RxvLk-C6APbD0vZoA"
      decimals="2"
      id="Narr_SgN6e2T4CkuE_5kJ2kzV2g"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pmn:DeferredDiscountForFairValueModificationOfWarrants
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg"
      decimals="0"
      id="Narr_MLyLZCb3yUqmSwbiSn3dtA"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">930841</pmn:DeferredDiscountForFairValueModificationOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Gqt906yAIEyMV9y-5GtbIg"
      decimals="2"
      id="Narr_buhpGw_SMU-6DcQYwfdu9g"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">14.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_dJb2jjHN40ybk15--NzTxA"
      decimals="2"
      id="Narr_BbfReSUmZ06TsjwGCtVFDw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_-BYZBHNW00qP6PIyK-XiTw"
      decimals="2"
      id="Narr_n9iPRc7kbUKoWpOCrJx3vg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">62.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DuvCQ_GM9UKztjhwWQu6pA"
      decimals="2"
      id="Narr_8E-RNcBwT0e96nW3577_Sg"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">0.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_DRD7WoeXBU-JH-rKWT9PFg"
      decimals="2"
      id="Narr_KllCQtgsWU20SyvbS3Fhyw"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">4.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_GvLUVdGT7kKjraQdVt5bsQ"
      decimals="3"
      id="Narr_bF1hvBALEkGK-MUP_OEkJg"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y-QIx4_sEUmBnP424eXzYw"
      decimals="3"
      id="Narr_ZfQadL056U6NkElVsMc0Aw"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.043</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_wj2kZqXnhEOGN-1dq0Xllg"
      decimals="3"
      id="Narr_v-5-113XmEajY50xVEvWmQ"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.065</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_neufGN5uEk2IUYIIK5t4qA"
      decimals="2"
      id="Narr_Q5gxx1ZlvEq2J1rTgKfaWw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.31</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q"
      decimals="INF"
      id="Narr_vJ4I8MQi4ke1JEx6u_Z6hg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">504673</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q"
      decimals="2"
      id="Narr_afA6-KFkzEeagiznlWW-BA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">4.69</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q"
      decimals="2"
      id="Narr_8Ba_Fme1X0OPttUKx5p_0A"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">31.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_8p7sdSDYXkmjsemPORVb8Q"
      id="Narr_Z2tbndalY0aUxxvUd49peg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pmn:BeneficialOwnershipLimitation
      contextRef="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_iEMqWL4XT0SxMr2o3-qqIQ"
      decimals="4"
      id="Narr_-eUeDOiRjkGlfuY1nYfnew"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.0499</pmn:BeneficialOwnershipLimitation>
    <pmn:BeneficialOwnershipLimitation
      contextRef="Duration_7_22_2025_To_7_22_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_Y36YA1aV8EG9tI8Bg4zyLw"
      decimals="4"
      id="Narr_AO4_tHuztkuSlhKlPDLGkQ"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.0999</pmn:BeneficialOwnershipLimitation>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_0I2NUUyQSkuP1T4GHvUZvA"
      decimals="0"
      id="Narr_c4O7aqFrYkOlMKj9zbBHag"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">4284557</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg"
      decimals="0"
      id="Narr_0CqbP3kanUqq2L0O3Be3Jw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">4106470</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_wGDp9xCG9UmcTTIs75Ca7g"
      decimals="0"
      id="Narr_nxGCATDmTUSlZ-uYOVDvCQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">8391027</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_y4m6ZNV0Q0Kp3hRUT7r-aA"
      decimals="2"
      id="Narr_dzNaRJ-T2kqCntTMnl6DNg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">14.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_AD1d2zJY0Ue1O3lheBiTPg"
      decimals="2"
      id="Narr_iNVU4gAodkW5P-TMmfJGpw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">31.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_aepTXAELwE2v1b_eEMAxzg"
      decimals="0"
      id="Narr_EU7RY5dTdEKRRQvmCRQM5w"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_xEmsDgSeNU-j_EYzMwwGPw"
      decimals="3"
      id="Narr_Ytr3Xf12RUit2GMVo9hZTg"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_22_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly222025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_YtOhhYng_UGNJq2bFO6jYw"
      decimals="3"
      id="Narr_yaiFsI08pE2P0Em3seuO5Q"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.065</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <pmn:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw"
      decimals="0"
      id="Narr__ef28c9RDEGJK9ZPE3l_bg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">11623047</pmn:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw"
      decimals="0"
      id="Narr_JtMdqQiCDkK-5IMWo0f0UA"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">478580</us-gaap:PaymentsOfStockIssuanceCosts>
    <pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA"
      decimals="INF"
      id="Narr_rXjncVEk70eefuki4snF7Q"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">416436</pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA"
      decimals="INF"
      id="Narr_mCStJj_PzEaDgr9A8cRocQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">416436</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferTrancheMember_qwFZGwi9q0GjlBqTpS8zEg"
      decimals="INF"
      id="Narr_wcaQGBYZjUKLrc7LA3jsTw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">138812</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_TP3g5_42vkuIAbWzNvhidg"
      decimals="2"
      id="Narr_-n7VupHmv0qNsE-4aOVvow"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pmn:DeferredDiscountForFairValueModificationOfWarrants
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA"
      decimals="0"
      id="Narr_nw2qoup9oEWxg69CLhD6AQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">1794146</pmn:DeferredDiscountForFairValueModificationOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_e9DEwqxr8EKiOrKOtaJIGA"
      decimals="2"
      id="Narr_QGCWxH7fC02ayZF7gNhtyw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_VQxtOloCU0Kve5DNgHGdOg"
      decimals="2"
      id="Narr_PTMOd77GVUeWkFjX7xWMKg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_uFsROG-NVU2k94DCS0QXRA"
      decimals="2"
      id="Narr_f90nSjWCkEawg5qRnN_34w"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">62.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_cyhzjHJjgkSJTrqFS2S_jw"
      decimals="2"
      id="Narr_efVOiKlqpUq20PbyF65oUw"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">0.52</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_rc0mwg3aNEm7zVK6UJmkYA"
      decimals="2"
      id="Narr_uBgRPtDI-UGakIqi_fvfPA"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">4.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_jgbAwglzZ0mcOj7IwSXxRw"
      decimals="3"
      id="Narr_aqIUIccb10mMQPvS6GXNSA"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_Gcz0PPFqSkCFQ8-TE6lbgw"
      decimals="3"
      id="Narr_hOlu3NSa_0WdCnudCWpZTw"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.043</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PreModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_FP_FrTOu2Uu1Wd6byIXwSQ"
      decimals="3"
      id="Narr_Zhfs21s9uUeL58Ebg2ciAw"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.074</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_srt_StatementScenarioAxis_pmn_PostModificationMember_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_aHA4MFp8MUyKpl5PvcxEWA"
      decimals="2"
      id="Narr_9j0I2-DBsEa00h-b25JT8w"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA"
      decimals="INF"
      id="Narr_XsO5YafoN0KHB7621GOn-w"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">624654</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA"
      decimals="4"
      id="Narr_IcN6jcp4bkG-W7YDcxzp-w"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0.1875</us-gaap:SaleOfStockPricePerShare>
    <pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA"
      decimals="2"
      id="Narr_d0rPN9gnu0K3H_3s-sdO3Q"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">31.25</pmn:ClassOfWarrantOrRightExercisedDiscountedExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_ATkdkBMwzUi8u2-NCDUQjA"
      id="Narr_FXNeUmhVSUu6h2t4_mjpdg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pmn:BeneficialOwnershipLimitation
      contextRef="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_SWJwnPT2MUWAT21zy7PWMg"
      decimals="4"
      id="Narr_NWQK2ylHMEyp9880EPF34w"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.0499</pmn:BeneficialOwnershipLimitation>
    <pmn:BeneficialOwnershipLimitation
      contextRef="Duration_7_28_2025_To_7_28_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_wj_YaF2jk02-OwZm2Ww4xw"
      decimals="4"
      id="Narr_zd_0YlACVEKsN7hZPoL4ug"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.0999</pmn:BeneficialOwnershipLimitation>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA"
      decimals="0"
      id="Narr__JY84CpgMEenElsLpEub8A"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5885032</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA"
      decimals="0"
      id="Narr_TRc4AOPqz0GmECcOgF1bWQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5259435</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025ExerciseOfDiscountedWarrantsAndPipeOfferingMember_fFJ_aliCdk-hiS7l3iL8zw"
      decimals="0"
      id="Narr_iOKqh8C2WEiuwL5WqRZ8IQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">11144467</pmn:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_sQgJPaD0DE-aVvUQ9j8Tng"
      decimals="2"
      id="Narr_9Xgkft5rnUavimICYj4ZZA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">20.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Ywf0QSn_MU67VjykM1HpRw"
      decimals="2"
      id="Narr_0sraNU6Zo0WJhWcHk4yvnA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">31.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputMaturityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_Okge8-wzBU2jlOsUJvycVQ"
      decimals="INF"
      id="Narr_sOaZ8SOE5EqpS64R8tZrrQ"
      unitRef="Unit_Standard_Y_Q2VHMoM0bUiKLJAaGXOVQQ">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_PVYYZPfc3UauSC4uMd_VJw"
      decimals="3"
      id="Narr_1LC9cTTD8E2yxhyoG92Wrg"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.04</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_28_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantJuly282025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_nNyk22XD9EK1oyNQIa_tUQ"
      decimals="3"
      id="Narr_Y08rEXbNNEG81sFcfWXWZw"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.074</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <pmn:CommonStockCapitalSharesReservedForFutureIssuanceAmount
      contextRef="Duration_9_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_Kfapro2AwUiDsFbp7-NsnQ"
      decimals="-5"
      id="Narr_75V63rDUo0idwS4C3_iyUg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">25000000</pmn:CommonStockCapitalSharesReservedForFutureIssuanceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg"
      decimals="INF"
      id="Narr_o2FOGoUStEKfFdyR_UAHiA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">3034</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2024Member_uOzQR2Gmp0u88d9sAgvbLg"
      decimals="0"
      id="Narr_b3_QaciH5kKnv7WOMgLvvg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">190274</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pmn:CommonStockCapitalSharesReservedForFutureIssuanceAmount
      contextRef="Duration_8_1_2025_To_8_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_TnDWza_UfEC6NE6VKGF_Kw"
      decimals="-5"
      id="Narr_jQyJQB6tlkWQxXllsBXVMQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">18000000</pmn:CommonStockCapitalSharesReservedForFutureIssuanceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g"
      decimals="INF"
      id="Narr_c9Q8wvQ2E0u_9zglb7JLCQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">40795</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_AtMarketOffering2025Member_8VhhpzLT_UKH1TP7vivU6g"
      decimals="0"
      id="Narr_YpjJbWMTe0O2ypP-h012wg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">708468</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pmn:WarrantsAndRightsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_GCFoFqM9akeDDqPTiz48kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/span&gt;WARRANTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;As of December&#160;31, 2025, outstanding Common Share warrants and exercise prices related to unit offerings are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:50%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price $&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry&#160;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$50.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 314,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;January 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$315.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;August 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$240.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,868&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;August 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$50.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 314,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;January 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$187.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;April 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$152.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;April 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$43.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 449,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;February 2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$62.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 314,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;July 2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$31.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,129,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;July 2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 74,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,639,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;During the year ended December 31, 2025, 51,197 pre-funded warrants, including 39,389 issued in the July 2025 RD Offering, were exercised for gross proceeds of $3,050. Refer to Note 6 for discussion on the discounted exercise of 336,449 July 2024 PIPE warrants on July 22, 2025, discounted exercise of 416,436 July 2024 PIPE warrants on July 28, 2025, issuance of 504,673 new warrants in the July 22, 2025 PIPE, and issuance of 624,654 new warrants in the July 28, 2025 PIPE. During the year ended December 31, 2025, 11,184 warrants expired without being exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;During the year ended December 31, 2024, 16,319 warrants expired without being exercised, and 112,150 pre-funded warrants were exercised for an equivalent number of common shares for net proceeds of $28,038.&lt;/p&gt;</pmn:WarrantsAndRightsDisclosureTextBlock>
    <pmn:ScheduleOfWarrantExercisePriceTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_dT9eDbDciUOBim-VNKI0Cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:50%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price $&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry&#160;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$50.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 314,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;January 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$315.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;August 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$240.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,868&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;August 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$50.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 314,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;January 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$187.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;April 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$152.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;April 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$43.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 449,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;February 2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$62.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 314,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;July 2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$31.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,129,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;July 2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;US$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 74,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,639,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pmn:ScheduleOfWarrantExercisePriceTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_BLU4_tV9gUySljXY2fjsag"
      decimals="2"
      id="Narr_Sp5YyUbc20eQjAVbG4Z1uw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_BLU4_tV9gUySljXY2fjsag"
      decimals="INF"
      id="Tc_v88j2VsvxEaO-5nbvtibqA_3_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">314170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd31500Member_xOPbGlUKKEeb6s_MpQYu2w"
      decimals="2"
      id="Narr_b48yznLxcEmgEgHN2HHVig"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">315</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd31500Member_xOPbGlUKKEeb6s_MpQYu2w"
      decimals="INF"
      id="Tc_rdgwFIpCjU6PQKKYP1dljw_4_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">20948</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd24000Member_3gS1r2Q7ikiBMcspRxwhdA"
      decimals="2"
      id="Narr_gTKCeWFhuEOXG3bFY6sk-Q"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">240</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_August2026Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd24000Member_3gS1r2Q7ikiBMcspRxwhdA"
      decimals="INF"
      id="Tc_lLhyc3q9J0qVGicYBPXWiA_5_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">5868</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2027Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_OxC1c99JokOfGf-9JXcpPQ"
      decimals="2"
      id="Narr_vHcKU1vnYkauui6a5Hy3Hw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">50.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_January2027Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd5050Member_OxC1c99JokOfGf-9JXcpPQ"
      decimals="INF"
      id="Tc_GOLRe8yVsEyNRVQBTWSSow_6_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">314170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd18750Member_DceMNtnvik6aFW0Sn6WY3Q"
      decimals="2"
      id="Narr_qLWtZs21IEeGWSzCsRBLbw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">187.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd18750Member_DceMNtnvik6aFW0Sn6WY3Q"
      decimals="INF"
      id="Tc_2HjMFyqnzkuSozQk45anSg_7_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">13831</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd15250Member_M2aoRgqepE2Z5hmL4ieMNg"
      decimals="2"
      id="Narr_CtXptywRhki_hfFv7k_dZA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">152.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_April2028Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd15250Member_M2aoRgqepE2Z5hmL4ieMNg"
      decimals="INF"
      id="Tc_bXOnEXzTOUSjuwYff3Ov6Q_8_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2767</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_February2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd4375Member_96PtobwXOEKcI7qN4vYumA"
      decimals="2"
      id="Narr_8NzIww5PP06g8d7ezellEQ"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">43.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_February2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd4375Member_96PtobwXOEKcI7qN4vYumA"
      decimals="INF"
      id="Tc_zrlqx30BxUGOjIrq1bB9LA_9_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">449084</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd6250Member_ZBhfqWXuAEO3TU5tCv6HmA"
      decimals="2"
      id="Narr_FtHqsavNx02psNhoVqUrEw"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">62.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2029Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd6250Member_ZBhfqWXuAEO3TU5tCv6HmA"
      decimals="INF"
      id="Tc_TWMfexqlC0CKZ72zlQsOKQ_10_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">314170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2030Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd3125Member_BEwiO-eDbUWWmJRIGGfGtQ"
      decimals="2"
      id="Narr_eUR1_etU3UWl1oszfj4WRg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">31.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_AwardDateAxis_pmn_July2030Member_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd3125Member_BEwiO-eDbUWWmJRIGGfGtQ"
      decimals="INF"
      id="Tc_Vmi1atTcl0KY07SrrMxALA_11_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1129324</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd025Member_QbxyhQijfEureNNbf38Kiw"
      decimals="2"
      id="Narr_whD9EXyNIECGlQf0rPNEZg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_WarrantExercisePriceUsd025Member_QbxyhQijfEureNNbf38Kiw"
      decimals="INF"
      id="Tc_wVHW91rM6U2ehyg2Is2d1Q_12_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">74673</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="INF"
      id="Tc_dPj0_188x0mojcXyFmA0Tw_13_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2639005</us-gaap:ClassOfWarrantOrRightOutstanding>
    <pmn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="INF"
      id="Narr_lXO6kxQzJUamKXpLjwBijA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">51197</pmn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <pmn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_RegisteredDirectOfferingMember_CC8gh5SgoE2iWhbtumf2UA"
      decimals="INF"
      id="Narr_a5-nCMgvlk2kNlyKx7qRlw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">39389</pmn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <pmn:ProceedsFromPreFundedWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Narr_s1gAcVqI-katDKUtjlECRw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3050</pmn:ProceedsFromPreFundedWarrantExercises>
    <pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025DiscountedWarrantExerciseOfferMember_0RBdSB8Wi0ODU0_PpqakSg"
      decimals="INF"
      id="Narr_J-doWVwbSUKADzQwFeAeRQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">336449</pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise>
    <pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025DiscountedWarrantExerciseOfferMember_dMdeWdlgYUeGQ894YZLlrA"
      decimals="INF"
      id="Narr_csopjPqpbkWJAiE244EAww"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">416436</pmn:StockIssuedDuringPeriodSharesDiscountedWarrantExercise>
    <pmn:ClassOfWarrantOrRightIssued
      contextRef="Duration_7_22_2025_To_7_22_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July222025PipeOfferingMember_0I2NUUyQSkuP1T4GHvUZvA"
      decimals="INF"
      id="Narr_d9iLWqHDvEaWKsZvlAb-0A"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">504673</pmn:ClassOfWarrantOrRightIssued>
    <pmn:ClassOfWarrantOrRightIssued
      contextRef="Duration_7_28_2025_To_7_28_2025_us-gaap_SubsidiarySaleOfStockAxis_pmn_July282025PipeOfferingMember_OBU8fQvrvUu6o9WSu_IhuA"
      decimals="INF"
      id="Narr_auLBB2dQVUiyRZvs--703A"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">624654</pmn:ClassOfWarrantOrRightIssued>
    <pmn:ClassOfWarrantOrRightExpired
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="INF"
      id="Narr_KWy1we1d4E6U1bE0FQ2j1w"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">11184</pmn:ClassOfWarrantOrRightExpired>
    <pmn:ClassOfWarrantOrRightExpired
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="INF"
      id="Narr_1sc0Lqf9sEudRmXmWtcvtA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">16319</pmn:ClassOfWarrantOrRightExpired>
    <pmn:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_yEzxtOjj-EyFV6MUX2x0TQ"
      decimals="INF"
      id="Narr_yLFZ8UGcUU2hLrMsm8lfmA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">112150</pmn:ClassOfWarrantOrRightExercised>
    <pmn:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_yEzxtOjj-EyFV6MUX2x0TQ"
      decimals="0"
      id="Narr_ch6QSwbgIkyiWZ4Bif88fg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">28038</pmn:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_nac5xMpRDkC5Lgfgl4BtBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/span&gt;SHARE-BASED COMPENSATION &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;2025 Stock Option Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;At its June 2025 Annual Meeting of Shareholders, the Company&#x2019;s 2025 Stock Option and Incentive Plan (&lt;b style="font-weight:bold;"&gt;&#x201c;2025 Option Plan&#x201d;) &lt;/b&gt;was approved by the shareholders. The 2025 Option Plan replaces the 2015 Stock Option Plan (&lt;b style="font-weight:bold;"&gt;&#x201c;2015 Option Plan&#x201d;&lt;/b&gt;), originally referred to as the 2007 Option Plan. No new awards can be issued under the 2015 Option Plan. &#160;The Company reserved 117,868 Common Shares for issuance under the 2025 Option Plan at the time of adoption. As of December 31, 2025 and 2024, the Company had 80,686 and 118,535 options available for grant under the 2025 Option Plan and 2015 Option Plan, respectively. The Common Shares underlying any awards under the 2025 Option Plan and 2015 Option Plan that are forfeited, canceled, or otherwise terminated (other than by exercise) are added back to the shares available for issuance under the 2025 Option Plan. Share options are granted in either USD or CAD. Upon the change in the Company&#x2019;s functional currency, effective July 1, 2023, CAD share options previously classified as equity were reclassified as liabilities. All grants following the Company&#x2019;s change in functional currency are in USD.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Canadian Dollar Share Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The following table summarizes the activity of the C$ share options under the 2015 Option Plan for the&#160;years ended December&#160;31, 2025 and 2024. All amounts are denominated in Canadian dollars, except&#160;year and share amounts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 189.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 229.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 32,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 184.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,346)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 209.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,704)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 54.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 170.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 170.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The aggregate intrinsic value of options outstanding, exercisable, and vested and exercisable is calculated as the difference between the exercise price of the underlying options, and the fair value of the Company&#x2019;s Common Shares. There were no C$ share options granted during the years ended December 31, 2025 or 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Upon the change in the Company&#x2019;s functional currency effective July 1, 2023 C$ share options previously classified as equity were reclassified as liabilities. The C$ options were re-measured as of December 31, 2024 and had a fair value of $199,263. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;A summary of share-based compensation liability activity, measured using level 3 fair value inputs, for the year ended December 31, 2025 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (170,081)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;A summary of share-based compensation liability activity for the year ended December 31, 2024 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 422,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (222,739)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The following table summarizes the weighted average of significant assumptions used to calculate the fair value of C$ share options using the Black Scholes option pricing model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:43.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of C$ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 106.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 99.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Expected volatility is based on historical volatility of the Company&#x2019;s Common Shares over the expected life of the option, as the Company&#x2019;s options are not readily tradable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;U.S. Dollar Share Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The Company began making share option grants denominated in US$ following the Company&#x2019;s change in functional currency in July 2023. The following table summarizes the US$ share options outstanding under the 2015 Option Plan for the years ended December 31, 2025 and 2024. All amounts are denominated in US$, except&#160;year and share amounts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 107,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 110,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 55,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (501)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 165,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The grant date fair value of 55,400 and 107,478 US$ share options granted during the years ended December 31, 2025 and 2024, respectively, was estimated using Black Scholes with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:88.88%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:48.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value of US$ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 22.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 107.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 101.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;In October 2024, the Company granted its Chief Executive Officer 19,614 options with an exercise price of $28.75, which will begin vesting if and when the Company&#x2019;s 10-day VWAP of its Common Shares trading on the Nasdaq Capital Market meets or exceeds $86.25. The Company determined the share price requirement to begin vesting represented a market condition and performed a Monte-Carlo simulation to determine the fair value of the award, discounted for the likelihood of achieving the market condition. The resulting fair value of the option award was $383,000, with $168,946 and $39,344 recognized during the years ended December 31, 2025 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;and 2024 in the accompanying consolidated statement of operations, with the remaining $174,710 expected to be recognized over approximately 1.4 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;DSU Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company has a Deferred Share Unit plan (&#x201c;&lt;b style="font-weight:bold;"&gt;DSU Plan&lt;/b&gt;&#x201d;) for senior officers. Under the DSU Plan, rights to the Company&#x2019;s Common Shares may be awarded on a deferred payment basis up to a maximum of 667 common share units. Each common share unit will fully vest upon cessation of employment with the Company and then can be redeemed for one common share of the Company by the unitholder. The Company has 42 units outstanding as of December&#160;31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;S&lt;b style="font-weight:bold;"&gt;hare-based Payment Expense&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The following table summarizes total share-based compensation for both the C$ and US$ share options included in the Company&#x2019;s accompanying consolidated statements of operations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 49,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 819,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 776,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 857,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 825,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;As of December&#160;31, 2025, there was $1,265,556 of unrecognized share-based compensation related to US$ options outstanding, which is expected to be recognized over a weighted-average remaining service period of 2.7&#160;years. There was no material liability yet to be recognized for C$ share-based compensation as of December 31, 2025.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_lzS6k88pCESIdR5eDOhhpw"
      decimals="INF"
      id="Narr_NEgvDBBIFEmsmhowSpHm2g"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionAndIncentivePlan2025Member_8TYcGUAhwU2A4TqH-py3Vw"
      decimals="INF"
      id="Narr_zvA365Qs-UCR0teATRDrWw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">117868</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_StockOptionAndIncentivePlan2025Member_8TYcGUAhwU2A4TqH-py3Vw"
      decimals="INF"
      id="Narr_tg4bPNbwvkuBDnODry1K8w"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">80686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_HkhKPStIm06ybEXHIFwi_Q"
      decimals="INF"
      id="Narr_H1FhTdyo_kexcMBIeIh-hQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">118535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Group_tLNDCx_EFkiSFThoL1Ez9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 189.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 229.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 32,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 184.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,346)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 209.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,704)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 54.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 170.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 170.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 107,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 110,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 55,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (501)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 165,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_DAPNYxdYn0qZikf9-Z1Hkg"
      decimals="INF"
      id="Tc_jmMZQ65o70mOqMteriQGKA_7_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">35930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_DAPNYxdYn0qZikf9-Z1Hkg"
      decimals="2"
      id="Tc_vCpSmde4fEGLkmK39DlIFg_7_5"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">189.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_LlWSStT2D0-0Npx7XslrPA"
      id="Tc__wSvSSsqNk2X-64fUoNc3w_7_7">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      decimals="INF"
      id="Tc_wCcWIsgxl0eD0SvPPl8YWg_8_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">3191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      decimals="2"
      id="Tc_ZTxY8GGwtk-TMzVgc7iQNA_8_5"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">229</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_535wZCcGeEeaUhW6qrPQIg"
      decimals="INF"
      id="Tc_YKHrbsa4eESR2He3hsND7Q_9_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">32740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_535wZCcGeEeaUhW6qrPQIg"
      decimals="2"
      id="Tc_8imK05adYU2qzsCS_i6efw_9_5"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      id="Tc_RerLel3NbkGo6owWvYAoZg_9_7">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="INF"
      id="Tc_ZmIjYZq6i0eEoWPRjGNWHA_10_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="2"
      id="Tc_ZfzhPMbcDEKqGgNsdyHEvw_10_5"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">209</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="INF"
      id="Tc_PUcWi2oKWkqVZsbJE9Ks6g_11_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">14704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="2"
      id="Tc_IVzCSGU6qU6TBuZi06Q9DQ_11_5"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">54.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ"
      decimals="INF"
      id="Tc_bZ2qusZjsEOCEEruftmMLw_12_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">15690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ"
      decimals="2"
      id="Tc__52-STRrIUqwDeCF6n6Q7w_12_5"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      id="Tc_1xTwZTJF_kKnCqWvu8e0yw_12_7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ"
      decimals="INF"
      id="Tc_-jTsP-ZbF0yUl7-ZwStWRA_13_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">15413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ"
      decimals="2"
      id="Tc__uLY1kDyWkWE4n6JBtTX-g_13_5"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">170.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      id="Tc_DZXQ4ip7AkCngvVU6WuOVA_13_7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      decimals="INF"
      id="Narr_je7wft_cJkGadaaTOxkMkQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="INF"
      id="Narr_GVPyzleTEEKNj-TGWJZRmg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_PXqycc-OFkC8BIsNs-1sLQ"
      decimals="0"
      id="Narr_LewLvYF8mU2FkH8YHjYxCw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">199263</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions>
    <pmn:ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Group_yNEShZzVVk6qJN3YCBIryA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (170,081)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 422,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase in additional paid-in-capital due to decrease in fair value of share-based compensation liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (222,739)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fair value at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 199,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pmn:ScheduleOfDeferredCompensationShareBasedArrangementsLiabilityTableTextBlock>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_qdx-huCIX0yk99CnRJD2IA_3_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">199263</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <pmn:DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_6X98GCSw50-drtKI7E_hbw_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">170081</pmn:DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_Jx6e2gLI_E-C0JZ8MfbY6A_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">29182</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2023_Py9vPURRWUeSibrjQ0OcXQ"
      decimals="0"
      id="Tc_1kSoBchZN0my0ocbv8-iyA_3_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">422002</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <pmn:DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_p_3KCKPx0EmKx01GBhoHCg_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">222739</pmn:DecreaseInFairValueOfShareBasedCompensationLiabilityIncreaseInAdditionalPaidInCapital>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_bXNntBgcu0m8zYW-ojbUNw_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">199263</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Group_I0KqKkFkfEWNA0_IZvqoPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:43.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of C$ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 106.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 99.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:88.88%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:48.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value of US$ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 22.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 107.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 101.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="2"
      id="Tc_hrdChYBSKUu9QNPTAtef2A_4_3"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">0.08</pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions>
    <pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      decimals="2"
      id="Tc_MZmfpVQeXUmPqkoL7KJXgw_4_6"
      unitRef="Unit_Divide_CAD_shares_H3urDpiMEU2nNpsnnX-Vzg">0.26</pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="3"
      id="Tc_nLl38PK4bUqr0JU5mdWK1Q_5_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      decimals="3"
      id="Tc_eEZthdYrhUiAg0iegkhy_g_5_6"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      decimals="4"
      id="Tc_85Omm_3s0U-W3zreDldNkg_6_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.0386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      decimals="4"
      id="Tc_aFernyEWUUacKvFbUju2pw_6_6"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_9ghvPIhUikCdynlLwPXDiQ"
      id="Tc_avpPx_kPH0SHPIcej8mK9A_8_3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_CanadianDollarShareOptionsMember_TNAt5YD32UqAvKtWvM1OjQ"
      id="Tc_l1NkQyuAVkWD8u8RcbwqgA_8_6">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_ZnKVIeo_bUW1r1sdCiTiBg"
      decimals="INF"
      id="Tc_bEykVHUzBkOWLzjkJ02J9g_7_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_ZnKVIeo_bUW1r1sdCiTiBg"
      decimals="2"
      id="Tc_b-WJPf8CSUGbLQAIxVAD9Q_7_5"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">46.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"
      decimals="INF"
      id="Tc_9DIop6bIQ0aP7inIriiC6Q_8_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">107478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"
      decimals="2"
      id="Tc_fFUV3NktDECPN_hYKT5tHg_8_5"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">27.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_oUDs-NDYv0qB68laQ04sGA"
      decimals="INF"
      id="Tc_rMt1A-1etEW-k3lpaVq7ZA_9_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">110238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_oUDs-NDYv0qB68laQ04sGA"
      decimals="2"
      id="Tc_hOKC63czHUaX8vzD8KTLeQ_9_5"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">28.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="INF"
      id="Tc_xRbUnpfMBEuzk5MzhCdVhg_10_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">55400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="2"
      id="Tc_hlOuk0OEQ0icNckJafDDPQ_10_5"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">11.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="INF"
      id="Tc_qh8ETLVb4ku0NbQjTKJgkA_11_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="2"
      id="Tc_KGFwPn2Da0mb7lz29Z4Q5w_11_5"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">46.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ"
      decimals="INF"
      id="Tc_F2BLtdt0pkO7HhDa-7XctA_12_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">165137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ"
      decimals="2"
      id="Tc_kaN-IG0GYEmLP9EGvDBoyg_12_5"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">22.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      id="Tc_gLkEIQy4mEGA1Wp1AwRuwA_12_7">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ"
      decimals="INF"
      id="Tc_iLevyS990UyiykI8YXCx4Q_13_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">47421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_xbop-ODcfkajjDIRvu0NpQ"
      decimals="2"
      id="Tc_dLgBiUaRDE6w3pnWIO2Mhg_13_5"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">28.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      id="Tc_ryAxBRZnekC1WJsiPBGpLA_13_7">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="0"
      id="Narr_0MFr0l0MC0ui-0J9pR6SIQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">55400</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"
      decimals="0"
      id="Narr_W6tZwUNL2EafCUOeJH1Q_w"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">107478</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="2"
      id="Tc_b8tLqvpeC0S3k9W_f3Nnig_4_3"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">9.8</pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions>
    <pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"
      decimals="2"
      id="Tc_-D14VugVKU-xg36FyAkglg_4_6"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">22</pmn:ShareBasedCompensationArrangementWeightedAverageFairValueOfOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="3"
      id="Tc_FHwoK_Hhf0SWnDXZklPRsw_5_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"
      decimals="3"
      id="Tc_ZiQR89iezkW49Bsz5TuMAA_5_6"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">1.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      decimals="4"
      id="Tc_7PpkaZ2D8Eqws36BwCiVUQ_6_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.0379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"
      decimals="4"
      id="Tc_XgxyiNx-U0qa1q8Gll68xA_6_6"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.0395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_LVirweIM1kmP9DH6FpJzZw"
      id="Tc_qPJTbG988kasZ78LclcyYA_8_3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_MRUFnKi7kku6UmOV5XkdPQ"
      id="Tc_zKGm4EmBAUevapgCBd6oOA_8_6">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q"
      decimals="INF"
      id="Narr_hlDapgXK7kiWM6q4c2AMIg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">19614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q"
      decimals="2"
      id="Narr_-5Or6TjPZE2TCHjWH7cmCg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">28.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pmn:VolumeWeightedAveragePriceThresholdTradingDays
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TIUc8IJz2UaqvYAL7z8b3Q"
      decimals="INF"
      id="Narr_gaD3FSUEJkWnYGhml5kIaw"
      unitRef="Unit_Standard_D_JjSvLYrH-EWdNko9j1YiTg">10</pmn:VolumeWeightedAveragePriceThresholdTradingDays>
    <pmn:ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger
      contextRef="As_Of_10_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_cuRNgn1GhEKPKyrtju0bxw"
      decimals="2"
      id="Narr_CgYWAt6oh0u0LgQpsKw2mQ"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">86.25</pmn:ThresholdVolumeWeightedAveragePriceOfCommonSharesStockPriceTrigger>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4m9O5GYGnEyywiNYhqVX6A"
      decimals="0"
      id="Narr_AlKcldAaV0al1IZe7AnK6A"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">383000</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_8kidyz1Xz0e1GRFRPcmD0g"
      decimals="0"
      id="Narr_NSw1Ri5PGE-cKMir0S5_xw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">168946</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_bAqN9UYOfk6qG8Vt8Q_g7A"
      decimals="0"
      id="Narr_ZJJkIEUVHUazMSG2RByorg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">39344</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4m9O5GYGnEyywiNYhqVX6A"
      decimals="0"
      id="Narr_MsbMQdAri0-WwA0Cy0xH2g"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">174710</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_pmn_UsDollarShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_8kidyz1Xz0e1GRFRPcmD0g"
      id="Narr_lpzCNUJvs02Uu2bmiCeCpA">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ"
      decimals="INF"
      id="Narr_43Sf9jwGKE-gVcgtsZ09GQ"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ"
      decimals="INF"
      id="Narr_c2OplC1spEiFAKfvsiO1Uw"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRedeemablePerUnit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_pmn_DeferredShareUnitPlanMember_JknRnTRWF0Gb8K6jPwoqJQ"
      decimals="INF"
      id="Narr_LFOfEBmVZ0KXodBvDDRA8w"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb__jqDPdsDiUen-kpVC8uBNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 49,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 819,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 776,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 857,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 825,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lI1_7YZGDkiVsD04bzBKuA"
      decimals="0"
      id="Tc_IQ_AqZi2qUysHfp-Ezrtzg_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">37674</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-qWN91AyB0iMTTieOzW1eQ"
      decimals="0"
      id="Tc_rJp8WAWRE0i9WHQVdd8Ltw_4_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">49405</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rhZmPGlkfEOEJZUvfYbOgw"
      decimals="0"
      id="Tc_y73omf4juU2qOgHccp4K1g_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">819954</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4me8oDqyvUC5VCBKaBFb0g"
      decimals="0"
      id="Tc_vM-L-Y32SE60S-09WlJUCw_5_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">776403</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_9DB9jBjlkEGaklDNhqL6SA_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">857628</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_8qt8OcE6KECPQ1WlwNVMnQ_6_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">825808</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2025_srt_CurrencyAxis_currency_USD_AW-HI8NCBUijoCTjKG1Vyw"
      decimals="0"
      id="Narr_Sk6Tvi12xESurRmVSiycxw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">1265556</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_CurrencyAxis_currency_USD_2N501AziF0iBtEVWWSNtGA"
      id="Narr_1K90xuSF5kSHl6ehyFz9CA">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_BYf3ujcjCE2PlLSkBM6-5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;9.&lt;/b&gt;&lt;/span&gt;INCOME TAXES &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;As of December&#160;31, 2025 and 2024, the net deferred tax assets have not been recognized in the accompanying consolidated financial statements. A valuation allowance is recognized to reduce the deferred tax asset as it is more likely than not that a tax benefit will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The following are the significant components of the Company&#x2019;s deferred taxes as of December&#160;31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-capital losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,810,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,850,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,022,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,175,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Investment tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,944,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,043,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax value of technology rights and property and equipment in excess of accounting basis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 160,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 193,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issue costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,066,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,275,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-deductible reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted interest and financing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 337,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 41,005,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,883,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,005,721)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,883,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;As of December&#160;31, 2025, the Company has available research and development expenditure credits for income tax purposes of approximately $11,407,000, which may be carried forward without expiration to reduce future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;As of December&#160;31, 2025, the Company has non-capital income tax loss carry-forwards of approximately $131,360,190 available to reduce future income for income tax purposes. The income tax loss carry-forwards have expiry dates between the&#160;years 2026 and 2046.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;As of December&#160;31, 2025, the Company has approximately $2,553,000 of non-refundable investment tax credits available to offset future income taxes. The non-refundable investment tax credits have expiry dates between 2025 and 2035. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;A reconciliation of the combined federal and provincial statutory income tax rate applied to the net (loss) income for the&#160;year to the income tax recovery as of December&#160;31 is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount ($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent (%)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Canadian federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,960,583)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provincial taxes (Ontario)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 127,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issue costs recorded, net of equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (372,011)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,027,731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Return to provision adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 161,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ek1qQB57M0uiwz7O77M-zA;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Effective Tax Rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company does not expect a significant change in the amount of unrecognized tax benefits over the next 12&#160;months. However, any adjustments arising from certain ongoing examinations by tax authorities could alter the timing or amount of taxable income or deductions and these adjustments could differ from the amount accrued. The Company&#x2019;s federal and provincial income tax returns files for all&#160;years remain subject to examination by the taxation authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_yRnhAGtSCkadCH0-xSXXyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-capital losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,810,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,850,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenditures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,022,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,175,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Investment tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,944,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,043,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax value of technology rights and property and equipment in excess of accounting basis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 160,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 193,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issue costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,066,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,275,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-deductible reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted interest and financing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 337,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 41,005,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,883,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,005,721)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,883,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_7GX3ca-3hki07P5a0ocZrw_2_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">34810450</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_iAsrMVmcoUOrHLvVDFEtIA_2_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">24850000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_zOgn9luOZkyPTxPDexTlbQ_3_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3022831</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_Vld610eOtEymMMTlCtCUCw_3_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3175000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_un1wZpKCpEqrjE_BsZWCGg_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">1944821</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_qFhCLgm2RUe_88kBLkaGSw_4_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2043000</us-gaap:DeferredTaxAssetsInvestments>
    <pmn:DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_ijndJg2H9Uar-thKkIljhQ_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">160999</pmn:DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis>
    <pmn:DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_1PqlKKVGLEqMtbJ_Q-6zwg_5_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">193000</pmn:DeferredTaxAssetsTaxValueOfTechnologyRightsAndPropertyAndEquipmentInExcessOfAccountingBasis>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_euw3mWxumE2eYJTl9y1V3w_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">1066620</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_BqW-2hfWLUSpxsAfCw3eEg_6_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">1275000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_HB7TFwVV0UWCE_roO2HywA_7_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">10000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <pmn:DeferredTaxAssetsRestrictedInterestAndFinancingExpenses
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_jZUYdE2a30iAnGo99nyEFA_8_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">337000</pmn:DeferredTaxAssetsRestrictedInterestAndFinancingExpenses>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_6TlbyoBJlEWmrbfAqmuOFQ_9_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">41005721</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_bRRLmX0rOEik0WzbxfXJNw_9_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">31883000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc_hHPWuAMSBUa2uH329-8tLQ_10_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">41005721</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_SPJbAehcN06of5sBV6W55g_10_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">31883000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Tc__jTw6h_2eUm95-sYB9JTxw_11_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_WZ0GrQk3xEyzHFwDYy2L6g"
      decimals="0"
      id="Tc_CLiX67AilEGOw3A7O32QxQ_11_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Narr_xnEVTHOZx0SevxirmKzu_A"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">11407000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_pmn_NonCapitalLossCarryforwardMember_i2OXSaXBF0CPpT0LBRI-Mw"
      decimals="0"
      id="Narr_Mjz6hzMWC06zmsaXxziEiQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">131360190</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember_QgKzyfBAJkiVQVpxeqeEuA"
      decimals="0"
      id="Narr_9lqGFBpY4E6tZ528UmNDWg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2553000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_xlAyWLbLAk6hcp9kDDptwQ_4_2"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-5960583</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="3"
      id="Tc_h4tUodCrnUO2v81qcP6KVg_4_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="3"
      id="Tc_9_31SV197ESWcWqOSUz_Kg_5_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.115</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_PwxYmnAsKECHRbUJNsnu1w_6_2"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">127981</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="3"
      id="Tc_7HLgK9SwkEyzCWCHplg3Dw_6_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_Ti6q2hwVYEee5ReE4dupJg_7_2"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-372011</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="3"
      id="Tc_CXYeAW3LuE-sdo3w60ISCg_7_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_Z4iHHxH_fEaYzNspXbZyZg_8_2"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">6027731</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="3"
      id="Tc_TS8c-PEOQEuL38E1-bPR7A_8_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">-0.268</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <pmn:EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_an6qKRYU60amIVAtfOXltA_9_2"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">15444</pmn:EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsAmount>
    <pmn:EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="3"
      id="Tc_EvpRPARpWEKbFYgzDkr58Q_9_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">-0.001</pmn:EffectiveIncomeTaxRateReconciliationReturnToAdjustmentsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_fTW44-id70CZIaPw59AVaw_10_2"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">161438</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="3"
      id="Tc_i8IR4ydLKEKP9DqSFY0zsQ_10_3"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb__IGS5wsrAUevQnCkhQazCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/span&gt;Segment Reporting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: life science. The life science segment consists of the development of clinical and preclinical product candidates. The Company&#x2019;s chief operating decision maker (&#x201c;&lt;b style="font-weight:bold;"&gt;CODM&lt;/b&gt;&#x201d;) is the chief executive officer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the life science segment based on net (loss) income, which is reported on the income statement as consolidated net loss (income). The measure of segment assets is reported on the balance sheet as total consolidated assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;As such, the CODM uses cash forecast models in deciding how to invest into the life science segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss (income) is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management&#x2019;s compensation, along with cash forecast models.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025, and 2024: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:45pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:89.6%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;Ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;PMN310 development program costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,226,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,275,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Other non-employee research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 885,907&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 772,501&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Employee costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,051,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,336,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Other general and administrative costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,004,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,443,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Operating Loss:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 40,167,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,827,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (448,161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,606,351)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Loss (Income):&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39,719,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,778,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reconciliation of Profit or Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Adjustments and reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consolidated Net Loss (Income):&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39,719,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,778,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="INF"
      id="Narr_i48rermic0m7T3ssgZo9kw"
      unitRef="Unit_Standard_segment_qF8_aFg47kyP9oDuGjAE0g">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_DBP0yMWEfUaid8z8ez0f0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:45pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:89.6%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;Ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;PMN310 development program costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,226,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,275,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Other non-employee research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 885,907&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 772,501&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Employee costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,051,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,336,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Other general and administrative costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,004,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,443,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Operating Loss:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 40,167,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,827,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (448,161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,606,351)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Loss (Income):&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39,719,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,778,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reconciliation of Profit or Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Adjustments and reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consolidated Net Loss (Income):&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39,719,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,778,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"
      decimals="0"
      id="Tc_K_opEzrTEU-k6e90ZUfyuA_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-30226059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"
      decimals="0"
      id="Tc_zgbdxIbjLE6rrXi3Z5IUpw_4_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-8275268</us-gaap:NetIncomeLoss>
    <pmn:SegmentReportingOtherSegmentItemAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"
      decimals="0"
      id="Tc_imZqBtuJ2UWmt2IYK2NYZQ_5_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-885907</pmn:SegmentReportingOtherSegmentItemAmount>
    <pmn:SegmentReportingOtherSegmentItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"
      decimals="0"
      id="Tc_-z3Oh2Sn7kOtayw7_1hKYA_5_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-772501</pmn:SegmentReportingOtherSegmentItemAmount>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"
      decimals="0"
      id="Tc_EmkT1VEDnUyEsmzY8t1DuQ_6_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">5051277</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"
      decimals="0"
      id="Tc_C5i05UXRAkSNnGXT6qrZKA_6_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">3336580</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"
      decimals="0"
      id="Tc_71jP0Vue3Eip6Ia7iG2DxQ_7_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">4004065</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"
      decimals="0"
      id="Tc_ZrwNCgZoZEO7VtN6Q_sieA_7_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">4443129</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"
      decimals="0"
      id="Tc_ePWpK_9je0SNhuyw9hr54w_8_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">40167308</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"
      decimals="0"
      id="Tc_wvN1vZ2cH0iHX2Gt0XTJzw_8_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">16827478</us-gaap:LaborAndRelatedExpense>
    <pmn:OtherNonEmployeeResearchAndDevelopmentCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"
      decimals="0"
      id="Tc_TbWf-HebFkWxt5lUpmUYKA_9_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-448161</pmn:OtherNonEmployeeResearchAndDevelopmentCosts>
    <pmn:OtherNonEmployeeResearchAndDevelopmentCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"
      decimals="0"
      id="Tc_aMFP_m3tLEy2xvkn43Gl-g_9_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-19606351</pmn:OtherNonEmployeeResearchAndDevelopmentCosts>
    <pmn:Pmn310DevelopmentProgramCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_p_3a2jaEI0C0AYHT4lMhyw"
      decimals="0"
      id="Tc_WC3o25owN0i-TWrYoSLQXg_10_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">39719147</pmn:Pmn310DevelopmentProgramCosts>
    <pmn:Pmn310DevelopmentProgramCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_uhKz6iB1aECXnDQ_qbEb6A"
      decimals="0"
      id="Tc_TjZ_0EzvCUWrDo2fSV0Lww_10_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-2778873</pmn:Pmn310DevelopmentProgramCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_WdhANRd9JEuHez3tjsdkRg_14_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-39719147</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_880keX0zlUKFOILQTaDj5Q_14_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2778873</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      id="Narr_5K2QM90CL0O9ZruQSaCdTA">Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_i6PFWvwQFE-SOfJE2EAIyg">Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_71g2nnudmUm1nA1r9X0dNg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/span&gt;RELATED PARTY TRANSACTIONS &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;UBC Collaborative Research Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"&gt;In April&#160;2016, the Company entered into a collaborative research agreement (&#x201c;&lt;b style="font-weight:bold;"&gt;CRA&lt;/b&gt;&#x201d;) with the University of British Columbia (&#x201c;&lt;b style="font-weight:bold;"&gt;UBC&lt;/b&gt;&#x201d;) and the Vancouver Coastal Health Authority in the amount of C$787,500, with the Company&#x2019;s Chief Scientific Officer, as principal investigator at the UBC. In January 2022, the UBC CRA was amended to extend the project for an additional three years, and in December 2024, for an additional 1 year. Aggregate funding under the agreement was increased to a total of C$5,830,000 through February 2026. During the&#160;years ended December&#160;31, 2025 and 2024, the Company made cash payments of $428,860 and $587,000, respectively, and incurred costs of $573,187 and $584,226, respectively, which are included in research and development expenses in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Neil Warma Employment Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;In October 2024, in connection with Mr. Neil Warma&#x2019;s appointment to the role of CEO, he entered into an employment agreement with the Company (the &#x201c;&lt;b style="font-weight:bold;"&gt;CEO Employment Agreement&lt;/b&gt;&#x201d;) providing for an annual base salary of $500,000 and annual discretionary bonus with a target of 50% of his base salary. Mr. Warma was also provided (i) severance in the amount of 12-months&#x2019; salary, a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a termination without cause and (ii) severance in the amount of the sum of 18-months&#x2019; salary and a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a change in control of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;In connection with his appointment, Mr. Warma was also granted (i) an option to purchase 45,765 of the Company&#x2019;s common shares (the &#x201c;&lt;b style="font-weight:bold;"&gt;Initial Award&lt;/b&gt;&#x201d;) and (ii) an option to purchase 19,614 of the Company&#x2019;s common shares (the &#x201c;&lt;b style="font-weight:bold;"&gt;Performance Award&lt;/b&gt;&#x201d;). Per the Company&#x2019;s 2015 Stock Option Plan, the exercise price of each of the Initial Award and the Performance Award is $28.75 &lt;span style="-sec-ix-hidden:Hidden_VGlBM7hgKUyWd-Dp-bhCdA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;per&lt;/span&gt;&lt;/span&gt; share, the 5-day volume-weighted average price (&#x201c;&lt;b style="font-weight:bold;"&gt;VWAP&lt;/b&gt;&#x201d;) as of October 8, 2024. The Initial Award is 25% vested upon grant with the remaining shares vesting ratably over thirty-six months. &#160;The Performance Award shall vest 25% on the date that the 10-day VWAP of the Company&#x2019;s common shares on the Nasdaq Capital Market exceeds three times the exercise price, with the remainder vesting ratably over the following thirty-six months. &#160;Refer to Note 8, Share-Based Compensation, for further discussion on the Performance Award.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pmn:RelatedPartyTransactionFundingCommitment
      contextRef="As_Of_4_30_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_DdNjmpvgs0aZ4rzq8r7w_g"
      decimals="0"
      id="Narr_5KxcwUcby0i1UYNyjfNh_Q"
      unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA">787500</pmn:RelatedPartyTransactionFundingCommitment>
    <pmn:RelatedPartyTransactionFundingCommitment
      contextRef="As_Of_1_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_pmn_CollaborativeResearchAgreementMember_yUl-HCLG1kqLzAcQbh7uGA"
      decimals="0"
      id="Narr_N2fA1B8TVUKFLycumtKoVQ"
      unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA">5830000</pmn:RelatedPartyTransactionFundingCommitment>
    <pmn:CashPaymentsRelatedParty
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Narr_KEyF3bjgSkeduvPNVoJwhw"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">428860</pmn:CashPaymentsRelatedParty>
    <pmn:CashPaymentsRelatedParty
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Narr_nYQWc8URWkWX9Q_N3MGRgQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">587000</pmn:CashPaymentsRelatedParty>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iyRZGqr_Ek6zR0Ofkljmjg"
      decimals="0"
      id="Narr_lQ9Qg2L8skmscUNxycXKSg"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">573187</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_v5tCRtG69EORGsNwZgNgJg"
      decimals="0"
      id="Narr_pi2sToRii0iTJ9umwMcU9g"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">584226</us-gaap:ProfessionalFees>
    <pmn:EmploymentAgreementAnnualBaseSalary
      contextRef="As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ"
      decimals="0"
      id="Narr_2QdZgMj1vEWUyMxkbbVCIA"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">500000</pmn:EmploymentAgreementAnnualBaseSalary>
    <pmn:EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary
      contextRef="As_Of_10_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_2UpMK89Vik2KIBs0LyDSMQ"
      decimals="2"
      id="Narr_37ocxLYcAkOsdW8ji790qg"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.50</pmn:EmploymentAgreementPercentageOfTargetBonusOnAnnualBaseSalary>
    <pmn:EmploymentAgreementSeveranceAmountCalculationTerm
      contextRef="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_TerminationWithoutCauseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Wm0yqUihf0aj0uy8QZAwtg"
      id="Narr_NnNPMI_9akmcDOAiwrEIMg">P12M</pmn:EmploymentAgreementSeveranceAmountCalculationTerm>
    <pmn:EmploymentAgreementSeveranceAmountCalculationTerm
      contextRef="Duration_10_1_2024_To_10_31_2024_srt_StatementScenarioAxis_pmn_ChangeInControlOfCompanyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_ce9A_GawfUqwocEsnGglEA"
      id="Narr_kSzkREZkq0WgMkJsajc5kA">P18M</pmn:EmploymentAgreementSeveranceAmountCalculationTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Pm7NX9q6C0GTLtp_fVq02Q"
      decimals="INF"
      id="Narr_uLkUUC9_g0yd-GXfd2aBXA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">45765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A"
      decimals="INF"
      id="Narr_DNu7rAGff0iie8PDPBHJ2w"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">19614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_Pm7NX9q6C0GTLtp_fVq02Q"
      decimals="2"
      id="Narr_UrBS_l8y50uR8ofr-Hz3QQ"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">28.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_I6q6e-G_hkObQ4WrMKNO1g"
      id="Narr_fiphv2wvNUCkR9_5k5M65A">P5D</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hegnycuWWk64ZdX1vlM55g"
      decimals="2"
      id="Narr_aCoWtDGz4k2ulx_j4lnsxg"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ArrangementOptionInitialAwardMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1Gx3t3xx065WtYKYn1A9w"
      id="Narr_f3mz0MAqY02TTKV_NeG2RA">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YXkmIVrXsUao5mEA8VBliw"
      decimals="2"
      id="Narr_-chveniyd0-eNtQAaGMy6g"
      unitRef="Unit_Standard_pure_8HiUhpiwK0OOG6c1Uwwq7Q">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A"
      id="Narr_709Klji1HkexmLdk58iK9Q">P10D</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsThresholdTradingDaysVolumeWeightedAveragePrice>
    <pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_nAK38oo0ykeaiTPFOGCI2A"
      decimals="INF"
      id="Narr_yMq2IkX6TUCaJ84sZdf9SQ"
      unitRef="Unit_Standard_item_ETwbko2pdkCFGeE5avOMiw">3</pmn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMultiplierForVolumeWeightedAveragePriceForCalculationOfExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_AwardTypeAxis_pmn_ShareBasedPaymentArrangementOptionPerformanceAwardsMember_us-gaap_PlanNameAxis_pmn_StockOptionPlan2015Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_CgSeHaCH60uJVtf2HXDdBQ"
      id="Narr_ZSPl9u12cUqPlhs3W1ls0Q">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_6FnWdys2tEqQnjMCdDcJ1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;12.&lt;/b&gt;&lt;/span&gt;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Research, Development and License Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company enters into research, development and license agreements with various parties in the ordinary course of business where the Company receives research services and rights to proprietary technologies. The agreements require compensation to be paid by the Company, typically, by a combination of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fees comprising amounts due initially on entering into the agreements and additional amounts due either on specified timelines or defined services to be provided;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;milestone payments that are dependent on products developed under the agreements proceeding toward specified plans of clinical trials and commercial development; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;royalty payments calculated as a&#160;percentage of net sales, commencing on commercial sale of any product candidates developed from the technologies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Milestone and royalty related amounts that may come due under various agreements are dependent on, among other factors, preclinical safety and efficacy, clinical trials, regulatory approvals and, ultimately, the successful development and commercial launch of a new drug, the outcomes and timings of which are uncertain. Amounts due per the various agreements for milestone payments will accrue once the occurrence of a milestone is likely. Amounts due as royalty payments will accrue as commercial revenues from the product are earned. Through December&#160;31, 2025, no events have occurred that require accrual of any milestone or royalty related amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"&gt;UBC and the Vancouver Coastal Health Authority Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;In April&#160;2016, the Company entered into a three-year, CRA with the UBC and the Vancouver Coastal Health Authority. The agreement was amended various times through November&#160;2021. Refer to Note&#160;11 Related Party Transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;"&gt;UBC Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;In February&#160;2009, the Company entered into an agreement with UBC to further the development and commercialization of certain technology developed, in part, by the Company&#x2019;s Chief Scientific Officer. The agreement was amended and restated in October&#160;2015. Under the amended and restated agreement, the Company is committed to make royalty payments based on revenue earned from the licensed technology. An annual license fee is payable over the term of the agreement. The agreement remains effective unless terminated under the provisions of the agreement. The Company made annual license payments of C$25,000 during each of the years ended December 31, 2025 and 2024. Through December&#160;31, 2025 no accruals for royalty payments have been made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;"&gt;Indemnification&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 36pt;"&gt;against liabilities that may arise by reason of their status or service as directors or officers. The Company currently has directors&#x2019; and officers&#x2019; insurance.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pmn:CollaborativeArrangementAccrualsForRoyaltyPayments
      contextRef="As_Of_12_31_2025_in6RWOMzjEC6vqtM6zmj3Q"
      decimals="0"
      id="Narr_pQZrKOIloEW3JgpPqlTuUA"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</pmn:CollaborativeArrangementAccrualsForRoyaltyPayments>
    <pmn:RelatedPartyTransactionTermOfAgreement
      contextRef="Duration_4_1_2016_To_4_30_2016_pOn31i6lLEW5JuoImgoy_w"
      id="Narr_gajVAtcbFE-qQblWEUlNQg">P3Y</pmn:RelatedPartyTransactionTermOfAgreement>
    <pmn:AnnualLicensePayment
      contextRef="Duration_1_1_2024_To_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_Oi4UAzx7LkqdsUQQKfYJbQ"
      decimals="0"
      id="Narr_bFG9dOSUb0OPb-WrCCk5hQ"
      unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA">25000</pmn:AnnualLicensePayment>
    <pmn:CollaborativeArrangementAccrualsForRoyaltyPayments
      contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_pmn_UbcAgreementMember_4lfKtp945kqn9mXeMmjskQ"
      decimals="-5"
      id="Narr_PepBElkpuUeKWiK6eWo3IQ"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">0</pmn:CollaborativeArrangementAccrualsForRoyaltyPayments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_MKBzRI5vFkOjsa3HksAiJw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common shareholders by the weighted average shares outstanding during the period, without consideration for common share equivalents. Diluted net earnings per share applicable to common shareholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common share equivalents outstanding for the period, determined using the treasury-stock method and the if-converted method. For purposes of the calculation of dilutive net (loss) income per share applicable to common shareholders, stock options, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share applicable to common shareholders when their effect would be anti-dilutive or would not add additional Common Shares to the denominator of the calculation due to being out-of-the-money.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:9pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;As of December 31, 2025 and 2024, respectively, 74,673 and 86,481 Pre-Funded Warrants to purchase common shares for little to no consideration, issued in connection with the August 2023 Private Placement and July 2024 Private Placement (see Note 6), were included in the basic and diluted net (loss) income per share calculation. The following table sets forth the computation of basic and diluted net loss (income) per share attributable to common shareholders:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:9pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;Ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Net (loss) income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,719,147)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,778,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,756,844&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,036,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Effect of potentially dilutive securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;          Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;          Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,756,844&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,058,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income per share attributable to common shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net (loss) income per share attributable to common shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The following outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been antidilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options issued and outstanding under stock option plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 180,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 142,978&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,564,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,199,175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,745,201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,342,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_igRnDfASGkG63gecqvoxGA"
      decimals="INF"
      id="Narr_3J8xfroNZEe4tPLyxr30bg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">74673</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_YLC21hJnUUecfOnIoqyf6w"
      decimals="INF"
      id="Narr_fzv-B_RE90q2oN0ofe_P5g"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">86481</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_nft6V7-qhEmkEUxiUSr1Cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:9pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&#160;Ended&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Net (loss) income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,719,147)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,778,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,756,844&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,036,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Effect of potentially dilutive securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;          Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;          Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,756,844&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,058,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income per share attributable to common shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net (loss) income per share attributable to common shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_KwyOB1TRekua5J7zJUHniQ_4_3"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">-39719147</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_18WCTTcRakaTCbXYt1vFZQ_4_6"
      unitRef="Unit_Standard_USD_ec91Khq9-Uq_0BXTTAQwuA">2778873</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_I8x7AN8xQU-Pi4tAU-Cd_A_6_3"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1756844</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_7SDnWwRNtky63qEEh6GLhw_6_6"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1036799</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="INF"
      id="Tc_RIS6dJwmREiyefXyjmor0A_8_6"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">20882</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="INF"
      id="Tc_1C8LvcOfXUeGyxN1ojO2hw_9_6"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">789</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="0"
      id="Tc_4Ed5hkdXY06Uu_aoSUe_Ow_10_3"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1756844</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="0"
      id="Tc_bIIlXlZvwkWcQgfJnhfU-Q_10_6"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">1058469</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="2"
      id="Tc_imb4lRdXkUOJ9fmr-QtdzA_12_3"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">-22.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="2"
      id="Tc_glBl5cjXG0K7a6ej4emZCA_12_6"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">2.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="2"
      id="Tc_n2XD9d7ebkG9x2lUOQH2Mw_13_3"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">-22.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="2"
      id="Tc_4cUPOTeojUifcYjJKXW2KA_13_6"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">2.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_is4mbi_jiEynqsqkqLlBWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options issued and outstanding under stock option plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 180,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 142,978&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,564,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,199,175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,745,201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,342,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DtZmtuC1ykum9CataBZk8g"
      decimals="INF"
      id="Tc_A1_7mCOFC06Serdxf3V61Q_4_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">180827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_a-CEo9VCBE-UkGXp15OLEg"
      decimals="INF"
      id="Tc_xovsJHYPTkebVKiobN7cZw_4_4"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">142978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I1pUDf-UVkWE1fMJu2oIPg"
      decimals="INF"
      id="Tc_d-7saYtRmUqwVmIeFIYH3A_5_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2564332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_I_iDsTdFrk6-anUo_VHT0g"
      decimals="INF"
      id="Tc_q8B7QEa6HkW7bcyZkHr5gg_5_4"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2199175</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_-Oj0jlKSiEGQv00Y8TYf4g"
      decimals="INF"
      id="Tc_rpJZZkWiCEW72woPi6a7KQ_6_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">42</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pmn_DeferredShareUnitsMember_fsghA6bgmEe7eA6MOqoAlg"
      decimals="INF"
      id="Tc_m02OFtOCREKlW4U15ekWTA_6_4"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">42</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      decimals="INF"
      id="Tc_N_nLjQZTTUOJRl_CYaGG0g_7_2"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2745201</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_7MV01UoEIka9Bx_fEkP0SA"
      decimals="INF"
      id="Tc_RRDLxFDytUGJw2nM0Hhojg_7_4"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">2342195</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Tb_Hs6uJgLiR0Sm52NjXkJOOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;14.&lt;/b&gt;&lt;/span&gt;SUBSEQUENT EVENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#191c1f;"&gt;On January 29, 2026, the Company completed a private placement &#160;for aggregate gross proceeds of &#160;&lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$75.5&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; million to sell an aggregate of (i) &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;6,815,296&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Shares, (ii) Common Share purchase warrants (&#x201c;&lt;/span&gt;&lt;b style="color:#191c1f;font-weight:bold;"&gt;Common Share &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"&gt;&lt;b style="color:#191c1f;font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;span style="color:#191c1f;"&gt;&#x201d;) to purchase &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;6,915,296&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Shares, (iii) Pre-Funded Warrants (&#x201c;&lt;/span&gt;&lt;b style="color:#191c1f;font-weight:bold;"&gt;Pre-Funded Warrants&lt;/b&gt;&lt;span style="color:#191c1f;"&gt;&#x201d;) to purchase &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;100,000&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Shares (collectively the &#x201c;&lt;/span&gt;&lt;b style="color:#191c1f;font-weight:bold;"&gt;January 2026 PIPE&lt;/b&gt;&lt;span style="color:#191c1f;"&gt;&#x201d;). &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;6,090,075&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Shares and &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;6,090,075&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Share Warrants were sold at a price of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$10.77&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; for one Common Share and &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_g2-t6Gg1-USHvtLxsXmEHw;"&gt;&lt;span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Share Warrant. &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;100,000&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Pre-Funded Warrants and &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;100,000&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Share Warrants were sold at a price of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$10.77&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; for one Pre-Funded Warrant and &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_z_3eEpwo3UirEsenSR7Cow;"&gt;&lt;span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Share Warrant, less an exercise price of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$0.0001&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; per Pre-Funded Warrant. &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;725,221&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Shares and &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;725,221&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Share Warrants were sold to certain of our directors and management at a price of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$12.13&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; for one Common Share and &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_bKWVPXSjm0mG5YAXBCSUsw;"&gt;&lt;span style="color:#191c1f;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; Common Share Warrant. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#191c1f;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#191c1f;"&gt;The Common Share Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$14.40&lt;/span&gt;&lt;span style="color:#191c1f;"&gt;, are exercisable immediately and will expire upon the earlier of (i) within &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;60 days&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#191c1f;"&gt;$0.0001&lt;/span&gt;&lt;span style="color:#191c1f;"&gt; per Pre-Funded Warrant, are immediately exercisable and will expire when exercised in full. For purposes of the foregoing, the &#x201c;Milestone Event&#x201d; means the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with multiple ascending doses of PMN310. Fees and other expenses are currently not estimable by the Company, as they are still being determined.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g"
      decimals="-5"
      id="Narr_VJQcwaFCd0a0jZupEeCuog"
      unitRef="Unit_Standard_CAD_0bIGG6MBEkexQleS433poA">75500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g"
      decimals="INF"
      id="Narr_kYdgWN5wP02-mAaUlx9HGA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">6815296</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_NrDzHyxGB0mKB6zttI9Mtw"
      decimals="INF"
      id="Narr__-UC8U2i7keh9U3cgah7Hg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">6915296</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg"
      decimals="INF"
      id="Narr_4AS1X6aDQkuCNq0ZGYhBVg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_6VuupOYBAkOYhCWeJHRGrg"
      decimals="INF"
      id="Narr_qNrqCFhB1EOozQ0L1DVyCA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">6090075</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pmn:ClassOfWarrantOrRightIssued
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceOneMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceOneMember_Q86c3TOUPUerZkUpsynvOQ"
      decimals="INF"
      id="Narr_CHxclR1QKU2beAOulyZDsA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">6090075</pmn:ClassOfWarrantOrRightIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_C9tRwMO6rE-LT1JzUAMX2g"
      decimals="2"
      id="Narr_QrLOk3QCb0W_qt-6TWmtXA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">10.77</us-gaap:SaleOfStockPricePerShare>
    <pmn:ClassOfWarrantOrRightIssued
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_br3i9uDnNUeb1G3P44Ok7A"
      decimals="INF"
      id="Narr_7C6uk0Fguk6wZ0UDCFh3hA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">100000</pmn:ClassOfWarrantOrRightIssued>
    <pmn:ClassOfWarrantOrRightIssued
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_MI2T6mOoo0yiJyx9T1pfEg"
      decimals="INF"
      id="Narr_39Wn1rYpR0WqJ75AsHwMkA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">100000</pmn:ClassOfWarrantOrRightIssued>
    <pmn:ClassOfWarrantOrRightPricePerWarrant
      contextRef="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceTwoMember_atViPoIYo0CLfKm49OwGMA"
      decimals="2"
      id="Narr_pZpbAuD-EkqcsKbBLzkAxg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">10.77</pmn:ClassOfWarrantOrRightPricePerWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg"
      decimals="4"
      id="Narr_lZRuz0TFckyJ2QplU-KoIA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_29_2026_To_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_hIXk7T7AhEypKsAQMXXglg"
      decimals="INF"
      id="Narr_LhwaTHZo0E2V_7RsaSS7nA"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">725221</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pmn:ClassOfWarrantOrRightIssued
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsIssuePriceThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_p9u06d6usECaMSjjXOcQkA"
      decimals="INF"
      id="Narr_LpxucblqcU-8ugfEn4CYLg"
      unitRef="Unit_Standard_shares_ock7lh-4hkyKuw6FKn0lpQ">725221</pmn:ClassOfWarrantOrRightIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_1_29_2026_srt_TitleOfIndividualAxis_pmn_DirectorsAndManagementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementIssuePriceThreeMember_Y-LkZ-hLQ0uB5SljT10LcA"
      decimals="2"
      id="Narr_bKFm5JPCcU2scxznNsxX1g"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">12.13</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_CommonShareWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_NrDzHyxGB0mKB6zttI9Mtw"
      decimals="2"
      id="Narr_48KMq7GmIkiCOENTCIHFYg"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">14.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pmn:ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm
      contextRef="Duration_1_29_2026_To_1_29_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_v26AYRnz306kGSOMbV46_g"
      id="Narr_kYknIZKDa0Sm7Gx0IJitlA">P60D</pmn:ThresholdDaysAfterCompletionOfMilestoneEventsConsideredForExpiryTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_29_2026_us-gaap_ClassOfWarrantOrRightAxis_pmn_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_pmn_January2026PrivatePlacementMember_81wLqXC1UESt66I4jWM7mg"
      decimals="4"
      id="Narr_OtzEHgzjV0eUQYldB3VUmA"
      unitRef="Unit_Divide_USD_shares_iqKums03AUW19NIuzw_Vxg">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pmn:Rule10b51ArrModifiedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A"
      id="Narr_XeYUkNMxskqstmRa9awcFQ">false</pmn:Rule10b51ArrModifiedFlag>
    <pmn:Rule10b51ArrModifiedFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA"
      id="Narr_NiOf2wMS2E-TlOagnYWznA">false</pmn:Rule10b51ArrModifiedFlag>
    <pmn:Rule10b51ArrModifiedFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg"
      id="Narr_n2Yv7CoTLUOeeyG5j1VwfA">false</pmn:Rule10b51ArrModifiedFlag>
    <pmn:Rule10b51ArrModifiedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q"
      id="Narr_SW4yVuwKx06U2iyH_OGwwQ">false</pmn:Rule10b51ArrModifiedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A"
      id="Narr_iL9ZEQgGpEqjT4YH9eOQhA">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA"
      id="Narr_wzQG6LI9UE294eM_yOpS1g">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg"
      id="Narr_QWcDm83JVEmrp0BQMHnhWw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q"
      id="Narr_nF5u_6t-SkyG4T49X71Q6Q">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A"
      id="Narr_N7LQkcXJik24RNEQtDcAUw">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA"
      id="Narr_kDKig7FWMUuKseDUWopxEg">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg"
      id="Narr_eWDq575M-UCQ2BQ0NyJw8Q">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q"
      id="Narr_n-2L09_yK0qaZEh7qPbkeQ">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A"
      id="Narr_jwolPkF9WEytmb2ZjSAGAg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA"
      id="Narr_Wh3sR-xU502qgv7D9Dj6JQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg"
      id="Narr_Ky0shOVAuk2oyL6_dpDBag">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q"
      id="Narr_7c1c8whtIk-i3ioGOt0uVg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A"
      id="Narr_aYJEBgTnuECQrqJ705bOog">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA"
      id="Narr_y122uXZWg0ebg5EGoIUIqQ">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg"
      id="Narr__eAunmpV2E2u5n7oNXNgyg">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q"
      id="Narr_oPbbRLLHK0qoVKfHKYcogw">false</ecd:NonRule10b51ArrTrmntdFlag>
    <pmn:NonRule10b51ArrModifiedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025__3-I9c-M90mN6qQ8ZFpG4A"
      id="Narr_1t543gD8TkKaZtIX4nP7uw">false</pmn:NonRule10b51ArrModifiedFlag>
    <pmn:NonRule10b51ArrModifiedFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_4rOMgbvoaUudWEU2rpArDA"
      id="Narr_0xfz56Qcx0utvmnMD-ZKtA">false</pmn:NonRule10b51ArrModifiedFlag>
    <pmn:NonRule10b51ArrModifiedFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_yeQUZkKkGUSMvQc0TWdZDg"
      id="Narr_XnD47_sgO0maKIF2YsscvQ">false</pmn:NonRule10b51ArrModifiedFlag>
    <pmn:NonRule10b51ArrModifiedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_MRx40fFdY0iF2UXYBvPe1Q"
      id="Narr_0rcuqlG1a02ej3N58t-pYQ">false</pmn:NonRule10b51ArrModifiedFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_u0NO5AHbdkmzvYLzsCiA7w"
      id="Narr_e1ZHRG95Z0OiNLEXg2amng">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
